Boca Raton London New York Singapore
Published in 2005 by Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite ...
86 downloads
1663 Views
24MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Boca Raton London New York Singapore
Published in 2005 by Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2005 by Taylor & Francis Group, LLC No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 0-8247-5833-1 (Hardcover) International Standard Book Number-13: 978-0-8247-5833-2 (Hardcover) Library of Congress Card Number 2005041805 This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Principles and practices in cutaneous laser surgery / editor, Arielle N.B. Kauvar ; associate editor, George J. Hruza. p. ; cm. – (Basic and clinical dermatology ; 33) Includes bibliographical references and index. ISBN 0-8247-5833-1 1. Skin—Laser surgery. I. Kauvar, Arielle N. B. II. Hruza, George J. [DNLM: 1. Laser Surgery—methods. 2. Skin Diseases—surgery. WR 650 P9566 2005] RL120.L37P75 2005 617.4’770598—dc22
Taylor & Francis Group is the Academic Division of T&F Informa plc.
2005041805
Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com
Dedication
To my husband, David R. Kauvar And my three wonderful sons, Ellery, Darien and Hadley Kauvar, For filling my life with love and happiness To my parents, Berta and Harry Bienenstock, For their enduring affection and steadfast guidance Arielle N.B. Kauvar
To my children Stephanie and Paul Hruza For giving my life joy and fulfillment To my parents Judita and Zdenek Hruza For their unwavering support and love George Hruza
Foreword
Almost all clinical texts on skin therapy with lasers and other non-invasive energy sources are in some way out of date, because this fascinating field is prone to making progress (which is discussed a bit more, below). So, read this excellent book as soon as possible. Part of it will be passe´ within a few years, although I don’t know exactly which part. In 25 years, however, this book will still be worth reading. Basic principles inherent in the science and art of medicine do not fade away, and nothing is ever “un-invented”. Indeed, our best stuff is not really new. Arielle Kauvar and George Hruza have given us something built to last, written by colleagues with clinical acumen based on a wealth of ideas and experience. This text should be fun for anyone who wields or thinks about wielding therapeutic photons. I plan to keep it handy for my own use, for residents and students, and for those stunningly inquisitive patients who seem to abound in Boston. Medical professionals have used light to treat skin problems for at least 3000 years. Thermal treatments of skin have been around on a fee-for-service basis for at least twice that long. The recent “explosion” of lasers, intense pulsed light (IPL) sources, lightactivated drugs (photodynamic therapy, PDT), ultrasound, and advanced radiofrequency treatments has occurred during ,1% of this long history, for good reasons. Laser skin surgery is undeniably “high-tech,” and new technology is neat stuff. Lasers are far smaller, more reliable, versatile, efficient, long-lived, and controllable. The recent optical telecommunications “bubble” created many new fiber-based lasers, amplifiers, scanners and detectors that are just beginning to trickle down into medicine. However, new technology is merely a stimulus, and not the primary reason for progress in this field. Very soon after the first laser was invented in 1960—a flashlamp-pumped, longpulsed ruby laser—Leon Goldman, MD and other admirable pioneers widely explored its potential for laser skin surgery. More than 30 years later, the same laser was used to create the “breakthrough” of permanent laser hair removal, which is now available around the world using other lasers and more recently, intense pulsed light sources. Why did it take so long? Intense pulsed light sources were invented long before lasers; why did they appear much more recently than lasers in dermatology? IPLs are xenon flashlamps with optical filters, which have been around for about 60 years. So, if IPLs are a great leap backward—why not keep going? Any sophomore at MIT could show that focused, filtered sunlight can achieve about the same spectrum and brightness as an IPL, because the surface of the sun is a plasma at the same temperature as that in our IPLs. Unless someone in the esthetic device industry with a death-wish does it first, v
vi
Foreword
I hope some day to enjoy making a scanned, focused, solar “photorejuvenator,” just for fun. How ironic it would be to use sunlight for treating skin damage caused by itself. So, if new technology is not the primary limitation to progress in this high-tech corner of medicine—what is? The answer is a humble one, pertinent to this book: we lack the understanding necessary for progress. I do not mean a basic physical or biological science understanding. What we lack most is the ability to pose clinical connections with existing science and technologies. The readership of this book (yes, you!) is in a position to contribute something to that kind of understanding. As a group of biomedical professionals we are no more or less intelligent, and no more or less naı¨ve, than those before us during millennia of using light to treat skin disease. Oddly enough, it is probably the most recent info in this book that runs the greatest risk of early obsolescence. The trick, apparently, is to do something both new and long-lasting. I like this book because it brings the attentive reader to the brink of our lack of understanding. Bon appetit! R. Rox Anderson, MD Prof. of Dermatology Director, Wellman Center for Photomedicine Harvard Medical School
Preface
Lasers have become integral to the modern practice of medicine in the fields of dermatology, plastic surgery, otolaryngology, and phlebology. With the skin being the most accessible organ in the body, many cutaneous disorders and conditions are ideally suited to treatment by laser technology. Lasers are safely used to destroy or alter epidermal and dermal processes and lesions comprising blood vessels or pigment. With the development of the principles of “selective photothermolysis” by Drs. R. Rox Anderson and John Parrish in the 1980s, selective site-specific destruction of skin lesions became a reality. The appropriate combination of laser wavelength and exposure time enabled the removal of blood vessels and pigment without affecting the surrounding tissue. For the first time in medical history, port wine stains were gradually lightened with a series of noninvasive treatments leaving these patients with normalappearing skin. Similarly, tattoos and melanocytic lesions could be targeted by pigmentabsorbing lasers without altering the normal skin pigmentation. The same basic principles have been used to create lasers that selectively damage leg veins and hair follicles. More recently, new technology has led to the development of skin resurfacing lasers and to the development of a whole new approach to facial rejuvenation and the treatment of wrinkles, photodamage, and scars. Dramatic clinical results and a low incidence of adverse side effects have generated much enthusiasm among physicians and patients for these procedures. Laser technology and its application to the treatment of skin disorders has developed at a rapid pace in recent years. Multiple types of laser systems are now available to treat a wide variety of cutaneous lesions, including vascular and pigmented lesions, tattoos, hair, leg veins, scars, and wrinkles. Clinicians using lasers as well as residents and fellows in training are faced with a perplexing array of technology with few resources for obtaining background knowledge and practical information necessary to perform these treatments. The purpose of this text is to provide an up-to-date, comprehensive yet straight-forward approach to understanding lasers and performing laser treatment for cutaneous disorders. The book is intended for use by practicing physicians. For convenience and clarity, information is readily available about each laser system as well as specific treatment indications. Section I provides the fundamentals for understanding laser instrumentation and physics. A comprehensive review of each laser system, its interaction with tissue and treatment indications are presented in Section II of the book. Existing technologies are compared and the details of operation are reviewed. Section III offers a step-by-step approach to laser treatment of specific skin disorders, with an emphasis on the selection vii
viii
Preface
of the appropriate laser for each clinical situation, treatment guidelines, and possible pitfalls. In Section IV, a guide to patient selection, appropriate education, and credentialing, as well as establishing a laser surgical unit is provided for clinicians new to the practice of laser surgery. The comprehensive scope of this text with its in-depth analysis yet practical approach make it a useful reference and teaching tool for both the novice and the experienced laser surgeon in the fields of dermatology, plastic surgery, otolaryngology, and phlebology. Arielle N. B. Kauvar
Acknowledgment
We are grateful to our many colleagues and friends whose hard work and dedication helped make this book a reality. This project would not have been possible without the patience, understanding, and support of our families and office staff. We sincerely appreciate the invaluable assistance and guidance of Sandra Beberman and the support staff at Marcel Dekker and Taylor & Francis. Arielle N.B. Kauvar and George J. Hruza
ix
Contents
Foreword . . . . . . . Preface . . . . . . . . . Acknowledgment . . List of Contributors
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
.. .. .. ..
. . . .
v vii ix xv
1. Cutaneous Laser Surgery: Historical Perspectives . . . . . . . . . . . . . . . . . . . . . Gary J. Brauner
3
Section I: Understanding Lasers
2. An Introduction to Lasers and Laser –Tissue Interactions in Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . J. Stuart Nelson 3. Laser Safety Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Christie Travelute Ammirati and George J. Hruza
59
79
Section II: Laser Science and Instrumentation 4. Continuous Wave Lasers: Argon, Dye, KTP, Copper Vapor, Krypton . . . . . . 105 Thomas O. McMeekin 5. Continuous Wave and Pulsed CO2 Lasers E. Victor Ross
. . . . . . . . . . . . . . . . . . . . . . . . . . 129
6. Er:YAG Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181 Ulrich Hohenleutner and Michael Landthaler 7. Pulsed Dye Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 Kristen A. Richards and Jerome M. Garden 8. Clinical Uses of the Long Pulse Duration Pulsed Dye Laser . . . . . . . . . . . . . 219 Eric F. Bernstein 9. Pulsed KTP and Diode (532 nm) Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245 Robert M. Adrian, Emil Tanghetti, and Arielle N. B. Kauvar xi
xii
10. Q-Switched Ruby Laser Vic A. Narurkar
Contents
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259
11. The Q-Switched Nd:YAG (1064 þ 532 nm) Laser . . . . . . . . . . . . . . . . . . . . 265 Suzanne L. Kilmer, Macrene R. Alexiades-Armenakas, Vicki J. Levine, and Robin Ashinoff 12. Q-Switched Alexandrite Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 Christopher A. Nanni 13. Long-Pulsed Alexandrite Laser . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297 Cathy A. Slater, John B. Newman, and David H. McDaniel 14. Diode Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 Murad Alam, David A. Wrone, and Beatrice Berkes 15. Long-Pulsed Nd:YAG (1064 nm) Lasers Neil Sadick and Arielle N. B. Kauvar
. . . . . . . . . . . . . . . . . . . . . . . . . . . 337
16. Noncoherent Light Source . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355 Robert A. Weiss and Margaret A. Weiss 17. Excimer Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375 James M. Spencer 18. Photodynamic Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387 Shirley Jean-Baptiste, David A. Wrone, and Murad Alam 19. Skin Cooling in Laser Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403 Kristen M. Kelly and J. Stuart Nelson 20. Reflectance Confocal Microscopy for Basic and Clinical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415 Salvador Gonza´lez, Robert H. Webb, R. Rox Anderson, and Milind Rajadhyaksha
Section III: Lasers Treatment of Cutaneous Disorders 21. Laser Treatment of Port Wine Stains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441 Arielle N. B. Kauvar 22. Lasers and the Treatment of Hemangiomas Milton Waner and Jay Kincannon
. . . . . . . . . . . . . . . . . . . . . . . . . 461
23. Laser Treatment of Acquired Vascular Lesions Tina B. West
. . . . . . . . . . . . . . . . . . . . . . 475
24. Lasers in the Treatment of Pigmented Lesions . . . . . . . . . . . . . . . . . . . . . . . 489 Jeffrey S. Dover, Kenneth A. Arndt, and Richard J. Ort
Contents
xiii
25. Laser Treatment of Tattoos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505 Suzanne L. Kilmer 26. Carbon Dioxide Laser Treatment of Epidermal and Dermal Lesions in Principles and Practices in Cutaneous Laser Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519 Leslie C. Lucchina and Suzanne M. Olbricht 27. Skin Resurfacing with CO2 Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535 Richard E. Fitzpatrick and Elizabeth Rostan 28. Skin Resurfacing with Erbium:YAG Lasers . . . . . . . . . . . . . . . . . . . . . . . . . 553 Kucy Pon, Vivek Iyengar, and Thomas Rohrer 29. Combined Laser Resurfacing Techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . 569 Mitchel P. Goldman and Elizabeth Roston 30. Combining Laser Resurfacing with Facial Surgery . . . . . . . . . . . . . . . . . . . . 589 Cynthia Weinstein 31. Laser Treatment of Scars and Striae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 Tina S. Alster and H. L. Greenberg 32. Nonablative Skin Rejuvenation and Acne Therapy . . . . . . . . . . . . . . . . . . . . 637 David J. Goldberg and Arielle N. B. Kauvar 33. Laser Treatment of Leg Veins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653 Arielle N. B. Kauvar 34. Laser Hair Removal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677 Christine C. Dierickx 35. Laser Assisted Hair Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703 Marc R. Avram 36. Treatment of Nonwhite Skin with Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . 717 Woraphong Manuskiatti and Mitchel P. Goldman Section IV: Considerations in the Practice of Laser Surgery 37. Legal Considerations in Laser Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749 David J. Goldberg 38. Establishing a Laser Unit Elizabeth I. McBurney
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 757
39. Anesthesia Options for Laser Surgery John A. Carucci and David J. Leffell Index
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 775
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 789
List of Contributors
Robert M. Adrian, M.D., F.A.C.P. Murad Alam, M.D. Illinois, USA
Center for Laser Surgery, Washington, DC, USA
Department of Dermatology, Northwestern University, Chicago,
Macrene R. Alexiades-Armenakas, M.D., Ph.D. New York, USA
Private Practice, New York,
Tina S. Alster, M.D. Dermatology and Pediatrics, Georgetown University Medical Center, Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA Christie Travelute Ammirati, M.D. Division of Dermatology, Penn State University College of Medicine, Pennsylvania, USA R. Rox Anderson, M.D. Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA Kenneth A. Arndt, M.D. SkinCare Physicians of Chestnut Hill, Chestnut Hill and Clinical Professor of Dermatology, Harvard Medical School, Massachusetts, and Clinical Professor of Dermatology, Yale University School of Medicine, Connecticut, USA Robin Ashinoff, M.D. Department of Dermatology, Hackensack University, Hackensack, New Jersey, USA Marc R. Avram, M.D. Department of Dermatology, Weill-Cornell Medical Center, New York, New York, USA Beatrice Berkes, M.D. California, USA
Department of Dermatology, Loma Linda University,
Eric F. Bernstein, M.D. Laser Surgery and Cosmetic Dermatology Centers, Marlton, New Jersey, USA; University of Pennsylvania, Pennsylvania, USA Gary J. Brauner, M.D. Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA John A. Carucci, M.D., Ph.D. Medicine, Connecticut, USA
Department of Dermatology, Yale University School of xv
xvi
List of Contributors
Christine C. Dierickx, M.D. Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA; Department of Dermatology, University of Ghent, Belgium Jeffery S. Dover, M.D. F.R.C.P.C. SkinCare Physicians of Chestnut Hill, Chestnut Hill, Massachusetts and Associate Clinical Professor of Dermatology, Yale University School of Medicine, Connecticut, USA Richard E. Fitzpatrick, M.D. San Diego, California, USA
Dermatology Associates of San Diego County, Inc.,
Jerome M. Garden, M.D. Department of Dermatology, Northwestern University Medical School and Divisions of Dermatology and Plastic Surgery, Children’s Memorial Hospital, Chicago, Illinois, USA David J. Goldberg, M.D., J.D. Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA Mitchel P. Goldman, M.D. Cosmetic Laser Associates of La Jolla, Inc., La Jolla and University of California, San Diego, California, USA Salvador Gonza´lez, M.D., Ph.D. Massachusetts General Hospital, Harvard Medical School and Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA Washington Institute of Dermatologic Laser Surgery,
H. L. Greenberg, M.D. Washington, DC, USA Ulrich Hohenleutner, M.D. Regensburg, Germany George J. Hruza, M.D. Medicine, Missouri, USA Vivek Iyengar, M.D.
Department of Dermatology, University of Regensburg,
Division of Dermatology, St. Louis University School of
SkinCare Physicians of Chestnut Hill, Massachusetts, USA
Shirley Jean-Baptiste, M.D.
Northwestern University, Chicago, Illinois, USA
Arielle N. B. Kauvar, M.D. New York Laser & Skin Care, Department of Dermatology, New York University School of Medicine and Department of Dermatology, SUNY Downstate Medical Center, New York, New York, USA Kristen M. Kelly, M.D. Department of Dermatology and Surgery, Beckman Laser Institute, University of California, California, USA Suzanne L. Kilmer, M.D. Laser & Skin Surgery Center of Northern California, Sacramento, California, USA Jay Kincannon, M.D. Department of Dermatology and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA Michael Landthaler, M.D. Regensburg, Germany David J. Leffel, M.D. cine, Connecticut, USA
Department of Dermatology, University of Regensburg,
Department of Dermatology, Yale University School of Medi-
Vicki J. Levine, M.D. Department of Dermatology, New York University School of Medicine, New York, New York, USA
List of Contributors
xvii
Leslie C. Lucchina, M.D. Department of Dermatology, Brigham and Women’s Hospital and Department of Dermatology, Harvard Medical School, Massachusetts, USA Woraphong Manuskiatti, M.D. Department of Dermatology, Siriraj Hospital, Mahidol University, Bangkok, Thailand Elizabeth I. McBurney, M.D. Department of Dermatology, Lousiana State University School of Medicine, Tulane University School of Medicine, Lousiana, USA David H. McDaniel, M.D. Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Eastern Virginia Medical School, Norfolk, Virginia, USA Thomas O. McMeekin, M.D. Department of Dermatology and Pediatrics, University of Rochester and Department of Dermatology, State University of New York at Buffalo, New York, New York, USA Christopher A. Nanni, M.D.
Private Practice, Glendore, California, USA
Vic A. Narurkar, M.D. Bay Area Laser Institute and Department of Dermatology, University of California at Davis, California, USA J. Stuart Nelson, M.D., Ph.D. Department of Surgery, Dermatology and Biomedical Engineering, Beckman Laser Institute, University of California, California, USA John B. Newman, M.D. Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Department of General Surgery, Naval Medical Center Portsmouth, Portsmouth, Virginia, USA Suzanne M. Olbricht, M.D. Department of Dermatology, Lahey Clinic and Department of Dermatology, Harvard Medical School, Massachusetts, USA Richard J. Ort, M.D. SkinCare Physicians of Chestnut Hill and Department of Dermatology, Beth Israel Deaconess Medical Center, Massachusetts, USA Kucy Pon, M.D.
SkinCare Physicians of Chestnut Hill, Massachusetts, USA
Milind Rajadhyaksha, Ph.D. Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA; Lucid, Inc., New York, New York, USA Kristen A. Richards, M.D.
Scripps Memorial Hospital, California, USA
Thomas Rohrer, M.D. SkinCare Physicians of Chestnut Hill, Chestnut Hill and Associate Clinical Professor of Dermatology, Boston University School of Medicine, Massachusetts, USA E. Victor Ross, M.D., C.D.R., M.C., U.S.N. Dermatology Department, Naval Medical Center San Diego and Division of Dermatology, University of California, San Diego, California, USA Elizabeth Rostan, M.D. California, USA
Dermatology Associates of San Diego County, Inc., San Diego,
Neil S. Sadick, M.D., F.A.C.P., F.A.A.C.S. Department of Dermatology, Weil Medical College of Cornell University, New York, New York, USA Cathy A. Slater, M.D., M.P.H. Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Boice-Willis Clinic, Rock Mount, North Carolina, USA
xviii
List of Contributors
James M. Spencer, M.D., M.S. Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA Emil Tanghetti, M.D.
Private Practice, Sacramento, California, USA
Milton Waner, M.D., F.C.S. Department of Otolaryngology, St. Lukes—Roosevelt Hospital, New York, New York, USA Robert H. Webb, Ph.D. Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA Cynthia Weinstein, M.B.B.S., F.A.C.D., F.R.A.C.P. Australia.
Private Practice, Melbourne,
Margaret A. Weiss, M.D. Department of Dermatology, Johns Hopkins University School of Medicine, Maryland, USA Robert A. Weiss, M.D. Department of Dermatology, Johns Hopkins University School of Medicine, Maryland, USA Tina B. West, M.D.
Private Practice, Chevy Chase, Maryland, USA
David A. Wrone, M.D. Chicago, Illinois, USA
Department of Dermatology, Northwestern University,
Section I: Understanding Lasers
1 Cutaneous Laser Surgery: Historical Perspectives Gary J. Brauner Mount Sinai School of Medicine, New York, New York, USA
1. 2. 3. 4.
5.
6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19.
Finding the Right Thread in the Cloak It Takes a Nobel Prize Winner to Think of it Ruby Other New Lasers 4.1. Argon Laser 4.2. CO2 Laser Multidisciplinary Societies 5.1. Laser Institute of America 5.2. International Society for Laser Medicine and Surgery 5.3. American Society for Laser Medicine and Surgery Laser safety—The American National Standards Institute Personnel and Patient Safety—Plume Patient Safety—SCAR Postoperative Wound Care Selective Photothermolysis Wellman Lab and Beckman Lab Nd:YAG LASER 12.1. Q-switching Pigment Lasers Serendipity Resurfacing Laser-Assisted Hair Transplantation Pulsed Light Sources Laser Hair Removal Chilling and Wrinkles
4 4 9 9 9 12 15 15 15 15 16 17 17 22 23 24 25 25 26 27 28 30 31 31 33 3
4
Brauner
20. Biostimulation 21. Photodynamic Therapy 22. Return of the Scientific Method—The Charge for the Future References
1.
34 35 36 39
FINDING THE RIGHT THREAD IN THE CLOAK
A proper history of lasers in dermatologic surgery requires not just a chronological recitation (1 – 3) of what we know as published fact by the sequential appearance of peer-reviewed and dated articles and Congress presentations but also an attempt to find the thread of true progress weaving through the fabric of the “cloak of magical claims.” The use of light and its many colors, both visible and invisible, for the treatment and healing of cutaneous disease is a true analog of Joseph’s multicolored cloak. How does the laser-surgeon-turned-historian achieve a sense of perspective over the laser miracles of the past 40 years while sitting in the midst of them? Is he/she woven too tightly into the woof and warp to see above it? This author’s selection of a few articles and concepts as seminal ones will trace this thread but it does not negate the importance of many other legitimate contributions in our cloak (Table 1.1). There is a sense and a nonsense to our history. The relentless march of technical, industrial, and military genius in developing new lasers after 1960 was at first random and certainly unrelated to dermatologic surgery at least until 1983 (4). But there were clearly identifiable and critical seminal events which brought about the flowering of cutaneous laser surgery. These events define the thread this author will trace—they span theoretical physics, inventive genius of laser manufacture, optical modeling schema of the skin and its chromophores to direct development of appropriate lasers to treat cutaneous disease (4–13), accidental discoveries, the advertising kingdom, the medical–industrial complex, and ethics of the marketplace and of the practice of medicine. All of these elements and events must be elaborated and reflected upon before a full though pro tem view of the evolution of cutaneous laser surgery is understood and hopefully utilized to direct its future. For spatial considerations the ever-expanding spectrum of laser technology for medical communication by fiberoptic networks, holographic reconstructions, or laser microsurgical manipulations of subcellular organelles or genes will not be reviewed.
2.
IT TAKES A NOBEL PRIZE WINNER TO THINK OF IT
Albert Einstein (Fig. 1.1) (14 –18), Time Magazine’s outstanding persona of the 20th century, also had the first insight into what has become our 21st century world of lasers. He elaborated the concept of stimulated emission of radiation in 1917 (19,20) wherein he postulated that if an electron were in an already excited state and were hit by a photon of the proper energy, instead of rising to a still higher energy level, it would fall to a lower level and emit a second photon of precisely the same wavelength as the initial photon, and the initial photon would also continue on without having been absorbed. Theoretically, one could then have a stream of unique and uniform photons arising in an incremental but massive exponential cascade (21). Laboratory experiments in the 1920s confirmed this postulate of stimulated emission but even in the experiments spontaneous emission of radiation and not stimulated emission predominated (21). According to Itzkan and Drake (22) Dirac’s theory of quantum electrodynamics in the
Cutaneous Laser Surgery: Historical Perspectives
5
Table 1.1 Seminal Events and Personae Albert Einstein Schawlow and Townes Theodore Maiman Leon Goldman, MD Argon laser-D Apfelberg, K. Arndt “Nonsense” science CO2 Laser Hyperbole and unreproducible results Interdisciplinary societies: LIA, ISLMS, ASLMSa Laser safety: ANSI standards Personnel and patient safety: plume Patient safety: scar Minimal dose: B. Cosman, scanners Chilling: C. Chess Postoperative wound care: G. Brauner, A. Schliftman Photothermolysis: R. Anderson, J. Parrish Wellman Lab and Beckman Lab Hyperbole? Corruption of scientific method Pigment lasers Q-switched lasers Serendipity: scars: T. Alster Resurfacing: R. Fitzpatrick, R. Kaufmann, A. Kauvar, J. Dover, R. Adrian Serendipity redux and hair removal: R. Anderson, M. Grossman Thermokinetics: J. Nelson, R. Anderson Biostimulation and “cool” lasers Real scientific method: side-by-side studies; Report of complications Nonphysician use of medical lasers a
LIA, Laser Institute of America; ISLMS, International Society for Laser Medicine and Surgery; ASLMS, American Society for Laser Medicine and Surgery.
1920s established the nature of coherence whereby the stimulated photons would not only have the same frequency as the inciting photon but phase and direction as well. In order to have a scenario where stimulated emission predominated, a population inversion of more excited atoms or molecules than unexcited ones had to be produced. Charles H. Townes (Fig. 1.2) was the first to manufacture such a functioning prototype which produced microwaves, thus the first MASER microwave amplified stimulated emission of radiation. He had been involved with radar in World War II and became interested in microwaves (21). Townes had first thought of the mechanism for amplification of the radiation on a park bench in Franklin Park in Washington in April 1951 (21,23). Also, in 1951 the Russian physicist V. A. Fabrikant applied for a Soviet patent on amplifying stimulated emission but it was not published until 1959 and did not influence the course of American laser physics (21). In the USA in 1953 Joseph Weber was the first to propose stimulated emission. Townes’ research group recognized in 1953 (23 – 25) that ammonia molecules in the ground state would be attracted by an electrical field and those in an excited state would be repelled and thus these researchers could separate out excited ammonia molecules and force them through a small hole into a cavity into a true population inversion. In their doing so, stimulated emission of 1.25 cm microwaves
6
Brauner
Figure 1.1 Albert Einstein in 1905 in the Swiss patent office in Berne (Lucien Chavan). (Courtesy, The Albert Einstein Archives, The Jewish National and University Library, The Hebrew University of Jerusalem, Israel.)
spontaneously occurred. In 1957 Schawlow (Fig. 1.3) and Townes (26,27) first elaborated their concept of an optical resonator which could amplify stimulated emission in a chamber with parallel opposing reflective mirrors and thus produce waves coherent in space, all in phase and of uniform frequency (and thus wavelength) (21). Townes and Schawlow thought that the first practical “optical maser” (i.e., “laser”) would be an electric
Figure 1.2 Charles Townes, coinventor of the maser. (Courtesy, Bell Labs/Lucent Technologies.)
Cutaneous Laser Surgery: Historical Perspectives
7
Figure 1.3 Theodore Schawlow, coinventor of the maser with the ruby optical maser (i.e., laser). (Courtesy, Bell Labs/Lucent Technologies.)
current pumping or energizing a gas but the first effective laser was made in Hughes Labs by Maiman (Fig. 1.4) in 1960 by surrounding a 4 cm long ruby crystal rod with a spiral flashlamp, which excited the chromium in the ruby crystal when it absorbed blue-green light and produced a chromium population inversion.
Figure 1.4 Theodore Maiman, inventor of the first laser, the ruby. (Courtesy, Hughes Research— Labs HRL.)
8
Brauner
The development of lasers 50 years after Einstein’s’ first conceptualization was of such importance to the scientific community that Townes as well as the Russian physicists Nikolai Basov and Aleksander Prokhorov received the Nobel Prize in 1964. Shawlow, who had collaborated in 1958 with Townes to obtain the first laser patents (27), shared the 1981 Nobel Prize for using lasers to study the nature of atoms and molecules (21). Hecht and Teresi provide a fascinating blow-by-blow account of the 20-year patent controversy between Gordon Gould and Townes and Schawlow and the race to produce the first laser in the late 1950s—the first of many laser controversies. Interestingly, Maiman’s seminal contribution, announced on July 7, 1960, in a brief four-paragraph article—the very first laser—was refused publication in the prestigious Physical Review Letters but was finally presented in Nature (28,29). Although “LASER,” as used now, is an acronym for light amplified stimulated emission of radiation, Orazio Svelto, an Italian professor of quantum electronics and laser pioneer (30) reflected on an ancient (1st century AD) but apparently timeless reference from Pliny the Elder in “Natural History XXII,” 49 that “the laser is numbered among the most miraculous gifts of nature and lends itself to a variety of applications.” Pliny was not prescient or more brilliant than Einstein or Townes and Schawlow; however, his “laser” was a celebrated, commercially important, but extinct since the 2nd century, plant raised in North Africa and used as a culinary dressing but more importantly also as a cure for a variety of diseases, even injuries such as scorpion stings or arrow wounds. A 1960s timeline (21) shows that rapid progress in laser research began around 1962 in scientific laboratories and commercial manufacture of lasers began at about the same time. The US military had a significant interest in laser development very early on; in fact, this interest and its associated elements of secrecy led to much of Gould’s problems with others’ recognition of his early contributions since he was under contract with the government. The first gas laser was also invented in 1960 but by 1965 laser activity had been found in gases in over 1000 different wavelengths. In the early 1960s Dr. Leon Goldman (Fig. 1.5), a Cincinnati dermatologist, started a center for medical laser research at the University of Cincinnati where he, also Chief of Dermatology, often used himself as the first human guinea pig at which to aim a newly developed laser and became thereby the father of laser medicine and surgery—another seminal event. He had originally been given a grant in 1961 to study the safety of lasers by the National Institute of Health and Occupational Medicine and so opened the laboratory to study the ruby laser. It was Leon Goldman who first realized the possibilities of therapeutic uses of lasers as medical instruments but he was unable to interest the Surgeon General in funding his research. The John A. Hartford Foundation did come up with support for him, enabling him to run a multidisciplinary laboratory of biologists, safety engineers, and physicians from other surgical disciplines (31) from 1961 to 1976. It was only because of the ingenuity and persistence of this one man that lasers finally were made applicable to the treatment of human malformation and disease and degenerative changes (32). Since the ruby laser was the only one available, it was that which he turned on himself, laboratory animals, and other humans (33). Goldman first exposed normal white and black skin and also white and black human skin covered with various black dyes to the ruby laser (34) and then attempted to treat cutaneous lesions such as seborrheic keratoses and superficial hemangiomas (33,35,36) and tattoos (37). Histologically, nonspecific thermal destruction of the cutaneous target occurred; clinically, there was long-lasting oozing and crusting, usually resulting in scarring, which was fortunately only rarely hypertrophic. By
He also experimented artistically and performed laser sculpting on a variety of media, which he exhibited at dermatologic meetings.
Cutaneous Laser Surgery: Historical Perspectives
9
Figure 1.5 Leon Goldman, MD, “father” of laser medicine and surgery. (Courtesy, American Society for Laser Medicine and Surgery.)
1967 (38) he had concluded that both long-pulsed ruby and “neodymium” (?Nd:YAG) laser were specifically absorbed more by colored tattoo pigments than by the surrounding normal skin and this distinguished laser surgery from techniques such as electrosurgery, which produced nonspecific coagulation necrosis. His first experiment with a Q-switched ruby laser in 1964 showed craters on normal and tattooed skin for focused beams as he had obtained with the normal mode ruby laser. With nonfocused impacts he noted a selective difference with no damage to normal skin but transient whitening of the tattooed area without significant damage to the skin but with only edema and spongiosis apparent (37). His contributions were the first to suggest the concept of selective targeting by lasers. 3.
RUBY
The ruby laser was first used on the eye by Zweng et al. (39) in 1962. It was the principal laser studied by Dr. Leon Goldman in his earliest work (40–48). Almost 15 years passed before others took up Goldman’s mantle and began in earnest to perform cutaneous laser surgery. Ohshiro’s extensive work with normal mode ruby laser and nevi and other dyschromias including port-wine stains (49) did not begin until 1975. Studies of Q-switched ruby lasers for treatment of tattoos took a full 20 years and FDA approval, still another decade. 4.
OTHER NEW LASERS
Javan developed the first gas laser, He–Ne, in 1961 (50). Johnson produced an infrared laser beam from a Nd-doped yttrium–aluminum–garnet rod (Nd:YAG) also in 1961 (51). By 1964 Goldman was using this laser for experiments on tattoos and normal skin (37,52). 4.1.
Argon Laser
Bennett et al. (53) invented the blue-green argon laser in 1962. It was first used on the eye by L’Esperance (54) in 1967. This laser became commercially available in 1971 (55) and
10
Brauner
was the first laser to be widely used for treatment of cutaneous disease once the initial excitement, and unfortunately concurrent disappointment, with the ruby laser had passed, which had proven to be uncontrollably too destructive for skin disease in its original industrial format. Reports by Apfelberg and coworkers (56 – 60) begining in 1976 about their experiences with the argon laser since 1972 were the stimulus and seminal event for the upsurge in interest by dermatologists and plastic surgeons, though Leon Goldman’s group (61 – 65) had earlier published data on its usefulness. The mid- to late-1970s, after now a second decade, were the formative years for cutaneous laser surgery. Numerous dermatologists and plastic surgeons began to use the argon laser (66) and a flood of laser-related papers began. Arndt and Noe and their coworkers in Boston (67) in a series of papers began the first formal introduction to the dermatologic readership of laser terminology and to the histologic, clinical, and spectrophotometric analysis of what argon lasers could perform on a variety of vascular lesions (68 –70). By the late 1970s and early 1980s these reports as well as thermal models to help understand the dynamics of laser –port-wine stain interaction were formulated in rapid succession. Concurrently, the carbon dioxide laser appeared in the cutaneous surgeon’s armentarium and the American Society for Laser Medicine and Surgery (ASLMS) was founded. What the argon laser allowed for the first time was a therapy for widespread telangiectasia that was sensible in that destruction proceeded from the vessel outward rather than from the surface of the skin inward as by electrodesiccation or electrofulguration, then the standard treatment. In practice, with early argon laser surgical techniques there was thin second-degree burn injury involving the papillary dermis and the entire epidermis. Still, since the maximal energy dissipation was in the vessel itself rather than on the surface of the skin it seemed more reliable particularly for more deeply situated and resistant spider angiomas and for treating networks of fine vessels extending over large areas of the cheeks as in extensive rosacea. For congenital port-wine stain this treatment was miraculous. Ten percent of patients could expect entire clearance of their vascular malformation and 75% of the remaining patients would have dramatic and long-lasting or permanent and significant lightening with only one treatment. With further treatments the stains continued to lighten further (71,72). Alternatives prior to laser included mutilating procedures such as cryosurgery in which nonspecific and unquantifiable damage led to improvement with scarring, or tattooing with skin-colored pigments which only lightened the areas slightly in an artificial-appearing manner, superficial radiation (Fig. 1.6) with progressively worsening radiation dermatitis and development of skin cancer, or excision with grafting (Fig. 1.7) which was often more of a technical than a cosmetic triumph. There were several historically relevant adverse sequelae that began with this instrument. The first was a seminal event whose importance took almost 20 years to gain recognition, the use of nonphysicians, in this instance, nurses, to perform argon laser surgery. In the “reproducible” or “sense” technique—which meant using a standard protocol of power setting, spot size, pulse duration, and prechilling (Gilchrest) or postchilling, and postoperative wound care appropriate for a second-degree burn injury, or one that could be repeated reliably from patient to patient and physician to physician and also could be quantifiably studied and reported in a series of patients treated with the same or precise but differing parameters—intense monotony was the rule. Imagine 5000 bursts of laser energy clicking off second by second for 1 h merely to cover a 2 by 3 in. square of port-wine stain! To some laser surgeons it seemed more appropriate to use one’s trained skills for “real surgery” whereas a trained assistant could hold a handpiece when given standard parameters and perform “laser surgery.” This time-saving assistance
Cutaneous Laser Surgery: Historical Perspectives
11
Figure 1.6 Port-wine stain, years after radiotherapy.
was used by Apfelberg (56 –60,73) but he also reported an acknowledged incidence of hypertrophic postoperative scarring of 16%, which was 3 –15 times higher than the experience of other laser surgeons (68,70,74 – 77). The question of nonphysicians performing laser surgery (vide infra) became a major issue by 1998 (78,79). Monotony of this technique and its slowness in covering large areas had many more aggressive laser surgeons using the nonreproducible or nonsense technique—passing the laser in a continuous beam rapidly by hand or “air-brushing” over the area to be treated.
Figure 1.7 Port-wine stain, after split thickness skin grafting.
12
Brauner
This could be a masterful and quick way of treating a port-wine stain without requiring multiple return visits but as a nonreproducible technique it was not universally reliable—not from patient to patient, not teachable and usable from physician to physician (certainly not from a printed article) and not even in the same patient in the same area since hand speed varied especially on turning corners. This was only surgical artistry at work. Avoiding excessive thermal damage and excessive flat or hypertrophic scarring required great skill. In addition, the lack of standard postoperative wound care consistent with the known care of burn injury in this technique made understanding literature and clinical abstracts a frustrating quest. Laser surgical interpretation was muddled by tremendously differing techniques and incomparability of results and style. The art of laser surgery flourished but the science lagged behind. A price was paid by patients for the lack of rigorous “reproducible” literature and the seeds of discord and controversy were laid down. Because of misinterpretation of the literature (70,74,76) only few laser surgeons (71,72,77,80) would treat children by argon laser; some would treat none under age 8, some arbitrarily none under age 12, assuming, in error, a 38% risk of scar, thus denying therapy to the age group in which the greatest emotional impact of having a port-wine stain was occurring (81 –85). A third adverse sequel of argon laser surgery reflected, in retrospect, poor judgment by the underreporting of scarring. The definition of only cosmetically unacceptable hypertrophic scar as “scar” was too limiting but was almost uniformly applied by cutaneous laser surgeons, who wished to focus instead on the dramatic overall beneficial results of argon laser surgery. 4.2.
CO2 Laser
The CO2 laser was invented by Patel (86 – 88) (Fig. 1.8) of Bell Labs in 1964, but the first surgical CO2 laser was developed by Polanyi et al. (89) in 1965 and was first exhibited in 1967. Jako (90) noted that the earliest laser work in otolaryngology was by Stahle and Hoegberg (91) in 1965, using a pulsed laser for inner ear irradiation, Conti and Bergomi (92) in 1966 for the posterior labyrinth, and Sataloff (93) in 1967 for otosclerotic stapes. About the same time in 1965 he first began studies with Polanyi on cadaveric vocal cords with the pulsed Nd:YAG laser hoping to find that the laser could be used to cut tissue, but it was able to produce only small lesions. By 1967 Jako and Polanyi
Figure 1.8 C.K.N. Patel, inventor of the CO2 laser. (Courtesy, Bell Labs/Lucent Technologies.)
Cutaneous Laser Surgery: Historical Perspectives
13
were examining the absorption of CO2 laser by human cadaveric vocal cords; they developed an endoscopic delivery system in 1968. Soon after, Strong, Jako, and Polanyi (94 –98) initiated laser laryngeal surgery. Jako (90) performed vocal cord nodule removal in a dog soon thereafter and first operated on a human in 1970. Jako described the “precision of the CO2 laser beam and good wound healing subsequent to its impacts” (94). Hall et al. (99) described incisional surgery by laser in 1971. For gynecologists serendipity (or better, foresight) initiated the specialty into laser surgery when Joseph Bellina (100 – 102), the father of the gynecologic laser, realized the potential of this instrument in treating neoplasia of the cervix when he observed CO2 laser surgery used to remove laryngeal lesions (103). Despite work by others such as Kaplan and coworkers (104 – 106), who in 1973 first used the CO2 laser on the cervix (104 – 106). Fischer claims that Bellina had great difficulty convincing other American surgeons to perform such surgery. The Gynecologic Laser Society was founded in 1979 and thereafter authors such as Dorsey and Diggs (107) and Baggish and coworkers (108,109) began to publish prolific studies on cervical, vaginal, and vulvar diseases. Cerullo and Burke (110) noted that experiments with laser on neural tissue began as early as 1964 but the laser was too destructive for the meticulous surgery required in neurosurgery; only when microsurgery also matured by the late 1970s did laser neurosurgery begin. Heppner and Ascher (111) initiated CO2 laser neurosurgery in 1976. The laser was ready and waiting but the rest of the technology for appropriate delivery was not. A similar hiatus between the development of lasers and their practical use in gastroenterology had occurred while the field waited for the development of appropriate fiberoptic technology for laser delivery—for such lasers as argon, Nd:YAG, and tunable dye (112 –116). Nd:YAG was first used for GI disease with fiberoptics in 1973 (112,113); Keifhaber et al. (113) reported its first use in GI bleeding in 1975. It was the early 1970s before cutaneous applications of CO2 laser began in studies by Goldman et al. (31,117,118) on skin cancer. Kaplan helped to develop the commercial Sharplan laser in 1972, which became a standard mass-produced surgical device. Among the early authors, Frishman et al. (119) and Kaplan and coworkers (105,106,120) also published on skin cancer, Kaplan et al. (121) on other plastic surgical applications, and, Stellar et al. on decubitus ulcers (122) and on excision of third-degree burns (123,124). Among dermatologists McBurney (125,126) pioneered its use in 1978, also after a hiatus of almost a decade, as a vaporizing instrument for the treatment of warts and tattoos. Adams and Price (127) decribed its use in treating basal cell carcinoma in 1979. Bailin’s group (128 –132) at the Cleveland Clinic authored numerous early anecdotal reports on tattoos and a variety of epidermal tumors and port-wine stains. Interestingly, Reid , a gynecologist, and Muller (133,134) were the first to use the CO2 laser on a large series of tattoo patients and the first to suggest that this laser had to be used in multiple stages with incomplete treatment in each stage since a .16% risk of hypertrophic scarring arose in their patients if the tattoo had been removed by laser in one visit. These observations were compatible with what was by then long known about removal of tattoos in multiple sessions by dermabrasion. Nevertheless, the authors exhibited an experience contrary to the innovative but conservative wisdom of Leon Goldman who advised repeatedly, and even framed a placard on his wall for emphasis, “If you don’t need the laser, you don’t use it” (31,135,136). Overzealous use of laser on cutaneous lesions here reflected the worst practice of experimenting with a new device merely because it was new and high-tech but without a total understanding of the nature of the destruction which would ensue (Fig. 1.9).
14
Brauner
Figure 1.9 Severe hypertrophic scars after CO2 laser surgery for port-wine stain by inexperienced laser surgeon.
A singular, but fortunately nonscarring, abuse of Goldman’s maxim took place in the early evolution of podiatric laser surgery where fees of thousands of dollars were charged for laser debridement of diseased nails (i.e., an expensive laser analog of a nail clipper), giving patients a sour taste about the ethics of laser surgeons. Another adverse side of this laser’s history is that it was the first cutaneous laser about which unreproducible results were first reported in the literature and heated controversy first began to appear at laser meetings, particularly with claims made for healing of keloids. Though initial reports were overwhelmingly enthusiastic (131,137), claiming almost universal and persistent clearing with laser alone subsequent authors found a significant recurrence rate even with adjunctive therapy (138 – 141). Also, the laser’s “basic advantages” were subject to hyperbole and were promoted as 1. 2. 3. 4. 5. 6. 7. 8.
Noncontact surgery Dry-field, almost bloodless surgery Highly sterile surgery Highly localized and precise microsurgery Clear field of view and easy access in confined areas Prompt healing with minimal postoperative swelling and scarring Apparent reduction in postoperative pain No electromagnetic interference with monitoring instrumentation (120)
The number of times the same Kodachrome of this table was shown by dozens of laser lecturers became countless and laser dogma with little or no basis in critical anecdotal or peer-reviewed science became well instilled early in cutaneous CO2 laser surgery. This instrument was wonderful in that it was noncontact surgery and could be
Cutaneous Laser Surgery: Historical Perspectives
15
used as a vaporizing or excisional tool in patients wearing electronic devices or on anticoagulants. However, it could not stop freely running blood from vessels greater than 0.5 mm in diameter. In fact, hemostasis was often better in wart surgery with topical application of hemostatic Monsel’s solution than by laser charring and overburning the base of the wart. On digits a tourniquet or digital compression could produce equal hemostasis without the need for the laser. The field was not necessarily sterile, particularly at low fluences when less that 500 W/cm2 was applied. With high fluences it was found useful to sterilize wound bases in decubitus ulcers, synergistic gangrene, burns, and osteomyelitis (120,142– 144). Healing was not prompt; in fact, it was slower than traditional cold steel surgery or dermabrasion (145,146). Furthermore, the subsequent re-epithelialized area of a vaporization site was often fragile for months, capable of producing spontaneous bullae and hypertrophic scarring if that new surface had broken down. Pain was not reduced since nerve endings were not neatly sealed (147). When employed appropriately (148) the CO2 laser can safely and effectively treat dozens of cutaneous conditions, often better than older techniques including vaporization of actinic cheilitis and actinic keratoses, adenoma sebaceum, angiokeratomas, appendageal tumors, Bowenoid papulosis, condyloma acuminata, digital mucous cysts, epidermal nevi, Hailey –Hailey disease, ingrown nails, lichen myxedematosus, lichen sclerosus, lymphangioma circumscriptum, neurofibromas, nodular amyloidosis, pyogenic granulomas, rhinophyma, rhytids, sebaceous hyperplasia, xanthelasma, as well as cosmetic applications of resurfacing. Excisional applications for blepharoplasty or for patients compromised by anticoagulation or electronic devices such as pacemakers are widely employed.
5. 5.1.
MULTIDISCIPLINARY SOCIETIES Laser Institute of America
In 1968, partly at the instigation of Arthur Shawlow, a group of laser researchers in California founded the Laser Institute of America. This first meeting was attended by 75 members and now has grown to 200 corporate and almost 2000 individual members. Based now in Orlando, Florida (www.LaserInstitute.org) this group focuses mostly on laser science and safety and credentialling standards. It also is the secretariat and publisher of the ANSI standards, the latest of which is Z136.3 last revised in 1996. It sponsors a variety of courses and both the annual International Congress on Applications of Lasers and Electro-Optics (ICALEO) and the biennial International Laser Safety Conference (ILSC). 5.2.
International Society for Laser Medicine and Surgery
In 1975 Israeli surgeon, Dr. Isaac Kaplan, and others founded the first major interdisciplinary medical-surgical laser society, the International Society for Laser Medicine and Surgery (ISLMS), and held the First International Symposium on Laser Surgery in Jerusalem in November 1975. 5.3.
American Society for Laser Medicine and Surgery
In March 1979 in the USA, Drs. Ellet Drake and Leon Goldman set about establishing a multidisciplinary group of physicians and scientists who might be interested in exchanging
16
Brauner
knowledge and exploring uses for lasers in medicine and surgery and invited 280 renowned scientists from around the world, of whom about half attended, to an organizational meeting in San Diego in January 1981, where the ASLMS was founded. This seed organization (Fig. 1.10) has blossomed into one with now over 3000 physicians, veterinarians, nurses, industrial innovators, and laser researchers, and is the largest of its type in the world. This group (www.aslms.org) has met annually since then, running several full-day single-subject symposia as well as providing the largest forum for presentation of original abstracts on laser medicine and surgery in the USA. It sponsors the journal Lasers in Surgery and Medicine, the sixth “most cited” surgical journal, and has established ethical standards for the use of lasers and also formulated general guidelines for hospitals to use in credentialling laser surgeons. The happy concurrence of publications of unique results of argon laser surgery, the availability of the CO2 laser, and now a society dedicated to promoting laser use and widespread education produced the first tidal wave of interest in lasers by cutaneous surgeons.
6.
LASER SAFETY—THE AMERICAN NATIONAL STANDARDS INSTITUTE
Although Leon Goldman had initiated studies on laser–tissue interaction in 1961 as a means of exploring laser hazards and safety precautions, it was not until 1975 that the FDA established a performance standard for laser products as a supplement to the Radiation Control for Health and Safety Act of 1969 (102). Four classes of risk (I through IV) were established. Safety features and labels required for each of these classes of lasers were outlined in the Federal Register (149) and are best summarized and explained in the manual from the American National Standards Institute (ANSI). Interestingly, hazards were concerned with the work environment and accidental human exposure—relative risks of accidental damage to the eye and skin defined the classification schema (150–153). Hazards and
Figure 1.10 American Society for Laser Medicine and Surgery group photograph of the second annual meeting, 1982. (L. Goldman, first row center; G. Brauner, third row, center.)
Cutaneous Laser Surgery: Historical Perspectives
17
controls cited by ANSI in document Z136.3 include engineering controls, administrative controls, procedural controls, and protective equipment (154,155). Strict protocols were formulated by hospital laser safety committees for patient and personnel safety. They reviewed electrical hazards, eye and skin burn hazards, protective eyewear of specific optical density and absorbance of the appropriate wavelength, protective clothing and absorbent wet drapings of flame-resistant materials, nonreflective instruments and anesthesia ventilation systems, and the ready presence of fire extinguishers (156,157). Communication patterns between the laser-operating technician and the surgeon for on– off and standby modes were formalized. Laser-specific in-servicing for nurses and technicians were made compulsory. Treatment of pathologic processes in a patient and hazards of incorrect or inappropriate use were not addressed and to this day have still not been written into law (vide infra).
7.
PERSONNEL AND PATIENT SAFETY—PLUME
Since lasers used in cutaneous surgery until the most recent thermally “cool” devices essentially generate much focal heat or mechanico-acoustic waves, either splatter debris or smoke are often generated. The presence of acrid smoke generated from boiling and charred skin by the CO2 laser and the need to remove such obvious pollution (158 –161) led to seminal discoveries of the nature of operative-generated smoke and splatter debris (162). Even though electrosurgical apparatuses used for decades produced visible smoke it had been tolerated without comment. This was clearly not so with the laser. Laser smoke or debris may contain tumor cells (163,164), blood, blood-borne pathogens such as papilloma virus or HIV (165 – 169), bacteria (170,171), particulates as small as 0.1 mm in diameter, and toxic gases including benzene, formaldehyde, and acrolein (154,158,160). For slower-moving particulates, such as those generated by CO2 laser, not only masks which filtered less than 0.3 – 0.1 mm (167,172,173) but also vacuum evacuators held within 1 cm of the target area became necessary (161). For faster-moving particulates such as those generated by the immensely energetic Q-switched lasers the value of suction and the speed required have not been ascertained since the velocity of ablated material is 10,000 m/s (174); physical obstructions and traps such as plastic cylinders attached to ruby or Nd:YAG handpieces or clear membranes applied directly to the skin surface and shot through have been used. Jako (164) notes that various pioneering researchers including himself who had first experimented with the Nd:YAG laser on tissue in the mid-1960s found that it exploded tissue and that scattered cells and tissue fragments were found in the operative area. Nevertheless, Fader and Ratner (173), citing several authors such as Gloster and Roenigk (175), who suggested that CO2 laser surgeons should have had a larger incidence of wart contamination, and Hughes (176) and Hughes who could not find human papilloma viral DNA in Er:YAG wart plume, de-emphasize the inherent risk of plume infection.
8.
PATIENT SAFETY—SCAR
The argon laser had not been developed specifically for the treatment of cutaneous disease but was used mostly for spectroscopy. Most manufacturers were supplying instruments with 1 or 2 mm spot sizes with 0.1 s being the shortest pulse duration (shutter speed). Even with the “minimal dose” technique of Cosman (71,72), wherein one selected the
18
Brauner
lowest power setting to produce a visible whitening of the skin after laser impact, one had to depend on this visual signal which reflected not vascular obliteration alone but that plus coagulation of the dermis and perhaps even the epidermis with a change in light reflectance, so-called “blanching.” Thus, an inside-out second-degree burn injury was produced. The necrotic collagen as well as the obliterated vessel had to be replaced by new collagen, which might end up as transparent as normal collagen or which frequently, even without excess elevation, became dense enough so that the area became opacified and lighter than normal skin color. For at least its first 12 years Leon Goldman’s laboratory deemed the desirable end point of treating PWS by long-pulsed ruby laser treatment (136) as an improvement by “producing collagen damage with superficial fibrosis [to] . . . change the optical quality of tissue.” In other words the end point was production of scar tissue but it was not ever called so except by Brauner (75) and Schliftman concerning argon laser, who also recognized the similarity of this “opacification” to the appearance of an opaque collagen skin test in transparent skin (Figs. 1.11 –1.13). Such opacification was later cited as an adverse effect by Geronemus (177) but was mistakenly thought to be hypopigmentation. It was not a reflection of total and permanent destruction of melanocytes by the argon laser since these areas did tan in sunlight and even hyperpigmented without sun but represented a true scar. As a typical example, in a large review as late as 1986, Apfelberg and McBurney (60) cited a 14% incidence of “scarring” in port-wine stains treated by argon laser with a variety of parameters and a 35% risk in strawberry hemangiomas. Nevertheless, photodocumentation of their results, even those reported as good results, clearly showed scars, but these were mischaracterized as not only “no change in sebaceous skin” but also exhibiting mild scarring in nasal telangiectases, “flattening and blanching . . . of strawberry mark” but with a densely opaque and hypertrophic lip scar, “lightening” but with a dense slightly hypertrophic scar on a treated tattoo, “without scarring” of a pyogenic granuloma which does have a small hypertrophic scar, “resolution of trichoepithelioma”
Figure 1.11
Flat opaque scars after argon laser surgery and appropriate dressing.
Cutaneous Laser Surgery: Historical Perspectives
Figure 1.12
19
Almost invisible opacification of an argon laser test area.
without mention of an opaque atrophic hairless patch on the lip. The results were so good in many authors’ experience as compared to their prior attempts at improvement that small amounts of scarring were similarly overlooked and certainly underreported by most laser surgeons who reserved the term “scarring” to mean real hypertrophic scarring. The reader of a paper or the audience of a lecture was led to believe that this instrument was not only wonderfully effective—which it was—but that it was also not as problematic as it really
Figure 1.13 Same area after stretching, exhibiting flat opacification and not true hypopigmentation.
20
Brauner
turned out to be. Time and time again, even with photographic documentation showing scarring, authors mentioned only improvement of the primary lesion and left it up to the reader to deduce that scarring was more prevalent than reported. A variety of methods were attempted to minimize hypertrophic scarring. Apfelberg tried to treat only small areas assuming that a larger second-degree burn injury would be more likely to hypertrophy. He spaced his treated areas with parallel untreated areas in a “banded” or “striped” pattern but eventually discarded the technique since scars continued to appear (73,178,179) (Fig. 1.14). Cosman tried to minimize the amount of thermal damage by using the lowest possible power setting to be effective. Unfortunately, the visible end point used in port-wine stains without magnification was not watching the vessel disappear or coagulate but watching the dermis and epidermis coagulate. With this minimal dose technique, Cosman used the lowest power setting to produce discrete whiteness of the epidermis after laser impact for each individual patient and used that dose uniquely for the patient with 0.2 s bursts. Many surgeons, including Cosman, used the dot-by-dot intermittent technique with slight or no overlap of the 1 or 2 mm bursts to produce uniform as well as reproducible injury. Scheibner and Wheeland (180,181) used the continuous wave tunable dye laser tuned to 577 nm with magnification by 8-power optical loupes to trace out vessels and observe them constrict and coagulate as the visual end point. Tracing was done in a continuous fashion but with the surgeon’s hand moving quickly. This meticulous and incredibly laborious method was thus more sparing of the epidermis and the dermis surrounding the vessels. Since the minimal achievable pulse duration was 50– 100 ms scanners were developed (182) which could move a beam so quickly over an area that the effective time of injury was 1 ms and much more focal to the vessel (183,184). Scanners were also developed for use in gynecologic surgery and by 1982 for the cutaneous CO2 laser with a microslad coupled to the Sharplan 733 laser (Fig. 1.15) and later a Sharplan 777 scanner; these scanners were not used primarily for vascular lesions but for more precise vaporization of large areas such as tattoos and for resurfacing of scarring from acne, varicella, or trauma and other contour defects such as rhytids. Robotized hexagonal scanners were introduced by Rottoleur et al. (185) in 1988 initially for use with the argon laser, but later they were used with continuous wave dye and copper vapor lasers (Fig. 1.16) which had appeared commercially. The release of pulsed dye lasers for vascular and pigmented lesions dimmed the aura and popularity of hexagonal scanners (186) but scanners appeared again in the mid-1990s as adjuncts for laser resurfacing with carbon dioxide and Er:YAG lasers.
Figure 1.14 Hypertrophic scarring after argon laser “stripe” technique and an undressed wound.
Cutaneous Laser Surgery: Historical Perspectives
21
Figure 1.15 Sharplan microslad scanner for CO2 laser cutaneous resurfacing and tattoo ablation. (Courtesy, Am J Cosmet Surg.)
Chilling heat-injured skin was long known to diminish the extent of overall burn injury so that postlaser cooling of the treated area became a common afterthought. Perhaps more importantly, if local anesthesia had not been used, it would have helped relieve the symptomatic burning pain. Preoperative chilling was attempted (187) to
Figure 1.16 Hexascan scanner, the first American application by Alan Schliftman, MD, of the most widely used scanner for continuous or quasi-continuous lasers (argon, continuous dye, copper vapor, copper bromide) for vascular and pigmented lesions. (Courtesy, Am J Cosmet Surg.)
22
Brauner
slow down and pool targeted erythrocytes in port-wine stains and not to diminish burn injury. Unfortunately, no pooling was statistically demonstrable and the main “benefit” was a lower incidence of atrophic scarring, scarring which could just as well have been caused by lack of closed dressings. Even intraoperative chilling (188 – 191) was attempted in the hope of preserving the epidermis so that there would be no open wound to become potentially infected and to preserve the upper papillary dermis. Since an inside-out thermal injury was produced by the laser, a lower set temperature point for the epidermis meant that the temperature rise from spread of heat from the injured vessel would still be below a necrosis threshold of 708C (9). Chess (190,191) has promulgated for years the importance of intraoperative chilling for a variety of lasers and invented the first practical “icing” device. Landthaler (189) had used an ice cube to chill the epidermis as he moved his deeply burning continuous Nd:YAG for hemangiomas. Leon Goldman (188) had toyed with a variety of unusual chilling implements in his laboratory. A deeper understanding of the thermokinetics of laser injury has led to resurgent interest in chilling in the late 1990s for maximal thermal injury to targets such as deeper or larger telangiectases (192) and venules, deeper or resistant port-wine stains (193 –202), and the hair follicle. A concurrent approach to greater selectivity of the laser for its target in the mid- to late-1980s centered on the greater relative absorption by oxyhemoglobin than melanin of yellow wavelengths (203). The argon-laser-pumped continuous tunable dye laser tuned to 577 nm (204), the quasi-continuous copper vapor laser (205 –210) at 578 nm, and the pulsed dye laser at 577 nm, had better absorption and deeper penetration so that theoretically deeper vessels could be targeted and more energy could be delivered to destroy vessels with less or no epidermal injury. The continuous dye and copper vapor were both found to be somewhat more effective than the blue-green argon but their clinical thermal effect was essentially unchanged from the argon experience (206) whether made freehand or by scanner. They were followed shortly in the cutaneous surgical marketplace by the quasi-continuous copper bromide laser (211,212) and the quasi-continuous krypton laser (7). Interestingly, the pulsed dye laser was shifted to 585 nm, which is less well absorbed than 577 nm, and now is also used at 595 nm (213).
9.
POSTOPERATIVE WOUND CARE
As noted before, interpretation of adverse events when continuous wave lasers were employed for cutaneous laser surgery and epidermal necrosis ensued became obscured by the fact that scarring was underreported or redefined and postoperative care was not standardized, not mentioned in the literature or in lectures, and sometimes not given. Second-degree thermal wounds all scar and it is likely that the absence of postoperative dressings over the necrotic wound in early argon laser surgery was responsible for much of the incidence of hypertrophic scars. With proper postoperative dressings and antibacterial ointment the incidence of such scarring dropped to less than 1% (75,77) from a range of 3 –16% or more (60,68,71,73,74,178,214,215) (Figs. 1.11 and 1.17). Brauner and Schliftman were early proponents of scrupulous postoperative wound care. Unfortunately, there was an accompanying and unexpected large incidence of contact dermatitis to bacitracin with large areas of coverage (216 –218). Though the need for scrupulous postoperative care is now well established for this type of laser induced wound, the most appropriate type of dressing has been controversial in the past half-decade as facial resurfacing became the leading example of cutaneous laser surgery (218 – 227).
Cutaneous Laser Surgery: Historical Perspectives
Figure 1.17
10.
23
Hypertrophic scars after argon laser surgery and an undressed wound.
SELECTIVE PHOTOTHERMOLYSIS
Leon Goldman was seminal in beginning and motivating the use of medical and surgical lasers but the direction of laser use was related to the industrial lasers provided to us. Micromanipulators, fiberoptics, scanners, and microscopic couplers were all cleverly invented accessories for the main item but the main item was never designed from the ground up for altering specific pathogenic targets, that is, not until 1983. The second most remarkable seminal event for laser surgery was the optical construct, which allowed us to understand the nature of the amount of thermal or acoustic alteration that was minimally necessary to produce our biologic result. Not only could we select a target and an appropriate laser using the target’s relative absorption characteristics but we could also construct a laser putting out a burst of light corresponding in its duration to the thermal relaxation time of the target. This combination of selection by absorption and by size became the theory of selective photothermolysis as elaborated by Anderson and Parrish (4,5) (Fig. 1.18). It was the first of many modeling constructs around which medical lasers would be manufactured. The courtship of laser industry and laser surgeons, which had begun after the institution of ASLMS, was now ready for the full-fledged partnership of marriage. Now laser surgeons could request industry machines capable of specific tasks. The pulsed dye laser for vascular lesions was the first of these many instruments (228 –235). Though shifted from its original experimental format of 577 nm (236,237), 360 ms pulses, and 5 mm spot size to 585 nm (235,238 – 244) and 450 ms and now up to 600 nm and 20 ms pulses with 5, 7, and 10 mm spot sizes, it allowed for rapid treatment of large areas—perhaps 100 times faster than the argon laser had been. Pain was usually not severe enough to require anesthesia except in children. There was almost no thermal damage to the epidermis except mild crusting by days 3– 4 postoperative and thus no second-degree burn injury and essentially no risk of either hypertrophic or flat opaque scar. In the mid- to late 1980s it very quickly became the vascular laser of choice despite the simultaneous appearance of other quasicontinuous yellow lasers (205 – 207,245 –248). Because of its greater safety and specificity it was widely offered to children who for the most part (74,76,77,80,241,249,250) had been denied continuous or quasi-continuous laser treatments. The dramatic impact of a laser able to treat deformed children without scarring and with a “100% cure rate” (240) was earth-shaking.
24
Brauner
Figure 1.18 R. Rox Anderson, MD, conceptualizer of “selective photothermolysis.” (Courtesy, Wellman Laboratories of Photomedicine.)
What actually happened was unfortunate as this drama had an adverse side as well. Tan et al.’s enthusiastic report in the widely publicized New England Journal of Medicine had the public convinced that the laser was painless and 100% effective, thus putting all cutaneous laser surgeons on the spot trying to re-explain that neither scenario was true. This laser has been documented to clear PWS in only 40% of patient populations (251) with repeated treatments, though the remainder of patients are very significantly improved. As initially with the carbon dioxide laser, hyperbole was fashioning unrealistic public demand. The second adverse sequel was that this industry –surgeon marriage meant that there was an increasingly important role that the medical – industrial complex would play, not just in the delivery of care, but also in its cost since the new lasers represented hundreds of thousands of dollars in investment to be paid off by the laser surgeon. There was, as well, the possible perversion of scientific methodology and reporting by not-so-subtle conflicts of interest such as special deals in pricing of lasers, free or loaned lasers, research grants, surgeons acting as spokespersons in advertising routines for companies; these same laser surgeons would then be called upon to present or publish new data in what the audience was supposed to think represented no conflict of interest. For the first time it would not be egos or ideas under attack by skeptical laser audiences but the very ethics and truthfulness of the presenters. This was a nasty and unexpected challenge to honest scientific methodology; vocal controversy and insult became an unfortunate coparticipant at laser meetings as evidenced by chairmen’s forewarning to their panelists at the 1998 ASLMS about personal (ad hominem) attacks.
11.
WELLMAN LAB AND BECKMAN LAB
Although Rox Anderson first immersed himself in lasers as an undergraduate student in 1976, in the Wellman Labs of Photomedicine (www.wellman.mgh.harvard.edu), of
Cutaneous Laser Surgery: Historical Perspectives
25
which he is now the research director, had opened at Massachusetts General Hospital (MGH) in Boston in 1974 as a multidisciplinary research laboratory devoted to basic and applied research in human photobiology. It is now the world’s largest biomedical laser research facility as well. In 1988 a laser applications research laboratory to develop specific medical laser applications was formalized. In 1992 the MGH laser center, a hospital-wide multispecialty center to deliver care by laser therapy to a variety of patients, was established in coordination with the Wellman Labs. In 1982 the Beckman Lab (www.bli.uci.edu) was founded by Drs. Michael Berns and Hugh Beckman, both bioengineering scientists. This institute is now part of the University of California, Irvine, and houses multidisciplinary basic research groups, as well as having a clinical laser surgical center for patient care. It, along with the Wellman Lab, are unique facilities in the USA for fundamental laser research. The rest of laser progress has essentially been the fruit of individual practicing laser surgeons or research grantees in concert with clever industrial invention.
12.
Nd:YAG LASER
The Nd:YAG laser was first used by Goldman in studies on tattoos shortly after its invention in 1961. Though used primarily in endoscopic gastrointestinal laser surgery, particularly for bleeding, since it had such deeply penetrating nonselective thermal necrosis of almost 4 mm when used in normal mode, Landthaler et al. (189) in Germany in the mid-1980s first advanced its use for therapy of large vascular cutaneous tumors. These cavernous hemangiomas (252–258) or large blebs of port-wine stains (52,215) were too thick to be affected by the available argon laser or even the pulsed dye laser when it appeared. Intraoperative chilling by moving an ice cube quickly over the skin just prior to single or a group of widely spaced bursts was necessary to attempt to preserve epidermal integrity. David and coworkers (253) noted that the scarred resultant area might then be excised in a secondary procedure with minimal bleeding for an even better cosmetic result. Apfelberg et al. (254,256,257) and Waner and coworkers (259,260) promoted the use of the Nd:YAG laser in the USA with both noncontact and contact surgery with a sapphire tip, (261,262). The laser heated the tip, which then acted as a hot hemostatic scalpel (254). With Q-switching (vide infra) this laser became widely employed worldwide for treatment of tattoos and pigmented lesions in the 1990s. Adaptation of the normal mode Nd:YAG laser by doubling its frequency and thus halving its wavelength to 532 nm makes it particularly applicable for the treatment of vascular lesions with a similar therapeutic profile compared to other continuous wave lasers such as argon (263). Only recently, in the late 1990s, when combined with a chill-tip, has its use been expanded again for the treatment of vascular lesions but now without epidermal thermal damage and mostly without purpura (vide infra). 12.1. Q-switching In 1967 Leon Goldman (38) published his 3-year experience with the long-pulsed 1.8 ms ruby laser and the neodymium laser to treat tattoos, producing nonspecific histologic necrosis and subsequent fibrosis with decreased pigment. In 1964 Goldman had already first compared the normal mode and the “new” Q-switched ruby laser (37) on tattoos. By increasing the power density, he was able to show permanent tattoo pigment removal with the Q-switched ruby laser by 1967 (38). In 1967, a full 15 years before Reid, Laub and coworkers (264) showed that Q-switched ruby laser with 10 ns pulses
26
Brauner
and 5.4 mm spot sizes with 2 – 4 J output could destroy tattoo pigment without epidermal damage (265). Kitzmiller (136) in 1974, reviewing Goldman’s Cincinnati experience, also claimed that Q-switched ruby laser in nanosecond bursts had been found to be more effective than normal mode ruby laser in tattoo removal. In 1983, Reid et al. (266,267) described the first series of patients treated successfully with Q-switched ruby laser without scarring. Another historical laser hiatus occurred, this time almost a decade before American publications on tattoo removal (268,269) and Polla et al. (270) and Dover et al. (271) on melanocyte destruction followed by FDA approval in 1989 (3), which allowed American use of commercial Q-switched ruby lasers for hyperpigmentation and tattoos, 25 years after Leon Goldman first used it. Q-switching is compatible with the principle of selective photothermolysis since the thermal relaxation time of targeted melanosomes or tattoo pigment granules are within the nanosecond range emitted by a Q-switched device. Soon after the appearance of the “new” Q-switched ruby laser, the Q-switched Nd:YAG laser emitting at both 1064 and 532 nm (272 – 274) and the Q-switched alexandrite (275 – 277) lasers were marketed in the early 1990s for treating similar conditions (Fig. 1.19). A non-Q-switched but nanosecond pulse flashlamp-excited dye laser (PLDL) for hyperpigmentation also appeared; its wavelength of 510 nm was close to the most effective wavelength for melanosome destruction (514 nm) (278,279).
13.
PIGMENT LASERS
The high prevalence of unsightly pigmented lesions such as solar lentigines, flat seborrheic keratoses, cafe´ au lait macules, and even nevi offered a large spectrum of potentially treatable lesions and spurred the boom in the use of pigment-targeting lasers. Q-switching was not essential for melanocyte destruction but allowed for more intense focal melanosome injury and lesser risk of scarring, but continuous wave green argon, KTP, krypton, and copper vapor lasers had been widely used in the 1970s through the early 2000s for benign pigmented lesions with acceptable results (280 – 283). Hyperbole reigned here too. Initial reports of very high success rates (284,285) for cafe´ au lait macules were tempered by frequent recurrences reported by subsequent investigators (276,279,286 – 288). Even the use of progressively deeper penetrating red alexandrite or ruby lasers seemed no more permanently effective than the more shallow-penetrating green lasers.
Figure 1.19 First observation of dermal holes immediately after tattoo pigment explosion in minipigs produced by alexandrite laser by Gary Brauner, MD, and Alan Schliftman, MD.
Cutaneous Laser Surgery: Historical Perspectives
27
“Nonsense” science also played a role when these lasers were used to treat lentigo maligna. Arndt’s initial anecdotal case report of success with the shallowly penetrating argon laser for lentigo maligna had to be retracted 2 years later by the recurrence of the melanoma since it was too deep to be entirely eradicated (289,290). Such nonsense application of laser was potentially life-threatening since obliteration of only the superficial component of a lentigo maligna allows deeper melanoma to metastasize (J. Spencer, personal communication). Treatment of tattoos and nevus of Ota (291) temporarily but inadequately moved the focus of laser – tissue interaction from merely the physics of light absorption by skin and adnexae to the equally pertinent subsequent biologic behavior of the injured tissue. These two conditions continued to improve and recede long after therapy—the rush to treat them as quickly as possible and maintain patient satisfaction undermined proper side-by-side studies to ascertain biologically appropriate treatment intervals. Unfortunate counterpoints in the 1990s were the unsettling discoveries of unanticipated very delayed (months) opacification of CO2-resurfaced areas or even of pulsed dye or continuous dye laser-treated poikiloderma of Civatte (292) as well as the fortuitous discovery of beneficial tightening of rhytids seen after CO2 resurfacing. Treatment of nevocellular nevi by lasers has reached no consensus or historical conclusion. Some of Leon Goldman’s first attempts with laser were centered on the treatment of melanoma (41,47). Much of Ohshiro’s early work in Japan in the late 1970s involved destruction of nevi by long-pulsed ruby lasers (49). Brauner and Schliftman (286) first raised the question of the “angry melanocyte” in discussing idiosyncratic hyperpigmentation of a cafe´ au lait patch as a result of the first use of the pulsed 510 nm PLDL laser for treating hyperpigmentation. Postinflammatory hyperpigmentation (293) was by then long known to occur after CO2 , argon, copper vapor, and now after Q-switched Nd:YAG (288), 1320 Nd:YAG (294), Q-switched ruby, and long-pulsed ruby hair removal lasers. Brauner’s was the first clinical recapitulation of Dover et al.’s (271) first experiments with pigmented guinea pig skin showing that guinea pigs treated at less than a “threshold” of 0.3 J/cm2 developed hyperpigmentation and Hruza et al.’s (295) 1991 electronmicroscopic studies of normal human skin showing subthreshold stimulation of melanogenesis, which was precisely the opposite of what was intended. Attempts to debulk congenital nevocellular nevi, which can be very unsightly, may be of a size or location where a mutilating scar might be left after excision, and among which the giant ones are considered potentially premalignant seemed reasonable. Multiple treatments with well-absorbed Q-switched alexandrite or ruby lasers are required for debulking and a significant though nonpigmented residue of dermal melanocytes may still be histologically present (296 –298). If these melanocytes retain latent subthreshold stimulation precisely what risks are latent?
14.
SERENDIPITY
In the early 1990s within a decade of the marriage of surgeon and industry serendipity reminded us that not all laser developments are predetermined rationally. In 1993, Alster reported that, when treating hypertrophic, persistently red scars for the erythema with a pulsed dye laser, she obtained not just improvement of the erythema but a distinct textural improvement, so much so that the scars flattened, occasionally dramatically, after several sessions (299). At first argon laser induced scars, then hypertrophic scars of other cause, facial acne scars, and even keloidal sternotomy scars responded. When Alster considered atrophic scars she found a similar result. The scar texture improved to the eye.
28
Brauner
The scar became less depressed and the surface was demonstrably changed on skin surface topographic textural analysis by optical profilometry, erythema reflectance spectrometry, scar height measurements, and pliability scores (300 – 306). The pulsed dye laser rapidly became an instrument widely used for scar treatment or as adjunctive therapy. McDaniel reported in 1995 and 1996 (307,308) his results with striae distensae, which are in some ways histologic equivalents of atrophic scars. Use of the pulsed dye laser with a 10 mm spot size and a low energy fluence of 3 J/cm2 showed clinical improvement and measurable improvement of skin texture by optical profilometry. These results are reproducible in some capable hands (306) but not in others (309,310). Since striae are not made to disappear but only contract slightly, hyperbole by the lay press played a prominent and unnecessary role.
15.
RESURFACING
Focal laser ablation of acne scars was one of the earliest procedures performed by cutaneous laser surgeons in the early 1980s. Although the freehand airbrush technique could be performed on tattoos and still leave a cosmetically acceptable scar on the trunk and extremities, the artistry required made laser resurfacing of large areas of acne scarring or rhytids on the face potentially more hazardous than dermabrasion. It was especially worrisome because the latter healed within a 2-week time frame while laser wound healing was prolonged often beyond the 2-week window of healing after which unsightly scars could develop. Though scanners had been coupled earlier to the CO2 laser for gynecologic cervical ablation, only in 1982 did Brauner and Schliftman first introduce to the USA the Sharplan microslad scanner (182) which allowed precise controllable movement of the beam in an X –Y grid pattern with uniform though Gaussian ablation. Such uniformity not only led to better results in tattoo removal but also allowed for more controlled ablation for resurfacing the face for acne scarring. Although this was the first mechanically assisted laser resurfacing, it did not gain widespread popularity for rhytid removal because the healing time still was slower than that for dermabrasion, presumably because of residual thermal damage. Focal laser resurfacing was done for treatment of rhinophyma since 1980 (132,311) and for actinic cheilitis for much of the 1980s (312 – 314). In 1989 David et al. (315) presented the first report of 4 years’ experience on “laser resurfacing” for facial wrinkles by a CO2 laser with clinical and histologic improvement. Their technique really represented a 50% trichloroacetic acid peel supplemented by focal epidermal and upper dermal coagulation without visible vaporization of the deeper rhytids by the defocused 0.1 s gated hand-held laser. Healing took 5– 14 days. Studies on superpulse CO2 laser had been done in the late 1980s (316,317), but in 1993 Fitzpatrick (318) presented studies showing that the principles of selective photothermolysis could be applied to the CO2 laser, that a re-engineered “ultrapulse” laser delivering up to 500 mJ in a single pulse with a pulse duration of less than 1 ms, which is the calculated thermal relaxation time of skin, would produce the most precise vaporization and leave the smallest possible thermal damage of 50 – 100 mm. With such a small residue, more rapid tissue healing could be expected and the collagen to be laid down would more likely be thinner and less likely opaque. Whereas more traditional CO2 laser resurfacing could take 2 or even 3 weeks to re-epithelialize and even David et al.’s combined trichloroacetic acid (TCA) –laser process took up to 2 weeks to heal this, new laser allowed for healing after two or three passes in about 10 days. Traditional dogma of wound healing had indicated that a wound taking longer than 2 weeks to heal
Cutaneous Laser Surgery: Historical Perspectives
29
was much more likely to result in a visible or even unsightly scar. Since Fitzpatrick’s technique was used alone to treat entire faces, it was the seminal event in laser resurfacing (319,320). The appearance commercially of both the scanner-driven SilkTouch laser by Sharplan (with much more precise ablation than its older-generation scanning microslad device) and the Coherent UltraPulse laser which provided individual ultrashort pulses and the clinical and histologic reports of Kauvar and coworkers (321 – 324), David et al. (325), Dover and Hruza (326,327), Cotton et al. (328), Ross et al. (329,330), Chernoff et al. (331,332), Lowe et al. (333), and Lask et al. (334) led to an unprecedented avalanche of cosmetic surgeons beginning to perform laser surgery mostly for actinic damage and rhytids but also for acne scarring (335). Although chemical peeling and dermabrasion were long-established and safe techniques for the treatment of wrinkles, the ability to easily remove wrinkles to a precise and uniform depth (unlike peels), to remove the need for artistry (unlike dermabrasion and peels), to remove the risk of exposure to sprayed blood (unlike dermabrasion) and the high-tech appeal of the laser instrumentation compounded interest in the laser (227). Serendipity gave a coup-de-grace to the older techniques when it was soon noted that improvement in laser-treated wrinkling continued as the healed areas tightened and contracted over a period of months (319). Competing claims of efficacy of scanned vs. Ultrapulse lasers in numerous anecdotal reports were based on experience with one or other laser. Comparative studies of side-by-side treatments, not just randomized or anecdotal surveys, were needed and were much delayed by the costs involved in having more than one equivalent laser. These competing claims were laid to rest by studies such as those by Burns (336) on half-faces and by Alster et al. (337) with four randomized CO2 lasers for quarter-face resurfacing. The perception by industry of the huge potential market spurred on marketing and advertising unprecedented with other lasers. The whole direction of cutaneous laser surgery shifted dramatically from a medical –scientific discipline to a medical – industrial commercial one (338). Courses were now driven not by medical interest in academic settings but by almost weekly promotional courses directly by laser companies using guest laser lecturers. Roving laser rental companies first appeared with a “have laser (and technician), will travel” motto. In-hospital laser peer credentialling became a practical though not a moral irrelevancy. The early 1990s saw a new federal administration with health care as its priority and fostering HMOs as its club to beat down costs. In 1992 Medicare law drastically cut physician reimbursements. With the appearance of safe cosmetic laser surgery as an alternative for diminished income, not only traditional cutaneous surgeons (dermatologists, otolaryngologists, and plastic surgeons) but even family practitioners, dentists, oral surgeons, and gynecologists began to perform cosmetic cutaneous laser surgery. A sudden influx of large numbers of cosmetic surgeons into ASLMS changed its balanced multidisciplinary format to a predominantly cutaneous surgical forum. Preceding the explosion of interest in laser resurfacing in the USA, Kaufmann and coworkers (339 – 343) in Ulm, Germany, had been studying since 1988 (almost a full decade earlier) the erbium:YAG laser, which held the potential for much more precise cutaneous ablation since its absorption by water was an order of magnitude greater than that of CO2 . It had been first researched in the USA in the mid-1980s for ophthalmologic use (344,345). Walsh and coworkers (346,347) published the first American cutaneous studies showing the markedly diminished zone of residual thermal dermal damage after erbium:YAG pulses. Kaufmann’s initial studies were not followed by American cutaneous laser surgeons until 1997 when Teikemeier (also German) and Goldberg published the first preliminary study on 20 patients (348). Immediately, the laser pendulum began to swing away from the CO2 laser (which had been so heavily touted as safer and more efficacious
30
Brauner
than all prior resurfacing modalities) to the erbium; the CO2 laser was suddenly no longer viewed as such a “safe” instrument. The precision of the Er:YAG laser and the much smaller demonstrable degree of thermal damage left behind was hyped by industry and speaker alike. The simultaneous discovery that delayed opacification, misconstrued as hypopigmentation (349,350), could occur with some frequency in CO2-resurfaced patients helped accelerate the swing. The faster healing and decreased postoperative erythema of the Er:YAG laser was considered powerful evidence of its effectiveness and safety but at the same time laser surgeons also reported that results did not seem as good with this laser (351 – 354). Qualified statements about its use for shallow rhytids rather than significant ones now had to be employed to explain the poorer results. The lack of controlled side-by-side studies permitted the hyperbole to sweep away much interest in the CO2 laser and dozens of manufacturers got on the Er:YAG bandwagon. Hyperbole was again marching at a much faster pace than true science. Authors such as Alster and Adrian with systematic side-by-side studies brought order to the scene. Alster (355) reviewed laser resurfacing by six randomized Er:YAG lasers in her patients. Adrian (351,352) in his seminal histologic studies had earlier admonished other laser surgeons using the CO2 laser for resurfacing that they had misunderstood the nature of vaporization and thermal damage, that with the parameters of UtraPulse 500 microsecond pulses, unlike older traditional CO2 laser vaporization, dermal ablation was limited to the upper reticular dermis and further applications of the CO2 laser only produced more thermal damage and increased the risk of scarring. With the waters muddied by conflicting claims of Er:YAG’s efficacy vs. CO2 , it was again Adrian who showed with his careful histologic studies that equally deep destruction by Er:YAG and CO2 lasers would produce equal clinical results with equal healing times and equal erythema. He clearly unmasked the errors of the initial excitement as due to the laser surgeon’s not truly understanding the nature of the the two types of injury and basically not performing equivalent surgery with each laser. Commercial adaptations, including variable pulse durations, of the Er:YAG laser, to more closely resemble the CO2, have evolved over the past 4 years (356 –358). Combination therapies (359) relying on the virtues of each of these lasers were employed, producing faster ablation and leaving less residue by using CO2 first then erbium or more precise ablation but better hemostasis by using erbium first then CO2 (360) or even using both lasers through the same handpiece in the same laser device (361,362). Even the variable-pulse Er:YAG followed by shortpulse Er:YAG has been tried and seems to work even better than CO2 followed by short Er:YAG (360).
16.
LASER-ASSISTED HAIR TRANSPLANTATION
Concurrent with resurfacing technology was the suggestion that a narrow band of thermally damaged tissue should be hemostatic and might allow for rapid and bloodless hair transplantation by insertion of thin slits of hair-bearing skin or individual follicular units into slits or holes made by one of these lasers. Although with the CO2 laser a bloodless wound can be produced by either an UltraPulse laser or laser with rapid scanning, the amount of oxygen diffusion through this area and the rapidity of establishment of a vascular supply to the hair matrix was questionable and so, yet another controversy (363 –366) began in the mid-1990s. Walter Unger (367 –370), a prominent hair transplant surgeon, first reported his experience in 1994 with the UltraPulse laser. He thought that laser-recipient sites had good hair growth but that it was delayed compared to control cold steel grafts. Fitzpatrick
Cutaneous Laser Surgery: Historical Perspectives
31
(371) found that the laser-assisted procedure was 50% faster than control cold steel grafting but healing was slower and graft take was not as good. Ho et al. (372) claimed that slit placement with the UltraPulse laser was 50% faster than cold steel and thought growth in lased slits was good. Grevelink and coworkers (373,374) first reported on the use of a CO2 laser with the Sharplan SilkTouch scanner to develop recipient sites. Smithdeal (375) in 1997 employed the Sharplan scanner with good results and Tsai et al. (376) using a similar scanner said that his patients thought the laser-prepared sites looked more natural and had better density than cold steel sites. Neidel et al. (377) recently reported a single case of Er:YAG laser-assisted transplantation with a good results. A small number of physicians are still promoting laser methodology (366,368,370,372, 376,378) but cold-steel surgery is still the predominant method of graft recipient design (365).
17.
PULSED LIGHT SOURCES
Though not true lasers, intense broad-band pulsed light sources with a wavelength range of 590 – 1200 nm have recently found widespread use as epilating devices (379 – 383). The first generation of these machines with 550 –1200 nm bandwidth have been used for the treatment of vascular lesions since M. Goldman’s work (384 –387) in 1994. Since these devices were also approved by the FDA in a different category from lasers, they have been a focus of controversy, especially when marketed and administered by lay personnel (78). Bitter’s (388) seminal article on “Fotofacials” by intense pulsed light treatments launched the huge demand for nonablative techniques for cosmetic facial improvement by lasers or light sources. He claimed “wrinkling, skin coarseness, irregular pigmentation, pore size and telangiectases showed visible improvement in more than 90% of subjects.” His optimistic observations were matched by some (389,390) but met with skepticism from many others. While most laser surgeons now agree that dyschromias are readily improved by this technique it is not clear that significant clinical improvement in wrinkling is effected (391) despite evidence of new papillary dermal collagen formation histologically (392).
18.
LASER HAIR REMOVAL
When Q-switched ruby lasers were employed in large numbers in cutaneous laser surgery another serendipitous enlightenment occurred. The immensely powerful though short bursts of energy generated to fragment tattoo particles were noted not only to vaporize darkly pigmented hairs but also to bleach them below their follicular exit and even to inhibit their reappearance. Studies by Dover et al. (271) in 1989 had shown selective pigment cell damage in follicles from this laser, which caused the leukotrichia. It seemed that laser energy had reached a portion of the pigmented hair bulb and disrupted it enough so that it might act also as a depilatory, or better still, a nonscarring permanent or epilatory instrument. The financial appeal of entering the 6 billion dollar-a-year industry of cosmetic hair removal was too enticing for laser manufacturers to avoid. Truly medical applications such as treating disfiguring hirsutism in women or pseudofolliculitis barbae in men (and rarely women) were an additional potential benefit. Thermally nonselective but effective destruction of hair follicles in hair-bearing grafts, or for trichiasis, had been reported as early as the 1970s (393 – 396) but hair
32
Brauner
removal by thermal damage confined to the hair follicle governed by the principle of selective photothermolysis had not been attempted. The first FDA-approved laser for hair removal did not depend on the pigmented hair as a target but instead a patented mineral oil lotion was used containing carbon-based material, which was presumed to seep into the follicles after waxing immediately prior to massaging of the lotion and thus provide a target for the laser. Presumably, the mechanico-acoustic wave appearing after the laser impact would then disrupt the base of the follicle so that the loosened hair would fall out and the damaged follicle would no longer produce hair. In 1995 Goldberg and coworkers (397,398) presented the first studies showing very short-term efficacy. Hyperbole from the mass media was unfortunately not countered immediately; neither the short 12 week duration of the study nor the low 25% hair loss at that time was widely publicized. The hairs grew back, in fact most of them by 3 months, although more slowly in lased sites, and all of them grew back (399) by 6 months. Nanni and Alster (399) also demonstrated that the scientific principle behind this laser was flawed in that the carbon suspension was not required for hair removal since, at 1 month, waxing plus laser alone was equivalent to carbon-assisted laser removal. Nevertheless, these flawed data became a public mantra that laser removes hair. The public was led to believe by the mass media that this was permanent hair removal done quickly, painlessly, and without potential for scarring, all unlike traditional electrolysis. The public again had unrealistic expectations driven by laser hyperbole and many patients became dissatisfied with this very expensive and temporary procedure. When educated properly about the relative long-lasting effects and the apparent diminution of caliber of hair, most of the treated public was content. Also in 1995, Grossman et al. (400) reported their preliminary results with normal mode ruby laser in black-haired dog skin and found that this laser with a pulse duration of 0.297 ms, shorter than the estimated thermal relaxation time for a 200– 300 mm hair follicle of 40 –100 ms (401), could produce selective thermal damage to the hair follicle. They soon followed this abstract with a published report on 13 patients treated only once with normal mode ruby laser (402), noting that four of them had less than 50% regrowth after 6 months. They also claimed that “selective thermal injury to follicles was observed.” Unfortunately, only horizontal sections of the upper follicle were shown. It was years before any investigator presented vertical sections exhibiting the nature of damage to the hair bulb and still no one has shown the numbers of scarred or atretic follicles on vertical section. Controversy again reigned because of the claims of “permanent” hair loss by these and other authors and the lack of both clinical and histologic proof (403). In mouse studies the Wellman Lab showed in 1998 that only anagen hairs were affected by ruby laser. This suggests that at least for mice the pigmented bulb and not the stemcell-containing bulge was the ruby laser’s target (404). Only one of Grossman et al.’s original 13 patients had lost all hair at 2 years’ follow-up and the four with diminished hair had no decrease in actual hair counts; histology showed hair follicles but with evidence of some miniaturization with vellus hairs replacing terminal hairs (405). Subsequent studies demonstrated long-term hair reduction with several long-pulse lasers, though patients required a series of treatments. The long-pulsed ruby, alexandrite, diode (810 nm), and Nd:YAG (1064 nm) are widely used for long-term hair reduction (406). In 1999 the word “permanent” was redefined in an Orwellian fashion by the FDA to no longer mean “forever” but, for the hair follicle, to mean absence of a visible hair for a period longer than one estimated anagen–telogen growth cycle for a particular body region. Such language manipulation served as a marketing ploy that only confused the public more. One positive redirection concurrent with attempts to make hair removal safer was a renewed interest in thermokinetics and protection of tissues not by selectivity of
Cutaneous Laser Surgery: Historical Perspectives
33
absorption and nonabsorption but protection even in the face of absorption by both the target and the nontarget. Because the thermal relaxation time of the pigmented epidermis is estimated at 3 – 10 ms, the epidermis is also a target for the ruby laser and with high fluences of 20 J/cm2 or more required for hair removal, significant destruction of the epidermis would occur if simultaneous cooling devices were not used. If two tissues shared too many common absorbents but were either physically different in size or were separated by some distance in the skin one could select pulse durations intermediate between each tissue’s estimated thermal relaxation time. One could preferentially heat smaller targets faster and larger targets slower to spare inversely their corresponding larger or smaller coabsorbers. One type of thermokinetically set alexandrite hair removal laser was manufactured which lengthened its pulse duration in order to deliver its energy over a longer period to the hair bulb and follicle and over too long a period to appreciably affect epidermal melanin in light-complexioned patients. Unfortunately, this theoretical enhancement did not provide a marked clinical difference (407). Such selectivity of longer pulse durations for larger targets to also protect smaller targets has more recently been employed for long-pulsed diode hair removal lasers for very darkly pigmented patients (408).
19.
CHILLING AND WRINKLES
Laser technologies seem to have a knack for recapitulating. Just as the ruby laser reappeared in the late 1980s after a 20-year hiatus, so renewed interest in green lasers for vascular lesions and a renewed understanding of the importance of chilling reappeared in the mid- to late 1990s, particularly by Wellman Lab (199,200) and Beckman Lab. Part of the interest in chilling was fostered by the large amounts of energy required to destroy or alter hair follicles and the need to protect the epidermis even better than theoretical thermokinetics alone. In 1994 Nelson’s group (193) at the Beckman Institute began a series of theoretical (194) and clinical (193,195 – 198,409) studies and first described the use of a spray cooling device using 20 – 80 ms bursts of a cryogen to cool and protect the epidermis during port-wine stain therapy. They saw no blistering appear after even 20 –36 J/cm2 with cooling spray but both blistering and necrosis without it. With this apparatus they could not only diminish intraoperative pain (197) and diminish epidermal injury with the 585 nm pulsed dye laser and with the 532 nm solid state laser (202) but, with the continuous Nd:YAG laser applied for thick vascular lesions in a cockscomb model (410), they could produce deep thermal effects to 6 mm without epidermal injury. Such dynamic cooling was adapted also for long-pulsed alexandrite hair removal systems. In the late 1990s, doubled-frequency 532 nm Nd:YAG laser with intermediate pulse widths of 2 – 10 ms and coupled with a sapphire water-cooled chill tip was introduced for treatment of vascular lesions without purpura. The chill tip was able to protect the epidermal integrity by keeping epidermal temperature at 5 – 5.58C and fluences of 9.5 –15 J were employed (190). Chill tips were consolidated with various long-pulsed ruby and diode lasers for hair removal also. Chilling by spray can be used just prior to, during, or even after the laser burst as a type of “thermal quenching.” Despite the dramatic and novel benefit of laser resurfacing, public demand has been driven by market forces as fast as development of the Web. Yesterday’s technology even for laser surgery rapidly and unjustifiably really becomes considered yesterday’s practice. Marketing forces the public to search for newer and quicker medical “fixes,” hence the appearance of the “lunchtime peel,” the “lunchtime microdermabrasion” and ultimately the lunchtime (i.e., no “downtime”) laser resurfacing by nonablative lasers (411,412).
34
Brauner
The public is confused into believing that these techniques all produce the same results as a true wounding resurfacing and without any hazard. Kelly et al. (294) in 1999 and Nelson et al. (409) showed that a small but statistically evident improvement in rhytids could be safely achieved with a 1320 nm Nd:YAG and dynamic cooling; there was rare blistering and hyperpigmentation and rarer pitted scarring. However, Ross et al. (413) thought that this process is too variable and prone to deep dermal collagen injury with resultant granulomatous inflammation, fibrosis, and pitted scarring. Muccini et al. (414) reported 18% shrinkage of collagen and new collagen synthesis without epidermal destruction in treating rhytids with a 980 nm diode laser with a spherical optical handpiece that focused the energy into the dermis. Goldberg and Whitworth (415) discovered subtle yet visible improvement of rhytids after slight epidermal ablation with uncooled Q-switched Nd:YAG laser, and Goldberg and Cutler (416) found that intense pulsed light sources with a precooled light guide did the same without epidermal ablation. Patients treated with pulsed dye laser for vascular lesions also report improved skin textures as have those treated for atrophic and hypertrophic scars. Nonablative skin remodeling has ballyhooed the promise of reduction of wrinkles, pore size, and oiliness, improvement of skin texture, and removal of pigmentary dyschromias, both brown and red, with no epidermal damage, no downtime from work, and no morbidity (417). Amazingly, the lasers and light sources touted to produce these changes have included the entire spectrum from 532 to 1540 nm—clinical improvement or histologic evidence of procollagen, new collagen synthesis or deposition was noted for 532 nm, 2 ms laser (418), 585 nm, 450 ms pulsed dye laser (419), low-fluence 595 nm long-pulse chilled pulsed dye laser (420), 585 nm, 360 ms pulsed dye laser (421), chilled 1320 nm Nd:YAG laser (422, 423), and chilled 1540 nm Er:glass laser (424). Similar claims were made for intense pulsed light (389,392). More realistic assessments of improvement indicated that though most subjects showed some improvement, it was at most minimal—only 18% by grading in Rostan’s study (420)—and could lead to patient dissatisfaction as for 80% of Trelles patients (423) even though they had histologic evidence of new collagen.
20.
BIOSTIMULATION
Numerous European authors, most prominently E. Mester in Hungary, have studied biostimulatory effects of lasers on cutaneous tissues in vivo and in vitro since the mid-1960s (425 –428). Beginning with the long-pulse ruby, then the He – Ne and argon lasers, he performed studies on 15 different biologic systems, such as Erlich’s ascites tumor cells, hair growth in mice, rat marrow hemoglobin synthesis, human fibroblast RNA and DNA protein synthesis, and wound healing, first reporting his results in 1968 (425). In general, he found that lower-intensity lasers produced biostimulatory effects while higher doses were inhibitory. In the mid-1980s a short burst of interest by American authors Abergel, Castro, and coworkers (429 – 437) showed that Nd:YAG laser could inhibit or stimulate fibroblast collagen production without destruction of the cells and without thermal effect and that He – Ne and Ga – As lasers could stimulate collagen production in vivo and in vitro. The Nd:YAG laser was also shown to inhibit keloidal fibroblasts in culture and to clinically shrink keloids. For the most part though, the American cutaneous surgical community did not follow Mester’s lead perhaps because of very few pertinent English language articles, or more likely the great difficulty of performing controlled clinical trials when the strict definition of biostimulation meant that no measurable immediate tissue changes (i.e., thermal) took effect. As a further
Cutaneous Laser Surgery: Historical Perspectives
35
example, although ASLMS annual meetings have always had a section on biostimulation, the papers presented most recently invariably are not from the USA. In the 1980s the gallium –arsenide laser was removed from cutaneous study protocols by the FDA. The He – Ne laser attained unfortunate notoriety at the same time when it was fraudulently promoted by lay practitioners and some chiropractors as a laser nonsurgical facelift. Ultimately, renewed interest in minimal thermal or acoustic damage inciting fibroblastic repair will undoubtedly spill over into biostimulation as well and, hopefully, more American literature will be forthcoming.
21.
PHOTODYNAMIC THERAPY
Photochemotherapy depends on an external light source activating an exogenous photosensitizer. This process has been employed to treat disease for over 3000 years, first used for vitiligo with plant extracts containing psoralens acting as the sensitizers. Modern studies of photosensitizers began with Raab (438) and his professor, von Tappeiner (439) just 100 years ago, who found that acridine and other dyes would kill paramecia when exposed to light. von Tappeiner (440) published the first text on the subject in 1907 and named the process photodynamic action. Interestingly, one of the first therapeutic applications he published was with the dermatologist Jesionek (441) on the use of eosin as a photosensitizer to treat cutaneous diseases including skin cancer (442). In 1942 Auler and Banzer (443) first exhibited the retention of hematoporphyrin by rat tumor tissue and the tumor’s selective destruction by subsequent quartz lamp radiation. Diamond et al. (444) in 1972, Dougherty (445) in 1974, and Tomson et al. (446) in 1974 started the modern era of photodynamic therapy, Diamond with hematoporphyrin derivative (HpD) and rat gliomas, Dougherty with fluorescein and mouse mammary carcinomas, and Tomson with acridine orange and mouse epithelial tissue where argon laser was the illuminating source. Dougherty’s report in 1975 of HpD injected intraperitoneally in animal models with application of deeply penetrating red light initiated intense study of HpD (441,447 –452). Both noncoherent light sources and lasers have been employed in the past several decades, although the laser’s monochromaticity and coherence would seem to make it a preferable choice. Since HpD and its purified product Photofrin (porfimer sodium) have been the most widely studied compounds, red light sources have been their complement. The continuous wave tunable dye laser tuned to red wavelengths from 630 to 690 nm and the quasi-continuous gold vapor laser at 628 nm were the lasers of choice. Photofrin and laser technique was approved for general use by the FDA (451,453) in 1995 but with limitations to pulmonary, gastrointestinal, and urologic malignancies. Only a few select experimental centers such as Dougherty’s in Buffalo were able to continue to provide information on applications for cutaneous carcinoma. Thus, 25 years of American studies of these photosensitizers and benzoporphyrin derivative, tin ethyl etiopurpurin, and monoaspartyl chlorin e6 have been retarded. Allison et al.’s (454) recent literature review and their own data showed enticing remission rates with clinical cures of up to 100% claimed by various authors (Table 1.2). Topical 5-aminolevulinic acid (with a nonlaser blue light source) has been approved in 2000 in the USA for cutaneous premalignancies (455). Bissonette and Lui’s (453) review showed that complete response of actinic keratoses ranged from 81% to 100%, which bodes well for a promising future for photodynamic therapy and skin disease.
36
Brauner
Table 1.2 Photodynamic Therapy of Cancer Involving the Skin Photodynamic therapy
Complete remission
Basal cell carcinoma Wilson, 151 BCC (125 primary, 26 recurring) Wilson, 588 lesions in Gorlin’s syndrome Warloe lesions ,2 mm thick lesions .2 mm thick
IV PDT 88% IV Photofrin 95% Topical ALA 90% Topical ALA 45%
Squamous cell carcinoma Hernnijton, 32 lesions Robinson, 500 lesions Jones, 6 Bowen’s
IV PDT 81% IV Photofrin 100% IV Photofrin 100%
Kaposi’s sarcoma Bernstein Allison, 121 lesions
IV Photofrin 33% IV SnET2 75%
Breast adenocarcinoma metastasis Allison, 86 lesions
IV SnET2 92%
Source: Adapted from Allison et al. (454).
However, when it comes to invasive cancer, another picture emerges. Warloe and coworkers (456 –458) obtained mediocre results with topical therapy of even thin 2 mm tumors; only with combined aggressive approaches were cure rates comparable to those of traditional therapy. Sacchini et al.’s (459) experience with topical TPPS in azone and 630 nm light in 14 cases of basal cell carcinoma (BCC) evidenced biopsy-proven complete remission in all tumors less than 2 mm thick but also only partial remission in those more than 2 mm thick. Biel’s (452) review of his own and others’ experience found poor results from systemic photodynamic therapy uniformly for tumors more than 5 mm thick.
22.
RETURN OF THE SCIENTIFIC METHOD—THE CHARGE FOR THE FUTURE
Industrial hyperbole and the seeming need by many cutaneous laser surgeons to be the first “kid on the block” by presenting anecdotal evidence for a new use of a particular laser (148), whether justifiable biologically or financially for the patient, swung the pendulum of laser activity and continues to do so at a violent pace toward the nonsense pole antithetical to Leon Goldman’s maxim. In recently reviewing laser skin resurfacing, Kauvar (324) bemoaned and warned that “rapid development of novel instrumentation is outpacing our ability to study fully their biological effects in tissue.” The immense cost of purchasing several similar lasers to compare their efficacy and the unlikely provision of loaned or free competing lasers by a laser manufacturer (anxious to market a new product) complicated interpretation of new data and even made those presented for one laser system only suspect and continued to foster divisiveness and antagonism even in the public arena. Even with panels of experts presenting their data, too often listeners would query, “Well, which of these very expensive instruments should I purchase?” Fortunately, a number of laser surgeons could occasionally swing the pendulum back toward “sense” science by doing side-by-side or randomized comparisons (Fig. 1.20) (186,192,197,205,207,208,329,337,352 –356,415,459,460). For example, Schliftman and
Cutaneous Laser Surgery: Historical Perspectives
37
Figure 1.20 Two comparative side-by-side studies of argon, copper vapor, and continuous dye lasers on a port-wine stain by Drs. Schliftman and Brauner.
Brauner (205,207) in 1990 showed that equivalently dosed copper vapor laser was more effective than continuous wave dye laser or argon laser on side-by-side test areas of port-wine stain after one treatment. In 1993 Waner et al. (208) compared two yellow lasers, the copper vapor and pulsed dye, for facial telangiectases. Upon side-by-side comparison the former laser healed more quickly and was more cosmetically acceptable to the patients but both gave equivalent clinical improvement. In 1995 Dover et al. (186) compared port-wine stains treated with hexascan-assisted continuous dye laser with those treated with matched side-by-side pulsed dye laser and found both lasers effective, with the pulsed dye more so. A minimal and equivalent side effect profile for both sites was shown. Waldorf et al. (197) compared dynamically cooled sites with uncooled sites on pulsed dye laser-treated paired sites in port-wine stains, illustrating the epidermal sparing and pain relief effects of this device. Adrian and Tanghetti (192) paired pulsed dye laser and sapphire-tip-chilled 532 nm Nd:YAG laser for facial telangiectasia. Leuenberger et al. (460) had better results with Q-switched ruby laser on black tattoos than sideby-side Q-switched Nd:YAG and Q-switched alexandrite, although all worked well. McDaniel et al. (356) compared CO2 laser for perioral rhytid resurfacing to combined sequential CO2 and then Er:YAG resurfacing and found no significant clinical differences. Alster et al. (337) found no significant clinical differences in four randomized simultaneous CO2 resurfacing lasers and in a second study (355), in six randomized Er:YAG resurfacing systems. Khatri et al. (353) found quicker recovery but lesser therapeutic effect in Er:YAG than in CO2-laser-resurfaced areas. Goldberg and Whitworth (415) compared side-by-side char-free CO2 lasers and QS Nd:YAG laser for periorbital rhytid removal. Grossman et al. (461) studied side-by side flashlamp-pulsed light source, two types of long-pulsed ruby laser, long-pulsed alexandrite, and long-pulsed diode lasers for hair removal. Determining optimal intervals for therapies requiring multiple treatments (as mentioned previously concerning pigmented lesion removal) requires paired side-byside comparisons as well, but the rush to publication and for rapid treatment obscured the need for understanding the biology of laser healing and tissue restoration. The emergence of on-line Internet laser discussion groups and even journals such as lasernews.net (http://lasernews.net) and Dermatology Online Journal (http://matrix. ucdavis.edu/DOJdesk/desk.html) fosters rapid communication and helps disseminates more quickly new insights and possible complications but accelerates the speed of what we think is laser “science” perhaps faster than the biology of healing and repair is willing to provide us with correct information. Time tempers judgment but accelerated internet time may only interfere with a cautious laser surgeon’s perspective.
38
Brauner
In a similar vein, hyperbole (308 –338) masked the true incidence of complications. Some cautious but perhaps courageous laser surgeons did report side effects and preached thoughtful reflection and methodology (222,319,349,355,462 – 469). This author raised the question of underreporting of scarring and the role of wound dressings in preventing hypertrophic scarring in 1984 (75). In a 1987 review Olbricht et al. (463) surveyed laser surgeons, 69% of whom had seen at least one case of hypertrophic scarring after argon laser and 64% after CO2 laser surgery, but no true incidence of scarring was tabulated. Lent and David (464) noted hyperpigmentation in 16% of laser-resurfaced patients postoperatively and Fitzpatrick et al. (319), 25%. Nanni and Alster (466) found a 37% incidence, more common in darker patients (up to 100% of Fitzpatrick type IV and V patients) (355,466), but this is reversible particularly with postoperative hydroquinones. Bernstein et al. (349) first made known the previously unreported late onset of hypopigmentation with CO2-laser-resurfaced patients, which may have represented both melanocyte destruction and delayed opacification. This delayed side effect, which seemed to correlate with prolonged erythema, was largely responsible for the shift to Er:YAG laser resurfacing systems. Rendon-Pellerano et al. (467) reviewed the rare but expectable early and late complications seen after laser resurfacing but reported four worrisome unpredictable outcomes, disseminated herpes simplex without prior clinical history of herpes, delayed wound healing with spontaneous breakdown of previously healed skin and protracted healing with scarring thereafter, granulomatous response of the lip margins, and a case of staphylococcal parapharyngeal abscess. Our past history, short as it has been in cutaneous laser surgery, has been one of brilliance, bringing unimaginable benefits to our patients with deformity, as well as convenience and safety for cosmetic surgery. Our future will undoubtedly continue in a similar vein. In an era of high technology we can only expect more extraordinary technical innovations and new seminal events. Hopefully, as physicians first, we will be mindful of the cautions laid down by Leon Goldman and by our sense of honest scientific inquiry and our ethos of “primum non nocere.” Hopefully, we will continue to view the potential of cutaneous laser surgery with the same excitement and joy that Leon Goldman did at laser’s very inception in 1960 as a potential for healing. Hopefully, future historians of cutaneous laser surgery will not record how our professionalism was swept away by a tidal wave of marketing hyperbole. Timeline of the Development of Cutaneous Laser Surgery Early 20th century 1906– 1917 1920s 1951 1957
Einstein’s conceptualization of stimulated emission of radiation Theory of coherence—Dirac Theory of amplification—Townes (USA), V. A. Fabrikant (USSR) Optical resonator—Schawlow and Townes
1960s 1960 1961 1961 1961 1961 1962 1962 1962 1962
First Laser, ruby—Maiman First gas laser, He-Ne, at Bell Labs Nd:YAG laser—Johnson and Naussau Ruby laser used on port-wine stain—Leon Goldman Nd:YAG laser for tattoos—Goldman Microscope coupled with ruby laser—Bessis and Coll Ruby laser used on eye by Zweng Argon laser invented First commercial production of lasers
Cutaneous Laser Surgery: Historical Perspectives 1962 1963 1964 1964 1964 1965 1966 1967 1967 1968 1970s 1970 Early 1970s Early 1970s 1971 1972 1974 1974 Late 1970s Late 1970s
39
Laser research laboratories founded Low-power lasers and wound healing—Endre Mester First article on laser surgery of the skin—Leon Goldman Q-switched ruby laser on tattoo—Goldman CO2 laser invented—Patel Nd:YAG to cut human tissue—Jako First surgical CO2 laser—Polanyi First commercial CO2 laser—American Optical Co. Argon laser used on eye—L’Esperance First CO2 laser use in urology—Mulvaney and Beck CO2 laser on human larynx—Jako Fiberoptics developed for lasers Photodynamic therapy of malignancy—Dougherty First commercial argon laser First use of CO2 laser for disease of cervix—Kaplan CO2 laser on vaginal tissue, cervical dysplasia, condylomas—Bellina Wellman Lab founded Argon laser for cutaneous disease—Apfelberg, Arndt, Noe, and others CO2 laser for cutaneous disease—McBurney and others
1980s Early 1980s Early 1980s 1981 1981 1982 1983 Mid 1980s Late 1980s to early 1990s 1988 1989
Intraoperative and postoperative wound care Mechanized scanners American Society of Laser Medicine and Surgery founded Q-switched ruby laser for tattoos—Reid Beckman Lab founded Theory of selective photothermolysis—Anderson and Parrish Continuous Nd:YAG laser for cutaneous vascular tumors “Yellow lasers”: pulsed dye, continuous wave dye, copper vapor, copper bromide, krypton Er:YAG for resurfacing—Kaufmann First commercial American Q-switched ruby laser for tattoos
1990s Early 1990s 1993 1993 1993 1994 1995 1997 1999 1999
Q-switched Nd:YAG, Q-switched alexandrite Pulsed dye laser treatment of scars Ultrapulse and high-speed-scanned CO2 laser resurfacing Pulsed light sources for vascular lesions Q-switched Nd:YAG laser-assisted hair removal Long-pulse ruby laser for hair removal First American Er:YAG laser for resurfacing Long-pulse diode laser for hair removal Long-pulse 1320 nm Nd:YAG laser for thermal remodeling
Source: Adapted partially from “The Development of Laser Medicine” (monograph, American Society for Laser Medicine and Surgery, 1987), Hecht and Teresi (21), and Bellina et al. (102).
REFERENCES 1. Enderby C. Laser instrumentation. In: Dixon J, ed. Surgical Application of Lasers. 2nd ed. Chicago: Yearbook Medical Publisher’s, 1987:52 – 78. 2. Alster T, Kohn S. Dermatologic lasers: three decades of progress. Int J Dermatol 1992; 31:601 – 610. 3. Wheeland R. History of lasers in dermatology. Clin Dermatol 1995; 13:3– 10.
40 4. 5. 6. 7. 8.
9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34.
Brauner Anderson R, Parrish J. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Anderson R, Parrish J. The optics of human skin. J Invest Dermatol 1981; 77:13 – 19. Anderson R, Parrish J. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med 1989; 1:263– 276. van Gemert M, Henning J. A model approach to laser coagulation of dermal vascular lesions. Arch Dermatol Res 1981; 270:429– 439. Hulsbergen Henning J, van Gemert M, Lahaye C. Clinical and histological evaluation of portwine stain treatment with a microsecond-pulsed dye-laser at 577. Lasers Surg Med 1984; 4:375 – 380. van Gemert M, Welch A, Amin A. Is there an optimal laser treatment for port wine stains? Lasers Surg Med 1986; 6:76 – 83. van Gemert M, Welch A, Tan O et al. Limitations of carbon dioxide lasers for treatment of port-wine stains. Arch Dermatol 1987; 123:71 – 73. van Gemert M, Nelson J, Milner T et al. Non-invasive determination of port wine stain anatomy and physiology for optimal laser treatment strategies. Phys Med Biol 1997; 42:937–950. Smithies D, van Gemert M, Hansen M et al. Three-dimensional reconstruction of port-wine stain vascular anatomy from serial histological sections. Phys Med Biol 1997; 42:1843 – 1847. Pfefer T, Barton J, Smithies D et al. Modeling laser treatment of port wine stains with a computer-reconstructed biopsy. Lasers Surg Med 1999; 24:151 – 166. American Institute of Physics. Albert Einstein (1879– 1955). http://www.aip.org/history/ esva/exhibits/ein.htm. Albert Einstein online. http://www.westegg.com/einstein. F. Einstein’s Legacy. Forward pp1– 2. http://www.achilles.net/%7Ejtalbot/history/ einstein.html. Hughes Research Labs. Our History: Published Highlights 1960’s. http://www.hrl.com/ tradition/Tradition.1960s.html. Laser Stars—Laser History (1917 – 1996). pp 1 – 2. http://www.achilles.net/%7Ejtalbot/ history/index.html. Einstein A. Zur Quanten Theorie der Strahlung. Physikal Zeitschr 1917; 18:121 – 128. Einstein A. Ideas and Opinions. Reprint ed. New York: Modern Library, 1994. Hecht J, Teresi D. Laser: Supertool of the 1980’s. New Haven, CT: Ticknor and Fields, 1982. Itzkan I, Drake E. History of lasers in medicine. In: Arndt K, Dover J, Olbricht S, eds. Lasers in Cutaneous Medicine and Surgery. Boston, MA: Little Brown, 1997:3 – 9. The Invention of the LASER at Bell Laboratories: 1958– 1998. pp 1 –9. http://www.belllabs.com/history/laser/invention. Gordon J, Zeigler H, Townes C. The MASER- new type of amplifier, frequency standard and spectrometer. Phys Rev 1955; 99:1264 – 1274. Townes CH. The Invention of the LASER at Bell Laboratories: 1958– 1998. pp 1 – 3. http://www-out.bell-labs.com/history/laser/invention/townes-bio.html. Schawlow AL. The Invention of the LASER at Bell Laboratories: 1958– 1998. pp 1 – 2. http://www-out.bell-labs.com/history/laser/invention/schawlow-bio.html. Schawlow A, Townes C. Infrared and optical masers. Phys Rev 1958; 112:1940 – 1949. Maiman T. Stimulated optical radiation in ruby. Nature 1960; 187:493– 494. Optical Laser. http://www.achilles.net/%7Ejtalbot/history/ruby.html. Svelto O. Principles of Lasers. 2nd ed. New York: Plenum Press, 1982. Goldman L. The CO2 laser in dermatology: the perspective of Leon Goldman, M.D. “Father of laser surgery”. Xanar Surgical Monograph, 1988. Goldman L. http://www.lasertraining.org/leon.htm. Goldman L, Blaney D, Kindel D et al. Effect of the laser beam on the skin. J Invest Dermatol 1963; 40:121 – 122. Goldman L, Blaney D, Kindel D et al. Pathology of the effect of the laser beam on the skin. Nature 1963; 197:912 – 914.
Cutaneous Laser Surgery: Historical Perspectives 35. 36. 37.
38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61.
62. 63. 64.
41
Tan O, Morelli J. Lasers in dermatology. Curr Probl Dermatol 1989; 1:1 – 26. Alster T, Kohn S, Dermatologic lasers: three decades of progress. Int J Dermatol 1992; 31:601 – 610. Goldman L, Wilson R, Hornby P et al. Radiation from a Q-switched ruby laser. Effect of repeated impacts of power output of 10 megawatts on a tattoo of man. J Invest Dermatol 1965; 44:69 – 71. Goldman L, Rockwell R, Meyer R et al. Laser treatment of tattoos: a preliminary survey of three years clinical experience. J Am Med Assoc 1967; 201:841 – 844. Zweng H, Flocks M, Kapany N et al. Experimental laser photocoagulation. Am J Ophthalmol 1964; 58:355. Goldman L, Hornby P, Long C. Effect of the laser on the skin. III. Transmission of laser beams through fiber optics. J Invest Dermatol 1964; 42:231 – 234. Goldman L, Igelman J, Richfield D. Impact of the laser on nevi and melanomas. Arch Dermatol 1964; 90:71 – 75. Goldman L. Comparison of the biomedical effects of the exposure of human tissues to low and high energy lasers. Ann NY Acad Sci 1965; 122:802 – 831. Goldman L et al. Laser radiation of malignancy in man. Cancer 1965; 18:533 –545. Goldman L. Dermatologic manifestations of laser radiation. Fed Proc 1965; 14:592– 593. Goldman L, Rockwell R. Lasers in Medicine. New York: Gordon and Breach, 1971. Goldman L. Laser surgery for skin cancer. NY State J Med 1977; 77:1897 – 1900. Goldman L. Surgery by laser for malignant melanoma. J Dermatol Surg Oncol 1979; 5:141 – 144. Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications. New York: Springer-Verlag, 1981. Ohshiro T. Laser Treatment for Nevi. Tokyo: Medical Laser Research Co., 1980. Javan A, Bennett W, Herriot D. Population inversion and continuous optical maser oscillator in a gas discharge containing a He– Ne mixture. Phys Rev 1961; 6:106 – 110. Johnson L. Optical maser characteristics of rare-earth ions in crystals. J Appl Physiol 1961; 34:897 – 909. Goldman L, Nath G, Schindler G et al. High-power neodymium – YAG laser surgery. Acta Dermatol Venereol 1973; 53:45 – 49. Bennett W, Faust W, McFarlane R et al. Dissociative excitation transfer and optical maser oscillation in NeO2 and ArO2 rf discharges. Phys Rev 1962; 8:470 – 473. L’Esperance F. An ophthalmic argon laser photocoagulator system: design, construction and laboratory investigation. Trans Am Ophthalmol Soc 1968; 66:827 –904. Bloom L, Brucker A. Lasers in ophthalmology. Surg Clin North Am 1984; 64:1013 –1024. Apfelberg D, Maser M, Lash H. Argon laser management of cutaneous vascular deformities. A preliminary report. West J Med 1976; 124:99 – 101. Apfelberg D, Kosek J, Maser M et al. Histology of port-wine stains following argon laser treatment. Brit J Plast Surg 1979; 32:232– 237. Apfelberg D, Maser M, Lash H. Extended clinical use of the argon laser for cutaneous lesions. Arch Dermatol 1979; 115:719 – 721. Apfelberg D, Maser M, Lash H et al. The argon laser for cutaneous lesions. J Am Med Assoc 1981; 245:2073 – 2075. Apfelberg D, McBurney E. Use of the argon laser in dermatologic surgery in lasers. In: Ratz J, ed. Cutaneous Medicine and Surgery. Chicago: Yearbook Medical Publishers, 1986:31–71. Solomon H, Goldman L, Henderson B et al. Histopathology of the laser treatment of port-wine lesions: biopsy studies of treated areas observed up to three years after laser impacts. J Invest Dermatol 1968; 50:141 – 146. Goldman L. Effects of new laser systems on the skin. Arch Dermatol 1973; 108:385 – 390. Goldman L et al. Treatment of port-wine marks by an argon laser. J Dermatol Surg Oncol 1976; 2:385 – 388. Goldman L, Dreffer R, Rockwell J et al. Treatment of portwine marks by an argon laser. J Dermatol Surg 1976; 2:385 – 388.
42 65. 66. 67. 68.
69. 70. 71. 72. 73.
74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90.
91.
Brauner Goldman L, Dreffer R. Laser treatment of extensive mixed cavernous and port-wine stains. Arch Dermatol 1977; 113:504 – 505. McBurney E, Leonard G. Argon laser treatment of port-wine hemangiomas: clinical and histologic correlation. South Med J 1981; 74:925 – 927. Arndt K, Noe J, Northam D et al. Laser therapy: basic concepts and nomenclature. J Am Acad Dermatol 1981; 5:649 – 654. Noe J, Barsky S, Geer D et al. Port-wine stains and the response to argon laser therapy: successful treatment and the predictive role of color, age and biopsy. Plast Reconstr Surg 1980; 65:130 – 136. Finley J, Barsky S, Geer D et al. Healing of port-wine stains after argon laser therapy. Arch Dermatol 1981; 117:486 – 489. Noe J. Complications of argon laser surgery for skin. In: Fried M et al. ed. Complications of Laser Surgery of the Head and Neck. Chicago: Yearbook Medical Publishers, 1986:124. Cosman B. Experience in the argon laser therapy of port-wine stains. Plast Reconstr Surg 1980; 65:119 – 129. Cosman B. Role of retreatment in minimal-power argon laser therapy for port-wine stains. Lasers Surg Med 1982; 2:43. Apfelberg D, Smith T, Maser M et al. Dot or pointillistic method of improvement in results of hypertrophic scarring in the argon laser treatment of portwine hemangiomas. Lasers Surg Med 1987; 6:552– 558. Dixon J, Huether S, Rotering R. Hypertrophic scarring in argon laser treatment of port-wine stains. Plast Reconstr Surg 1984; 73:771 –777. Brauner G. Scarring from laser surgery. In: Lasers in Dermatology (Course). American Academy of Dermatology Annual Meeting, Washington, DC, Dec 1984. Dixon J, ed. Surgical Application of Lasers, 2nd ed. Chicago: Yearbook Medical Publishers, 1987. Brauner G, Schliftman A, Cosman B. Evaluation of argon laser surgery in children under 13 years of age. J Plast Reconstr Surg 1991; 87:37 – 43. Gold M, Brauner G. Point/counterpoint: should surgeons delegate laser procedures to ancillary staff?—Only physicians should be laser surgeons. Skin Aging 2000; 8:57– 59. Wagner R, Brown T, Archer R et al. Dermatologists’ attitudes toward independent nonphysician electrolysis practice. Dermatol Surg 1998; 24:357 –362. Brauner G, Schliftman A. Laser surgery for children. J Dermatol Surg Oncol 1987; 13:178–186. Geronemus R, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17:76– 79. van der Horst C, Koster P, de Borgie C et al. Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser. N Engl J Med 1998; 338:1028 – 1033. Troilius A, Wrangsjo B, Ljunggren B. Potential psychological benefits from early treatment of port-wine stains in children. Br J Dermatol 1998; 139:59– 65. Miller A, Pit-Ten Cate I, Watson H et al. Stress and family satisfaction in parents of children with facial port-wine stains. Pediatr Dermatol 1999; 16:190 – 197. Troilius A, Wrangsjo B, Ljunggren B. Patients with port-wine stains and their psychosocial reactions after photothermolytic treatment. Dermatol Surg 2000; 26:190 –196. Patel CKN, McFarlane R, Faust W. Selective excitation through vibrational energy transfer and optical maser action in N2 –CO2. Phys Rev 1964; 136:617– 619. Patel CKN. High-power carbon dioxide lasers. Sci Am 1968; 219:23. Patel CKN, Wood O. In: Baggish M, ed. History of the Laser in Basic and Advanced Laser Surgery. Gynecology, Norwalk: Appleton-Century-Crofts, 1985:1 – 22. Polanyi T, Bredemeier H, Davis T. A CO2 laser for surgical research. Med Biol Eng Computs 1966; 8:541 – 548. Jako G. Laser biomedical engineering: clinical applications in otolaryngology. In: Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications, New York: Springer-Verlag, 1981:175– 198. Stahle J, Hoegberg L. Laser and the labyrinth. Acta Otolaryngol 1965; 85:367– 374.
Cutaneous Laser Surgery: Historical Perspectives 92. 93. 94. 95. 96. 97. 98.
99. 100. 101.
102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119.
43
Conti A, Bergomi A. Irradiazione laser del labirinto posteriore. Arch Ital Biol 1966; 77:546 – 567. Sataloff J. Experimental use of laser in otosclerotic stapes. Arch Otolaryngol 1967; 85:614 – 616. Jako G. Laser surgery of the vocal cords: an experimental study with carbon dioxide lasers on dogs. Laryngoscope 1972; 82:2204– 2216. Strong M, Jako G. Laser surgery in the larynx. Ann Otol Rhinol Laryngol 1972; 81:791 – 798. Strong M, Jako G, Polanyi T et al. Laser surgery in the aerodigestive tract. Am J Surg 1973; 126:529 – 533. Strong M. Laser management of premalignant lesions of the larynx. Can J Otolaryngol 1974; 3:560 – 563. Jako G, Vaughn C, Strong M et al. Surgical management of malignant tumors of the aerodigestive tract with carbon dioxide laser microsurgery. Int Adv Surg Oncol 1979; 1:265 – 284. Hall R, Beach A, Baker E et al. Incision of tissue by carbon dioxide laser. Nature 1971; 232:131 – 132. Bellina J. Gynecology and the laser. Contrib Gynecol Obstet 1974; 4:24– 34. Bellina J, Polanyi T. Management of vaginal adenosis and related cervicovaginal disorders in DES-exposed progeny by means of carbon dioxide laser surgery. J Reprod Med 1976; 16:295 – 296. Bellina J, Fick A, Jackson J. Lasers in gynecology: an historical/developmental overview. Lasers surg Med 1985; 5:1– 22. Fisher J. The Laser Education Foundation Syllabus on Basic Laser Biophysics and Safety and Resurfacing of Skin with the Carbon-Dioxide Laser. 1998:vi. Kaplan I, Goldman L, Ger R. The treatment of erosions of the uterine cervix by means of the CO2 laser. Obstet Gynecol 1973; 41:795 – 796. Kaplan I, Ger R. The carbon dioxide laser in clinical surgery Israel. J Med Sci 1973; 9:79– 83. Kaplan I, Sharon U, Ger R. The carbon dioxide laser in clinical surgery. In: Wolbarsht M, ed. Laser Applications in Medicine and Biology. Vol. 2. New York: Plenum Press, 1974:295–308. Dorsey J, Diggs E. Microsurgical conization of the cervix by carbon dioxide laser. Obstet Gynecol 1979; 54:565– 570. Baggish M, Keye W. Lasers in gynecology. In: Dixon J, ed. Surgical Application of Lasers, 2nd ed. Chicago: Yearbook Medical Publishers, 1987:183 – 217. Baggish M, ed. Basic and Advanced Laser Surgery in Gynecology, Norwalk, CT: Appleton-Century-Crofts, 1989. Cerullo L, Burke L. Use of the laser in neurosurgery. Surg Clin North Am 1984; 64:995 – 1000. Heppner F, Ascher P. Uber den Einsatz des Laserstrahls in der Neurochirurgie. Medizinalmarkt 1976; 12:424. Nath G, Gorisch W, Kiefhaber P. First laser endoscopy via a fiberoptic transmission system. Endoscopy 1973; 5:208 – 213. Keifhaber P, Nath G, Moritz K. Endoscopic control of massive gastrointestinal hemorrhage by irradiation with a high-power neodymium– YAG laser. Prog Surg 1977; 15:140– 155. LaForet E, Berger R, Vaughn C. Carcinoma obstructing the trachea; treatment by laser resection. New Engl J Med 1976; 294:941. Casey K, Unger M. Laser bronchoscopy. In: Dixon J, ed. Surgical Application of Lasers, 2nd ed. Chicago: Yearbook Medical Publishers, 1987:287 – 309. Toty L, Personne C, Colchen A et al. Bronchoscopic management of tracheal lesions using the neodymium yttrium aluminum garnet laser. Thorax 1981; 36:175– 178. Goldman L, Rockwell R, Naprstek Z et al. Some parameters of high output CO2 laser experimental surgery. Nature 1970; 228:1344 – 1345. Goldman L et al. CO2 laser surgery for cancer of man. Laser J 1971; 3:21– 23. Frishman A et al. Excision of subcutaneous fibrosarcoma in mice. Isr J Med Sci 1974; 10:637 – 641.
44 120.
121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142.
143. 144. 145.
146.
Brauner Kaplan I, Raif J. The Sharplan carbon dioxide laser in clinical surgery: 7 years’ experience. In: Goldman L, ed. The Biomedical Laser, Technology and Clinical Applications. New York: Springer-Verlag, 1981:89– 97. Kaplan I, Ger R, Sharon U. The carbon dioxide laser in plastic surgery. Brit J Plast Surg 1973; 26:359 – 362. Stellar S, Meijer R, Walia S et al. Carbon dioxide laser debridement of decubitus ulcers: followed by immediate rotation flap or skin graft closure. Ann Surg 1974; 79:230– 237. Stellar S et al. Laser excision of acute third degree burns followed by immediate autograft replacement: an experimental study in the pig. J Trauma 1973; 13:45 – 53. Stellar S, Levine N, Ger R et al. Carbon-dioxide laser for excision of burn eschars. Lancet 1971; 1:945. McBurney E. Carbon dioxide laser surgery of dermatologic lesions. South Med J 1978; 71:795 – 797. McBurney E. Dermatologic laser surgery. Otolaryngol Clin North Am 1990; 23:77 – 97. Adams E, Price N. Treatment of basal cell carcinomas with a carbon-dioxide laser. J Dermatol Surg Oncol 1979; 5:803 – 806. Bailin P, Ratz J, Levine J. Removal of tattoos by CO2 laser. J Dermatol Surg Oncol 1980; 6:977 – 1001. Bailin P, Ratz J, Lutz-Nagey L. CO2 laser modification of Mohs’ surgery. J Dermatol Surg Oncol 1981; 7:621– 623. Ratz J, Bailin P, Levine H. CO2 laser treatment of port-wine stains: a preliminary report. J Dermatol Surg Oncol 1982; 8:1039– 1044. Ratz J. Laser applications in dermatology and plastic surgery. In: J Dixon J, ed. Surgical Application of Lasers. 2nd ed. Chicago: Yearbook Medical Publishers, 1987:160 – 182. Wheeland R, Bailin P, Ratz J. Combined carbon dioxide laser excision and vaporization in the treatment of rhinophyma. J Dermatol Surg Oncol 1987; 13:172– 177. Reid R, Muller S. Tattoo removal with laser. Med J Aust 1978; 1:389. Reid R, Muller S. Tattoo removal by CO2 laser dermabrasion. Plast Reconstr Surg 1980; 65:717 – 728. Goldman L. Laser medicine: when you need it, when you don’t. Ohio Med 1987; 83:861– 865. (Published erratum appears in Ohio Med 1988; 84:168). Kitzmiller W. Laser treatment of angiomas and tattoos. Cutis 1974; 13:251 – 254. Kantor G, Wheeland R, Bailin P et al. Treatment of earlobe keloids with carbon dioxide laser excision: a report of sixteen cases. J Dermatol Surg Oncol 1985; 11:1063– 1067. Apfelberg D, Maser M, Lash H et al. Preliminary results of argon and carbon dioxide laser treatment of keloid scars. Lasers Surg Med 1984; 4:283– 290. Apfelberg D, Maser M, White D et al. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9:382 – 388. Stern J, Lucente F. Carbon dioxide laser excision of earlobe keloids. A prospective study and critical analysis of existing data. Arch Otolaryngol Head Neck Surg 1989; 115:1107 – 1111. Norris J. The effect of carbon dioxide laser surgery on the recurrence of keloid. Plast Reconstr Surg 1991; 87:44 –49, discussion 50– 53. Madden J, Edlich R, Custer J et al. Studies in the management of the contaminated wound. IV. Resistance to infection of surgical wounds made by knife, electrosurgery and laser. Am J Surg 1970; 119:222 – 224. Hishimoto K, Rockwell R, Epstein R et al. Laser wound healing compared with other surgical modalities. Burns 1975; 1:13. Brauner G, Schliftman A, Sottile E. Lasers in dermatologic surgery. Infect Sur 1987; 6:242 – 247. Hambley R, Hebda P, Abell E et al. Wound healing of skin incisions produced by ultrasonically vibrating knife, scalpel, electrosurgery, and carbon dioxide laser. J Dermatol Surg Oncol 1988; 14:1213 –1217. Molgat Y, Pollack S, Hurwitz J et al. Comparative study of wound healing in porcine skin with CO2 laser and other surgical modalities: preliminary findings. Int J Dermatol 1995; 34:42–47.
Cutaneous Laser Surgery: Historical Perspectives 147. 148. 149. 150. 151. 152. 153. 154. 155.
156. 157. 158. 159. 160. 161. 162. 163. 164.
165. 166. 167.
168. 169. 170. 171. 172. 173.
45
Strohecker J, Piotrowski W, Lametschwandtner A. Ultrastructural findings after the use of a CO2 laser in carpal tunnel surgery. Lasers Surg Med 1985; 5:123 – 128. Dover J, Arndt K, Dinehart S et al. Guidelines of care for laser surgery. J Am Acad Dermatol 1999; 41:484 – 495. Department of Health, Education and Welfare/Food and Drug Administration. Report on Laser Products. Federal Register 40(148):Part II, July 1975. Sliney D. Safety with biomedical lasers. In: Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications. New York: Springer-Verlag, 1981:11 – 24. Lundergun D, Rockwell R. ANSI medical laser standards. Clin Laser Monthly 1984; 2:99 – 100. Ossoff R. ANSI standards for clinical laser safety. Clin Laser Monthly 1986; 4:7– 9. ANSI Z 136.3 for the Safe Use of Lasers in Health Care Facilities. New York: American National Standards Institute, 1996. Smalley P. Laser safety—more than goggles and signs. Plas Surg Prod 1998; Nov/Dec:66–68. Holmes J. A summary of safety considerations for the medical and surgical practitioner. In Apfelberg D, ed. Evaluation and Installation of Surgical Laser Systems. New York: Springer Verlag, 1987. Fretzin S, Beeson W, Hanke C. Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Dermatol Surg 1996; 22:699 – 702. Rohrich R, Gyimesi I, Clark P et al. CO2 laser safety considerations in facial skin resurfacing Plast Reconstr Surg 1997; 100:1285 – 1290. Baggish M, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156:1260 – 1265. Nezhat C, Winer W, Nezhat F et al. Smoke from laser surgery: Is there a health hazard? Lasers Surg Med 1987; 7:376 – 382. Baggish M, Baltoyannis P, Sze E. Protection of the rat lung from the harmful effects of laser smoke. Lasers Surg Med 1988; 8:248– 253. Smith J, Moss E, Bryant C et al. Evaluation of a smoke evacuator used for laser surgery. Laser Surg Med 1989; 9:276 – 281. Wentzell J, Robinson J, Wentzell J et al. Physical properties of aerosols produced by dermabrasion. Arch Dermatol 1989; 125:1637 – 1643. Hoye R, Ketcham A, Riggle G. The air-borne dissemination of viable tumor by high energy neodymium laser. Life Sci 1967; 6:119 –125. Jako G. Laser biomedical engineering: clinical applications in otolaryngology. In: Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications. New York: Springer-Verlag, 1981:175. Garden J, O’Banion K, Shelnitz I et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. J Am Med Assoc 1988; 259:1199– 1202. Garden J. The hazards of laser plume: a mid-year committee report. Am Soc Laser Med Surg 1989, 3:6. Sawchuck W, Weber P, Lowy D et al. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989; 20:41 – 49. Baggish M, Poiesz B, Doret D et al. Presence of human immunodeficiency virus DNA in laser smoke. Lasers Surg Med 1991; 11:197– 203. Ziegler B, Thomas C, Meier T et al. Generation of infectious retrovirus aerosol through medical laser irradiation. Lasers Surg Med 1998; 22:37 –41. Capizzi P, Clay R, Battey M. Microbiologic activity in laser resurfacing plume and debris. Lasers Surg Med 1998; 23:172 – 174. Frenz M, Mathezloic F, Stoffel M et al. Transport of biologically active material in laser cutting. Lasers Surg Med 1988; 8:562– 566. Beeson W. Laser safety—effective risk management and outcomes monitoring. 8th International Symposium for Cosmetic Laser Surgery, New Orleans, LA, Mar 1999. Fader D, Ratner D. Principles of CO2/erbium laser safety. Dermatol Surg 2000; 26:235 – 239.
46 174. 175. 176. 177. 178.
179. 180.
181. 182. 183. 184.
185. 186.
187. 188. 189. 190. 191.
192. 193. 194. 195.
196.
197.
Brauner Hughes P. Boiling and splattering liquid with the Er:YAG laser. Lasers Surg Med 1998; 23:248. Gloster H, Roenigk R. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995; 32:436 – 441. Hughes P, Hughes A. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol 1998; 38:426 –428. Geronemus R. Argon laser surgery in children under 13 years of age. Plast Reconstr Surg 1991; 87:37 – 43. Apfelberg D, Flores J, Maser M et al. Analysis of complications of argon laser treatment for portwine hemangiomas with reference to striped technique. Lasers Surg Med 1983; 2:357 – 371. Apfelberg D. Biophysics, advantages, and installation of laser systems. In: Evaluation and Installation of Surgical Laser Systems. New York: Springer Verlag, 1987:1. Scheibner A, Wheeland R. Argon-pumped tunable dye laser therapy for facial port-wine stain hemangiomas in adults: a new technique using small spot size and minimal power. J Dermatol Surg Oncol 1989; 15:277 – 282. Scheibner A, Wheeland R. Use of the argon-pumped tunable dye laser for port-wine stains in children. J Dermatol Surg Oncol 1991; 17:735 – 739. Brauner G. Laser scanners in dermatologic surgery. Am J Cosmet Surg 1992; 9:197 – 203. Itzkan I, Bourgelais D. Established Dermascan treatment parameters using cherry angiomas as a model. SPIE 1986; 712:206– 208. (Abstract.) Tang S, Arndt K, Gilchrest B et al. Clinical comparisons of millisecond versus conventional argon laser treatment of in vivo vascular skin lesions. Laser Med Surg 1985; 5:177 – 178. (Abstract.) Rotteleur G, Mordon S, Buys B et al. Robotized scanning laser handpiece for the treatment of port-wine stains and other angiodysplasias. Lasers Surg Med 1988; 8:283– 287. Dover J, Geronemus R, Stern R et al. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 – 240. Gilchrest B, Rosen S, Noe J. Chilling port-wine stains improves the response to argon laser therapy. Plast Reconstr Surg 1982; 69:278 – 283. Goldman L, Stefanovsky D, Gregory R et al. Research and development of additional aids for dermatologic and plastic surgery. Lasers Surg Med 1983; 2:323 – 330. Landthaler M, Haina D, Brunner R et al. Neodymium-YAG laser therapy for vascular lesions. J Am Acad Dermatol 1986; 14:107 – 117. Chess C, Chess Q. Cool laser optics treatment of large telangiectasia of the lower extremities. J Dermatol Surg Oncol 1993; 19:74– 80. Chess C. Does simultaneous contact cooling reduce intravascular temperature during laser irradiation and impinge on selective vascular destruction? Dermatol Surg 1997; 23:657 – 662; Dermatol Surg 1998; 24:404– 405. Adrian R, Tanghetti E. Long pulse 532-nm laser treatment of facial telangiectasia. Dermatol Surg 1998; 24:71 –74. Nelson J, Milner T, Anvari B et al. Dynamic cooling of the epidermis during laser port-wine stain therapy. Laser Surg Med 1994; (suppl 6):48. (Abstract.) Anvari B, Milner T, Tanenbaum B et al. Selective cooling of biological tissues: application for thermally mediated therapeutic procedures. Phys Med Biol 1995; 40:241 –252. Nelson J, Milner T, Anvari B et al. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain. A new methodology with preliminary clinical evaluation. Arch Dermatol 1995; 131:695 – 700. Nelson J, Milner T, Anvari B et al. Dynamic epidermal cooling in conjunction with laser-induced photothermolysis of port-wine stain blood vessels. Lasers Surg Med 1996; 19:224 – 229. Waldorf H, Alster T, McMillan K et al. Effect of dynamic cooling on 585 nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg 1997; 23:657 – 662.
Cutaneous Laser Surgery: Historical Perspectives 198. 199. 200. 201. 202. 203. 204. 205.
206.
207. 208.
209.
210.
211. 212. 213. 214. 215. 216. 217. 218.
219. 220.
221.
47
Anvari B, Milner T, Tanenbaum B et al. A comparative study of human skin thermal response to sapphire contact and cryogen spray cooling. IEEE Trans Biomed Eng 1998; 45:934 – 941. Altshuler G, Zenzie H, Erofeev A et al. Contact cooling of the skin. Phys Med Biol 1999; 44:1003 – 1023. Zenzie H, Altshuler G, Smirnov M et al. Evaluation of cooling methods for laser dermatology. Lasers Surg Med 2000; 26:130 – 144. Pfefer T, Smithies D, Milner T et al. Bioheat transfer analysis of cryogen spray cooling during laser treatment of port wine stains. Lasers Surg Med 2000; 26:145 – 157. Anvari B, Ver Steeg B, Tanenbaum B et al. Cryogenic spray cooling: a preliminary study during 532 laser irradiation of port wine stains. Cosmet Dermatol 2000; 13:22– 26. Ross B, Levine V, Ashinoff R. Laser treatment of acquired vascular lesions. Dermatol Clin 1997; 15:385 – 396. Keller G, Doiron D, Keller R. Treatment of vascular lesions with a CW yellow dye laser— initial trials. Otolaryngol Head Neck Surg 1986; 95:527– 530. Schliftman A, Brauner G. The comparative tissue effects of copper vapor laser (578 nm), argon/dye laser and argon laser (488,514 nm) on vascular lesions. Lasers Surg Med 1988; 8:188. (Abstract.) Brauner G. Comparison of argon, Argon Dye, Copper Vapor Lasers in the Treatment of Telangiectases and Port-Wine Stains. Little Rock, AR: University of Arkansas for Medical Sciences, 1990. Schliftman A, Brauner G. Test results comparing copper vapor and flashlamp pumped dye laser. Lasers Surg Med 1991; (suppl 3):69. (Abstract.) Waner M, Dinehart S, Wilson M et al. A comparison of copper vapor and flashlamp pumped dye lasers in the treatment of facial telangiectasia. J Dermatol Surg Oncol 1993; 19:992 – 998. Sheehan-Dare R, Cotterill J. Copper vapour laser treatment of port-wine stains: clinical evaluation and comparison with conventional argon laser therapy. Br J Dermatol 1993; 128:546 – 549. Sheehan-Dare R, Cotterill J. Copper vapour laser (578 nm) and flashlamp-pumped pulsed tunable dye laser (585 nm) treatment of port wine stains: results of a comparative study using test sites. Br J Dermatol 1994; 130:478 – 482. McCoy S, Hanna M, Anderson P et al. An evaluation of the copper-bromide laser for treating telangiectasia. Dermatol Surg 1996; 22:551 – 557. McCoy S. Copper bromide laser treatment of facial telangiectasia: results of patients treated over five years. Lasers Surg Med 1997; 21:329 – 340. Bernstein E, Lee J, Lowery J et al. Treatment of spider veins with the 595 nm pulsed-dye laser. J Am Acad Dermatol 1998; 39:746 –750. Dixon J, Rotering R, Huether S. Patients’ evaluation of argon laser therapy of portwine stain, decorative tattoo, and essential telangiectasia. Laser Surg Med 1984; 4:181 – 190. Dixon J, Gilbertson J. Argon and neodymium YAG laser therapy of dark nodular port wine stains in older patients. Lasers Surg Med 1986; 6:5 –11. Fisher A, Lasers and allergic contact dermatitis to topical antibiotics, with particular reference to bacitracin. Cutis 1996; 58:252– 254. David L, Ruiz-Esparza J. Fast healing after laser skin resurfacing. The minimal mechanical trauma technique. Dermatol Surg 1997; 23:359– 361. Ruiz-Esparza J, Barba-Gomez J, Gomez-de-la-Torre O. Wound care after laser skin resurfacing. A combination of open and closed methods using a new polyethylene mask. Dermatol Surg 1998; 24:79 –81. Fitzpatrick R. Laser resurfacing of rhytids. Dermatol Clin 1997; 15:431 – 447. Trelles M, Rigau J, Mellor T, Garcia L. A clinical and histological comparison of flashscanning versus pulsed technology in carbon dioxide laser facial skin resurfacing. Dermatol Surg 1998; 24:43 – 49. Weinstein C, Ramirez O, Pozner J. Postoperative care following carbon dioxide laser resurfacing. Avoiding pitfalls. Dermatol Surg 1998; 24:51 –56.
48 222. 223. 224. 225. 226.
227. 228.
229. 230. 231. 232.
233. 234.
235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246.
Brauner Fulton J. Complications of laser resurfacing. Methods of prevention and management. Dermatol Surg 1998; 24:91 –99. Shim E, Tse Y, Velazquez E et al. Short-pulse carbon dioxide laser resurfacing in the treatment of rhytides and scars. A clinical and histopathological study. Dermatol Surg 1998; 24:113–117. Suarez M, Fulton J. A novel occlusive dressing for skin resurfacing. Dermatol Surg 1998; 24:567 – 570. Geronemus R, Alster T, Brandt F et al. Table talk: common questions about laser resurfacing. Dermatol Surg 1998; 24:123 –124. Davis S, Badiavas E, Rendon-Pellerano M et al. Histological Comparison of postoperative wound care regimens for laser resurfacing in a porcine model. Dermatol Surg 1999; 25:387 – 393. Ratner D, Tse Y, Marchell N et al. Cutaneous laser resurfacing. J Am Acad Dermatol 1999; 41:365 – 389. Greenwald J, Rosen S, Anderson R et al. Comparative histological studies of the tunable dye (at 577 nm) laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Nakagawa H, Tan O, Parrish J. Ultrastructural changes in human skin after exposure to a pulsed laser. J Invest Dermatol 1985; 84:396 –400. Garden J, Tan O, Kerschmann R et al. Effect of dye laser pulse duration on selective cutaneous vascular injury. J Invest Dermatol 1986; 87:653 –657. Morelli J, Tan O, Garden J et al. Tunable dye laser (577 nm) treatment of port-wine stains. Lasers Surg Med 1986; 6:94 – 99. Tan O, Carney J, Margolis R et al. Histologic responses of port-wine stains treated by argon, carbon dioxide, and tunable dye lasers. A preliminary report. Arch Dermatol 1986; 122:1016 – 1022. Garden J, Polla L, Tan O. The treatment of port-wine stains by the pulsed dye laser. Analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124:889 – 896. Tan O, Whitaker D, Garden J et al. Pulsed dye laser (577 nm) treatment of port-wine stains: ultrastructural evidence of neovascularization and mast cell degranulation in healed lesions. J Invest Dermatol 1988; 90:395 – 398. Tan O, Murray S, Kurban A. Action spectrum of vascular specific injury using pulsed irradiation. J Invest Dermatol 1989; 92:868 – 871. Nakagawa H, Tan O, Parrish J. Ultrastructural changes in human skin after exposure to a pulsed laser. J Invest Dermatol 1985; 84:396 –400. Garden J, Tan O, Kerschmann R et al. Effect of dye laser pulse duration on selective cutaneous vascular injury. J Invest Dermatol 1986; 87:653 –657. Garden J, Polla L, Tan O. The treatment of port-wine stains by the pulsed dye laser. Analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124:889 – 896. Kurban A, Sherwood K, Tan O. What are the optimal wavelengths for selective vascular injury? Lasers Surg Med 8:189, 1988. Tan O, Sherwood K, Gilchrest B. Treatment of children with port-wine stains using the flashlamp-pulsed tunable dye laser. N Engl J Med 1989; 320:416 – 421. Garden J, Burton C, Geronemus R. Dye laser treatment of children with portwine stains. N Engl J Med 1989; 321:901 – 902. Tan O, Morrison P, Kurban A. 585 nm for the treatment of port-wine stains. Plast Reconstr Surg 1990; 86:1112 – 1117. Garden J, Bakus A, Paller A. Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: prospective analysis. J Pediatr 1992; 120:555 – 560. Garden J, Bakus A. Laser treatment of port-wine stains and hemangiomas. Dermatol Clin 1997; 15:373 – 383. Walker E, Butler P, Pickering J et al. Histology of port wine stains after copper vapour laser treatment. Br J Dermatol 1989; 121:217– 223. Pickering J, Walker E, Butler P et al. Copper vapour laser treatment of port-wine stains and other vascular malformations. Br J Plast Surg 1990; 43:273– 282.
Cutaneous Laser Surgery: Historical Perspectives 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273.
49
Dinehart S, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. Lasers Surg Med 1990; 10:52 – 53. Neumann R, Knobler R, Leonhartsberger H et al. Comparative histochemistry of port-wine stains after copper vapor laser (578) and argon laser treatment. J Invest Dermatol 1992; 99:160–167. Reyes B, Geronemus R. Treatment of port-wine stains during childhood with the flashlamppumped dye laser. J Am Acad Dermatol 1990; 23:1142 – 1148. Garden J, Bakus A. Laser treatment of portwine stains and hemangiomas. Dermatol Clin 1997; 15:373 – 383. Renfro L, Geronemus R. Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser. Arch Dermatol 1993; 129:182 – 188. Rosenfeld H, Sherman R. Treatment of cutaneous and deep vascular lesions with the Nd:YAG laser. Lasers Surg Med 1986; 6:20– 23, 50– 51. Shapshay S, David L, Zeitels S. Neodymium-YAG laser photocoagulation of hemangiomas of the head and neck. Laryngoscope 1987; 97:323 –330. Apfelberg D, Smith T, Lash H et al. Preliminary report on use of the neodymium – YAG laser in plastic surgery. Lasers Surg Med 1987; 7:189 – 198. Achauer B, Vanderkam V. Capillary hemangioma (strawberry mark) of infancy: comparison of argon and Nd:YAG laser treatment. Plast Reconstr Surg 1989; 84:60 –69, discussion 70. Apfelberg D, Maser M, Lash H et al. YAG laser resection of complicated hemangiomas of the hand and upper extremity. J Hand Surg Am 1990; 15:765– 773. Apfelberg D, Maser M, White D et al. Benefits of contact and noncontact YAG laser for periorbital hemangiomas. Ann Plast Surg 1990; 24:397 – 408. Landthaler M, Hohenleutner U, el Raheem T. Laser therapy of childhood haemangiomas. Br J Dermatol 1995; 133:275 – 281. Suen J, Waner M. Treatment of oral cavity vascular malformations using the neodymium:YAG laser. Arch Otolaryngol Head Neck Surg 1989; 115:1329 –1333. Waner M, Suen J, Dinehart S. Treatment of hemangiomas of the head and neck. Laryngoscope 1992; 102:1123– 1132. Hukki J, Krogerus I, Casteren M et al. Effects of different contact laser scalpels on skin and subcutaneous fat. Lasers Surg Med 1987; 7:189– 198. Daikuzono N, Joffe S. Artificial sapphire probe for contact photocoagulation and tissue vaporization with the Nd:YAG laser. Med Instrument 1988; 19:173. Apfelberg D, Bailin P, Rosenberg H. Preliminary investigation of KTP/532 laser light in the treatment of hemangiomas and tattoos. Lasers Surg Med 1986; 6:38 – 42, 56 – 57. Yules R, Laub D, Honey R et al. The effect of Q-switched ruby laser radiation on Dermatolal tattoo pigment in man. Arch Surg 1967; 95:179– 180. Laub D, Yules R, Arras M et al. Preliminary histopathologic observation of Q-switched ruby laser radiation on Dermatolal tattoo pigment in man. J Surg Res 1968; 8:220– 224. Reid W, McLeod P, Ritchie A et al. Q-switched ruby laser treatment of black tattoos. Brit J Plast Surg 1983; 36:455 – 459. Reid W, Miller I, Murphy M et al. Q-switched ruby laser treatment of tattoos: a 9-year experience. Br J Plast Surg 1990; 43:663 –669. Taylor C, Gange R, Dover J et al. Treatment of tattoos by Q-switched ruby laser. Arch Dermatol 1990; 126:893 – 899. Taylor C, Anderson R, Gange R et al. Light and electron microscopic analysis of tattoos treated by Q-switched ruby laser. J Invest Dermatol 1991; 97:131– 136. Polla L, Margolis R, Dover J et al. Melanosomes are a primary target of Q-switched ruby laser irradiation in guinea pig skin. J Invest Dermatol 1987; 89:281 – 286. Dover J, Margolis R, Polla L et al. Pigmented guinea pig skin irradiated with Q-switched ruby laser pulses. Arch Dermatol 1989; 125:43– 49. Kilmer S, Lee M, Grevelink J et al. The Q-switched Nd:YAG laser (1064 nm) effectively treats tattoos: a controlled, dose-response study. Arch Dermatol 1993; 129:971 – 978. Kilmer S, Anderson R. Clinical use of the Q-switched ruby and Q-switched Nd:YAG (1064 and 532 nm) lasers for the treatment of tattoos. J Dermatol Surg Oncol 1993; 19:330–338.
50 274. 275. 276. 277. 278. 279.
280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291.
292. 293. 294. 295. 296. 297.
298. 299. 300.
Brauner Kilmer S. Laser treatment of tattoos. Dermatol Clin 1997; 15:409– 417. Brauner G, Schliftman A. Treatment of pigmented lesions of the skin with alexandrite laser. Lasers Surg Med 1992; (suppl 4):72. (Abstract.) Fitzpatrick R, Ruiz-Esparza J, Goldman M. The alexandrite laser for tattoos: a preliminary report. Lasers Surg Med 1992; 4S:321. Fitzpatrick R, Goldman M. Tattoo removal using the alexandrite laser (755 nm, 100 ns). Arch Dermatol 1994; 130:1508 – 1514. Sherwood K, Murray S, Kurban A et al. Effect of wavelength of cutaneous pigment using pulsed irradiation. J Invest Dermatol 1989; 92:717 – 720. Fitzpatrick R, Goldman M, Ruiz-Esparza J. Laser treatment of benign pigmented epidermatolal lesions using a 300 ns pulse and 510 nm wavelength. J Dermatol Surg Oncol 1993; 19:341 – 347. Murphy G, Shepard R, Paul B et al. Organelle-specific injury to melanin- containing cells in human skin by pulsed laser irradiation. Lab Invest 1983; 49:680 – 685. Margolis R, Dover J, Polla L et al. Visible action spectrum for melanin-specific selective photothermolysis. Lasers Surg Med 1989; 389– 397. Goldberg D. Benign pigmented lesions of the skin. Treatment with the Q-switched ruby laser. J Dermatol Surg Oncol 1993; 19:376– 379. Goldberg D. Laser treatment of pigmented lesions. Dermatol Clin 1997; 15:397– 407. Alster T. Complete elimination of large cafe-au-lait birthmarks by the 510 nm pulsed dye laser. Plast Reconstr Surg 1995; 96:1660 – 1664. Alster T, Williams C. Cafe-au-lait macule in type V skin: successful treatment with a 510 nm pulsed dye laser. J Am Acad Dermatol 1995; 33:1042 – 1043. Brauner G, Schliftman A. Treatment of pigmented lesions with the flashlamp pumped PLDL (brown spot) laser. Lasers Surg Med 1992; (suppl 4):73. (Abstract.) Grossman M, Anderson R, Farinelli W et al. Treatment of cafe au lait macules with lasers. a clinicopathologic correlation. Arch Dermatol 1995; 131:1416 – 1420. Levy J, Mordon S, Pizzi-Anselme M. Treatment of individual cafe´ au lait macules with the Q-switched Nd:YAG: a clinicopathologic correlation. J Cutan Ther 1999; 1:217 – 223. Arndt K. Argon laser treatment of lentigo maligna. J Am Acad Dermatol 1984; 10:953 – 957. Arndt K. New pigmented macule appearing four years after argon laser treatment of lentigo maligna. J Am Acad Dermatol 1986; 14:1092. Suzuki H, Kobayashi S, Yamamoto K et al. The optimal age to begin and optimal interval for treatment of nevus of Ota with the Q-switched Nd:YAG laser. Lasers Surg Med 1996; (suppl 8):39. Haywood R, Monk B. Treatment of poikiloderma of Civatte with the pulsed dye laser: a series of seven cases. J Cutan Laser Ther 1999; 1:45– 48. Nanni C, Alster T. Complications of cutaneous laser surgery. A review. Dermatol Surg 1998; 24:209 – 219. Kelly K, Nelson J, Lask G et al. Cryogen spray cooling in combination with non-ablative laser treatment of facial rhytids. Arch Dermatol 1999; 135:691 – 694. Hruza G, Dover J, Flotte T et al. Q-switched ruby laser irradiation of normal human skin. Histologic and ultrastructural findings. Arch Dermatol 1991; 127:1799 – 1805. Waldorf H, Kauvar A, Geronemus R. Treatment of small and medium congenital nevi with the Q-switched ruby laser. Arch Dermatol 1996; 132:301 – 304. Rosenbach A, Williams C, Alster T. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg 1997; 23:239 –244, discussion 244– 245. Ueda S, Imayama S. Normal-mode ruby laser for treating congenital nevi. Arch Dermatol 1997; 133: 355 –359. Alster T, Kurban A, Grove G et al. Alteration of argon laser-induced scars by the pulsed dye laser. Lasers Surg Med 1993; 13:368 –373. Alster T. Improvement of erythematous and hypertrophic scars by the 585 nm pulsed dye laser. Ann Plast Surg 1994; 32:186 – 190.
Cutaneous Laser Surgery: Historical Perspectives 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317.
318. 319. 320.
321.
322. 323. 324. 325. 326. 327. 328.
51
Alster T. Laser treatment of erythematous/hypertrophic pigmented scars in 26 patients. Plast Reconstr Surg 1995; 95:91. Alster T, Williams C. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345:1998 – 2001. Dierickx C, Goldman M, Fitzpatrick R. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 1995; 94:84 – 90. Goldman M, Fitzpatrick R. Laser treatment of scars. Dermatol Surg 1995; 21:685 – 687. Alster T, McMeekin T. Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. J Am Acad Dermatol 1996; 35:79 – 81. Alster T. Laser treatment of hypertrophic scars, keloids and striae. Dermatol Clin 1997; 15:419 – 429. McDaniel D. Laser resurfacing of stretch marks. Laser Surg Med 1995; S7:52. (Abstract.) McDaniel D, Ash K, Zukowski M. Treatment of stretch marks with he 585 nm flashlamppumped pulsed dye laser. Dermatol Surg 1996; 22:332 – 337. Nehal K, Levine V, Ashinoff R. Treatment of mature striae with the pulsed dye laser. Lasers Surg Med 1998; s10:41. (Abstract.) Nehal K, Lichtenstein D, Kamino H et al. Treatment of mature striae with the pulsed dye laser. J Cutan Laser Ther 1999; 1:41– 44. Shapshay S, Strong M, Anastasi G et al. Removal of rhinophyma with the carbon dioxide laser: a preliminary report. Arch Otolaryngol 1980; 106:257 – 259. David L. Laser vermilion ablation for actinic cheilitis. J Dermatol Surg Oncol 1985; 11:605–608. Whitaker D. Microscopically proven cure of actinic cheilitis by CO2 laser. Lasers Surg Med 1987; 7:520 – 523. Zelickson B, Roenigk R. Actinic cheilitis. Treatment with the carbon dioxide laser. Cancer 1990; 65:1307 – 1311. David L, Lask G, Glassberg E et al. Laser abrasion for cosmetic and medical treatment of facial actinic damage. Cutis 1989; 43:583 – 587. Hobbs E, Bailin P, Wheeland R et al. Superpulsed lasers: minimizing thermal damage with short duration, high irradiance pulses. J Dermatol Surg Oncol 1987; 13:955 –964. Fitzpatrick R, Goldman M, Ruiz-Esparza J. Clinical advantage of the CO2 laser superpulsed mode. Treatment of verruca vulgaris, seborrheic keratoses, lentigines, and actinic cheilitis. J Dermatol Surg Oncol 1994; 20:449 –456. Fitzpatrick R. The ultrapulse CO2 laser: selective photothermolysis of epidermatolal tumors. Lasers Surg Med 1993; (suppl 5):56. (Abstract.) Fitzpatrick R, Goldman M, Satur N et al. Pulsed carbon dioxide laser resurfacing of photoaged facial skin. Arch Dermatol 1996; 132:395 – 402. Fitzpatrick R, Tope W, Goldman M et al. Pulsed carbon dioxide laser, trichloroacetic acid, Baker Gordon phenol, and Dermatolabrasion: a comparative clinical and histologic study of cutaneous resurfacing in a porcine model. Arch Dermatol 1996; 132:469 – 471. Kauvar A, Geronemus R, Waldorf H. Char free tissue ablation: a comparative histopathological analysis of new carbon dioxide (CO2) laser systems. Lasers Surg Med 16 1995; (suppl 7):50. Waldorf H, Kauvar A, Geronemus R. Skin resurfacing of fine to deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg 1995; 21:940 – 946. Kauvar A, Geronemus R. Histology of laser resurfacing. Dermatol Clin 1997; 15:459 – 467. Kauvar A. Laser skin resurfacing: perspectives at the millennium. Dermatol Surg 2000; 26:174 – 177. David L, Sarne A, Unger W. Rapid laser scanning for facial resurfacing. Dermatol Surg 1995; 21:1031 – 1033. Dover J, Hruza G. Laser skin resurfacing. Semin Cutan Med Surg 1996; 15:177 – 188. Hruza G, Dover J. Laser skin resurfacing. Arch Dermatol 1996; 132:395 – 402. Cotton J, Hood A, Gonin R et al. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulse carbon dioxide laser. Arch Dermatol 1996; 132:425 – 428.
52 329.
330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354.
Brauner Ross E, Grossman M, Anderson R. Treatment of facial rhytides: comparing a pulsed CO2 laser with a collimated beam to a CO2 laser enhanced by a flashscanner. Lasers Surg Med 15 1995; (suppl 7):50. (Abstract) Ross E, Grossman M, Duke D et al. Long-term results after CO2 laser skin resurfacing: a comparison of scanned and pulsed systems. J Am Acad Dermatol 1997; 37:709 – 718. Chernoff W, Schoenrock L, Cramer H et al. Cutaneous laser resurfacing. Int J Aesthet Restor Surg 1995; 3:57– 68. Chernoff G, Slatkine M, Zair E et al. Silk touch: a new technology for skin resurfacing in aesthetic surgery. J Clin Laser Med Surg 1995; 13:97 – 100. Lowe N, Lask G, Griffin M et al. Skin resurfacing with the Ultrapulse carbon dioxide laser. Observations on 100 patients. Dermatol Surg 1995; 21:1025 –1029. Lask G, Keller G, Lowe N et al. Laser skin resurfacing with the SilkTouch flashscanner for facial rhytides. Dermatol Surg 1995; 21:1021 – 1024. West T. Laser resurfacing of atrophic scars. Dermatol Clin 1997; 15:449 –457. Burns A. Combined use of lasers in facial resurfacing. Laser skin resurfacing. American Society for Laser Medicine and Surgery Annual Meeting, Phoenix AK, Apr 1997. Alster T, Nanni C, Williams C. Comparison of four carbon dioxide resurfacing lasers. A clinical and histopathologic evaluation. Dermatol Surg 1999; 25:153 – 158. Field L. Laser resurfacing hysteria. The media, the marketers, the companies and us. Dermatol Surg 1998; 24:684 –686. Kaufmann R, Hibst R. Pulsed Er:YAG and 308 nm UV-Excimer laser: an in vitro and in vivo study of skin-ablative effects. Lasers Surg Med 1989; 9:132– 140. Kaufmann R, Hibst R. Pulsed Erbium:YAG laser ablation in cutaneous surgery. Lasers Surg Med 1989; 19:324– 330. Kaufmann R, Hibst R. Pulsed 2.94 mm erbium:YAG laser skin ablation: experimental results and first clinical application. Clin Exp Dermatol 1990; 15:389– 393. Hibst R, Kaufmann R. Effects of laser parameters on pulsed erbium:YAG laser skin ablation. Lasers Med Sci 1991; 6:391– 397. Kaufmann R, Hartmann A, Hibst R. Cutting and skin-ablative properties of pulsed midinfrared laser surgery. J Dermatol Surg Oncol 1994; 20:112 – 118. Wolbarsht M, Esterowitz L, Tran D et al. A mid-infrared (2.94) surgical laser with an optical fiber delivery system. Lasers Surg Med 1986; 6:257 – 258. Wolbarsht M, Foulks G, Esterowitz L et al. Corneal surgery with an Er:YAG laser at 2.94 um. Lasers Surg Med 1986; 6:241. Walsh J, Flotte T, Deutsch T. Er:YAG laser ablation of tissue: effect of pulse duration and tissue type on thermal damage. Lasers Surg Med 1989; 9:314 – 326. Walsh J, Deutsch T. Er:YAG laser ablation of tissue: measurement of ablation rates. Lasers Surg Med 1989; 9:327 – 337. Teikemeier G, Goldberg D. Skin resurfacing with the erbium:YAG laser. Dermatol Surg 1997; 23:685 – 687. Bernstein L, Kauvar A, Grossman M et al. The short- and long-term side effects of carbon dioxide laser resurfacing. Dermatol Surg 1997; 23:519– 525. Schwartz R, Burns A, Rohrich R et al. Long-term assessment of CO2 facial laser resurfacing: aesthetic results and complications. Plast Reconstr Surg 1999; 103:592– 601. Adrian R. Pulsed carbon dioxide and erbium-YAG laser resurfacing: a comparative clinical and histologic study. J Cutan Laser Ther 1999; 1:29– 35. Adrian R. Pulsed carbon dioxide and long pulse 10-ms erbium-YAG laser resurfacing: a comparative clinical and histologic study. J Cutan Laser Ther 1999; 1:197– 202. Khatri K, Ross V, Grevelink J et al. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol 1999; 135:391 – 397. Newman J, Lord J, Ash K, McDaniel D. Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26:208 – 214.
Cutaneous Laser Surgery: Historical Perspectives 355. 356.
357.
358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383.
53
Alster T. Clinical and histologic evaluation of six erbium:YAG lasers for cutaneous resurfacing. Lasers Surg Med 1999; 24:87– 92. McDaniel D, Lord J, Ash K et al. Combined CO2/erbium:YAG laser resurfacing of peri-oral rhytides and side-by-side comparison with carbon dioxide laser alone. Dermatol Surg 1999; 25:285 – 293. Newman J, Lord J, Ash K et al. DH.Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26:208 – 214. Zachary C. Modulating the Er:YAG laser. Lasers Surg Med 2000; 26:223 –226. Alster T, Lupton J. Erbium:YAG cutaneous laser resurfacing. Dermatol Clin 2001; 19:453–466. Rostan E, Fitzpatrick R, Goldman M. Laser resurfacing with a long pulse erbium:YAG laser compared to the 950 ms pulsed CO(2) laser. Lasers Surg Med 2001; 29: 136 – 141. Trelles M, Allones I, Luna R. One-pass resurfacing with a combined-mode erbium:YAG/ CO2 laser system: a study in 102 patients. Br J Dermatol 2002; 146: 473 – 480. Weinstein C, Scheflan M. Simultaneously combined ER:YAG and carbon dioxide laser (Dermatola K) for skin resurfacing. Clin Plast Surg 2000; 27:273– 285, xi. Comment in: Dermatol Surg 1995; 21:564– 565 on Unger W, David L. Laser hair transplantation. J Dermatol Surg Oncol 1994; 20:515 – 521. Dzubow L. Hair transplantation. Process and product. [(Published erratum appears in J Dermatol Surg Oncol 1994; 20:571.) J Dermatol Surg Oncol 1994; 20:509 – 510.] Bernstein R, Rassman W. Laser hair transplantation: is it really state of the art? Lasers Surg Med 1996; 19:233– 235, discussion 236– 238. Fitzpatrick R, Marchell N. Laser hair transplantation II. Dermatol Surg 2000; 26:419– 424. Unger W, David L. Laser hair transplantation. J Dermatol Surg Oncol 1994; 20:515 – 521. Unger W. Laser hair transplantation. Dermatol Surg 1995; 21:186– 187. Unger W. Laser hair transplantation II. Dermatol Surg 1995; 21:759– 765. Unger W. Laser hair transplantation III. Computer-assisted laser transplanting. Dermatol Surg 1995; 21:1047 – 1055. Fitzpatrick R. Laser hair transplantation. Tissue effects of laser parameters. Dermatol Surg 1995; 21:1042 – 1046. Ho C, Nguyen Q, Lask G et al. Mini-slit graft hair transplantation using the Ultrapulse carbon dioxide laser handpiece. Dermatol Surg 1995; 21:1056– 1059. Grevelink J, Brennick J. Hair transplantation facilitated by flashscanner-enhanced carbon dioxide laser operative techniques. Otolaryngol Head Neck Surg 1994; 5:278 – 280. Grevelink J, Farinelli W, Bua D et al. Hair transplantation aided by CO2 lasers. Lasers Surg Med 1995; S7:S47. Smithdeal C. Carbon dioxide laser-assisted hair transplantation. The effect of laser parameters on scalp tissue—a histologic study. Dermatol Surg 1997; 23:835 – 840. Tsai R, Chen D, Chan H et al. Experience with laser hair transplantation in Orientals. Dermatol Surg 1998; 24:1065 – 1068. Neidel F, Fuchs M, Krahl D. Laser-assisted autologous hair transplantation with the Er:YAG laser. J Cutan Laser Ther 1999; 1:229 –231. Grevelink J. Laser hair transplantation. Dermatol Clin 1997; 15:479 – 486. Gold M, Bell M, Foster T et al. Long term epilation using the Epilight broad band, intense pulsed light hair removal system. Dermatol Surg 1997; 23:909 – 913. Schroeter C. Hair removal with the PhotoDermatol VL as an intense light source: a histopathological study. Lasers Surg Med 1998; (suppl 10):3. Lask G, Eckhouse S, Slatkine M et al. The role of laser and intense light sources in photoepilation: a comparative evaluation. J Cutan Laser Ther 1999; 1:3 – 14. Sadick N, Shea C, Burchette J et al. High-intensity flashlamp photoepilation: a clinical, histological, and mechanistic study in human skin. Arch Dermatol 1999; 135:668–676. Johnson F, Dovale M. Intense pulsed light treatment of hirsutism: case reports of skin phototypes V and VI. J Cutan Laser Ther 1999; 1:233– 237.
54 384. 385. 386. 387. 388. 389.
390. 391. 392. 393. 394. 395. 396. 397. 398. 399.
400. 401. 402. 403. 404. 405. 406.
407. 408. 409. 410.
Brauner Goldman M. Leg veins and laser. Lasers Surg Med 1994; (suppl 6):48. Schroeter C, Neumann H. An intense light source. The photoderm VL-flashlamp as a new treatment possibility for vascular skin lesions. Dermatol Surg 1998; 24:743 – 748. Dover J, Sadick N, Goldman M. The role of lasers and light sources in the treatment of leg veins. Dermatol Surg 1999; 25:328 – 336. Raulin C, Schroeter C, Weiss R et al. Treatment of port-wine stains with a noncoherent pulsed light source: a retrospective study. Arch Dermatol 1999; 135:679 – 683. Bitter P. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg 2000; 26:835 – 842, discussion 843. Hernandez-Perez E, Ibiett E. Gross and microscopic findings in patients submitted to nonablative full-face resurfacing using intense pulsed light: a preliminary study. Dermatol Surg 2002; 28:651 –655. Negishi K, Tezuka Y, Kushikata N et al. Photorejuvenation for Asian skin by intense pulsed light. Dermatol Surg 2001; 27:627 – 631, discussion 632. Goldberg D, Cutler K. Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 2000; 26:196– 200. Goldberg D. New collagen formation after dermal remodeling with an intense pulsed light source. J Cutan Laser Ther 2000; 2:49– 61. Berry J. Recurrent trichiasis: treatment with laser photocoagulation Ophthalmic Surg 1979; 10:36 – 38. Kuriloff D, Finn D, Kimmelman C. Pharyngoesophageal hair growth: the role of laser epilation. Otolaryngol Head Neck Surg 1988; 98:342– 345. Finkelstein L, Blatstein L. Epilation of hair-bearing urethral grafts using the neodymium: YAG surgical laser. J Urol 1991; 146:840 – 842. Gossman M, Yung R, Berlin A et al. Prospective evaluation of the argon laser in the treatment of trichiasis. Ophthalmic Surg 1992; 23:183 – 187. Goldberg D. Topical solution—assisted laser hair removal. Lasers Surg Med 1995; 7S:47. Goldberg D, Littler C, Wheeland R. Topical suspension-assisted Q-switched Nd:YAG laser hair removal. Dermatol Surg 1997; 23:741 –745. Nanni C, Alster T. Optimizing treatment parameters for hair removal using a topical carbonbased solution and 1064-nm Q-switched neodymium:YAG laser energy. Arch Dermatol 1997; 133:1546 – 1549. Grossman M, Farinelli W, Flotte T et al. Laser targeted at hair follicles. Lasers Surg Med 1995; S7:47. Wheeland R. Laser-assisted hair removal Dermatol Clin 1997; 15:469– 477. Grossman M, Dierickx C, Farinelli W et al. Damage to hair follicles by normal-mode ruby laser pulses. J Am Acad Dermatol 1996; 35:889– 894. Anderson R, Burns A, Garden J et al. Multicenter study of long-pulse ruby laser hair removal. Lasers Surg Med suppl 1999; 11:56. (Abstracts.) Lin T, Manuskiatti W, Dierickx C et al. Hair growth cycle affects hair follicle destruction by ruby laser pulses. J Invest Dermatol 1998; 111:107 – 113. Dierickx C, Grossman M, Farinelli W et al. Permanent hair removal by normal-mode ruby laser. Arch Dermatol 1998; 134:837 –842. Nanni C, Alster T. A practical review of laser assisted hair removal using the Q-switched Nd:YAG, long-pulsed ruby and long-pulsed alexandrite lasers. Dermatol Surg 1998; 24:1399 – 1405. Goldberg D, Ahkami R. Evaluation comparing multiple treatments with a 2-msec and 10-msec alexandrite laser for hair removal. Lasers Surg Med 1999; 25:223– 228. Battle E. Hypertrichosis [treatment modalities for dark skin types]. American Academy of Dermatology Annual Meeting, San Francisco, CA, Mar 14, 2000. Nelson J, Milner T, Dave D et al. Clinical study of non-ablative laser treatment of facial rhytides. Lasers Surg Med 1997; 95:32– 33. Hoffman W, Anvari B, Said S et al. Cryogen spray cooling during Nd:YAG laser treatment of hemangiomas. A preliminary animal model study. Dermatol Surg 1997; 23:635– 641.
Cutaneous Laser Surgery: Historical Perspectives 411. 412. 413.
414. 415. 416. 417. 418.
419. 420.
421. 422. 423. 424.
425. 426. 427. 428. 429. 430. 431. 432. 433.
434. 435.
55
Goldman M. Non-ablative laser treatment of wrinkles. Cosmet Dermatol 2000; 13:17 – 20. Menaker G, Wrone D, Williams R et al. Treatment of facial rhytids with a non-ablative laser: a clinical and histologic study. Dermatol Surg 1999; 25:440– 444. Ross E, Sajben F, Hsia J et al. Nonablative skin remodeling: selective dermal heating with a mid-infrared laser and contact cooling combination. Lasers Surg Med 2000; 26:186 – 195. Muccini J, O’Donnell F, Fuller T et al. Rapid report; laser treatment of solar elastosis with epithelial preservation. Lasers Surg Med 1998; 23:121– 127. Goldberg D, Whitworth J. Laser skin resurfacing with the Q-switched Nd:YAG laser. Dermatol Surg 1997; 23:903 –906, discussion 906 – 907. Goldberg D, Cutler K, Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 2000; 26:196 – 200. Hardaway C, Ross EV. Nonablative laser skin remodeling. Dermatol Clin 2000; 20:97 – 111,ix. Bernstein E, Ferreira M, Anderson D. A pilot investigation to subjectively measure treatment effect and side-effect profile of non-ablative skin remodeling using a 532 nm, 2 ms pulseduration laser. J Cosmet Laser Ther 2001; 3:137– 141. Zelickson B, Kilmer S, Bernstein E et al. Pulsed dye laser therapy for sun damaged skin. Lasers Surg Med 1999; 25:229 – 236. Rostan E, Bowes L, Iyer S et al. A double-blind, side-by-side comparison study of low fluence long pulse dye laser to coolant treatment for wrinkling of the cheeks. J Cosmet Laser Ther 2001; 3:129 – 136. Bjerring P, Clement M, Heickendorff L et al. Selective non-ablative wrinkle reduction by laser. J Cutan Laser Ther 2000; 2:9– 15. Goldberg D. Non-ablative subsurface remodeling: clinical and histologic evaluation of a 1320-nm Nd:YAG laser. J Cutan Laser Ther 1999; 3:153– 157. Trelles M, Allones I, Luna R. Facial rejuvenation with a nonablative 1320 nm Nd:YAG laser: a preliminary clinical and histologic evaluation. Dermatol Surg 2001; 27:111– 116. Fournier N, Dahan S, Barneon G et al. Nonablative remodeling: clinical, histologic, ultrasound imaging, and profilometric evaluation of a 1540 nm Er:glass laser. Dermatol Surg 2001; 27:799 –806. Mester E et al. Laserstrahlenwirkung auf das Wachstum des Erlichsen Ascitestumor. Arch Geschwultsforsch 1968; 32:201. Mester E et al. Stimulation of wound healing by laser rays. Acta Chir Acad Sci Hung 1972; 13:315. Mester E, Mester A, Mester A. The biomedical effects of laser application. Lasers Surg Med 1985; 5:31 – 39. Wheeland R. Lasers for the stimulation or inhibition of wound healing. J Dermatol Surg Oncol 1993; 19:747 –752. Castro D, Abergel R, Meeker C et al. Effects of the Nd:YAG laser on DNA synthesis and collagen production in human skin fibroblast cultures. Ann Plast Surg 1983; 11:214 – 222. Abergel R, Meeker C, Dwyer R et al. Nonthermal effects of Nd:YAG laser on biological functions of human skin fibroblasts in culture. Lasers Surg Med 1984; 3:279– 284. Abergel R, Dwyer R, Meeker C et al. Laser treatment of keloids. Lasers Surg Med 1984; 4:291 – 295. Abergel R, Meeker C, Lam T et al. Control of connective tissue metabolism by lasers; recent developments and future prospects. J Am Acad Dermatol 1984; 11:1142– 1150. Castro D, Saxton R, Fetterman H et al. Biostimulative effects of Nd:YAG Q-switch dye on normal human fibroblast cultures: study of a new chemosensitizing agent for the Nd:YAG laser. Laryngoscope 1987; 97:1454 – 1459. Abergel R, Lyons R, Castel J et al. Biostimulation of wound healing by lasers: experimental approaches in animal models and in fibroblast cultures. J Dermatol Surg Oncol 1987; 13:127–133. Lyons R, Abergel R, White R et al. Biostimulation of wound healing in vivo by a helium-neon laser. Ann Plast Surg 1987; 18:47 – 50.
56 436.
437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458.
459. 460. 461. 462. 463.
Brauner Castro D, Saxton R, Fetterman H et al. Bioinhibition of human fibroblast cultures sensitized to Q-switch II dye and treated with the Nd:YAG laser: a new technique of photodynamic therapy with lasers. Laryngoscope 1989; 99:421 – 428. Saxton R, Haghighat S, Plant D et al. Dose response of human tumor cells to rhodamine 123 and laser phototherapy. Laryngoscope 1994; 104:1013 – 1018. Raab O. Uber die Wirkung fluorescierendes stoffe und Infusorien. Z Biol 1900; 39:524. Tappeiner H. Uber die Wirkung fluorescierender Stoffe auf Infusorien nach versuchen von O. Raab. Munch Med Wochenschr 1900; 47:5. Tappeiner H, Jodlbauer A. Die sensibilisierende Wirkung fluorescierender Substanzen. In: Vogel F, ed. Gesammelte Untersuchungen uber die photodynamische Erscheinung. Leipzig, 1907. Jesionek A, Tappeiner H. Zur Behandlung der Hautcarcinome nmit fluorescierenden Stoffen. Arch Klin Med 1905; 82:223. Straight R. Photodynamic therapy in laser surgery and medicine. In: Dixon J, ed. Surgical Application of Lasers. 2nd ed. Chicago: Yearbook Medical Publishers, 1987:310 – 349. Auler H, Banzer G. Untersucheungen uber die Rolle der Porphyrine bei geschwulstkranken Menschen und Tieren. Z Krebsforsch 1942; 53:65. Diamond I, McDonagh A, Wilson C et al. Photodynamic therapy of malignant tumors. Lancet 1972; II:1175 – 1177. Dougherty T. Activated dyes as antitumor agents. J Natl Cancer Inst 1974; 52:1333 – 1336. Tomson S, Emmett E, Fox S. Photodestruction of mouse epithelial tumors after acridine orange and argon laser. Cancer Res 1974; 34:3124 – 3127. Dougherty T, Grindey G, Fiel R et al. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975; 55:115– 121. Dougherty T. Photoradiation therapy for cutaneous and subcutaneous malignancies. J Invest Dermatol 1981; 77:122 – 124. Dougherty T. Hematoporphyrin as a photosensitizer of tumors. Photochem Photobiol 1983; 38:377 – 379. Daniell M, Hill J. A history of photodynamic therapy. Aust NZ J Surg 1991; 61:340 – 348. Lui H, Anderson R. Photodynamic therapy in dermatology: recent developments. Dermatol Clin 1993; 11:1 – 13. Biel M. Photodynamic therapy and the treatment of head and neck cancers. J Clin Laser Med Surg 1996; 14:239 –244. Bissonette R, Lui H. Current status of photodynamic therapy in dermatology. Dermatol Clin 1997; 15:507 – 519. Allison R, Mang T, Wilson B. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin Cutan Med Surg 1998; 17:153 – 163. Henney J. First drug device to treat actinic keratoses. J Am Med Assoc 2000; 283:596. Peng Q, Warloe T, Moan J et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62:906 – 913. Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79:2282– 2308. Soler A, Warloe T, Tausjo J et al. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Dermatol Venereol 1999; 79:204 – 206. Sacchini V, Melloni E, Marchesini R et al. Preliminary clinical studies with PDT by topical TPPS administration in neoplastic skin lesions. Lasers Surg Med 1987; 7:6– 11. Leuenberger M, Mulas M, Hata T et al. Comparison of the Q-switched alexandrite, Nd:YAG, and ruby lasers in treating blue-black tattoos. Dermatol Surg 1999; 25:10 – 14. Grossman M, Lou W, Kauvar A et al. Comparison of different lasers and light sources hair removal. Lasers Surg Med 1999; (suppl 11):14. (Abstracts.) Fried M, Kelly J, Strome M. Complications of Laser Surgery of the Head and Neck. Chicago: Yearbook Medical Publishers, 1986. Olbricht S, Stern R, Tang S et al. Complications of cutaneous laser surgery. A survey. Arch Dermatol 1987; 123:345 – 349.
Cutaneous Laser Surgery: Historical Perspectives 464. 465. 466. 467. 468. 469.
57
Lent W, David L. Laser resurfacing: a safe and predictable method of skin resurfacing. J Cutan Laser Ther 1999; 1:87 – 94. Nanni C. Complications of laser surgery. Dermatol Clin 1997; 15:521 – 534. Nanni C, Alster T. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. Dermatol Surg 1998; 24:315 – 322. Rendon-Pellerano M, Lentini J, Eaglstein W et al. Laser resurfacing: usual and unusual complications. Dermatol Surg 1999; 25:360 – 367. Anderson R, Geronemus R, Kilmer S et al. Cosmetic tattoo ink darkening: a complication of Q-switched and pulsed laser treatment. Arch Dermatol 1993; 129:1010 – 1014. Nanni C, Alster T. Laser-assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. J Am Acad Dermatol 1999; 41:165– 171.
2 An Introduction to Lasers and Laser –Tissue Interactions in Dermatology J. Stuart Nelson Beckman Laser Institute, University of California, Irvine, California, USA
1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
Introduction Electromagnetic Radiation Light Bulb vs. a Laser Basic Laser Principles Lasers in Dermatology Continuous Wave vs. Pulsed Lasers Q-Switching Laser Delivery Dosimetry Basic Laser – Tissue Interactions: Reflection, Scattering, Transmission, and Absorption 11. The Process of Absorption 12. Chromophores in Human Skin 13. Heat 14. Ablation of Human Skin 15. Selective Photothermolysis 16. Selective Photothermolysis of Cutaneous Blood Vessels 17. Selective Photothermolysis of Tattoos 18. Selective Photothermolysis of Pigmented Lesions 19. Selective Photothermolysis and Laser Assisted Hair Removal 20. Skin Cooling 21. Photochemistry and Photodynamic Therapy 22. Fluorescence 23. Conclusion References
60 60 61 62 64 65 66 66 67 67 68 69 71 71 72 73 74 74 74 74 76 76 76 77 59
60
1.
Nelson
INTRODUCTION
Dermatologic laser surgery is regarded as one of the fastest growing areas in the emerging fields of photomedicine and biomedical optics. The unique properties of lasers create an enormous potential for specific therapy of skin diseases. As with any device, the most efficacious and appropriate use requires an understanding of the basic photobiological and photophysical principles of laser –tissue interaction as well as the properties of the laser itself. Modifications of current lasers and innovative advances in biomedical laser instrumentation may eventually allow the physician to match optimally the laser and treatment procedure with the lesion. This chapter provides a brief description of the nature of the laser, how it works, and the fundamental mechanisms of its interaction with human skin.
2.
ELECTROMAGNETIC RADIATION
Electromagnetic radiation is a fundamental form of energy that exhibits both wave properties, because of alternating electric and magnetic fields, and particle properties, comprising packets of energy called photons. A relationship exists between the energy of the photon (E) and the speed of light (c), and frequency (n) and wavelength (l) of the radiation. The constant of proportionality (h) is Planck’s constant. E ¼ hn and E ¼ hc=l
n ¼ c=l
(2:1) (2:2)
These equations show that the energy of an electromagnetic wave is proportional to its frequency and inversely proportional to wavelength. Long-wavelength photons carry less energy than short-wavelength photons as expressed by Planck’s law. The electromagnetic spectrum is portrayed in Fig. 2.1. It can be seen that visible light lasers
Figure 2.1 The spectrum of electromagnetic radiation.
Lasers and Laser –Tissue Interactions
61
occupy a relatively small region of the entire spectrum. However, with the continued development of the free-electron laser, the region occupied by lasers eventually might be extended into the near-X-ray part of the spectrum with wavelengths as short as 10 nm.
3.
LIGHT BULB
VS .
A LASER
Photons are the fundamental units of light, and they are the same whether produced by a light bulb or a laser (Fig. 2.2). The laser and the light bulb differ in how their photons are organized. Light from a light bulb radiates in all directions, and there is a direct mathematical relationship between the loss of light intensity and the distance one moves away from the bulb. In the laser, photons are emitted parallel (or nearly parallel) to, and in phase with, each other as they travel toward infinity. This property is known as coherence and explains why the light intensity of a laser does not decrease very much with distance. Another feature of light from a light bulb is that it is white or yellow-white in color because it contains all the different colors and wavelengths in the visual portion of the electromagnetic spectrum and, hence, is polychromatic. A glass prism placed in front of a light bulb refracts the different wavelengths and allows the constituent colors to be seen. With the laser, the prism produces light of one wavelength and one color. The light from the laser is therefore pure or monochromatic. This property, under some circumstances, allows for selective absorption of laser energy by a targeted chromophore within human skin—structures with high absorption at a laser wavelength can be selectively altered or destroyed. Another difference between the two light sources is their intensity. The number of photons per unit area of emission produced by the laser is much greater than for any
Figure 2.2 Characteristics of light from a conventional light bulb and from a laser.
62
Nelson
other light source. In fact, millions more photons are emitted by a laser than by a comparable surface area of the sun. For example, peak powers of 1012 W can be obtained with certain short-pulsed lasers. Laser power can also be varied over a wide range to achieve quite different tissue effects. For example, a low-power laser may be used to heat gently a tissue, with perhaps the only change being an increase in metabolic rate. A high-power pulsed laser may be used to achieve nonlinear optical effects (e.g., optical breakdown) causing explosions within the tissue (1). As a result of these three basic differences—coherence, monochromaticity, and intensity—the laser produces a highly unique form of electromagnetic radiation. Otherwise, photons from the light bulb and the laser obey the same basic laws and principles governing their interaction with human skin.
4.
BASIC LASER PRINCIPLES
The word laser is an acronym derived from light amplification by the stimulated emission of radiation. The amplification of the stimulated emission of radiation is the actual physical process that goes on within the laser device (2 – 5). Figure 2.3 illustrates the process of lasing: the stimulated emission of one photon by the action of another photon. To understand the acronym, it is necessary to examine some basic atomic physics. Figure 2.3(a) illustrates two atoms existing in what is termed the ground state, the lowest possible energy level. If by some mechanism the electrons of these atoms are excited from the ground state by the input of energy, they move to a higher energy level called the excited singlet state [Fig. 2.3(b)]. The source of this energy or “pumping system” can be electrical, chemical, radiofrequency waves, or light from a flashlamp or another laser. When these atoms are in the excited singlet state, they very quickly drop down to an in-between, long-lived energy level called the metastable state [Fig. 2.3(c)]. This state may last as long as a few seconds, as compared
Figure 2.3 Energy transitions characteristic of atoms in stimulated emissions. (a) Two groundstate atoms (1,2). (b) Excitation to the singlet state by input of energy (black arrows). (c) Transition to the metastable state. (d) Atom 1 spontaneously drops to the ground state, emitting a photon that stimulates atom 2 also to drop to the ground state. Both photons (yellow arrows) from atoms 1 and 2 have the same wavelength and travel parallel to each other and in phase.
Lasers and Laser –Tissue Interactions
63
with 1026 – 1029 s for most excited states. This explains why some materials can go through the lasing process and others cannot. Only atoms and molecules with a metastable state in their energy structure can achieve what is called a population inversion and undergo stimulated emission. What happens next is a spontaneous event. Those atoms existing in the metastable state spontaneously, and by random action, return to the ground state with the loss of some energy. This loss of energy occurs in the form of light—the release of a photon [Fig. 2.3(d)]. If the photon is in close proximity to another atom still in the metastable state (recall that the metastable state is long-lived so that there are going to be many atoms still at that energy level at a given moment), it collides (interacts) with that atom. This interaction stimulates the second atom to return to its ground state and, in the process, emit another photon of light. This phenomenon is termed stimulated emission of radiation. It is a basic principle of physics that since both photons come from identical energy levels, they are of the same wavelength (color) and are moving parallel and in phase with each other (the property of coherence). The first laser built in 1960 used synthetic red ruby, which is an aluminum trioxide crystal doped with chromium atoms. It was the chromium atoms inside the aluminum trioxide crystal that underwent the lasing process to produce red light. Figure 2.4 presents the foregoing on a much grander scale. Here, the atoms in the lasing medium in the ground state are represented by violet circles and those in the metastable state, by red circles [Fig. 2.4(a)]. Most of the atoms initially are in the ground state and are subsequently excited to the singlet state by a flash of light. They rapidly drop
Figure 2.4 Schematic of laser action illustrating photon cascade. (a) Unstimulated crystal; a few atoms (red circles) are spontaneously in the singlet or metastable state, but most are in the ground state (violet circles). (b) Energy input excites ground-state atoms to the singlet state whence they drop down to the metastable state. (c) Stimulated emission of excited atoms by photons of stimulated emitting atoms. (d) Photon cascade is produced by reflection at reflecting ends of the laser cavity; stimulated emission continues. (e) Further photon cascade occurs and laser light passes out the partially reflective end of the laser cavity.
64
Nelson
down to the metastable state [Fig. 2.4(b)]. Following this event, spontaneous emission occurs as described previously. The two emitted photons strike other atoms in the metastable state causing them to emit photons in parallel and in phase with those already present [Fig. 2.4(c)]. All this occurs within a fraction of a second creating an intense buildup of many photons, or a photon cascade. If the laser cavity has opposing reflective surfaces, the photons are oscillated through the medium at the speed of light, stimulating the emission of more photons [Fig. 2.4(d)]. This buildup of intensity by oscillation between two reflecting surfaces results in the final process in lasing: amplification. By permitting the release of some photons through a partially reflective surface at one end of the cavity, the result is a bright, intense monochromatic beam of light: a laser beam [Fig. 2.4(e)].
5.
LASERS IN DERMATOLOGY
Different kinds of lasers (Fig. 2.5) are identified by the type of material that undergoes the lasing process (e.g., the argon laser has argon gas as the lasing medium) inside the device. There are four types of lasing materials: solid, gas, liquid, or semiconductor. It is possible to obtain lasing action from any of these types of lasing materials provided that their atomic structures have metastable states that permit the stimulated emission process to occur. Examples of solid-state lasers are the ruby, alexandrite, and neodymium yttrium –aluminum – garnet (Nd:YAG) lasers. Examples of gas lasers are the excimer, argon, and carbon dioxide lasers. An example of a liquid laser is the pulsed dye laser. Liquid lasers employ complex organic dyes, such as rhodamine or coumarin, in solution or suspension. Diode lasers use two layers of a semiconductor material, such as gallium arsenide. Some diode lasers are tuneable over a broad wavelength range. They can be operated on battery power and, due to their small size which provides for efficient packaging, are useful for remote operation.
Figure 2.5 Identification of different types of medical lasers.
Lasers and Laser –Tissue Interactions
65
Generally and by convention, a medical laser is referred to in terms of its wavelength in either nanometers (nm) or micrometers (mm). There are also ways to modify the wavelengths obtainable from lasers. The simplest of these is frequency doubling or harmonic generation, where high-intensity light propagating through a nonlinear, asymmetric crystal generates laser light at twice the input frequency (Fig. 2.6). For example, light from high-power Nd:YAG lasers can be doubled in frequency by placing a KTP (potassium-titanyl-phosphate) crystal inside the laser cavity itself and focusing the beam into the crystal. Since the frequency of light is inversely proportional to wavelength, the result is light emitted from the crystal with twice the frequency or half the wavelength of the incident light. In practice, invisible near-infrared 1064 nm wavelength light is passed through a KTP crystal producing green visible light at a wavelength of 532 nm. The resulting laser is sometimes referred to as a KTP laser. Similar complicated physical processes can be used to double, triple, or quadruple the wavelengths from the primary laser source. Dye lasers contain a tube filled with flowing dye solution that is excited within the laser cavity. The output wavelength may be “tuned” from 400 to 1000 nm as desired by changing the dye. Precise wavelength tuning is controlled by the individual dye’s fluorescence, typically in the 30 –100 nm range, and is accomplished through the use of prisms, diffraction gratings, or birefringent filters placed within the cavity. By choosing different dyes, laser light of virtually any wavelength in the visible spectrum can be produced. Unfortunately, all of the dye lasers must contend with photoinduced dye disintegration, necessitating frequent changes of the dye after a certain number of pulses. In summary, there are a wide range of lasers available for clinical use. The dye lasers, and in the future the free-electron laser, can be precisely tuned to emit photons at wavelengths that match absorption peaks of tissue chromophores, thus permitting their selective destruction and subsequent tissue ablation.
6.
CONTINUOUS WAVE vs. PULSED LASERS
A continuous wave (CW) laser may be differentiated from a pulsed laser, which provides bursts of energy. In the CW mode, the laser delivers a continuous beam of light with little or no variation in power output over time In CW operation, laser output is controlled by the physician, typically by depressing a foot pedal. A pulsed laser delivers its energy in the form of a single pulse or a train of pulses. The frequency or pulse repetition rate is the number of pulses emitted in 1 s (Hertz).
Figure 2.6 Frequency doubling by passing an Nd:YAG laser beam through an asymmetric potassium-titanyl-phosphate (KTP) crystal.
66
Nelson
The duration of the pulse, or pulse width, is defined as the total time required for the pulse to rise from zero intensity, build to a maximum, and then return to zero intensity. An alternative definition for pulse width (used for short pulses) is the time between the 50% points on the pulse curve. This is called full width at half maximum. “Superpulse” is a term specific to some carbon dioxide lasers that have been modified to produce very short pulses with high peak powers in a repetitive fashion, commonly several hundred pulses per second. From the physician’s point of view, superpulse is most useful for incisional surgery with a focused beam. High peak power maximizes tissue vaporization, and short pulse duration minimizes adjacent thermal injury.
7.
Q-SWITCHING
Q-switching of lasers is a mechanism often used to control the light output by concentrating all the energy into a single, intense pulse with a duration on the order of nanoseconds and an energy of 10 J or more. With Q-switching (the Q-factor stands for “quality factor,” used in electronics theory terminology), a fast electromagnetic switch (Pockel’s cell) in the laser cavity causes excitation of the active medium to buildup far in excess of the level of the medium when the shutter is open. In operation, the flashlamp is turned on and the population inversion gradually grows. Lasing is prevented by the shutter. When the population inversion is at a maximum, the shutter is opened so that lasing occurs and a large burst of energy is emitted as the cavity rapidly depletes the population inversion. The net result is an extremely high peak power (greater than 106 W) nanosecond duration pulse or series of pulses. Several methods are available to create laser pulses with pulse widths on the order of femtoseconds (10215 s). Because the techniques can be quite complicated, especially for producing very short pulse widths, they are not discussed here.
8.
LASER DELIVERY
Transmission of laser energy from the laser cavity to the tissue is provided by one of three devices: articulated arms, optical fibers, or micromanipulators. Articulated arms direct laser energy from the laser cavity to the desired location through a series of hollow, rigid tubes with reflecting mirrors at each connection. The series of mirrors is chosen to be reflective of the laser wavelength being transmitted so that coherence and power are maintained, allowing the fine focusing of the exiting beam. A hand piece at the end of the arm contains a lens that focuses the beam to various spot sizes with uniform light intensity. Several limitations remain in articulated arm systems. Despite recent advances to improve their mobility, articulated arms are somewhat cumbersome to use in a clinical setting. The mirrors are easily misaligned when either the laser device or the articulated arm is disturbed. Despite the aforementioned limitations, carbon dioxide or Er:YAG lasers almost exclusively utilize articulated arms because their infrared wavelengths are not transmissible along currently available optical fibers. The most common and convenient way of delivering laser energy to the skin is through flexible optical fibers. Most visible light can be transmitted along optical fibers which are composed of two or more concentrically arranged optical materials and light is carried through the fiber by total internal reflection. Most optical fibers contain a quartz core surrounded by a silicone rubber cladding. Optical fibers can be hand-held or coupled to a hand piece with a focusing lens for cutaneous applications.
Lasers and Laser –Tissue Interactions
67
Both articulated arms and optical fibers can be coupled through a microscope with a micromanipulator which provides a controlled means of moving the laser beam across the surface of human skin. The micromanipulator can also be coupled with a computer for completely preprogrammed and precise skin irradiation. 9.
DOSIMETRY
Laser light is a form of energy that is subject to certain fundamental physical laws defined by a set of equations. An understanding of these relationships is required in order to properly use the laser as a medical device (6). Laser light emitted from the customized medical device is generally characterized in terms of power, measured in watts. The energy (stated in Joules) is defined as the power times the time interval during which light is emitted: Energy (J) ¼ power (W) time (s)
(2:3)
The power density or irradiance is then defined as the power applied per unit area of target tissue: Power density ¼ power (W)=p r 2 (cm2 )
(2:4)
Fluence is defined as the energy applied to an area of target tissue: Fluence (J=cm2 ) ¼ power density (W=cm2 ) time (s)
(2:5)
It can readily be appreciated that the effect of the laser beam on human skin can be affected by any of three variables: power, time, and spot size. The effects of power and time are proportional whereas that of spot size (radius) is an inverse square. If either the power or time is doubled, fluence increases by a factor of 2. However, if the spot size is decreased by a factor of 2, fluence increases by a factor of 4. Doubling the spot size results in a fourfold reduction in fluence. 10.
BASIC LASER – TISSUE INTERACTIONS: REFLECTION, SCATTERING, TRANSMISSION, AND ABSORPTION
How can this intense, pure beam of light be used in the clinical management of patients? The successful applications of lasers to dermatologic surgery rely upon an adequate appreciation of the principles of light interactions with human skin. It is important to recognize that these interactions are complex phenomena influenced not only by laser parameters, such as power, spot size, pulse duration, repetition rate, and wavelength, but also by properties of the tissue itself. If a laser beam is directed at the skin, light may be reflected back to the source or to another undesired surface. Reflection occurs as a result of changes in the indices of refraction at the air – skin interface. When light strikes the skin surface, approximately 5% is reflected. Since tissues reflect light, their reflectance properties are important considerations. Instruments in the operative field may also reflect the light, creating potential health hazards for the patient and attending medical personnel. If reflectance is adequately controlled and light enters human skin, the ultimate determinant affecting that tissue is the absorption of light. However, two things can happen other than absorption. Light can scatter from particles and structures in the skin to places where it is not wanted. Scattered energy is a major reason for the spread of tissue damage around the focused spot because it changes the direction of the incident
68
Nelson
beam. In human skin, collagen fibers are particularly important scattering structures. The degree of scatter is heavily dependent on the wavelength of the light and the composition of the tissue. Light scattering in human skin is greater and more random at shorter wavelengths. Light scattering at longer wavelengths is less and more forward directed. Finally, light might be transmitted through the tissue with only a minimal amount being absorbed. Since every tissue has reflective, scattering, and transmissive properties, understanding these tissue characteristics is an important aspect of knowing how to use the laser. 11.
THE PROCESS OF ABSORPTION
When photons enter the tissue, those that are not reflected, scattered, or transmitted are absorbed. Without absorption, there is no response. Absorption is the key to effective laser use (Fig. 2.7). Absorption refers to a process that occurs when energy supplied by electromagnetic radiation (e.g., light) is transferred to an absorbing molecule, M, so that a more energetic, excited-state species, M , is produced. This excitation can be depicted by the equation: M þ hn ! M
(2:6)
where hv represents the amount of energy absorbed. Within 1026 –1029 s following excitation, the energy is lost, most often as heat, and the species relaxes to its former state: M ! M þ heat
(2:7)
Relaxation may also result from decomposition of M to form a new species; such a process is called photochemical decomposition (see section on Photochemistry and Photodynamic Therapy). Alternatively, relaxation may involve fluorescent or phosphorescent re-emission of a photon (see section on Fluorescence). It is important to
Figure 2.7 Laser –tissue interactions.
Lasers and Laser –Tissue Interactions
69
note that the lifetime of M is so short that its concentration at any instant is ordinarily negligible. All molecules contain a unique energy level structure. In order to have light energy absorbed, the energy level structure of the absorbing molecules in the tissue must correspond to the energy of the incident radiation (light). These energy-absorbing molecules in human skin are generally referred to as chromophores. When light is absorbed by a chromophore, energy is transferred from the incoming photon to the chromophore in the skin that is to be altered or changed. Once this energy is absorbed, the energy has to go somewhere, and this is really the key to producing the changes seen in human skin after laser irradiation. Normally, we think of lasers as producing heat, and most laser dermatologic procedures initiate a local thermal event. Radiation, from high-energy sources such as X-rays and gamma rays, ionizes molecules in the tissue and results in relatively nondiscriminant tissue damage. The nonionizing wavelengths, which include visible light electromagnetic radiation, can cause electronic excitations in specific atoms or molecules in the skin which permit selective targeting of chromophores with specific wavelengths of light. Although not demonstrating the same degree of target specificity as visible energy, infrared energy excites vibrational modes in certain tissue molecules that result in a generalized heating of human skin.
12.
CHROMOPHORES IN HUMAN SKIN
Hemoglobin has significant light absorption in the violet, blue/green, and yellow portions of the spectrum (7,8). This absorption starts to decline in the red region. These absorption features permit the scattering and transmission of red light thus causing hemoglobin to appear red in color. In the case of laser treatment of cutaneous blood vessels, the wavelengths suitable for consideration are the hemoglobin Soret absorption band at 418 nm and the absorption bands at 542 and 577 –595 nm (Fig. 2.8). Despite the higher extinction coefficient of the Soret band, this wavelength can be rejected for clinical use because penetration of photons into the dermis in insufficient. However, if one takes advantage of the longer-wavelength hemoglobin absorption band at 577 – 595 nm, where tissue penetration is increased and melanin absorption is reduced, less heating of the epidermis should occur and more incident light energy is transmitted to the blood vessels. For these reasons, the pulsed dye laser (577 – 595 nm) has been the mainstay of treatment for multiple cutaneous vascular lesions. The yellow light is absorbed by hemoglobin in these lesions causing thermal damage and thrombosis of targeted vessels. Melanosomes are the fundamental sites for melanin synthesis and occur as organelles within melanocytes. Absorption is the dominant process by epidermal melanin. Although highest in the ultraviolet portion of the spectrum, melanin absorption is also significant in the visible and near-infrared wavelengths. For these reasons, Q-switched green (KTP), red (ruby, alexandrite), and near-infrared wavelengths have been utilized for the treatment of certain epidermal and dermal pigmented lesions. Water has no light energy absorption in the visible portion of the spectrum and very minimal absorption in the near-infrared portion. However, further out in the infrared (beyond 2 mm), water in the tissue has significant absorption. The Er:YAG and carbon dioxide lasers are currently the most frequently used surgical lasers. Since human skin contains water as a major constituent, the Er:YAG (2.94 mm) and carbon dioxide (10.6 mm) lasers producing infrared photons that are specifically absorbed by water can have a direct effect on the epidermis and dermis. If used properly, the
70
Figure 2.8
Nelson
Chromophores in human skin—absorption spectra of hemoglobin, melanin, and water.
Er:YAG and carbon dioxide lasers are clinically equivalent to dermabrasion because the laser gradually removes cell layer after cell layer through volatilization of water present in human skin. Photons emitted by the Nd:YAG laser (at a wavelength of 1.06 mm), on the other hand, are very poorly absorbed by hemoglobin, melanin, water, and other chromophores in human skin. Light penetration into skin is very deep (4 – 6 mm) resulting in a large volume of coagulated tissue—substantially larger than that created by either the Er:YAG or the carbon dioxide laser. Because of the extensive penetration of the Nd:YAG laser into skin, its use in the continuous mode is somewhat limited in cutaneous surgery. For example, the Nd:YAG laser cannot be used to ablate superficial lesions like the Er:YAG or carbon dioxide laser. Recently, however, Nd:YAG lasers pulsed in the millisecond domain have been used to target telangiectasia and reticular veins of the legs. These lasers take advantage of the small peak in the hemoglobin absorption curve, with relatively no competition from melanin or water. Wavelengths suitable for nonablative laser skin rejuvenation must have low melanin absorption, which favors the choice of longer wavelengths (i.e., near- and mid-infrared) over visible light (9). Therefore, most attempts at nonablative laser skin regeneration have used wavelengths with low (650 – 1100 nm) or intermediate tissue water absorption to deposit laser energy nonselectively in the upper (100 – 400 mm) dermis. Wavelengths from 1.3 to 1.8 mm meet this need, which currently limits the selection of light sources to the 1.32 and 1.44 mm Nd:YAG lasers, the 1.45 mm diode laser, and the 1.54 mm Er:glass laser. Because deposited heat is redistributed within the skin by heat diffusion, the ultimate depth of thermal injury is affected not only by the optical penetration of the selected wavelength but also by a multitude of other variables beyond the scope of this chapter.
Lasers and Laser –Tissue Interactions
71
In summary, selection of the correct laser for a particular clinical procedure requires an understanding of the absorptive as well as the reflective, scattering, and transmissive properties of the target tissue. 13.
HEAT
Given that one goal of laser therapy is the precise control of thermal energy, a thorough understanding of the sequelae of tissue heating is required. Ideally, from the clinical point of view, the physician should be able to confine the heating process to produce the desired result. Physicians experienced in laser therapy acquire the ability to discern these tissue changes visually so that the heating process can be stopped at the desired point. It is therefore important that physicians planning to use lasers take a basic course in laser theory and clinical management and complete a preceptorship with an experienced instructor who can help them develop the requisite skills. Figure 2.9 shows the effect of a rise in temperature in human skin during laser irradiation. As the tissue is heated and the temperature rises to between 378C and 608C, the skin starts to retract and conformational changes occur. At a temperature above 608C, there is protein denaturization and coagulation. From 908C to 1008C, drying and shrinkage of the skin occur. Above 1008C, the skin is carbonized and subsequently vaporized and ablated.
14.
ABLATION OF HUMAN SKIN
The Er:YAG and carbon dioxide lasers are currently the lasers of choice for human skin ablation. Since light is absorbed so intensely by water, penetration depths are only a few micrometers. Absorption of many photons in such a small volume of tissue produces a
Figure 2.9 Thermal interaction of laser irradiation with human skin.
72
Nelson
rapid rise in skin temperature. As energy is added, the temperature of water is raised to its boiling point. Internal vapor pressure builds up until a microexplosion occurs. The rapid expansion created by this excitation give rise to the actual ejection of microscopic tissue fragments at high velocities. Since most of the energy of the laser pulse goes into the thermal phase change associated with tissue vaporization, ablated fragments ejected from the skin surface carry most of the energy with them, leaving little energy in the form of heat to damage surrounding tissue. Because vaporization is such a rapid process, thermal damage to adjacent tissue, although varying with the duration of exposure, is usually limited to a zone of 100–200 mm (carbon dioxide) or less (Er:YAG) in human skin.
15.
SELECTIVE PHOTOTHERMOLYSIS
The laser has many inherent properties that contribute to its ability to effect a specific biological outcome. Most important, from a clinical point of view, are the properties of emitted wavelength and pulse duration. If the clinical objective is to cause selective destruction of a specific chromophore, the wavelength chosen should match the highest absorption of the targeted chromophore relative to other optically absorbing molecules. Given that one goal of treatment is the precise control of thermal energy, the pulse duration of laser irradiation is just as important as optical and tissue factors. One way to maximize the spatial confinement of heat is to use a laser with a pulse duration on the order of the thermal relaxation time (Tr) of the target chromophore (10). Tr is defined as the time required for the heat generated by the absorbed light energy within the target chromophore to cool to half of the original value immediately after the laser pulse. During a lengthy laser exposure, most of the heat produced diffuses away despite its origin in the target structure. The target does not become appreciably warmer than its surroundings because the absorbed energy is invested almost uniformly in heating of the tissue during exposure. As a result, longer pulse durations offer a more generalized heating and, therefore, less spatial selectivity resulting in nonspecific thermal damage to adjacent structures regardless of how carefully one has chosen a wavelength. However, if the laser pulse is suitably brief, its energy is invested in the target chromophore before much heat is lost by thermal diffusion out of the exposure field. A transient maximum temperature differential between the target and adjacent structures is then achieved. Shorter pulse durations confine the laser energy to progressively smaller targets with more spatial selectivity. The transition from specific to nonspecific thermal damage occurs as the laser exposure equals and then exceeds Tr . Therefore, selective target damage depends on delivering a pulse of light of shorter duration than Tr , which can be estimated because the latter is directly proportional to the square of the diameter of the target and inversely proportional to the thermal diffusivity of the tissue (Table 2.1). A laser emitting at a Table 2.1 Relationship of Target Chromophore Diameters and Their Thermal Relaxation Times (Tr) Target Microvessel Blood vessel Tattoo pigment Melanosome Melanocyte
Diameter (mm)
Tr
50 150 0.5 – 100 0.5– 1.0 7
1.4 ms 12.8 ms 20 ns – 3 ms 20– 40 ns 1 ms
Lasers and Laser –Tissue Interactions
73
selectively absorbed wavelength with a pulse duration less than Tr can be expected to cause highly selective target damage (Fig. 2.10). This process, termed selective photothermolysis, was introduced in 1983 as a means of achieving target chromophore destruction by careful selection of wavelength and pulse duration.
16.
SELECTIVE PHOTOTHERMOLYSIS OF CUTANEOUS BLOOD VESSELS
The pulsed dye lasers at 577 – 595 nm, wavelengths well absorbed by the targeted hemoglobin molecule relative to other optically absorbing structures, cause selective thermal damage to dermal blood vessels while minimizing epidermal melanin absorption. Furthermore, because the Tr for cutaneous blood vessels 50 –150 mm in diameter is between 1.4 and 12.8 ms, the 0.45– 50 ms pulse duration produced by these lasers matches the Tr for dermal blood vessels, thus confining the laser energy to the targeted vessel before much heat is lost by thermal diffusion out of the exposure field (11). Patients with a wide range of vascular abnormalities, such as port wine stains, hemangiomas, telangiectasias, angiomas, venous lakes, poikiloderma of Civatte, and angiokeratomas, have benefited from pulsed dye laser therapy (12). The green light (532 nm) produced by the frequency-doubled Nd:YAG laser (KTP laser) is also preferentially absorbed by hemoglobin. Although melanin absorption is higher and light penetration into human skin is less at this shorter wavelength, the KTP laser has been approved by the FDA for many of the same procedures as the pulsed dye laser.
Figure 2.10 Selective photothermolysis. With relatively long laser exposure times, selective target damage is followed by thermal diffusion and damage to adjacent structures. Selective thermal damage can be confined to the tissue target by choosing a pulse duration that is shorter than Tr .
74
17.
Nelson
SELECTIVE PHOTOTHERMOLYSIS OF TATTOOS
Amorphous carbon, graphite, India ink, and organometallic dyes, typically found in dark blue-black amateur and professional tattoos, have a broad absorption in the visible and near-infrared portions of the spectrum. At visible wavelengths longer than 600 nm, hemoglobin and melanin light absorption is minimized and tattoo dyes can be targeted selectively (13). The pigment granules characteristically found in tattoos have diameters of 0.5– 100 mm, which correspond to Tr of 20 ns to 3 ms. With the development of the Q-switched ruby (694 nm), alexandrite (755 nm), and Nd:YAG (1.06 mm) lasers, tattoo removal without scarring can be achieved. The frequency-doubled, Q-switched Nd:YAG laser (KTP laser) emits at a wavelength of 532 nm, which provides improved removal of red dye.
18.
SELECTIVE PHOTOTHERMOLYSIS OF PIGMENTED LESIONS
Although highest in the ultraviolet portion of the spectrum, melanin absorption is also significant in the visible and near-infrared wavelengths. The diameters of individual melanosomes (0.5 –1.0 mm) and melanocytes (7 mm) correspond to Tr of 20 –1000 ns. Therefore, Q-switched green, red, and near-infrared wavelengths have been utilized for this indication. Studies have shown that the effects of Q-switched lasers are melanosome dependent, and vacuolization of pigment-laden cells has been seen immediately after laser irradiation on examination by light and electron microscopy (14). Disruption of melanosomes at pulse widths less than Tr presumably resulted from a shock wave or cavitation induced by thermal expansion or by the temperature gradient generated across the pigmented cells. Q-switched lasers have been used successfully to treat a wide variety of pigmented lesions including lentigines, ephelides, and nevus of Ota (12).
19.
SELECTIVE PHOTOTHERMOLYSIS AND LASER ASSISTED HAIR REMOVAL
The human hair follicle is a complex structure derived from both epidermal and dermal components. The target chromophores, primarily melanin-rich hair shafts, are located deep in human skin (bulge around 1.5 mm and bulb at 2 –7 mm). At this depth, only red and near-infrared wavelengths are useful (690 –900 nm). The follicular structure responsible for regeneration has not been conclusively identified and, therefore, current systems target the entire follicle. As a result, long pulse widths on the order of milliseconds and high fluences capable of heating large volumes of tissue are required (15). Millisecond-domain ruby, alexandrite, diode, and Nd:YAG lasers using high light doses can produce selective injury to human hair follicles resulting in prolonged growth delay and, in some cases, permanent hair loss after a single treatment.
20.
SKIN COOLING
The clinical objective of laser therapy is to maximize thermal damage to target chromophores while minimizing injury to overlying skin. Unfortunately, for many skin types, the threshold light dosage for epidermal injury due to melanin absorption can be very close to
Lasers and Laser –Tissue Interactions
75
that for permanent removal of target chromophores. A valuable method to overcome this problem is to cool selectively the superficial layers of the skin during laser therapy which prevents thermal injury despite some melanin absorption. Rapid and spatially selective epidermal cooling can be achieved by active skin cooling (16). The first and intuitively simple objective of skin cooling is to decrease epidermal damage. So long as the epidermis is prevented from reaching a temperature in response to laser exposure that is above its threshold for denaturation (60 – 658C), the epidermis and upper dermis can be preserved. The second objective is to permit the use of higher light dosages for treatment of laser resistant lesions. The third objective is the treatment of patients with all skin types. For patients with darker skin types (types IV – VI), it is not possible to treat lesions without cooling due to epidermal damage with a sufficiently high light dosage. The fourth objective is reduction of pain and posttreatment swelling or edema. Several different methods have been developed for cooling human skin in conjunction with laser therapy. All methods utilize a precooled medium brought in contact with the skin surface. Deeper skin layers are cooled by heat diffusion toward the cooled surface with subsequent transfer to the cooling medium. The rate of heat transfer across the interface between the skin and the cooling medium depends primarily on the temperature difference between the two adjacent materials, as well as other parameters, specific to each cooling method. Therefore, cooling efficiency using any method can be adequately characterized by the proportionality constant, termed heat transfer coefficient (h), regardless of the physical mechanisms involved. Contact cooling (CC) of human skin is achieved by heat conduction into an adjacent precooled solid body, usually an optically transparent plate, kept at constant temperature (210 to 48C) by a cooling system. Laser exposure is delivered through the plate, which is pressed against the patient’s skin. CC can be very efficient especially when a highly conductive material, such as sapphire, is used for the cooling plate. However, in practice, the thermal resistance at the interface of the intervening layer between the skin and the plate inevitably impairs the rate of heat extraction with CC. Air, bubbles, hair, or other substances may impede the direct contact between the skin surface and the cooling plate. Human skin can also be cooled by air precooled (AC) and blown onto or across the surface at temperatures as low as 2308C. Despite the low air temperature used, AC is characterized by the lowest cooling rate since the heat transfer coefficient for forced convection in gas is very low. As a result, long cooling times (on the order of several seconds) are necessary to induce significant temperature reductions in the basal layer. Therefore, the final outcome is inevitably general (“bulk”) cooling of the entire skin with minimal spatial selectivity. Rapid and spatially selective epidermal cooling can be achieved by active cooling using a cryogen spray (CSC) or dynamic cooling (17). Tetrafluoroethane (TFE) is the only cryogenic compound currently FDA approved for use in dermatologic laser surgery. TFE is a nonflammable, nontoxic, environmentally compatible freon substitute which does not deplete atmospheric ozone or contribute to global warming (18). CSC’s main cooling mechanism is rapid evaporation of cryogen, which extracts the necessary latent heat from the skin. Liquid cryogen is “atomized” into a fine spray and directed toward the skin surface. During flight, spray droplets cool rapidly due to cryogen evaporation. Therefore, the droplet temperature when impinging on the skin surface is typically between 2408C and 2608C. As a result, CSC provides a rapid, large, and spatially selective epidermal temperature reduction. A layer of liquid cryogen can remain on the skin surface after spurt termination. Consequently, cooling continues for a much longer time than the actual user-specified spurt duration. The presence of liquid
76
Nelson
cryogen on the skin surface after spurt termination constitutes de facto skin cooling during and after the laser exposure. Cryogen spurt duration and delay between spurt termination and the laser pulse can be controlled electronically, which results in predictable cooling with reproducible spatial selectivity. The development of skin cooling methodology has definite advantages for patients receiving laser therapy: (1) cooling permits safe and effective laser treatment by increasing the threshold for epidermal damage, (2) cooling permits the use of higher-incident light doses for treatment of resistant lesions, (3) cooling permits the treatment of patients with all skin types, and (4) for all patients, particularly children, pain and distress associated with laser therapy are significantly reduced.
21.
PHOTOCHEMISTRY AND PHOTODYNAMIC THERAPY
Photon energy may also be dissipated by photochemistry. The basic concept of photochemistry is that certain molecules (natural or applied) can function as photosensitizers. The presence of these photosensitizers in certain cells makes them vulnerable to light at wavelengths absorbed by the chromophore. The excited photosensitizer subsequently reacts (transfers its energy) with a molecular substrate, such as oxygen, to produce highly reactive singlet oxygen which causes irreversible oxidation of some essential cellular component. All of this occurs without the generation of heat. Although photodynamic therapy (PDT), using porphyrin derivatives and visible light, has primarily focused on the treatment of skin cancer, PDT is also being used for the clinical management of selected nonmalignant, dermatological indications, such as actinic keratosis, psoriasis, and PWS (19).
22.
FLUORESCENCE
Photon energy may be dissipated as the re-emission of light. If this happens within 1026 s after absorption, it is called fluorescence. The fluorescent photon is emitted as the excited atom returns to the ground state. However, because some energy is lost by collisions with other atoms in the excited state, the energy of the fluorescent photon is lower (and therefore the wavelength is longer) than that of the absorbed photon. It appears that many of the photosensitizing dyes used to induce photochemistry are also fluorescent. If in the case of porphyrins, 400 nm blue-violet light from a krypton laser is used with an appropriate filter and image intensifier, fluorescence can be observed (19). Clinical trials are now in progress in which the effectiveness of fluorescence for detection and localization of certain premalignant and malignant skin lesions is being evaluated.
23.
CONCLUSION
Since the laser was first developed in 1960, it has found many uses in dermatology. Moreover, lasers are now the treatment of choice for several clinical entities for which no reliable or effective modality was previously available. Research into increasing our understanding of the optical characteristics of skin has made it possible to concentrate not on the effects of any particular laser system but on the basic biological and physical principles of laser – tissue interaction. Modern technology allows us to manipulate the physical characteristics of lasers and design them for specific therapeutic purposes.
Lasers and Laser –Tissue Interactions
77
REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
12.
13. 14.
15. 16. 17.
18. 19.
Boulnois JL. Photophysical processes in recent medical laser developments. A review. Lasers Med Sci 1986; 1:47– 66. Elion HA. Laser Systems and Applications. New York: Pergamon Press, 1967. Hitz CB. Understanding Laser Technology. Tulsa, OK: PennWell Publishing, 1985. O’Shea DC, Callen WR, Rhodes WT. Introduction to Lasers and Their Applications. Menlo Park, CA: Addison-Wesley Publishing, 1978. Siegman AE. Lasers. Mill Valley, CA: University Science Books, 1986. Sliney D, Wolbarsht M. Safety with Laser and Other Optical Sources. New York: Plenum Press, 1985. Anderson RR, Parrish JA. Optical properties of skin. In: Regan JD, Parrish JA, eds. The Science of Photomedicine. New York: Plenum Press, 1982:147 – 194. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981; 77:13– 19. Kelly KM, Majaron B, Nelson JS. Nonablative laser and light rejuvenation. Arch Facial Plast Surg 2001; 3:230– 235. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 529. Dierickx CC, Casparian JM, Venugopalan V, Farinelli WA, Anderson RR. Thermal relaxation of port-wine stain vessels probed in vivo: the need for 1– 10 millisecond laser pulse treatment. J Invest Dermatol 1995; 105:709 – 714. Kelly KM, Nelson JS. Critical review of lasers in dermatology. Critical reviews of optical science and technology. In: Ryan TP, ed. Matching the Energy Source to the Clinical Need. Vol. CR75. Bellingham, WA: SPIE Optical Engineering Press, 2000:3 – 23. Cesario-Kelly KM, Nelson JS. Q-switched laser treatment of tattoos. Lasers Med Sci 1997; 12:89 – 98. Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd:YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 1989; 93:28– 32. Ross EV, Ladin Z, Kriendel M, Dierickx CC. Theoretical considerations in laser hair removal. Dermatol Clin 1999; 17:333 – 355. Nelson JS, Majaron B, Kelly KM. Active skin cooling in conjunction with laser dermatologic surgery. Semin Cutan Med Surg 2000; 19:253– 266. Nelson JS, Milner TE, Anvari B, Tanenbaum BS, Kimel S, Svaasand LO, Jacques SL. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain. A new methodology with preliminary clinical evaluation. Arch Dermatol 1995; 131:695 – 700. Nelson JS, Kimel S. Safety of cryogen spray cooling during pulsed laser treatment of selected dermatoses. Lasers Surg Med 2000; 26:2 – 3. Nelson JS, McCullough JL, Berns MW. Principles and applications of photodynamic therapy in dermatology. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery. Philadelphia, PA: Lippincott-Raven Publishers, 1997:349 – 382.
3 Laser Safety Measures Christie Travelute Ammirati Penn State University College of Medicine, Hershey, Pennsylvania, USA
George J. Hruza St. Louis University School of Medicine, St. Louis, Missouri, USA
1. Introduction 2. Laser Safety Organizations and Regulations 2.1. American National Standards Institute 2.2. The Center for Devices and Radiological Health 2.3. Occupational Safety and Health Administration 2.4. The National Institute for Occupational Safety and Health 3. Laser Hazard Classification 4. Eye Hazards 4.1. Eye Anatomy 4.2. Electromagnetic Spectrum 4.3. Retinal Injury 4.4. Corneal Injury 4.5. Lenticular Injury 5. Eye Protection 5.1. Patient Protection 5.2. Medical Surveillance 6. Skin Hazards 7. Teeth Hazards 8. Fire Hazards 8.1. Fire Prevention 8.2. Fire Containment 9. Electrical and Mechanical Hazards 9.1. Controlled Access 10. Chemical Hazards 10.1. Chemical Protection 11. Accoustic Hazards
80 80 80 82 82 82 82 83 84 85 87 87 88 88 90 90 91 91 91 91 92 93 93 95 95 95 79
80
Ammirati and Hruza
12. Laser Plume Hazards 12.1. Organic Compounds 12.2. Particulate Debris 12.3. Pathogenicity 12.4. Protection and Evacuation 12.5. Smoke Evacuators 12.6. Laser Masks References
1.
95 95 96 96 97 97 98 98
INTRODUCTION
Lasers produce intense monochromatic, collimated, and coherent light. These properties, which allow for the highly selective destruction of target chromophores, also carry significant safety concerns. There are an ever-increasing number of cutaneous lasers available today and it can prove challenging to remain current with the unique safety issues of each system. Overall, surgical lasers have a good safety record but their potential hazards can cause significant injury and even death (1). This chapter provides an overview of laser safety issues as they apply to the patient, laser surgeon, and staff. It augments, but cannot hope to replace, formal instruction.
2.
LASER SAFETY ORGANIZATIONS AND REGULATIONS
There are several organizations that concern themselves with laser safety. In the USA these organizations include the American National Standards Institute (ANSI), the Center for Devices and Radiological Health (CDRH), the Occupational Health and Safety Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH). Many of these organizations publish laser safety manuals that are available free of charge (see Table 3.1).
2.1.
American National Standards Institute
The ANSI is a consensus group of industry, university, and government laser experts who developed the ANSI-Z136 series. This set of standards provides recommendations for the safe use of lasers and laser systems. There is no inherent requirement for adherence to their guidelines and compliance is voluntary unless mandated by an employer or organization. The American National Standard for Safe Use of Lasers (ANSI-Z136.1) and the American National Standard for Safe Use of Lasers in Health Care Facilities (ANSI-Z136.3) are the expected standards of care in the USA and are often cited in litigation. OSHA and the Joint Commission for Accreditation of Healthcare Organizations (JCAHO) reference these standards when evaluating laser-related occupational safety issues. The ANSI-Z136 series provides information on laser classification, safety calculations, and control measures. These standards of care apply to all laser operators, regardless of the clinical application or practice setting. Specifically, private office-based laser centers are expected to have training policies and safety protocols similar to those used in hospitals.
Laser Safety Measures
81
Table 3.1 Laser Safety Resources Laser safety source University of Waterloo “Laser Manual” OSHA Technical Manual Section III: Chapter 6 “Laser Hazards” OSHA PUB 8-1.7 “Guidelines for Laser Safety and Hazard Assessment” Berkely Lab Health and Safety Manual Chapter 16 “Lasers” NIOSH Hazard Control “Control of Smoke from Laser/Electrosurgical Procedures” LaserFX “Basic Laser Safety” Rockwell Laser Institute “Statistical Data for Laser Accidents” Laser Institute of America “Laser Generated Air Contaminants (LGAC)” Laser Institute of America “Laser Safety Information Bulletin” American Society for Lasers in Medicine and Surgery “Smoking Guns” Lawrence Livermore National Laboratory “Environment, Safety and Health Manual” Center for Devices and Radiological Health “21CFR 1040.10 and 1040.11” University of Illinois “UIUC Laser Safety Tutorial” Navy Laser Safety Page U.S. Army Laser/Optical Radiation Program Oklahoma State University Optical Radiation Branch (AFRL/HEDO) Air Force Canadian Centre for Occupational Health & Safety (CCOHS) “Lasers in Health Care” University of Pennsylvania Laser Safety
Website www.adm.uwaterloo.ca/infohs/lasermanual/documents www.osha-slc.gov/dts/osta/otm_iii/otm_iii_6.html
www.osha-slc.gov/OshDoc/Directive_data/PUB_8-1_7.html
ehssun.lbl.gov/ehsdiv/pub3000/CH16.html
www.cdc.gov/niosh/hc11.html
www.laserfx.com/sci4.html www.iac.net/rli/accidents/stat_dat.html
www.rli.com/lgac.html
www.laserinstitute.org/safety_bulletin
www.aslms.org/general-smokegunsl.html
www.llnl.gov/es_and_h/hsm/chapter_28
www.fda.gov/cdrh/index.html
phantom.ehs.uiuc.edu/rad/laser/laser.html www.nswc.navy.mil/safety/laser chppm-www.apgea.army.mil/laser/laser.html www.pp.okstate.edu/ehs/links/laser.html www.brooks.af.mil/AFRL/HED/HEDO www.ccohs.ca/oshanswers/phys_agents/lasers.html
www.oehs.upenn.edu/laser/laser_manual.html
Note: There are many laser safety resources available on the Internet. Many have safety manuals that can be downloaded free of charge.
82
2.2.
Ammirati and Hruza
The Center for Devices and Radiological Health
The CDRH U.S. Federal Laser Product Performance Standard (FLPPS) regulates the manufacture of commercial lasers. Under guidelines 21 CFR Part 1040.10 and 1040.11, the manufacturer is required by federal law to classify and appropriately label a laser with its hazard class. These regulations are designed to insure product safety and do not pertain to or regulate laser use once they have been purchased. 2.3.
Occupational Safety and Health Administration
OSHA is a federal regulatory agency concerned with safety and health conditions in the workplace. While it does not have a comprehensive standard for medical lasers, it has issued several regulations that pertain to laser safety. The Eye and Face Protection Standard (29CFR 1926.102) and Personal Protective Equipment Standard (29CFR 1910.132-138) mandate that employees who are exposed to laser beams by occupation or assignment be provided with appropriate laser-specific eye protection. The BloodBorne Pathogen Standard (29CFR 1910.1030) addresses employee protection from potentially infectious exposures and has been extrapolated to include laser-generated debris (2). The OSHA Technical Manual and, Guidelines for Laser Safety and Hazard Assessment are available free of charge from OSHA (see Table 3.1). These manuals provide an excellent overview of laser safety and are highly recommended. 2.4.
The National Institute for Occupational Safety and Health
NIOSH is a federal agency responsible for conducting research and making recommendations for preventing work-related illness and injury. In 1996, NIOSH published Control of Smoke from Laser/Electric Surgical Procedures (HC11). This hazard control discusses the rationale for controlling the smoke from laser or electrosurgical procedures and makes recommendations for optimal smoke evacuation. 3.
LASER HAZARD CLASSIFICATION
In general, lasers are classified according to their relative hazards. The basis for this classification scheme is the ability of the laser beam to cause unintended injury to the eye or skin (2). The ANSI classification, which is the most commonly cited standard, stratifies risk from I to IV (Table 3.2). Class I lasers are very low-power lasers that do not emit hazardous radiation (typically ,0.4 mW) and are considered to be safe for continued viewing. Few lasers function at this very low level and most Class I lasers are in this category by virtue of an enclosure that prevents access to their radiation (embedded). An example of an embedded laser would be a laser printer. Class I lasers are exempt from control measures or warning labels. The Class IIa subclassification was developed for bar-code scanners, which emit visible light and are not intended for viewing. They have an upper power limit of 4 mW and are considered safe unless viewed directly for .1000 s. Class IIa lasers are required to carry the label, “Avoid Long-Term Viewing of Direct Laser Radiation” but are exempt from other hazard controls. Class II lasers emit ,1 mW of visible (400–760 nm) light. The human eye will blink and look away within 250 ms when exposed to a bright visible light. This is known as the blink reflex or aversion response and it is usually sufficient to protect the eye from Class II laser injury (4). With intentionally prolonged viewing (.250 ms), these lasers are capable of damaging the eye (5). Alignment beams or low-power helium–neon laser pointers are
Laser Safety Measures
83
Table 3.2 ANSI Classification of Risk Class
Energy (mW)
Exposure limits
I IIa II
,0.0004 ,0.004 ,1
IIIa
1 –5
Hazardous in ,0.25 s when viewed with collecting optics
IIIb
5– 500
IV
.500
Direct beam or specular reflection hazardous in ,0.25 s Direct beam, specular or diffuse reflection hazardous in ,0.25 s
None Safe for ,1000 s Safe for ,0.25 s
Comments Safe for viewing Not intended for direct viewing Do not purposely stare into the beam Do not view through collecting optics without protective eyewear Do not view direct beam or specular reflection without protective eyewear Do not view direct beam, specular or diffuse reflection without protective eyewear; skin and fire hazard as well
Source: Refs. (2,3).
examples of Class II lasers. They require a “CAUTION” warning with the phrase, “LASER RADIATION—DO NOT STARE INTO BEAM.” Class III lasers, which include ultraviolet (UV), visible, and infrared lasers are divided into subclasses IIIa and IIIb. Class IIIa lasers, such as diode aiming beams, emit 1–5 mW of energy (6). These lasers are safe for brief viewing (,250 ms) but can be hazardous when viewed through collecting optics (i.e., microscope or endoscope). All Class IIIa lasers require a “CAUTION” warning with the phrase, “LASER RADIATION—DO NOT STARE INTO BEAM OR VIEW DIRECTLY WITH OPTICAL INSTRUMENTS.” (Note: Prescription eyewear is not considered to be a collecting optic.) Class IIIb lasers, such as retinal photocoagulators, produce 5– 500 mW and exposure to their direct or reflected beam can cause eye and skin damage (7). Class IIIb lasers are not considered to be fire hazards but they are subjected to all other control measures outlined in this chapter. They require a “DANGER” warning with the phrase, “LASER RADIATION—AVOID DIRECT EXPOSURE TO THE BEAM.” Almost all medical lasers are designated as Class IV and have power levels greater than 500 mW (continuous wave) or generate more than 10 J/cm2 in 250 ms (pulsed system). Even brief exposures to their direct, reflected, or scattered emissions pose eye, skin, and fire hazards. These lasers require a “DANGER” warning with the phrase, “LASER RADIATION—AVOID EYE OR SKIN EXPOSURE TO DIRECT OR SCATTERED RADIATION.”
4.
EYE HAZARDS . . . I was not wearing protective goggles at the time, although they were available in the laboratory. When the beam struck my eye, I heard a distinct popping sound, caused by a laser-induced explosion at the back of my eyeball. My vision was obscured almost immediately by streams of blood floating in the vitreous humor. It was like viewing the world through a round fish bowl full of glycerol into which a quart of blood and a handful of black pepper have been partially mixed. Decker, CD. Laser accident victim’s view. Laser Focus August 1977.
84
Ammirati and Hruza
The above account was written by a researcher who suffered permanent eye damage from a 1064 nm Nd:YAG laser beam. The eye is an intricate and complex organ, comprising several structures, each with their own absorption spectrum. As with all laser – tissue interactions, photon energy must be absorbed to have an effect (Grothus –Draper Law) and the ocular structure at risk will vary with the wavelength in use (8). To understand how this selective injury can occur, eye anatomy and basic principles of optical physics should be reviewed.
4.1.
Eye Anatomy
The cornea is the main focusing element for vision and is protected from the environment by its tear film and numerous sensory receptors (9) (Fig. 3.1). The cellular turnover of the outer corneal layers is approximately 48 h and allows most of the superficial injury to heal without residual damage. Permanent corneal scarring will occur if the damage extends to the deeper layers. The lens performs fine focusing of images onto the retina. Normally, the lens is transparent but changes in its proteins can produce a cataract. The space between the cornea and lens is filled with the aqueous humor and the interior of the eyeball is filled with the gelatinous vitreous humor. The cornea and lens, along with the aqueous and vitreous humors, comprise the anterior segment of the eyeball. The retina is divided into two major components. The pigmented monolayer is called the retinal pigmented epithelium and the multilayered neural component is called the neural retina. The rods and cones, which function as photoreceptors, are located adjacent to the neural retina. Rods are mainly concerned with low light vision and are found predominantly in the periphery of the retina. Cones are responsible for color perception and visual acuity. They are concentrated centrally within the macula. The fovea is in the center of the macula and is responsible for fine focusing activities such as
Figure 3.1 Anatomic structures of the human eye.
Laser Safety Measures
85
reading. The retina, which is rich in photoreceptors, does not contain pain receptors. The choroid is a vascular layer that is separated from the retina by Bruch’s membrane.
4.2.
Electromagnetic Spectrum
The divisions between the different portions of the electromagnetic spectrum (EMS) are somewhat arbitrary and the regions tend to overlap (10) (Fig. 3.2). The EMS includes radiation that extends from cosmic rays to radiowaves. The UV spectrum includes radiation from 100 to 400 nm and is divided into four subdivisions: vacuum UV (100 –200 nm), UV-C (200 –290 nm), UV-B (290 – 315 nm), and UV-A (315 –400 nm). The visible
Figure 3.2 Diagrammatic representation of the electromagnetic spectrum and the specific sites of laser-induced ocular damage. The optical spectra used for cutaneous lasers are expanded to present more detail. [Adapted from Refs. (8,10,11,13– 15).]
86
Ammirati and Hruza
spectrum is often referred to as visible light and extends from 400 to 760 nm. The infrared (IR) spectrum spans from 760 to 106 nm and has three subdivisions: near-IR (760 – 1400 nm), mid-IR (1400 – 3000 nm), and far-IR (3000 –106 nm). The term specular describes mirror-like reflections, which can reflect close to 100% of incident light (11). Specular reflection by a flat surface will not change a fixed beam’s diameter, only its direction (Fig. 3.3). Convex surfaces will cause beam divergence and concave surfaces will make the beam converge. Diffuse reflections result when surface irregularities scatter light in all directions. Whether the reflection is specular or diffuse will depend on the wavelength of light that strikes the surface (12). A given surface, which will diffuse visible light, may produce specular reflections when struck by longer IR wavelengths. Although oversimplified, wavelengths in the UV, mid- and far-IR regions are primarily absorbed by the anterior segment while the posterior segment absorbs the majority of visible and near-IR wavelengths. There are two transition zones in which both segments of the eye may be damaged. These zones are found at the transition from UV to visible light and where near-IR light becomes mid-IR (2). An example would be the Nd:YAG laser at 1340 nm, which can simultaneously damage the cornea, lens, and retina (13).
Figure 3.3 Diagrammatic representation of reflections by various specular and anodized surfaces. Convex specular surfaces cause beam convergence. Concave specular surfaces cause beam divergence. Flat specular surfaces change a fixed beam’s direction but not its diameter. Anodized, brushed or matte surfaces cause beam diffusion. [Adapted from Refs. (11,12,16).]
Laser Safety Measures
4.3.
87
Retinal Injury
Light of 400– 1400 nm wavelength poses the most serious risk to the retina and is known as the retinal hazard zone (8). For Class IV lasers, the blink reflex is not protective, as by the time it can engage, the damage has already occurred. The human eye can focus collimated laser light down to a 10– 20 mm spot (11). The law of the conservation of energy applies to this convergence and the energy density will increase geometrically as the spot diameter decreases. Thus, normal focusing by the eye results in a 100,000-fold increase in energy fluence. This can be likened to a magnifying lens focusing sunlight onto paper and causing it to burn. The eye focuses and intensifies the laser beam in a similar fashion onto the retina. Visible and near-IR lasers can produce retinal injury via thermal and photoacoustic mechanisms (8). Thermal injury may remain confined to the dimensions of the laser spot or if the energy is excessive, heat may extend the damage peripherally. Q-switched lasers produce powerful nanosecond pulses that create shock waves (photoacoustic effects) within the retina. This type of mechanical damage forcibly expels burned debris into the vitreous and due to its global effect on the retina often produces more destruction than thermal damage alone (17,18). The location and extent of the damage within the retina determines the degree of perceived visual loss. A small lesion, at the periphery of the fundus, may go unnoticed while damage to even the smallest portion of the fovea will produce a decrease in visual acuity and color perception. Since retinal tissue does not regenerate, any damage will be permanent. Unprotected eye exposure to visible (400 – 760 nm) laser light produces an intense flash of colored light followed by an after-image. Exposure to near-IR (760 –1400 nm) laser light may not be initially apparent because wavelengths much longer than 760 nm are invisible to the human eye (14). Since there are no pain receptors in the retina and the beam is invisible, accidental exposure to a near-IR beam may go unnoticed until the damage is severe. By far, the most common laser associated with retinal injury is the 1064 nm Nd:YAG laser (19). Symptoms from Nd:YAG laser injury can range from a headache to the audible “pop” and appearance of “floaters” as described by Decker (20). Treatment for laser-induced retinal injury is largely anecdotal but the majority of the literature supports observation or the use of corticosteroids (21,22). Apparently, as long as the fovea is not damaged, the potential for spontaneous recovery of vision is favorable (23,24).
4.4.
Corneal Injury
The cornea is susceptible to damage from radiation within the UV spectrum and above 1400 nm (13,15). As with all laser – tissue interactions, the extent of injury will depend on the wavelength, energy, and duration of exposure. Since amplification by the lens is not involved, injury thresholds for the cornea are significantly higher than those that cause retinal injury (11). Corneal injury from wavelengths beyond 2800 nm (i.e., 2940 nm Er:YAG and 10,600 nm CO2 lasers) is usually confined to the superficial layers, which are capable of regeneration (25). While superficial corneal burns can be intensely painful, they usually resolve in 2–3 days without sequelae. Both lasers are capable, with sufficient energy, of producing deeper injury with scarring and corneal opacification (25). Treatment of superficial corneal injury consists of topical antibiotics and an eye patch. There is no effective medical treatment for deeper injury and corneal transplantation may be the only hope for restoring vision. Surgical preparations used before laser surgery can also injure the cornea. Chlorhexidine, apart from being flammable, can cause severe keratitis with permanent opacification
88
Ammirati and Hruza
if allowed to come in contact with the cornea (26,27). Regardless of the treatment location, chlorhexidine should not be used before laser surgery since it could be potentially aerosolized in the laser plume. This vapor could injure the eyes of the patient, laser operator, or assistant if adequate laser smoke evacuation is not in use. 4.5.
Lenticular Injury
The human lens strongly absorbs UV-A and to a lesser extent visible and near-IR (760 –1400 nm) light (13,15). Visible and near-IR light is thought to damage the lens by conductive heating of the iris. If the energy is sufficient, acute exposure can produce an immediate burn. More commonly, the exposure is chronic and it can take years for the cataract to become evident. 5.
EYE PROTECTION
If there is any possibility of viewing a Class IIIb or Class IV laser beam, appropriate eye protection must be provided for all personnel and patients within the laser control area. OSHA’s Eye and Face Protection Standard [29CFR 1926.102 (b)(2)] addresses the safety of employees who work with lasers. An employer’s obligation to provide and pay for personal protective equipment is outlined in OSHA’s Personal Protective Equipment Standard (29CFR 1910.132 –138). To better understand eye protection requirements, the maximum permissible exposure (MPE) and the nominal hazard zone (NHZ) should be defined (2). MPE is the level of laser radiation to which a person may be exposed without damage to the eye or skin. The MPE will vary with laser wavelength, duration of exposure and pulse repetition and is expressed in joules per square centimeter or watts per square centimeter. ANSI Z-136.1 tables A3(a) and (b) list the MPE for specific wavelengths. Exposure to energy above these limits can result in tissue damage. The NHZ is the distance from the laser at which the level of direct, reflected, or scattered radiation exceeds the MPE. As such, it defines the space in which control measures are required. The NHZ is a function of the laser settings in use such as spot size, energy, and pulse duration. These parameters are often changed during a procedure and continual calculation of the NHZ would be unrealistic. To simplify this situation, the NHZ for Class IV lasers is defined as the entire surgery room. Laser protective eyewear (LPE) provides the primary means to guard against ocular injury and must be worn whenever the laser is enabled. To be effective, the LPE must be wavelength specific and have sufficient optical density (OD) for the laser in use. OD is a logarithmic function that defines the ability of a protective lens to absorb a specific wavelength: OD ¼ log10
incident light (in J=cm2 or W=cm2 ) transmitted light (in J=cm2 or W=cm2 )
For example, an OD of 4 allows 1/104 of the laser energy to be transmitted. Cutaneous lasers range from 308 to 10,600 nm and there is no single lens filter that will provide protection throughout this range of wavelengths without being opaque. A higher OD does not always mean improved safety (28). Lenses with higher OD values are often dark in color, which can limit color discrimination and visualization of the treatment area (29). Clearly, there must be a balance between maximal eye protection and visibility because compliance will be low if eyewear is difficult to see through.
Laser Safety Measures
89
There are a variety of reflective and absorbent optical filters available. A reflective filter allows the transmission of as much of the remaining visible spectrum as possible but may create potentially hazardous reflections. Other disadvantages of glass reflective filters are that they are heavy and if the coating is scratched, radiation may reach the eye. Absorbent filters molecularly convert, rather than reflect, laser energy. They can be made from polymeric materials, which weigh less, are easily molded into comfortable shapes, and are not affected by surface scratches (30). Their disadvantage is that they are easily cracked and can melt with sufficient heat. Any damage to the optical filter, be it reflective or absorptive, can lower the OD value in an unpredictable manner (31). Therefore, LPE should be handled carefully and examined prior to each use for cracks, scratches, or loose-fitting lenses. Do not rely on the color of the lens or style of the LPE to identify the level of protection, as this can be misleading. Different types of LPE often look alike and it is important to check the wavelength and OD prior to relying on them for protection. Some laser facilities have more than one laser in each room. In that case, color coded tape can be applied to the laser handpiece and matching LPE to minimize confusion. There are several styles of LPE available. Goggles can be worn over prescription glasses but must fit snugly if they are to be effective. The disadvantages of this style are that they may be cumbersome and can produce a tunnel vision effect. Spectacles resemble eyeglasses with side shields (Fig. 3.4). Wraps consist of a single lens, which is usually made from lightweight plastic and wraps across the eyes from temple to temple. While it is true that optical glass will filter wavelengths below 300 nm and above 2700 nm, prescription eyeglasses do not have side shields and therefore do not confer adequate protection (16). Class IV laser beams may be reflected by specular surfaces in the surgical field and still maintain sufficient energy to cause thermal damage. Metallic surfaces that appear dull and nonreflective may be specular to 10,600 nm CO2 light (12). Therefore, all jewelry should be removed from the field and the laser should not be aimed at any metallic or shiny surface. Metallic instruments or items that are needed in the field during treatment should be anodized (have a brushed or matte finish) to decrease the reflectivity of the beam. A black coating (ebonizing) augments anodizing but does not provide sufficient beam diffusion when used alone. Plastic devices can melt and should only be used if they are known to be laser-resistant.
Figure 3.4 Wavelength-specific laser eye protection. Note the side shields and prominently labeled optical density. These can be manufactured with prescription corrective lenses as well.
90
5.1.
Ammirati and Hruza
Patient Protection
Ideally, nonsedated patients should be offered the same eye protection as that worn by the operating staff. This allows them to see the actions taking place in the room and can reduce unnecessary anxiety. Nonsedated patients can also wear opaque mini goggles, with a few caveats. This type of LPE is often stiff and the elastic strap must be tightened until there is a lightproof seal around the eyes. The strap itself can be flammable and should be maneuvered away from the treatment area or “strapless” goggles can be taped into place. For infants and children, it may be necessary to cut the goggles at the nosepiece and individually tape them over the eyelids. Moistened gauze or Telfaw can be placed over the closed lids and under the mini goggles to add a second level of protection (32). Laser treatment on or near the eyelids requires corneal eyeshields (Fig. 3.5). After topical anesthetic drops (e.g., 0.5% tetracaine HCl ophthalmic solution) have been instilled onto the conjunctiva, the eyeshield concavity is lubricated with a water-based lubricant (e.g., Lacri-lubew) and carefully placed under the eyelid against the eyeball. Studies investigating the thermal response curves and rates of warming for various types of eyeshields have shown them to be variable (33). Metallic eyeshields provide the best protection from transmitted light and heat but can be highly reflective. To decrease the risk of beam reflection, the convex surface should be anodized. Plastic eyeshields, especially those of darker color, should be avoided since they tend to melt when struck with sufficient laser energy (34). Well-intentioned family members, present for emotional support, are also at risk for injury. Their lack of laser safety training further increases their risk and whenever possible they should be discouraged from staying for the procedure.
5.2.
Medical Surveillance
ANSI-Z136.1 requires preassignment medical surveillance exams for all laser personnel who will be exposed to Class IIIb or IV laser energy. This examination must be documented before participation in laser surgery and establishes the baseline ocular history, visual acuity, peripheral fields, and color vision. Any abnormal finding would warrant a dilated
Figure 3.5 Corneal eye shields. Note the anodized convex exterior surface to decrease specular reflection.
Laser Safety Measures
91
ophthalmologic exam and other tests as deemed appropriate. A second rationale for preassignment examinations is to identify certain personnel who may be at increased risk from laser exposure. This includes workers who use photosensitizing medications, which have been shown to lower the threshold for laser damage to the eye (35). Periodic examinations are not required for asymptomatic personnel but ANSI does require an examination after any suspected laser injury has occurred. At his/her discretion, an employer may elect to obtain an examination when employment is terminated to provide legal protection against future claims of injury.
6.
SKIN HAZARDS
Although the skin is more likely to be exposed to laser injury, it is not usually given the same priority as eye protection. This is because there is a vast difference in the magnitude of injury produced by a laser strike to the eye as compared to the skin. Depending on the energy and wavelength in use, lasers can produce cutaneous burns that range from superficial erythema to extensive blistering and charring. However, most skin injuries are relatively minor because an alert person will quickly remove the exposed skin from the path of the laser beam. A sedated patient, however, can suffer more severe skin burns since they will not reflexively withdraw from the laser impact. As a rule, when treating anesthetized patients, it is good practice to protect the surrounding skin with wet towels.
7.
TEETH HAZARDS
Dental enamel absorption is high in the UV and IR regions (36). When lasers are used around the lips and in the oral cavity, care must be taken that a stray laser beam does not damage or discolor tooth enamel or dental prosthetics (37,38). A moistened gauze or dental roll can be used as protection if the teeth are near the treatment field.
8.
FIRE HAZARDS
Class IV lasers can cause flash fires or electrical fires. A flash fire can result if the laser beam strikes a flammable material within the surgical field. An electrical fire would be one that occurs within the laser unit itself. To limit injury, each of these emergent situations requires an immediate response and personnel must be familiar with all safety protocols. 8.1.
Fire Prevention
A flash fire can occur if a direct or reflected beam ignites gauze, hair, cosmetics, or drapes within the surgical field (Fig. 3.6) (34). Nylon or rayon fabrics are especially hazardous since they can melt and adhere to the skin. To avoid this risk, all unnecessary material should be removed from the treatment site. Makeup is also flammable and must be removed before treatment begins. Drapes and gauze pads used in the field should be wet or nonflammable. If wet gauze or drapes are used, they should be periodically checked to make sure that they have maintained their moisture. One study found Telfaw pads to be more flame-resistant than gauze and their preferential use might be warranted (32). For small treatment areas, hair can be positioned away from the field with water-soluble lubricating gel (i.e., K-Yw Jelly). For larger areas, a wet towel should be used.
92
Ammirati and Hruza
Figure 3.6 Ignition of dry gauze by the continuous wave argon laser. (Ignition occurred within seconds.)
Alcohol readily ignites when exposed to the heat of a laser impact (39). Hair sprays and gels often contain alcohol, as do topical preparations such as chlorhexidine surgical scrub and some lidocaine gels. Iodophors may also ignite at high temperatures, especially if they accumulate near the operative field (40). The use of any potentially flammable preparation should be discouraged. If its use is absolutely necessary, it should be washed completely from the site before treatment begins. Methane release, during laser treatment of the anogenital area, also poses a fire hazard. A moist rectal tampon can be used to decrease this risk. Medical grade silicone can ignite when exposed to CO2 laser energy. This was first discovered during CO2 laser vaporization of silicone deposits in breast tissue (41). This “silicone flash” has now been experimentally produced by microdroplet silicone, which is the form used for dermal augmentation on the face (42). Even tiny fractions of silicone produced a visible flare with a flame extending as far as an inch from the experimental test site. This presents a theoretical concern and although it has not been shown in practice, it is unclear whether a history of silicone facial augmentation should be considered a relative contraindication to CO2 resurfacing. There have been several reports of ignition during the use of the pulsed dye laser treatment when supplemental oxygen was in use (32,39,43). Oxygen greatly increases the combustion potential of any flammable material, even those that are saturated with water (32,43). If possible, supplemental oxygen should be momentarily discontinued when any surgical laser is in use. Alternatively, spontaneous respiration with a laryngeal mask airway can be used (44). 8.2.
Fire Containment
During treatment, a bowl of water should be within reach of the laser operator at all times since an immediate response could limit the potential damage to the patient. A separate safety protocol is required if an electrical fire occurs within the laser unit itself. These situations require extreme caution and the staff should be trained to handle this emergency as well. It should be stressed that water must never be used on an electrical fire as this could lead to electrocution. A fire extinguisher should be available in each laser treatment room
Laser Safety Measures
93
or it can be attached to the side of the laser itself. The extinguisher of choice, for a laser unit electrical fire, is a halon fire extinguisher (45). Common dry chemical extinguishers emit a fine dust, which can damage laser optics or circuitry, and should not be used.
9.
ELECTRICAL AND MECHANICAL HAZARDS
The most lethal hazard associated with lasers is the high voltage that powers them. Most medical lasers operate on 220 or higher AC voltage. This is typically doubled or tripled by the laser exciter (power supply). Several deaths have occurred when persons working with the high-voltage portions of laser systems did not follow safety practices (2). Untrained personnel should never manipulate or access the laser power supply. If an emergent situation arises and it is absolutely necessary to access the power supply, first insure that the main power has been disconnected. Second, call for assistance and do not attempt repairs alone. In the event of high-voltage injury, a second person will be needed to call for emergency medical personnel and administer cardiopulmonary resuscitation until they arrive. Cutaneous lasers are designed to be portable but a significant jolt to the unit can result in misalignment of the laser head or optical fiber. Prior to beginning laser surgery the operator should verify the alignment of the laser beam and the integrity of the spot size. The Baggish 1 J test can be used for focused-beam CO2 lasers (46). To perform this test, the laser power is set to 10 W with an exposure duration of 100 ms. At these settings, 1 J of energy should be produced. A well-focused 1 J CO2 laser beam should penetrate through a standard wooden tongue depressor. If the beam does not penetrate, calibration is indicated. Visible and near-IR laser alignment can be checked by firing at an appropriately colored photopaper (i.e., red photopaper for 585 nm pulsed dye laser). The resultant laser spot on the photopaper should match exactly with the location of the alignment beam. The spot should also be of the appropriate diameter with its edges sharply defined and its center without “hotspots” (uneven burn patterns).
9.1.
Controlled Access
OSHA regulations state that access to the laser and entrance to the surgery room must be strictly controlled (47). The CDRH mandates that Class IIIb and IV lasers incorporate a key activated control switch (3). The laser must be rendered inoperable if the key is not in place. When the laser is not in use, the key should be removed from the control panel and stored in a secure location. The ANSI standards recommend that a door interlock system be used during laser procedures (2,48). While this may be effective in nonmedical settings, its use is impractical for most medical laser procedures. An interlock system would disengage the laser if the door to the laser room were opened. While this would provide safety for the person entering the room, it could compromise patient care since the operator may be at a critical point in the procedure. It is far better to post warning signs on the door when the laser is in use and train personnel to limit all nonessential entrance. Wavelength-specific eyewear can be hung next to the sign if unplanned entrance is necessary (Fig. 3.7). Laser warning signs should be promptly removed when the procedure is completed or their significance may be forgotten. Windows, doorways, and open portals, through which laser light might escape, must be adequately covered or shielded. Visible and near-IR laser wavelengths readily penetrate
94
Ammirati and Hruza
Figure 3.7 A laser warning sign should be prominently displayed on the door leading into the surgical suite. The sign should be removable and taken down when treatment has been completed. Laser-specific eye protection should be hung next to the sign to allow safe entrance once treatment has commenced.
window glass. If the windows are at eye level, opaque, laser-resistant coverings will be needed. To prevent accidental discharge of the laser, foot pedals are designed with protective housing (Fig. 3.8). To engage the laser, the foot must be purposely placed within the device and the pedal depressed. To limit any confusion, the smoke evacuator foot pedal is placed near the assistant, who is usually on the other side of the patient. When it is not in use, the laser should be placed in stand-by mode. This provides a second line of defense against accidental discharge.
Figure 3.8 Laser foot pedal on the left equipped with protective housing. This is compared to the unprotected smoke evacuator foot pedal on the right. The protective housing on the laser foot pedal decreases any risk for laser misfire.
Laser Safety Measures
10.
95
CHEMICAL HAZARDS
Some laser systems use toxic gases, organic dyes, and solvents that can be hazardous if not properly handled. Excimer lasers, which are not routinely used for cutaneous surgery, may contain toxic halogens mixed with an inert gas and special training is required to service these units (49). Dye lasers use a lasing medium that consists of a complex organic dye dissolved in an organic solvent. Limited animal studies have shown some laser dyes to be toxic, mutagenic (Ames/Salmonella assay), and possibly carcinogenic (50 – 52). Since specific data are limited, all dyes should be treated as hazardous chemicals. 10.1. Chemical Protection Impervious gloves and protective eyewear are to be used when handling laser dye and quencher solutions. If skin contact occurs, the area should be washed immediately with soap and water. Eye contact is a medical emergency and requires copious irrigation with water and prompt medical attention. In the case of accidental ingestion, the local poison control center should be contacted. Prolonged inhalation is also not recommended and persistent symptoms will require medical attention. OSHA’s Employee Right to Know Act of 1988 requires that employees who work with potentially hazardous materials have certain rights. This includes access to the material safety data sheet that accompanies each dye laser. This sheet will supply appropriate information pertaining to toxicity, personal protective equipment, and the storage of chemicals.
11.
ACCOUSTIC HAZARDS
The noise level of certain lasers, such as the Er:YAG, may be of sufficient intensity to warrant hearing protection during their use.
12.
LASER PLUME HAZARDS
A plume, consisting of smoke, vapor, and particulate debris, is generated whenever a laser ablates tissue. Depending on the type of medical procedure, the laser plume may contain carcinogens, mutagens, irritants, tissue fragments, potentially infectious viral particles, and bacteria (2). The hazard potential of this plume has been the subject of understandable concern as well as debate. In 1992, the EUREKA international project STILMED (Safety Technology in Laser Medicine) began systematic investigations of the chemical, particulate, and microbiological hazards of laser plume (53). Their final results were summarized and are available from SPIE—The International Society of Optical Engineering (see Table 3.1). 12.1. Organic Compounds The laser plume’s smell is nauseating and its particulate matter can cause eye, nose, and throat irritation. Chemical analysis of continuous wave CO2 and Nd:YAG laser plumes identified carbon monoxide, hydrogen cyanide, ammonia and more than 150 volatile organic compounds, including benzene, formaldehyde, and toluene (54 – 56). Extreme
96
Ammirati and Hruza
laser-generated temperatures split tissue molecules into free radicals, which catalyze the generation of these toxic compounds. If an oxygen donor, such as aerosolized water, is available, then the formation of free radicals and other harmful laser plume substances can be reduced (57). Wiping away charred tissue, prior to continued lasing, will also reduce the emission of toxic compounds (58). The particulate aerosol of the laser plume is known to have in vitro mutagenic, genotoxic, and clastogenic (disruption or breakage of chromosomes) potential (59,60). Laser-generated carcinogens are similar to those found in cigarette smoke and vaporization of 1 g of tissue produces the same amount of mutagenic smoke as smoking three to six cigarettes (60). While there is no epidemiologic evidence of increased malignancies in personnel chronically exposed to laser smoke, safe levels of ambient mutagens remain to be determined and unnecessary exposure should be avoided (61). 12.2.
Particulate Debris
The majority of CO2 laser-generated particles range from 0.1 to 0.8 mm in diameter (62). Particles of this size are easily deposited in the lower respiratory tract and can cause parenchymal damage (63). Experimental rats, when forced to breathe CO2 laser smoke for prolonged periods, developed congestive interstitial pneumonia, bronchiolitis, and emphysema (64). Similar experimental changes have been induced by the continuous wave 1064 nm Nd:YAG laser plume (65,66). 12.3.
Pathogenicity
The infectious potential of laser-generated cellular debris has been the focus of understandable concern. Early studies with the Nd:YAG and CO2 lasers failed to culture laser plume debris and it was hoped that the extreme temperatures generated by these lasers would sterilize any debris (67 –69). Recent findings, however, have been to the contrary (70 – 73), which may be due to different collection techniques as well as variations in the laser settings used (62,74). Transmission of human papilloma virus (HPV) from laser ablation of infected tissue remains a serious concern among laser surgeons. Infectious bovine papilloma virions and intact DNA from HPV have been recovered from the CO2 laser plume (75,76). The degree of risk that these findings represent in actual practice is not completely known. A comparative study of CO2 laser surgeons, who frequently treated HPV-infected lesions, failed to find an increased incidence of common warts (77). However, when grouped by anatomic site, CO2 laser surgeons were found to have a higher risk of acquiring nasopharyngeal papillomas. This is due to the ability of HPV types 6 and 11, which cause genital condyloma acuminata through contact, to induce nasopharyngeal papillomas after inhalation (78 –80). These findings also imply that there is a true infectious hazard, albeit small, from laser ablation of HPV-infected tissue and that strict adherence to protective measures is indicated. Transmission of human immunodeficiency virus (HIV) or hepatitis via the laser plume represents a serious potential hazard, but studies thus far have been limited (81 –84). Proviral HIV DNA and HIV p24 protein from CO2 laser smoke were detectable in culture at 14 days but were not sustained at 28 days (81). Examination of the Er:YAG laser plume, which failed to reveal HPV DNA (85), did recover infectious retrovirus (86). Hepatitis B virus, which can survive for 72 h outside the body, poses a theoretical risk during laser procedures but has not been studied. To date, there have been no cases of HIV or hepatitis transmission from a patient to a physician via laser plume. However,
Laser Safety Measures
97
since the degree of risk has not been clearly delineated and the consequences of infection are so severe, protective measures are a must. Additional concern surrounds the tissue debris that is ejected at supersonic speed by Q-switched lasers, such as the alexandrite, ruby, and Nd:YAG. Q-switched lasers cause a heat-induced explosion within tissue cells, which can liberate viable surface cells into the air at supersonic speeds. These ejection speeds are beyond the capture of a smoke evacuator and different protective measures will be needed (87). 12.4. Protection and Evacuation In 1996, NIOSH issued the Health Hazard Control, Control of Smoke from Laser/Electric Surgical Procedures (HC-11). This was the first federal statement calling for the evacuation of smoke generated by lasers and electrosurgery. In HC-11, NIOSH clearly identifies laser and electrosurgery smoke as a health hazard and provides guidelines for optimal evacuation. 12.5. Smoke Evacuators Smoke evacuation provides the first line of defense against laser plume hazards and there are several methods available. In-line wall suction filters have been used for small amounts of laser plume evacuation but are not recommended. They clog easily and the plume is exhausted elsewhere in the facility, usually without adequate filtration, and creates an airborne hazard (66). A high-efficiency laser smoke evacuator is a more reliable unit that consists of a vacuum, charcoal filter, high-efficiency particulate air (HEPA) filter, and ultra-low particulate air (ULPA) filter. The activated charcoal filter serves to trap toxic chemicals and noxious vapors. The HEPA filter traps particles as small as 0.3 mm in diameter with .99% efficiency. The ULPA filter captures 0.1 mm particles and this additional efficiency has a significant clinical impact. Recall that rats, when forced to inhale CO2 laser smoke, developed microscopic pulmonary changes (64). When laser smoke was filtered through an HEPA filter, prior to being inhaled, the rats developed similar but less severe pulmonary lesions. After a ULPA filter was added to the filtration system, no pathologic lung changes were observed (88). A high-efficiency smoke evacuator will only be effective when the nozzle is kept within 2 in. of the treatment site (89). Evacuation efficiency is dramatically reduced when the tube is held farther away (90). The vacuum tubing is changed after each patient and treated as biohazardous waste (81). Any lingering odor or smoke in the air suggests that the filter should be inspected and changed if necessary. Currently, there are two types of filter monitor systems available on laser smoke evacuators, pressure drop monitors, and time-based monitors (83). Pressure monitors measure the drop in pressure across the filter. When a critical pressure is reached, an indicator light signals that the filter should be changed. A time-based monitor will signal the need for a filter change after a preset period of use. Its signal may be premature if the vacuum has been left running while the laser was not engaged. To limit exposure to Q-switched laser-generated debris, a collecting cone or shield can be placed over the handpiece during use. The laser can also be fired through a transparent membrane, such as Cling Filmw or Vigilonw to reduce the ejection of particulate matter into the air (Fig. 3.9). Comparative studies with the Q-switched Nd:YAG laser found Cling Filmw to be superior to Tegadermw, Opsitew, or 2nd Skinw (91). Collecting cones and transparent membranes may reduce the ejected debris but not reliably eliminate it. Additional protective equipment such as gloves and laser masks are recommended.
98
Ammirati and Hruza
Figure 3.9 Ejected cellular debris trapped by a clear membrane. The Q-switched Nd:YAG laser was fired through acetate sheeting during laser treatment of a tattoo.
12.6.
Laser Masks
Laser plume particles 0.1 –0.8 mm in size are too small to be effectively filtered by a standard surgical mask (92). Specially designed laser masks trap particles down to 0.1 mm. To be effective, they must fit snugly and have a moldable nosepiece and flexible side panels. It is recommended that laser masks be changed after each case or if they become wet during the procedure. To achieve 0.1 mm particle filtration, laser masks use electrostatically charged synthetic fibers. Moisture can eliminate the electrostatic charge and compromise the filtration capacity of the mask (88).
REFERENCES 1. 2. 3. 4. 5. 6. 7.
8. 9.
Dierkesmann R, Huzly A. Side effects of endobronchial laser treatment. Endoscopy 1985; 17:49 – 53. American National Standards Institute. American National Standard for the Safe Use of Lasers. Orlando, FL: Laser Institute of America, 1993. US Department of Health and Human Services. Title 21 CFR, Subchapter J. Part 1040.10 Performance Standards for Laser Products. Sliney D, Trokel S. Safety standards and laser exposure limits. In: Sliney D, Trokel S, eds. Medical Lasers and Their Safe Use. New York: Springer-Verlag, 1993:87 – 94. Luttrull JK, Hallisey J. Laser pointer-induced macular injury. Am J Ophthalmol 1999; 127:95–96. Marshall J. The safety of laser pointers: myths and realities. Br J Ophthalmol 1998; 82:1335 – 1338. McHugh JD, Marshall J, Ffytche TJ, Hamilton AM, Raven A, Keeler CR. Initial clinical experience using a diode laser in the treatment of retinal vascular disease. Eye 1989; 3:516 – 527. Marshall J. Structural aspects of laser-induced damage and their functional implications. Health Phys 1989; 56:617 –624. World Health Organization. Lasers and Optical Radiation. Geneva: World Health Organization Press, 1982.
Laser Safety Measures 10. 11. 12. 13.
14. 15. 16. 17. 18. 19. 20. 21.
22. 23. 24. 25. 26. 27. 28. 29.
30. 31. 32. 33. 34. 35. 36.
99
Pitts D. The electromagnetic spectrum. In: Pitts D, Kleinstein R, eds. Environmental Vision. Boston: Butterworth-Heinemann, 1993:87 – 136. Sliney DH. Laser safety. Lasers Surg Med 1995; 16:215– 225. Wood RL Jr, Sliney DH, Basye RA. Laser reflections from surgical instruments. Lasers Surg Med 1992; 12:675– 678. Zuchlich J, Gagliano D, Chaney F, Stuck B, Zwick H, Edsall P, Lund D. Ocular effects of penetrating IR laser wavelengths. Proceedings SPIE Laser-Tissue Interaction VI, Vol. 2391, Bellingham, WA, 1995:112 – 125. Pitts D. Ocular effects of radiant energy. In: Pitts D, Kleinstein R, eds. Environmental Vision. Boston: Butterworth-Heinemann, 1993:151 – 208. Zuclich JA, Connolly JS. Ocular damage induced by near-ultraviolet laser radiation. Invest Ophthalmol Vis Sci 1976; 15:760 – 764. Sliney D, Wolbarsht M. Safety with Lasers and Other Optical Sources. New York: Plenum Press, 1980. Ham WT Jr, Clarke AM, Geeraets WJ, Cleary SF, Mueller HA, Williams RC. The eye problem in laser safety. Arch Environ Health 1970; 20:156 –160. Thach AB. Laser injuries of the eye. Int Ophthalmol Clin 1999; 39:13– 27. Rockwell R. Laser accidents: Reviewing thirty years of incidents. J Laser Appl 1994; 6:203–211. Decker C. Laser accident victim’s view. Laser Focus Aug 1977. Takahashi K, Lam TT, Fu J, Tso MO. The effect of high-dose methylprednisolone on laserinduced retinal injury in primates: an electron microscopic study. Graefes Arch Clin Exp Ophthalmol 1997; 235:723 – 732. Potthofer S, Foerster MH. Vitrectomy and autologous thrombocyte adhesion of an accidental macular hole caused by Nd:YAG laser. Br J Ophthalmol 1997; 81:803 –804. Thach AB, Lopez PF, Snady-McCoy LC, Golub BM, Frambach DA. Accidental Nd:YAG laser injuries to the macula. Am J Ophthalmol 1995; 119:767 – 773. Alhalel A, Glovinsky Y, Treister G, Bartov E, Blumenthal M, Belkin M. Long-term follow up of accidental parafoveal laser burns. Retina 1993:13:152– 154. Sliney D, Trokel S. Laser injury and potential hazards. In: Sliney D, Trokel S, eds. Medical Lasers and Their Safe Use. New York: Springer-Verlag, 1993:72 – 85. Varley GA, Meisler DM, Benes SC, McMahon JT, Zakov ZN, Fryczkowski A. Hibiclens keratopathy. A clinicopathologic case report. Cornea 1990; 9:341 –346. van Rij G, Beekhuis WH, Eggink CA, Geerards AJ, Remeijer L, Pels EL. Toxic keratopathy due to the accidental use of chlorhexidine, cetrimide and cialit. Doc Ophthalmol 1995; 90:7– 14. Boucek C, Freeman JA, Bircher NG, Tullock W. Impairment of anesthesia task performance by laser protection goggles. Anesth Analg 1993; 77:1232 – 1237. Teichman JM, Vassar GJ, Yates JT, Angle BN, Johnson AJ, Dirks MS, Thompson IM. Color vision deficits and laser eyewear protection for soft tissue laser applications. J Urol 1999; 161:874–880. Kaufman JG, Tucker R. Proper eye protection needed as lasers gain industry popularity. Occup Health Saf 1986; 55:76, 79. Tanner M. Increasing use, power of lasers make eye protection essential. Occup Health Saf 1990; 59:44 – 46. Epstein RH, Brummett RR Jr, Lask GP. Incendiary potential of the flash-lamp pumped 585-nm tunable dye laser. Anesth Analg 1990; 71:171– 175. Ries WR, Clymer MA, Reinisch L. Laser safety features of eye shields. Lasers Surg Med 1996; 18:309 – 315. Rohrich RJ, Gyimesi IM, Clark P, Burns AJ. CO2 laser safety considerations in facial skin resurfacing. Plast Reconstr Surg 1997; 100:1285 – 1290. Fraunfelder F. Drug Induced Ocular Side Effects and Drug Interactions. Philadelphia, PA: Lea & Febiger, 1976. Lueschner F, Lotriet CJ, Denner BF. Spectral reflectance and transmittance in dental enamel for UV, visible and NIR light. Proceedings SPIE Laser Interaction with Hard and Soft Tissue II, Vol. 2323, Bellingham, WA, 1995:317– 322.
100 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53.
54. 55. 56.
57.
58.
59.
60.
61. 62.
Ammirati and Hruza Pogrel MA, Muff DF, Marshall GW. Structural changes in dental enamel induced by high energy continuous wave carbon dioxide laser. Lasers Surg Med 1993; 13:89– 96. Shariati S, Pogrel MA, Marshall GW Jr, White JM. Structural changes in dentin induced by high energy, continuous wave carbon dioxide laser. Lasers Surg Med 1993; 13:543 – 547. Bean AK, Ceilley RI. Reducing fire risks of the flashlamp pumped 585-nm pulse dye laser. J Dermatol Surg Oncol 1994; 20:224. Rosio T. Basic laser safety. In: Roenigk R, Roenigk H, eds. Roenigk and Roenigk’s Dermatologic Surgery: Principles and Practice. New York: Marcel Dekker, Inc., 1996. Becker DW Jr. Laser silicone flash. Plast Reconstr Surg 1988; 81:600. Zager W, Huang J, McCue P, Reiter D. Laser resurfacing of silicone-injected skin: the “silicone flash” revisited. Arch Otolaryngol 2001; 127:418 – 421. Fretzin S, Beeson WH, Hanke CW. Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Dermatol Surg 1996; 22:699 – 702. Epstein RH, Halmi BH. Oxygen leakage around the laryngeal mask airway during laser treatment of port-wine stains in children. Anesth Analg 1994; 78:486 –489. Ball K. Lasers: The Perioperative Challenge. 2nd ed. St. Louis, MO: Mosby, 1991. Sliney D, Trokel S. Laser checkout and demonstration procedures. In: Sliney D, Trokel S, eds. Medical Lasers and Their Safe Use. New York: Springer-Verlag, 1993. US Department of Labor. Guidelines for Laser Safety and Hazard Assessment: OSHA Instructional PUB 8-1.7, 1991. American National Standards Institute. American National Standards for the Safe Use of Lasers in the Health Care Environment. Orlando, FL: Laser Institute of America, 1996. Lorenz A. Gas handling safety for laser makers and users. Lasers Appl 1987; 6:69– 73. Mosovsky JA. Laser Dye Toxicity, Hazards and Recommended Controls. Livermore, CA: Lawrence Livermore National Laboratory, 1983. Kues H, Lutty G. Dyes can be deadly. Laser Focus 1975; 11:58 – 60. Anonymous. Lasers. In: Health & Safety Manual. California, CA: Lawrence Livermore National Laboratory, 1995:1 – 20. Woellmer W. Results of EUREKA project STILMED: transfer to standards. Proceedings APIE Laser-Tissue Interaction and Tissue Optics II, Vol. 2923, Bellingham, WA, 1996:189 – 193. Kokosa JM, Benedetto MD. Probing plume protection problems in the health care environment. Laser J Appl 1992; 4:39 – 43. Ott D. Smoke production and smoke reduction in endoscopic surgery: preliminary report. Endosc Surg Allied Technol 1993; 1:230– 232. Albrecht H, Hagemann R, Waesche W, Wagner G, Mueller G. Volatile organic components in laser and electrosurgery plume. Proceedings SPIE Laser Interaction with Hard and Soft Tissue, Vol. 2077, Bellingham, WA, 1994:310 – 317. Lademann J, Weigmann H, Meffert H, Sterry W. Radical formation during laser-tissue interaction. Proceedings SPIE Laser-Tissue Interaction and Tissue Optics II, Vol. 2923, Bellingham, WA, 1996:156 –163. Weigmann H, Lademann J, Meffert H, Sterry W. Permanent gases and highly volatile organic compounds in laser plume. Proceedings SPIE Laser-Tissue Interaction and Tissue Optics, Vol. 2923, Bellingham, WA, 1996:164 – 167. Plappert UG, Stocker B, Helbig R, Fliedner TM, Seidel HJ. Laser pyrolysis products— genotoxic, clastogenic and mutagenic effects of the particulate aerosol fractions. Mutat Res 1999; 441:29 – 41. Tomita Y, Mihashi S, Nagata K, Ueda S, Fujiki M, Hirano M, Hirohata T. Mutagenicity of smoke condensates induced by CO2-laser irradiation and electrocauterization. Mutat Res 1981; 89:145 – 149. Hunter JG. Laser smoke evacuator: effective removal of mutagenic cautery smoke. Aesthetic Plast Surg 1996; 20:177 – 178. Nezhat C, Winer WK, Nezhat F, Forrest D, Reeves WG. Smoke from laser surgery: is there a health hazard? Lasers Surg Med 1987; 7:376– 382.
Laser Safety Measures 63. 64. 65. 66. 67. 68. 69. 70.
71. 72. 73. 74.
75.
76. 77.
78.
79. 80. 81. 82. 83. 84. 85. 86. 87.
101
Schwab JA, Zenkel M. Filtration of particulates in the human nose. Laryngoscope 1998; 108:120 – 124. Baggish MS, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156:1260 – 1265. Freitag L, Chapman GA, Sielczak M, Ahmed A, Russin D. Laser smoke effect on the bronchial system. Lasers Surg Med 1987; 7:283– 288. Wenig BL, Stenson KM, Wenig BM, Tracey D. Effects of plume produced by the Nd:YAG laser and electrocautery on the respiratory system. Lasers Surg Med 1993; 13:242– 245. Bellina JH, Stjernholm RL, Kurpel JE. Analysis of plume emissions after papovavirus irradiation with the carbon dioxide laser. J Reprod Med 1982; 27:268 – 270. Oosterhuis JW, Verschueren RC, Eibergen R, Oldhoff J. The viability of cells in the waste products of CO2-laser evaporation of Cloudman mouse melanomas. Cancer 1982; 49:61– 67. Mihashi S, Jako GJ, Incze J, Strong MS, Vaughan CW. Laser surgery in otolaryngology: interaction of CO2 laser and soft tissue. Ann N Acad Y Sci 1976; 267:263 – 294. Mullarky MB, Norris CW, Goldberg ID. The efficacy of the CO2 laser in the sterilization of skin seeded with bacteria: survival at the skin surface and in the plume emissions. Laryngoscope 1985; 95:186 – 187. Walker NP, Matthews J, Newsom SW. Possible hazards from irradiation with the carbon dioxide laser. Lasers Surg Med 1986; 6:84 – 86. McKinley IB Jr, Ludlow MO. Hazards of laser smoke during endodontic therapy. J Endod 1994; 20:558 – 559. Byrne PO, Sisson PR, Oliver PD, Ingham HR. Carbon dioxide laser irradiation of bacterial targets in vitro. J Hosp Infect 1987; 9:265 – 273. Kunachak S, Sithisarn P, Kulapaditharom B. Are laryngeal papilloma virus-infected cells viable in the plume derived from a continuous mode carbon dioxide laser, and are they infectious? A preliminary report on one laser mode. Laryngol J Otol 1996; 110:1031 –1033. Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989; 21:41 – 49. Sawchuk WS, Felten RP. Infectious potential of aerosolized particles. Arch Dermatol 1989; 125:1689 – 1692. Gloster HM Jr, Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995; 32:436 – 441. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80:560– 563. Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Otorhinolaryngol 1991; 248:425 – 427. Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci USA 1982; 79:5425 –5429. Baggish MS, Poiesz BJ, Joret D, Williamson P, Refai A. Presence of human immunodeficiency virus DNA in laser smoke. Lasers Surg Med 1991; 11:197– 203. O’Grady KF, Easty AC. Electrosurgery smoke: hazards and protection. J Clin Eng 1996; 21:149 – 155. Romig CL, Smalley PJ. Regulation of surgical smoke plume. AORN J 1997; 65:824 – 828. Winstin C. The effects of smoke plume generated during laser and electrosurgical procedures. Minim Invasive Surg Nurs 1994; 8:99 – 102. Hughes PS, Hughes AP. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol 1998; 38:426 –428. Ziegler BL, Thomas CA, Meier T, Muller R, Fliedner TM, Weber L. Generation of infectious retrovirus aerosol through medical laser irradiation. Lasers Surg Med 1998; 22:37– 41. Voorhies RM, Lavyne MH, Strait TA, Shapiro WR. Does the CO2 laser spread viable braintumor cells outside the surgical field? J Neurosurg 1984; 60:819– 820.
102 88. 89. 90.
91. 92.
Ammirati and Hruza Baggish MS, Baltoyannis P, Sze E. Protection of the rat lung from the harmful effects of laser smoke. Lasers Surg Med 1988; 8:248– 253. Smith JP, Moss CE, Bryant CJ, Fleeger AK. Evaluation of a smoke evacuator used for laser surgery. Lasers Surg Med 1989; 9:276 – 281. Mihashi S, Ueda S, Hirano M, Tomita Y, Hirohata T. Some problems about smoke condensates induced by carbon dioxide laser irradiation. Procedings of the 4th Congress of the International Society for Laser Surgery, Tokyo, Japan, 1981:225 – 227. Pay AD, Kenealy JM. Laser transmission through membranes using the Q-switched Nd:YAG laser. Lasers Surg Med 1999; 24:48– 54. Kunachak S, Sobhon P. The potential alveolar hazard of carbon dioxide laser-induced smoke. J Med Assoc Thai 1998; 81:278 –282.
Section II: Laser Science and Instrumentation
4 Continuous Wave Lasers: Argon, Dye, KTP, Copper Vapor, Krypton Thomas O. McMeekin University of Rochester and State University of New York at Buffalo, Rochester, New York, USA
1. Continuous Wave Argon Laser 1.1. Laser Parameters 1.2. Indications—Port-Wine Stains 1.3. Perioperative Considerations 1.4. Telangiectasias 1.5. Other Vascular Lesions 1.6. Hemangiomas 1.7. Pigmented Lesions 2. Continuous and Quasicontinuous Argon-Pumped Tunable Dye Laser 2.1. Laser Parameters 2.2. Indications—Port-Wine Stains 2.3. Perioperative Considerations 2.4. Facial Telangiectasias 2.5. Argon-Pumped Tunable Dye Laser Pigmented Lesions 3. Copper Vapor Lasers/Copper Bromide Lasers 3.1. Laser Parameters 3.2. Indications—Port-Wine Stains 3.3. Perioperative Considerations 3.4. Facial Telangiectasia 3.5. Other Vascular Lesions 3.6. Pigmented Lesions 4. KTP Lasers 4.1. Laser Parameters 4.2. Indications—Port-Wine Stains/Telangiectasias 4.3. Perioperative Considerations 4.4. Hemangioma 5. Krypton Laser 5.1. Laser Parameters
106 106 106 108 109 110 110 112 112 112 112 113 113 114 114 114 116 117 117 117 118 119 119 120 121 121 123 123 105
106
McMeekin
5.2. Indications—Telangiectasia 5.3. Operative Considerations References
1. 1.1.
123 124 124
CONTINUOUS WAVE ARGON LASER Laser Parameters
Although the argon laser emits at six wavelengths from 457.9 to 514.5 nm, 80% of the total emissions occur at 488 and 514 nm. A filter can be used to limit the wavelength to green light at 514 nm, or all the blue-green light can be delivered by a fiber optic cable in a continuous beam. The fiber optic delivery cable comes with spot sizes of 0.1–1.0 mm, with a fluence range of 0–2.0 W. A scanner is available, but no cooling is built into the system. Optional cooling with ice pretreatment or using a commercial cooling chamber is available. The light can penetrate into tissue up to 1 mm, however, thermal injury in port wine stains is seen at ,0.5 mm. Argon light is well absorbed by both melanin and oxyhemoglobin. The argon laser is no longer manufactured, but an ophthalmic argon laser is made by Lumenis Laser Corporation (Palo Alto, CA).
1.2.
Indications—Port-Wine Stains
The argon laser was developed in the 1970s for the treatment of vascular lesions. Although the ruby laser and the CO2 laser antedated the argon laser, neither was greeted with the enthusiasm that heralded the first results published in 1976 in port-wine stains (1,2). This enthusiasm was partially due to the poor treatment options for port-wine stains which included radiation, cryosurgery, excisional surgery with grafting, tattooing with skin-colored pigments, dermabrasion, and electrosurgery. The optimism was also heightened by the now disproved theory that the blue-green light was specific for the chromophore oxyhemoglobin and would penetrate the necessary depth to coagulate the ectatic vessels in the vascular malformation. A trial-and-error approach characterized the experience over the first 5 years. Few attempts were initially made to study the histology and correlate the successes that were observed with prognostic factors or treatment parameters. The results of argon laser treatment of port-wine stains were essentially that 60– 75% of cases showed good to excellent results, only 10% showed complete disappearance, and 10% showed no response or only slight fading [see Fig. 4.1(a) and (b)] (3 –5). The risk of scarring varied from a low of 4% (6), to .50% (6), and with a survey of patient perceptions as high as 86%, when skin texture changes were included (7). Hypopigmentation was also common because of the high absorption of melanin at 514 nm (7). Particularly disturbing was the high incidence of scarring noted in children (7,8). The predictive values of age, color of the port-wine stain, and biopsy were helpful in defining prognostic parameters (8). Those patients over age 37, with purple-colored lesions, and a large target (large mean vascular area filled with erythrocytes) responded favorably (8). Darkly pigmented patients responded less than lighter skinned patients due to competitive absorption by melanin. A variety of manipulations to improve results included: prechilling the port-wine stain (9), using mechanical shutters and lower fluences (10), recommending test sites and observing for 2–4 months to predict outcome (11) and altering the treatment technique.
Continuous Wave Lasers
107
Figure 4.1 (a) Preoperative argon laser treatment of port-wine stain lip. (b) Postoperative argon laser treatment of port-wine stain lip.
Four treatment techniques were used to treat port-wine stains. A point-by-point or continuous technique with adjacent, but not overlapping spots (2), a striping technique utilizing parallel strokes that leaves a zebra look to the lesion while trying to minimize collateral heat damage (12), a dot or pointillistic technique delivering spots separated by 1 –2 mm (13), and, finally, a microspot tracing technique using a spot size equal to the blood vessel being photocoagulated (14). This latter technique proved to be tedious and time-consuming so that only small areas could be treated in a single session (15). Despite the attempts to improve clinical results, the argon laser was limited by the small spot sizes, the long pulse durations, and the short wave lengths (488 – 514 nm), which did not reach the depth necessary to coagulate the deeper vessels of port-wine stains (16). Histologic studies confirmed that the clinical finding observed with the argon lasertreated port-wine stains was the result of nonspecific coagulative necrosis of the superficial dermal ectatic blood vessels with subsequent fibrosis and small vascular channels replacing the superficial part of the lesion (16 – 18). The diffusion of heat collaterally caused nonspecific thermal damage leading to the potential of epidermal atrophy, depigmentation, dermal fibrosis, and scarring (19). The scarring was also more prominent in difficult areas such as the upper lip, nasolabial fold, angle of the jaw, and neck. The trunk responded less well than the face, the arms less well than the trunk, and the lower extremities responded poorly.
108
McMeekin
The role of argon laser therapy in the treatment of port-wine stains diminished with the development of lasers capable of selective photothermolysis (20) and the development of computerized robotized scanning devices (see section “Argon-Pumped Tunable Dye Laser”). The current role of argon laser treatment is for the treatment of nodules of hypertrophic port-wine stains in adults (Table 4.3). 1.3.
Perioperative Considerations
Preoperatively, laser patients should avoid sunlight for several weeks prior to argon irradiation or use total sunblocks such as zinc oxide or titanium dioxide. A representative consent form for laser surgery is included in Table 4.1. Topical anesthetics such as EMLA or lidocaine cream 30% can be used prior to intralesional anesthesia. Large lesions require either field blocks or intralesional lidocaine 1%. The use of epinephrine is not felt to alter the result of laser therapy of vascular lesions, and will prolong the duration of anesthesia. Toxicity with large quantities of topical or intralesional lidocaine must be avoided (21). Buffered lidocaine reduces the pain of injection and is recommended for larger areas. For the treatment of port-wine stains, a 1.0 mm spot is used with the handpiece held perpendicular to the skin at its focal length and 0.5– 0.8 W power. It is moved slowly enough to produce a white to grey response which represents thermal coagulation of tissue proteins and is the endpoint for port-wine stains. A continuous back-and-forth airbrushing method, either vertical, horizontal, or in concentric circles, is used. Solitary
Table 4.1 Consent Form for Laser Treatment of Vascular Lesions I certify that I have been informed by Dr. ________________ of the following: 1. The outcome of ________ laser therapy. 2. No guarantee of results has been made. 3. Possible side effects include hypopigmentation, hyperpigmentation, scarring, infection, and incomplete removal of lesion, discomfort, swelling, prolonged wound healing. 4. Alternative treatment methods including no treatment. 5. Treatment protocol, anesthesia requirements, laser safety and precautions necessary with laser goggles during procedure. For the treatment of _______________________________________. To minimize the chances of side effects and complications it is important that I follow all postoperative instructions carefully. I understand it may take multiple treatments to clear some lesions and no guarantee as to exact number of treatments has been made to me. I authorize the taking of photographs throughout the course of my laser treatment. These photographs may be used for the purpose of medical publication, education, and treatment decisions. I have been given the opportunity to ask questions, and have received satisfactory answers. I have read the contents of this consent and fully understand them before signing my name below. _______________________________________ Patient Signature
___________________ Date
_______________________________________ Witness Signature
___________________ Date
I have explained the above statements to the patient and answered all questions. _______________________________________ Physician Signature
___________________ Date
Continuous Wave Lasers
109
nodules can be coagulated, then the coagulum wiped away between subsequent passes until they flatten. If test sites are performed, an area representative of the entire lesion in the least conspicuous area is chosen. A 1 –2 cm area should be used for each fluence tested. Immediate postlaser irradiation, a topical antibiotic ointment or a bland healing ointment such as Aquaphor should be applied (Table 4.2). A semiocclusive dressing such as Opsite or Vigilon will speed wound healing and provide protection to the wound which takes several days to re-epithelialize. The patient may wash with soap and water twice daily and reapply the dressings until full healing occurs. Sunblocks are recommended for 2 months postoperatively to avoid hyperpigmentation. 1.4.
Telangiectasias
Telangiectasia treated with the argon laser lesions often results in complete disappearance of the vessels without significant sequelae [Fig. 4.2(a) and (b)] (22,23). Excellent results in linear ectatic vessels of the nose [Fig. 4.3(a) and (b)] (23), diffuse telangiectasia of rosacea (24), nevus araneus (25), and telangiectasia from scleroderma and radiation (23,24) were reported frequently with only one or two treatment sessions. Postrhinoplasty “red nose syndrome” has also been reported to respond to argon laser treatment, especially if superficial ectatic vessels were present (26). Although the success rate has been high in 65– 99% of patients with telangiectasia (2,24), the same problems with hypopigmentation, hyperpigmentation, recurrence of vessels, and depressed scars has been reported (27). To minimize these side effects, a small beam size and 50 ms shuttering has been recommended (15,28). With these caveats, the treatment of telangiectasia has been successful in the hands of skilled laser surgeons, making this application one of the remaining indications for argon laser therapy (Table 4.3). Higher power outputs are required for the shuttered method of treating linear telangiectasia. For a vessel 0.5 mm in diameter a laser spot of 0.5 mm should be used with a pulse duration of 0.03 s and 1 –3 W of power output or just enough to cause disappearance of the vessel without skin whitening. The vessels are traced with the handpiece perpendicular to the skin at the correct focal length.
Table 4.2 Patient Care Sheet for Post-Laser Treatment of Vascular Lesions 1. Wash twice daily with soap and water. Apply a topical antibiotic (Polysporin Ointment) or Aquaphor healing ointment. 2. Apply a semi-occlusive dressing after the ointment (Telfa or Vigilan) until the wound has healed (1 – 4 days). 3. If swelling occurs elevated use ice bag compresses several times daily for the first few days. 4. Take a nonaspirin analgesic such as Tylenol as needed should you experience any pain or discomfort. 5. Avoid direct sunlight for 2 months following laser treatment. 6. A sunscreen of 45 or higher (Solbar 50 or UVA Guard 45) or a titanium dioxide sunblock (PreSun for Sensitive Skin) should be used before sun exposure once the wound has healed. Sun-protective clothing and hats should be used when appropriate. 7. Avoid trauma to the area including contact sports until healing is complete. 8. Makeups are allowed immediately to camouflage the treated area, but care should be taken to avoid rubbing and irritation when removing. 9. Please call your physician if you have any questions or concerns regarding your postoperative care.
110
McMeekin
Figure 4.2 (a) Preoperative argon laser treatment of telangiectasias cheek. (b) Postoperative argon laser treatment of telangiectasias cheek.
Despite the success in facial telangiectasia, the treatment of lower extremity spider veins has been uniformly disappointing with worsening or no change in more than 49% of patients (29). 1.5.
Other Vascular Lesions
Many other benign lesions can be treated with the argon laser if they are vascular or have a vascular component. Cherry angioma (23), angiokeratoma (30), and venous lakes (24,31) all respond to continuous wave argon therapy, but may require several treatment sessions. Coagulation of the vascular lesion is the endpoint. Retraction or shrinkage of the lesion and superficial whitening of the epidermis occurs. Adenoma sebaceum (32,33), angiolymphoid hyperplasia (34), granuloma faciale (23), and Kaposi’s sarcoma (35) have also been treated with mixed results and a risk of scarring. 1.6.
Hemangiomas
Hemangiomas are the most common tumor of infancy and most commonly involve the head and neck. They usually develop after birth and undergo a rapid proliferative phase, followed by involution and regression. Many lesions leave fibro-fatty tissue and atrophy with telangiectasia as they resolve. Reconstructive surgery or treatment with
Continuous Wave Lasers
111
Figure 4.3 (a) Preoperative argon laser treatment of linear ectatic vessels nose. (b) Postoperative argon laser treatment of linear ectatic vessels nose.
the flashlamp pulsed dye laser at this late stage may lead to further improvement (35). Argon laser therapy has been used to treat these proliferative hemangiomas (36 – 39). The risks of scarring, inability to prevent the deeper component from continuing to proliferate, and the lack of depth of penetration (,1 mm) outweigh the potential benefit of treatment by argon laser (40). The treatment of choice for most hemangiomas that are superficial remains the flashlamp pulsed dye laser.
Table 4.3 Current Clinical Indications for Argon Laser Therapy 1. Nodules in mature port wine stains 2. Large linear telangiectasias of nose and face 3. Small vascular lesions: Angiokeratoma Cherry angioma Venous lakes 4. Small lesions with a vascular component: Angiolymphoid hyperplasia Adenoma sebaceum Granuloma faciale
112
1.7.
McMeekin
Pigmented Lesions
The majority of epidermal and dermal pigmented lesions can now be treated more selectively with Q-switched lasers (Chapters 10 – 13). A high complication rate of hypopigmentation and texture change accompanied the treatment of lentigines, cafe´ au lait, junctional nevi, seborrheic keratoses and nevus of Ota (41). Failure was noted in larger lesions of Becker’s nevi and cafe´ au lait (35). Tattoos are no longer treated with the argon laser due to the scarring noted and the new lasers (Chapter 24) capable of selective photothermolysis (42).
2. 2.1.
CONTINUOUS AND QUASICONTINUOUS ARGON-PUMPED TUNABLE DYE LASER Laser Parameters
The argon laser provides the power to an organic dye rhodamine, which can emit wavelengths from 488 to 638 nm. Most typically, the wavelength is tuned to 577 or 585 nm, where the absorption of oxyhemoglobin is maximal (20). Other wavelengths such as 540 nm have also been used to treat port-wine stains (43). The chromophores of melanin and oxyhemoglobin absorb the emitted light in varying degrees based on the selected wavelength. At 585 nm, the penetration of the light is approximately 1.0 mm. Spot sizes of 100 mm to 1.0 mm are available for fiber optic cable delivery. The beam can be delivered either in a continuous wave form, or mechanically shuttered to produce pulse durations from 20 ms to 2.0 s. Scanners are available with the Hexascan used the most extensively (44,45). Cooling is not available with the scanners, but a commercial cooling chamber can be adapted (cool laser optics, Westborough, MA). The argon-pumped tunable dye laser previously was manufactured by CoherentLihtan, but is no longer available. 2.2.
Indications—Port-Wine Stains
The development of the argon-pumped tunable dye laser paralleled the publication of the theory of selective thermolysis (20). Disappointment with argon laser therapy of port-wine stains was growing because of the high rate of scarring and the relative nonspecific coagulative necrosis observed (16). Early histologic studies of vessel damage at longer wavelengths (577 nm) showed more selective damage to vessels was feasible (46 –48). Two methods were developed to minimize collateral damage from the argon pumped tunable dye laser. The first was the use of low power, a small spot size, and a tracing technique previously described (section “Perioperative Considerations Under Continuous Wave Argon Laser”) (14,15). The second was a computerized scanner which gave precise control of dosimetry and allowed placement of small, 1 mm diameter treatment spots in nonadjacent locations in a grid. Using the tracing method, the early results published showed a good response in older patients with port-wine stains in over two-thirds [Figs. 4.4(a) and (b) and 4.5(a) and (b)], but a continued risk of hypopigmentation (15%), atrophic scarring (15%), and hypertrophic scarring (5%) (49). Other studies showed the argon pumped tunable dye laser to be as good as the argon laser in treating port-wine stains (50), or more effective (51). Children have also responded to this tracing method, but the average total treatment time per patient was 3 21 h (52). The use of scanners shortened the treatment times, but the development of more selective flash lamp pumped pulse dye lasers (PDLs) became the treatment of choice
Continuous Wave Lasers
113
Figure 4.4 (a) Preoperative argon pumped tunable dye laser treatment of port-wine stain cheek. (b) Postoperative argon pumped tunable dye laser treatment of port-wine stain cheek.
for children and adults (Chapters 7 and 23). Comparison studies of port-wine stains treated with a hexascan and the argon-pumped tunable dye laser at 585 nm vs. the PDL at 585 nm show greater lightening with the PDL in 40% after one treatment, with less hypopigmentation and hyperpigmentation (53).
2.3.
Perioperative Considerations
The preoperative planning and postoperative care are similar to the argon laser (see section “Continuous Wave Argon Laser”). For the tracing method, the argon-pumped tunable dye laser set at 577 nm is used with a 100 mm beam and power settings of 0.08–0.5 W. Using loupes of 8–10 power magnification vessels of 30–300 mm are traced using increasing power until the vessel disappears completely. The vessels are traced outward in concentric circles from a control point, with treatment sessions of 45–60 min, and areas covered averaging 1–2 in.2 (15). Retreatment can be performed after several months. With a hexascan, the suggested treatment parameters are 585 nm wavelength, 18–24 J/cm2 (depending on area, age of patient and vessel size) with 1–2 mm overlapping fields to prevent geometric patterning (45).
2.4.
Facial Telangiectasias
Comparison studies have also been done for facial telangiectasia (54,55). Using the tracing method and shuttered pulses, the flashlamp PDL had excellent results in 11 of 14 patients vs. just 4 of 14 with the tunable dye laser [Fig. 4.6(a) and (b)]. The purpura was a problem to 6 of 13 who preferred the tunable dye laser despite the poorer results (55). The same conclusions were reached in another study of facial telangiectasia using a robotized scanner and a tunable dye laser vs. the PDL. All patients in the pulsed dye laser treatment had 100% excellent results vs. 47% in the tunable dye group. Likewise, half the
114
McMeekin
Figure 4.5 (a) Preoperative argon pumped tunable dye laser treatment of port-wine stain neck. (b) Postoperative argon pumped tunable dye laser treatment of port-wine stain neck.
patients preferred the tunable dye due to the lower incidence of hyperpigmentation and lack of bruising (54). 2.5.
Argon-Pumped Tunable Dye Laser Pigmented Lesions
The results for pigmented lesions are similar to those of the argon laser. The use of the hexascan with the green light (514 nm) speeds up the treatment and clears lentigines in one or two treatments, and allows treatment of cafe´ au lait macules, nevus spilus, and Becker’s nevi (45). The longer pulse durations of 30 ms and the small relative spot size of 1 mm may limit the effectiveness in larger lesions. More selective wavelengths, and short pulse durations that approximate the thermal relaxation time of melanin makes the further use of this laser in pigmented lesions questionable (Chapter 26).
3. 3.1.
COPPER VAPOR LASERS/COPPER BROMIDE LASERS Laser Parameters
Both copper laser systems produce yellow light at 578 nm and green light at 511 nm by heating elemental copper or copper salts in the optical cavity. They differ only in the
Continuous Wave Lasers
115
Figure 4.6 (a) Preoperative argon pumped tunable dye laser treatment of telangiectasias nose. (b) Postoperative argon pumped tunable dye laser treatment of telangiectasias nose.
efficiency [1% copper bromide laser (CBL) vs. 0.5% copper vapor laser (CVL)] in energy conversion, the temperature at which they operate (6008C CBL and 16008C CVL) and the power output (CBL watts vs. CVL milliwatts). The light emitted is a train of 20 –40 ns high-energy pulses with pulse intervals of 63 ms and a frequency of 10– 16 kHz, with a peak power of 4 kW per pulse. Because the pulse intervals are too short for the targeted tissue (blood vessels) to thermally cool, the physiologic effect is a quasicontinuous pulse. The power output is generally measured as an average of the train of pulses. This quasicontinuous pulse train may be mechanically shuttered, used with a scanning device (see previous section) or used in a quasicontinuous mode to trace vessels. The light is delivered to a handpiece with spot sizes of 100 mm to 1.0 mm via a flexible quartz fiber. The chromophores for halide lasers are the same as argon, and argon PDLs, with absorption by melanin and oxyhemoglobin. The green band at 511 nm is used to target melanin, but the exposure times are longer than the thermal relaxation time of melanin. Q-switched lasers have since replaced the benign pigmented lesion applications of this laser. There were two manufacturers for the CVL: 1. 2.
Aesculap Meditec North America (Irvine, CA). Continuum Biomedical, Inc. [Livermore, CA (CBL)].
116
3.2.
McMeekin
Indications—Port-Wine Stains
At 578 nm, copper vapor laser light is mostly absorbed by oxyhemoglobin, and penetrates deeper than the argon laser. With melanin absorbing maximally at 300 –500 nm, the energy is less well absorbed by melanin. Histologically, the effects of this quasicontinuous laser on vessels is similar to other continuous wave lasers when used to trace vessels or treat port-wine stains freehand (56). More selective histology showing specific necrotic endothelial cells of ectatic vessels without rupture or hemorrhage while sparing epidermal and adjacent dermal structures was reported using a robotized scanner (57) and by mechanically shuttering the beam (58). Results comparing the argon laser to the copper vapor in treatment of port-wine stains are equivalent with the copper laser producing better fading (59). Thicker and darker port-wine stains with the so-called large vessels have been reported to respond well [Fig. 4.7(a) and (b)] (60). For subsequent treatments, the more selective pulsed dye lasers can be used to finish the smaller vessels. Excellent results were reported in 24% of 25 patients using the CVL with a hexascan and fluences of 12– 15 J/cm2. There was no response in 20% and adverse sequelae of hypopigmentation and scarring in 11 of 25 (60). The risk of hypopigmentation, especially in Fitzpatrick Type V skin, has been reported by several studies (61,62). CVL treatment of port-wine stains is not as selective in brown skin as compared to white skin. When treating brown skin, selection of minimal pulse widths and maximum power outputs are recommended (62). Two studies compared the CVL with a Hexascan and the flashlamp PDL in treatment of port-wine stains (63,64). The first found better fading of macular blanchable port-wine stains in the flashlamp PDL group without a significant difference in adverse reactions (63). An edge in clearing with the flashlamp PDL was also seen in the second study, but more adverse side effects such as hyperpigmentation were noted (64). It is generally felt that the PDL is safer, more effective and has an acceptable rate of side
Figure 4.7 (a) Preoperative copper vapor laser treatment of port-wine stain cheek. (b) Postoperative copper vapor laser treatment of port-wine stain cheek.
Continuous Wave Lasers
117
effects. It is noteworthy that copper vapor has been supplemented with PDL for port-wine stains except for port-wine stain nodules. 3.3.
Perioperative Considerations
The treatment of small lesions with the yellow light (578 nm) may not require anesthesia, but larger lesions or children require topical and/or field block anesthesia to minimize pain. The patient should avoid tanning preoperatively and caution should be used in Fitzpatrick skin types III –VI. Postoperatively, the wounds may occasionally blister or be edematous for several days. Ice packs, cool compresses, and topical antibiotic ointments are recommended routinely. Sun avoidance or sunblocks are advised for 2 months postoperatively. With magnifying loupes, the laser can be operated in a continuous tracing technique delivering 15,000 pulses per second with vessel disappearance at the end point. The actual dosimetry will depend on hand speed, the spot size, and average power settings. Typical port-wine stain settings for a 100 mm spot size would be 90 –140 mW for children under age 12; 120 – 180 mW for children age 12– 18; and 180 –260 mW for adults (65). For a field blanch or spot-by-spot method an entire contiguous area is treated using spot-byspot placement. Higher powers (25 – 50%) are required for the shuttered technique. Typically, a common setting is 0.2 s on and 0.2 s off. The endpoint again is vessel blanch or disappearance. Vessels are traced with treatment sessions varying from 5 –60 min (66). Typical settings for a CVL with a 150 mm spot size and a 600 mm optical fiber, using the above shuttering (0.2 s on, 0.2 s off ) were the lowest power (300 – 600 mW ) to achieve the end point (67). 3.4.
Facial Telangiectasia
One of the best indications for the CVL has been the treatment of facial telangiectasias [Fig. 4.8(a) and (b)]. The lack of purpura is a major factor in the success this treatment has enjoyed. Using the free-hand technique, one study of 20 patients showed good clearing in 18 of 20, with punctate scabbing seen in 50% and temporary hyperpigmentation in 15% [Fig. 4.9(a) and (b)] (67). The only nonresponders were the fine diffuse telangiectasias of rosacea, which respond better to PDL. Another study of 33 patients with telangiectasias had good to excellent results in two-thirds and only 19% with poor results (60). They also used the shuttered method with a 1 mm spot and pulse duration of 50– 200 ms. The nose and nasolabial fold were the most difficult areas with 7 of 33 showing atrophic scarring (60). Transient edema on the cheeks and eyelids lasting 1– 3 days was also observed. Similar transient edema has been reported in a study of 180 patients with almost 50% developing hypopigmentation (68). Good results were seen in 47% with further improvement to 86% seen in patients with combined CVL treatment and sclerotherapy of facial vessels (68). 3.5.
Other Vascular Lesions
Cherry angioma, venous lakes, and pyogenic granuloma have been reported to respond well to CVL treatment [Fig. 4.10(a) and (b)] (65). An advantage of quasicontinuous
118
McMeekin
Figure 4.8 (a) Preoperative copper vapor laser treatment of telangiectasias nose. (b) Postoperative copper vapor laser treatment of telangiectasias nose.
wave lasers such as the copper vapor in treating larger diameter vessels in venous malformations, as well as hypertrophic nodular port-wine stains, has been reported (69). Hemangiomas in the early proliferative phase have been treated with the CVL successfully with less than 1% risk of scarring (70). It is hypothesized that a photothermal reaction which provides a vasoconstrictive effect deeper than photothermolysis is responsible for some of the improvement (70). Other lasers such as the long-pulsed (1.5 ms) dye laser are more selective and have supplanted the CVL for the treatment of hemangioma as well as port-wine stains (Chapter 7). 3.6.
Pigmented Lesions
The green light band (511 nm) of the CVL may be used to treat benign pigmented lesions such as lentigines, freckles, dermatosis papulosa nigra, and seborrheic keratoses (71). Excellent results with few side effects were reported (71). A variable response is seen with larger lesions such as cafe´ au lait, Becker’s nevus, and melasma (72). Transient hyperpigmentation may be seen in up to 10%, which clears with hydroquinones (71). Other types of hyperpigmentation such as seen after sclerotherapy may respond in up to 69% of patients after one session with the CVL (73). The newer Q-switched lasers have replaced the copper vapor in treating pigmented lesions today.
Continuous Wave Lasers
119
Figure 4.9 (a) Preoperative copper vapor laser treatment of linear ectatic vessels nose. (b) Postoperative copper vapor laser treatment of linear ectatic vessels nose.
4. 4.1.
KTP LASERS Laser Parameters
The KTP laser is a frequency doubled Nd:YAG laser that produces a train of pulses at a frequency of 25,000 Hz at 532 nm wavelength. The 1064 nm light is converted to 532 nm
Figure 4.10 (a) Preoperative copper vapor laser treatment of hemangioma lip. (b) Postoperative copper vapor laser treatment of hemangioma lip.
120
McMeekin
with a KTP crystal (potassium titanyl phosphate). The Nd:YAG laser is continually pumped laser with a krypton arc lamp that is a switched type, producing nanosecond pulses. The light is delivered to the tissue via a fiberoptic cable (0.2 – 0.6 mm) with 1, 2, and 4 mm spot sizes. A scanner (Smartscan) is available, as is a cooling chamber. The quasicontinuous wave KTP laser, manufactured by Lasercope (San Jose, CA), has a modulated arc lamp that produces a greater average power (160 W) and can produce single pulses of 1 –50 ms, each composed of multiple nanosecond pulse trains. The 532 nm wavelength is near to one of oxyhemoglobin’s absorption peaks at 540 nm, and can be used to treat a variety of vascular cutaneous lesions.
4.2.
Indications—Port-Wine Stains/Telangiectasias
Histologically, the results from KTP laser are similar to argon laser, with obliteration of vessels in the upper dermis, dermal fibrosis, and normal re-epithelialization (74). Clinically, the results for port-wine stains are equivalent to CVL or the argon pumped tunable dye laser (75,76). The results on telangiectasia and port-wine stains have been good, producing vessel clearing with little to no purpura [see Figs. 4.11(a) and (b) and 4.12(a) and (b)] (77,78). Further comparison studies with the newer long PDLs and long pulse KTP lasers are needed (Chapters 7 and 9).
Figure 4.11 (a) Preoperative KTP laser treatment of telangiectasias nose/cheeks. (b) Postoperative KTP laser treatment of telangiectasias nose/cheeks.
Continuous Wave Lasers
121
Figure 4.12 (a) Preoperative KTP laser treatment of spider veins legs. (b) Postoperative KTP laser treatment of spider veins legs.
4.3.
Perioperative Considerations
The pre/postoperative considerations are similar to the argon and CVLs (see sections under “Continuous Wave Argon Lasers” and “Copper Vapor Lasers/Copper Bromide Lasers”). The treatment techniques vary. Using a 0.6 mm bore fiber passed directly into an hemangioma via a 20 gauge needle and 15 J of energy, hemangiomas can be treated. Using a 1 –4 mm spot at 5 W and 0.1 –1.0 s pulses with 0.2 s pulse duration generating a fluence of 127 J/cm2, nodular or adult port-wine stains can be treated. Finally, using a hexascan with fluences between 10 and 20 J/cm2 and pulse widths of 3 –5 ms, port-wine stains can be treated. A tracing technique similar to the copper vapor (see section under “Copper Vapor Lasers/Copper Bromide Lasers”) can be used for telangiectasia. 4.4.
Hemangioma
Intralesional bore fiber treatment of hemangiomas has been reported until shrinkage is seen or overlying heat is felt (79). About 92% of 12 patients had a greater than 50% reduction of hemangioma size, but only 8% maintaining this reduction at 6 months. Since one-third ulcerated after therapy and ulceration is associated with scar formation, this technique should be used with caution (40).
122
McMeekin
Figure 4.13 (a) Preoperative Krypton laser treatment of diffuse telangiectasia cheeks. (b) Postoperative Krypton laser treatment of diffuse telangiectasia cheeks.
Figure 4.14 (a) Preoperative Krypton laser treatment of matted telangiectasia cheeks. (b) Postoperative Krypton laser treatment of matted telangiectasia cheeks.
Continuous Wave Lasers
5. 5.1.
123
KRYPTON LASER Laser Parameters
Although the krypton laser has been used extensively in ophthalmology, it has more recently been introduced to dermatology. The krypton laser is a gas medium laser producing green light at 520 and 530 nm and yellow light at 568 nm. It is a continuous wave laser that can be shuttered to 50 ms pulses with pulse trains of 0.2– 10 s. It has two watts of green power and 1.0 W of yellow power in the HGM K1 Krypton Laser (HGM, Salt Lake City, UT). Selecting appropriate filters one can produce either yellow light at 568 nm, or green light with all three wavelengths. With all three wavelengths and a 1.0 mm spot, a fluence of 16 J/cm2 can be attained, which is enough to produce an endpoint of vessel disappearance. A digital autoscan is available. No external cooling chamber or spray are available. The chromophores are identical to the copper vapor previously discussed. 5.2.
Indications—Telangiectasia
Clinical studies using this laser are minimal. A retrospective questionnaire surveying 200 patients treated with the krypton laser in conjunction with microsclerotherapy found similar results to a CVL study by the same author (80). Sixty-four percent of patients had significant to total reduction in areas of their telangiectatic lesions, with 94% of
Figure 4.15 (a) Preoperative Krypton laser treatment of venous lake lip. (b) Postoperative Krypton laser treatment of venous lake lip.
124
McMeekin
patients reporting a better to much better appearance [Fig. 4.13(a) and (b)]. However, 11% of patients reported atrophic scarring. A second article describing the treatment technique for spider nevi [Figs. 4.14(a) and (b) and 4.15(a) and (b)], reported that a small scar is almost inevitable from krypton laser photocoagulation of these vessels, but was acceptable to the patients (81). Since PDLs rarely leave any scars, they remain the gold standard for the treatment of telangiectasias. Further study on the krypton lasers’ safety and efficacy in dermatology are needed. 5.3.
Operative Considerations
The preoperative and postoperative patient directions are similar to the other continuous wave lasers. The operative pain is less than with the CVL and only 13% require a local anesthetic (80). The technique for facial telangiectasia is to use the 1.0 mm spot and 50 ms pulse duration with exposure times of 0.1–0.2 s when treating central feeding arterioles of spider telangiectasia, or 0.2–0.4 s when used to treat linear telangiectasias, with powers of 1.8–2.5 W. Generally, all three wavelengths are used together to get sufficient energy to photocoagulate the vessels (80). Blanching of the epidermis is avoided and a visual and audible popping of the central vessel is an endpoint on spider telangiectasia (81).
REFERENCES 1. 2. 3. 4. 5. 6. 7. 8.
9. 10. 11. 12.
13.
Goldman L, Dfreffer R, Rockwell JR Jr, Perry E. Treatment of port wine marks by an argon laser. J Dermatol Surg 1976; 2:385 –388. Apfelberg DB, Maser MR, Lash H. Argon laser management of cutaneous vascular deformities. A preliminary report. West J Med 1976; 124:99 – 101. Touquet VL, Carruth JA. Review of the treatment of port wine stains with the argon laser. Lasers Surg Med 1984; 4:191 – 199. Silver L. Argon laser photocoagulation of the port wine stain haemangiomas. Lasers Surg Med 1986; 6:24 – 28, 52– 55. Dixon JA, Gilbertson JJ. Argon and neodynium YAG laser therapy of dark nodular port wine stains in older patients. Lasers Surg Med 1986; 6:5– 11. Masser MR, Sammut DP, Jones SG, Saxby PJ. Argon laser therapy of port wine stains— prediction of the effect by transcutaneous microscopy. Lasers Med Sci 1989; 4:237– 240. Dixon JA, Huether S, Rotering R. Hypertrophic scarring in argon laser treatment of port wine stains. Plast Reconstr Surg 1984; 73:771– 780. Noe JM, Barsky SH, Geer DE, Rosen S. Port wine stains and the response to argon laser therapy: successful treatment and the predictive role of color, age, and biopsy. Plast Reconstr Surg 65:130– 136. Gilchrest BA, Rosen S, Noe JM. Chilling port wine stains improves the response to argon laser therapy. Plast Reconstr Surg 1982; 69:278 – 283. Brauner G, Schliftman A, Cosman B. Evaluation of argon laser surgery in children under 13 years of age. Plast Reconstr Surg 1991; 87:37 – 43. Cosman B. Experience in argon laser therapy of port wine stains. Plast Reconstr Surg 1980; 65:119 – 129. Apfelberg DB, Flores JT, Maser MR, Lash H. Analysis of complications of argon laser treatment for port wine hemangiomas with reference to striped technique. Lasers Surg Med 1983; 2:357 – 371. Apfelberg DB, Smith T, Maser MR, Lash H. Dot or pointillistic method for improvement in results of hypertrophic scarring in the argon laser treatment of port wine hemangiomas. Lasers Surg Med 1987; 6:552 – 558.
Continuous Wave Lasers 14.
15.
16.
17. 18. 19.
20. 21. 22. 23. 24. 25. 26. 27. 28. 29.
30. 31. 32. 33. 34.
35. 36.
37.
125
Schreibner A, McCarthy WH. An improved method of removal of port wine stains, venule and capillary flares using an argon laser with minimal power, small spot and longer duration exposure. Lasers Surg Med 1984; 3:368– 371. Scheibner A, Wheeland RG. Argon-pumped tunable dye laser for facial port stain hemangiomas in adults—new technique using a small spot size and minimal power. J Dermatol Surg Oncol 1989; 15:277– 282. Tan OT, Carney JM, Margoli R, Seki Y, Bell J, Anderson RR, Parrish JA. Histologic responses of port-wine stains treated by argon, carbon dioxide, and tunable dye lasers. A preliminary report. Arch Dermatol 1986; 122:1016 –1022. Finley JL, Barsky SH, Geer DE, Kamat BR, Noe JM, Rosen S. Healing of port-wine stains after argon laser therapy. Arch Dermatol 1981; 117:486 – 489. Finley JL, Arndt KA, Noe J, Rosen S. Argon laser –port-wine stain interaction. Immediate effects. Arch Dermatol 1984; 120:613– 619. Greenwald J, Rosen S, Anderson RR, Harrist T, MacFarland F, Noe J, Parrish JA. Comparative histologic studies of the tunable dye (at 577 nm) laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Anderson RR, Parrish JR. Selective photothermolysis precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Goodwin D, McMeekin T. A case of lidocaine cream absorption from topical administration of 40% lidocaine cream. J Am Acad Dermatol 1999; 41:280– 281. Apfelberg DB, Maser MR, Lash H, Rivers JL. Progress report on extended clinical use of the argon laser for cutaneous lesions. Lasers Surg Med 1980; 1:71– 83. Arndt KA. Argon laser therapy of small cutaneous vascular lesions. Arch Dermatol 1982; 118:220 – 224. Achauer BM, Vanderkam VM. Argon laser treatment of telangiectasia of the face and neck: 5 years experience. Lasers Surg Med 1987; 7:495 –498. Tan OT, Gilchrest BA. Laser therapy for selected cutaneous vascular lesions in the pediatric population: A review. Pediatrics 1988; 82:652 –662. Noe JM, Finley J, Rosen S, Arndt KA. Postrhinoplasty “red nose”: differential diagnosis and treatment by laser. Plast Reconst Surg 1981; 67:661 – 664. Dolsky RL. Argon laser surgery. Surg Clin N Am 1984; 64:861 – 879. Cosman B. Role of retreatment in minimal-power argon laser therapy for port wine stains. Laser Surg Med 1982; 2:43 – 57. Apfelberg DB, Maser MR, Lash H, White DN, Flores JT. Use of the argon and carbon dioxide lasers for treatment of superficial venous varicosities of the lower extremity. Lasers Surg Med 1984; 4:221 – 231. Flores JT, Apfelberg DB, Maser MR, Lash H, White D. Angiokeratoma of fordyce: successful treatment with the argon laser. Plast Reconstr Surg 1984; 74:835– 838. Landthaler M, Haina D, Waidelich W, Braun-Falco O. Laser therapy of venous lakes (BeonWalsh) and telangiectasias. Plast Reconstr Surg 1984; 73:78 – 83. Janniger CK, Goldberg DJ. Angiofibromas in tuberous sclerosis: comparison of treatment by carbon dioxide and argon laser. J Dermatol Surg Oncol 1990; 16:317– 320. Arndt KA. Adenoma sebaceum: successful treatment with the argon laser. Plast Reconstr Surg 1982; 70:91 – 93. Cheney ML, Googe P, Bhatt S, Hibbard PL. Angiolymphoid hyperplasia with eosinophilia (histiocytoid hemangioma): evaluation of treatment options. Ann Otol Rhinol Laryngol 1993; 102:303 – 308. Dover JS, Arndt KA, Geronemus RG, Alora MBT. Illustrated Cutaneous and Aesthetic Laser Surgery. 2nd ed. Stamford, CT: Appleton and Lange, 2000:147 – 181. Apfelberg DB, Greene RA, Maser MR, Lash H, Rivers JL, Laub DR. Results of argon laser exposure of capillary hemangiomas of infancy—preliminary report. Plast Reconstr Surg 1981; 67:188 – 193. Hobby LW. Further evaluation of the potential of the argon laser in the treatment of strawberry hemangiomas. Plast Reconstr Surg 1993; 71:481 – 489.
126 38. 39. 40. 41. 42. 43. 44. 45. 46.
47. 48.
49. 50. 51. 52. 53.
54.
55. 56. 57.
58. 59.
60.
61.
McMeekin Achauer BM, Vanderkam VM. Argon laser treatment of strawberry hemangioma in infancy. West J Med 1984; 143:628– 632. Hobby LW. Visible light CW and quasi-CW laser treatment of superficial vascular lesions in children. Lasers Surg Med 1986; 6:16– 19. Goldman MP, Fitzpatrick RE. Cutaneous Laser Surgery. 2nd ed. St. Louis, MO: Mosby, 1999: 19– 178. McBurney EI. Clinical usefulness of the argon laser for the 1990s. J Dermatol Surg Oncol 1993; 19:359 – 362. Spicer MS, Goldberg DJ. Lasers in dermatology. J Am Acad Dermatol 1996; 34:1– 25. Hulsbergen-Henning JP, VanGemert MS. Port wine stain coagulation experiments with a 540-nm continuous wave dye laser. Lasers Surg Med 1983; 2:205– 210. Mondon S, Rotteleur G, Brunetaud JM, Apfelberg DB. Rationale for automatic scanners in laser treatment of port wine stains. Lasers Surg Med 1993; 13:113 – 123. McDaniel DH. Clinical usefulness of the hexascan. J Dermatol Surg Oncol 1993; 19:312 – 319. Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med 1981; 1:263 – 276. Anderson RR, Jaenicke KF, Parrish JA. Mechanisms of selective vascular changes caused by dye lasers. Lasers Surg Med 1983; 3:211 – 215. Greenwold J, Rosen S, Anderson RR, Harrist T, MacFarland F, Noe J, Parrish J. Comparative histological studies of the tunable dye (at 577 nm) laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Lanigan SW, Cartwright P, Cotterill JA. Continuous wave dye laser therapy of port wine stains. Br J Dermatol 1989; 121:345 – 352. Malm M, Rigler R, Jurell G. Continuous wave (CW ) dye laser vs CW argon laser treatment of port wine stain (PWS). Scand J Plastic Reconstr Surg Hand Surg 1988; 22:241 – 244. Bandol Y, Yanai A, Tsuzuki K. Dye laser treatment of port-wine stains. Aesthetic Plast Surg 1990; 14:287 – 291. Scheibner A, Wheeland RG. Use of the argon-pumped tunable dye laser for port wine stains in children. J Dermatol Surg Oncol 1991; 17:735 – 739. Dover JS, Geronemus R, Stern RS, O’Hare D, Arndt KA. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 –240. Ross M, Watcher MA, Goodman MM. Comparison of the flashlamp pulsed dye laser with the argon tunable dye laser with robotized handpiece for facial telangiectasia. Lasers Surg Med 1993; 13:374 – 378. Broska N, Martinho E, Goodman M. Comparison of the argon tunable dye laser in treatment of facial telangiectasia. J Dermatol Surg Oncol 1994; 20:749– 753. Tan OT, Stafford TJ, Murray S, Kurban AK. Histologic comparison of the pulsed dye laser and copper vapor laser effects on pig skin. Lasers Surg Med 1990; 10:552– 558. Neumann RA, Knobler RM, Leonhartsberger H, Gebhart W. Comparative histochemistry of port wine stains after copper vapor laser (578 nm) and argon laser treatment. J Invest Dermatol 1992; 99:160 – 167. Walker EP, Butler PH, Pickering JW, Day WA, Fraser R, Van Halewyn CN. Histology of port wine stains after copper vapor laser treatment. Br J Dermatol 1989; 121:217 – 223. Sheehan-Dare RA, Cotterill JA. Copper vapour laser treatment of port wine stains: clinical evaluation and comparison with conventional argon laser therapy. Br J Dermatol 1993; 128:546 – 549. Neumann RA, Leonhartsberger H, Bohler-sommeregger K, Knebler R, Kokoschka EM, Honigsmann H. Results and tissue healing after copper-vapour laser (at 578 nm) treatment of port wine stains and facial telangiectases. Br J Dermatol 1993; 128:306– 312. Haedersdal M, Wolf HC. Risk assessment of side effects from copper vapor and argon laser treatment: the importance of skin pigmentation. Lasers Surg Med 1997; 20:84 –89.
Continuous Wave Lasers 62. 63.
64.
65.
66. 67. 68. 69. 70. 71. 72.
73.
74. 75. 76. 77. 78. 79. 80. 81.
127
Chung JH, Koh WS, Youn JI. Histologic responses of port wine stains in brown skin after 578 nm copper vapor laser treatment. Lasers Surg Med 1996; 18:358– 366. Sheehan-Dare RA, Cotterill JA. Copper vapor laser (578 nm) and flashlamp-pumped pulsed dye laser (585 nm) treatment of port wine stains: result of a comparative study using test sites. Br J Dermatol 1994; 130:478 – 482. Dover JS, Geronemus R, Stern RS, O’Hare D, Arndt KA. Dye laser treatment of port wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 – 240. Waner M, Dinehart S. Lasers in facial plastic surgery and reconstructive surgery. In: Davis RK, Sharpstrag S, eds. Lasers in Otolaryngology/Head and Neck Surgery. Philadelphia, PA: Saunders, 1989:156 – 191. McCoy SE. Copper bromide laser treatment of facial telangiectasia: results of patients treated over five years. Lasers Surg Med 1997; 2:329 – 340. Key JM, Waner M. Selective destruction of facial telangiectasia using a copper vapor laser. Arch Otolaryngol Head Neck Surg 1992; 118:509– 513. Thibault PK. Copper vapor laser and microsclerotherapy of facial telangiectases. J Dermatol Surg Oncol 1994; 20:48 – 54. Pickering JW, Walker RHB, Haleway CN. Copper vapor laser treatment of port wine stains and other vascular malformations. Br J Plast Surg 1990; 43:273– 282. Waner M, Suen JY, Dinchart S. Treatment of hemangiomas of the head and neck. Laryngoscope 1992; 10:1123– 1132. Dinchart SM, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. J Dermatol Surg Oncol 1993; 19:370– 375. Levine VJ, Lee MS, Geronemus RG, Arndt KA. Continuous-wave and quasi-continuous save lasers. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery Ch 5. Philadelphia, PA: Lippincott-Raven Publishers, 1997:67 – 107. Thibault P, Wlodanarczyk J. Postsclerotherapy hyperpigmentation. The role of ferritin levels and the effectiveness of treatment with the copper vapor laser. J Dermatol Surg Oncol 1992; 18:42 – 52. Apfelberg DB, Bailin P, Rosenberg H. Preliminary investigation of KTP/532 laser light in the treatment of hemangiomas and tattoos. Lasers Surg Med 1986; 6:38 – 42. Keller GS. Use of the KTP laser in cosmetic surgery. Am J Cosmetic Surg 1992; 9:177– 182. Routteleur G, Mordon S, Brunetaud JM. Argon 488 – 415, Nd:YAG 532, and CW dye 585 lasers for port wine stain treatment using the hexascan. Lasers Surg Med Suppl 1991; 3:68. Dierickx CC, Farinelli WA, Flotte T, Anderson RR. Effect of long pulsed 532 nm Nd:YAG laser on port wine stains. Lasers Surg Med Suppl 1996; 8:188. Be Silver, Livshots YL. Preliminary experience with the KTP/532 nm laser in the treatment of facial telangiectasia. Cosmetic Dermatol 1996; 9:61 – 64. Achauer BM, VanderKam VM, Celikoz B. Intralesional bore fiber laser treatment of hemangioma. Lasers Surg Med 1997; 9:41. Thibault PK. A patients questionnaire evaluation of krypton laser treatment of facial telangiectases—a comparison with the copper vapor laser. Dermatol Surg 1997; 23:37 – 41. Patel BC. The krypton yellow-green laser for the treatment of facial vascular and pigmented lesions. Semin Ophthalmol 1998; 13:158 –170.
5 Continuous Wave and Pulsed CO2 Lasers E. Victor Ross Naval Medical Center and University of California, San Diego, California, USA
1. Background 1.1. Physical Properties 1.2. Beam Profiles 1.3. Mechanically Shuttered Pulses and Superpulsing 1.4. Laser Spot Size 1.5. Delivery Systems 1.6. General Operating Principles 2. Laser – Tissue Interactions 2.1. Physics 2.2. Residual Thermal Damage 2.3. Clinical Examples of Laser – Tissue Interactions 2.3.1. High PD, Short Exposure Time 2.3.2. Long Exposures in CW Low –Medium PD Defocused Mode 2.3.3. Very Low PDs and Short Exposures 2.3.4. High PDs with Small Spots (0.1 – 0.3 mm), Used in Incisions 3. Comparison of the Resurfacing Lasers 3.1. UltraPulse 3.2. The SilkLaser 3.3. The NovaPulse 3.4. Nidek Unipulse 3.5. TruPulse 3.6. Summary of Resurfacing Systems 4. Wound Healing after CO2 Laser 5. Ultrastructure after CO2 LSR 6. Applications 6.1. Applications Where the Laser Performs Better Than Most Other Modalities 6.1.1. Trichoepitheliomas 6.1.2. Adenoma Sebaceum 6.1.3. Common Warts
131 131 131 132 133 133 134 134 134 135 138 138 139 140 140 141 142 142 143 143 144 144 144 145 145 146 147 147 148 129
130
6.1.4. Condyloma Acuminata 6.1.5. Nail Matrixectomy 6.1.6. Earlobe Keloids 6.1.7. Larger Keloids and Nonearlobe Keloids 6.2. Acne Keloidalis Nuchae 6.2.1. Pyogenic Granuloma 6.2.2. Actinic Cheilitis 6.2.3. Sebaceous Hyperplasia 6.2.4. Epidermal Nevi 6.2.5. Syringoma 6.2.6. Xanthelasma 7. Lesions that Might Be Treated Equally Well with Other Modalities 7.1. Seborrheic Keratoses 7.2. Dermatosis Papulosis Nigra 7.3. Neurofibromas 7.4. Steatocystomas 7.5. Pearly Penile Papules 7.6. Basal Cell Carcinoma 7.7. Bowen’s Disease 7.8. Hidradenitis Suppurativa 7.9. Scar Revisions 7.10. Chondrodermatitis Nodularis Helicus 7.11. Lymphangioma Circumscriptum 7.12. Nevus Sebaceous 7.13. Hydrocystoma 7.14. Histiocytoma or Xanthoma Disseminatum 7.15. Hailey – Hailey and Darier’s Disease 7.16. Kaposi’s Sarcoma 7.17. Tattoos 7.18. Disseminated Superficial Actinic Porokeratosis 7.19. Actinic Keratosis 8. Laser Sterilization 9. Technique Pearls 9.1. CW Vaporization 9.2. Cutting 10. Laser Safety Issues Specific to the CO2 Laser 11. New Developments 12. Pre- and Postoperative Considerations 12.1. Preoperative Considerations 12.1.1. Relative Contraindications 12.1.2. Preoperative Regimen 12.1.3. Postoperative Care 13. Conclusions References Appendix I: Sample Operative Note Appendix II: Consent Form Appendix III: Sample Postoperative Instructions Appendix IV: Patient Information Handout
Ross
150 150 151 151 152 152 153 154 155 156 156 157 157 157 157 158 158 159 159 159 159 160 160 160 160 160 161 161 161 162 162 162 162 162 163 163 164 164 164 164 165 165 165 166 176 177 178 178
Continuous Wave and Pulsed CO2 Lasers
1.
131
BACKGROUND
The CO2 laser was one of the first lasers to be used surgically. Since its invention by Patel in 1964, the laser’s strength is linked to its high absorption by water at 10.6 mm. The first published studies using the CO2 laser emphasized the device as a cutting tool with improved hemostatic capabilities over scalpel surgery, and typically the laser was used with a tightly focused beam (1). Subsequently, especially in dermatology, the laser has been used more as a defocused vaporizing or controlled heating tool. With the CO2 laser, one can simultaneously hold a coagulator, scalpel, and vaporizer, depending on the power density (2). 1.1.
Physical Properties
CO2 lasers are pumped electrically, that is, the laser cavity is excited by electrical discharges. All but one of the CO2 lasers presently used in cutaneous surgery are longitudinally excited, meaning that the pumping occurs at the ends of the sealed tube. One laser, the TruPulse (Tissue Technologies, Albuquerque, NM) is transversally excited, meaning that the electrical discharge occurs across the tube. Carbon dioxide lasers use a mixture of CO2 , N2 , and helium as the lasing medium. Doping of the CO2 gas with other elements, particularly nitrogen, increases the laser’s efficiency. There are multiple energy transitions for the CO2 laser, so that 10.6 mm is not the only possible emitted wavelength. The 10.6 mm photons are created when CO2 molecules drop from a higher-energy asymmetric stretching mode to a lower-energy stretching or bending mode. The wavelengths are longer than those in visible light lasers because the transitions are of the rotational/vibrational type, whereas the ruby laser, for example, involves moving electrons into higher and lower stages (electronic transitions) (3 – 8). The overall efficiency (5 –20% from the wall plug) of CO2 lasers is among the highest of all lasers. This efficiency is one reason why a room with a CO2 laser tends to get less hot than a room with a solid state laser, where the efficiency is less than 1%, and much of the remainder of the energy is wasted as heat (6). CO2 lasers are capable of a large range of powers. In medicine the range is usually 10 – 100 W continuous wave (CW) power, and up to 10,000 W peak power for pulsed applications. Conventional medical CO2 lasers develop about 50 W average power per meter length of the tube, so that a taller laser tower (the upright part of the laser) is associated with more power (6). 1.2.
Beam Profiles
Most CO2 laser beam profiles are Gaussian (TEM 00), which is a function of the way the beam is created in the laser cavity. The Gaussian beam profile is bell shaped, and because it tends to be stable and easy to propagate through an articulated arm, it is a desirable beam profile to have from an engineering perspective. However, the Gaussian beam profile also creates nonuniform local fluences at the skin surface (4,9,10). These nonuniformities, however, are typically mitigated by (1) the delivery device, (2) the user’s choice of fluences, and (3) the skin lesion itself. For example, scanners can be configured to deliver various degrees of overlap that decrease the effects of the “wings” of the Gaussian profile, creating a more uniform surface fluence. Also, the user can choose lower fluences (at or near the ablation threshold) in resurfacing that allow for fairly uniform heating across the spot. Finally, many skin lesions are bell-shaped, which naturally accommodates the bell-shaped beam profile if one is trying to ablate an exophytic lesion such as a verruca or an adnexal tumor.
132
Ross
The TruPulse laser runs multimode, so that it has a flatter beam profile. However, multimode beam profiles usually have a larger beam waist and are more difficult to focus to a uniform spot. Like the TruPulse, the Novapulse laser (Lumenis, Norwood, MA) beam profile is more flat-topped than Gaussian. In this case, the flatter beam profile is the result of mode mixing as the beam bounces along the inside walls of the hollow waveguide delivery device (11). Top hat profiles have been described as ideal, but it is the specific application and the skill of the physician that determines the “idealness” of a beam profile.
1.3.
Mechanically Shuttered Pulses and Superpulsing
Older CO2 lasers were either truly CW or operated at such a high frequency that the laser tissue interaction was, for all intents and purposes, CW. Early attempts to control laser exposure times involved the use of mechanical shutters to “chop” the pulse. The shortest possible exposures available with these devices were typically 50 –100 ms. Because the peak powers were low (the same as the average power, or 10– 30 W), the power densities were often subablative or marginally supra-ablative, and the only advantage was confinement of thermal injury to a level not observed with longer exposures (and higher fluences). The next generation of CO2 lasers used so-called “superpulsed (SP) technology”. Pulses were on the order of 50– 200 mJ and were delivered with varying repetition rates (50 –500 Hz). Sometimes they were delivered as couplets spaced very close together temporally. Unlike gated or mechanically shuttered pulses, however, these laser emissions were truly pulsed, that is, they were generated at the electrical source as pulsed exposures. These lasers delivered average powers similar to CW lasers, but the lasers were not “on” all of the time (Fig. 5.1). The older SP lasers only performed at very high repetition rates [so-called rapid superpulsed mode (RSP)], because of engineering limitations. The laser used a train of pulses, as few as 12, in trains of 50 ms or more. Even some newer SP lasers run only at repetition rates of 300 Hz, so that single-pulse ablation/heating is not
Figure 5.1 Differences between CW, mechanically shuttered, and RSP modes.
Continuous Wave and Pulsed CO2 Lasers
133
possible. Most SP lasers have a nonconstant pulse profile, so that the tail of the micropulse has a lower irradiance than the initial portion of the micropulse. This characteristic, and the rapid repetition rate, has contributed to levels of thermal damage not much lower than those of CW lasers. To minimize residual thermal damage (RTD) with RSP lasers, duty cycles should be low, or the repetition rate will be too high and thermal damage will accumulate (12 –14). Even though thermal damage was reduced somewhat by RSP lasers (typically by 10 – 30% using the same average power and fluence as in comparable CW applications) (15,16), it was not until the introduction of high-energy pulsed lasers with low repetition rates (single-pulse effects) and scanners that the full advantages of SP CO2 lasers were realized for defocused ablative and near-ablative applications (17,18). The term “UltraPulse,” used by a leading manufacturer, refers to a subset of superpulsed lasers with a rectangular pulse profile, capability of low repetition rates, and higher peak powers than older first-generation SP lasers. In a pulsed CO2 laser, there is a capacitor network that stores charge across the cavity electrode. Pulsed CO2 lasers can be excited by either direct current (DC) or radiofrequency (RF) power supplies. The RF laser develops high peak powers more easily than DC lasers, as RF excitation achieves and maintains the population inversion more efficiently within the cavity (see Chapter 2). Analogous to the ideal beam profile (top hat), the ideal temporal pulse shape should be rectangular, that is, the pulse is instantaneously turned on or off. The RF laser is the most capable of producing these “rectangular pulses” with a minimal tail. Most CO2 lasers in medicine are excited by a DC. The exceptions are the UP and Novapulse lasers, which are RF excited (11,13). For the remainder of the chapter, we will describe exposures as RSP mode, UltraPulse (UP) mode, or CW mode. We will refer to “mechanically shuttered” pulses simply as shorter exposures in CW mode.
1.4.
Laser Spot Size
Spot size can be estimated by irradiating a tongue blade for a brief period. However, these simple spot size measurements are sometimes deceptive, because they depend partly on the damage threshold of the target. For example, if one takes the UltraPulse laser and uses the 3 mm spot with very low pulse energy, only the center of the spot will be heated sufficiently, and the operator might mistakenly underestimate the spot size. Rigorous spot size measurements are made by profiling the beam by either moving a pinhole, using a knife edge, or using a dedicated beam profiler. The method allows one to see the point where the local power density is 14% of that at the center, which has arbitrarily been defined as the edge of the spot for a Gaussian beam.
1.5.
Delivery Systems
Usually, CO2 lasers work with a rigid articulated arm. The arm preserves the profile of the beam but sometimes results in cumbersome positioning between the operator and target. Arms may be fragile and mirrors may be knocked out of alignment during movement of the laser, making it imperative to test the laser on a tongue depressor prior to each use. Solid fiber delivery systems presently are impractical for IR radiation, as the materials are hygroscopic and not durable enough for pulsed laser systems (8,11). Hollow waveguide delivery devices will be discussed later.
134
1.6.
Ross
General Operating Principles
In general, when the CO2 laser runs in CW mode, a footswitch or mechanical shutter controls the total time on tissue. In CW mode the operator is using the laser in either a defocused or a focused manner. This is dependent on the distance between the skin and the handpiece. Most lasers have a focusing handpiece whose focal length is roughly 100 mm. The focal length is the distance from the end of the spatula tip to the lens. Normally, the focal plane is at the end of the tip. Longer focal lengths are usually associated with larger spots and greater depths of field. The depth of field is how much one can move the handpiece to and from the target and skin without significantly altering the spot size. The lens in the handpiece, which one can see by peering into the proximal portion of the handpiece, is usually made of zinc selenide, as standard glass absorbs CO2 energy. The lens focuses a somewhat collimated 7– 12 mm beam that has propagated from “knuckle to knuckle” to the distal end of the articulated arm. The operator can rapidly switch from a vaporizing to a heating mode (or vice versa) by moving the handpiece away from or toward the skin. As one pulls back from the skin, the beam is defocused. In this way, one can vary the power density according to the individual goals of the application. Some manufacturers provide handpieces with lenses that produce collimated beams, such as the TruSpot by Coherent. These allow the physician to work at varying distances from the skin surface with constant spot sizes. Regardless of the handpiece, one will see the greatest power density (PD) at the middle of the spot for Gaussian beams. The power density at the beam center is two times that of the average power density across the spot (12,19). It follows that one sees the greatest ablation at the center of the spot, and normally charring at the periphery.
2. 2.1.
LASER – TISSUE INTERACTIONS Physics
There are four important components in the CO2 laser – tissue interaction (20,21): 1. The propagation of the beam in tissue: When the CO2 laser beam impacts the skin surface, attenuation of the beam is guided by Beer’s law, which describes an exponential reduction in beam strength. Optical absorption and scattering determine the optical penetration depth (OPD) of the laser beam in the skin. The beam is rapidly attenuated (by about 85% within 40 mm) due to the high water content of the epidermis and dermis. This implies that if there is no ablation, the depth of the thermal effect will only be about 20 –40 mm if there is perfect thermal confinement (see Chapter 2) (22 –24). One might ask, if the beam is attenuated so much after only 20 –40 mm, why is there thermal damage and vaporization hundreds of micrometers and even millimeters into the skin? The reason is that Beer’s law describes only the optical attenuation of the beam. However, ablation and tissue heating during the pulse as well as postpulse heat conduction, result in deeper tissue injury. If there is significant ablation, the front (or boundary of the laser – tissue interaction) is constantly changing. In other words, the beam impact point is starting at increasing depths in the skin but still maintaining 20 – 40 mm of optical penetration beyond the front. 2. The instantaneous absorption of laser energy: The next step in laser – tissue interaction is conversion of laser irradiation to heat, which is instantaneous within the optical field. For all lasers, except ultra-SP lasers and the excimer laser, the major means of destroying tissue is the conversion of light to heat. The resulting heat deposition results
Continuous Wave and Pulsed CO2 Lasers
135
in either ablation or coagulation at the local level, depending mostly on the PD, or the time rate of energy delivery (W/cm2). Interestingly, the original PD ranges for CO2 lasers were chosen somewhat arbitra1 rily, but loosely based on the principle that it required 2.5 J over 10 s to convert 1 mm3 of water to steam. This required about 25 W average power (1). The threshold for tissue vaporization with the CO2 laser is about 100 –150 W/cm2, but at this low power density, there is much wasted heat with as much as 55% of the energy not used in ablation (12). It follows that the highest PD possible should be used that allows for control of the depth of injury. With standard CW lasers, the surgeon was forced to use a lower PD for control of vaporization depth, thereby increasing collateral thermal damage, or a higher PD for minimal RTD, but with more difficulty controlling the amount of removed tissue. One can think of the CO2 laser with high PD as delivering energy in such a rapid way that vaporization predominates over heating. In contrast, at lower irradiances of ,1000 W/cm2, heating predominates over vaporization (12,19). In both cases, the level of tissue destruction, which is the sum of depth of ablation plus residual thermal damage, will increase with exposure time. In the former case, the damage will be by tissue heating, and in the latter, by tissue vaporization. 3. The conduction of heat outside the OPD: This occurs on a much slower time scale than the aforementioned instantaneous heating due to absorption of the beam by tissue water and collagen. There is some absorption of 10.6 mm photons by dry collagen, but it is very small compared to tissue water. Because skin possesses high density and specific heat much like that of water, thermal diffusivity is high, and subsequently heat conduction is relatively poor. The temperature profiles deep to the OPD depend largely on the PD. If the energy is deposited before there is time for heat diffusion, thermal damage will be minimized (20,22,25 – 28). 4. Local denaturation of tissue: Finally, thermal damage is predicted from models that predict protein denaturation based on time – temperature combinations. This denaturation is based on integral equations where the denaturation is linearly dependent on time and exponentially dependent on temperature. In other words, by raising the temperature only by 10 – 208C, one requires only 1/10 the exposure time for equal denaturation (29).
2.2.
Residual Thermal Damage
Venugopalan and others have critically examined the various parameters that affect RTD in ablative and nonablative laser applications and have found the following (26): 1. Effect of ablation: Supra-ablative fluences and power densities are generally considered to be associated with less thermal damage than laser –tissue interactions without ablation. Theory predicts that if the ablation front outpaces the speed of heat conduction, thermal damage will be minimized. While this is true in principle and practice for prolonged irradiation times of .0.25 s, there are instances where the lack of ablation is associated with less injury than in those applications with ablation. For example, if one uses 3 J/cm2, one will observe less RTD at the base of the wound than at 10 J/cm2. The reason is that the total energy dose is less. Also, there is always a tail end of the penetrating beam as it is attenuated by tissue water. This “tail” fluence will not achieve ablation threshold, and therefore there will always be some RTD at the base of the ablation crater. To achieve large zones of thermal damage without ablation requires either overlapped low-energy pulses, or a low PD beam applied for times of over 50 ms (Fig. 5.2). The threshold for ablation is variable, and tends to increase with pulse duration and the strength
136
Ross
Figure 5.2 (a) Microscopic view of pigskin after a single 1 ms pulse at 8 J/cm2 laser with Gaussian beam profile. Note that there is less RTD at the edges of the wound due to lower energy at the beam edge. (b) In contrast, after 10 pulses at 1 Hz, there is ablation at the center of the wound, and the RTD has “built up” to be slightly greater at the wound edge. This sequence shows that subablative fluences only result in more RTD when the heating is cumulative. Ablation at the center of the crater limited the RTD to 80 mm.
of the tissue. The dermis has a higher threshold than the friable cellular epidermis (23,24,30). 2. Effect of pyrolysis: Pyrolysis refers to the thermal decomposition of organic compounds in the absence of O2 (31). The resulting char acts as a heat source for several seconds after laser exposure. As air is a better insulator than the underlying skin, heat tends to travel to deeper tissues. With continued heating of the char, one sees a flame or a bright spot at the surface (“flash” point 5008C) and smoke formation, as the gaseous molecules on the surface of the char undergo combustion. Simultaneously, continued heating of the solid char component can result in “white-hot” plasmas that are so bright that the surgeon will be tempted to turn his eyes away from the operative field. 3. Effect of a nonsquare pulse shape: With older SP lasers, the laser pulse typically had a sharp rise time, followed by a slow tail. Thus, the PD was not constant during the pulse, leading to more thermal damage than predicted. However, if the pulse is short-lived, and there is sufficient interpulse cooling, the tail should not be clinically important. 4. Effect of pulse duration: According to the literature the pulse duration should be shorter than the thermal relaxation time. Thermal damage will be minimized if the laser pulse is delivered faster than the time it takes a heated layer of water equal to the optical penetration depth to cool. This time is based on the geometry and dimensions of the target, which in this case is assumed to be a layer of water 30 mm thick. Although the thermal relaxation time is approximately 1 ms, this number is reported with widely different values, partly because different models are used to determine the time for cooling (32). Experimental data support this argument (Fig. 5.3), as Walsh et al. (28) showed that with longer pulses (50 vs. 0.6 ms), there was more RTD. However, Venugopalan et al. (25,26) argued that a more important contributor to the increase in RTD in Walsh’s study was the decrease in PD for the longer exposures. Furthermore, the increases in RTD observed by Walsh et al., were the result of up to 50 pulses (overlapping at 1 Hz); single-pulse effects would have most likely not shown such a dramatic difference in RTD as a function of pulse duration. In our own study, we showed that for single pulses over a range of 0.25– 10 ms, there were no significant increases in RTD for fluences of 1, 3, and 10 J/cm2 on the basis of pulse duration (30). However, this is only a 40-fold range of pulse durations. Studies with shorter pulsed lasers have shown (33), along with our on experiments, that with 60 – 120 ms pulses, thermal damage is reduced to about 30 –50 mm compared to the 70– 120 mm levels observed in
Continuous Wave and Pulsed CO2 Lasers
137
Figure 5.3 (a) RTD in pigskin after defocused CW CO2 laser beam (8 W, 2 mm spot, 0.5 s exposure, 115 J/cm2). Damage extends 500 mm deep to surface. (b) RTD is only about 90 mm after a 7 J/cm2 exposure with a pulse duration of 1 ms. (H&E stain, original magnification 100).
millisecond domain lasers. Moreover, Littler (34) found RTD intermediate between millisecond CO2 and erbium:YAG lasers with 130 ns CO2 laser pulses. The primary advantage of shorter pulses is (1) spatial confinement of thermal injury and (2) lowering of the ablation threshold. In general, the RTD with a very short pulse is roughly equal to two times the OPD, whereas that of longer pulses scales as the square root of the pulse duration assuming fluences above the damage threshold for tissue (28). 5. Power density: If one examines the study of Schomaker et al. (35) of RTD in CO2 laser surgery, there was no systematic association between PD and RTD over a range of 360 to 740,000 W/cm2. However, over this PD range, theory predicts only a 33% increase for the lowest PD over the highest PD. Dobry et al. (36) found that RTD and scar increased with PD in rats from 141 to 849 W/cm2. They used the same 0.1 s application times in all their experiments. It follows that the doses of energy were not the same, so that this study actually showed that increasing the fluence caused more RTD by increasing the wound depth. In practical terms, one must remember that by increasing the power, one only linearly increases the PD over any focal point in the beam profile, but by decreasing the spot size, because the area of a circle varies with the square of its radius, there is a quadratic increase in the PD at the impact site. Hobbs et al. (12) summarized that wound edge necrosis is minimized for PD .20,000 W/cm2 and exposures of about 0.1 ms. 6. Repetition rate: Early estimates of the critical repetition rate for minimizing thermal damage were as high as 1000 Hz. These rates, based on the inverse of the thermal relaxation time, which is the time for the target to cool to 37% of the peak temperature for the CO2 laser, were too high, as tissue requires more than 100 ms to cool completely before the next pulse. This is also known as the thermal recovery time. As long as ablation occurs, 20 Hz is the maximum rate that will limit RTD to near the theoretical minimum (25). Without ablation, the rate decreases to 1 – 5 Hz with the CO2 laser (37,38). Older RSP lasers showed that with high repetition rates, RTD was only modestly decreased vs. CW lasers (16,39,40). For vaporizing applications, Fitzpatrick (41)
138
Ross
noted that the RSP mode was most helpful when the total string of pulses was short (i.e., when the macropulse ,50 ms), regardless of the duty cycle and repetition rate. 7. Fluence: Kamat et al. (42,43) studied fluence effects and noted that there was increased RTD with increasing fluence. They found that the greatest effect was in the basal layer. Since heating should have been greatest at the upper epidermis, this was somewhat unexpected; however, the authors suggested that weaknesses in the lamina lucida might have played a role. They found selective epidermal damage for fluences of less than 10 J/cm2. In agreement with their results, we have experimentally found that for pulse durations ,10 ms fluence (and not power density or achievement of ablation) is a more important parameter in determining the extent of RTD; that is, lower fluences usually result in less RTD. 8. Plasmas: Plasmas have been observed with the CO2 laser (22,44,45) with fluences above 19 J/cm2 for 100 ns and 2 ms pulse durations. Plasmas are PD-dependent, generally requiring PD .107 W/cm2 in tissue, so that either increasing the fluence or decreasing the pulse duration will increase the likelihood of their formation. As plasmas absorb incoming energy and also create very high, although focal, surface temperatures of 10008C, they are generally undesirable. It follows that one should choose pulse duration/fluence combinations that avoid optical breakdown. 9. Temperature profiles in CO2 laser surgery: Choi et al. (46) measured the temperature profile at the surface with a pulsed CO2 laser and found experimentally that the thermal relaxation time was about 20– 40 ms (the time for the peak temperature to decay to 37% of the maximum). They found that temperatures increased from about 2208C (after one pulse) to 4008C after 15 pulses at 1 Hz and 3.5 J/cm2, without wiping. They noted carbonization after four pulses and a simultaneous sharp increase in temperature to 3508C. They also found tissue burning (combustion) after the 10th pulse. The high temperatures (.1008C) are due to water superheating and are not unexpected. They noted that the time for total tissue cooling (to baseline temperature) was about 150 ms. It should be noted that with continued low-PD charring, one might expect peak surface temperatures of about 10008C (47,48). 2.3.
Clinical Examples of Laser – Tissue Interactions
2.3.1. High PD, Short Exposure Time Laser resurfacing (LSR) is the best example of this scenario, where there is some vaporization (ablation) and a small residual zone of thermal damage. The zone of thermal damage is the result of both (1) subablative localized energy densities (at the base of the wound, as the beam is rapidly attenuated) and (2) heat conduction during and after the pulse. For typical fluences used in LSR, the following cascade of events, corroborated by both human and animal histologies, occurs with each pass. After the first pass, the entire epidermis, for fluences of 5 – 8 J/cm2 with a 1 ms domain laser is heated plus about 10 – 40 mm of the dermis. With lower fluences or with treatment with the ultra-short pulse Tru-pulse laser, thermal damage can be reduced to lower levels (10,30,49 – 52). At this point, the epidermis is normally wiped away with wet gauze, and the papillary dermis is exposed. However, there is a case to be made for not wiping. If one knows the extent of the injury after one pass and is confident that this level of injury will successfully reverse the skin pathology, wiping only serves to increase patient discomfort and prolong healing. More importantly, there appears to be a level of dermal thermal injury beyond which long-term hypopigmentation is almost inevitable in selected patients, especially appearing along the lateral cheeks and extending to the jawline. Thus,
Continuous Wave and Pulsed CO2 Lasers
139
one can titrate the injury according to the level of desired injury with one pass if one reliably knows the laser end points. For example, with the UP at 300 mJ and a density of 6, if the scans are laid down accurately, one can rely on complete epidermal denaturation and about 20 mm of dermal thermal damage. Of course, this is somewhat anatomy dependent, as in the thinner skin of the eyelids, neck, and temples, the thermal damage will extend deeper into the dermis. Thus, the same total thermal damage will result regardless of the delivery location. However, the level of dermal injury will increase in areas with a thinner epidermis. With the CO2 laser, once the denatured friable epidermis is wiped off, it takes many pulses to ablate the residual acellular dermis (53). With the typical Gaussian beam of the CO2 laser, there will be some ablation at 7 J/cm2 average fluence at the center of the spot, but very little at the perimeter. Overall, using this average fluence, the ablation is about 10 – 15 mm per pass, much less than was reported in the early days of LSR. Of course, as the average fluences reach 10, 15, and 20 J/cm2, the relative ratio of ablation to tissue heating will increase. That is, roughly the same RTD will result, but the amount of ablation per pass will increase, Depending on the patient’s pathology and age, one sees different surface characteristics after wiping the denatured epidermis. For younger patients with modest photodamage, normally a pink to red dermis is exposed. For an older patient with severe solar elastosis, one sees yellowing immediately. If the patient has either actinic keratoses (AKs) or incipient dysplasia, there is usually hyperemia and sometimes frank bleeding upon wiping. Often, vigorous wiping is helpful in unmasking early AKs that might not have been obvious from the surface prior to laser surgery. In these cases, it is wise to proceed with additional passes until there is mild yellowing. The RTD at the base of these wounds is often enough to remove the remainder of the AK. Fulton et al. (54) recently reported that the CO2 laser was inferior to dermabrasion for AKs and used examples of AKs and basal cell carcinomas (BCCs) recurring in LSR sites not long after laser surgery. He referred to the penetration depth of the laser as being the main limiting feature of this technique. This is true if one makes only one pass and does not wipe, a technique I do not advise when treating AKs. Once the AK is uncovered by wiping, however, the remaining lesion can be vaporized or heated to achieve a complete cure. 2.3.2. Long Exposures in CW Low – Medium PD Defocused Mode This is the so-called vaporization mode, which is actually a combination of simultaneous heating and vaporization, and is used for treating warts and other exophytic lesions where some tissue heating at the base of the wound is tolerated. Usually, one will encounter vaporization at the center of the spot and charring at the periphery. To decrease char, one must move in a pirouetting motion so that the char is not continuously heated. When the CO2 laser burns a hole in the skin, the mechanism for ablation is the rapid conversion of water to steam (23,55 – 57). In the epidermis, the fragility of this layer provides for easy ablation, as the water vapor easily escapes the intracellular space, typically carrying with it a solid residue of exploded cells. This debris will continue to be heated as it is carried off, thus one sees “burning” or combustion. The onset of vaporization by CW irradiation in this PD regime is not completely characterized, but Verdaasdonk et al. (47) studied it intensively. They found the following sequence at the tissue surface. Initially, there was slight tissue discoloration. Coincident with a “pop,” the surface was lifted slightly, suggesting boiling bubbles underneath. The sound was due to the rapid ejection of air through the ablation front (nozzle effect), like bursting a balloon. Next, a small black spot was noted in the center of the beam,
140
Ross
presumably from carbonization of the dehydrated tissue. Within a few tenths of a second, this charred zone expanded and a ring was formed. Next, the char underwent combustion, unveiling a new hydrated surface. Later, there were cyclical rings of carbonization and vaporization, following each other in rapid succession as a progressively deeper crater was formed. The temperature associated with the onset of ablation was around 150 – 2008C (48). In contrast to the above scenario, for lower PDs with long exposure times, the char is never “blown off” (either by vaporization of water below the char or by combustion), and there is deep heating beneath the skin surface, as temperatures .10008C may occur at the surface. Indeed, this can be observed occasionally in the treatment of warts and rhinophyma, where prolonged application times of .0.5 –1 s can result in a brownish color and finally deep blackening of the surface. With increased blackening, the char acts as a nearly perfect absorber, and the char becomes hotter and hotter. This is why using lower PDs for prolonged periods is usually not advisable, as it simply results in very deep “invisible” tissue heating. It is advisable in these cases to wipe the char, thus exposing hydrated tissue, so that additional vaporization can take place. 2.3.3. Very Low PDs and Short Exposures With this technique (also known as thermabrasion), the laser is used in low power mode at 1 – 5 W with a defocused beam with very short bursts of CW radiation of about 0.1 s, and a total fluence of 1 –5 J/cm2 (58). Although the thermal gradient is not steep, that is, the temperature decay as a function of depth is small, there is so little total heat that this is safe as long as one pass is made, and this application will typically restrict RTD to the epidermis and superficial papillary dermis. It is useful in lentigos and mild photodamage. The goal is to use short bursts of subablative PDs to heat a specific thickness of tissue. In the case of dermatosis papulosis nigra (DPN), for example, one can heat the tissue just to a level similar to that of the hyfercator of 0.5– 2 mm. The end point is slight whitening of the tissue. This technique is best reserved for those who do not have access to a pulsed CO2 laser (43,59). 2.3.4. High PDs with Small Spots (0.1 –0.3 mm), Used in Incisions Most skin surgeons do not use the CO2 laser in cutting mode, with the exception of eyelid surgery. In addition to the cumbersomeness of using the laser as a cutting tool including the need to work around the articulated arm, the need for a smoke evacuator, and the constant vigilance that is required not to inadvertently strike an innocent bystander target, the laser cannot be endorsed as a first choice for incisions because healing is delayed compared with scalpel incisions. It is therefore not recommended for most routine skin surgeries (60). The indications for using CO2 for cutting regardless of the mode, include: Bleeding disorders Where epinephrine is not indicated Vascular lesions (hemangiomas and scalp tumors) Infected surgical sites In patients with pacemakers or implanted defibrillators (58) The advantages, on the other hand, are ease of excision and a relatively bloodless field. The lack of perfect hemostasis is partly explained by the paucity of RTD in a standard excision with CO2 laser. Because the small spot sizes of 0.1– 0.3 mm allow for high PDs, thermal damage is minimal (61). Microscopically, one finds 90 mm of basophilic change and 100 – 500 mm of lateral glassy hypereosinophilic change on routine staining
Continuous Wave and Pulsed CO2 Lasers
141
(62 –64). It follows that high-flow vessels larger than 500 mm are likely to bleed after CO2 transection. In contrast, without blood flow, vessels up to 2 mm have been coagulated (55,65 –72). Also, Kaplan (personal communication) has noted that in adults the maximum coagulated vessel diameter is about 0.5 mm, but in children it is greater at about 1 –1.5 mm. One should note that minimizing RTD and achieving hemostasis are antagonistic (4). Ideally, one should choose the laser parameters with the least RTD that still achieves adequate control of bleeding. The amount of bleeding vs. other modalities such as diathermy and scalpel has been compared, and it appears that the CO2 laser performs as well as a cutting electrosurgical current. In our experience, however, we have found that a blended electrosurgical current achieves better hemostasis than a well-focused laser beam. Defocusing only works to stop bleeding when the bleeding is mild. Mullins et al. (73) found that by using suction ahead of the beam they could achieve better hemostasis. Another purported advantage of the CO2 laser is that it seals nerve endings (74), which presumably results in less postoperative pain than in scalpel excision.
3.
COMPARISON OF THE RESURFACING LASERS
There are over 10 lasers with resurfacing capabilities (Table) of lasers would be helpful. I will discuss the ones more commonly used. Most of these devices are also capable of CW operation. Alster et al. compared (75) four resurfacing lasers and found that they were similar in histologic and clinical outcomes. The same was true for clinical studies comparing the Sharplan SilkTouch and UltraPulse lasers (76 – 78). In another study, the TruPulse and UltraPulse were compared (79,80). Although the RTD was greater with the UltraPulse, the final cosmetic outcomes were similar. Kauvar et al. (51) studied the histology of superpulsed, SilkTouch, and UltraPulse lasers in human skin and found that after three passes, the SP and SilkTouch RTDs were both 150 mm, the UltraPulse RTD was 70 mm, and the CW laser RTD (10 W and 0.2 s exposure) was 400 mm. Many investigators have compared the various levels of RTD after three passes in LSR: a summary is provided in Table 5.1 (30,76,77,79,81,82). Table 5.1 Lasers with Resurfacing Capabilities
Typical “settings” UltraPulse (Lumenis, Norwood, MA) NovaPulse (Lumenis, Norwood, MA) SilkLaser (SilkTouch mode/ FeatherTouch mode) (Lumenis, Norwood, MA) TruPulse (Tissue Technologies, Albuquerque, NM) Unipulse (Nidek, Freemont, CA)
Typical safe fluence (J/cm2)
Typical RTD after two to three passes (mm)
Density 6, 300 mJ
7.5
90 – 110
Computer scanner E16, 7 W 18 W/36 W (with 200 mm handpiece)
6–7
60– 80
15/8
110/70
500 mJ
16– 18 W/20% overlap
5
50
14
70
142
3.1.
Ross
UltraPulse
The UltraPulse laser is one of the two most popular resurfacing systems (14,81,83–95). In its initial configuration, the laser was equipped with a 3 mm spot-size handpiece with a collimated beam (TruSpot). Typical pulse energies were 250–500 mJ giving a fluence of 3–7 J/cm2 in these first efforts at skin resurfacing with single short pulses of ,1 ms. With the addition of the computer pattern generator (CPG) in 1995, the laser became more popular and easier to use over larger surface areas. The CPG scans a 2.25 mm beam in an x–y fashion with varying user controllable degrees of overlap. The popularity of the system is borne out by the frequent reference in the literature to the proprietary laser settings as if everyone should know their significance. Frequently, one will see, for example, in the methods and materials of a paper, the laser settings referred to as 3–5–5, which refers to the pattern–size–density. The pattern is one of seven different geometric configurations including squares, triangles, circles, diamonds, and even a ring. The size refers to the number of spots laid down per scan, and does not represent an absolute dimensional value. For the square pattern the size is the square root of the number of spots in the scan. Thus, for a size 5, there are 25 spots in the scan. The density refers to the overlap between spots; for example, density 5 implies about 30% overlap, and is typically chosen because it allows for overlap of the wings of the Gaussian beam and thus a fairly uniform tissue effect across the scan. Density 9 is about 60% overlap and is usually only used for exophytic lesions where rapid ablation is required and the concern for thermal damage is minimal. The density is important in determining RTD. Ross et al. (37) showed that after three passes with 300 mJ with wiping between passes, the respective RTDs based on basophilic collagen changes were 70, 95, and 145 mm for densities of 3, 6, and 9, respectively. The UltraPulse can also be used in a quasicontinuous mode (CW on panel, 3000 Hz) for cutting with the 0.2 mm handpiece. A 1 mm handpiece can be used for treatment of small exophytic lesions such as syringomas either in UltraPulse or in CW mode.
3.2.
The SilkLaser
This is a CW laser coupled with a flashscanner that sweeps the beam over a microspot in approximately 1 ms in SilkTouch mode and 0.4 ms in FeatherTouch mode. The early models possessed only the SilkTouch mode. In this mode, the laser dwell time, that is, the time the microbeam is in contact with any local area of tissue, is about 1 ms. Arbitrarily, the device was used with a 125 mm (focal length) focusing handpiece which spiraled a 220 mm beam at the focal plane. Typical powers were 6– 7 W with a 3– 4 mm scan size and 0.2 s “on-time.” These settings resulted in fluences of 16 J/cm2 and RTD levels of about 80 – 120 mm after three passes. As this was slightly greater than that usually observed with the UltraPulse with a similar pass number, Sharplan introduced the FeatherTouch. The dwell time was reduced to 0.4 ms, and the thermal damage after three passes with FeatherTouch was reduced to about 50 –80 mm (96). The SilkLaser can be used with newer 200 and 260 mm focal length handpieces. These spiral 360 and 420 mm microbeams, respectively. Because of the larger beam, higher powers must be used to achieve the same local PDs as with the shorter handpiece. Typical recommended powers are 18 W in SilkTouch mode and 36 W in FeatherTouch mode. Modern versions of the scanner interface with the laser directly, so that once the user chooses the power and handpiece, the panel provides representative settings that have been found to be safe and effective in LSR. Overall, using the longer handpiece is preferable because the depth of focus is greater, that is although one still should hold the handpiece tip close to the skin, the
Continuous Wave and Pulsed CO2 Lasers
143
microbeam size will not change as significantly as when one uses the 125 mm handpiece. With this shorter handpiece, even holding the tip 2 mm above the skin surface can result in a 70% reduction in PD due to rapid divergence of the beam past the focal plane. In SilkTouch mode the laser beam overlaps on itself. This was due to the nature of the early device, where the laser and the scanner were not synchronized. This necessitated an “in and out” spiral to ensure complete coverage of all areas within the scan. With the FeatherTouch mode, there is only one spiral per pass, and the tangential velocity of the laser increases by about 1.3, thus the dwell time overall is decreased by about 60%. More importantly, because there is no overlap, RTD is significantly reduced. With the newer synchronized system, the panel gives suggested settings for power for a given handpiece and mode. For example, with the 125 mm handpiece (220 mm spot), the suggested laser power is 7 W, and for a given scan size such as 5 mm, the scan on-time is programmed for 0.43 s. For FeatherTouch mode with the same handpiece, the suggested power is 14 W, and for a 5 mm scan, the on-time is reduced to about 0.12 s. We have examined multiple tongue depressor impressions made by the laser with an operating microscope, and have confirmed that the SilkTouch mode does overlap almost, if not directly, on itself. This undoubtedly has contributed to the increase in RTD vs. the FeatherTouch mode as well as the increased fluence and slower tangential velocity. 3.3.
The NovaPulse
The NovaPulse can be used in pulsed or CW mode (75,97,98). This is an RF excited laser with 20 W average CW power capability and peak powers of upto 50 W in RSP mode. We have used the NovaPulse system for resurfacing, in which case it is coupled with either a 3 mm handpiece or a scanner, and found it to be a capable laser. The overall treatment times are somewhat longer than with the UltraPulse due to lower average powers for the NovaPulse. The laser scans a very small spot of 0.8 mm with the scanner. The pulse duration for a single pulse ranges from 50 to 1400 ms, depending on the pulse energy of 20 – 45 mJ. In other words, the duty cycle and average power increase slightly with each increase in pulse energy. The Nova Scan system generates a 3 mm spot size in a daisy pattern. A motor rotates the fiber tip, the 0.8 mm microspot, at about 1000 rpm 12 times to cover a 3 mm macrospot. For example, with a 6 W average power setting, the laser generates 360 mJ over 60 ms with a series of submillisecond pulses of about 30 mJ. A larger scanner, Dermascan, is also available with similar patterns and densities as the UltraPulse CPG. Depending on the application, the laser is capable of a number of programmed settings in CW (P programs) and pulsed (A, P, E, and F programs) modes. The unique feature of the NovaPulse laser is the delivery device, which is a proprietary hollow waveguide. The waveguide is a tube with a highly reflective coating on the inside wall. The waveguide is made of dielectric coated molybdenum encased in a stainless steel jacket. The laser beam enters at one end, and propagates down the guide into the handpiece. One problem with waveguides is that the transmission decreases from a maximum of about 85% to less than 40% if they are bent more than the arc of a basketball. This potentially introduces an unwanted variable into treatment if care is not taken by the operator (99,100). 3.4.
Nidek Unipulse
In skin resurfacing, the Unipulse (Nidek, Freemont, CA) scans a 1 mm spot at 100 –300 Hz with pulse energy ranging from 30 to 100 mJ depending on the pulse duration with a range from 200 to 800 ms. Typical operating parameters are 18 W average power and 20%
144
Ross
overlap between adjacent spots or about 60 mJ pulses for an average calculated fluence of 16 J/cm2. For younger, less photodamaged patients, the power can be reduced to 14– 16 W. The laser also offers an array of SP and CW modes that can be used with a range of focusing handpieces. Of the SP, Unipulse, modes, Mode I is a very high-duty cycle mode with relatively long on-times and short off-times. This mode is designed for coagulation. With increasing numbers (II –V), the duty cycle decreases and the peak powers increase. Also, there is more time for cooling between pulses. 3.5.
TruPulse
This laser is fundamentally different from the others in that it is transversally excited, meaning that the electrodes are placed across the tube. This allows for brief highenergy pulses of 60 –100 ms and pulse energies of up to 500 mJ (79,80,101,102). The laser only operates in pulsed mode: there is no CW availability. The laser produces a multimode beam called “mesa” mode or flat top beam. The beam size is roughly 2 2 mm with the scanning handpiece for resurfacing (103). A 0.2 mm handpiece is also available for cutting. Because of the short pulse duration, the laser produces peak powers of up to 10,000 W. 3.6.
Summary of Resurfacing Systems
All of the resurfacing systems above are capable of achieving a combination of ablation and RTD that is suitable for obtaining a good cosmetic outcome. The physician should become comfortable with one system and have another system as a backup. Each different laser system, and even different lasers of the same model type, usually has unique features and idiosyncrasies that should be mastered prior to use. One should always look closely at the skin surface during irradiation. I normally have the aiming beam turned off or dimmed during pulsing. If something seems odd, stop the procedure, go back to the tongue depressor, and recheck the beam. For example, a mirror in the articulated arm once deteriorated during a CO2 laser case and the only sign was that the skin surface showed a collage of crescents rather than circles with the UltraPulse CPG.
4.
WOUND HEALING AFTER CO2 LASER
Early studies of wound healing after CO2 laser treatment focused on incisional wounds (104 –106). These studies found a delay in epithelial migration at the wound surface and a delay in fibroblast migration. Presumably, the RTD associated with CO2 wounds produces the delayed inflammatory response that crescendoes somewhat later than scalpel wounds of similar depth (39,107– 115). Consistent with this delayed inflammatory response, and possibly the delayed deposition of new collagen, Pogrel et al. (114) showed that CO2 wounds were associated with greater amounts of hyaluronidase production vs. scalpel wounds after 3 weeks. Harmon et al. (116) studied erbium and CO2 wounds and showed more platelet cell adhesion molecule in the CO2 wounds 6 weeks after injury. All of these findings suggest that the initial thermal damage in CO2 laser injury modulates the healing response vs. wounds without thermal damage. Wound healing has been compared between CO2 laser, cautery, and scalpel surgery. Lunkenheimer et al. (106) examined minipig incisions and found that wounds that were left unsutured healed best after scalpel surgery, with fine scars after 16 days, whereas the laser wounds and cautery wounds tended to appear as oval dents “filled up” by
Continuous Wave and Pulsed CO2 Lasers
145
pinkish scars. They identified a microscopic transition zone “in a fairly unchanged condition that was particularly engaged in the process of tissue restoration.” Sloughing occurred above and within the transition zone. Hall examined sutured CO2 incisions and scalpel wounds and found that sutured laser wounds were weaker than scalpel wounds in rats after 21 days, but that by 40 days the wounds showed similar tensile strength. The delay in healing was blamed on the shedding of the eschar, which occurred around the sixth to eighth postoperative days just deep to the zone of basophilic staining collagen. Kamat et al., examined both sutured and unsutured human skin wounds after CW laser irradiation. They found that inflammation was delayed in laser wounds and that there was sloughing collagen, beneath which a new epidermis was formed (42). However, in deeper sutured wounds, there was also some entrapment of denatured collagen that remained unchanged and mummified for as long as 10 weeks after surgery. This study and our own results suggest that damaged collagen is handled differently in the skin depending on the depth of the damage, where superficially damaged collagen is more likely to be rapidly degraded within 1–2 weeks even when re-epithelialization has occurred over the specimen. In brief, CO2 laser-induced open wounds heal differently from wounds of similar depth with less than 75 mm RTD. They show delayed re-epithelialization and a different pattern of wound contraction. The wound contracts immediately, relaxes to a degree, and then undergoes a second contraction vs. dermatome, dermabrasion, or erbium:YAG laser wounds, which show little or no immediate contraction, then a one-time contraction and subsequent relaxation beginning about 2 –5 days after injury. Also, there is more fibroplasia per micrometer depth of injury and different patterns of enzymatic and cytokine activity in CO2 laser-induced wounds (50).
5.
ULTRASTRUCTURE AFTER CO2 LSR
Zweig et al. (61) studied both routine histology and electron microscopy in laser excisions and divided the zones ultrastructurally into two zones: (1) coagulation zone, where collagen fibers lost their periodicity, and (2) a transition region, where the periodicity of collagen fibers was partly retained. He also correlated the collagen changes seen in laser excisions with collagen changes after exposure to various controlled temperatures in a hot bath. In the bath, the minimum coagulation temperature was 738C, and the transition zone minimum temperature was 578C. Unfortunately, the exposures in the hot bath were for 160 s, much longer than the brief laser exposures. Undoubtedly, the temperatures required for similar collagen changes during short laser exposures would be much higher. More recently, Kirsch et al. (117) and Collawn et al. (118) have published separate studies on the ultrastructure of CO2 LSR with millisecond domain CO2 lasers. Kirsh et al., described two zones of damage, where Zone 2 represented a transition zone and, as in Zweig’s study, in this zone collagen fibers showed an increased cross-sectional area consistent with linear shrinkage. Zone I represented the tissue surface with more severely damaged fibers whose ultrastructure showed no distinct fibrillar component. Collawn et al., suggested that loss of the extracellular matrix rather than collagen shrinkage was responsible for the skin tightening seen during LSR.
6.
APPLICATIONS
The appeal of the CO2 laser is largely based on its utility, which increases rapidly with increasing physician skill. Since water is the chromophore, almost every skin lesion is a
146
Ross
potential target. However, one must examine the selectivity of the laser before deciding that it is a better choice than other wavelengths that either target discrete chromophores or allow for shallower tissue effects due to higher water absorption, such as the erbium:YAG laser. Unlike most of the other lasers in this book where selectivity is based on spatial confinement of injury to a discrete target the CO2 laser’s selectivity is based only on how precisely the block of ablated or heated tissue matches the dimensions of tolerability of the skin for scarring and dyspigmentation. As long as everything within the block of tissue vaporized or heated can be sacrificed without adverse side effects, the CO2 laser is an attractive “what you see is what you get laser.” Once the CO2 laser light impacts on the skin, there is immediate absorption, so that the injury is always top to bottom unless one irradiates the skin from the undersurface, which is a technique used by some physicians. For this reason, the CO2 laser demands a high level of operator practice and skill to achieve reliable results. It follows that with greater use, one finds that the laser is as good or nearly as good as some of the pigment selective or vascular selective lasers for particular lesions. In the ensuing discussion of applications, if not specified, wiping with either a H2O2 or a saline soaked gauze pad or applicator stick is done between serial passes with the CO2 laser. Also, in all applications using a defocused CW mode, the reader should assume that an “airbrush” technique was used for plaque-like lesions.
6.1.
Applications Where the Laser Performs Better Than Most Other Modalities (In Addition to Resurfacing—See Chapter 29)
Rhinophyma can be treated with excellent results with the CO2 laser in either the pulsed or the CW mode (Fig. 5.4). The author exclusively used the CW mode until recently.
Figure 5.4 (a) Rhinophyma preop. (b) Just after surgery, 8 – 20 W CW CO2 laser, 1 –4 mm spot, airbrush technique. (c) 12 Weeks after surgery note improved cosmesis and lack of scarring.
Continuous Wave and Pulsed CO2 Lasers
147
The advantage of this mode is that one can combine heating and vaporization by varying the spot size and power. By decreasing the former and increasing the latter, vaporization is observed, and the nose can be sculpted to its original shape. My recently adopted technique is to initiate treatment with 15–25 W in the defocused mode, using a pirouetting motion to vaporize the nose to a roughly desirable contour, followed by fine tuning in the UltraPulse mode. By using the high-energy short pulse mode at the end of the case, charring can be avoided and more of a “what you see is what you get” result is observed. One should use older photographs of the patient to guide the final silhouette. Also, one should periodically view the nose from different positions to ensure that the contour is even. Finally, no matter what method is used, occasionally one will encounter bleeding, in which case either aluminum chloride may be used or the laser can be used in the defocused mode for coagulation. One treatment end point is achieving the final nasal contour and another is using the sebaceous glands as a guide to treatment. Normally, if one can squeeze sebum from the glands near the end of the procedure, the ablation plane is not too deep. Several investigators have reported their experience in treating rhinophyma with the CO2 laser. Wheeland et al. (119) used a combined laser excision and vaporization approach, employing a focused 0.2 mm spot for excision with 15 W and an irradiance of about 50,000 W/cm2. The nose was grossly reshaped in this manner by cutting off the excess tissue. Next, they defocused the beam to 2 mm and decreased the power to about 4–5 W. This was used to gently smooth the remaining surface irregularities. Karim and Streitmann (120) retrospectively analyzed 20 patients after treatment with 12 W CW, using a combination of 0.2 mm spots for excision and defocused beams for vaporization. Simo and Sharma (121) reported three cases with good results. They used 5 W CW and a 1 mm spot to mark the perimeter of the field, then 15 W with a 2 mm spot to vaporize excess tissue. El-Azhary et al. (122) treated 30 patients with a 0.1 mm spot to excise, followed by a defocused beam at 15–20 W. They reported one case of scar and one case of leukoderma. 6.1.1.
Trichoepitheliomas
Both CW and UltraPulse lasers have been used to treat these lesions (123–127). Generally, the end point has been destruction to a level just below the adjacent skin surface. Deeper ablation results in scarring and more superficial ablation results in early recurrence. The typical laser settings in CW mode include 1–3 mm spot sizes and powers of 2–5 W. We have been using the 1 mm spot size in UltraPulse mode at 200–250 mJ, defocusing and focusing the beam to accommodate the skin dimensions and the ratio of ablation to heating. 6.1.2.
Adenoma Sebaceum
We have used both pulsed and CW lasers for these papules (Fig. 5.5). One can use the CO2 laser with a low power of 2 – 3 W and 1 –2 mm spot size with short application times of 0.25 – 0.5 s to gently vaporize/heat the papules so that they shrink over the subsequent few weeks. Alternately, one can use the pulsed laser to vaporize the lesions, but we have found that the pulsed mode results in mild bleeding in some areas. Once the exophytic portion of the lesions has been removed, the base at a different session 4 – 6 weeks later undergoes vascular lesion laser treatment. Janniger and Goldberg (128) performed a comparison study of argon and CO2 lasers (5 W, 2 mm CW) in a single-patient side-by-side study and found overall that the CO2 laser showed superior cosmetic results. We have similarly found that the CO2 laser works better than a vascular specific laser, at least for the exophytic component of the lesions. Boixeda et al. (129) compared CO2 , argon, and pulsed dye laser (PDL) in 10 patients and concluded that the CO2 laser overall was a better therapeutic tool.
148
Ross
Figure 5.5 (a) Tuberous sclerosis patient preop. (b) Six months after treatment of exophytic lesions with CW CO2 laser, 2 – 3 mm spot, 2– 4 W, 0.5– 1 s exposures.
6.1.3.
Common Warts
Even with the large armamentarium of available wart treatments, including interferon, 5-fluorouracil, imiquimod, as well as traditional therapies such as liquid nitrogen, some warts persist. Generally speaking, CO2 laser is not a first-line destructive therapy because the pain, while usually not severe, tends to be prolonged vs. cryosurgery. The healing time is prolonged, some scarring is very likely in most areas, and there is a requirement for injectable anesthesia. However, warts which have persisted over 1 year despite therapy, especially if they interfere with some aspect of the patient’s life (either functionally or through significant cosmetic disfigurement), are good candidates for CO2 laser treatment (Fig. 5.6). Advantages of CO2 laser therapy include precise control of the
Figure 5.6 (a) Periungal wart preop. (b) Immediately postop, note that the wound is carried out deep into the sulcus. (c) Four weeks postop there is no evidence of recurrence and the nailfold contour is returning to normal.
Continuous Wave and Pulsed CO2 Lasers
149
depth of injury, usually adequate hemostasis, immediate gratification of having the wart removed, and good “cure” rates. Technique: If a wart is very exophytic, I use higher PDs of 15 –20 W and a 2 mm spot size first, to vaporize the wart to a slightly raised level. The goal is to move quickly so as to minimize char. Residual debris is wiped away with moist gauze. At this point, a curet is use to separate the denatured tissue from the dermis. If the heating plane at the dermal – epidermal (DE) junction is sufficient, the wart will separate without much difficulty and the underlying dermal base will be only slightly heated. If one undertreats, the unheated remaining epidermis will still be attached to and interdigitated with the underlying dermis. Another pass will then need to be made, as attempting to forcibly separate the wart with the curet will result in unnecessary bleeding. Once the denatured wart is separated, the base should be heated gently with a lower power of 3– 5 W. Also, a rim 2 –5 mm from the clinically obvious wart should be heated. The underlying dermis can be identified by the appearance of skin lines or the observation of slight tissue shrinkage. CO2 laser treatment is often complicated by previous aggressive CO2 laser or liquid nitrogen therapy, and foci of wart can be intermixed with scar. Normally this requires that the entire previous treatment area be vaporized away. Otherwise, the recurrence rate will approach 100%. Periungal warts (Fig. 5.7) must be removed down to the level of the sulcus of the lateral nail fold (130 – 132). This requires that the physician be fairly aggressive in curettage. It is easy to stop the treatment too soon, mistaking the “hard” wart tissue in the nailfold for normal dermis. When the warty tissue has been completely removed the surface should be smooth and resist further curettage. One caveat: One should be careful not to continue to heat the remaining dermis in the nailfold, as often it is only hundreds of micrometers thick. Occasionally, one will expose focal fatty globules, which is an indication of too deep treatment. Bleeding can be a problem in wart treatment with the CW laser, particularly in the periungal area. We have found that use of a tourniquet greatly aids in hemostasis. For lesions where a tourniquet is not possible, pressure at the periphery of the lesion will usually slow down the bleeding enough so that a defocused beam can be applied to achieve hemostasis. Ashinoff et al. (133) found human papillomavirus (HPV) in 60% of SCC in the periungal region, therefore if the lesion in the nailfold is longstanding, a biopsy is warranted in adults. The literature contains many reports of CO2 laser treated verrucae. In a study by Street et al. (134) of recalcitrant periungal lesions, there was a 71% cure rate after 1 year, where the cure end point was the return of dermatoglyphic skin lines. Overall, long-term remission rates in CO2 laser wart treatment are difficult to assess; studies
Figure 5.7 (a) Preop view of a wart on the little toe. (b) 12 Weeks postop, note excellent result. Wart is still clinically resolved 1 year later.
150
Ross
have suggested 5-year cure rates of 50 – 80% (130,131,135 – 137). Patient satisfaction with CO2 laser treatment is good; Sloan et al. (138) found in a retrospective evaluation of resistant warts that 71% of patients would have the treatment again, with the major adverse effect being pain. If common verrucae are in a cosmetically compromising position, one can use interferon to complement the destructive effect of the laser (139). 6.1.4.
Condyloma Acuminata
The CO2 laser has been used extensively in the treatment of condylomata. Although the laser is effective in the removal of the clinical lesions, viral particles can be recovered after laser treatment in peripheral skin. The literature reports cure rates ranging from 31% to 95% (140 – 145), with higher recurrence rates with 16/18 vs. 6/11 HPV subtypes. Lassus et al. (146) reported good clinical clearing at 24 months of 50% of resistant condylomata in 38 males after three treatments (3– 5 W CW, 2 mm spot). However, only 26% of patients showed elimination of the HPV genome. They concluded that although CO2 laser is ineffective in eradicating the HPV genome from therapy-resistant penile warts, the treatment reduces the recurrence of atypical changes and visible warts. Ferenzcy et al. (147) found HPV as far away as 1.5 cm from the clinical lesion. Duus et al. (148) found higher rates of recurrence after CO2 laser vs. electrocautery in vulvar condylomata. Recently, it was reported (149) that in condylomata treated by CO2 laser, there was no change in T-cell subsets, that is, the ratio of suppressor to helper cells was not changed by clinical elimination of the wart by CO2 laser. The CO2 laser has been especially helpful in pediatric patients under general anesthesia. Johnson et al. (150) examined 17 children with condylomata in a retrospective analysis and found 4/17 with early recurrences (within 3 months) using RSP mode at 3 – 5 W and 2 mm spot. After retreatment of the four recurrences, only one recurred. Davis and Noble (151) treated multiple condylomata with CW CO2 laser and found that the recurrence rate was 9/20 with laser alone and only 3/14 with laser plus sublesional interferon alpha 2 beta. Technique: For multiple very small lesions, acetowhitening is performed just prior to the procedure. Next, the area is anesthetized with lidocaine. We use the laser in CW mode with powers from 3 to 8 W, using lower powers for smaller lesions (2 –3 mm papules) and higher powers for more extensive exophytic lesions. The gross raised portion of the lesion is vaporized using a defocused spot of 1 –3 mm. The beam is brushed over the wart until whitening occurs. Wiping with wet gauze should allow easy separation of the wart from the underlying dermis. Using magnification loupes, any residual wart can be vaporized, and the surface is rewiped; this series is repeated until slight shrinking of the surface is observed. Finally, a 5 –10 mm rim of clinically normal tissue is grayed with a low-power brushing technique. Some caveats: Bleeding can be a problem in the treatment of some larger lesions, especially in the perianal region. Stretching the skin surface during lasing will decrease the risk of bleeding. Gentle vs. vigorous wiping also tends to reduce the likelihood of disrupting the vessel walls. Finally, for some smaller lesions, with skill one can use one pass to eliminate the lesion, leaving the browned dome intact without wiping. This technique increases the recurrence rate, as a portion of the deeper wart might persist, but the cosmetic result is enhanced, particularly in pediatric patients, where making a second pass tends to result in scarring. 6.1.5. Nail Matrixectomy Like phenol and electrosurgical ablation, the CO2 laser can be used to eliminate the nail matrix conditions such as chronic ingrown nails (152).
Continuous Wave and Pulsed CO2 Lasers
151
Technique: The portion of the ingrown nail is removed with a nail splitter and hemostat, and the matrix visualized. Next the proximal nailfold skin is retracted and the laser is used in 0.5 s gated pulses in the 3 –5 W CW mode with a 1 mm spot. The area is allowed to heal by secondary intention. Complete ablation of the matrix sometime requires additional treatments. 6.1.6. Earlobe Keloids Earlobe keloids are particularly well suited to treatment with the CO2 laser. As long as most of the keloid is vaporized and care is taken in the postoperative period, we have found a low rate of recurrence and a high degree of patient satisfaction. We generally use the 3 mm handpiece with the UltraPulse laser with maximum pulse energy and a high repetition rate of 20 –40 Hz. We vaporize the lesion down to a point where one feels and sees very little keloid at the base. This requires many passes, so many that we do not count how many times we have treated one area but rather continue to vaporize until the area is contoured to a good end point. We generally use our thumb to push the keloidal tissue toward the laser handpiece. After many passes, one will begin to feel mild heating on the finger as the keloidal tissue is vaporized. The pulsed mode allows for relatively char-free tissue removal. However, because we do not try to avoid pulse stacking, the thermal damage is probably hundreds of micrometers deep rather than the 60 – 100 mm after traditional CO2 LSR for nonexophytic lesions. One can easily see the coarse collagen fibers in the keloid as the lesion is vaporized away. Remarkably, even though a substantial amount of tissue may be removed, we have not encountered any major loss of contour of the lower earlobe. Also, except for some mild hypopigmentation at the center of the laser site, the lesions tend to repigment after several months. In one patient we treated one keloid with the CO2 laser and the other with standard excisional surgery by shelling out the keloid and using the overlying skin as a graft and found the results to be as good or better on the laser treated side, with the laser treatment taking about a quarter of the time. For dumbell keloids, we generally ablate from both sides, leaving only a big-sized keloid remnant at the center. Conejo-Mir et al. (153) have reported that CO2 laser ablation plus interferon alpha 2 beta has resulted in better clearing than CO2 laser alone. Perilesional and sublesional interferon injections were performed three times a week for 3 weeks. As expected, earlobe keloids responded better than other sites. Stern and Lucente (154) found no difference in recurrence rates after CO2 vs. scalpel excision of earlobe keloids. Kantor et al. (155) excised 16 keloids, many of the “dumbell” type, on the ear with CO2 laser and found no recurrence after 6 months. They used a focused beam (0.1 – 0.2 mm) and closed the lesion anteriorly if the excision resulted in a through and through lesion. Although there were four early hypertrophic scars, these resolved with one to two IL injections of 40 mg/mL Triamcinolone acetonide. Recently imiquimod cream has been advocated postoperative after keloid excision vaporization. 6.1.7.
Larger Keloids and Nonearlobe Keloids
The literature shows considerable variability in the success of the CO2 laser in the treatment of keloids. Different investigators have used various techniques and postoperative interventions, so that advice based on sound prospective studies is generally lacking. Also, keloids have been removed both by laser excision and laser vaporization, and with and without primary closure in the case of laser excision. Despite all of these variables, some useful information can be summarized. Overall, studies have shown
152
Ross
that the CO2 laser probably offers little advantage over excisional surgery of keloids (156 –161), but in some cases the CO2 laser might represent the best option. Like most other laser surgeons, we have found that keloids in scalp and beard areas almost always recur if the lesions are merely vaporized to the level of the dermis. Stucker and Shaw (156) examined 37 patients with keloids that were excised with a 1 mm spot and 10 W. For nonearlobe keloids they found that with second-intention healing, 25/31 lesions recurred, usually at the edge of the wound, within 3– 4 weeks of treatment. They showed that aggressive early IL corticosteroid injections seemed to determine the final outcome more than the laser’s use as the excision modality. Lim and Tan (162) studied CO2 laser use for keloids and found that deltoid keloids allowed to granulate did no better with laser than after scalpel excision. Norris (159) followed 23 patients after laser excision of nonfacial keloids and likewise found a 100% recurrence rate after secondintention healing. He used 8– 14 W and a 0.75 mm spot and concluded that laser was no better than scalpel for recurrence. We have also treated some larger keloids with the CO2 laser, combining vaporization and excision with variable success. Typically, we have found that the keloids on the chest return, and have performed test sites on any patient where this treatment is entertained. In one patient, we removed several large keloids with postoperative radiation therapy (XRT), and after 1 year the keloid had not returned. One recently published study supports the use of the CO2 laser in some keloids. This is based on CO2 laser irradiation of cell cultures from normal and keloidal tissue (163). In this study, CO2 laser treatment was associated with higher levels of beta fibroblast growth factor (b-FGF) than untreated keloid controls. Because higher levels of b-FGF tend to inhibit excess collagen secretion, the authors felt that superpulsed CO2 laser exposure might be beneficial in the treatment of keloids. More recently, the same group has reported that in chest keloids, the laser tends to cause decreased b-FGF levels vs. untreated keloid controls whereas facial keloids showed the opposite pattern, suggesting that the lower b-FGF level might be responsible for the high rate of scar recurrence after CO2 laser treatment in the chest area (164). 6.2.
Acne Keloidalis Nuchae
We have treated the small papules of acne keloidalis nuchae with the CO2 laser, but have found that the recurrence rate is high unless the lesions are vaporized to the cutaneous fat and the hair follicles are destroyed. Unfortunately, at this level, blood vessels may be encountered that are larger than 0.5 mm and the lesions often bleed profusely, requiring electrosurgical coagulation. For larger plaques of acne keloidalis nuchae, we have used the CO2 laser as an excisional tool and found that bleeding was much better controlled by using a blended electrosurgical cutting device. Kantor et al. (165) treated eight patients with the CO2 laser and found that as long as the lesions were excised to the level of the fat, there were no recurrences. Lesions were allowed to heal by secondary intention. The primary advantage of the use of CO2 laser in acne keloidalis nuchae is hemostasis vs. cold steel. Related to the use for acne keloidalis nuchae, the CO2 laser has also been used to excise areas of dissecting cellulitis of the scalp, after which the wounds were allowed to heal by secondary intention (166). 6.2.1.
Pyogenic Granuloma
Pyogenic granulomas (PGs) (68,167 –169) respond well to CO2 laser vaporization, provided that the level of destruction is adequate (Fig. 5.8). The author has treated many PGs that have recurred after electrodesiccation and curettage (ED&C) and cryotherapy.
Continuous Wave and Pulsed CO2 Lasers
153
Figure 5.8 (a) Pyogenic granuloma preop, lesion had failed two ED&C attempts and one CO2 laser attempt. (b) Note depth of vaporization with CW CO2 laser, 1 – 3 mm spot, 5– 8 W. (c) Six months postop there is no recurrence and there is excellent restoration of the distal digit contour.
In most cases, the lesions have responded to CO2 laser in CW mode after only one treatment (Fig. 5.8). There have been reports of satellite lesion formation after treatment of PG, but only one case after CO2 laser treatment, and this occurred after laser excision, not vaporization (169). Technique: After injectable anesthesia, the lesion is vaporized with 3 –5 W power and a 2– 4 mm spot. Once the lesion is grossly flush with the surrounding skin, the denatured friable surface is curetted. Normally, this reveals a central feeder vessel surrounded by dermis or fibro-fatty tissue. At this point the vessel is vaporized using a more focused spot that is just large enough to accommodate the diameter of the vessel and the surrounding tissue is lightly grayed with a defocused beam. The key to effective one-time treatment is the depth of destruction. Patients who have been referred after treatment failure have invariably noted that the initial treatment had been more superficial. 6.2.2.
Actinic Cheilitis
Until recently the CW mode was used almost exclusively for widespread actinic cheilitis. Powers from 3 to 8 W using defocused 2– 4 mm beams were typically employed (18,157,170 – 178). The end point after the first pass in CW mode is white bubbling of the surface (opalescence). Higher powers will result in charring unless the handpiece is moved very quickly. This is wiped away with saline-soaked gauze. In mildly damaged areas, a bright pink papillary dermis is exposed. However, in areas where there is severe actinic damage, one sees a yellow-gray surface. Normally, an additional pass is performed in this area with a very low power of about 2 W for 0.5– 1 s. The importance of moving the handpiece in a rapid brushing manner cannot be overstated. When using the CW mode, the hand becomes a scanner, limiting the dwell time in a somewhat primitive manner, but one that becomes increasingly precise and reliable with practice.
154
Ross
Recently, Dufresne and Curlin (175) reviewed 140 patients in seven studies. They found 15 cases of scarring and an average of 21 days for healing. They found that there was a low failure rate and better results than with trichloroacetic acid peel. Clearly, there is much variability in the literature results, presumably at least partly due to variability in technique. Sexton (179) reported correctly that since actinic cheilitis is an epidermal lesion, the injury should be limited to this top layer of skin. Johnson et al. (180) used histology to correlate clinical and microscopic findings after laser treatment and found that there were three depth categories which could be matched to wound color. Superficial to deep, these colors were pink, white/gray, and white coarse. The authors advised remaining in the two most superficial planes. We have encountered the same planes. However, one can see various surface colors after even a first uniform “light” pass of the laser. It follows that the pretreatment variability in the depth of solar damage also determines the spectrum of surface colors. Accordingly, we suggest the whiter areas are those focal areas with the greatest clinical damage prior to treatment. Moreover, we suggest the lack of surface pinkness is not only due to deeper treatment, but also due to pre-existing fibrosis in these areas, as well as increased acanthosis and interdigitations between the lesion and the underlying dermis. Zelickson and Roegnik (171) treated 43 patients and found good results after one laser pass (3–5 W, CW, 2 mm spot). He encountered three small postoperative scars that resolved after treatment with IL triamcinolone acetonide. Robinson (172) found in a prospective study that the CO2 laser was a better choice than 5-fluorouracil or 50% trichloroacetic acid, with decreased recurrence rates vs. those modalities after 4 years. David (176) treated eight patients and found good results with a rapid laser sweep with 15 W and 3 mm spot. He wiped after one pass and then stopped unless there were persistent white areas. Fitzpatrick et al. (18) reported 35 patients treated with either RSP mode or CW mode. They found that if the length of the envelope of superpulses or the length of a mechanically shuttered CW “pulse” was limited to ,50 ms, there was no difference in outcomes between these two regimes. They also found that both CW and continuous SP modes resulted in the same incidence of side effects. Their conclusion was that the repetition rate of the RSP mode (250 Hz) was so high that there was insufficient time for interpulse cooling. More recently, we have used the UltraPulse laser in pulsed mode for actinic cheilitis. We do not feel the technique is necessarily better than our older CW technique, only more reproducible and safer. On the first pass, we use the 3 mm Tru-spot handpiece and a pulse energy of 350– 400 mJ. After wiping with wet gauze the epidermis is removed, after which a second pass is made with the pulse energy reduced to 250 mJ. Additional passes are made to areas with severe photodamage (Fig. 5.9). These areas are identified by a whitened surface. We have noted that H2O2 is useful in wiping after the first pass, as its application helps to identify residual epidermal fragments. In retrospect, we suspect that some of our early recurrences were due to incomplete removal of focal thickened epidermis when using saline-soaked gauze. With saline, the residual epidermis is more difficult to distinguish from the sometimes fibrotic dermis. The H2O2 causes the epidermis to whiten dramatically, and with gentle use of a curette, the epidermis can be separated from the dermis. 6.2.3.
Sebaceous Hyperplasia
This is one of the more rewarding lesions to treat. The 1 mm handpiece is used with the UltraPulse laser, and the distance between the skin and handpiece tip is varied to accommodate the size of the lesion, which is usually about 1 – 2 mm. A pulse energy of 200 mJ is used, and a few overlapping passes are made to expose the yellow fatty nodules. Once exposed, these punctate 0.5 mm lobules are treated with additional
Continuous Wave and Pulsed CO2 Lasers
155
Figure 5.9 (a) Preop view of 40-year-old white female (WF) with actinic cheilitis. (b) Immediately after treatment with two UltraPulse laser passes at 350 mJ with 3 m spot. (c) Appearance 4 weeks after treatment; note smooth surface.
pulses until they are either extruded are heated. The final result is a slight dell that resolves uneventfully in 1– 3 months. 6.2.4.
Epidermal Nevi
Although the histology suggests an epidermal lesion, there are abnormalities of the dermis that result in rapid recurrence if only the epidermis is removed. We have used electrodesiccation, dermabrasion, and the erbium:YAG laser, and have found that the CO2 laser and erbium:YAG lasers result in the best combination of excellent cosmesis and long remission. We use the UltraPulse laser in the initial pass, usually with the 3 mm handpiece and a pulse energy of 450 – 500 mJ. This results in epidermal ablation at the center of the spot, and after carefully heating the epidermis, the denatured epithelium can be wiped away. With magnifying loupes, the remaining areas of altered dermis can then be visualized. Usually, one can see fine papillomatosis where the epidermal nevus remains. At this point, we change to the 1 mm handpiece and ablate the remaining areas with pulse energies ranging from 150 to 250 mJ. The handpiece can be focused or defocused to either heat or ablate. As the handpiece is moved closer to the lesion, one increases the fluence and a louder pop is heard. After a few passes, the papillomatosis disappears and the area is smooth. We do not try to achieve complete removal of this surface finding, but rather “yellow” it slightly with the CO2 laser. The RTD is usually sufficient to obtain long-term remissions without significant scaring or pigmentation changes. In a recent study Cohen et al. (181) compared the CW CO2 laser and UltraPulse and found no significant differences in the two with respect to cosmesis or side effects. Losee et al. (182) used the FeatherTouch mode (120 W with 200 mm handpiece) to remove a large epidermal nevus. Hohenleutner and Landthaler (183) treated a large epidermal
156
Ross
nevus with 20– 25 W CW and a 2 – 3 mm spot with a good result. They used yellowing of the dermis and loss of papillations as an end point. Ratz et al. (184) treated 15 patients with epidermal nevi with 15 –20 W and a 2 mm spot and noted scarring on the torso. They subsequently decreased the power to 5 W and noted better results. 6.2.5.
Syringoma
Syringomas are another adnexal tumor that can be easily treated with the CO2 laser (Fig. 5.10). We have used both the CW mode at a low power of 1– 3 W, with 0.1 s mechanically shuttered “pulses,” as well as the UltraPulse mode with the 1 mm handpiece. We have found that the UltraPulse mode is more elegant in that one can ablate the lesions by 100– 200 mm increments. Our typical end point is removing about half to two-thirds of the whitish lesion. This results in a small dell in the skin that heals with minimal hypopigmentation and scarring. Dark-skinned patients should be warned that there will usually be some hyperpigmentation starting about 3 weeks after the procedure. This usually resolves within 2 –3 months with or without bleaching creams. We normally do a test site with one or two lesions prior to treating an entire area (185). Wang and Roenigk (186) treated multiple syringomas with the SilkTouch (5 W, 125 mm handpiece) laser with one to three passes with good results. Wheeland et al. (187) treated 25 patients using 5 W and 2 mm defocused mode. They used 0.1 s gated bursts for each lesion. Two to three passes were required to remove the glistening white tumor. Healing was complete within 7– 10 days. 6.2.6.
Xanthelasma
Xanthelasma has been treated with both the CW mode as well as the pulsed CO2 laser. Apfelberg et al. treated six patients with the superpulsed CO2 laser (188). They used magnification loupes and 10 W average power and focused the beam in the initial pass, followed by a defocused beam and curettage to remove any remaining yellow material. Alster and West (189) have reported treatment with the UltraPulse laser, and we have treated seven patients in the past 4 years with both erbium:YAG and pulsed CO2 lasers. Our approach is to use the 1 mm handpiece with the UltraPulse and defocus the beam in the initial pass to denature the epidermis, followed by a more focused beam to pick out the remaining yellow material. Typically, even when some material remains grossly, the subsequent fibrosis masks the yellow color well; furthermore, treatment to remove all of the pigment increases the risk of pitted scarring (Fig. 5.11).
Figure 5.10 (a) Syringomas preop in 25-year-old white male (WM). (b) Eight weeks after treatment. Some lesions were treated with the UltraPulse laser using 150 – 250 mJ pulses with 1 mm spot. Others were treated with CW CO2 laser at 2 W, 1 mm spot with 0.5– 1 s gated “pulses.”
Continuous Wave and Pulsed CO2 Lasers
157
Figure 5.11 (a) Xanthelasma preop. (b) Just after treatment with the UltraPulse laser at 200 – 350 mJ and 1 – 3 mm spot. Note that some yellow material remains at the end of treatment. (c) After 6 weeks, note good cosmetic result.
7. 7.1.
LESIONS THAT MIGHT BE TREATED EQUALLY WELL WITH OTHER MODALITIES Seborrheic Keratoses
The CO2 laser is a reasonable choice for treatment. We have treated patients with both CW and UltraPulse modes and have found that the pulsed mode results in faster healing and easier identification of end points (Fig. 5.12). The lesion can be vaporized away after many passes of the UltraPulse CO2 laser with 500 mJ and 3 mm spot size. Care should be taken near the base of the lesion so that unnecessary heating and subsequent pigmentation changes and scarring do not occur. Fitzpatrick et al. (17,18) treated seborrheic keratoses in both CW and RSP modes and found only a slight advantage in the RSP mode, once again supporting the concept that rapid overlapping pulses offer little advantage in RTD vs. conventional CW vaporization. 7.2.
Dermatosis Papulosis Nigra
We treat DPN with the 1 mm spot size with the UltraPulse laser. For smaller lesions, usually one 100–150 mJ pulse will desiccate the lesion adequately enough so that it falls off after a few days. Alternatively, the CW mode can be used at 1–2 W for 100–150 ms. 7.3.
Neurofibromas
We have used the UltraPulse laser, 1 –3 mm spots with pulse energies ranging from 200 to 500 mJ, and found that, after exposure of the dermis, the remaining tumor, which has a rubbery consistency, can be manually expelled by gentle pressure around the wound.
158
Ross
Figure 5.12 (a) A Seborrheic keratosis in the right infraorbital area preop. (b) Larger portion was treated with the UltraPulse laser at 400 mJ, 3 mm spot up, and three to five passes. The smaller portion, to the reader’s right, was treated with CW CO2 laser at 5 W and 2 –3 mm spot. (c) Both sites showed good results after 10 weeks.
Following this, additional passes of the laser vaporize the rubbery lesions, and the wounds are allowed to heal by secondary intention. The areas heal with slight hyperpigmentation, which resolves after 6 months. Roenigk and Ratz (190) used the CW CO2 laser with a 2 mm beam and power of 4– 6 W (160 W/cm2), in a similar manner. Becker (191) treated a patient with multiple pedunculated and sessile lesions. He used the cutting 0.2 mm spot to excise the stalks in the pedunculated lesions, and a defocused beam at 35 – 60 W CW while squeezing the rubber nodule outward to remove the sessile lesions. 7.4.
Steatocystomas
We have treated these tumors of the sebaceous glands by first piercing the central portion with the 1 mm spot in the UltraPulse mode, after which gentle pressure can be used to extrude the small wall, which can be vaporized with subsequent passes. The wounds are allowed to heal by second intention. Krahanbuhl et al. (192) treated a single patient in a similar fashion using the CW CO2 (1 mm spot and 5 W, 100 ms gated pulse) with good results. 7.5.
Pearly Penile Papules
We have treated two patients with this variant of angiofibromas. In one patient we used both UltraPulse and CW modes and found that the pulsed mode resulted in more bleeding and just as long a recovery period (193). As the additional thermal damage from CW application using low 1–3 W powers and short 0.25–0.5 s exposures did not result in a clinically relevant scar, we recommend this technique. Magid and Garden (194) also reported two cases treated successfully with CW laser (5 W, 0.1 s burst with a 1–2 mm spot).
Continuous Wave and Pulsed CO2 Lasers
7.6.
159
Basal Cell Carcinoma
Basal cell carcinoma (BCC) has been treated with the CO2 laser and curettage. In early reports the pulsed or CW laser replaced the hyfercater. Because no large studies have been performed, the role of this technique is unclear, particularly since the thermal damage induced by the hyfercater might be one reason for the relatively good success of traditional electrodesiccation and curettage. Superficial BCCs logically should have the best outcome with this technique. Wheeland et al. (195) reported the use of CO2 laser with curettage in the treatment of BCC. In this study, the CW laser was used in 52 patients for superficial lesions. They used powers of 4 – 5 W and 1 – 2 mm spot size that yielded a PD of 160– 510 W/cm2. The technique resulted in light charring at the skin surface, after which removal with H2O2 gauze showed a whitish yellow base. The base was then curetted, and this was repeated with the laser until the wound base was uniformly firm and no friability was observed. They found good overall cosmetic results with a hypertrophic scar rate of only 5% and no recurrence over a mean follow-up of 19 months. More recently, Kilmer and Chozen (196) reported the use of the UltraPulse laser in the treatment of BCCs, excluding those with a known infiltrative or morpheaform pattern. They used 450 mJ pulses with the 3 mm spot after curettage. In some patients, second passes were made. In subsequently excised specimens no tumor was found after laser treatment, and lesions followed clinically also did not show visible recurrence. Humphreys et al. (197) reported their experience with high-energy pulsed CO2 treatment of BCC and Bowen’s disease. They treated 30 tumors and found that BCC responded better than Bowen’s disease, whose full depth was not vaporized in excised specimens. Curettage was not performed in this study. Grobbelaar et al. (198) treated six BCC nevus syndrome patients, with up to 110 lesions treated in one session with the SilkTouch laser. The end point was the absence of punctate bleeding. Multiple passes were made, with wiping between passes. After a mean follow-up of 20 months, no clinical or histologic evidence of recurrence was noted. 7.7.
Bowen’s Disease
We have treated one patient with erythroplasia of Queyrat of the penis with the CO2 laser in UltraPulse mode (300 mJ, 3 mm spot, two passes) with excellent results. The patient had a poor response to Efudex. As with electrodesiccation and curettage, there is no margin control with this technique, so close clinical follow-up is required. Gordon and Robinson (199) recently reported laser vaporization of the finger for Bowen’s disease (3 W CW, 2–3 mm spot) with multiple passes. A postoperative biopsy showed no recurrence. 7.8.
Hidradenitis Suppurativa
Finley and Ratz (200) reported the use of the CW CO2 laser to excise axillary and inguinal lesions in seven patients with a power of 40 W and 0. 2 mm spot. The base of the wounds was lightly coagulated in the defocused mode. Time to healing by second intention ranged from 4 to 11 weeks. Only one recurrence was noted after 10 –27 months of follow-up. 7.9.
Scar Revisions
CO2 lasers have been used to resurface scars, both at the time of the excision (201,202) as well as after traumatic wounds. Like dermabrasion, the de-epithelialization of the scarred region appears to improve the excision line. Alster et al. (203) examined the use of the
160
Ross
UltraPulse CO2 laser alone vs. CO2 plus PDL in hypertrophic scars, and found that the addition of PDL helped in most cases. Grevelink and White (202) performed simultaneous LSR and punch excisions and found that the wounds healed well with minimal scarring. Their conclusion was that there was no need for the traditional 1 – 2 month delay between punch grafts/excisions and facial resurfacing. 7.10.
Chondrodermatitis Nodularis Helicus
Taylor (204) reported 11 patients treated with the CO2 laser in RSP mode. He vaporized the affected nodule and allowed the wounds to heal by secondary intention. He noted no recurrence after 2– 15 months. 7.11.
Lymphangioma Circumscriptum
Haas and Narurkar (205) recently reported the use of the UltraPulse laser where two to three passes were made or treatment was carried out until the point where no visible lymphatic drainage was observed. There was mild hypertrophic scarring but no recurrence in the same area after 2 years. Others have reported success with the CW CO2 laser for this condition (206). Because of the deep nature of the lesions, lesions usually recur regardless of the treatment modality. The author has treated two patients and has followed a patient treated with the CW CO2 laser. The CW treated patient had developed hypertrophic scarring; subsequent treatment with the UltraPulse laser (300 – 500 mJ) with multiple passes resulted in resolution of the majority of the nodules and only mild textural changes at the surface. As expected, at the periphery of the scarred areas and even within the scars, there were recurrences of the translucent nodules. 7.12.
Nevus Sebaceous
These usually broad-based plaques are vaporized with many passes to a level where most of the yellow papules embedded in the lesion are removed. The final result is a smooth pink surface. Healing is by secondary intention. Like epidermal nevi, attempts to ablate the lesion down to the reticular dermis will result in longer remission but also in a greater likelihood of scarring. Where resection is possible, because of the risk of BCC or BCC-like lesions developing in these lesions, excision should be strongly considered. Ashinoff (207) reported treatment of an extensive nevus sebaceous on the midface in a 10-year-old girl with 6 W CW power in the defocused mode in three separate sessions. The intention was to remove only the exophytic portion, as the case would have resulted in extensive scarring after surgery for definitive removal. 7.13.
Hydrocystoma
We have treated these with the UltraPulse laser with good results. Bickley et al. (208) reported a case treated with the CW CO2 laser (5 W, 2 mm spot). 7.14.
Histiocytoma or Xanthoma Disseminatum
Carpo et al. (209) reported treatment with an SP CO2 laser. We have also treated a case with the UltraPulse laser (Fig. 5.13). We used the 3 mm spot and 500 mJ pulse energy for lesions 3 mm in diameter. For smaller lesions, we used the 1 mm spot-size handpiece. This handpiece can be focused or defocused depending on the size of the lesion. Once the epidermis is removed, the yellow base of the lesions is seen. At this point the smaller
Continuous Wave and Pulsed CO2 Lasers
161
Figure 5.13 (a) Preop view of eruptive histiocytomas. (b) Six months after treatment with the UltraPulse laser at 200–350 mJ, 1– 3 mm spot, and multiple passes.
spot is used to ablate the remaining lesion. This will leave a depression if the lesion is completely removed. We have found that leaving about 20% of the lesion at the base results in a very nice cosmetic result without recurrences. 7.15. Hailey – Hailey and Darier’s Disease The author has only used the erbium:YAG laser for Hailey – Hailey disease, and has never treated a patient with the CO2 or erbium laser for Darier’s disease. However, there are reports of treatment with the CW CO2 laser for both of these dyskeratotic processes (210 –213). In one report (212) the CO2 laser was used defocused (2 mm spot, 10 W) to vaporize to a level without apparent disease, usually after two passes. In the case series, there were varying disease-free periods. The authors noted that the papillary dermis probably must be removed for long-term remission. More recently, Kruppa et al. (214) treated two patients with the SilkTouch system with good results (6 W, three passes with 125 mm handpiece). Christian and Moy (210) treated Hailey – Hailey disease with a short-dwelltime CO2 laser and showed that more passes resulted in superior outcomes. Touma et al. (213) used the UltraPulse laser for treatment of active lesions with success, and also found that prophylactic treatment of inactive lesions led to prolonged remissions in the majority of the treated areas. They also reported some mild scarring on the chest. 7.16. Kaposi’s Sarcoma Chun et al. (215) used the SilkTouch laser with 7 W and 6 mm scan size with good results on the penis. Kaplan (55) had reported the use of a CW CO2 laser many years earlier. 7.17. Tattoos The CW CO2 laser has been used to treat tattoos, but offers only slight advantages over other nonselective means of tattoo removal. The author had treated one large cosmetic
162
Ross
tattoo with the CW CO2 laser combined with urea paste, and found long-term erythema and mild textural change, along with incomplete pigment removal. Although sometimes very effective (2,216 –219), as a general rule, because of a 20 – 50% risk of hypertrophic scarring, the CO2 laser cannot be advocated as the treatment of choice, particularly if dedicated shorter-pulsed lasers are available (Q-switched lasers) in the patient’s geographic region. An exception is treating brown- and skin-colored tattoos. Often, these will darken after a test site treatment with a Q-switched laser (paradoxical ink darkening), in which case the CW or pulsed CO2 laser can be used to gently de-epithelialize the skin. The resulting extrusion of ink, particularly if repeated, can result in an excellent final cosmetic result (220). Use of the CO2 laser prior to Q-switched laser has been attempted (221). One study concluded that the disadvantages (textural changes, increased need for anesthesia, and infection) outweighed the modest improvement in tattoo lightening over Q-switched laser treatment alone. 7.18.
Disseminated Superficial Actinic Porokeratosis
We have treated one patient with extensive disseminated superficial actinic porokeratosis (DSAP) on the legs with the UltraPulse (400 mJ, 3 mm spot) with two passes. EMLA alone was used for anesthesia. After 3 months, there was no clinical evidences of recurrence and only mild hypopigmentation at the treatment site. 7.19.
Actinic Keratosis
Like DSAP, the lesions can be treated with an SP laser with multiple passes. Treatment should be aggressive enough so that the final surface is smooth, as we have observed two patients after full-face LSR who developed squamous cellcarcinoma in what appeared to be small actinic keratoses at the time of treatment. The squamous cellcarcinoma occurred within 12 weeks of LSR. 8.
LASER STERILIZATION
Laser wounds have been shown to support bacterial growth after treatment, that is, if implanted with bacteria, they show a higher rate of infection than similar scalpel wounds (222). In contrast, the CO2 laser has also been used to sterilize wounds. In these cases, the wound base is treated in the defocused mode, and this material is then excised by the laser, after which the wound is closed primarily. Wounds deliberately contaminated by Pseudomonas were shown in a rat study to be sterilized more completely than after an iodine scrub (223). Lee et al. (224) treated infected sterniotomy wounds with a CW CO2 laser, excised the eschar, and then closed the wounds with good results. Hinshaw et al. (225) reported the use of the CO2 laser to sterilize purulent wounds. They sterilized the base with a defocused beam, followed by laser excision and primary closure. Irrigation of the wound was an important contributor to the success of the procedure. 9. 9.1.
TECHNIQUE PEARLS CW Vaporization
In review of the CW applications described earlier, it becomes clear that most CO2 laser surgeons somewhat arbitrarily choose the power and pulse duration. Typically, the surgeon repeats the cycle of irradiation and inspection, continuing until almost or no
Continuous Wave and Pulsed CO2 Lasers
163
lesional tissue remains. Fleiming and Brody (226) proposed a more logical approach to the treatment of lesions with the CW CO2 laser. They cited several limitations in the empirical techniques commonly employed in the many publications cited earlier. (1) In many cases, the surgeon’s dependence on visual differentiation of normal from lesional tissue leads to possible overtreatment and scar, or undertreatment and rapid recurrence. (2) This technique is slow, because the cycle is repeated for each lesion. This was cited as a major drawback in a publication comparing electrosection and CW CO2 in the treatment of trichoepitheliomas (227). In Fleming and Brody’s study, they used a constant power in plotting the depth of the resulting crater as a guide in planning treatments. They noted that crater depth depended on fluence for the powers used (5–18 W and 1 mm spot). They found that the application time determined the crater depth for constant power and spot size. Based on their data and our own data with SP lasers, one can calculate an ablation depth of roughly 2500 mm for a fluence of 2000 J/cm2, as long as the irradiance is .1000 W/cm2, for example, a 10 W pulse delivered with a 1 mm spot and application time of 1 s. 9.2.
Cutting
The reader should note that 15 – 25 W will give a cutting depth of 3– 5 mm with a hand movement rate of 1.5 mm/s with a 0.3 mm spot (228). Also, wet gauze should always be used as a backstop so that the beam does not injure unintended targets (229). 10.
LASER SAFETY ISSUES SPECIFIC TO THE CO2 LASER
A primary area of concern is the eye, where the cornea can be injured. In one case, the cornea was damaged during LSR and required corneal transplant to restore vision (230). Eyeshields with the CO2 laser should be metal, as Ries et al. (231) showed that plastic shields will burn with prolonged CW irradiation. In the case of LSR lasers, although nine passes were required for shield perforation, melting of the surface was noted as early as the first pass. Also, Rohrich et al. (232) noted that plastic corneal protectors melted by the third pass and produced significant heat in LSR. Black surfaces have been advocated for laser surgery, but these may deteriorate after many passes. Roughened instruments are most effective but may not always be available. Therefore, protection of the eye should include side shields to prevent corneal injury from a reflection. Wood et al. (233) found that with the exception of silver finish polish, the hazard distances for laser reflections usually extend only to the immediate area of the operative field. The teeth should be covered during resurfacing, as dentin charring and cracking have been reported (234,235). Another area of concern is fire (236). Rohrich et al. (232) noted that dry but not wet gauze produced a flame with UltraPulse and SilkTouch irradiation. Wald et al. (237) found that the UltraPulse did not start a fire in an animal study, even with supplemental 6 L/min O2 close by (at 0.5 cm separation). However, the authors caution the reader that this is only so long as combustion does not occur. Other hazards peculiar to the CO2 laser are related to the plume. There are carcinogenic nitrosamines, and some particles are either too small to be filtered by the upper airway or too large to be removed from the alveoli. These particles can cause pulmonary fibrosis. The particulate matter in the plume has a mean diameter of 0.3 mm (238). Baggish et al. (239) found that rats showed interstitial lung changes after prolonged exposure to a CO2 plume. These changes were reduced with the use of an ultra-low-penetration air filter. Smoke evacuation systems have been reported to protect animals if they can trap particles of 0.3 mm or less (239). The smoke evacuator
164
Ross
should provide at least 40 CFM (cubic feet per minute) suction as the lower limit for efficient collection of debris. The nozzle should be ,1–2 cm from the treatment area (240). It has been shown that the CW laser plume contains viable bacterial spores at low irradiance (,500 W/cm2). Despite studies showing HIV in the laser plume, there appears to a low rate of infection transmission in experimental systems (241). Fader et al. (236) suggested that this is due to a low concentration of viral particles in the plume compared to a normal infective load, the use of adequate filtration and masks, or the fact that it is too early to tell. In Baggish et al.’s study (241), the PD was 500 W/cm2 and they studied DNA capture. This study showed that proviral HIV DNA was present in smoke. There was infection in cultured cells but the infection was not maintained. The study showed that most if not all of the potentially infectious debris was present in the plume. It is unclear whether HIV can be transmitted by inhalation. Garden et al. (242) found intact HPV DNA in the laser plume. Gloster and Roenigk (243) sent out a questionnaire and found that 5% of the respondents believed the plume had infected them. This percentage was not significantly different from the incidence of warts in the population. They did find a significantly higher incidence of nasopharyngeal lesions, which is consistent with the likelihood that inhalation is the primary means of transmission of the virus. They did not find a difference when a smoke evacuator was used, but admitted that the denominator was small for the unprotected group. Overall, they found that CO2 laser surgeons were no more likely to develop hand warts than their non-CO2 laser counterparts. Ideally, one should use a mask designed with a pore size no greater than 0.1 mm.
11.
NEW DEVELOPMENTS
At the time of writing, various strategies were being developed to reduce thermal damage with the CO2 laser, both in resurfacing and in incisional surgery. These strategies have included reducing the pulse duration, changing the repetition rate, employing computer scanners with temperature feedback (244), and using other wavelengths such as 9.6 mm (3). Also of current interest is the dependence of collagen shrinkage on wavelength. Presently, CO2 laser wavelengths have targeted water in the dermis and epidermis. However, using other wavelengths, one can target molecular bonds in the dermis. For example, Ellis et al. (245) found that 7.2 –7.4 mm was better than 10.6 mm in inducing collagen contraction, suggesting that selective protein absorption might provide a better clinical effect than water absorption. They also considered that collagen denaturation and contraction are not necessarily associated, so that collagen denaturation alone is not responsible for collagen shrinkage, or that collagen denaturation might look different with light microscopy at different wavelengths. Investigators are also studying metal templates that surround the incisional field. These devices conduct heat away from the site to reduce lateral thermal damage (246).
12.
PRE- AND POSTOPERATIVE CONSIDERATIONS
12.1. 12.1.1.
Preoperative Considerations Relative Contraindications
The ideal patient for treatment, regardless of disease, is either very dark or very light, as patients tend to return to their constitutive color after CO2 laser surgery. Bronzed patients with Type II and III skin are at high risk for permanent hypopigmentation with increasing depth of injury; this should be discussed with the patient within the context of likelihood
Continuous Wave and Pulsed CO2 Lasers
165
for cosmetic improvement. Whether the hypopigmentation is relative (i.e., lighter than the surrounding tanned untreated skin) or an absolute leukoderma is probably irrelevant, because the end result is similar potential line of demarcation. Any patient with decreased adnexal structures from previous radiation therapy or even laser hair removal or electrolysis should probably receive at least a test site. This advice is controversial for laser hair reduction, as there are no reports of compromised healing in CO2 laser induced areas previously treated with hair reduction lasers. The recommended minimum time interval between isotretinoin treatment and resurfacing (and vice versa) ranges from 6 months to 2 years (247,248). Weinstein found that two out of four cases of severe scarring in a review of 1925 CO2 resurfacing patients had received isotretinoin within 2 years. 12.1.2.
Preoperative Regimen
For adnexal tumors, test sites, and small-scar abrasions, no systemic or topical medications are prescribed. We have found that topical retinoids and bleaching preparations do not appear to alter the postoperative course. 12.1.3.
Postoperative Care
With the exception of excised wounds, in which sutures should be left in 3– 5 days longer than in scalpel wounds, wounds are left to heal by secondary intention and will heal optimally when kept moist and clean. Dressings will speed healing if they are changed (at least every 2 days). We have used Silon TSR (Biomedsciences, Allentown, PA) and Second Skin (SPENCO, Waco, TX), all with good results. The most important postoperative intervention is the use of a truly effective sunscreen. Until recently, we observed an almost 100% incidence of hyperpigmentation in our Hispanic and Asian patients, undoubtedly largely due to the omnipresent sun in southern California. The increase in color typically appears around Days 13 – 19, and has been most severe in areas with slightly deeper ablation (i.e., at the edge of discrete acne scars). While some of this increased color might be due to mechanical rubbing in making second passes with the CO2 laser, we have also routinely encountered this phenomenon after the erbium:YAG laser, where absolutely no wiping with gauze was performed. Most recently, we have observed a dramatic decrease in postinflammatory hyperpigmentation with the use of Total Block Sunscreen (Total Block, Fallene Ltd., King of Prussia, PA). In patients who have used this block, starting just after re-epithelialization is complete, we have noted a significant reduction in hyperpigmentation. More disturbing than the almost always temporary, especially on the face, postinflammatory hyperpigmentation, is the delayed onset of hypopigmentation after the CO2 laser in some cases. Laws et al. (249) examined the histology of a patient after CO2-induced loss of pigment and found that there were a normal number of melanocytes, but that they were simply not making melanin. Stuzin et al. (250) examined CO2 and phenol wounds in human skin and found postoperatively that epidermal melanocytes appeared to function normally in laser treated wounds. In the CO2 laser wounds there was a more regular distribution of melanosomes. In both wound types, there were melanocytes. In the phenol wounds, there simply was no melanin.
13.
CONCLUSIONS
It is interesting that in review of the vast literature of CO2 laser in skin, the laser has not enjoyed even greater popularity in dermatology. Particularly in CW and RSP modes, the laser is a very versatile tool whose uses are only limited by the creativity of the physician.
166
Ross
REFERENCES 1. 2. 3. 4.
5. 6. 7. 8. 9.
10. 11. 12.
13.
14. 15.
16.
17.
18.
19. 20. 21. 22.
Polanyi T. History of the CO2 laser in surgery. In: Andrews A, Polanyi T, eds. Microscopic and Endoscopic Surgery with the CO2 Laser. Boston: John Wright, 1982:1 – 25. McBurney EI. Carbon dioxide laser treatment of dermatologic lesions. South Med J 1978; 71(7):795– 797. Payne BP, Nishioka NS, Mikic BB, Venugopalan V. Comparison of pulsed CO2 laser ablation at 10.6 microm and 9.5 microm. Lasers Surg Med 1998; 23(1):1 – 6. Fisher J. Fundamentals of laser physics, optics, and operating characteristics for the physician. In: Wright V, FIsher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: W.B. Saunders, 1993. Fisher JC. The medical laser: an indispensable tool of the physician and surgeon. Med Instrum 1983; 17(6):398– 400. Duley W. Gas lasers. In: Meyers R, ed. Encyclopedia of Lasers and Optical Technology. San Diego, CA: Academic Press, 1991:139. Hecht J. Understanding Lasers: An Entry Level Guide. New York: IEEE Press, 1994. Katzir A. Lasers and Optical Fibers in Medicine. San Diego, CA: Academic Press, 1993. Fisher J. Qualitative and quantitative tissular effects of light from important surgical lasers: optimal surgical principles. In: Wright V, FIsher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: WB Saunders, 1993:58– 82. Ross EV, McKinlay JR, Anderson RR. Why does carbon dioxide resurfacing work? A review. Arch Dermatol 1999; 135(4):444– 454. Fisher J. Surgical Delivery Systems. In: Wright V, Fisher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: WB Saunders, 1993:23– 41. Hobbs ER, Bailin PL, Wheeland RG, Ratz JL. Superpulsed lasers: minimizing thermal damage with short duration, high irradiance pulses. J Dermatol Surg Oncol 1987; 13(9):955– 964. Fisher J. The Concept, Calculation, and Surgical Importance of Power Density: Significance of Superpulsing. In: Wright V, Fisher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: WB Saunders, 1993:41– 58. Fisher JC. Basic biophysical principles of resurfacing of human skin by means of the carbon dioxide laser. J Clin Laser Med Surg 1996; 14(4):193 – 210. Paulsen J. CO2 lasers thermal changes on laryngeal tissue after different application modes. In: Berlien H, Biamino G, Muller G, Ringelhan H, Schaldach B, eds. Safety and Laser Tissue Interaction. Berlin: SPIE, 1981. Hukki J, Lipasti J, Castren M, Puolakkainen P, Schroder T. Lactate dehydrogenase in laser incisions: a comparative analysis of skin wounds made with steel scalpel, electrocautery, superpulse – continuous wave mode carbon-dioxide lasers, and contact Nd:YAG laser. Lasers Surg Med 1989; 9(6):589– 594. Fitzpatrick RE, Ruiz-Esparza J, Goldman MP. The depth of thermal necrosis using the CO2 laser: a comparison of the superpulsed mode and conventional mode. J Dermatol Surg Oncol 1991; 17(4):340– 344. Fitzpatrick RE, Goldman MP, Ruiz-Esparza J. Clinical advantage of the CO2 laser superpulsed mode. Treatment of verruca vulgaris, seborrheic keratoses, lentigines, and actinic cheilitis. J Dermatol Surg Oncol 1994; 20(7):449 – 456. Reid R. Physical and surgical principles governing expertise with the carbon dioxide laser. Obstet Gynecol Clin North Am 1987; 14(2):513 – 535. Welch AJ, Motamedi M, Rastegar S, LeCarpentier GL, Jansen D. Laser thermal ablation. Photochem Photobiol 1991; 53(6):815– 823. Welch AJ, Gardner CM. Monte Carlo model for determination of the role of heat generation in laser-irradiated tissue. J Biomech Eng 1997; 119(4):489– 495. Walsh JT Jr, Deutsch TF. Pulsed CO2 laser tissue ablation: measurement of the ablation rate. Lasers Surg Med 1988; 8(3):264– 275.
Continuous Wave and Pulsed CO2 Lasers 23. 24. 25. 26.
27.
28. 29. 30.
31. 32. 33. 34. 35.
36. 37.
38.
39. 40.
41. 42. 43. 44. 45.
46.
167
McKenzie AL. How far does thermal damage extend beneath the surface of CO2 laser incisions? Phys Med Biol 1983; 28(8):905– 912. McKenzie AL. A three-zone model of soft-tissue damage by a CO2 laser. Phys Med Biol 1986; 31(9):967 –983. Venugopalan V, Nishioka NS, Mikic BB. The effect of CO2 laser pulse repetition rate on tissue ablation rate and thermal damage. IEEE Trans Biomed Eng 1991; 38(10):1049– 1052. Venugopalan V, Nishioka NS, Mikic BB. The effect of laser parameters on the zone of thermal injury produced by laser ablation of biological tissue. J Biomech Eng 1994; 116(1):62– 70. Venugopalan V, Nishioka NS, Mikic BB. Thermodynamic response of soft biological tissues to pulsed infrared-laser irradiation. Biophys J 1996; 70(6):2981– 2993 (published erratum appears in Biophys J 1996; 71(6):3530). Walsh JT Jr, Flotte TJ, Anderson RR, Deutsch TF. Pulsed CO2 laser tissue ablation: effect of tissue type and pulse duration on thermal damage. Lasers Surg Med 1988; 8(2):108 – 118. Anderson R. Laser tissue interactions. In: Goldman M, Fitzpatrick R, eds. Cutaneous Laser Surgery. St. Louis, MO: Mosby, 1999:1 – 19. Ross EV, Domankevitz Y, Skrobal M, Anderson RR. Effects of CO2 laser pulse duration in ablation and residual thermal damage: implications for skin resurfacing. Lasers Surg Med 1996; 19(2):123 –129. Fessenden R, Fessenden J. Organic Chemistry. Boston, MA: Willard Grant Press, 1979. Zweig A. A thermo-mechanical model for laser ablation. Appl Phys 1991; 70(3):1684– 1691. Sanders DL, Reinisch L. Wound healing and collagen thermal damage in 7.5-microsec pulsed CO(2) laser skin incisions. Lasers Surg Med 2000; 26(1):22 – 32. Littler C. The micrscopic effect of the nanosecond CO2 laser on ex-vivo human skin (abstract). Lasers Surg Med 1999; 11(suppl):27. Schomacker KT, Walsh JT Jr, Flotte TJ, Deutsch TF. Thermal damage produced by high-irradiance continuous wave CO2 laser cutting of tissue. Lasers Surg Med 1990; 10(1):74– 84. Dobry MM, Padilla RS, Pennino RP, Hunt WC. Carbon dioxide laser vaporization: relationship of scar formation to power density. J Invest Dermatol 1989; 93(1):75 – 77. Ross E, Barnette D, Glatter RD, Grevelink JM. Effects of overlap and pass number in CO2 laser skin resurfacing: a study of residual thermal damage, cell death, and wound healing. Lasers Surg Med 1999; 24(2):103– 112. Brugmans M, Kemper J, Gijsbers GH, van der Meulen FW, van Gemert MJ. Temperature response of biological materials to pulsed non-ablative CO2 laser irradiation. Lasers Surg Med 1991; 11(6):587– 594. Lanzafame RJ, Naim JO, Rogers DW, Hinshaw JR. Comparison of continuous-wave, chop-wave, and super pulse laser wounds. Lasers Surg Med 1988; 8(2):119 – 124. Bellina J, Meandzija M, Schillt V et al. Analysis of electronically pulsed versus quasicontinuous wave carbon dioxide lasers in an animal model. Am J Obstet Gynecol 1984; 150(8):934– 940. Fitzpatrick R. Carbon dioxide laser surgery. In: Goldman M, Fitzpatrick R, eds. Cutaneous Laser Surgery. St. Louis, MO: Mosby, 1999:279 – 337. Kamat BR, Carney JM, Arndt KA, Stern RS, Rosen S. Cutaneous tissue repair following CO2 laser irradiation. J Invest Dermatol 1986; 87(2):268 – 271. Kamat BR, Tang SV, Arndt KA, Stern RS, Noe JM, Rosen S. Low-fluence CO2 laser irradiation: selective epidermal damage to human skin. J Invest Dermatol 1985; 85(3):274–278. Green HA, Domankevitz Y, Nishioka NS. Pulsed carbon dioxide laser ablation of burned skin: in vitro and in vivo analysis. Lasers Surg Med 1990; 10(5):476 – 484. Green HA, Burd E, Nishioka NS, Bruggemann U, Compton CC. Middermal wound healing. A comparison between dermatomal excision and pulsed carbon dioxide laser ablation. Arch Dermatol 1992; 128(5):639 –645. Choi B, Barton JK, Chan EK, Welch AJ. Imaging of the irradiation of skin with a clinical CO2 laser system: implications for laser skin resurfacing. Lasers Surg Med 1998; 23(4):185 – 193.
168
Ross
47.
Verdaasdonk RM, Borst C, van Gemert MJ. Explosive onset of continuous wave laser tissue ablation. Phys Med Biol 1990; 35(8):1129– 1144. LeCarpentier GL, Motamedi M, McMath LP, Rastegar S, Welch AJ. Continuous wave laser ablation of tissue: analysis of thermal and mechanical events. IEEE Trans Biomed Eng 1993; 40(2):188– 200. Ross EV, Mowlavi A, Barnette D, Glatter RD, Grevelink JM. The effect of wiping on skin resurfacing in a pig model using a high energy pulsed CO2 laser system. Dermatol Surg 1999; 25(2):81– 88. Ross EV, Naseef GS, McKinlay JR et al. Comparison of carbon dioxide laser, erbium:YAG laser, dermabrasion, and dermatome: a study of thermal damage, wound contraction, and wound healing in a live pig model: implications for skin resurfacing. J Am Acad Dermatol 2000; 42(1, Pt 1):92 – 105. Kauvar AN, Waldorf HA, Geronemus RG. A histopathological comparison of “char-free” carbon dioxide lasers. Dermatol Surg 1996; 22(4):343 – 348. Cotton J, Hood AF, Gonin R, Beesen WH, Hanke CW. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulse carbon dioxide laser. Arch Dermatol 1996; 132(4):425 –428. Walsh JT Jr, Deutsch TF. Pulsed CO2 laser ablation of tissue: effect of mechanical properties. IEEE Trans Biomed Eng 1989; 36(12):1195– 1201. Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG. Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 1999; 25(9):729– 732. Kaplan I, Ger R, Sharon U. The carbon dioxide laser in plastic surgery. Br J Plast Surg 1973; 26(4):359– 362. Bailin PL. Lasers in dermatology—1983. Cleve Clin Q 1983; 50(2):53 – 55. Kirschner RA. Cutaneous plastic surgery with the CO2 laser. Surg Clin North Am 1984; 64(5):871– 883. Dover J, Arndt K, Geronemus R, Olbricht S, Noe J, Stern R. Illustrated Cutaneous Laser Surgery. Norwalk, CT: Appleton Lange, 1990. Herbich G. Epidermal changes limited to the epidermis of guinea pig skin by low-power carbon dioxide laser irradiation. Arch Dermatol 1986; 122(2):132– 133. Kaplan I, Ger R. The carbon dioxide laser in clinical surgery. A preliminary report. Isr J Med Sci 1973; 9(1):79 – 83. Zweig AD, Meierhofer B, Muller OM et al. Lateral thermal damage along pulsed laser incisions. Lasers Surg Med 1990; 10(3):262 –274. Pogrel M, McCracken KJ, Daniels TE. Histologic evaluation of the width of soft tissue necrosis adjacent to carbon dioxide laser incisions. Oral Surg Oral Med Oral Pathol 1990; 70(5):564– 568. Polanyi TG. Laser physics. Otolaryngol Clin North Am 1983; 16(4):753 –774. Hukki J, Lipasti J, Castren M, Puolakkainen P, Schroder T. Lactate dehydrogenase in laser incisions: a comparative analysis of skin wounds made with steel scalpel, electrocautery, superpulse – continuous wave mode carbon-dioxide lasers, and contact Nd:YAG laser. Lasers Surg Med 1989; 9(6):589– 594. Goldbaum AM, Woog JJ. The CO2 laser in oculoplastic surgery. Surv Ophthalmol 1997; 42(3):255– 267. Goldman L. Effects of new laser systems on the skin. Arch Dermatol 1973; 108(3):385– 390. Goldman L. Laser medical instrumentation. Med Instrum 1976; 10(2):125 – 129. Goldman L, Perry E, Stefanovsky D. A flexible sealed tube transverse radio frequency excited carbon dioxide laser for dermatologic surgery. Lasers Surg Med 1983; 2(4):317 – 322. Kaplan I, Ger R. The carbon dioxide laser in clinical surgery. A preliminary report. Isr J Med Sci 1973; 9(1):79 – 83. Kaplan I, Gassner S, Shindel Y. Carbon dioxide laser in head and neck surgery. Am J Surg 1974; 128(4):543 –544. Kaplan I. The CO2 laser in plastic surgery. Lasers Surg Med 1986; 6(4):385 – 386.
48.
49.
50.
51. 52.
53. 54.
55. 56. 57. 58. 59. 60. 61. 62.
63. 64.
65. 66. 67. 68. 69. 70. 71.
Continuous Wave and Pulsed CO2 Lasers 72. 73. 74. 75.
76. 77.
78. 79.
80.
81. 82. 83.
84.
85.
86. 87.
88. 89.
90. 91. 92.
93.
169
Kaplan I SATEB-BM. The CO2 laser in pediatric surgery. J Pediatr Surg 1984; 19(3):248– 257. Mullins F, Jennings B, McClusky L. Liver resection with the continuous wave carbon dioxide laser: some experimental observations. Am Surg 1968; 34(10):717– 722. Ascher P, Ingolitsch E, Walter G et al. eds. Ultrastructural Findings in CNS Tissue with CO2 Laser. Jerusalem: Jersalem Academic Press, 1978. Alster TS, Nanni CA, Williams CM. Comparison of four carbon dioxide resurfacing lasers. A clinical and histopathologic evaluation. Dermatol Surg 1999; 25(3):153 – 158, discussion 159. Bernstein E, Brown DB, Kenkel J, Burns A. Residual thermal damage resulting from pulsed and scanned resurfacing lasers. Dermatol Surg 1999; 25(10):739– 744. Ross EV, Grossman MC, Duke D, Grevelink JM. Long-term results after CO2 laser skin resurfacing: a comparison of scanned and pulsed systems. J Am Acad Dermatol 1997; 37(5, Pt 1):709 –718. Kauvar AN, Geronemus RG. Histology of laser resurfacing. Dermatol Clin 1997; 15(3):459– 467. Duke D, Khatri K, Grevelink JM, Anderson RR. Comparative clinical trial of 2 carbon dioxide resurfacing lasers with varying pulse durations. 100 microseconds vs 1 millisecond. Arch Dermatol 1998; 134(10):1240– 1246. Moy RL, Bucalo B, Lee MH et al. Skin resurfacing of facial rhytides and scars with the 90-microsecond short pulse CO2 laser. Comparison to the 900-microsecond dwell time CO2 lasers and clinical experience. Dermatol Surg 1998; 24(12):1390– 1396. Alster TS. Comparison of two high-energy, pulsed carbon dioxide lasers in the treatment of periorbital rhytides. Dermatol Surg 1996; 22(6):541 – 545. Alster TS, Kauvar AN, Geronemus RG. Histology of high-energy pulsed CO2 laser resurfacing. Semin Cutan Med Surg 1996; 15(3):189– 193. Apfelberg DB. The ultrapulse carbon dioxide laser with computer pattern generator automatic scanner for facial cosmetic surgery and resurfacing. Ann Plast Surg 1996; 36(5):522– 529. Bisaccia E, Sequeira M, Magidson J, Scarborough D. Surgical intervention for the aging face. Combination of mini-face-lifting and superficial carbon dioxide laser resurfacing. Dermatol Surg 1998; 24(8):821– 826. Fitzpatrick RE, Smith SR, Sriprachya-anunt S. Depth of vaporization and the effect of pulse stacking with a high-energy, pulsed carbon dioxide laser. J Am Acad Dermatol 1999; 40(4):615– 622. Fulton JE, Shitabata PK. CO2 laser physics and tissue interactions in skin. Lasers Surg Med 1999; 24(2):113 –121. Lowe NJ, Lask G, Griffin ME, Maxwell A, Lowe P, Quilada F. Skin resurfacing with the Ultrapulse carbon dioxide laser. Observations on 100 patients. Dermatol Surg 1995; 21(12):1025– 1029. Rosenberg GJ. Full face and neck laser skin resurfacing. Plast Reconstr Surg 1997; 100(7):1846– 1854. Ruiz-Esparza J, Barba Gomez JM, Gomez de la Torre OL, Huerta Franco B, Parga Vazquez EG. UltraPulse laser skin resurfacing in Hispanic patients. A prospective study of 36 individuals. Dermatol Surg 1998; 24(1):59– 62. Ruiz-Esparza J. A pictorial diary of complete healing in 6 days after UltraPulse laser skin resurfacing. Dermatol Surg 1998; 24(1):15 – 17. Seckel BR, Younai S, Wang KK. Skin tightening effects of the ultrapulse CO2 laser. Plast Reconstr Surg 1998; 102(3):872– 877. Shakespeare PG, Dewar AE, Carruth JA. Re: UltraPulse carbon dioxide laser with computer pattern generator for facial cosmetic surgery and resurfacing. Ann Plast Surg 1997; 38(5):547– 550. Trelles MA, David LM, Rigau J. Penetration depth of Ultrapulse carbon dioxide laser in human skin. Dermatol Surg 1996; 22(10):863– 865.
170
Ross
94.
Trelles MA, Rigau J, Mellor TK, Garcia L. A clinical and histological comparison of flashscanning versus pulsed technology in carbon dioxide laser facial skin resurfacing. Dermatol Surg 1998; 24(1):43– 49. Yang CC, Chai CY. Animal study of skin resurfacing using the ultrapulse carbon dioxide laser. Ann Plast Surg 1995; 35(2):154 –158. Carniol P. Laser resurfacing technique: feathertouch, SilkTouch, and SureTouch resurfacing lasers. In: Carniol P, ed. Laser Skin Rejuvenation. Philadelphia, PA: Lippincott-Raven, 1998:115 – 123. Koch RJ. Initial clinical evaluation of the NovaScan carbon dioxide laser handpiece. Dermatol Surg 1998; 24(3):369 –371. Hausfeld J. Laser Resurfacing Technique: Luxar. In: Carniol P, ed. Laser Skin Rejuvenation. Philadelphia, PA: Lippincott-Raven, 1998:123 – 135. Gannot I, Dror J, Calderon S, Kaplan I, Croitorn N. Flexible waveguides for IR laser radiation and surgery applications. Lasers Surg Med 1994; 14(2):184 – 189. Cossmann P, Romano V, Sporri S et al. Plastic hollow waveguides: properties and possibilities as a flexible radiation delivery system for CO2-laser radiation. Lasers Surg Med 1995; 16(1):66– 75. Bucalo BD, Moy RL. Quantitative comparison of inflammatory infiltrate and linear contraction in human skin treated with 90-microsecond pulsed and 900-microsecond dwell time carbon dioxide lasers. Dermatol Surg 1998; 24(12):1314– 1316. Smith KJ, Skelton HG, Graham JS, Hamilton TA, Hackley BE Jr, Hurst CG. Depth of morphologic skin damage and viability after one, two, and three passes of a high-energy, shortpulse CO2 laser (Tru-Pulse) in pig skin. J Am Acad Dermatol 1997; 37(2, Pt 1):204– 210. Bucalo B, Moy R. Laser resurfacing technique: TruPulse laser. In: Carniol P, ed. Laser Skin Rejuvenation. Philadelphia, PA: Lippincott-Raven, 1998:153– 161. Hall RR, Hill DW, Beach AD. A carbon dioxide surgical laser. Ann R Coll Surg Engl 1971; 48(3):181– 188. Hall RR. The healing of tissues incised by a carbon-dioxide laser. Br J Surg 1971; 58(3):222– 225. Lunkenheimer P, Druen B, Sowislo W, Weritz D, Freytag G, Dittrich H. Wound healing after scalpel, laser, and thermocautery surgery. In: Kaplan I, ed. 2nd International Symposium on Laser Surgery. Dallas, TX: Jerusalem Academy Press, 1977. Cochrane JP, Beacon JP, Creasey GH, Russell RC. Wound healing after laser surgery: an experimental study. Br J Surg 1980; 67(10):740– 743. Hambley R, Hebda PA, Abell E, Cohen BA, Jegasothy BV. Wound healing of skin incisions produced by ultrasonically vibrating knife, scalpel, electrosurgery, and carbon dioxide laser. J Dermatol Surg Oncol 1988; 14(11):1213– 1217. Jarmuske MB, Stranc MF, Stranc LC. The effect of carbon dioxide laser on wound contraction and epithelial regeneration in rabbits. Br J Plast Surg 1990; 43(1):40 – 46. Middleton WG, Tees DA, Ostrowski M. Comparative gross and histological effects of the CO2 laser, Nd-YAG laser, scalpel, Shaw scalpel and cutting cautery on skin in rats. J Otolaryngol 1993; 22(3):167– 170. Molgat YM, Pollack SV, Hurwitz JJ et al. Comparative study of wound healing in porcine skin with CO2 laser and other surgical modalities: preliminary findings. Int J Dermatol 1995; 34(1):42– 47. Nemeth AJ. Lasers and wound healing. Dermatol Clin 1993; 11(4):783 – 789. Pogrel MA, Yen CK, Hansen LS. A comparison of carbon dioxide laser, liquid nitrogen cryosurgery, and scalpel wounds in healing. Oral Surg Oral Med Oral Pathol 1990; 69(3):269– 273. Pogrel MA, Pham HD, Guntenhoner M, Stern R. Profile of hyaluronidase activity distinguishes carbon dioxide laser from scalpel wound healing. Ann Surg 1993; 217(2):196–200. Robinson JK, Garden JM, Taute PM, Leibovich SJ, Lautenschlager EP, Hartz RS. Wound healing in porcine skin following low-output carbon dioxide laser irradiation of the incision. Ann Plast Surg 1987; 18(6):499– 505.
95. 96.
97. 98. 99. 100.
101.
102.
103. 104. 105. 106.
107. 108.
109. 110.
111.
112. 113.
114. 115.
Continuous Wave and Pulsed CO2 Lasers 116. 117.
118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129.
130. 131. 132. 133.
134. 135. 136. 137. 138. 139.
140.
171
Harmon C, Zelickson B, McBurney E, Yarborough J. Ultrastrucural and immunohistochemical comparison of CO2 resurfacing lasers (abstract). Lasers Surg Med 1998; 10(suppl):3. Kirsch KM, Zelickson BD, Zachary CB, Tope WD. Ultrastructure of collagen thermally denatured by microsecond domain pulsed carbon dioxide laser. Arch Dermatol 1998; 134(10):1255 –1259. Collawn SS, Boissy RE, Vasconez LO. Skin ultrastructure after CO2 laser resurfacing. Plast Reconstr Surg 1998; 102(2):509– 515. Wheeland R, Bailin PL, Ratz JL. Combined carbon dioxide laser excision and vaporization in the treatment of rhinophyma. J Dermatol Surg Oncol 1987; 13(2):172 –177. Karim A, Streitmann M. Excision of rhinophyma with the carbon dioxide laser: a ten-year experience. Ann Otol Rhinol Laryngol 1997; 106(11):952– 955. Simo R, Sharma V. Treatment of rhinophyma with carbon dioxide laser. J Laryngol Otol 1996; 110(9):841 –846. el-Azhary RA, Roenigk RK, Wang TD. Spectrum of results after treatment of rhinophyma with the carbon dioxide laser. Mayo Clin Proc 1991; 66(9):899 – 905. Rosenbach A, Alster TS. Multiple trichoepitheliomas successfully treated with a high-energy, pulsed carbon dioxide laser. Dermatol Surg 1997; 23(8):708 – 710. Buecker JW, Estes SA, Zalla JA. Multiple trichoepitheliomas treated with the carbon dioxide laser. J Ky Med Assoc 1986; 84(10):543– 544. Wheeland RG, Bailin PL, Kronberg E. Carbon dioxide (CO2) laser vaporization for the treatment of multiple trichoepithelioma. J Dermatol Surg Oncol 1984; 10(6):470 – 475. Sawchuk WS, Heald PW. CO2 laser treatment of trichoepithelioma with focused and defocused beam. J Dermatol Surg Oncol 1984; 10(11):905– 907. Gerretsen AL, Toonstra J. Carbon dioxide laser treatment of multiple tricho-epitheliomas. Br J Dermatol 1991; 125(3):284 –285. Janniger CK, Goldberg DJ. Angiofibromas in tuberous sclerosis: comparison of treatment by carbon dioxide and argon laser. J Dermatol Surg Oncol 1990; 16(4):317 – 320. Boixeda P, Sanchez-Miralles E, Azana JM, Arrazola JM, Moreno R, Ledo A. CO2 , argon, and pulsed dye laser treatment of angiofibromas. J Dermatol Surg Oncol 1994; 20(12):808– 812. Lim J, Goh CL. Carbon dioxide laser treatment of periungual and subungual viral warts. Australas J Dermatol 1992; 33(2):87– 91. Brauner GJ, Schliftman A. Laser surgery for children. J Dermatol Surg Oncol 1987; 13(2):178– 186. Sood S, Hruza G. Treatment of vuruca vulgaris and condyloma acunimatum with lasers. Dermatol Ther 2000; 13:90– 101. Ashinoff R, Li JJ, Jacobson M, Friedman-Kien AE, Geronemus RG. Detection of human papillomavirus DNA in squamous cell carcinoma of the nail bed and finger determined by polymerase chain reaction. Arch Dermatol 1991; 127(12):1813– 1818. Street M, Roenigk RK. Recalcitrant periungual verrucae: the role of carbon dioxide laser vaporization. J Am Acad Dermatol 1990; 23(1):115 – 120. Logan R, Zachary CB. Outcome of carbon dioxide laser therapy for persistent cutaneous viral warts. Br J Dermatol 1989; 121(1):99– 105. Apfelberg DB, Maser MR, Lash H, White DN. Efficacy of the carbon dioxide laser in hand surgery. Ann Plast Surg 1984; 13(4):320– 326. Taylor MB. Successful treatment of warts. Choosing the best method for each situation. Postgrad Med 1988; 84(8):126– 128, 131– 136. Sloan K, Haberman H, Lynde CW. Carbon dioxide laser-treatment of resistant verrucae vulgaris: retrospective analysis. J Cutan Med Surg 1998; 2(3):142 – 145. Petersen C, Nurnberg BM. Carbon dioxide laser vaporization combined with perilesionally injected interferon alfa-2b in the treatment of a hyperkeratotic verruca vulgaris on the upper eyelid. Arch Dermatol 1994; 130(11):1369– 1370. Baggish MS. Carbon dioxide laser treatment for condylomata acuminata venereal infections. Obstet Gynecol 1980; 55(6):711– 715.
172
Ross
141.
Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol 1985; 153(5):545– 550. Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol 1983; 147(4):375– 378. Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984; 63(5):703– 707. Hahn GA. Carbon dioxide laser surgery in treatment of condyloma. Am J Obstet Gynecol 1981; 141(8):1000 –1008. Kryger-Baggesen N, Falck-Larson J, Hjortkjaer Pederson P. CO2-laser treatment of condylomata acuminata. Acta Obstet Gynecol Scand 1984; 63(4):341 –343. Lassus J, Happonen HP, Niemi KM, Ranki A. Carbon dioxide (CO2)-laser therapy cures macroscopic lesions, but viral genome is not eradicated in men with therapy-resistant HPV infection. Sex Transm Dis 1994; 21(6):297– 302. Ferenczy A, Mitao M, Nagai N et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1984; 313:784. Duus B, Philipsen T, Christensen J, Lundvall F, Sondergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med 1985; 61(1):59– 61. Petersen C, Munkvad S, Christiansen CB. CO2 laser eradication of recalcitrant condyloma acuminatum does not influence T-lymphocyte subsets. Acta Dermatol Venereol 1998; 78(5):389. Johnson P, Mirzai TH, Bentz ML. Carbon dioxide laser ablation of anogenital condyloma acuminata in pediatric patients. Ann Plast Surg 1997; 39(6):578 – 582. Davis B, Noble M. Initial experience with combined interferon-alpha 2B and carbon dioxide laser for the treatment of condylomata acuminata. J Urol 1992; 147(3):627– 629. Kaplan I, Labandter H. Onychogryphosis treated with the CO2 surgical laser. Br J Plast Surg 1976; 29(1):102– 103. Conejo-Mir J, Corbi R, Linares M. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. J Am Acad Dermatol 1998; 39(6):1039– 1040. Stern J, Lucente F. Carbon dioxide laser excision of earlobe keloids. A prospective study and critical analysis of existing data. Arch Otolaryngol Head Neck Surg 1989; 115(9):1107– 1111. Kantor G, Wheeland RG, Bailin P, Walker N, Ratz J. Treatment of earlobe keloids with carbon dioxide laser excision: a report of 16 cases. J Dermatol Surg Oncol 1985; 11(11):1063–1067. Stucker FJ, Shaw GY. An approach to management of keloids. Arch Otolaryngol Head Neck Surg 1992; 118(1):63– 67. Sinclair RJ, Sinclair PJ. Carbon dioxide laser in the treatment of cutaneous disorders. Australas J Dermatol 1991; 32(3):165 –171. Ries WR, Speyer MT. Cutaneous applications of lasers. Otolaryngol Clin North Am 1996; 29(6):915– 929. Norris JE. The effect of carbon dioxide laser surgery on the recurrence of keloids. Plast Reconstr Surg 1991; 87(1):44– 49; discussion 50 – 53. Friedman M, Gal D. Keloid scars as a result of CO2 laser for molluscum contagiosum. Obstet Gynecol 1987; 70(3, Pt 1):394– 396. Apfelberg D, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9(4):382– 388. Lim T, Tan W. Carbon dioxide laser for keloids. Plast Reconstr Surg 1991; 88(6):1111. Nowak K, McCormack M, Koch R. The effect of superpulsed carbon dioxide laser energy on keloid and normal dermal fibrblast secretion of growth factors: a serum free study. Plast Reconstr Surg 2000; 105:2039– 2048. Cheng E, Koch R. Regional differences in the secretion of growth factors by facial and chest fibroblasts utilizing blended CO2 and erbium YAG laser energy: a serum free study (abstract). Lasers Surg Med 2000; 12(suppl):11.
142. 143. 144. 145. 146.
147. 148.
149.
150. 151. 152. 153.
154.
155. 156. 157. 158. 159. 160. 161. 162. 163.
164.
Continuous Wave and Pulsed CO2 Lasers 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177.
178. 179. 180.
181. 182. 183. 184. 185. 186. 187. 188. 189. 190.
173
Kantor G, Ratz J, Wheeland R. Treatment of acne keloidalis nuchae with carbon dioxide laser. J Am Acad Dermatol 1986; 14(2, Pt 1):263 –267. Glass L, Berman B, Laub D. Treatment of perifolliculitis capitis abscedens et suffodiens with the carbon dioxide laser. J Dermatol Surg Oncol 1989; 15(6):673 – 676. Modica LA. Pyogenic granuloma of the tongue treated by carbon dioxide laser. J Am Geriatr Soc 1988; 36(11):1036– 1038. Lee CT, Tham SN, Tan T. Initial experience with CO2 laser in treating dermatological conditions. Ann Acad Med Sing 1987; 16(4):713– 715. Blickenstaff RD, Roenigk RK, Peters MS, Goellner JR. Recurrent pyogenic granuloma with satellitosis. J Am Acad Dermatol 1989; 21(6):1241– 1244. Stanley R, Roenigk R. Actinic cheilitis: treatment with the carbon dioxide laser. Mayo Clin Proc 1988; 63(3):230– 235. Zelickson B, Roenigk R. Actinic cheilitis. Treatment with the carbon dioxide laser. Cancer 1990; 65(6):1307 –1311. Robinson JK. Actinic cheilitis. A prospective study comparing four treatment methods. Arch Otolaryngol Head Neck Surg 1989; 115(7):848– 852. Frankel DH. Carbon dioxide laser vermilionectomy for chronic actinic cheilitis. Facial Plast Surg 1989; 6(3):158– 161. Dufresne R, Garrett A, Bailin P, Ratz J. Carbon dioxide laser treatment of chronic actinic cheilitis. J Am Acad Dermatol 1988; 19(5, Pt 1):876 –878. Dufresne RG Jr, Curlin MU. Actinic cheilitis. A treatment review. Dermatol Surg 1997; 23(1):15– 21. David LM. Laser vermilion ablation for actinic cheilitis. J Dermatol Surg Oncol 1985; 11(6):605– 608. Alamillos-Granados FJ, Navai-Gias L, Dean-Ferrer A, Alonso del Hoyo JR. Carbon dioxide laser vermilionectomy for actinic cheilitis. J Oral Maxillofac Surg 1993; 51(2): 118 – 121. Ries W, Duncavage J, Ossoff R. Carbon dioxide laser treatment of actinic cheilitis. Mayo Clin Proc 1988; 63(3):294– 296. Sexton J. Carbon dioxide laser treatment for actinic cheilitis. J Oral Maxillofac Surg 1993; 51(8):953. Johnson T, Sebastien T, Lowe L, Nelson B. Carbon dioxide laser treatment of actinic cheilitis. Clinicohistopathologic correlation to determine the optimal depth of destruction. J Am Acad Dermatol 1992; 27(5, Pt 1):737– 740. Cohen E, Nouri K, Jimenez G, Weiss E. Treatment of verrucous epidermal nevi with UltraPulse CO2 laser. Lasers Surg Med (abstract) 2000; 12(suppl):15. Losee JE, Serletti JM, Pennino RP. Epidermal nevus syndrome: a review and case report. Ann Plast Surg 1999; 43(2):211 –214. Hohenleutner U, Landthaler M. Laser therapy of verrucous epidermal naevi. Clin Exp Dermatol 1993; 18(2):124 –127. Ratz JL, Bailin PL, Wheeland RG. Carbon dioxide laser treatment of epidermal nevi. J Dermatol Surg Oncol 1986; 12(6):567 – 570. Sajben F, Ross E. The use of the 1.0 mm handpiece in high energy, pulsed CO2 laser destruction of facial adnexal tumors. Dermatol Surg 1999; 25(1):41 – 44. Wang J, Roenigk H Jr. Treatment of multiple facial syringomas with the carbon dioxide (CO2) laser. Dermatol Surg 1999; 25(2):136– 139. Wheeland R, Bailin P, Reynolds O, Ratz J. Carbon dioxide (CO2) laser vaporization of multiple facial syringomas. J Dermatol Surg Oncol 1986; 12(3):225 – 228. Apfelberg DB, Maser MR, Lash H, White DN. Treatment of xanthelasma palpebrarum with the carbon dioxide laser. J Dermatol Surg Oncol 1987; 13(2):149 – 151. Alster T, West T. Ultrapulse CO2 laser ablation of xanthelasma. J Am Acad Dermatol 1996; 34(5, Pt 1):848 –849. Roenigk RK, Ratz JL. CO2 laser treatment of cutaneous neurofibromas. J Dermatol Surg Oncol 1987; 13(2):187– 190.
174
Ross
191.
Becker DW Jr. Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas. Ann Plast Surg 1991; 26(6):582– 586. Krahenbuhl A, Eichmann A, Pfaltz M. CO2 laser therapy for steatocystoma multiplex. Dermatologica 1991; 183(4):294– 296. McKinlay JR, Graham BS, Ross EV. The clinical superiority of continuous exposure versus short-pulsed carbon dioxide laser exposures for the treatment of pearly penile papules. Dermatol Surg 1999; 25(2):124– 126. Magid M, Garden JM. Pearly penile papules: treatment with the carbon dioxide laser. J Dermatol Surg Oncol 1989; 15(5):552– 554. Wheeland RG, Bailin PL, Ratz JL, Roenigk RK. Carbon dioxide laser vaporization and curettage in the treatment of large or multiple superficial basal cell carcinomas. J Dermatol Surg Oncol 1987; 13(2):119 –125. Kilmer S, Chozen V. Ultrapulse laser treatment of basal cell carcinomas (abstract). Lasers Surg Med 1996; 8(suppl):36. Humphreys TR, Malhotra R, Scharf MJ, Marcus SM, Starkus L, Calegari K. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 1998; 134(10):1247– 1252. Grobbelaar AO, Horlock N, Gault DT. Gorlin’s syndrome: the role of the carbon dioxide laser in patient management. Ann Plast Surg 1997; 39(4):366 – 373. Gordon KB, Robinson J. Carbon dioxide laser vaporization for Bowen’s disease of the finger. Arch Dermatol 1994; 130(10):1250– 1252. Finley E, Ratz J. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol 1996; 34(3):465 – 469. Greenbaum S, Rubin M. Surgical pearl: the high-energy pulsed carbon dioxide laser for immediate scar resurfacing. J Am Acad Dermatol 1999; 40(6, Pt 1):988– 990. Grevelink JM, White VR. Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring. Dermatol Surg 1998; 24(5):527 – 530. Alster TS, Lewis AB, Rosenbach A. Laser scar revision: comparison of CO2 laser vaporization with and without simultaneous pulsed dye laser treatment. Dermatol Surg 1998; 24(12):1299– 1302. Taylor MB. Chondrodermatitis nodularis chronica helicis. Successful treatment with the carbon dioxide laser. J Dermatol Surg Oncol 1991; 17(11):862– 864. Haas AF, Narurkar VA. Recalcitrant breast lymphangioma circumscriptum treated by UltraPulse carbon dioxide laser. Dermatol Surg 1998; 24(8):893 – 895. Bailin PL, Kantor GR, Wheeland RG. Carbon dioxide laser vaporization of lymphangioma circumscriptum. J Am Acad Dermatol 1986; 14(2, Pt 1):257– 262. Ashinoff R. Linear nevus sebaceus of Jadassohn treated with the carbon dioxide laser. Pediatr Dermatol 1993; 10(2):189– 191. Bickley LK, Goldberg DJ, Imaeda S, Lambert WC, Schwartz RA. Treatment of multiple apocrine hidrocystomas with the carbon dioxide (CO2) laser. J Dermatol Surg Oncol 1989; 15(6):599– 602. Carpo B, Grevelink SV, Brady S, Gellis S, Grevelink J. Treatment of cutaneous lesions of xanthoma disseminatum with a CO2 laser. Dermatol Surg 1999; 25(10):751– 754. Christian M, Moy R. Treatment of Hailey-Hailey disease (or benign familial pemphigus) using short pulsed and short dwell time carbon dioxide lasers. Dermatol Surg 1999; 25(8):661– 663. Kartamaa M, Reitamo S. Familial benign chronic pemphigus (Hailey-Hailey disease). Treatment with carbon dioxide laser vaporization. Arch Dermatol 1992; 128(5):646–648. McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier’s disease. J Am Acad Dermatol 1990; 23(5, Pt 1):893 – 897. Touma DJ, Krauss M, Feingold DS, Kaminer MS. Benign familial pemphigus (Hailey-Hailey disease). Treatment with the pulsed carbon dioxide laser. Dermatol Surg 1998; 24(12):1411– 1414.
192. 193.
194. 195.
196. 197.
198. 199. 200. 201. 202. 203.
204. 205. 206. 207. 208.
209. 210.
211. 212.
213.
Continuous Wave and Pulsed CO2 Lasers 214.
215.
216. 217. 218. 219. 220. 221. 222.
223. 224. 225.
226. 227. 228.
229. 230. 231. 232. 233. 234.
235. 236. 237.
175
Kruppa A, Korge B, Lasch J, Scharffetter-Kochanek K, Hunzelmann N. Successful treatment of Hailey-Hailey disease with a scanned carbon dioxide laser. Acta Dermatol Venereol 2000; 80(1):53– 54. Chun YS, Chang SN, Park WH. A case of classical Kaposi’s sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol 1999; 26(4):240– 243. Apfelberg DB, Manchester GH. Decorative and traumatic tattoo biophysics and removal. Clin Plast Surg 1987; 14(2):243 –251. Apfelberg DB. Summary of carbon dioxide laser usage in plastic surgery. Scand J Plast Reconstr Surg 1986; 20(1):19– 24. Bailin PL, Ratz JL, Levine HL. Removal of tattoos by CO2 laser. J Dermatol Surg Oncol 1980; 6(12):997 –1001. Levine H, Bailin P. Carbon dioxide laser treatment of cutaneous hemangiomas and tattoos. Arch Otolaryngol 1982; 108(4):236 – 238. Herbich GJ. Ultrapulse carbon dioxide laser treatment of an iron oxide flesh-colored tattoo. Dermatol Surg 1997; 23(1):60– 61. Ort R, Anderson R, Arndt K, Dover J. CO2 laser resurfacing of tattoos prior to Q-switched laser treatment. 2000. Madden J, Edlich R, Custer J, Panek P, Thul J, Wangensteen O. Studies in the management of the contaminated wound. IV. Resistance to infection of surgical wounds made by knife, electrosurgery, and laser. Am J Surg 1970; 119(3):222– 224. al-Qattan MM, Stranc MF, Jarmuske M, Hoban DJ. Wound sterilization: CO2 laser versus iodine. Br J Plast Surg 1989; 42(4):380 – 384. Lee JS, Tarpley SK, Miller AS III. CO2 laser sterilization in the surgical treatment of infected median sternotomy wounds. South Med J 1999; 92(4):380 – 384. Hinshaw JR, Herrera HR, Lanzafame RJ, Pennino RP. The use of the carbon dioxide laser permits primary closure of contaminated and purulent lesions and wounds. Lasers Surg Med 1987; 6(6):581– 583. Fleming MG, Brody N. A new technique for laser treatment of cutaneous tumors. J Dermatol Surg Oncol 1986; 12(11):1170– 1175. Shaffelburg M, Miller R. Treatment of multiple trichoepithelioma with electrosurgery. Dermatol Surg 1998; 24(10):1154– 1156. Karbe E, Beck W, Englisch G, Konigsmann H, Kramer H, Peterson W, eds. Experimental Surgery with Neodymium, Holmium, CO, and CO2 Lasers. Jerusalem: Jerusalem Academic Press, 1975. Lee MS, Hunt M, Richards S. Wet gauze in CO2 laser resurfacing. Australas J Dermatol 1999; 40(4):230– 231. Widder RA, Severin M, Kirchhof B, Krieglstein GK. Corneal injury after carbon dioxide laser skin resurfacing. Am J Ophthalmol 1998; 125(3):392– 394. Ries WR, Clymer MA, Reinisch L. Laser safety features of eye shields. Lasers Surg Med 1996; 18(3):309 –315. Rohrich RJ, Gyimesi IM, Clark P, Burns AJ. CO2 laser safety considerations in facial skin resurfacing. Plast Reconstr Surg 1997; 100(5):1285 – 1290. Wood RL Jr, Sliney DH, Basye RA. Laser reflections from surgical instruments. Lasers Surg Med 1992; 12(6):675– 678. Anic I, Segovic S, Katanec D, Prskalo K, Najzar-Fleger D. Scanning electron microscopic study of dentin lased with argon, CO2 , and Nd:YAG laser. J Endod 1998; 24(2):77– 81. Lobene R, Bhussry B, Fine S. Interaction of carbon dioxide laser radiation with enamel and dentin. J Dent Res 1968; 47(2):311– 317. Fader DJ, Ratner D. Principles of CO2/erbium laser safety. Dermatol Surg 2000; 26(3):235– 239. Wald D, Michelow BJ, Guyuron B, Gibb AA. Fire hazards and CO2 laser resurfacing. Plast Reconstr Surg 1998; 101(1):185– 188.
176
Ross
238.
Nezhat C, Winer W, Nezhat F, Forrest D, Reeves W. Smoke from laser surgery: is there a health hazard? Lasers Surg Med 1987; 7(4):376 – 382. Baggish MS, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156(5):1260 –1265. Smith JP, Moss CE, Bryant CJ, Fleeger AK. Evaluation of a smoke evacuator used for laser surgery. Lasers Surg Med 1989; 9(3):276–281. Baggish M, Poiesz B, Joret D, Williamson P, Refai A. Presence of human immunodeficiency virus DNA in laser smoke. Lasers Surg Med 1991; 11(3):197 – 203. Garden JM, MK OB, Shelnitz LS et al. Papillomavirus in the vapor of carbon dioxide lasertreated verrucae. J Am Med Assoc 1988; 259(8):1199– 1202. Gloster HJ, Roenigk R. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995; 32(3):436– 441. Howard J, Arango P, Ossoff J, Ossoff RH, Reinisch L. Healing of laser incisions in rat dermis: comparisons of the carbon dioxide laser under manual and computer control and the scalpel. Lasers Surg Med 1997; 20(1):90 – 96. Ellis DL, Weisberg NK, Chen JS, Stricklin GP, Reinisch L. Free electron laser infrared wavelength specificity for cutaneous contraction. Lasers Surg Med 1999; 25(1):1 – 7. Spector N, Reinisch L, Spector J, Ellis DL. Free-electron laser and heat-conducting templates: a study of reducing cutaneous lateral thermal damage. Lasers Surg Med 2002; 30(2):117 – 122. Weinstein C, Ramirez OM, Pozner JN. Postoperative care following CO2 laser resurfacing: avoiding pitfalls. Plast Reconstr Surg 1997; 100(7):1855– 1866. Weinstein C. Carbon dioxide laser resurfacing. Long-term follow-up in 2123 patients. Clin Plast Surg 1998; 25(1):109 –130. Laws RA, Finley EM, McCollough ML, Grabski WJ. Alabaster skin after carbon dioxide laser resurfacing with histologic correlation. Dermatol Surg 1998; 24(6):633 – 636. Stuzin JM, Baker TJ, Baker TM, Kligman AM. Histologic effects of the high-energy pulsed CO2 laser on photoaged facial skin. Plast Reconstr Surg 1997; 99(7):2036 –2050, discussion 2051– 2055.
239. 240. 241. 242. 243.
244.
245. 246. 247. 248. 249. 250.
APPENDIX I: SAMPLE OPERATIVE NOTE Procedure: CO2 Laser Ablation (Removal) Indication: Adnexal tumor Location: Face Procedure: The patient was counseled regarding the risks and potential benefits of the procedure. After giving informed consent, the skin was hydrated with a wet towel for 10 min. Ninety minutes before surgery, a thick layer of EMLA cream was applied to the treatment site. The cream was removed just prior to surgery. Just before surgery, metal eye shields were placed after instillation of anesthetic eyedrops. The face was cleansed with Septisol solution to include a 2 cm perimeter of untreated skin. A Gentian violet pen was used to demarcate the nodules to be treated. The entire treatment area was surrounded with wet towels and the hair was wetted with sterile saline. Approximately 0.2 cm3 of 2% lidocaine with 1:1,000,000 epinephrine was injected intradermally just deep to each lesion. The lesions were treated with 175–250 mJ with the UltraPulse laser. The 1 mm spot size was used to ablate the lesion to a level where only stippled remnants of the base were observed. Bacitracin ointment was applied, and written and verbal postoperative instructions were provided. The patient will be followed up in 7–10 days. After treatment, the eye shields were removed, and postoperatively, antibiotic ointment was placed over the lesions. The patient was counseled regarding postoperative care and will return within 48 h for evaluation,
Continuous Wave and Pulsed CO2 Lasers
177
dressing removal, and wound cleansing. The patient was discharged from the clinic in good condition.
APPENDIX II: CONSENT FORM Name I understand that Dr. will perform carbon dioxide laser surgery on my (specify location) . I understand laser surgery consists of removing a bump on my skin. I understand that despite the ability of the device to precisely remove skin, the following restrictions apply to the treatment: 1. 2.
3. 4. 5. 6.
The goal is improvement rather than perfection. There is no guarantee that the anticipated results will be achieved. There will be significant swelling, oozing, and crusting, which may last for 1 – 2 weeks. In some cases redness may persist for up to 1 year, particularly in hot weather or after exercising. Improvement may continue as time elapses after treatment. The final result may not be apparent for up to 1 year. If additional improvement is desired after this time, it may be possible to re-treat areas, at additional cost. Although pain management is a primary concern during treatment, some mild transient discomfort may occur, especially “stinging” after the procedure. Generally, the carbon dioxide laser results in skin improvement. However, there is no guarantee that the results will be permanent. In rare cases, the skin can even look worse than before treatment. This may or not be due to one of the complications or consequences of laser surgery. These are outlined below.
I understand that the following complications, although infrequent, can occur after CO2 laser treatment: 1.
2. 3. 4.
Scarring: This can occur in the form a raised or depressed red area with change in skin texture. Over time these may turn white. It is important that any prior history of abnormal scarring is reported. Infection: Despite preventive measures, infection may occur, and additional medications may be necessary for treatment. Color changes: There is a risk of temporary or permanent dark or light changes to the skin. The likelihood of side effects will be decreased by my strict adherence to written postoperative instructions. Besides caring for the wound, avoiding sunlight exposure is critical, especially in the first 12 weeks after surgery.
Alternatives to carbon dioxide laser treatment are: accepting the present skin condition, use of cosmetics, or application of other procedures, including dermabrasion, erbium laser treatment, or surgical excision (cutting the skin lesion out). I have read this form and have been given the opportunity to discuss any questions I may have regarding the nature and aims of this procedure. Patient Witness
Date Date
Surgeon
Date
178
Ross
APPENDIX III: SAMPLE POSTOPERATIVE INSTRUCTIONS 1.
2. 3.
4. 5.
6.
7. 8.
Immediately after treatment, an antibiotic with or without a dressing will be applied. Any dressing will be removed 1 –2 days after treatment. The dressing should be left alone until your follow-up visit. Avoid strenuous exercise for 10 days. Walking before sunrise and after sundown is recommended. There may be swelling after treatment, especially around the eyes (they may even be closed shut for 1 day). This will resolve within 3 days. An ice pack may be placed over swollen sites once the dressing has been removed. This may be done as often as 5 –10 min every hour while awake. Sleeping with your head elevated may reduce swelling (use two pillows). For the next 1–3 days, the wound should be cleaned at home by applying a dilute vinegar solution (about one teaspoon vinegar in one cup water) with a cloth or gauze. After soaking with this for 10–15 min, any excess crusts can be gently removed by using a Q-tip. Cleaning should be done often enough to keep the face clear of cumulated debris. This may require three to five sessions per day for the first 3 days. Occasionally, pinpoint bleeding may occur; this can be stopped by applying gentle pressure for several minutes. After cleaning the wound, a petrolatum-type ointment or antibiotic ointment should be applied. You are encouraged to allow shower water to irrigate the wound. Hair can be washed at the same time, preferably only with baby shampoo until after 5 days. You should not apply soaps to the open skin. Once the skin is healed (no open areas), your normal soap may be resumed. Before cleaning your face, you should wash your hands with an antibacterial soap (e.g., Dial or Safeguard) to avoid contamination of the treatment area. We will normally want to see you for follow-up visits weekly for the first 3 weeks after treatment. Call the office immediately for any rash, fever, or severe pain. These may be early signs of infection.
After 1 Week 1. After 1 week normally, the skin will be healed enough for you to be able to venture outside. When outside, the face should be covered with a broadspectrum sunscreen (at least SPF 15) and the head covered with a broad-brim hat. Total block 60 (Fallene Ltd., King of Prussia, PA) is recommended. It is most important to avoid any sun exposure as long as the skin is pink. Even a brief trip across the parking lot without protection can result in dark brown splotches. 2. A green concealer can be used to neutralize residual redness. A flesh-tone foundation can then be applied to conceal the green tone. 3. A light moisturizer can be applied ad lib (Curel, Moisturel, or Purpose) 4. Apply a steroid cream every night if your doctor prescribes it for redness. APPENDIX IV: PATIENT INFORMATION HANDOUT The carbon dioxide laser has become a popular method for skin surgery. By precisely removing and gently heating skin wrinkles, for example, new healthier skin will appear during the healing period. Also, the contour of acne scars can be improved. Other benign skin bumps can also be removed with the carbon dioxide laser. The carbon
Continuous Wave and Pulsed CO2 Lasers
179
dioxide laser has been the most popular machine used to peel the skin. Although it works well, the heat generated causes prolonged healing. Often, 10 days to 2 weeks are required before crusts completely resolve and you can comfortably return to work. Also, often red skin is noted up to 4 months after surgery. Sometimes only a cream application is required for skin numbing, but usually an injection (with a needle—like at the dentist’s office) will be required to make you comfortable during the laser surgery. At the consultative visit, you will be counseled about the risks and benefits of carbon dioxide laser surgery. Representative photographs will be shown. If you are interested in carbon dioxide laser treatment, a date will be scheduled for surgery and a handout specific for your skin condition type of surgery will be provided.
6 Er:YAG Lasers Ulrich Hohenleutner and Michael Landthaler University of Regensburg, Regensburg, Germany
1. Introduction 2. Laser – Tissue Interaction 2.1. Er:YAG Laser Physics 2.2. Laser – Tissue Interaction 2.3. Ablation Efficacy 2.4. Residual Thermal Damage 2.5. Laser Plume and Noise 3. Commercially Available Er:YAG Lasers 4. Er:YAG Laser Treatment 4.1. General Treatment Considerations and Contraindications 4.2. Treatment Techniques 4.3. Anesthesia 4.4. Pre- and Perioperative Care 4.5. Postoperative Care 4.6. Wound Healing and Side Effects 5. Treatment Results 5.1. Skin Resurfacing (Rhytides, Actinically Damaged Skin) 5.1.1. Er:YAG Lasers Alone 5.1.2. Comparisons/Combinations of Er:YAG and CO2 Laser 5.2. Pigmentory Abnormalities 5.3. Acne Scars 5.4. Other Skin Lesions 6. Conclusion References
1.
181 182 182 182 183 183 184 186 186 187 188 189 189 189 190 190 190 191 192 192 193 193 194 194
INTRODUCTION
The introduction of Er:YAG lasers has considerably broadened the therapeutic possibilities for skin disorders. Er:YAG lasers allow an extremely precise but superficial ablation of the skin with considerably faster healing and reduced side effects compared to the CO2 laser. 181
182
Hohenleutner and Landthaler
Their ablative effect is comparable to mechanical dermabrasion, but the technique is simpler to perform without the risk of injury from the high-speed rotating fraises. In areas of loose or thin skin like lips or eyelids, where even pulsed CO2 lasers carry a considerable risk of scarring, Er:YAG lasers are safe and effective. This chapter will present an overview of the laser–tissue interaction of Er:YAG lasers, their clinical applicability, therapeutic indications, and results, and the general considerations in Er:YAG laser therapy.
2. 2.1.
LASER – TISSUE INTERACTION Er:YAG Laser Physics
Like neodymium:YAG lasers, Er:YAG lasers are solid state lasers that mostly are flash lamp pumped. The laser medium is a crystal rod consisting of yttrium aluminum garnet that is doped with erbium. Er:YAG lasers emit light at 2940 nm wavelength, which is in the near-infrared spectrum. Like Nd:YAG lasers, they can be Q-switched (1), but most Er:YAG lasers for clinical applications work in the so-called free-running mode. Typical pulse times are 250 ms (250–350 ms). During this macropulse, Er:YAG lasers emit a chain of highenergy, 1 ms short pulses, so-called spikes (1,2). For clinical applications, the light of the Er:YAG laser usually is transmitted to the operating field by mirror arms and focusing lens handpieces, rather than via the usual quartz fibres because they absorb the Er:YAG lasers’ wavelength. 2.2.
Laser – Tissue Interaction
At 2940 nm, water has an absorption maximum. The absorption coefficient of water at this wavelength is approximately 13,000 cm21 (3–5). Additionally, the wavelength of the Er:YAG laser is very close to an absorption maximum of collagen at 3030 nm (6). Therefore, skin containing 70– 80% water has an absorption coefficient of approximately 8000 – 9000 cm21 at 2940 nm (1,3,4). In comparison, at the wavelength of CO2 laser radiation (10,600 nm), the absorption coefficient of water is approximately 790 cm21 (5). This very high absorption of the Er:YAG laser radiation in skin directly explains the precise and effective ablation properties of Er:YAG lasers. The irradiated light is absorbed in very small tissue volumes that are maximally heated and explosively vaporized. The theoretical skin penetration depth of Er:YAG laser radiation is 1 mm (3 – 5), as stated before. This penetration depth cannot explain the highly effective tissue vaporization that is possible with these lasers. Experimental ablation efficacies in skin of up to 200 mm and more per pulse (at 80 J/cm2) (1) have been observed. These ablation depths, nevertheless, can be explained by the model of dynamic vaporization and by the changed optical properties of water at high temperatures and high pressures (1,3,4). During a high-irradiance laser pulse, small layer after small layer of skin is irradiated and maximally heated while the more superficial layers are vaporized (4). The high temperatures and high pressures in the thin tissue layers change the optical properties of water and, consecutively, of the tissue. The water absorption decreases by two orders of magnitude (3) and allows a higher penetration depth of the laser radiation, which increases the ablation efficacy. Additionally, water vapor is nearly transparent for Er:YAG laser radiation (1). Therefore, the ejected particles and the vapor that are in the laser beam during the ablating macropulse cannot significantly weaken the incident irradiation. Hence, tissue layer after tissue laser is effectively removed, the particles are ejected at supersonic speed (1), and a deep tissue ablation becomes possible.
Er:YAG Lasers
183
These dynamic optical properties of water during infrared laser ablation (3) also explain the typical residual thermal damage zones of 10– 50 mm that are seen with Er:YAG lasers. With static optical properties and a theoretical penetration depth of 1 mm, these residual thermal damage zones would be limited to exactly this penetration depth and not exceed 1 mm. 2.3.
Ablation Efficacy
The threshold for ablation of skin with Er:YAG lasers in free-running mode with a pulse time around 250 ms is 1.5 J/cm2 (0.7 – 1.7 J/cm2) (2,7 –9). At fluences up to 20 J/cm2, the ablation per pulse strongly increases with the irradiant fluence. This has been demonstrated in many in vitro studies using pig or human skin (3,8 –10). Above 20 J/cm2, the ablation efficacy increases more slowly, but still linearly with the fluence (3). Above 60 J/cm2, the additional ablation that is achievable by an increase of the fluence further decreases (3). The application of multiple consecutive pulses to the same spot of tissue (“pulse stacking”) leads to decreased ablation efficacy and increased thermal damage. Although Hibst and Kaufmann (8) could not observe this effect at repetition frequencies of 1 Hz and 1 mm spot size, in our own study with repetition rates of 7 – 10 Hz we could clearly demonstrate this effect for 3 –4 mm spot sizes (9). The thermal damage zone was clearly dependent on the number of pulses applied and increased from 25 mm with less than 10 pulses to 100 mm with 40 pulses. This effect was confirmed by Ross et al. (11), who observed a 12-fold increase of thermal necrosis due to pulse stacking. In clinical application, pulse stacking, as defined by 100% overlap of pulses, is prevented by the sweeping motion of the handpiece over the skin that is used for most indications. Even at higher repetition frequencies, 100% pulse overlap is improbable when using this technique, and even if two or three pulses should be applied on the same spot, the thermal coagulation depth is not yet increased (see later). The ablation efficacy of skin with Er:YAG lasers at above-threshold fluences is between 2.5 and 6 mm per pulse per 1 J/cm2 (1,8 – 10). For example, with 1 mm spot size at 5 J/cm2 the ablation is about 10 mm per pulse (1,9) and increases to 20 mm at 10 J/cm2 and to 60 mm at 20 J/cm2 (1). To estimate the ablation depth per pass (in mm) for clinical purposes, it is recommended to multiply the applied fluence by 4 (12). These high ablation rates result in a relatively fast and effective ablation of skin in vivo. With typical clinical settings of 5 J/cm2 and repetition rates of 10 Hz, 20 – 60 mm of tissue is vaporized with one to two passes; with three passes, the vaporization increases to 80– 120 mm (13). In contrast to CO2 lasers, an increased number of passes with Er:YAG lasers does not lead to a decreased ablation efficacy (14 –16). With CO2 lasers, after several passes the tissue becomes increasingly dehydrated due to the fluid sealing effect of the coagulation zones, which can amount to up to 200 mm (17 – 20). Due to the lack of water, the skin can no more be vaporized and is only heated, which further increases the coagulation damage (16). With Er:YAG lasers, due to the minimal coagulation zones, there is no dehydration of tissue, hence no limit to tissue vaporization (14 –16). 2.4.
Residual Thermal Damage
Compared to the CO2 laser, the main advantage of Er:YAG lasers is the minimal to almost absent residual thermal damage in the skin. Many studies, either in vitro or in vivo, have clearly demonstrated that with output parameters as they are used in clinical application
184
Hohenleutner and Landthaler
(fluences up to 25 J/cm2, spot sizes up to 6 mm, repetition frequencies up to 20 Hz), the zone of residual thermal damage as visualized by collagen denaturation is typically about 10 – 30 mm and does not exceed 50 mm (2,9,10,12,13,17,21 – 24). Even with up to 10 passes at fluences of 14 – 24 J/cm2, the thermal necrosis remains constant at 15– 40 mm (14). Compared to the CO2 laser, this dramatically reduced thermal damage leads to reduced healing times, reduced postlaser erythema, and a lower frequency of side effects. Nevertheless, for the clinical effect of wrinkle reduction, the reduced coagulation of collagen and elastic fibers is a disadvantage. Some studies directly comparing Er:YAG and CO2 lasers for rhytides showed that although the Er:YAG laser leads to faster healing and reduced side effects, wrinkle improvement was better and more prolonged with the CO2 laser (17,25 –29). For non-skin-resurfacing indications, the nearly complete absence of residual thermal damage makes the Er:YAG laser the more precise and safer tool. Nevertheless, this holds true only for relatively superficial and not strongly vascularized skin lesions. The main disadvantage of the Er:YAG lasers in skin ablation is their inability to stop bleeding. Due to the absence of coagulation, there is a profuse capillary bleeding as soon as the papillary dermis with its superficial vessel loops is reached (2,7). This bleeding considerably interferes with further ablation in a clinical setting. Further ablation is only possible when the bleeding has stopped, since the blood film on the tissue prevents any further vaporization. Therefore, the clinical applicability of Er:YAG lasers for deeper vaporization, cutting, or the treatment of highly vascularized skin lesions (e.g., common or genital warts) is limited. Some Er:YAG lasers provide subablative pulses at subthreshold energy densities or with longer pulse times which produce a coagulation effect similar to CO2 lasers and are hemostatic. With pulse lengths up to 700 ms, decreased bleeding was noted without increasing residual thermal damage (30). Other authors, nevertheless, found that with subthreshold, longer pulses (“heating pulses”) the thermal damage zones increase up to 80 mm (31) and 100 mm, respectively (32). In contrast to ablative (above-threshold) pulses, “pulse stacking” with subablative pulses leads to greatly increased residual thermal damage, which can reach 200 mm (33). These increased coagulation zones lead to more hemostasis in the operating field and also to prolonged healing times and increased side effects compared to the pure ablative mode. In the clinical setting, these subablative pulses, provided by some Er:YAG lasers (Table 6.1), are used to produce a larger zone of thermal damage, with CO2 laser like clinical effects. The resultant “collagen shrinkage” and “collagen remodeling” have improved the long-term efficacy of Er:YAG laser skin resurfacing (34,35).
2.5.
Laser Plume and Noise
Several studies have demonstrated that the CO2 laser plume may carry infectious particles and is hazardous for the lungs due to the particle size (36 – 40). Regarding the Er:YAG laser plume, only one study exists so far. Hughes and Hughes (41) could not demonstrate HPV-DNA in the Er:YAG laser plume when treating human warts. Possibly, the intensive fragmentation and heating that occur when tissue is explosively vaporized and the particles are ejected at supersonic speed (1) prevent the survival of infectious particles in the Er:YAG laser plume. Nevertheless, until further data are available, it is recommended that infectious patients (hepatitis B and C, HIV) should not be treated with ablative lasers including Er:YAG lasers (7) since the risk of disseminating the infection cannot be totally excluded.
TM
2
No
–15 Hz –15 Hz –50 Hz
250 ms 350 ms
–1.2 J/pulse
2 J/pulse
45 W 100 ms–200 ms (Nd:YAG) ND ND
0.1– 45 W (Nd:YAG) –2 J/pulse
–2 J/pulse
500 ms
ND
–20 Hz
–45 Hz
1– 4 Hz
a ND ¼ no data available. Note: This table may be incomplete and implies no recommendation for specific machines!
Wavelight GmbH BuraneTM, www.wavelight-laser.net Wavelight GmbH SuperbTM, www.wavelight-laser.net
Sciton ProfileTM, www.sciton.com
Yes
–15 Hz
100/300/750/ 1000 ms 250 ms
2 J/pulse
Laserscope VenusTM Laser System, www.laserscope.com Limmer Laser UNILAS 2940, www.limmermt.com Lynton Lasers Ltd. SkinlightTM, www.lyntlaz.demon.co.uk Lynton Lasers Ltd. Skinlight PlusTM, www.lyntlaz.demon.co.uk Sciton ContourTM, www.sciton.com
–1 J/pulse
No
–20 Hz
300 ms
0.8 J/pulse
Yes
Yes
ND
Yes
No
ND
ND
2.5–3.5–5 mm, focused
2, 3, 4, 6, 10 mm, focused
Collimated, 4 mm
Focused, 1.5– 7 mm
Focused, 1.5– 7 mm
Focused, 1.2– 5 mm
Collimated, 3/5/7 mm
Focused, –10 mm collimated and contact fibers also available Focused, 1–8 mm
IrradiaTM, www.irradia.se
Yes
1 J/pulse
Fotona FidelisTM, www.fotona.de –50 Hz
ND
Yes
ND
ND
–3 J/pulse 100, 300, 750, 1000 ms
Focused, 1–10 mm
No
–28 Hz
250 ms
0.8–1–1.2 mm and 1–10 mm focused ND
Focused, 1.5– 5 mm fiber
Handpiece and spot size
–2 J/pulse
No
No
Yes
Long pulses (subablative)
–15 Hz
–28 Hz
–20 Hz
Repetition rate
250 ms
250 ms
ND
a
Pulse length
–1.2 J/pulse
–2 J/pulse
4–40 J/cm
Output
Asclepion-Meditec MCL 29 DermablateTM, www.asclepion.com Asclepion-Meditec DermablateTM, www.asclepion.com Fotona NovalisTM, www.fotona.si
Asclepion-Meditec Derma Star , www.asclepion.com Asclepion-Meditec Dermablate HareTM, www.asclepion.com
Company, web address
Table 6.1 Commercially Available Nd:YAG Lasers
ND
ND
Available
Integrated
ND
ND
ND
Available
ND
ND
ND
Available
ND
Available
ND
Scanner
Built-in Nd:YAG/KTP laser at 532 nm Variable coagulation depths up to 100 mm Built-in Nd:YAG for hair and vascular lesions
Cutting handpiece available
Built-in ruby and KTP 532 nm lasers Desktop size
Smoke evacuation in handpiece Built-in ruby laser for hair removal
Additional handpiece for hair transplant holes
Specialities
Er:YAG Lasers 185
186
Hohenleutner and Landthaler
Safety considerations as well as the prevention of unpleasant odors make an effective smoke evacuation device absolutely necessary for Er:YAG laser as well as for CO2 laser treatment. Another problem that is specific to the Er:YAG laser is the typical cracking noise that is associated with the explosive skin vaporization. Especially with higher fluences and high repetition rates, the resulting hammering noise is not unlike machine gun fire and can be quite bothersome (7). Depending on the distance to the treatment field, the noise intensity can reach levels that can possibly damage the ears [at least with chronic exposure (42)]. Therefore, for extensive procedures, the use of ear protection is recommended or at least should be taken into consideration.
3.
COMMERCIALLY AVAILABLE Er:YAG LASERS
As solid state lasers, Er:YAG lasers normally are reliable machines without high running expenses. Due to internal cooling circulation systems, they are air cooled and run on 110 or 220 V. In contrast to CO2 lasers, where different pulse lengths and different scanners lead to significantly different laser – tissue interactions and coagulation zones, the various commercially available Er:YAG lasers, at least with respect to their ablative pulses, produce similar effects on skin. This has been shown in a study by Alster (13), who performed a clinical and histological evaluation of six different Er:YAG lasers for skin resurfacing. Nevertheless, the Er:YAG laser machines offer different options for subablative pulses. Subthreshold pulses are available alone or in (fixed) combination with ablative pulses, and the irradiation parameters can be chosen either directly as fluence and/or pulse length or as the desired depth of coagulation. Also, the machines are different regarding their technical equipment. Output energies up to 2 J per pulse, spot sizes up to 10 mm, and various repetition frequencies are available. There are handpieces using focusing lenses with distance holders and handpieces with collimated beams, the latter being independent of the handpiece – skin distance. Spot sizes can be selected by changing the lenses or the distance holders, or directly at the handpiece. Additionally, for various lasers there are automatic or computerized scanner systems available. These can produce different shapes and sizes of treatment areas, and the pulse overlap can be selected. In some lasers, the smoke evacuation system is integrated into the handpiece. Table 6.1 gives an alphabetical overview of the Er:YAG laser systems commercially available at present. It should be emphasized that the therapeutic results achievable are more or less identical with those of the different lasers available (13), even if some lasers can treat faster due to higher output or may be more comfortable due to convenient handling.
4.
Er:YAG LASER TREATMENT
There have been a large number of publications regarding the application of Er:YAG lasers to a variety of skin disorders. The main field of application of the Er:YAG lasers is in skin resurfacing. The precise and effective ablation properties of these lasers have made them useful for many other cutaneous applications (Table 6.2).
Er:YAG Lasers
187
Table 6.2 Possible Indications for Er:YAG Laser Therapy Pigmentation
Resurfacing Scars Epidermal lesions
Dermal lesions
Warts Inflammatory dermatoses Others
4.1.
Lentigines Melasma/chloasma Postinflammatory hyperpigmentation Wrinkles, rhytides Solar elastosis Acne scars Surgical/traumatic scars Seborrhoeic keratoses Actinic keratoses Actinic cheilitis Epidermal nevi (M. Bowen) (Superficial basal cell carcinoma) (Erythroplasia of Queyrat) Dermal nevi Fibromata Xanthelasma Plane xanthoma Syringoma Sebaceous gland hyperplasia Nevus sebaceus Osteoma cutis Plane warts Vulgar warts, palmoplantar warts Psoriatic plaques Zoon’s balanitis M. Darier M. Hailey – Hailey Rhinophyma Hole boring for hair transplantation
General Treatment Considerations and Contraindications
As with all lasers, appropriate safety precautions for eye protection are required. As mentioned previously, efficient plume evacuation systems are necessary, and ear protection should be taken into consideration at least for more extensive procedures. Since Er:YAG laser ablation is precise and the residual thermal damage is almost negligible, it is quite comparable to mechanical dermabrasion. The clinical end point of treatment is either the apparent removal of the target lesion or, in resurfacing procedures, as soon as the desired depth of ablation is reached. There are only a few absolute contraindications to Er:YAG laser therapy, which include, in our opinion, the treatment of patients with infectious diseases that are contagious by blood or lymph fluid (hepatitis B and C, HIV) (7). The relative contraindications include (7,16,43) – – –
concomitant systemic retinoid treatment (which may produce prolonged healing time and atypical scarring) skin with a reduced number of dermal appendages (e.g., following electroepilation, burns) history of a tendency toward keloidal scarring
188
Hohenleutner and Landthaler
– – –
4.2.
prior blepharoplasty or ectropion collagen vascular or immune disorder (16) increased bleeding tendency (coagulation disorders, anticoagulation, high-dose acetylsalicylic acid treatment).
Treatment Techniques
Small or exophytic lesions (seborrhoic keratoses, warts, xanthelasmata, etc.) are treated with an appropriate spot size and average repetition rates (up to 10 Hz) until they are removed. For flat lesions, average fluences of 5 – 10 J/cm2 are often sufficient. With more exophytic lesions, higher fluences, if available, are often desirable to accelerate the procedure. If bleeding occurs, it is necessary to wait until the bleeding stops, otherwise further ablation will be ineffective. For skin resurfacing or other indications requiring extensive ablation, most authors recommend fluences of 5 J/cm2 (13,16), but higher fluences up to 20 J/cm2 have been described, too (7). The handpiece is led across the treatment area in a sweeping motion with a velocity that depends on the repetition rate chosen (12). The pulses and lines of pulses should overlap about 30%, resulting in a uniform ablation without leaving untreated spots (7). Pulse stacking on one point of the skin should be avoided due to increasing residual thermal damage (9,12). After each pass, the superficial fluffy debris may be cautiously removed by wet gauze, but, unlike with CO2 lasers, this usually is unnecessary with Er:YAG lasers (12,16,44). The subsequent passes should be oriented perpendicular or at an angle to the preceding passes to further enhance the uniformity of the ablation (7,12,45). The margins of the treatment areas can be blended into the untreated skin by using pulses of lower fluence (6) or by defocusing the handpiece or scanner (7) (which, in effect decreases the fluence). Using this technique and fluences of 5 J/cm2, the following ablation depths are usually achieved: one pass, 20 –40 mm or down to the granular layer of the epidermis; two passes, up to 60 mm or down to the basal cell layer; three to four passes, 80 – 120 mm or down to the papillary dermis, and deeper into the papillary and superficial reticular dermis after five to six passes (13,21). Weinstein (24) describes the following ablation depths using a scanner of 20 Hz and 30% pulse overlap: 5 J/cm2, superficial epidermal injury (30 – 40 mm) with negligible thermal necrosis; 10 J/cm2, epidermal injury to the level of the basal layer (50 mm) with minimal thermal necrosis (5 mm); 15 J/cm2, full-thickness epidermal injury through the basement membrane, minimal ablation of the papillary dermis (20 mm), and a narrow band of thermal necrosis (10 –15 mm). These schematic histological ablation depths provide an approximation of the real ablation depth achievable with different fluences and numbers of passes, and should not be relied on in patient treatment. A distinct advantage of the Er:YAG lasers is that, as in mechanical dermabrasion, one can directly evaluate the achieved depth by inspecting the skin surface after careful removal of the debris. Since there is almost no coagulation zone, some clinical end points can be used as guidelines for the depth of ablation in tissue. These end points are best visualized with magnifying lenses, as defined by Weinstein (7): Epidermis: Resurfacing within the epidermis produces a yellowish brown appearance on the epidermis. Epidermo-dermal junction: Once the epidermis is removed, a pinkish appearance of the upper papillary dermis will be readily appreciated. The follicle openings look small and regular like a fine sponge.
Er:YAG Lasers
189
Lower papillary dermis: When proceeding into the papillary dermis, pinpoint bleeding and a transsudate develop, indicating injury to the small capillaries. The follicle openings become wider and begin to stand out from the surrounding dermis. Upper reticular dermis: When the upper reticular dermis is reached, bleeding increases and the transsudate becomes more profuse. Follicle openings become much wider and the collagen bands become coarser and more haphazard in orientation. At this point it is generally best to proceed no further. 4.3.
Anesthesia
With Er:YAG lasers, the type and amount of anesthesia needed depends on the depth of ablation or resurfacing and the fluences used. Very superficial ablation procedures or the removal of very small lesions mostly can be performed using topical anesthesia only (EMLATM cream, tetracaine or lidocaine preparations) or with no anesthesia at all. With higher fluences above 5 –10 J/cm2, in the treatment of extensive lesions or if deeper ablation is required, local anesthesia, nerve blocks, and/or intravenous sedation, even general anesthesia may become necessary. The kind of anesthesia required depends on the kind of procedure that is planned and the individual sensitivity of the patient (7,11,16,46).
4.4.
Pre- and Perioperative Care
For the treatment of small, circumscribed, or exophytic lesions with Er:YAG lasers, no special pre- or perioperative measures are necessary. For extensive procedures like full-face resurfacing procedure for photodamage or acne scars, the same pre- and perioperative prophylactic measures are applicable as with CO2 laser treatment (7,16,46). These include pre- and postoperative skin conditioning with topical retinoic acid, weak chemical peels or creams, glycolic acid, and bleaching agents like hydroquinone (46). Oral antiviral therapy is used for prophylaxis against herpes simplex virus (7,16,46), but there is some debate regarding the used for oral antibiotics (46). Topical or systemic steroids are recommended by some authors to prevent significant postoperative swelling. For details, see the “Guidelines of Care for Laser Surgery” (47), the appropriate review articles (46,48,49), or the chapters on resurfacing later in this book.
4.5.
Postoperative Care
For small lesions, we recommend topical antibiotic ointments or ointments specifically designed to accelerate wound healing (e.g., BepantholTM ointment). This should be used until complete re-epithelialization has occurred and prevents the formation of irritating crusts. For extensive lesions as in skin resurfacing, either the open technique (application of ointments several times a day, following irrigation with water or vinegar solutions) or the closed technique (application of various kinds of occlusive dressings for several days) can be used (12,46). Weinstein (7) prefers using the closed technique with occlusive dressings for the first 1 –2 days to provide sufficient fluid absorption capacities. Due to the absence of the coagulation zone, there is much more postoperative exudate after Er:YAG than after CO2 laser ablation.
190
Hohenleutner and Landthaler
There has been much controversey regarding the preferred method of postoperative care (46,48,49), but in our opinion, either technique leads to good results if performed properly by a cooperative and intelligent patient with close physician monitoring. In our clinic, we use an occlusive dressing (CutinovaTM thin) for 1 –2 days for treatment of small lesions followed by the application of BepantholTM ointment several times a day. For extensive resurfacing procedure for photodamage or scar treatment, we use a semiocclusive jelly dressing for 2 – 3 days, followed by the application of BepantholTM ointment several times a day until reepithelialization is complete. 4.6.
Wound Healing and Side Effects
Depending on the depth of ablation, complete epithelialization of the skin is typically achieved in 3 – 10 days (6,13,21,44,50). The postoperative side effects with the Er:YAG laser are significantly reduced compared to CO2 lasers (7,21), because of the limited thermal damage zones. Postoperative erythema is a temporary side effect and resolves after 2–6 weeks according to the depth of ablation (6,12,21,44,50,51). Hyperpigmentation of the treatment areas, which is also a common side effect with CO2 lasers, is significantly less frequent with the Er:YAG laser (7,17). In the largest published series of 625 patients treated with an automatic scanner Er:YAG laser, temporary hyperpigmentation occurred in 3.4% and was transient in nature (7). Other authors report comparably low rates of hyperpigmentation between 0% and 10% of patients (6,44,51,52), whereas frequencies of up to 25% are reported after deeper ablation (17) or after additional complications like dermatitis or superinfection (13). Late-onset (up to 6 months postop) permanent hypopigmentation, the most feared long-term complication of CO2 laser resurfacing, seems to occur with Er:YAG lasers only in very deep ablation procedures. Its frequency has been reported to be 4.0% in the Weinstein series of 625 patients (7), 5% by Khatri et al. (17), and 2% by Riedel et al. (51). Many authors, however, found no occurrence of hypopigmentation with Er:YAG laser therapy (6,44,50,52 – 55). Other side effects include herpes simplex, bacterial or fungal superinfection, exacerbation of acne, irritant or contact dermatitis, pruritus, acneiform pustules, and milia formation. Most of these side effects are temporary and can be managed by proper topical or systemic treatment (6,12,56). An observation made by most authors is that with increasingly deep ablation, by either high fluences or repeated passes, the frequency of side effects increases accordingly and becomes progressively similar to CO2 laser treatment, especially if subthreshold pulses are added to increase the collagen shrinking effect (28,46). Atrophic scarring, hypertrophic scarring, or even keloid formation can occur with Er:YAG lasers, as with CO2 lasers (7) if the ablation is to deep for the skin area that has been treated or if superinfection occurs (e.g., ulcerating herpes). Special caution with a reduced number of passes or reduced fluences should be used in the treatment of sensitive areas with thin skin, like the eyelids or neck (7,12,16,43,50,57).
5. 5.1.
TREATMENT RESULTS Skin Resurfacing (Rhytides, Actinically Damaged Skin)
Literature abounds with the description of treatment techniques for Er:YAG lasers used in skin resurfacing (7,12,16,46). For more information, see the chapter “Skin Resurfacing with Er:YAG Lasers” later in this book. Here, only a short overview will be given over
Er:YAG Lasers
191
the treatment results that are achievable with Er:YAG lasers, with or without additional CO2 laser treatment, in skin resurfacing. 5.1.1.
Er:YAG Lasers Alone
Weiss et al. (6) report an average good to excellent improvement of periorbital rhytides 1 year after Er:YAG laser treatment with two passes at 21.2 J/cm2 and one additional pass at 15 J/cm2 direct over the wrinkle line. Perez et al. (21) used up to seven passes at 4 – 5 J/cm2 and found marked improvement of classes I– II rhytides in 8 of 15 patients. Moderate improvement was seen in six patients. Riedel et al. (58) treated with one to three passes at 1.4– 1.5 J per pulse (spot size not given) and could achieve a good to very good effect in the improvement of small to medium rhytides. Deep rhytides mostly recurred after 3 months. In Asian patients, Polnikorn et al. (54) achieved an 80% improvement of wrinkles and a 70% improvement of photoaged skin 6 months after Er:YAG laser treatment with several passes at 0.8 –1 J per pulse at 3.5 or 5 mm spot size. Clinical improvement (without further classification) was seen in facial rhytides treated with 2.5 to 5 mm spot size and up to 800 mJ pulse energy 2 months after treatment by Teikemeier and Goldberg (50). Goldberg and Cutler (55) treated patients with deep, class III rhytides with four passes at 5 J/cm2. Three consecutive treatment sessions were performed at 3-month intervals. After the first treatment session, no improvement was seen. Six months after the third treatment, 14 patients showed mild, 4 moderate, and 2 excellent improvement. Goldman et al. (43) treated photoaged skin of the neck and reported an improvement between 28% and 48%, according to the treatment method used [for details see Ref. (43)]. Likewise, Goldberg and Meine (44) achieved at least 25% improvement of rhytides and 50% improvement of photodamage-induced discoloration of the neck of patients treated with 3– 4.5 J/cm2 (four passes with an additional three to four passes directly over the rhytides). Jimenez and Spencer (52) performed Er:YAG laser resurfacing of the hands, arms, and neck for photodamaged skin. They observed prolonged healing times of up to 3 weeks after two to three passes at 5 J/cm2 (one to two passes in the neck) and the cosmetic results were disappointing: only one patient of seven showed a fair improvement in the hands, and only one patient of five showed a good result in the neck. With the introduction of modulated Er:YAG lasers with subablative pulses that lead to more thermal damage and hence to more collagen shrinkage, the efficacy of the Er:YAG laser for skin resurfacing and wrinkle treatment has improved. Rostan et al. (34) found a similar degree of improvement in facial laser resurfacing in a side-by-side comparison of pulsed CO2 laser and long-pulse Er:YAG laser treatment, with accelerated healing and fewer side effects on the Er:YAG-side. Zachary (35), too, observed a comparable efficacy of modulated Er:YAG and pulsed CO2 lasers with less side effects with the Er:YAG laser. In contrast, Newman et al. (29), in a side-by-side comparison in lip resurfacing, found fewer side effects with the long-pulse Er:YAG laser but better clinical improvement with the CO2 laser. Most authors performing Er:YAG laser resurfacing agree that the ideal indications for Er:YAG laser resurfacing are relatively mild, class I –II rhytides and mild photodamage of the skin, even if the subablative pulses have somewhat improved its clinical efficacy. Severe actinic elastosis, pronounced actinic keratoses, and deep rhytides respond better to CO2 laser resurfacing or combined procedures (7,13,16,46,56).
192
Hohenleutner and Landthaler
5.1.2. Comparisons/Combinations of Er:YAG and CO2 Laser Although the Er:YAG laser has been shown to provide some amount of intraoperative and postoperative skin contraction (59), the CO2 lasers, due to their increased coagulation depth leading to collagen denaturation and skin contraction, show improved efficacy for treatment of severe wrinkling or severe photodamage. For the treatment of rhytides, we performed a side-by-side comparison of Er:YAG (5 J/cm2, four to five passes) and CO2 laser (SilkTouchTM, 3 mm/5 W or 5 mm/10 W, two to three passes) treatment (25). After 8 weeks, the CO2-treated side showed marked improvement in 73% and moderate improvement 27%, whereas in the Er:YAG-treated side, moderate improvement was seen in 43% and only slight improvement in 57%. These results remained stable for over 1 year (26). Likewise, Khatri et al. (17) compared a pulsed CO2 laser (up to 6.5 J/cm2, 800 ms pulse length, two to three passes) with Er:YAG laser treatment (5 – 8 J/cm2, three or more passes). They found that the CO2treated side had better wrinkle improvement when using an identical numbers of passes. With five or more passes of the Er:YAG laser, the improvement scores were no longer significantly different. The frequency of erythema was significantly lower with the Er:YAG laser at 2 weeks (67% vs. 95%) and 8 weeks (24% vs. 62%), and hypopigmentation occurred in 5% with the Er:YAG laser and in 43% with the CO2 laser. Nevertheless, in the more aggressively treated Er:YAG patients, the incidence of erythema increased to 100% and 78% (at 2 and 8 weeks, respectively). McDaniel et al. (53) treated patients with deep rhytides with the pulsed CO2 laser and added, on one side of the face, three passes with an Er:YAG laser at 5.2 J/cm2. They found that the addition of the Er:YAG laser reduced crusting from 7.4 to 6.5 days and itching from 4.5 to 4.8 days. Otherwise, the results were identical, the average improvement of rhytides being 70%. These results were confirmed by Goldman and Manuskiatti (60), who found a significant reduction of healing time and erythema with an additional two passes of Er:YAG laser after Ultrapulse CO2 laser resurfacing without changes in the clinical result. Millman and Mannor (61) performed eyelid resurfacing with two passes of the Er:YAG laser followed by one pass of the CO2 laser and compared the results with a historical group of CO2 laser therapy only. They found that the combination therapy shortened the re-epithelialization time and the duration of erythema with a similar, satisfying cosmetic outcome in both groups. Similar results were achieved by Trelles et al. (62) by a fixed combination of an ablative Er:YAG and a nonablative CO2 laser pulse. These results are explained by the histological examinations of Utley et al. (23), who found the following residual thermal damage zones after ablation with an Er:YAG and a pulsed CO2 laser (at 4.7 J/cm2 each): CO2 alone (four passes) 89 mm, Er:YAG (four passes) þ CO2 (two passes) 97 mm, Er:YAG alone (eight passes) 43 mm, and CO2 (two passes) þ Er:YAG (four passes) 56 mm. Accordingly, Collawn (56) proposes to use the CO2 laser for severe and deep rhytides, CO2 laser followed by Er:YAG laser for moderate rhytides, and Er:YAG laser alone for fine wrinkles and discolorations.
5.2.
Pigmentory Abnormalities
Weinstein (24) treated 87 patients with pigmentation due to sun damage or chloasma with the Er:YAG laser using a computerized scanner with 30% pulse overlap. Three passes were performed (at 14, 10, and 7.5 J/cm2). All patients were reported to have shown excellent results with the removal of superficial and deeper pigmentation without recurrences.
Er:YAG Lasers
193
Polnikorn et al. (54) reported an average 16% improvement in the treatment of melasma in Asian skin (5 – 15 J/cm2, number of passes not specified). Drnovsek-Olup and Vedlin (63) reported an 80% clearing in two patients with chloasma after one treatment with 1.3 –1.7 J/cm2 and two to five passes. Manaloto and Alster (64) treated 10 patients with refractory melasma with three passes at 5– 7.6 J/cm2. The early results after 6 weeks showed a good initial response, followed by the development of a severe postinflammatory hyperpigmentation that had to be treated by sun screens, azelaic acid cream, and glycolic acid peels. Six months after treatment, the melasma was clinically improved in all patients but this had required intensive medical treatment of the hyperpigmentation. The authors, therefore, recommend Er:YAG laser treatment only in severe cases of otherwise refractory melasma.
5.3.
Acne Scars
The standard Er:YAG-laser treatment technique for acne scars is to perform to two to three passes over the entire anatomical unit followed by ablation of the shoulders of the acne scars with higher fluences or smaller spot sizes (7). Using this technique, Riedel et al. (51) could achieve good to very good results in 10 patients with acne scars. In Asian patients, Polnikorn et al. (54) reported an average 55% improvement using comparable techniques. Weinstein (24) first flattened the shoulders of the scars by single spots at 8 J/cm2, two to five passes, followed by treatment of the entire anatomical unit with the computerized scanner at 15 J/cm2 and 30% pulse overlap with two to three passes. For deeper acne scars, she used the CO2 laser (SilkTouchTM scanning device, 30 –40 J/cm2) for the shoulders followed by the Er:YAG laser as described before. Using this technique, she achieved no excellent, seven good (70 –90% improvement), and three fair results (50 –70% improvement). The long-pulsed Er:YAG laser has also been used for this indication. Jeong and Kye (65) achieved excellent and good results in 36% and 57% of 35 patients, respectively, for the treatment of found acne scars.
5.4.
Other Skin Lesions
Good to excellent results using Er:YAG laser ablation have been reported for a variety of small, circumscribed, and mostly exophytic skin lesions like seborrhoic warts, lentigines, epidermal nevi, milia, xanthelasmata, plane xanthomas, hidradenoma, plane warts, and fibroepithelial papillomata (10,46,51,54,58,66 –68). The Er:YAG laser is used to vaporize the small exophytic lesions until they have resolved. Good results in rhinophyma ablation are possible with Er:YAG lasers (46,54,69), but profuse bleeding makes this a tedious procedure (7). Combined procedures with the CO2 laser or conventional scalpel/razor/dermabrasion sculpting should be considered. As reported for dermabrasion and CO2 laser, Er:YAG laser ablation can achieve good results in Darier’s disease and Hailey– Hailey disease (70). A very rare disease, miliary osteoma cutis, reportedly can be treated by Er:YAG lasers with satisfying results (71,72). The same holds true for treatment of multiple eruptive vellus hair cysts (73). As with the CO2 laser, single recalcitrant plaques of psoriasis vulgaris refractory to conventional therapy can be treated with good clinical results by Er:YAG laser
194
Hohenleutner and Landthaler
ablation (74). In a single case of Zoon’s balanitis, this dermatosis responded well to Er:YAG laser ablation (75). Er:YAG lasers have also been used in the preparation of an adequate graft recipient bed on vitiligo skin for the transplantation of cultured melanocytes into these vitiligo lesions. The Er:YAG laser with its exact ablation and no residual thermal damage is ideal for preparing transplantation beds in these often bizarre and geometrically complicated lesions (76,77). In hair transplantation, Er:YAG lasers may be used to “drill” holes for recipient sites. Even in scarring alopecia, modern Er:YAG lasers with high pulse energy can drill holes for hair transplants efficiently, with less bleeding than with punches, and with less tissue damage as with CO2 lasers, which is important for graft take (78). 6.
CONCLUSION
Er:YAG lasers have become useful tools for facial resurfacing of mild to moderate facial scars, rhytids, and photodamage. These lasers have a high ablative capacity and produce very thin zones of residual thermal damage. Faster healing times and fewer side effects are therefore observed compared to CO2 laser treatment. The degree of number or scar improvement and skin contraction, however, is less than with CO2 lasers. Er:YAG lasers are useful devices for the treatment of benign epidermal lesions, leaving rapidly re-epithelializing wounds and minimal erythema. There are also considerable advantages in combining CO2 laser treatment with Er:YAG laser treatment to decrease residual thermal damage and speed re-epithelializing without compromising the efficacy. REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9.
10. 11.
12.
Walsh JT, Deutsch TF. Er:YAG laser ablation of tissue: measurement of ablation rates. Lasers Surg Med 1989; 9:327 – 337. Kaufmann R, Hibst R. Pulsed 2.94-mm erbium-YAG laser skin ablation—experimental results and first clinical application. Clin Exp Dermatol 1990; 15:389– 393. Walsh JT, Cummings JP. Effect of the dynamic optical properties of water on midinfrared laser ablation. Lasers Surg Med 1994; 15:295 – 305. Berger JW. Erbium-YAG laser ablation: the myth of 1-micron penetration. Arch Ophthalmol 1998; 116:830 – 831. Walsh JT, Flotte TJ, Deutsch TF. Er:YAG laser ablation of tissue: effect of pulse duration and tissue type on thermal damage. Lasers Surg Med 1989; 9:314 – 326. Weiss RA, Harrington AC, Pfau RC, Weiss MA, Marwaha S. Periorbital skin resurfacing using high energy erbium:YAG laser: results in 50 patients. Lasers Surg Med 1999; 24:81 –86. Weinstein C. Erbium laser resurfacing: current concepts. Plast Reconstr Surg 1999; 103:602–616. Hibst R, Kaufmann R. Vergleich verschiedener Mittelinfrarot-Laser fu¨r die Ablation der Haut. Lasermedizin 1995; 11:19– 26. Hohenleutner U, Hohenleutner S, Ba¨umler W, Landthaler M. Fast and effective skin ablation with an Er:YAG Laser: determination of ablation rates and thermal damage zones. Lasers Surg Med 1997; 20:242– 247. Kaufmann R, Hibst R. Pulsed erbium:YAG laser ablation in cutaneous surgery. Lasers Surg Med 1996; 19:324– 330. Ross EV, Glatter RD, Duke D, Grevelink JM. Effects of pulse and scan stacking in CO2 laser skin resurfacing: a study of residual thermal damage, cell death and wound healing. Lasers Surg Med 1997; 20(suppl 9):42. Ratner D, Tse Y, Marchell N, Goldman MP, Fitzpatrick RE, Fader DJ. Cutaneous laser resurfacing. J Am Acad Dermatol 1999; 41:365 – 389.
Er:YAG Lasers 13. 14.
15.
16. 17. 18. 19.
20. 21. 22. 23.
24. 25.
26. 27. 28.
29.
30. 31.
32. 33. 34. 35.
195
Alster TS. Clinical and histologic evaluation of six erbium:YAG lasers for cutaneous resurfacing. Lasers Surg Med 1999; 24:87– 92. Tse Y, Manuskiatti W, Detwiler SP, Fitzpatrick RE, Goldman MP. Tissue effects of the erbium:YAG laser with varying passes, energy and pulse overlap. Lasers Surg Med 1998; 22(suppl 10):70. Kauvar AN, Grossman MC, Bernstein LJ, Kovacs SQ, Quintana AT, Geronemus RG. Comparison of tissue effects of carbon dioxide, erbium:YAG and novel infrared lasers for skin resurfacing. Lasers Surg Med 1998; 22(suppl 10):37. Alster TS. Cutaneous resurfacing with CO2 and erbium:YAG lasers: preoperative, intraoperative, and postoperative considerations. Plast Reconstr Surg 1999; 103:619– 632. Khatri KA, Ross V, Grevelink JM, Magro CM, Anderson RR. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol 1999; 135:391– 397. Alster TS, Kauvar AN, Geronemus RG. Histology of high-energy pulsed CO2 laser resurfacing. Semin Cutan Med Surg 1996; 15:189– 193. Cotton J, Hood AF, Gonin R, Beeson WH, Hanke CW. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulse carbon dioxide laser. Arch Dermatol 1996; 132:425 – 428. Rubach BW. Comparison of chemical peel and dermabrasion to carbon dioxide (CO2) laser resurfacing. Oper Tech Otolaryngol Head Neck Surg 1997; 8:9 –14. Perez MI, Bank DE, Silvers D. Skin resurfacing of the face with the erbium:YAG laser. Dermatol Surg 1998; 24:653 –659. Kaufmann R, Hartmann A, Hibst R. Cutting and skin-ablative properties of pulsed midinfrared laser surgery. J Dermatol Surg Oncol 1994; 20:112 – 118. Utley DS, Koch RJ, Egbert BM. Histologic analysis of the thermal effect on epidermal and dermal structures following treatment with the superpulsed CO2 laser and the erbium:YAG laser: an in vivo study. Lasers Surg Med 1999; 24:93– 102. Weinstein C. Computerized scanning erbium:YAG laser for skin resurfacing. Dermatol Surg 1998; 24:83 – 89. Hohenleutner S, Hohenleutner U, Ba¨umler W, Landthaler M. Laser skin resurfacing— Er:YAG-Laser und cw-CO2 Laser mit Scannersystem im Seitenvergleich. Hautarzt 1998; 49:367 – 371. Hohenleutner S, Hohenleutner U, Landthaler M. Comparison of erbium:YAG and carbon dioxide laser for the treatment of facial rhytides. Arch Dermatol 1999; 135:1416– 1417. Fitzpatrick RE, Rostan EF, Marchell N. Collagen tightening induced by carbon dioxide laser versus erbium:YAG laser. Lasers Surg Med 2000; 27:395 – 403. Greene D, Egbert BM, Utley DS, Koch RJ. In vivo model of histologic changes after treatment with the superpulsed CO2 laser, erbium:YAG laser, and blended lasers: a 4- to 6-month prospective histologic and clinical study. Lasers Surg Med 2000; 27:362 – 372. Newman JB, Lord J, Ash K, McDaniel DH. Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26:208 – 214. Khatri KA. The effects of variable pulse width of Er:YAG laser on facial skin. Dermatol Surg 2001; 27:332 – 334. Ross EV, McKinlay JR, Sajben FP, Miller CH, Barnette DJ, Meehan KJ, Chhieng NP, Deavers MJ, Zelickson BD. Use of a novel erbium laser in a Yucatan minipig: a study of residual thermal damage, ablation, and wound healing as a function of pulse duration. Lasers Surg Med 2002; 30:93 – 100. Pozner JM, Goldberg DJ. Histologic effect of a variable pulsed Er:YAG laser. Dermatol Surg 2000; 26:733 – 736. Majaron B, Srinivas SM, Huang HL, Nelson JS. Deep coagulation of dermal collagen with repetitive Er:YAG laser irradiation. Lasers Surg Med 2000; 26:215 –222. Rostan EF, Fitzpatrick RE, Goldman MP. Laser resurfacing with a long pulse erbium: YAG laser compared to the 950 ms pulsed CO2 laser. Lasers Surg Med 2001; 29:136 – 141. Zachary CB. Modulating the Er:YAG laser. Lasers Surg Med 2000; 26:223 – 226.
196 36. 37.
38. 39.
40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53.
54. 55. 56. 57. 58. 59. 60. 61.
Hohenleutner and Landthaler Ediger MN, Matchette LS. In vitro production of viable bacteriophage in a laser plume. Lasers Surg Med 1989; 9:296 – 299. Mullarky MB, Norris CW, Goldberg ID. The efficacy of the CO2 laser in the sterilization of skin seeded with bacteria: survival at the skin surface and in the plume emissions. Laryngoscope 1985; 95:186 – 187. Baggish MS, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156:1260 – 1265. Garden JM, O’Banion MK, Shelnitz LS, Pinski KS, Bakus AD, Reichmann ME, Sundberg JP. Papillomavirus in the smoke of carbon-dioxide laser treated verrucae. J Am Med Assoc 1988; 259:1199 – 1202. Nezhat C, Winer WK, Nezhat F, Forrest D, Reeves WG. Smoke from laser surgery: is there a health hazard? Lasers Surg Med 1987; 7:376– 382. Hughes PSH, Hughes PA. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol 1998; 38:426 – 428. Kirkpatrick JJR, Mackay IR. Sound levels produced by Erbium YAG lasers: health and safety issues. Lasers Med Sci 2000; 15:263– 265. Goldman MP, Fitzpatrick RE, Manuskiatti W. Laser resurfacing of the neck with the erbium: YAG laser. Dermatol Surg 1999; 25:164 – 167. Goldberg DJ, Meine JG. Treatment of photoaged neck skin with the pulsed erbium:YAG laser. Dermatol Surg 1998; 24:619 –621. Goldman MP. Techniques for erbium:YAG skin resurfacing: initial pearls from the first 100 patients. Dermatol Surg 1997; 23:1219 – 1221. Dover JS. Roundtable discussion on laser skin resurfacing. Dermatol Surg 1999; 25:639 – 653. Dover JS, Arndt KA, Dinehart SM, Fitzpatrick RE, Gonzalez E. Guidelines of care for laser surgery. J Am Acad Dermatol 1999; 41:484– 495. Roenigk RK, Rigel DS, Glogau RG. Table talk: common questions about laser resurfacing. Dermatol Surg 1997; 24:121 –130. Duke D, Grevelink JM. Care before and after laser skin resurfacing. A survey and review of the literature. Dermatol Surg 1998; 24:201– 206. Teikemeier G, Goldberg DJ. Skin resurfacing with the erbium:YAG laser. Dermatol Surg 1997; 23:685 – 687. Riedel F, Bergler W, Baker SA, Stein E, Hormann K. Kontrollierte Feinstdermablation im Gesichtsbereich mit dem Erbium:YAG-Laser. HNO 1999; 47:101– 106. Jimenez G, Spencer JM. Erbium:YAG laser resurfacing of the hands, arms, and neck. Dermatol Surg 1999; 25:831 –835. McDaniel DH, Lord J, Ash K, Md JN. Combined CO2/erbium:YAG laser resurfacing of peri-oral rhytides and side-by-side comparison with carbon dioxide laser alone. Dermatol Surg 1999; 25:285 –293. Polnikorn N, Goldberg DJ, Suwanchinda A, Ng SW. Erbium:YAG laser resurfacing in Asians. Dermatol Surg 1998; 24:1303 –1307. Goldberg DJ, Cutler KB. The use of the erbium:YAG laser for the treatment of class III rhytids. Dermatol Surg 1999; 25:713 –715. Collawn SS. Combination therapy: utilization of CO2 and erbium:YAG lasers for skin resurfacing. Ann Plast Surg 1999; 42:21 –26. Stuzin JM, Baker TJ, Baker TM. CO2 and erbium:YAG laser resurfacing: current status and personal perspective. Plast Reconstr Surg 1999; 103:588– 591. Riedel F, Windberger J, Stein E, Hormann K. Behandlung periokula¨rer Hautvera¨nderungen mit dem Erbium:YAG-Laser. Ophthalmologe 1998; 95:771 –775. Hughes PSH. Skin contraction following erbium:YAG laser resurfacing. Dermatol Surg 1998; 24:109 – 111. Goldman MP, Manuskiatti W. Combined laser resurfacing with the 950-microsec pulsed CO2 þ Er:YAG lasers. Dermatol Surg 1999; 25:160– 163. Millman AL, Mannor GE. Histologic and clinical evaluation of combined eyelid erbium:YAG and CO2 laser resurfacing. Am J Ophthalmol 1999; 127:614 – 616.
Er:YAG Lasers 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78.
197
Trelles MA, Allones I, Luna R. One-pass resurfacing with a combined-mode erbium:YAG/ CO2 laser system: a study in 102 patients. Br J Dermatol 2002; 146:473 – 480. Drnovsek-Olup B, Vedlin B. Use of Er:YAG laser for benign skin disorders. Lasers Surg Med 1997; 21:13 – 19. Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25:121 – 123. Jeong J-T, Kye J-C. Resurfacing of pitted facial acne scars with a long-pulsed Er:YAG laser. Dermatol Surg 2001; 27:107 –110. Lorenz S, Hohenleutner S, Hohenleutner U, Landthaler M. Treatment of diffuse plane xanthoma of the face with the Er:YAG laser. Arch Dermatol 2001; 137:1413– 1415. Kaufmann R, Beier C. Erbium:YAG laser therapy of skin lesions. Med Laser Appl 2001; 16:252 – 263. Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med 2001; 29:260 – 264. Orenstein A, Haik J, Tamir J, Winkler E, Frand J, Zilinsky I, Kaplan H. Treatment of rhinophyma with Er:YAG laser. Lasers Surg Med 2001; 29:230 – 235. Beier C, Kaufmann R. Efficacy of erbium:YAG laser ablation in Darier disease and Hailey-Hailey disease. Arch Dermatol 1999; 135:423– 427. Ochsendorf FR, Kaufmann R. Erbium:YAG laser-assisted treatment of miliary osteoma cutis. Br J Dermatol 1998; 138:371 – 372. Hughes PS. Multiple miliary osteomas of the face ablated with the erbium:YAG laser. Arch Dermatol 1999; 135:378 – 380. Kageyama N, Tope WD. Treatment of multiple eruptive hair cysts with erbium:YAG laser. Dermatol Surg 1999; 25:819 –822. Boehncke WH, Ochsendorf F, Wolter M, Kaufmann R. Ablative techniques in psoriasis vulgaris resistant to conventional therapies. Dermatol Surg 1999; 25:618 – 621. Albertini JG, Holck DEE, Farley MF. Zoon’s balanitis treated with erbium:YAG laser ablation. Lasers Surg Med 2002; 30:123 – 126. Kaufmann R, Greiner D, Kippenberger S, Bernd A. Grafting of in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. Acta Derm Venereol 1998; 78:136 –138. Yang JS, Kye YC. Treatment of vitiligo with autologous epidermal grafting by means of pulsed erbium:YAG laser. J Am Acad Dermatol 1998; 38:280 – 282. Podda M, Spieth K, Kaufmann R. Er:YAG laser-assisted hair transplantation in cicatricial alopecia. Dermatol Surg 2000; 26:1010 – 1014.
7 Pulsed Dye Lasers Kristen A. Richards Scripps Memorial Hospital, La Jolla, California, USA
Jerome M. Garden Northwestern University Medical School and Children’s Memorial Hospital, Chicago, Illinois, USA
1. Introduction 2. Basic Concepts 3. Safety 4. Laser Parameters 5. Clinical Effectiveness 6. Port-Wine Stains 7. Telangiectasias 8. Hemangiomas 9. Other Benign Vascular Disorders 10. Nonvascular Lesions 11. Rhytides 12. Pre- and Postoperative Considerations 13. Summary References
1.
199 199 202 202 203 203 207 208 209 210 211 211 212 212
INTRODUCTION
The pulsed dye laser’s clinical applications are diverse including vascular and nonvascular lesions as well as its newer use as a nonablative resurfacing tool. The paucity of side effects associated with the development of the dye laser in a pulsed mode has allowed the practitioner to treat lesions in all age groups and anatomical sites. 2.
BASIC CONCEPTS
In order to understand the reasons for the therapeutic advancements, it is important to evaluate several basic laser parameters. All lasers emit at specific wavelengths depending 199
200
Richards and Garden
upon the type of lasing medium in the optical cavity. As such, many different wavelengths can potentially be used as a source of lesional irradiation. For cutaneous blood vessel processes, such as port-wine stains (PWS), hemangiomas, spider angiomas, or telangiectasias, the main lesional chromophore is hemoglobin. It is assumed oxyhemoglobin is the major hemoglobin species which is present. It is an excellent target for laser emission, being located intravascularly and in high concentration. Oxyhemoglobin has major absorption peaks at 418, 542, and 577 nm (1,2). Although the strongest peak is at 418 nm, and, therefore, this wavelength would be most readily absorbed, the laser emission wavelength chosen for therapy centers around the 577 nm peak. The reasons for deciding on the weaker 577 nm absorption band are twofold. First, the major competing chromophore in the skin is melanin. Melanin absorbs very well in the ultraviolet range and has a diminishing absorption capacity throughout the visible range. Absorption of melanin at 418 nm is significantly greater than at 542 or 577 nm, with the latter wavelength having the least amount of absorption. The other reason is the penetration depth of laser emission. For the nonionizing, visible range of wavelengths, the longer the wavelength the deeper is the tissue penetration. Therefore, 577 nm has the advantage of coinciding with an oxyhemoglobin absorption band which has decreased melanin absorption and the advantage of increased tissue penetration (3). Recent evidence suggests that the use of longer wavelengths still maintains selective oxyhemoglobin absorption and vascular damage while increasing the depth of penetration over 577 nm (4 –6). Tissue response to laser emission is not only wavelength dependent but also time dependent. Since the effect of most cutaneous medical lasers is mainly through photothermal conversion, a longer tissue exposure results in a greater thermal response. Mathematical tissue modeling has been used to predict optimum laser time emissions to effect selective destruction of cutaneous blood vessels (2). An index used to assist in these computations is the thermal relaxation time. This is the time in which a heated container, such as the cutaneous blood vessel, loses about two-thirds of its maximum heat. Depending on blood vessel size, optimum pulse durations, at a specific wavelength, can be estimated through these formulae to produce the desired selectivity. The goal of these calculations is to find the amount of time necessary to heat and denature the vasculature while sparing the surrounding tissue (1). Dierickx et al. (7) found that pulse durations for ideal laser treatment are in the 1– 10 ms region for PWS and depend on vessel diameter. Selective heating of the targeted blood vessels can be best accomplished through the containment of high temperatures to the vessels, followed by the slow diffusion of cooler temperatures to the perivascular area. If the pulse duration produces vascular destruction and does not remain on long enough to allow diffusion of undesired high temperatures to the surrounding tissue, tissue sparing occurs. Clinical studies initially evaluated normal skin response, and subsequently, PWS response. Analysis of the 350 ns to 20 ms pulse duration range at 577 nm revealed vascular selective laser-induced damage (8 – 10), but these pulse durations were unable to produce PWS lightening (11). Although the confinement of thermal damage was vascular-specific with no apparent perivascular change, the vessels were able to repair sufficiently to effect no clinical change. When pulse durations were extended to the 20 – 450 ms range, at 577 nm, vascular selectivity remained (9). However, with these longer pulse durations, lesional lightening also occurred. Histological evaluation revealed an intravascular coagulum and not the extravasation of RBC seen at the shorter pulse durations (9,12). The longer pulse durations, especially those .200 ms, had an increased tendency to produce lesional lightening. Perivascular changes remained unremarkable with only a few areas of scattered focal epidermal spongiosis. The epidermal changes occurred most commonly adjacent to the
Pulsed Dye Lasers
201
areas of superficial blood vessels, which may have reflected direct thermal diffusion to the epidermis from these vessels. From these studies it appears that the time for the intravascular photothermal conversion must be long enough to cause significant endothelial damage and still short enough not to allow high temperatures to diffuse into the perivascular area. After analysis and selection of the appropriate wavelength and pulse duration for optimizing selective destruction of cutaneous blood vessels, another important laser parameter is the amount of energy delivered to the tissue (13). Based on mathematical projections at 577 nm and modeled for cutaneous blood vessels, energy fluences may be estimated which can elevate the core vessel temperature to 708C, producing the desired permanent endothelial denaturation (1). When initially studied in normal skin, the necessary energies for purpura and vessel damage were remarkably similar to these estimated values. Indeed, when much higher energy densities were tested in normal skin, there was significant perivascular damage with collagen denaturation. The data assisted the clinician in developing a therapeutic energy range for the PWS. On normal skin, the energy necessary to produce purpura at 577 nm and a 360 ms pulse duration with a 3 mm spot size was found to be 3.5 –4.25 J/cm2, depending on skin temperature (14,15) and color (16). Both of these factors influence laser –tissue interaction. The colder the tissue, the more is the energy fluence necessary to produce purpura. This is due either to vessel constriction and a decrease in target size or the need to heat the tissue over a greater temperature range. Also, epidermal melanin, acting as a shield or barrier to the incoming photons, necessitated using higher energies for darker skin types. The PWS, with its dilated vessels, requires a higher-energy fluence to produce lesional lightening. Again, the tissue factors of temperature and color play a similar role in lesional skin response as in normal skin (17). Another laser parameter that has been analyzed is the spot size. The spot size is the area of laser impact on the tissue during each pulse. Animal studies observed inconsistent laser tissue effects with a circular spot size of ,3 mm in diameter (18). It is believed that optical effects secondary to dermal scattering are important factors in the clinical outcome with changing spot size. Recent clinical work with a 2 mm spot size in the treatment of solitary telangiectatic vessels demonstrates the necessity for higher-energy fluences than used with 3 mm or greater spot sizes (19). Dinehart et al. (20) studied the beam profile of the flashlamp-pumped pulsed dye laser and found that 13% overlap of pulses could occur to better cover large vascular lesions without an increase in postoperative side effects. The selective thermal destruction of blood vessels with sparing of surrounding tissue using the above approach of optimizing laser and tissue parameters has been termed selective photothermolysis (21). It allows for the incorporation of laser light into tissues, targeted for specific structures, producing photothermal selective damage, without the need for structure-specific laser focusing. It is this approach which has produced an advancement in the desired clinical outcome. While the theoretical concepts were being developed, it was necessary to have a laser which could properly deliver the optimized laser parameters to the tissue. The flashlamp-pumped tunable pulsed dye laser was chosen because of its inherent flexibility. An emission in the 577 nm range was achieved by selecting the appropriate organic dye as the lasing medium and tuning to the desired wavelength with a filter. Recent modifications mix different organic dyes at set concentrations, producing the desired wavelength emission and forgoes the need of a filter. Also, the pulsed dye laser excited the dye long enough to achieve a pulse duration in the 400– 500 ms range, with sufficient energy to produce spot sizes of 3 mm and above.
202
Richards and Garden
Other lasers available for the treatment of cutaneous lesions either do not emit at the desired wavelength (argon, CO2 , Nd:YAG, ruby, current diodes, alexandrite and KTP) or are unable to produce pulse durations in the desired time range (argon, CO2 , Nd:YAG, ruby, KTP, copper-vapor, krypton, and argon laser-pumped tunable dye laser). Although many of these lasers are used beneficially to treat cutaneous blood vessel lesions, the decrease in laser – tissue selectivity with these lasers has limited patient selection, increased the need for technical expertise and, most importantly, potentially increased the occurrence of undesired side effects (22,23).
3.
SAFETY
The greatest risk to the patient and to the treating staff is eye damage. Because of good absorption of 585 nm light by the pigmented and vascular portions of the retina, there is a great potential for significant retinal damage if the appropriate protective eyewear is not worn. Goggles made from didymium, which has a narrow band of absorption high in the 500 nm visible spectrum are ideal for eye protection while at the same time allowing the operator to see. The patient can either wear these protective goggles, opaque goggles, or their eyes may be covered with gauze, or in the case of periorbital treatment, with metallic eye shields. Other risks include flash fire with the use of ethyl chloride cryogen spray, supplemental oxygen, and green vinyl tubing (24,25).
4.
LASER PARAMETERS
Pulsed dye laser parameters vary widely and are largely dependent on the lesion being treated. Table 7.1 outlines the parameters for currently used pulsed dye laser systems. Table 7.1 Pulsed Dye Laser Systems
Brand name
Wavelength (nm)
Pulse duration (ms)
Spot size and fluence (Maximum)
Candela
ScleroPLUS-HP
585– 600
1.5
Candela
V beam
595
Cynosure
Photo-Genica VLS
585– 600
Cynosure
Photo-Genica V-Star
595
5 mm, 20 J/cm2 7 mm, 15 J/cm2 10 mm, 6.0 J/cm2 2 7 mm, 30 J/cm2 7 mm, 15 J/cm2 10 mm, 7.5 J/cm2 3 10 mm, 25 J/cm2 3 mm, 20 J/cm2 5 mm, 20 J/cm2 7 mm, 10 J/cm2 10 mm, 5 J/cm2 3 5 mm, 20 J/cm2 7 mm, 20 J/cm2 10 mm, 10 J/cm2 12 mm, 7 J/cm2 3 5 mm, 25 J/cm2
Manufacturer
0.5– 40
0.45– 1.5
0.5– 40
Cooling Cryogen spray
Cryogen spray Air-cooled
Air-cooled
Pulsed Dye Lasers
203
The clinical information below more precisely addresses the settings indicated for the treatment of specific lesions. 5.
CLINICAL EFFECTIVENESS
There are many types of cutaneous blood vessel lesions that have been successfully treated with the pulsed dye laser including PWS, capillary hemangioma, telangiectasia, spider and senile angioma, permanent erythema from rosacea or trauma, angioma serpiginosum, angiofibroma, venous ectasia, and minor varicosities. It appears that in any small-caliber vessel, superficial tissue process is amenable to pulsed dye laser therapy (26 – 28). The most data and experience have been accumulated with PWS. In addition, there are many nonvascular lesions that have also been effectively treated using the pulsed dye laser. 6.
PORT-WINE STAINS
The major laser parameter which is varied with this laser is the emitted energy. However, wavelengths from 585 to 600 nm and pulse durations from almost 0.5 –10 ms are being used (29,30). Pulse durations past 20 ms are also being evaluated for effectiveness. Therapeutic energy dosages for PWS range from 3.5 up to 12 J/cm2 when using epidermal sparing methods such as cryogen sprays prior to laser impact for the higher fluences. The spot size generally used in treating PWS is either 7 or 10 mm. Originally in the treatment of PWS, test sites were placed over the lesion using energies of 1.5– 2 times the purpura dose. This was defined as the least amount of energy necessary to cause normal, nonlesional skin, to become purpuric within a set amount of time after laser exposures. However, as experience developed threshold testing was found unnecessary and test site energies are now chosen based on age, anatomical area, lesional thickness, and color (31). When the laser light impacts the tissue, two events occur. The patient experiences discomfort, described by many as a hot pin-prick or an elastic band snapping the skin, and the tissue becomes purpuric. The sensation is generally well tolerated by the adult patient except over anatomical sites of increased sensitivity such as the upper lip or periorbital areas. Larger diameter spot sizes may increase the perceived sensation. Epidermal cooling through cryogen sprays or cold water chambers also reduces associated pain. Local anesthesia, topical or injected, is helpful (32). In the adolescent or pediatric patient, several local anesthetic formulations have been useful. Four percent lidocaine gel (available in Great Britain) was found to be significantly better than eutectic mixture of local anesthetics (EMLA) in reducing pain caused by laser treatment (33). Twenty-five percent lidocaine in 70% dimethyl sulfoxide – ethanol was found to provide significantly greater permeation than EMLA cream but only provided some degree of anesthesia (10 – 100%) in 8/14 pediatric patients (34). Studies of pain control during pulsed dye laser treatments have shown iontophoresis using lidocaine 4% or 5% with or without epinephrine significantly decreases discomfort (35,36). The older child may find nitrous oxide beneficial, while infants have been helped by chloral hydrate or other oral mild sedating agents. Many of the children need even deeper sedation, with outpatient intramuscular or intravascular anesthesia being necessary. Popular anesthetics include propofol and ketamine for early infancy. Halothane can also be administered with ease when desired without the need for intubation (37). A newer fast-acting inhalation anesthetic agent, Sevoflurane, is now used in most patients for mask induction (38).
204
Richards and Garden
The purpura which occurs after laser impact, appears immediately or within a few minutes. It gradually darkens over the initial 24 h. Histologically, the purpura represents an intravascular coagulum (12). Within 24 h a leucocytoclastic vasculitis develops in treated vessels. Resorption of the vessel occurs over 4 weeks. The vessels are replaced by normal diameter vessels within a few months of treatment (39). Clinically, the purpura remains with the PWS patient for an average of 7 –14 days (40). During this time, the pediatric patient applies a topical antibiotic ointment as part of postoperative care. The adult patient, however, is allowed to place a cosmetic cover-up over the treated area immediately after therapy. Occasionally, there is some epidermal scaling or crusting at the higher energies used in the adult patient, which is treated with a topical antibiotic ointment. An atopic dermatitis-like reaction occasionally develops with PWS treatment which usually responds to treatment with mild topical corticosteroids (41). Test sites are placed over the PWS during the initial evaluation to judge clinical efficacy and optimal energy dosage. Multiple sites are generally placed using various parameters. Since the PWS is nonhomogeneous, different energies, wavelengths, or pulse durations may be needed to achieve the same clinical effect over various anatomical areas of the PWS. The goal is to use the least amount of energy to achieve the maximum acceptable outcome. There appears to be a dose-dependent clinical therapeutic window. Too little energy does not produce enough clinical lightening and too much energy may cause undesired pigmentary and texture changes with the potential of scarring. Although the PWS darkening that occurs with the laser impact generally resolves in 7 – 14 days, it may remain slightly longer with the 7 mm spotsize and higher fluences and shorter when using longer pulse durations and wavelengths. Eventual lesional lightening may take 2– 3 months (26 –28,40). In fact, after the darkening resolves, the lesion may appear redder or unchanged for several weeks. There is almost always a need to re-treat the same lesional area to enhance the PWS lightening. These retreatment sessions are repeated every 2 –3 months until a maximum degree of lesional clearing is achieved. It is not uncommon for the full lesion to undergo many treatment sessions. Lesional lightening may be achieved even after 20 treatment sessions. However, the percentage of lightening with each treatment continues to decrease and eventually it becomes appropriate to suspend therapy. Lesional lightening outcome can range from total clearing to very little perceptible change. It is assumed that a more superficial vessel having a smaller caliber will clear easier than a larger vessel situated deep in the dermis. Response to treatment also seems to vary based on two major patterns of vascular abnormality. Type 1 vessels composed of superficial, tortuous end capillary loops responded more effectively than Type 2 vessels composed of dilated, ectatic vessels in the superficial horizontal vascular plexus (42). Analysis of posttreatment vessels showed coagulated vessels to be superficially located (within 400 mm of the dermoepidermal junction) and of moderate size (38+19 mm) whereas lesions that showed poor blanching were significantly smaller (19+6.5 mm) or deeper (.800 mm from the dermoepidermal junction). In addition, red PWS predict a good response due to superficial location of the PWS whereas pink PWS predict a poor response due to the small vessel size and deep location (43). Since these lesions are composed of various caliber vessels with differing depths of involvement, inconsistent lightening occurs when comparing patient outcome, even within the same lesion. Analysis of lesional lightening reveals that 36 – 44% of adult PWS patients have 75% or greater color lightening and approximately 75% of the patients have at least 50% lightening after a total of four treatments (44,45). These results were based on a limited number of retreatments. It is likely that continued lightening would have occurred
Pulsed Dye Lasers
205
with more retreatment sessions [Fig. 7.1(a) and (b)]. The adult patients in which repeated treatments do not produce a substantial amount of lightening, fortunately account for ,10% of the total treated patients. Some of these patients possess the nodular and thickened PWS, which do not respond well to this laser. In patients who failed to achieve .75% lesional lightening within nine treatment sessions, significant improvement was seen after 10– 25 repetitive treatments (46). Very resistant PWS may respond better to continuous wave or quasicontinuous wave lasers, such as the argon, coppervapor, Nd:YAG, or krypton lasers, or intense pulsed noncoherent light sources which incorporate a greater degree of nonselective thermal energy necessary to decrease the soft tissue and vascular enlargements (22). Of interest are the PWS patients who do not respond well and have clinically identical lesions to other patients who do achieve an acceptable degree of lightening. Apparently, the clinical presentation of the lesion is not a consistent predictor as to therapeutic outcome with this laser. Anatomical areas respond differently to this laser, as with other types of lasers. Central cheeks and the upper lip areas are more resistant to therapy. V2 distributed PWS were found to clear ,25% after repeated laser treatments (47). The lower extremities and the distal upper extremities also are less responsive. The periorbital, lateral facial, neck, chest, and upper arm areas generally respond the best to the pulsed dye laser (48,49). Lesion size also plays a role in determining the response to the treatment. In one study, none of four adult patients with PWS .100 cm2 achieved 50% clearing following a mean of 17.2 + 5.7 treatments (50). In another study 15 (32%) of 47 patients with PWS ,20 cm2 at initial evaluation were totally cleared vs. 3 (8%) of 36 patients with PWS .20 cm2 (51). Even more significant than the degree of lesional lightening in the adult PWS patient has been the paucity of undesired adverse effects. A retrospective study of 701 patients with PWS treated with the pulsed dye laser showed hyperpigmentation as the most frequently observed adverse event in 9.1% of patients. Generally, this darkening slowly resolved over 6 – 12 months. Hypopigmentation was only seen in 1.4% of patients. Blistering and crusting were seen in 5.9% and 0.7% of patients, respectively. There was also a small but definite risk of scarring. Atrophic scarring occurred in 4.3% of patients with a predisposition for younger patients. Hypertrophic scarring was seen rarely in only 0.7% of patients and had a predisposition toward the neck (52). The clinical outcome in the pediatric PWS population using the pulsed dye laser has also been remarkable (28,53 – 57). Some studies affirm a greater ability to achieve lesional
Figure 7.1 (a) A 40-year-old female with right cheek PWS. (b) Same patient after 10 treatments with the pulsed dye laser. Photograph was taken 4 months after the last treatment (7 mm spot size, 7.25 J/cm2, 585 nm, 0.5 ms pulse duration).
206
Richards and Garden
lightening in the child than in the adult. The range of reported PWS lightening in these pediatric patients is from 100% clearing in all treated patients (53,54), to .95% clearing in 18% with the rest achieving 65 –70% response (55), to 42% of patients achieving .75% clearing and 84% of patients .50% response (56) to finally, 87% of patients reaching 50% lightening (57). These studies had differing age ranges, number of treatment sessions (ranging from two to more than six), and laser parameters, which make direct comparison difficult. Another study examined 91 patients younger than 18 years of age with PWS and found that the most successful response was seen in patients ,1 year old with small PWS (,20 cm2) which were located over bony areas of the face such as the central forehead (58). Other studies support the concept that there is no difference in response rates according to age. Alster and Wilson (59) reported that the number of treatments necessary to clear PWS in children 9 –16 years of age and patients .16 years of age was not greater than the number required to treat PWS in infants 0 –2 years of age. Van der Horst et al. (60) also found that there were no significant differences in color diminution of PWS amongst 89 patients divided into four different age groups. The small vessel caliber of the pediatric PWS compared to the adult may be a factor. The natural clinical progression of the PWS is to appear pink to red in childhood and to gradually darken and thicken in adulthood. This is due to progressive widening of the vessels with age. Unfortunately, there are infants who present with deeply colored PWS which indeed may lighten with greater difficulty (54). It is still necessary to perform retreatment sessions of lesional sites in the pediatric population. Whether with pediatric or adult PWS, after therapy is completed, when there is residual lesion that does not continue to sufficiently respond to warrant further procedures, there is always the potential of the lesion darkening with time. Indeed, that already has occurred in several patients. One would anticipate this happening due to natural evolution of vessel dilatation with aging. It is hoped that these treated lesions will not revert back to their original presentation since many of the vessels after treatment are of normal caliber. However, should the underlying etiology of PWS be a defect in PWS vessel nerve innervation, a greater than expected recurrence may happen. A prospective study examined 102 patients of ages 1 month to 66 years, with PWS who had good to complete responses after treatment with the pulsed dye laser. The authors found that PWS showed a tendency to recur at a rate approaching 50% between 3 and 4 years after completion of treatment (61). The energy dosages necessary for treatment of the pediatric PWS patient is less than in the adult, with the therapeutic window being smaller. However, energies as low as 3.5 J/cm2 have been used successfully in some pediatric PWS in certain anatomic areas, such as the neck and chest, using the 10 mm spot size. The potential to produce textural changes are greater in the pediatric population. Even energies above 6.5 J/cm2 have a tendency to produce these cutaneous changes in the younger ages. It is appropriate to treat these lesions with a greater number of repeat sessions at lower energies. The introduction of epidermal sparing using cold water chambers and cryogen sprays have allowed for a significant increase in energy to be tolerated. At 595 nm, in some cases, energies of 10 J/cm2 or greater may be used with a 7 mm spot size (30). Overlapping of the individual circular pulses is recommended in an effort to prevent a honeycomb pattern of clearing. This not only improves the appearance of the PWS as it clears but it also reduces the total number of needed treatments. However, overlapping should be limited to 10 –15% of the spot size (62). This is especially true in pediatric PWS, where there may be an increased risk of scarring if too much overlap occurs. The size of the treatment area is mainly determined by the patients’ tolerance of the procedure.
Pulsed Dye Lasers
207
Although treatment with the pulsed dye laser is far less painful than with continuous wave lasers, each pulse does produce discomfort. As the number of pulses increases, the pain associated with the treatment increases. Thus, pain may become the limiting factor of treatment if appropriate anesthetic intervention, such as that described earlier, is not used. Several new methods have been developed recently that more effectively increase clearance of PWS while minimizing side effects. Four patients completed clearing of their PWS after three to five sessions using a “multilayer technique.” During the first pass, the wavelength ranged from 590 to 600 nm with a long pulse (1.5 ms) while the second pass was performed utilizing the classic short pulse (450 ms) and wavelength (585 nm). One patient was noted to have mild blistering that eventually healed without scarring (63). Cryogen spray used in conjunction with the pulsed dye laser has allowed the use of higher fluences and improved PWS clearance while minimizing epidermal damage. In addition to increased clinical efficacy, a reduction in pain was also noted, especially in patients with darker skin types (64 – 66).
7.
TELANGIECTASIAS
Cutaneous vascular lesions, other than PWS, also respond well to the pulsed dye laser. Face, neck, and trunk telangiectases can be treated generally using a 2 7 mm or 2 mm spot size. Textural changes and hypopigmentation have been reported following treatment of facial telangiectasias (67). Telangiectasias may arise from a variety of causes, including actinic damage, rosacea, connective tissue disease, progressive ascending telangiectasia, telangiectasia macularis eruptiva perstans, hepatic dysfunction, or posttrauma (68 – 72). Darkening of the treated area resolves faster than with the PWS, lasting 5 –10 days. However, the dark appearance posttherapy is still of concern to many patients. Fortunately, the smaller 2 mm spot size has significantly diminished the posttherapy bruised appearance as does the use of the 595 nm wavelength or those even longer. Longer pulse durations may also reduce or eliminate the posttherapy darkening. Patient discomfort is less with the smaller spot size. Test site placement is only occasionally necessary with telangiectatic processes. Energies higher than 7.0 J/cm2 are usually necessary when using the 2 mm spot size. Lesional lightening may occur immediately after the posttherapy darkening resolves or up to 4– 6 weeks later. Retreatment sessions may be necessary but less often than with the PWS. The final therapeutic outcome is usually excellent with a significant reduction of the telangiectasias with only rare cases of skin texture change and/or depression. Vessels on the face respond best [Fig. 7.2(a) and (b)]. A study of 182 patients undergoing pulsed dye laser treatment showed that vessels .0.2 mm in diameter required multiple treatments, while vessels .0.4 mm in diameter were poorly responsive to pulsed dye laser treatment (73). Although lower extremity telangiectasias do not respond as favorably, very small caliber red vessels can be effectively treated. The fine caliber “star-burst”-type vessels, those ,0.2 mm in diameter, which often develop as a consequence of sclerotherapy may respond well to pulsed dye laser therapy, in one or two treatment sessions. A combined approach using other therapeutic modalities, such as sclerotherapy, on the larger caliber vessels and the laser on the very small caliber vessels which are more difficult to inject, has been used effectively. Unfortunately, even with these very small caliber vessels, postlaser hyperpigmentation may persist for many months.
208
Richards and Garden
Figure 7.2 (a) A 55-year-old female with perinasal telangiectasia. (b) Same patient after one treatment with the pulsed dye laser. Photograph was taken 8 months after the last treatment (37 mm spot size, 9.5 J/cm2, 585 nm, 0.5 ms pulse duration).
A study of 30 women with leg telangiectasias showed treatment to be most efficacious if vessels .0.2 mm in diameter were treated first with the pulsed dye laser at fluences between 7 and 8 J/cm2, followed by treatment of vessels 0.2 mm in size or less. Treatment results were not affected by the vessel location on the legs. Concomitant use of polidocanol in varying concentrations from 0.25% to 0.75% did not show increased efficacy of treatment (74). Studies using wavelengths up to 600 nm and pulse durations at 1.5 ms for the treatment of up to 1.0 mm lower extremity vessels have been promising. Elliptically shaped spot sizes at energies of 15 J/cm2 or greater have been shown to be effective at both 450 and 1.5 ms (75 – 79). Posttherapy hyperpigmentation even under these varying parameters remains an undesired sequela.
8.
HEMANGIOMAS
Capillary hemangiomas have responded well to pulsed dye laser therapy (80 – 83). However, only the superficial type of hemangioma appear to therapeutically benefit from laser therapy while the deep, cavernous type is unaffected [Fig. 7.3(a) and (b)]. It is in the early phase of clinical presentation, before or immediately at the onset of the proliferative stage, that the best outcome is achieved. The flatter, superficial lesions, those
Figure 7.3 (a) A 4-month-old female with a palmar capillary hemangioma. (b) Same patient after three treatments with the pulsed dye laser. Photograph was taken 1 month after the last treatment (5 mm spot size, 6.00 J/cm2, 585 nm, 0.5 ms pulse duration).
Pulsed Dye Lasers
209
which are 3 mm or less raised off the skin surface, respond to treatment with almost complete resolution. Low-energy doses are delivered every few weeks until the lesion flattens and resolves. If the lesion is raised .3 mm above the skin surface, it is more difficult to interrupt active proliferation and achieve total resolution. After completed therapy, some areas have developed texture changes of atrophy and hypopigmentation. There are criteria suggested in assisting the laser clinician in deciding when it is appropriate to use the laser for the treatment of capillary or mixed hemangiomas (Table 7.2). Ulcerated capillary hemangiomas and proliferative hemangiomas in areas causing functional impairment have also responded rapidly to pulsed dye laser treatment enabling the return of normal function (84,85).
9.
OTHER BENIGN VASCULAR DISORDERS
Areas of permanent cutaneous erythema and/or diffuse telangiectasia as occurs in rosacea, postrhinoplasty red-nose, postradiotherapy (86), poikiloderma of Civatte (87), keratosis pilaris, posttrauma, or with scars, respond to the pulsed dye laser. The therapeutic approach is similar to the PWS, using a 5 mm spot size or greater and treating a wide surface area. Outcome has been very favorable, with significant reduction and elimination of the underlying permanently dilated vessels and manifested erythema. Use of the 10 mm spot size using low energies which are immediately below the purpura threshold are encouraging. It may be possible to treat telangiectasias and permanent erythema while not inducing significant purpura with this large spot size or in using longer wavelength and/or pulse duration. Controversy exists surrounding the efficacy of the pulsed dye laser in the treatment of hypertrophic scars as well as the mechanism by which improvement seems to occur. One controlled study of 16 adult patients treated with the pulsed dye laser for keloid sternotomy scars showed significant improvement in erythema, scar height, skin surface texture, and pruritus (88). Another study examined histologic features before and after treatment of hypertrophic burn scars. The author showed laser-irradiated scars to have decreased numbers of fibroblasts with nonsclerotic dermal collagen and normal vascularity. These patients were found to have a reduction in scar erythema and pruritus and Table 7.2 Criteria for Consideration in the Use of Laser Therapy for Hemangiomasa 1. 2.
3.
a
Potential for functional impairment Risk of ulceration Rapid enlargement Recurrent trauma Moist area Cosmetic disfigurement Highly visible lesion Extensive surface area
Richards KA, Garden JM. The pulsed dye laser for cutaneous vascular and nonvascular lesions. In: Hruza GJ, ed. Seminars in Cutaneous Medicine and Surgery. Vol. 19, No. 4. Philadelphia: W.B. Saunders, 2000:276– 286.
210
Richards and Garden
improved scar pliability and skin surface texture (89). A recent controlled study of pulsed dye laser vs. silicone gel sheeting treatment of hypertrophic scars showed no difference from controls in clinical appearance or symptoms for either modality. In addition, examination of five biopsy specimens taken at week 0 and week 40 after treatment showed no change in fibrosis, number of telangiectasias, or number of mast cells when compared with healthy skin controls (90). The diversity of opinions on the efficacy of the pulsed dye laser in treating hypertrophic scars as well as the lack of a firm mechanism for scar reduction, leaves the door open for further studies. Solitary vascular lesions such as venous lakes, spider or cherry angiomas, angioma serpiginosum, and angiolymphoid hyperplasia with eosinophilia also respond favorably (26 –28,91,92). However, as with the PWS and hemangioma, the thicker lesions do not respond as well. A study of 18 patients with pyogenic granulomas showed clinical and symptomatic clearing of the lesions in 16 out of 18 patients with excellent cosmetic results (93). However, enlarged pyogenic granulomas are especially difficult to treat, even with multiple, repetitive, high-energy pulses to the lesion.
10.
NONVASCULAR LESIONS
Other cutaneous clinical processes which have been treated with the pulsed dye laser and evaluated for efficacy include plaque-type psoriasis (94,95) and warts (96). Both appear to respond but only in a limited manner (97). Psoriatic lesions do flatten but generally incompletely and can recur. One study showed that psoriatic plaques with vertically oriented vessels and few horizontal vessels responded better to treatment than plaques with numerous tortuous vessels (98). Warts which are not located over the periungual or plantar surfaces and are flat may resolve readily with laser therapy. However, very keratotic lesions and/ or those over the periungual or plantar surfaces have a much greater initial failure and follow-up recurrence rate. In both disease processes it is assumed that the laser interaction with the underlying vasculature plays a beneficial but uncertain role [Fig. 7.4(a) and (b)]. Recent applications of the pulsed dye laser in the treatment of cutaneous lesions are almost too numerous to count. Successful treatment has occurred in stretch marks (99), molluscum contagiosum (100), facial acne scars (101), xanthelasma palpebrarum (102), sebaceous gland hyperplasia (103), acne fulminans-associated granulation tissue (104), focal dermal hypoplasia (105), linear porokeratosis (106), nodular amyloidosis (107), Kaposi’s sarcoma (108), and granuloma faciale (109).
Figure 7.4 (a) A 29-year-old female with a left plantar verruca. (b) Same patient after three treatments with the pulsed dye laser. Photograph was taken 1 year after the last treatment (5 mm spot size, 10.00 J/cm2, 585 nm, 0.5 ms pulse duration).
Pulsed Dye Lasers
11.
211
RHYTIDES
It has been noted for sometime that pulsed dye laser treatment of vascular lesions incidentally improved the appearance of rhytides in treated skin. This observation has been evaluated for its potential use as a primary nonablative resurfacing modality (110 – 114). In one study by Zelickson et al. (112) 9 of 10 patients with mild to moderate rhytides showed at least 50% improvement 6– 14 months after one treatment with the pulsed dye laser and 4 of 10 patients with moderate to severe rhytids showed improvement ranging from 4% to 38%. Treatment fluences in this study ranged from 3.0 to 6.5 J/cm2 and both 7 and 10 mm spot sizes were used with 10– 15% overlap. Long-term follow-up of patients with moderate to severe rhytides showed some regression to baseline and a blinded panel was unable to differentiate between pre- and postoperative images. Side effects included purpura and swelling in all patients which lasted 1 –2 weeks and postinflammatory hyperpigmentation in two patients. Histopathology showed a thickened stratum spinosum, thickened collagen within the papillary dermis and increased mucin (112). Another ultrastructural study examining periorbital rhytids following pulsed dye laser analysis showed stimulation of fibroblast-mediated extracellular matrix remodeling (113). Bjerring and colleagues (114) examined the response of Fitzpatrick rhytides Classes I –III following pulsed dye laser in 30 patients. Parameters included a fluence of 2.4 J/cm2, pulse duration of 0.35 ms and a 5 mm spot size. Classes II and III rhytides demonstrated an improvement of 20% 6 months after a single treatment. Class I rhytides showed even less improvement. Using the same parameters, the same authors then compared single-pass sites to double-pass sites in a study examining the upper arms and forearms of 10 volunteers. Suction blisters were placed on each area as well as a control site following treatment with the pulsed dye laser and the blister fluid was then examined. A statistically significant increase was seen in the production of Type III procollagen in the single-pass sites compared with the control sites. The double-pass sites did not demonstrate a significant improvement (114). The authors speculated that the higher energy produced by the double-pass treatment had a suppressive effect on fibroblast collagen production. They also proposed that because only smaller vessels with a diameter of 15 mm or less trigger fibroblast activity, the short 0.35 ms pulse duration is essential to the pulsed dye laser’s photorejuvenation properties (114). Histopathologic analysis of scars treated with pulsed dye laser show an increase in dermal collagen as well as an increase in regional mast cells. Since mast cells release a variety of stimulatory cytokines, this may also explain the therapeutic improvement in appearance of the skin following pulsed dye laser treatment (111).
12.
PRE- AND POSTOPERATIVE CONSIDERATIONS
Since the majority of the treated cases do not develop significant crusting or erosions, it is not necessary to prophylactically prescribe antibacterials or antivirals. Postoperative care in the majority of cases ranges from none in those cases where the skin remains intact or antibacterial ointments for areas of scaling or erosions. Postoperative dressings are rarely placed, especially in the pediatric cases, where movement of adhesive dressings may injure the skin with removal.
212
Richards and Garden
Sun exposure and tanning need to be minimized prior to therapy due to increased melanin content absorbing the laser light. Both decreased effectiveness and increased chance of hypopigmentation may occur with laser therapy. After treatment, several weeks should pass before any UV exposure over the treated site to reduce the potential of dyspigmentation.
13.
SUMMARY
As the variety of pulsed dye lasers continue to expand so do the number of clinical applications to both vascular and nonvascular lesions. New topical anesthetic options make using the pulsed dye laser in the pediatric population even more feasible. In general, most types of cutaneous blood vessel disease have responded favorably to pulsed dye laser therapy. The best response occurs with processes which are superficially located and have small caliber vessel involvement, while the other types of vascular lesions may achieve a beneficial outcome but with greater difficulty. Nonvascular lesions of many types have also proven to respond effectively to pulsed dye laser therapy. Photodamaged skin and wrinkles have been shown to improve modestly following pulsed dye laser nonablative treatment. Side effects are rare and often transitory (115), but have been reported to include hypertrophic (116) and keloidal (117) scarring, pigmentary changes (118), and atrophic blanche-type scarring (119). Often these side effects were found to occur after using higher fluences than indicated (24,116), excessively overlapping pulses (120), or during concomitant Accutane use (117). Limitations in its ability to treat all lesions consistently well places an incentive on improving its design and use. Research into the methods of optimizing wavelength, pulse duration, spot size, and energy for the treatment of specific lesions is continuing. REFERENCES 1. 2. 3. 4. 5. 6. 7.
8.
9. 10.
Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med 1981; 1:263 – 276. Van Gemert MJC, Hulsbergen Henning JP. A model approach to laser coagulation of dermal vascular lesions. Arch Dermatol Res 1981; 270:429– 439. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981; 77:13– 19. Tan OT, Murray S, Kurban AK. Action spectrum of vascular specific injury using pulsed irradiation. J Invest Dermatol 1989; 92:868 – 871. Tan OT, Morrison P, Kurban AK. 585 nm for the treatment of portwine stains. Plast Reconstr Surg 1990; 86:1112 – 1117. Goldman L, Kerr JH, Larkin M, Binder S. 600 nm flash pumped dye laser for fragile telangiectasia of the elderly. Lasers Surg Med 1993; 13:227– 233. Dierickx CC, Caspanion JM, Venugopalan V et al. Thermal relaxation of port-wine stain vessels probed in vivo: The need for 1 –10 ms laser pulse treatment. J Invest Dermatol 1995; 105:709 – 714. Greenwald J, Rosen S, Anderson RR et al. Comparative histological studies of the tunable dye laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Garden JM, Tan OT, Kerschmann R et al. Effect of dye laser pulse duration on selective cutaneous vascular injury. J Invest Dermatol 1986; 87:653 –657. Nakagawa H, Tan OT, Parrish JA. Ultrastructural changes after pulsed laser radiation. J Invest Dermatol 1985; 84:396 – 400.
Pulsed Dye Lasers 11.
12. 13. 14.
15. 16. 17. 18. 19.
20. 21. 22. 23.
24. 25. 26. 27. 28. 29. 30. 31. 32. 33.
34.
213
Hulsbergen Henning JP, Van Gemert MJC, Lahaye CTW. Clinical and histological evaluation of portwine stain treatment with a microsecond-pulsed dye-laser at 577 nm. Laser Surg Med 1984; 4:375 – 380. Morelli JG, Tan OT, Garden J et al. Tunable dye laser (577 nm) treatment of portwine stains. Lasers Surg Med 1986; 6:94 – 99. Van Gemert MJC, Welch AJ, Amin AP. Is there an optimal laser treatment for portwine stains? Lasers Surg Med 1986; 6:76 – 83. Paul BS, Anderson RR, Jarve J, Parrish JA. The effect of temperature and other factors on selective microvascular damage caused by pulsed dye laser. J Invest Dermatol 1983; 81:333 – 335. Tan OT, Kerschmann R, Parrish JA. Effect of skin temperatures on selective vascular injury caused by pulsed dye laser irradiation. J Invest Dermatol 1985; 85:441– 444. Tan OT, Kerschmann R, Parrish JA. The effect of epidermal pigmentation on selective vascular effects of pulsed laser. Lasers Surg Med 1985; 4:365 – 374. Ashinoff R, Geronemus RG. Treatment of a portwine stain in a black patient with the pulsed dye laser. J Dermatol Surg Oncol 1992; 18:147 – 148. Tan OT, Motemedi M, Welch AJ, Kurban AK. Spotsize effects on guinea pig skin following pulsed irradiation. J Invest Dermatol 1988; 90:877 – 881. Grekin RC, Flynn TC, Cooper D. Efficacy of a 2 mm spotsize lens for the treatment of superficial vascular lesions with a flash-lamp pulsed dye laser. Int J Dermatol 1997; 36:865 – 869. Dinehart SH, Flock S, Waner M. Beam profile of the flashlamp pumped pulsed dye laser: support for overlap of exposure spots. Lasers Surg Med 1994; 15:277 – 280. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Tan OT, Stafford TJ, Murray S, Kurban AK. Histologic comparison of the pulsed dye laser and copper vapor laser effects on pig skin. Lasers Surg Med 1990; 10:551 – 558. Dover JS, Geronemus R, Stern RS, O’Hare D, Arndt KA. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 – 240. White J-M, Siegfried E, Boulder M et al. Possible hazards of cryogen use with pulsed dye laser. Dermatol Surg 1999; 25(3):250– 253. Waldorf HA, Kauvar ANB, Geronemus RG et al. Remote fire with the pulsed dye laser—risk and prevention. J Am Acad Dermatol 1996; 34:503 – 506. Garden JM, Geronemus RG. Dermatologic laser surgery. J Dermatol Surg Oncol 1990; 16:156 – 168. Garden JM, Bakus AD. Clinical efficacy of the pulsed dye laser in the treatment of vascular lesions. J Dermatol Surg Oncol 1993; 19:321– 326. Geronemus RG. Pulsed dye laser treatment of vascular lesions in children. J Dermatol Surg Oncol 1993; 19:303 –310. Edstrom DW, Ros AM. The treatment of port-wine stains with the pulsed dye laser. Brit J Dermatol 1997; 136:360 – 363. Geronemus RG, Quintana AT. High-fluence modified pulsed dye laser photocoagulation with dynamic cooling of portwine stains in infancy. Arch Dermatol 2000; 136:942 – 943. Sommer S, Sheehan-Dare RA. Pulsed dye laser treatment of port-wine stains in pigmented skin. J Am Acad Dermatol 2000; 42:667– 671. Tan OT, Stafford TJ. EMLA for laser treatment of portwine stains in children. Lasers Surg Med 1992; 12:543– 548. McCafferty DF, Woolfson AD, Handley J et al. Effect of percutaneous local anesthetics on pain reduction during pulsed dye laser treatment of portwine stains. Br J Anesth 1997; 78:286 – 289. Mallory SB, Lehman PA, Vanderpcol DR et al. Topical lidocaine for anesthesia in patients undergoing pulsed dye laser treatment for vascular malformations. Ped Dermatol 1993; 10(4):370– 375.
214
Richards and Garden
35.
Kennard CD, Whitaker DC. Iontophoresis of lidocaine for anesthetic during pulsed dye laser treatment of port-wine stains. J Dermatol Surg Oncol 1992; 18:287 –294. Nunez M, Mirolles ES, Boirelos P et al. Iontophoresis for anesthesia during pulsed dye laser treatment of port-wine stains. Pediatr Dermatol 1997; 14(5):397 – 400. Rabinowitz L, Esterly N, eds. Anesthesia and/or sedation for pulsed dye laser therapy: special symposium. Pediatr Dermatol 1992; 9:132 – 153. Grevelink JM, White VR, Bonodr R et al. Pulsed laser treatment in children and the use of anesthesia. J Am Acad Dermatol 1997; 37:75 – 81. Tan OT, Whitaker D, Garden JM, Murphy G. Pulsed dye laser (577 nm) treatment of portwine stains: ultrastructural evidence of neovascularization and mast cell degranulation in healed lesions. J Invest Dermatol 1988; 90:395 – 398. Garden JM, Tan OT, Parrish JA. The pulsed dye laser: its use at 577 nm wavelength. J Dermatol Surg Oncol 1987; 13:134– 138. Shahidullah H. Eczema as a complication of pulsed dye laser therapy. Arch Dermatol 1999; 135:215 – 216. Motley RJ. Videomicroscopy predicts outcome in treatment of port-wine stains. Arch Dermatol 1997; 133:921 –922. Fiskarstrand EJ, Svaasand LO, Kopstad G et al. Photothermally induced vessel-wall necrosis after pulsed dye laser treatment: lack of response in PWS with small sized or deeply located vessels. J Invest Dermatol 1996; 107:671 – 674. Garden JM, Polla LL, Tan OT. The treatment of portwine stains by the pulsed dye laser: analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124:889 – 896. Glassberg E, Lask GP, Tan EML, Uitto J. The flashlamp-pumped 577 nm pulsed tunable dye laser: clinical efficacy and in vitro studies. J Dermatol Surg Oncol 1988; 14:1200 – 1208. Kauvar ANB, Geronemus RG. Repetitive pulsed dye laser treatments improve persistent port wine stains. Dermatol Surg 1995; 21:515 – 521. Kane KS, Smoller BR, Fitzpatrick RE et al. Pulsed dye laser-resistant port-wine stains. Arch Dermatol 1996; 132:839 – 844. Holy A, Geronemus RG. Treatment of periorbital portwine stains with the flashlamp-pumped pulsed dye laser. Arch Ophthalmol 1992; 110:793 – 797. Renfro L, Geronemus R. Anatomical differences of portwine stains in response to treatment with the pulsed dye laser. Arch Dermatol 1993; 128:182 – 188. Yohn JJ, Huff JC, Aeling JL et al. Lesion size is a factor for determining the rate of port-wine stain clearing following pulsed dye laser treatment in adults. Cutis 1997; 59:267– 270. Morelli JG, Weston WL, Huff JC. Initial lesion size as a predictive factor in determining the response of port-wine stains in children treated with the pulsed dye laser. Arch Pediatr Adolesc Med 1995; 149:1142 – 1144. Seukeran DC, Collins P, Sheehan-Dare RA. Adverse reactions following pulsed tunable dye laser treatment of port wine stains in 701 patients. Br J Dermatol 1997; 136:725– 729. Tan OT, Sherwood K, Gilchrest BA. Treatment of children with portwine stains using the flashlamp-pumped tunable dye laser. N Engl J Med 1989; 320:416– 421. Garden JM, Burton CS, Geronemus R. Dye laser treatment of children with portwine stains. N Engl J Med 1989; 321:901 – 902. Goldman MP, Fitzpatrick RE, Ruiz-Esparaza J. Treatment of portwine stains (capillary malformation) with the flashlamp-pumped pulsed dye laser. J Pediatr 1993; 122:71– 77. Ashinoff R, Geronemus RG. Flashlamp-pumped pulsed dye laser for portwine stains in infancy: earlier versus later treatment. J Am Acad Dermatol 1991; 24:467 – 472. Reyes BA, Geronemus R. Treatment of portwine stains during childhood with the flashlamppumped pulsed dye laser. J Am Acad Dermatol 1990; 23:1142 – 1148. Nguyen CM, Yohn JJ, Huff C. Facial port wine stains in childhood; prediction of the rate of improvement as a function of the age of the patient, size and location of the port wine stain and the number of treatments with the pulsed dye (585 nm) laser. Br J Dermatol 1998; 138:821 – 825.
36. 37. 38. 39.
40. 41. 42. 43.
44. 45.
46. 47. 48. 49. 50. 51.
52. 53. 54. 55. 56. 57. 58.
Pulsed Dye Lasers 59. 60.
61. 62. 63. 64. 65. 66.
67. 68. 69. 70.
71. 72. 73. 74. 75. 76. 77.
78.
79. 80.
81. 82.
215
Alster TS, Wilson F. Treatment of port wine stains with the flashlamp pumped pulsed dye laser: extended clinical experience in children and adults. Ann Plast Surg 1994; 32:478 – 484. Van der Horst C, Koster PHL, DeBorgre CAJM et al. Effect of the timing of treatment of port wine stains with the flash-lamp-pumped pulsed dye laser. N Engl J Med 1998; 338:1028 – 1033. Orten SS, Warner M, Flock S. Port wine stains: an assessment of 5 years of treatment. Arch Otolaryngol Head Neck Surg 1996; 122:1174 – 1179. Dinehart SM, Flock S, Waner M. Beam profile of the flashlamp-pumped pulsed dye laser: support for overlap of exposure spots. Lasers Surg Med 1994; 15:277 – 280. Bencini PL. The multilayer technique: a new and fast approach for flashlamp-pumped pulsed dye laser treatment of port-wine stains. Dermatol Surg 1999; 25(10):786– 789. Walderf HA, Alster TS. Effect of dynamic cooling on 585 nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg 1997; 23:657– 660. Nelson JS, Milner TE, Anvari B. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain. Arch Dermatol 1995; 131:695 – 700. Chang CJ, Nelson JS. Cryogen spray cooling and higher fluence pulsed dye laser treatment improve port-wine stain clearance while minimizing epidermal damage. Dermatol Surg 1999; 25(10):767 –772. Swinehart JM. Textural change following treatment of facial telangiectasias with the tunable pulsed-dye laser. Arch Dermatol 1999; 135:472 – 473. Polla LL, Tan OT, Garden JM, Parrish JA. Tunable pulsed dye laser for the treatment of benign cutaneous vascular ectasia. Dermatologica 1987; 174:11– 17. Gonzalez E, Gange RW, Momtaz KT. Treatment of telangiectasias and other benign vascular lesions with the 577 nm pulsed dye laser. J Am Acad Dermatol 1992; 27:220 – 226. Lowe NJ, Behr KL, Fitzpatrick R, Goldman M, Ruiz-Esparza J. Flashlamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol 1991; 17:522 – 525. Perez B, Nunez M, Boixeda P et al. Progressive ascending telangiectasia treated with the 585 nm flashlamp-pumped pulsed dye laser. Lasers Surg Med 1997; 21:413– 416. Ellis DE. Treatment of telangiectasia macularis eruptiva perstans with the 585-nm flashlamppumped dye laser. Dermatol Surg 1996; 22:33 – 37. Ruiz-Esparza J, Goldman MP, Fitzpatrick RE et al. Flash lamp-pumped dye laser treatment of telangiectasia. J Dermatol Surg Oncol 1993; 19:1000 – 1003. Goldman MP, Fitzpatrick RE. Pulsed dye laser treatment of leg telangiectasia with or without simultaneous sclerotherapy. J Dermatol Surg Oncol 1990; 16:338 –344. Bernstein EF, Lee J, Lowery J, Brown DB, Geronemus R, Lask G, Hsia J. Treatment of spider veins with the 595 nm pulsed-dye laser. J Am Acad Dermatol 1998; 39:746 – 750. Hsia J, Lower JA, Zelickson B. Treatment of leg telangiectasia using a long-pulse dye laser at 595 nm. Lasers Surg Med 1997; 20:1– 5. Hohenleutner U, Walther T, Wenig M, Baumler W, Landthaler. Leg telangiectasia treatment with 1.5 ms pulsed dye laser, ice cube cooling of the skin and 595 vs 600 nm: preliminary results. Lasers Surg Med 1998; 23:72– 78. Alora MB, Seven RS, Arndt KA, Dover JS. Comparison of the 595 nm long-pulse (1.5 ms) and ultralong-pulse (4 ms) lasers in the treatment of leg veins. Dermatol Surg 1999; 25:445 – 449. Dover JS, Sadick NS, Goldman MP. The role of lasers and light sources in the treatment of leg veins. Dermatol Surg 1999; 25:328 – 336. Glassberg E, Lask G, Rabinowitz LG, Tunnessen WW. Capillary hemangiomas: case study of a novel laser treatment and a review of therapeutics options. J Dermatol Surg Oncol 1989; 15:1214 – 1223. Ashinoff R, Geronemus RG. Capillary hemangiomas and treatment with the flashlamp pumped dye laser. Arch Dermatol 1991; 127:202 – 205. Garden JM, Bakus AD, Paller AS. Treatment of cutaneous hemangiomas by the flashlamppumped pulsed dye laser: prospective analysis. J Pediatr 1992; 120:555 – 560.
216
Richards and Garden
83.
Morelli JG, Tan OT, West WL. Treatment of ulcerated hemangiomas with the pulsed tunable dye laser. Am J Dis Child 1991; 145:1062 – 1064. Lacour M, Syed S, Linward J et al. Role of the pulsed dye laser in the management of ulcerated capillary haemangiomas. Arch Dis Child 1996; 4:161 – 163. Barlow RJ, Walker NPJ, Markey AC. Treatment of proliferative haemangiomas with the 585 nm pulsed dye laser. Br J Dermatol 1996; 134:700 – 704. Ahmad M, Mirza S, Foo ITH. Pulsed dye laser treatment of telangiectasia after radiotherapy for breast carcinoma. Br J Plast Surg 1999; 52:236– 237. Geronemus RG. Poikiloderma of civatte. Arch Dermatol 1990; 126:547– 548. Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamppumped pulsed-dye laser. Lanolt 1995; 345:1198 – 1200. Alster TS, Nanin CA. Pulsed dye laser treatment of hypertrophic burn scars. Plast Reconstr Surg 1998; 102:2190 – 2198. Wittenberg GP, Fabian BG, Bogomilsky JL et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585 nm flashlamp-pumped pulsed dye laser and silicone gel sheeting in hypertrophic scar treatment. Arch Dermatol 1999; 135:1049 – 1055. Long CC, Lanigam SW. Treatment of angioma serpiginosum using a pulsed tunable dye laser. Br J Dermatol 1997; 136:631 – 632. Lertzman BH, McMeekin T, Gaspari AA. Pulsed dye laser treatment of angiolymphoid hyperplasia with eosinophilia lesions. Arch Dermatol 1997; 133:920 – 921. Gonzalez S, Vibnagool C, Folo LD et al. Treatment of pyogenic granulomas with the 585 nm pulsed dye laser. J Am Acad Dermatol 1996; 35:428 – 431. Hacker SM, Rasmussen JE. The effect of flashlamp-pulsed dye laser on psoriasis. Arch Dermatol 1992; 128:853 – 855. Ros AM, Garden JM, Bakus AD, Hedblad MA. Psoriasis response to the pulsed dye laser. Lasers Surg Med 1996; 19:331 – 335. Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report. Lasers Surg Med 1993; 13:127 –137. Ross BS, Levine VJ, Nehal K, Tse Y, Ashinoff R. Pulsed dye laser treatment of warts: an update. Dermatol Surg 1999; 25:377– 380. Zelickson BD, Mehregan DA, Wendelschfer-Crabb G et al. Clinical and histologic evaluation of psoriatic plaques treated with a flashlamp pulsed dye laser. J Am Acad Dermatol 1996; 35:64 – 68. McDaniel DH, Ash K, Zukowski M. Treatment of stretch marks with the 585 nm flashlamppumped pulsed dye laser. Dermatol Surg 1996; 22:332 – 337. Hughes PSH. Treatment of molluscum contagiosum with the 585 nm pulsed dye laser. Dermatol Surg 1998; 24:229 –230. Alster TS, McMeekin TO. Improvement of facial acne scars by the 585 nm flashlamppumped pulsed dye laser. J Am Acad Dermatol 1996; 35:79 – 81. Schonermark MP, Raulin C. Treatment of xanthelasma palpebrarum with the pulsed dye laser. Lasers Surg Med 1996; 19:336 –339. Gonzalez S, White WM, Rajadhyaksha M et al. Confocal imaging of sebaceous gland hyperplasia in vivo to assess efficacy and mechanism of pulsed dye laser treatment. Lasers Surg Med 1999; 25:8– 12. Wasner AM, Cunningham B. Effective treatment of acne fulminans-associated granulation tissue with the pulsed dye laser. Pediatr Dermatol 1998; 15(5):396 – 398. Alster TS, Wilson F. Focal dermal hypoplasia (Goltz’s syndrome). Arch Dermatol 1995; (13):143– 144. Alster TS, Nanni CA. Successful treatment of porokeratosis with 585 nm pulsed dye laser irradiation. Cutis 1999; 63:265 – 266. Alster TS, Manaloto RMP. Nodular amyloidosis treated with the pulsed dye laser. Dermatol Surg 1999; 25:133 –135. Marchell N, Alster TS. Successful treatment of cutaneous Kaposi’s sarcoma by the 585 nm pulsed dye laser. Dermatol Surg 1997; 23:973 – 975.
84. 85. 86. 87. 88. 89. 90.
91. 92. 93. 94. 95. 96. 97. 98.
99. 100. 101. 102. 103.
104. 105. 106. 107. 108.
Pulsed Dye Lasers 109. 110. 111. 112. 113.
114. 115. 116. 117. 118.
119. 120.
217
Ammirati CT, Hruza GJ. Treatment of granuloma faciale with the 585 nm pulsed dye laser. Arch Dermatol 1999; 135:903 – 905. Tope WD, Kageyama N. New methods in cutaneous resurfacing. Adv Dermatol 2001; 17:301 – 323. Goldberg DJ. Nonablative resurfacing. Clin Plast Surg 2000; 27(2):287 – 292, xi. Zelickson BD, Kilmer SL, Bernstein E et al. Pulsed dye laser therapy for sun damaged skin. Lasers Surg Med 1999; 25:229 – 236. Zelickson BD, Kist DA. Pulsed dye laser and photoderm treatment stimulates production of type-I collagen and collagenase transcripts in papillary dermis fibroblasts. Lasers Surg Med 2001; 27:33S. Bjerring P, Clement M, Heickendorff L et al. Selective non-ablative wrinkle reduction by laser. J Cutan Laser Ther 2000; 2:9– 15. Boixeda P, Nunez M, Perez B et al. Complications of 585 nm pulsed dye laser therapy. Int J Dermatol 1997; 36:393 – 397. Gaston DA, Clark DP. Facial hypertrophic scarring from pulsed dye laser. Dermatol Surg 1998; 24:523 – 525. Bernstein LJ, Geronemus RG. Keloid formation with the 585-nm pulsed dye laser during isotretinoin treatment. Arch Dermatol 1997; 133:111 –112. Levine VJ, Geronemus RG. Adverse effects associated with the 577 and 585-nanometer pulsed dye laser in the treatment of cutaneous vascular lesions: a study of 500 patients. J Am Acad Dermatol 1995; 32:613 – 617. Sommer S, Sheehan-Dare RA. Atrophie blanche-like scarring after pulsed dye laser treatment. J Am Acad Dermatol 1999; 41:100 – 102. Buscaglia DA. Hypertrophic scarring from pulsed dye laser treatment. Dermatol Surg 1999; 25(1):75.
8 Clinical Uses of the Long Pulse Duration Pulsed Dye Laser Eric F. Bernstein Laser Surgery and Cosmetic Dermatology Centers, Marlton, New Jersey and University of Pennsylvania, Philadelphia, Pennsylvania, USA
1. Port-Wine Stains 2. Keloids and Hypertrophic Scars 3. Verrucae 4. Rosacea and Facial Telangiectasias 5. Lower-Extremity Telangiectasias 6. Lupus Erythematosis 7. Striae 8. Sebaceous Gland Hyperplasia 9. Psoriasis 10. Nonablative Skin Remodeling with the PDL 11. Future Developments in Long-Pulse PDL 12. Laser Physics: Suggested Parameters References
220 225 227 228 231 233 233 234 235 236 241 241 241
Based on the original work by Anderson and Parrish (1,2), pulsed lasers have become the mainstay of treatment for an ever-expanding number of cutaneous conditions. The rapid proliferation in the number and types of lasers used to selectively heat target tissues is even more remarkable when considering that this evolution occurred during less than two decades. Anderson and Parrish used a predictive model to choose a laser that would selectively target blood vessels. They modeled the wavelength, duration of exposure, and energy density necessary to destroy blood vessels. Initially, they chose a wavelength of 577 nm due to the strong hemoglobin absorption at this wavelength. They estimated that the optimal pulse duration for targeting unwanted cutaneous vessels was approximately 1 ms, based on experimental estimates of thermal relaxation for microvessels in Caucasian skin (1 – 3). The laser they selected had a pulse duration of 0.3 ms, less than the 1 ms pulse 219
220
Bernstein
duration that they estimated to be optimal for targeting of cutaneous vessels, but at the limits of what was technically achievable at the time (1). Previously, continuous nonpulsed vascular lasers had an unacceptable side effect profile, resulting in necrosis of skin overlying blood vessels (1 – 3). This necrosis often resulted in permanent scarring. Anderson and Parrish proposed that the pulsed dye laser (PDL) would prove useful for the treatment of vascular malformations such as port-wine stains (PWS), hemangiomas, and other vascular lesions, with a satisfactory side effect profile (1). Following their initial observations (1,3), Anderson and Parrish published their landmark manuscript describing the concept of selective photothermolysis, detailing the ability of pulsed lasers to selectively remove unwanted blood vessels, pigmented structures, cells, and organelles without significant collateral damage to surrounding tissues (4). Selective damage to microvessels in the skin as well as melanosomes contained within melanocytes was demonstrated using 577 and 351 nm pulsed lasers. Physiologic responses to these pulsed lasers were also described (4). Since these initial observations, the evolution of the PDL has made treatment of PWSs more efficacious, resulting in fewer treatments being necessary, as well reducing the pain and pigmentary alterations following treatment. The PDL evolved from having small spot sizes of 4 –5 mm and pulse durations in the 0.3 – 0.5 ms range, to spot sizes of 7 – 10 mm and pulse durations of 1.5 ms and beyond. Longer pulse durations and larger spot sizes often yield improved clinical results, most likely due to the greater penetration depths afforded by larger spot sizes and gentler heating of larger vessels with longer pulse durations. An even newer generation of PDLs has evolved that attempt to create pulse durations in the 10–50 ms domain. True continuous pulses in this range have not been reliably achieved with PDLs. The characteristics of the rhodamine dyes used in PDLs are such that they begin to break down at the high temperatures reached when attempting to generate these longer pulse durations. Current lasers claiming pulse durations in the 40 ms range actually generate pulses composed of three to four shorter pulses separated by “off” times of various intervals. These shorter pulses are spread over 10–40 ms, although the laser does not fire throughout the entire time interval. Although the clinical effects of these longer pulse duration lasers differ from those of traditional PDLs, they still do not have the characteristics of a truly continuous 10–40 ms pulse. Currently, solid state neodymium:yttrium, aluminum, and garnet (Nd:YAG) lasers are capable of generating true long pulses of up to 50 ms at the 532 nm green wavelength (5–7). Comparable lasers capable of delivering yellow/orange light at these pulse durations are still years away.
1.
PORT-WINE STAINS
Following the initial experimental evidence that blood vessels could be destroyed using pulsed yellow-light lasers, PWSs were among the first clinical conditions to be treated. Initial attempts were made using lasers in the microsecond domain with relatively small spot sizes. Vascular injury was documented as was a negative correlation between skin pigmentation and treatment effect, although significant clinical improvement was not demonstrated (8,9). The authors postulated the need for lasers with pulse durations in the millisecond domain. Despite the landmark discoveries by Anderson and Parrish, the replacement of older laser technologies with the PDL for the treatment of PWSs was occurring slowly. Gradually, the PDL began to emerge as the frontrunner, as opposed to previously available laser technologies for the treatment of PWSs (10). Initial reports using PDLs with a wavelength of 577 nm and pulse durations of 0.3–0.4 ms demonstrated favorable clinical results for the treatment of PWSs (11). These results were reported 6 years after
Clinical Uses of the Long Pulse Duration PDL
221
the initial observations by Anderson and Parrish (1) that pulsed yellow light could effectively remove unwanted cutaneous vessels. At that time, the argon laser was still reported to be the laser of choice for most physicians treating PWSs, despite the relatively high incidence of scarring when using these lasers (12). Clinical use of PDLs was limited largely due to the constraints of the available technologies. PDLs with pulse durations approaching 0.3–0.4 ms were being developed and utilized for the treatment of PWSs, yielding superior results over previously available systems (13–15). Wavelengths longer than 577 nm were evaluated and found to be more effective, presumably due to the deeper penetration of longer wavelengths within target vessels (16,17). Patients previously treated for PWSs with a 577 nm PDL were subsequently treated with a 585 nm PDL and demonstrated further clearing of their PWSs (16). Deeper penetration of the 585 nm light was demonstrated as compared to 577 nm light (16). The 585 nm PDL proved quite effective for the treatment of PWSs. The safety and improved efficacy of the PDL enabled treatment of infants with PWSs, yielding improved clearance over previous modalities. Ashinoff and Geronemous (18) demonstrated 50% clearance in 10 of 12 treated children, after a mean of only 3.8 treatments. These results were achieved without any pigmentary alterations, textural change, or evidence of scarring, demonstrating the safety of the 585 nm PDL for treating PWSs. These authors also demonstrated the ability of this laser system to induce regression in capillary hemangiomas, with an overall 70% improvement (19). The 585 nm PDL also proved effective for improving ulcerations and associated bleeding in hemangiomas (20). Goldman and Fitzpatrick reported on the treatment of 46 PWSs in 43 patients using the 585 nm PDL, and demonstrated 50% clearance after the first treatment. Subsequent treatments resulted in an additional 10% clearing. Overall, 16% of patients demonstrated 95% or greater clearance after an average of approximately four treatments. The laser proved extremely safe, with no evidence of scarring (21). Alster and Wilson reported on 76 patients treated with the 585 nm, 0.45 ms pulse duration PDL, showing .90% improvement in approximately half the patients, after an average of nine treatments. The overall improvement was 79% after nine treatments (22). Although the rate of improvement of PWSs was significant with an extremely low side effect profile, a large number of treatments were still required for near complete clearance. Treatments extended over years, still with incomplete clearing in many patients. Although the initial results with the PDL for treating PWSs were remarkable as compared to previously available technologies, further improvements in the PDL were incremental for a relatively long period of time. The development of a PDL with a pulse duration of 1.5 ms was a major stride forward. The initial 1.5 ms pulse duration PDL offered an elliptical 2 7 mm spot and 595 and 600 nm wavelengths. This laser was primarily designed for the treatment of facial and lower extremity telangiectasias. Subsequently, a 7 mm spot was offered with this laser, enabling delivery of a maximum fluence of 10 J/cm2. Initial results with this system demonstrated improved clearing of PWSs that had stopped progressing with conventional 585 nm, 0.45 ms pulse duration PDL treatment (Fig. 8.1). Improvement was again incremental, with many lesions failing to progress after a number of treatments using the 595 nm wavelength, 1.5 ms pulse duration, and a maximum fluence of 10 J/cm2 (author’s unpublished results). The highest available energy of 10 J/cm2 was not near the maximum tolerated fluence at this wavelength and spot size; however, earlier machines were limited to this energy. Subsequently, the 585 nm wavelength was offered, in addition to 595 and 600 nm, with the 1.5 ms pulse duration. A maximum fluence of 10 J/cm2 was also available with the 585 nm wavelength, using a 7 mm spot size. This energy was close to the maximally tolerated fluence, as demonstrated clinically by crusting in certain areas of treated PWSs, in a number of patients during 1– 2 weeks following treatment. Crusting of the
222
Bernstein
Figure 8.1 (a) A patient with a PWS prior to treatment with the PDL. (b) Treatment with the 595 nm, 1.5 ms pulse duration PDL using a 7 mm spot produced further clearing of the PWS than was possible using the short pulse duration (0.45 ms), 585 nm PDL. (c) After initial improvement using 595 nm, the PWS again failed to improve after a number of treatments with the 1.5 ms pulse duration PDL at 595 nm. During this patient’s course of treatment, 585 nm became available with the 1.5 ms pulse duration PDL. Treatment at this wavelength resulted in the further improvement shown here.
treated site is indicative of epidermal damage, and is not uncommon in isolated areas of a PWS in some patients. Although undesirable, crusting very rarely results in scarring. Initial clinical observations revealed the potential for improved clinical results using 585 nm and the longer 1.5 ms pulse duration [Fig. 8.1(a) and (b)]. To demonstrate the effect of a longer pulse duration alone, a patient previously treated seven times with the 585 nm, 0.45 ms pulse duration PDL was subsequently treated with the 585 nm, 1.5 ms
Clinical Uses of the Long Pulse Duration PDL
223
pulse duration laser. This patient was treated with the identical fluence, wavelength, and spot size that were used with the 0.45 ms laser, with the only variable being the longer, 1.5 ms pulse duration. The response in this patient was quite dramatic, with complete clearing of his PWS at the sites of laser impact (Fig. 8.2). While subsequent patients
Figure 8.2 (a) A PWS as it appeared following seven treatments with the conventional 0.5 ms pulse duration PDL. The patient reported considerable lightening to the point shown, but failure to improve with subsequent treatments. (b) The PWS was treated using the identical fluence, spot size, and wavelength used the previous seven treatments, but using the 1.5 ms pulse duration PDL. The circles at the site of laser impact demonstrate complete clearing, illustrating the potential benefit of longer pulse durations for treating PWSs. (c) Close-up view of the treated areas. The upper region was treated 4 weeks prior to this photo, while the lower portion was treated 6 weeks before the photo. The lower portion demonstrates the further clearing that has occurred with two additional weeks of healing time.
224
Bernstein
have demonstrated a range of improvement, these results have proven to be typical in a substantial percentage of patients (Fig. 8.3). This initial report and further clinical experience have stimulated a more comprehensive ongoing study of the role of pulse duration in PWS clearance. Interestingly, a 1.5 ms pulse duration approximates the optimal parameters suggested by Anderson and Parrish (1) almost two decades ago. Currently, this author uses the 1.5 ms pulse duration PDL (Sclerolaser; Candela Laser Corp., Wayland, MA) with a maximum fluence of 6 J/cm2 using a 10 mm spot size and 585 nm. For higher energy densities a 7 mm spot and up to 10 J/cm2 are used. When PWSs fail to continue improving at the 585 nm wavelength, this author then treats using 595 nm. Higher fluences may be tolerated with 595 nm as compared to 585 nm in the same PWS. PWSs with linear vessels visible to the naked eye often respond better to 595 nm, as do many thicker PWSs. Higher fluences than have been used with 585 nm are often used with 595 nm to achieve clearance. Care must be taken not to injure the epidermis, and gradually increasing doses should be tested in small areas in as cosmetically unimportant an area as possible. Specific fluences are not recommended here, since various PDLs may result in significantly different clinical effects despite administration of treatments with identical wavelengths, fluences, and spot sizes (23). Thus, clinicians must develop experience with their particular laser, initially erring on the side of undertreatment. Indicators of clinical response such as purpura can indicate that an adequate fluence is being administered. However, when using long pulse duration PDLs, purpura may take a few minutes to fully appear, as compared to PDLs with pulse durations approximating 0.5 ms, which result in almost immediate purpura. In addition, the melanin content of a patient’s epidermis can influence side effects. Melanin is a major chromophore in skin, and is an undesired target. Care should be taken when treating dark-skinned or tanned patients. Often, epidermal pigment may drop into the dermis resulting in longer-standing hyperpigmentation. In addition, hemosiderin from resolving PWSs can reside in the dermis for some time acting as an unwanted chromophore. Hemosiderin also stimulates inflammation resulting in epidermal melanin pigment incontinence. Re-treating too soon to allow for this pigment to resolve can result in skin injury and the possibility of scarring. The administration of topical alphahydroxy acids, such as glycolic acid or ammonium lactate lotions, can increase epidermal turnover and stimulate dermal inflammation resulting in more rapid pigment clearance. Future improvements in the PDL may yield even quicker resolution of PWSs, with more complete responses.
Figure 8.3 (a) A patient with a large lower-extremity PWS prior to (a) and after (b) a single treatment with the 1.5 ms pulse duration, 585 nm PDL demonstrating near complete clearance at the sites of laser impact after a single treatment session. PWSs in this location are often difficult to treat.
Clinical Uses of the Long Pulse Duration PDL
225
The newer very long pulse duration PDLs have been used to treat PWSs as well. These lasers use a train of three to four shorter pulses to achieve pseudo-long pulses in the 1.5 –40 ms range. Initial treatment regimens for PWSs have demonstrated clearing at short (1.5 ms) and longer (up to 40 ms) pulse durations, but required higher fluences to achieve results with the longer pulse durations. Although these lasers were developed for treatment of vascular lesions without purpura, at least one investigator demonstrated that improvement of PWSs correlated with the development of purpura. Treatments at various pulse durations resulted in improved clearance as a function of the amount of purpura that developed. Clearance was achieved at numerous pulse durations provided the purpuric threshold was reached (24). Further studies are necessary to determine if these newer pseudo-long pulse duration lasers offer any improvement over previous generation lasers for the treatment of PWSs.
2.
KELOIDS AND HYPERTROPHIC SCARS
Hypertrophic scars and keloids are similar in appearance with the exception that keloids may persist for many years and extend beyond the original boundaries of the injury that caused them. Both are large, smooth, erythematous, and often hyperpigmented nodules and plaques at sites of cutaneous injury. Keloids and hypertrophic scars are composed of very large bundles of collagen fibers, often arranged parallel to the epidermis. The erythema, pruritus, and pain that often accompany keloids and hypertrophic scars are indicative of the inflammatory infiltrate that maintains or enlarges them. This erythema provides clinical evidence of the vascular and inflammatory components of these lesions, and gives an indication that treatment with the PDL may help improve them. Alster (25) and Williams demonstrated the efficacy of the PDL for the treatment of hypertrophic or keloidal sternotomy scars. Patients were treated for one-half of their sternotomy scar with a 585 nm PDL, and evaluated for changes in erythema, height of the scar, surface texture, and subjective assessment of pruritis. A significant improvement in these parameters was noted, and this improvement persisted for a minimum of 6 months. Dierickx et al. (26) reported improvement of erythematous, hypertrophic scars treated with the 585 nm PDL. Improvement was rated at 77% after an average of two treatments. They reported 100% improvement in 40% of their patients. Goldman and Fitzpatrick (27), treated 48 patients with erythematous, hypertrophic scars using the PDL, with or without intralesional triamcinolone. Scars present for less than 1 year had a greater rate of complete clearance than scars present for longer than 1 year. Facial scars resolved completely more often than those on other sites. Seventy-three percent of scars on the face less than 1 year cleared after approximately two treatments, as compared to only 20% of scars on the face present for over 1 year and treated over four times on average. Sheridan et al. (28) investigated the safety of treating hypertrophic burn scars in children. Purpura was seen in all patients. However no pain, ulceration, or worsening of the lesions was seen, demonstrating the safety of the PDL for treating burn scars in children. Alster and Nanni (29) also demonstrated improvement of hypertrophic burn scars following 585 nm PDL treatment. Patients’ pruritis or pain improved after a single treatment. Decreased erythema and improved texture and pliability were noted after an average of only 2.5 treatments. A decrease of dermal sclerosis was also measured by histopathologic examination. Patients who were restricted in their range of motion by scarring from burns or other trauma often reported an increase in their ability to move the affected part, and a decrease in the symptoms of pain or pruritis. This was in addition to any cosmetic improvement noted, due to a reduction in erythema and thickness of the hypertrophic
226
Bernstein
scar or keloid. More recently, investigators have been studying the effect of early PDL treatment in prophylactically preventing the development of hypertrophic scarring. McCraw et al. (30) reported prophylactic laser scar reduction during the early phases of wound healing. They suggested that early PDL treatment alters the physiology of a healing wound in the early phases, thus preventing later hypertrophic scar formation. Shakespeare et al. (31) used the PDL to help prevent hypertrophic scar formation following breast reduction surgery. They found a disruption in the vessel pattern after PDL treatment of early healing scars on histopathologic evaluation. PDL treatment led to early maturation of scars following surgery. For the treatment of hypertrophic scars and keloids, many clinicians (this author included) always combine PDL treatments with intralesional corticosteroids. Fitzpatrick (32) reports the combination of PDL treatment with intralesional triamcinolone and also investigates the use of intralesional 5-flourouracial. He reports that the most effective treatment was the combination of intralesional agents and PDL treatment. Because intralesional corticosteroid administration (this author uses 40 mg/mL of triamcinolone in most cases) often results in neovascularization and an increase in erythema in treated scars, the PDL is an ideal modality to combine with intralesional corticosteroid use. Intralesional corticosteroids can often dramatically flatten even very large keloids or hypertrophic scars (Fig. 8.4). Of course, not all keloids or hypertrophic scars respond to intralesional injections. When administering intralesional corticosteroids, care must be taken to inject only within the keloid. Triamcinolone injected beyond the keloid into the surrounding normal skin at a concentration of 40 mg/mL can produce significant atrophy, hypopigmentation, and neovascularization. A clinician must have a degree of patience, since initially the firm dense collagen matrix of a keloid accepts very little triamcinolone. Once the keloid starts to soften, larger amounts of triamcinolone may be administered. It often requires a strong doctor –patient relationship to convince the patient to persist with monthly treatments beyond the initial treatment period when very little improvement is noted. A well-known side effect of corticosteroid administration is the development of atrophy, the desired effect in this case, along with telangiectasia, an unwanted side effect. Because some of the vessels in keloids may be as large as typical lower-extremity spider veins, this author uses the 1.5 ms pulse duration PDL with a wavelength of 595 nm to treat them (Fig. 8.5). The 595 nm wavelength is more efficacious than 585 nm for treating larger linear vessels. In addition, hyperpigmentation following treatment seems to be reduced with 595 nm as compared to 585 nm, using identical fluences (unpublished observations). Typically, for treating keloids or hypertrophic scars with
Figure 8.4 (a) A patient with a hypertrophic, traumatic scar on his left cheek, present for 3 years, was treated with the long pulse duration PDL combined with intralesional injection of triamcinolone 40 mg/mL. (b) After triamcinolone injection and subsequent treatment with the 595 nm, 1.5 ms pulse duration PDL on two occasions 6 weeks apart, followed by two treatments with the PDL alone.
Clinical Uses of the Long Pulse Duration PDL
227
Figure 8.5 (a) A patient presented for treatment of a very large, keloid that initially resulted following development of a cyst, and further enlarged following excision. (b) The same keloid following eight sessions of intralesional injection of triamcinolone (40 mg/mL), followed on three occasions by PDL treatment using the 595 nm, 1.5 ms pulse duration PDL. The patient is continuing treatment at this time.
the long pulse duration PDL, this author uses a 7 or 10 mm spot and fluences lower than those used to treat PWSs, in the range of 5.5 –7.0 J/cm2. The fluence is lowered for darker-skinned individuals. If posttreatment hyperpigmentation is present, bleaching agents (such as hydroquinone, with retinoids or alpha-hydroxy acids and possibly topical corticosteroids) are used prior to administration of the next treatment. Treatment may be delayed until a significant amount of the pigmentation has resolved. The newer lasers offering pseudo-long pulse durations in the 3– 40 ms range are quite effective in improving erythematous scars. As with the shorter pulse duration PDLs, this author uses intralesional corticosteroids in conjunction with laser treatment of thick, hypertrophic scars or keloids. One of these lasers, the V-beam (Candela), offers only the 595 nm wavelength. This wavelength is ideal for treating hypertrophic scars or keloids, due to the common occurrence of larger linear vessels within these lesions. When keeping the parameters such as fluence, wavelength, pulse duration, and spot size equal, the longer pulse duration lasers can actually result in more purpura at the 1.5 ms pulse duration. This is because the longer pulse duration lasers, such as the V-beam, actually break their pulses up into three to four shorter pulses administered within the 1.5 ms time frame. Thus, as compared to the previous generation of lasers delivering a fixed 1.5 ms pulse (where the laser is “on” for the entire 1.5 ms), the newer generation of lasers deliver higher peak powers resulting in more purpura when all other parameters are equal. However, newer lasers like the V-beam have the option of spreading the three to four minipulses over a 40 ms time frame. This results in significantly less purpura, and remarkably selective targeting of erythematous scars, while sparing the surrounding skin from significant erythema or purpura.
3.
VERRUCAE
Tan et al. (33) reported on the ability to treat recalcitrant verrucae with the 585 nm, 0.45 ms pulse duration PDL using a 5 mm diameter spot. They treated 39 patients and found a 72% clearance rate using energies of 6.25–7.50 J/cm2 after an average of 1.7 treatments. A further 18% had 80–95% of their warts cleared after an average of 1.3 more treatments. After 3 months of follow-up only one of the 39 patients had a recurrence of their verrucae. Thus, it was established that the PDL is an effective treatment for verrucae. Human papilloma virus resides in the viable epidermis causing hypertrophy of the epidermis and
228
Bernstein
the associated stratum corneum. This thickened epidermis relies solely on the underlying dermis for nutrients. Presumably to support this increased growth in the epidermis, new capillary loops emerge within elongated dermal papillae. The justification for laser treatment of verrucae rests on the belief that the laser will damage these underlying vessels. In addition, light absorbed by the stratum corneum and epidermis produces thermal damage that further injures the epidermis where the wart virus particles reside, and possibly stimulates growth factors that may cause involution of the verrucae. The inflammatory infiltrate may alert the immune system to the presence of the wart virus in the relatively immuneisolated epidermis. Kauvar et al. (34) treated 703 recalcitrant and 25 previously untreated warts in 142 patients with the PDL. Response rates were 99% for body, limb, and anogenital warts, 95% for warts on the hands, 84% for plantar warts, and 83% for periungual warts. Side effects in the study were limited and rare. Jacobson et al. (35) reported a slightly lower success rate, with 68% of recalcitrant warts responding to treatment. Other investigators showed an even lower clearance rate for recalcitrant verrucae, with 48% of verrucae responding to treatment (36). A recent study by Robson et al. (37) prospectively studied the efficacy of PDL therapy for verrucae as compared to conventional treatments. They found the PDL to be highly effective, but only as effective as conventional therapies. Response rates were 66 and 70%, for PDL treatment and conventional therapy, respectively. Thus, PDL treatment is efficacious for the treatment of verrucae, but due to its greater expense as compared to most other treatments, may be reserved for treatment of verrucae refractory to conventional therapy. Practitioners most commonly use pulses administered one immediately after the other (often referred to as stacking of pulses) to treat verrucae. This deposits additional energy at the treatment site, increasing the amount of thermal damage to the epidermis. Although this would normally be undesirable for treating most vascular lesions, the added energy may serve to destroy some of the wart-infected cells in the epidermis. In addition, PDLs with longer pulse durations are being increasingly used to treat verrucae as this new technology replaces older, more conventional PDLs. Although the more modern lasers may deliver less peak power at longer pulse durations, a significant advantage in reducing unwanted thermal side effects when treating most conditions with the PDL, this may have an undesirable effect on clearance of warts. Thus, shorter pulse durations may prove more efficacious for treating verrucae. Conversely, the longer pulse duration may be more ideally suited to damaging the larger vessels underlying verrucae, which are evident as black dots at their base. This author uses a 1.5 ms pulse duration PDL (Sclerolaser, Candela) with a wavelength of 585 nm, and the maximum available fluence of 10 J/cm2 with a 7 mm spot when treating larger verrucae, or a 5 mm spot and 11 J/cm2 for smaller lesions. From one to four pulses are delivered to each treatment site depending on the size of the wart and the location. Treatments are administered through a clear wound dressing to eliminate the plume that often accompanies treatment of warts at high fluences with stacking of pulses. Typically, the dressing reduces the amount of administered energy reaching the target by only 9% (38). Care should be taken to remove the plastic coverings on the front and back of the dressing to prevent further loss of laser energy due to the dressing.
4.
ROSACEA AND FACIAL TELANGIECTASIAS
Facial telangiectasias often develop on the cheeks due to chronic photodamage. Patients often have an asymmetric number of telangiectasias on one side of their faces, with the greater number being on the side adjacent to the car window when they are driving
Clinical Uses of the Long Pulse Duration PDL
229
(left side) or riding as the passenger (right side). Thus, in patients with asymmetric photodamage, a physician can often accurately predict whether the patient is the driver or the passenger. Since window glass blocks UV-B radiation, this implies that UV-A radiation and longer wavelengths, possibly including infrared radiation, contribute to the development of telangiectasias. Therefore, use of broad-spectrum sunscreens is a crucial component in any plan to eradicate sun-induced telangiectasias. Non-sun-induced telangiectasias develop most commonly in women on the lateral aspects of the nose and the inferiorlateral portion of the cheeks. These linear telangiectasias respond extremely well to PDL treatment using 1.5 ms, 595 nm light administered with a 2 7 mm spot (39). The longer 595 nm wavelength is quite effective at removing linear telangiectasias, and the laser energy can be limited mainly to the target vessel by using an elliptical spot to deliver the laser energy along the target vessel. In patients with widespread telangiectasias or diffuse erythema, a 7–10 mm spot should be used to treat the entire affected area. In addition to sun exposure and a hereditary predisposition to the development of spider veins, rosacea is one of the more common causes of facial telangiectasias and erythema in adults. Individuals with rosacea have a predisposition to develop telangiectasias and erythema in response to sun exposure. These vessels become more prominent when rosacea patients are exposed to stimuli such as alcohol consumption, and warm foods or beverages. Lowe et al. (40) studied the ability of the 585 nm PDL to treat facial telangiectasias and erythema in rosacea patients. They treated 27 patients who had both telangiectasia and erythema associated with rosacea. They demonstrated a good to excellent response in 89% of patients receiving from one to three treatments. Of particular interest was the ability of PDL treatment to reduce both the papular and the pustular component of rosacea in 59% of patients. In addition, those with the most severe rosacea had the largest degree of improvement. Thus, the telangiectasias that form as a result of long-term rosacea may play a role in maintaining or exacerbating the more acneiform component of rosacea. Facial telangiectasias respond quite well to PDL treatment, much better than telangiectasias on the lower extremities. Because rosacea patients often have linear vessels superimposed upon a background of erythema, this author uses the 1.5 ms pulse duration PDL with a wavelength of 595 nm, because this wavelength has proven superior for treating linear vessels as compared to 585 nm (unpublished observations). In addition, 595 nm administered at lower fluences than those commonly used for PWSs is less likely to result in overtreatment of facial skin (Fig. 8.6). Overtreatment of rosacea patients, who tend to have naturally ruddy complexions, results in excessive blanching at the site of laser impact. This excessive blanching of the skin can create a visible waffle pattern on the face showing the sites of laser impacts. Numerous further treatments may then be required to remove this patterning, often leaving the patient with an excessively light appearance. Thus, the lowest effective fluence should be used with the largest available spot size when treating rosacea to avoid this unwanted result. This author finds fluences from 5.0 to 6.5 J/cm2 to be effective in the majority of patients using the 595 nm, 1.5 ms pulse duration PDL (Sclerolaser, Candela). Test spots are always necessary to determine the minimally effective fluence, and multiple treatments may be necessary. The PDL is extremely effective for reducing erythema in rosacea patients, and further investigation of the ability of this treatment to reduce the papular and pustular component of rosacea may increase its role in management of this chronic, and often difficult to treat, condition. The ultra-long pulse duration PDLs have been successful in treating facial erythema and telangiectasias with reduced purpura. Purpura is significant with the 1.5 ms pulse duration lasers, and is often a reason why patients decline treatment. Patients with smaller vessels or diffuse erythema respond best to the ultra-long pulse duration PDLs. This author uses pulse durations of 6– 10 ms with the Candela V-beam, and fluences in
230
Bernstein
Figure 8.6 (a) A patient with a long-standing history of rosacea presents for PDL treatment of numerous telangiectasias, superimposed on a background of erythema. (b) Purpura is evident immediately after treatment. (c) Two months after two treatments, spaced 6 weeks apart, with the 595 nm, 1.5 ms pulse duration PDL using relatively low fluences.
the range of 6 J/cm2 with the 6 ms pulse duration and in the range of 8.5 J/cm2 with the 10 ms pulse duration. Rohrer has shown that pulse stacking improves the clinical response for rosacea associated telangiectasia when subpurpuric pulse durations are used. While increasing the fluence beyond a certain point can increase purpura, stacking lower fluence pulses can deliver the same result as a single higher energy pulse without purpura formation. The effective fluence is roughly approximated by the fourth root of the stacked fluences. Cumulative heating is produced with less trauma. In this way, telangiectasia that may not respond to one pass with a 6 –10 ms pulse will resolve following treatment when 2– 4 pulses are stacked using a 10 mm spot, 6– 10 ms pulses, a 30 ms cryogen spray and a fluence of 7.5 J/cm2 (Fig. 8.7) (41). During treatment one observes a transient purpuric response followed by erythema that usually lasts for a few hours. An urticarial response may last for a few days following treatment, and may be responsible for the improvement often seen in fine lines, wrinkles, and enlarged pores following treatment. Multiple treatments are often required to achieve vessel clearance.
Clinical Uses of the Long Pulse Duration PDL
231
Figure 8.7 Before (a) and after treatment of facial erythema and telangiectasia with a 595 nm pulsed dye laser using a 10 mm spot, 10 ms pulse duration and fluence of 7.5 J/cm2. (Courtesy of Thomas Rohrer, M.D.)
5.
LOWER-EXTREMITY TELANGIECTASIAS
Sclerotherapy has been and remains the mainstay of treatment for lower-extremity telangiectasias. However, patients are increasingly looking for adjunctive therapy, either due to incomplete clearing of telangiectasias or due to the development of matt telangiectasias as a result of sclerotherapy. Matt telangiectasias are very small, red, often clustered vessels that can occur following sclerotherapy injections of larger veins. Further injection of matt telangiectasias once they develop may be technically difficult due to their small size, or may even lead to the development of more matt telangiectasias resulting from the subsequent injections. The incidence of matt telangiectasias following sclerotherapy is reported to be approximately 15–24% (42). Thus, a need exists for adjuvant therapy to treat lower-extremity spider veins. In properly selected patients, lasers may offer additional improvement of matt telangiectasias that occur following sclerotherapy. In addition to the substantial number of patients developing matt telangiectasias, those patients who refuse sclerotherapy due to an aversion to needles are potential candidates for primary laser treatment, as are those whose vessels fail to clear following sclerotherapy. Hsia et al. (43) reported on treatment of lower extremity telangiectasias using the 1.5 ms pulse duration 595 nm PDL. Earlier results suggested that 595 nm was more successful at removing linear telangiectasias than the conventionally used 585 nm. This improved efficacy using 595 nm was presumably due to the ability of 595 nm to penetrate through a relatively large vessel, as opposed to the typical vessels comprising PWSs, due to the decreased hemoglobin absorption at 595 nm as compared to 585 nm. They treated vessels ranging from 0.5 to 1.0 mm in diameter using fluences of 15 and 18 J/cm2. A 2 7 mm elliptical spot was used to focus laser energy along the desired target vessel. Clearance was .50% in over 40% of patients 6 weeks following a single treatment at both energies. Six months following treatment, over 50% of patients demonstrated .50% improvement. Further improvement was noted with longer follow-up without additional treatment. These authors report an acceptable complication rate and suggest that the long pulse duration PDL may have a role in treating lower-extremity telangiectasias. A subsequent study investigated the effect of three consecutive treatments administered
232
Bernstein
Figure 8.8 (a) Spider veins on the lower leg prior to PDL treatment. (b) Resolution of the veins following three PDL treatments using a fluence of 20 J/cm2, a wavelength of 595 nm, a 2 7 mm elliptical spot, and a 1.5 ms pulse duration. Hyperpigmentation is present in the area of the treated veins. [From Bernstein et al. (38).]
6 weeks apart using fluences of 15 and 20 J/cm2, a wavelength of 595 nm, and a 2 7 mm elliptical spot. Only patients with Fitzpatrick skin types I and II were included in the study. Clearance rates were approximately 80% on average (Fig. 8.8). Treatments were well tolerated although hyperpigmentation occurred in 30% of subjects (38). As recent experience dictates, more hyperpigmentation would have been seen if patients with skin types darker than type II, or tanned patients, were included in the treatment group. The development of the dynamic cooling device subsequent to this study may reduce the incidence of hyperpigmentation following treatment. However, hyperpigmentation following treatment of lower-extremity telangiectasias with the PDL has continued to limit their use for this application. Kauvar demonstrated that she was able to achieve greater than 75% clearance of red vessels ,1 mm in diameter after one treatment session using an elliptical spot, a 1.5 ms pulse duration and fluences of 22 –23 J/cm2 and 30 ms of cryogen (44). Others have used the elliptical spot with a 20 ms pulse duration, a fluence of 15 J/cm2 and 30 ms of cryogen (Fig. 8.9). Further improvements in the PDL with the availability of adequate fluences at longer pulse durations, and methods for improved protection of the epidermis, may increase the value of PDLs for treating lower-extremity telangiectasias in the future. Although true long pulse duration lasers with pulse durations as long as 50 ms have been produced using the Nd:YAG crystal, such long pulse durations in the yellow or
Figure 8.9 Leg veins before (a) and after (b) 2 treatments with a 20 ms pulse and a fluence of 15 J/cm2 using cryogen spray cooling. (Courtesy of Craig Trigueiro, M.D.)
Clinical Uses of the Long Pulse Duration PDL
233
orange wavelengths are not yet available. Current long pulse duration lasers in these wavelength ranges utilize “pulses” that are actually composed of trains of shorter pulses to achieve pulse durations longer than 1.5 ms. Thus, the current generation of long pulse duration PDLs do not deliver dramatically improved performance for treating leg veins over the previously available 1.5 ms devices. A true 40 – 50 ms pulse duration, 595 nm PDL (or solid state laser offering this wavelength) would represent a major leap over currently available technology. As yet, this technology is not available.
6.
LUPUS ERYTHEMATOSIS
Discoid lupus erythematosis (DLE) often presents as telangiectatic, atrophic plaques, while systemic lupus erythematosis (SLE) presents as the classic butterfly rash with more diffuse erythema and telangiectasia. Since lesions of lupus erythematosis have a significant vascular component, the PDL is a rational treatment alternative. This is especially true because many lesions of DLE are refractory to treatment. In addition, after resolution of DLE lesions, the vascular component may remain. Raulin et al. (45) treated 12 patients with cutaneous lupus erythematosis with the PDL. In 10 of the patients the cutaneous lesions were limited to the skin, while two had SLE and the associated cutaneous eruption. They reported a median clearance rate of 70% in 9 of their 12 patients. Two patients had symptomatic improvement of pain and pruritus, without visible improvement, and one patient failed to improve. Of interest is the long follow-up period ranging from 3 to 32 months, with a median of 7 months, in which only one of the patients who had had complete clearance demonstrated a small relapse. This study suggests that perhaps the vessels that develop in cutaneous lesions of DLE and SLE may serve as targets for sun-induced exacerbations of these conditions. PDL treatment of the telangiectatic component of lupus may also affect the other symptoms of the disease. This author has treated patients with lesions of DLE. One such patient was initially treated only on one side of her face at her request. The referring physician reported that upon going into the sun against medical advice, her skin would flare only in the untreated site with erythema and edema (Fig. 8.10). The treated site demonstrated no reaction to sun exposure (personal communication). Since the lesions of lupus erythematosis often contain visible telangiectasias, the longer pulse duration PDL using a 595 nm wavelength appears to yield superior results to the conventional 585 nm PDL. Even somewhat large vessels on the face are easily removed in a single treatment session. The potential for PDL treatment to improve DLE and even sun-induced flares of SLE should be further investigated, since as in rosacea, the cutaneous blood vessels may be participating in exacerbating and maintaining the overall disease as a target for sun exposure. However, care should be taken especially when treating patients with SLE. Flaring of cutaneous lesions of SLE has been observed following PDL treatment in some patients (personal communications). Limiting test spots to small areas and limiting treatment sizes during a single session to small areas are advisable when treating patients with lupus.
7.
STRIAE
Striae result from acquired defects in cutaneous elastic fibers and, despite their quite obvious clinical appearance, show very subtle changes under histopathologic examination. Elastic fibers are among the last components to appear in a healing wound, and many wounds fail to develop a normal elastic fiber network. Thus, generation of new elastic fibers in skin by
234
Bernstein
Figure 8.10 A patient with DLE prior to treatment (the clear area on the superior-lateral aspect of the left cheek is from a previous PDL test site) (a) and 2 months after two PDL treatments to the left cheek, using 595 nm and a 1.5 ms pulse duration (b). The treated site reportedly did not flare with the rest of the face on excessive sun exposure.
exogenous stimulation, such as PDL treatment, is quite difficult. McDaniel et al. (46) reported improvement of striae following PDL treatment. Clinically, they evaluated striae as more resembling normal skin following treatment with the PDL. Shadow profilometry supported these observations, demonstrating reduced skin shadowing in striae following treatment. They also reported an apparent return to more normal dermal elastic fiber morphology under histopathologic examination. These authors used relatively low energy densities, and reported superior results using a large, 10 mm-diameter spot with only 3.0 J/cm2. The increased effectiveness of the larger-diameter spot size may be due to the deeper penetration afforded by large spot sizes. Although lasers do induce an inflammatory response that may lead to extracellular matrix deposition, results thus far in improving the textural component of striae have been somewhat disappointing, as compared to treatment of other conditions exploiting the ability of the PDL to induce dermal remodeling. However, removing the erythema often present in striae is fairly easily accomplished with the PDL. The 1.5 ms pulse duration PDL works well using 7–10 mm spot sizes, 595 nm, and relatively low fluences between 5.5 and 6.5 J/cm2. Low fluences and the 595 nm wavelength offer the advantage of less hyperpigmentation in darker-skinned or tanned individuals following treatment, as compared to 585 nm and higher-energy densities. The new ultra-long pulse duration PDLs offer similar results to earlier PDLs. These lasers also remove the erythema that typifies striae quite easily, while inducing variable amounts of dermal remodeling. The remodeling achievable by PDLs is still somewhat disappointing. As our understanding of striae and elastic fiber metabolism advances, improved strategies for treating these difficult lesions should emerge.
8.
SEBACEOUS GLAND HYPERPLASIA
Sebaceous gland hyperplasia is one of the many signs of cutaneous photodamage, and is also seen in association with acne and rosacea. Clinically, yellow papules, typically
Clinical Uses of the Long Pulse Duration PDL
235
2 – 4 mm in size develop on the face, in sun-exposed sites or sites of active acne and rosacea. Schonermark et al. (47) presented an initial report of two patients with sebaceous gland hyperplasia treated with the short pulse duration, 585 nm PDL. Two patients were treated using 6.5 –8.0 J/cm2, 585 nm, and a pulse duration of 0.3– 0.45 ms. Sebaceous gland hyperplasia completely resolved in these patients following two to three consecutive treatments with the PDL, with no side effects. Confocal imaging of sebaceous gland hyperplasia demonstrates prominent dermal vasculature associated with the hyperplastic sebaceous glands, and the targeting of these vessels by the PDL (48). Aghassi et al. (49) reported on 10 patients with 29 lesions of sebaceous gland hyperplasia treated with PDL. They administered three PDL pulses in succession, using a wavelength of 585 nm, fluences of 7 –7.5 J/cm2, and a 5 mm spot. The great majority of lesions responded to a single treatment session, with 28% of lesions resolving completely, 66% decreasing in diameter, and 93% flattening. Because these authors stacked pulses with the PDL, they suggest that either temporary ischemia induced by selective vessel destruction or nonspecific thermal damage may be responsible for resolution of the lesions. A number of the patients treated in this study developed depressions in the treated sites before complete healing. This may be indicative of excessive thermal damage due to stacking of pulses. Although pulse stacking is commonly used to treat verrucae, this technique may not be well suited to the treatment of sebaceous gland hyperplasia. Perhaps a number of treatment sessions, with one pulse administered to each lesion per session, would decrease the incidence of this side effect. The long pulse duration PDL may prove even more effective for treatment of sebaceous gland hyperplasia. Longer pulse durations and wavelengths may better penetrate through the vessels supplying these lesions. Future studies should clarify whether the more advanced PDLs offer advantages for treatment of sebaceous gland hyperplasia, possibly negating the need for stacking of pulses in order to destroy these lesions.
9.
PSORIASIS
Psoriasis is a chronic inflammatory process clinically characterized by a greatly thickened epidermis and stratum corneum. To support this substantially thickened epidermis, dilated capillary loops emerge in elongated dermal papillae. Because of the significant vascular component underlying the epidermal component in lesions of psoriasis, as demonstrated by the Auspitz sign, vascular lasers have been used in an attempt to treat psoriasis. Zelickson et al. (50) demonstrated resolution of psoriatic plaques in response to PDL treatment. Both clinical and histopathologic evidence of resolution of psoriatic plaques was documented. Of particular interest was the long-lasting nature of remissions in treated areas. The remissions lasted for up to 13 months following treatment. Thus, the PDL, presumably due to its vascular specificity, can induce long-term remission of psoriatic plaques. To further characterize the PDL parameters that optimize treatment of psoriasis, Zelickson et al., examined variable pulse durations and wavelengths for the treatment of psoriatic plaques. They treated four patients with relatively short wavelengths of 585 and 578 nm, and longer wavelengths of 595 and 755 nm. In addition, shorter pulse durations of 0.15 and 0.45 ms were compared to longer pulse durations of 1.5 and 5 ms. Superior results were obtained with the shorter wavelengths and shorter pulse durations (Brian Zelickson, MD, personal communication). It is possible that disruption of smaller vessels optimally targeted by these parameters is the key to treating psoriasis with the PDL, or that heating of other targets including the epidermal keratinocytes stimulates an inflammatory response that causes involution of the psoriatic plaques. Preliminary
236
Bernstein
evidence suggests that longer pulse duration lasers may not have a significant benefit over the previous generation of PDLs for the treatment of psoriasis.
10.
NONABLATIVE SKIN REMODELING WITH THE PDL
The clinical observation made by patients that facial skin treated with the PDL for telangiectasias looked not only vein free, but also generally improved in texture and appearance, led to investigation of the use of the PDL for skin rejuvenation. Although the development of the high-energy carbon dioxide laser for skin resurfacing has become a standard for the treatment of facial photoaging and acne scarring, the improvements come at a price. Ablative lasers remove the epidermis and a portion of the dermis, requiring significant healing time. In addition, risks such as infection and pigmentary alterations must be considered. Also, persistent erythema may last for months following treatment. Still, for patients with severe photodamage, carbon dioxide laser resurfacing is the mainstay of treatment. However for patients with minimal photodamage, the associated risks and downtime may not be worth the relative improvements offered by carbon dioxide laser resurfacing. For patients with minimal to moderate photodamage, nonablative wrinkle reduction may be ideal, especially as an adjunct to topical treatment regimens. In addition, improvements in hypotrophic acne scarring after carbon dioxide laser resurfacing have been less impressive than results following treatment of severely wrinkled patients. Nonablative facial resurfacing with vascular lasers such as the PDL is a desirable alternative for these patients as well. The newer generation PDLs result in significantly less purpura than previous generation lasers [Fig. 8.11(a) and (b)]. Although purpura is reduced with the longer pulse duration PDLs, a hive reaction is often present following treatment. This reaction may be indicative of activation of resident mast cells and may presage tissue remodeling. A hive response occurs following treatment with 585 or 595 nm at virtually any pulse duration provided a threshold fluence is administered. Lowering the administered fluence or increasing the pulse duration can limit or eliminate purpura, making treatments more cosmetically acceptable. Coupling patient observations with physician assessments led to a more formal investigation of the ability of the short pulse duration PDL to improve and remodel photodamaged skin. Zelickson et al. (51) evaluated 20 patients, half with mild to moderate photodamage and half with moderate to severe photodamage. Clinically observable improvement was noted in 90% of the patients with mild to moderate wrinkling, and 50% of the patients with moderate to severe wrinkling. Nine of 10 patients with mild to moderate wrinkling demonstrated 25% or more improvement with 3 out of the 10 showing 75% improvement. In the mild to moderately wrinkled group, all patients maintained their level of improvement for 6 months, and five of the six patients maintained their improvement 12– 14 months posttreatment. Of the patients with moderate to severe wrinkling, only three patients had clinically observable improvement 12 weeks after treatment. Side effects of this treatment regimen included purpura and some swelling, which occurred in all subjects and lasted for 1– 2 weeks. Two patients experienced postinflammatory hyperpigmentation, which subsequently cleared. Histopathologically, increased cellularity and glycosaminoglycan (GAG) deposition were noted in treated skin. Both short pulse duration and long pulse duration PDLs have been shown to improve photodamaged skin via nonablative dermal remodeling. The N-lite laser (ICN Pharmacauticals, Costa Mesa, CA) is a short pulse duration (,0.5 ms) 585 nm PDL used at low fluences for nonablative dermal remodeling. This device has been shown to improve fine lines and wrinkles, and to stimulate production of dermal procollagen.
Clinical Uses of the Long Pulse Duration PDL
237
Figure 8.11 (a) A patient with telangiectasias before treatment with the conventional PDL, 6.75 J/cm2, 585 nm, and a pulse duration of 0.45 ms. (b) One day after treatment, substantial purpura is evident. (c) The opposite cheek of the same patient before treatment with the long pulse duration PDL. (d) One day after treatment with 8.4 J/cm2, 595 nm, and a pulse duration of 10 ms, demonstrating minimal purpura following treatment. (Photos courtesy of Steven J. Ugent, MD, and Candela Corporation, Wayland, MA.)
The long pulse duration 595 nm PDL has also been shown to improve rhytides and stimulate dermal remodeling. Eleven of 15 patients demonstrated improvement of rhytides following 4-monthly laser treatments, as compared to only 3 of 15 patients improving on the control side, which was treated with the cryogen spray alone without laser treatment. An 18.1% improvement in clinical grading of photodamage was measured. This clinical improvement correlated with an increase in procollagen staining as evaluated by immunohistochemical evaluation (52). Patients undergoing treatment of mild to moderate photodamage may be unwilling to endure purpura if multiple treatments are required or alternatives are available. Fluences below the purpura threshold may be required for widespread use of the PDL
PWS
Hypertrophic
Trunk, extremities
PWSs Facial Neck, head
Periorbital Wrinkles
Matting
7 7 10 7 10 7
5 10
7 10 3 10 3 10 7 7, 10
Nasal
Leg
7 10 3 10
Telangiectasia Facial
Lesion
Spot size (mm)
3, 6
3, 6 3, 6
6 1.5, 3, 6, 10
1.5, 3, 6, 10
0.45 6
6, 10 6, 10 10, 20 6, 10, 20 20 20, 30
3, 6, 10 6 10, 20, 30
Pulse (ms)
10– 15 8– 12 4– 7.5 6– 12 6– 7.5 10– 15
3– 5 6
Up to 11 7.5 8– 12 11– 22 10– 12 11– 15
7– 9 5.5– 7.5 11– 14
Energy fluence (J/cm2)
Table 8.1 Candela V-beam 595 nm Treatment Guidelines
30/30 30/10 –30 30/10 –30 30/10 –30 30/10 –30 40/10
30/10 20/30
30/20 –30 30/20 –30 30/20 –30 30 –40/20 30/10 –30 30/10
30/20 –30 30/20 –30 30/20 –30
DCDa spray/ delay
8 –12 8 –12 8 –12 8 –12 8 –12 8 –12
2 –4 4
4 –6 4 –6 4 –6 8 –12 8 –12 6 –10
4 –6 4 –6 4 –6
Interval (weeks)
Use lower fluences for infants Begin at longer pulse widths and move to shorter pulse widths as the treatment progresses; development of purpura is less with longer pulse widths, but may decrease clearance obtained Use lower fluence on neck and extremities If end point is purpura, it should be present on PWS vessels only and not on surrounding skin overlap or retreat at same session. Observe epidermal response carefully when treating at higher fluences. Ectatic vessels may be double-pulsed ( pulse stacking)
Treat patient in supine or prone position. Expect purpura regardless of pulse width Pulse stacking or double pulsing may induce blisters; higher fluences may induce blistering and hyperpigmentation; observe vessel for intravascular spasm Perform compression check for vessel patency Larger spot size may improve results Four treatments, one treatment every 4 weeks; shorter pulse widths and higher fluences may induce purpura
Higher fluences and shorter pulse widths will cause purpura, but clearance may be faster May double or triple pulse depending on the refill of the vessel Treating first with the round spot followed by the 3 10 may eliminate vessels that do not clear
Comments
238 Bernstein
1.5 1.5 0.45
7 10 7
4.5– 5 3.5– 4 4– 5
7– 9 4– 6 4– 7 3– 6 12– 15 7.5
7– 10 8– 11.5 5– 7 6.5– 7 5– 6
7– 10
8– 11 6– 7.5
30/10 30/10 30/20
30/10 30/10 30/10 30/10 0/0 0/0
30/10 20 –30/10 –20 20 –30/10 –20 30/10 30/10
30/10
30/10 –30 30/10 –30
8 8 2 –4
6 2 –3 2 –3
6 6 6
4 –6 4 –6 4 –6 4 –6 4 –6
2
4 –6 4 –6
Always do test spots laterally; when treating, apply pulses close to one another to minimize uneven pattern; “feather” edges to minimize sharp line of demarcation with untreated skin; several gentle treatments may be required Treat as soon as possible (2 weeks after suture removal) and avoid treating keloids Newer, more vascular striae may respond better than older, whiter striae May repeat treatment every 3 – 4 weeks When treating warts, 100 ms of cryogen may be sprayed pre- and postlaser pulse to wart to cool area and/or topical anesthetic may be applied prior to treatment; may triple pulse (pulse stacking) if tolerated; treat wart and at least a 1 cm ring of uninvolved skin, since wart virus has been biopsied out to 1 cm; use concurrent topical therapies at home Look for light purpura, which will require test spots at a variety pulse durations and fluences May require three to four treatments or more
Decreased fluence and longer pulse duration may cause less purpura Vessels may be pulsed two to three times to get transient intravascular purpura which disappears and becomes blush pink May use 10 mm spot to treat entire cosmetic unit, then re-treat remaining larger vessels with a smaller spot Use caution with neonates Treat every 2 weeks for proliferative hemangiomas; improper treatment may cause scars; refer to a specialist if not within your typical practice One to two treatments may be required Double pulse center of hemangioma first, then treat peripheral veins
Dynamic cooling device (DCD) parameters will vary based on lesion, location, and level of patient’s comfort.
a
Benign vascular Gynecological lesions Psoriasis
Warts (verruca)
Striae
1.5,3 3, 6, 10 10 10 1.5 1.5
7 10 7 10 7 10
Scars
1.5 10, 20 20 10, 20 1.5
1.5, 3
3, 6, 10 6, 10, 20
7 7 10 7 10
7
7 10
Venous lake Angioma/spider angioma Poikiloderma of Civatte
Hemangioma
Rosacea
Clinical Uses of the Long Pulse Duration PDL 239
7 mmþ Upto 7 mm 10 mmþ Up to 7 mm Up to 10 mm Elliptical 7 mm 10 mmþ Elliptical 7 mm 10 mmþ Up to 7 mm 7 mm
Up to 7 mm 10 mmþ 7 mm (Pediatric) 7 mm (Adult) 10 mm (Pediatric) Up to 7 mm 10 mmþ
7 mmþ
Up to 10 mm 10 mm Up to 10 mm 7 mmþ
6.5 – 7.5 5.0 – 7.0 3.0 – 3.5 5.5 – 6.0 3 7.0 – 7.5 4.0 – 5.0 3.0 – 3.5 7.0 – 7.5 4.0 – 5.0 3.0 – 3.5 6.5 – 7.0 7.0 – 9.0
2.0 – 4.5 (First pass) 4.0 – 5.0 3.5 – 4.0 4.5 – 6.0 5.0 – 6.5 3.0 – 4.5 5.5 – 6.5 3–5
5.5 – 6.0 2.0 – 4.0 5.0 – 8.0 2.5 – 6.0
Parameters 0.5 ms (J/cm2) (purpuric doses)
Not recommended 6– 8 5– 7 5– 7 3– 6 7– 9 7– 10 4– 7.5 7– 9 7– 9 6– 7.5 Not recommended 8– 12
5– 8.5 4– 8 4.5– 6.0 5.0– 6.5 3.0– 4.5 Not recommended
Not recommended
5.0– 6.0 Not known 4.0– 8.0 4– 9
Parameters 2 ms (J/cm2) (purpuric doses)
Not recommended 8– 11 6– 7.5 5– 8 3– 6 9– 20 7– 14 6– 10 9– 14 7– 12 7– 10 Not recommended Not recommended
11– 14 11– 14 10– 10.5 Not recommended
7– 9
Not recommended
5– 7 Not known 5– 9 7– 12
Parameters 20 ms (J/cm2)
Not recommended Not recommended
Not recommended 8 – 12 6.5 – 8 5 – 10 Not recommended 9 – 20 7 – 16 7 – 14 7 – 14 7 – 13
11– 14 11– 14 10– 10.5 Not recommended
5–9 5–8 6.0 – 12.0 Not recommended 8 – 10 (Second pass, for chromophore) 7–9
Parameters 40 ms (J/cm2)
8– 12
2– 3
3– 4
4– 6 3– 6 4– 6 4– 6
Tx interval (weeks)
4– 6 3
4– 6
3– 4 6– 24 4– 6
4 – 6 weeks (Salicylic acid for 1 week prior to treatment) 3– 4 3– 4
Note: Multipass (Not multipulse or pulse stacking) treatment may be used with lower fluences to achieve intravascular coagulation with minimal collateral purpura.
Venous lakes Warts
Telangiectasia, face
Spider angioma Striae Telangiectasia, leg
Pyogenic granuloma Rosacea
Psoriasis
Port-wine birthmark
Hemangioma
Angiokeratoma Acne vulgaris Cherry angioma Erythematous, hypertrophic, and keloid scars Facial rejuvenation
Lesion
Spot size
Table 8.2 Cynosure V-Star 595 nm Treatment Parameters
240 Bernstein
Clinical Uses of the Long Pulse Duration PDL
241
for nonablative skin remodeling. The long pulse duration PDL offers not only longer pulse durations, but also the potential to treat with longer wavelengths, such as 595 nm. As the pulse duration is increased for equivalent fluences, clinical purpura is usually reduced. Future studies comparing various pulse durations and wavelengths may shed light on the optimal PDL parameters for nonablative resurfacing. Because quantification of the improvement following nonablative resurfacing is difficult due to the subtle nature of the improvement, this issue may not be resolved for some time.
11.
FUTURE DEVELOPMENTS IN LONG-PULSE PDL
PDLs with increasingly longer pulse durations are being developed. The longer pulse durations are currently achieved by creating a series of pulses that can be separated by various off times. Advances in cooling of the epidermis should also optimize PDL treatment of a variety of conditions. Currently, a series of pulses are used to simulate a continuously longer pulse because current limitations in PDL technology prevent generation of single pulses in the 40 –50 ms range. Potential advantages of these systems are lessened purpura and the potential to more effectively treat larger vessels, such as lower-extremity telangiectasias (Fig. 8.11). However, at least some of the clinical response seen following PDL treatment correlates with the development of purpura. Generation of continuous pulses in the 40 – 50 ms second range still eludes laser developers. As longer pulse durations and higher energies are made available for the PDL, clinical experience should determine which conditions will benefit from these advances in technology.
12.
LASER PHYSICS: SUGGESTED PARAMETERS
Tables 8.1 and 8.2 document suggested parameters from the manufacturers for the newest available PDLs from the companies listed.
REFERENCES 1. 2. 3. 4. 5.
6. 7. 8.
Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med 1981; 1(3):263 – 276. Parrish JA, Anderson RR, Harrist T, Paul B, Murphy GF. Selective thermal effects with pulsed irradiation from lasers: from organ to organelle. J Invest Dermatol 1983; 80(suppl):75s– 80s. Anderson RR, Jaenicke KF, Parrish JA. Mechanisms of selective vascular changes caused by dye lasers. Lasers Surg Med 1983; 3(3):211– 215. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220(4596):524 –527. Bernstein EF, Kornbluth S, Brown DB, Black J. Treatment of spider veins using a 10 millisecond pulse-duration frequency-doubled neodymium YAG laser. Dermatol Surg 1999; 25(4):316– 320. Adrian RM. Treatment of leg telangiectasias using a long-pulse frequency-doubled neodymium:YAG laser at 532 nm. Dermatol Surg 1998; 24(1):19 – 23. Kauvar AN, Frew KE, Friedman PM, Geronemus RG. Cooling gel improves pulsed KTP laser treatment of facial telangiectasia. Lasers Surg Med 2002; 30(2):149 – 153. Tan OT, Kerschmann R, Parrish JA. The effect of epidermal pigmentation on selective vascular effects of pulsed laser. Lasers Surg Med 1984; 4(4):365 –374.
242 9.
10.
11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22.
23. 24. 25. 26. 27. 28.
29. 30. 31.
32. 33.
Bernstein Hulsbergen Henning JP, van Gemert MJ, Lahaye CT. Clinical and histological evaluation of portwine stain treatment with a microsecond-pulsed dye-laser at 577 nm. Lasers Surg Med 1984; 4(4):375– 380. Tan OT, Carney JM, Margolis R, Seki Y, Boll J, Anderson RR et al. Histologic responses of port-wine stains treated by argon, carbon dioxide, and tunable dye lasers. A preliminary report. Arch Dermatol 1986; 122(9):1016– 1022. Garden JM, Tan OT, Parrish JA. The pulsed dye laser: its use at 577 nm wavelength. J Dermatol Surg Oncol 1987; 13(2):134– 138. van Gemert MJ, Welch AJ. Treatment of port-wine stains: analysis. Med Instrum 1987; 21(4):213– 217. Garden JM, Polla LL, Tan OT. The treatment of port-wine stains by the pulsed dye laser. Analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124(6):889– 896. Glassberg E, Lask GP, Tan EM, Uitto J. The flashlamp-pumped 577-nm pulsed tunable dye laser: clinical efficacy and in vitro studies. J Dermatol Surg Oncol 1988; 14(11):1200– 1208. Tan OT, Sherwood K, Gilchrest BA. Treatment of children with port-wine stains using the flashlamp-pulsed tunable dye laser. N Engl J Med 1989; 320(7):416 –421. Tan OT, Morrison P, Kurban AK. 585 nm for the treatment of port-wine stains. Plast Reconstr Surg 1990; 86(6):1112– 1117. Nelson JS, Applebaum J. Clinical management of port-wine stain in infants and young children using the flashlamp-pulsed dye laser. Clin Pediatr (Phila) 1990; 29(9):503–508, discussion 509. Ashinoff R, Geronemus RG. Flashlamp-pumped pulsed dye laser for port-wine stains in infancy: earlier versus later treatment. J Am Acad Dermatol 1991; 24(3):467 – 472. Ashinoff R, Geronemus RG. Capillary hemangiomas and treatment with the flash lamppumped pulsed dye laser. Arch Dermatol 1991; 127(2):202– 205. Morelli JG, Tan OT, Weston WL. Treatment of ulcerated hemangiomas with the pulsed tunable dye laser. Am J Dis Child 1991; 145(9):1062– 1064. Goldman MP, Fitzpatrick RE, Ruiz-Esparza J. Treatment of port-wine stains (capillary malformation) with the flashlamp-pumped pulsed dye laser. J Pediatr 1993; 122(1):71 – 77. Alster TS, Wilson F. Treatment of port-wine stains with the flashlamp-pumped pulsed dye laser: extended clinical experience in children and adults. Ann Plast Surg 1994; 32(5):478– 484. Jackson BA, Arndt KA, Dover JS. Are all 585 nm pulsed dye lasers equivalent? A prospective, comparative, photometric, and histologic study. J Am Acad Dermatol 1996; 34(6):1000– 1004. Lou WW, Geronemus RG. Treatment of port-wine stains by variable pulse width pulsed dye laser with cryogen spray: a preliminary study. Dermatol Surg 2001; 27(11):963 –965. Alster TS. Improvement of erythematous and hypertrophic scars by the 585-nm flashlamppumped pulsed dye laser. Ann Plast Surg 1994; 32(2):186 – 190. Dierickx C, Goldman MP, Fitzpatrick RE. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 1995; 95(1):84 – 90, discussion 91 – 92. Goldman MP, Fitzpatrick RE. Laser treatment of scars. Dermatol Surg 1995; 21(8):685 – 687. Sheridan RL, MacMillan K, Donelan M, Choucair R, Grevelink J, Petras L et al. Tunable dye laser neovessel ablation as an adjunct to the management of hypertrophic scarring in burned children: pilot trial to establish safety. J Burn Care Rehabil 1997; 18(4):317 – 320. Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. Plast Reconstr Surg 1998; 102(6):2190– 2195. McCraw JB, McCraw JA, McMellin A, Bettencourt N. Prevention of unfavorable scars using early pulse dye laser treatments: a preliminary report. Ann Plast Surg 1999; 42(1):7 – 14. Shakespeare PG, Tiernan E, Dewar AE, Hambleton J. Using the pulsed dye laser to influence scar formation after breast reduction surgery: a preliminary report. Ann Plast Surg 2000; 45(4):357– 368. Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999; 25(3):224– 232. Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report. Lasers Surg Med 1993; 13(1):127 – 137.
Clinical Uses of the Long Pulse Duration PDL 34. 35. 36. 37.
38. 39. 40.
41. 42.
43. 44.
45. 46. 47. 48.
49.
50.
51. 52.
243
Kauvar AN, McDaniel DH, Geronemus RG. Pulsed dye laser treatment of warts. Arch Fam Med 1995; 4(12):1035– 1040. Jacobsen E, McGraw R, McCagh S. Pulsed dye laser efficacy as initial therapy for warts and against recalcitrant verrucae. Cutis 1997; 59(4):206 – 208. Ross BS, Levine VJ, Nehal K, Tse Y, Ashinoff R. Pulsed dye laser treatment of warts: an update. Dermatol Surg 1999; 25(5):377– 380. Robson KJ, Cunningham NM, Kruzan KL, Patel DS, Kreiter CD, O’Donnell MJ et al. Pulseddye laser versus conventional therapy in the treatment of warts: a prospective randomized trial. J Am Acad Dermatol 2000; 43(2, Pt 1):275 –280. Bernstein EF, Lee J, Lowery J, Brown DB, Geronemus R, Lask G et al. Treatment of spider veins with the 595 nm pulsed-dye laser. J Am Acad Dermatol 1998; 39(5, Pt 1):746– 750. West TB, Alster TS. Comparison of the long-pulse dye (590 – 595 nm) and KTP (532 nm) lasers in the treatment of facial and leg telangiectasias. Dermatol Surg 1998; 24(2):221 – 226. Lowe NJ, Behr KL, Fitzpatrick R, Goldman M, Ruiz-Esparza J. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol 1991; 17(6):522– 525. Rohrer TE, Chatrath V, Iyengar V. Does pulse stacking improve the results of treatment with variable pulse pulsed dye lasers? Dermatol Surg 2004; 30(2 Pt 1):163 –167; discussion 167. Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg 1995; 21(1):19– 29, quiz 31– 32. Hsia J, Lowery JA, Zelickson B. Treatment of leg telangiectasia using a long-pulse dye laser at 595 nm. Lasers Surg Med 1997; 20(1):1 – 5. Kauvar ANB, Grossman MC, Bernstein LJ, Kovacs SO, Quintana AT, Geronemus RG. The effects of cryogen spray cooling on pulsed dye laser treatment of vascular lesions. Lasers Surg Med 1998; (suppl 10):211. Raulin C, Schmidt C, Hellwig S. Cutaneous lupus erythematosus-treatment with pulsed dye laser. Br J Dermatol 1999; 141(6):1046– 1050. McDaniel DH, Ash K, Zukowski M. Treatment of stretch marks with the 585-nm flashlamppumped pulsed dye laser. Dermatol Surg 1996; 22(4):332 – 337. Schonermark MP, Schmidt C, Raulin C. Treatment of sebaceous gland hyperplasia with the pulsed dye laser. Lasers Surg Med 1997; 21(4):313 – 316. Gonzalez S, White WM, Rajadhyaksha M, Anderson RR, Gonzalez E. Confocal imaging of sebaceous gland hyperplasia in vivo to assess efficacy and mechanism of pulsed dye laser treatment. Lasers Surg Med 1999; 25(1):8 – 12. Aghassi D, Gonzalez E, Anderson RR, Rajadhyaksha M, Gonzalez S. Elucidating the pulseddye laser treatment of sebaceous hyperplasia in vivo with real-time confocal scanning laser microscopy. J Am Acad Dermatol 2000; 43(1, Pt 1):49– 53. Zelickson BD, Mehregan DA, Wendelschfer-Crabb G, Ruppman D, Cook A, O’Connell P et al. Clinical and histologic evaluation of psoriatic plaques treated with a flashlamp pulsed dye laser. J Am Acad Dermatol 1996; 35(1):64– 68. Zelickson BD, Kilmer SL, Bernstein E, Chotzen VA, Dock J, Mehregan D et al. Pulsed dye laser therapy for sun damaged skin. Lasers Surg Med 1999; 25(3):229 –236. Rostan E, Bowes LE, Iyer S, Fitzpatrick RE. A double blind side-by-side comparison study of low fluence long pulse dye laser to coolant treatment for wrinkling of the cheeks. J Cosmet Laser Ther 2001; 3:129– 136.
9 Pulsed KTP (532 nm) Lasers Robert M. Adrian Center for Laser Surgery, Washington, DC, USA
Emil Tanghetti Private Practice, Sacramento, California, USA
Arielle N. B. Kauvar New York Laser and Skin Care, New York; New York University School of Medicine, New York; and Suny Downstate Medical Center, New York, New York, USA
1. 2. 3. 4.
Introduction Laser – Tissue Interaction Laser Physics Laser Techniques 4.1. Facial Telangiectasias 4.2. Leg Telangiectasias 4.3. Port-Wine Stains 4.4. Poikiloderma of Civatte 4.5. Hemangioma, Venous Lakes, Cherry Angioma, and Spider Telangiectasia 4.6 Lentigines, Freckles, Macular Seborrheic Keratoses 5. Summary References
1.
245 246 250 251 251 252 253 254 254 254 255 255
INTRODUCTION
Although numerous laser and nonlaser pulsed photothermal devices are currently available for the treatment of vascular lesions, no single system has proven uniformly effective in the treatment of the wide variety of disorders encountered in clinical practice (1). Over the past few years, multiple individual case reports and clinical studies have highlighted the fact that any single laser system can show some degree of efficacy in the treatment of vascular lesions. Argon at 488 and 514 nm (2–4), argon pumped dye at 577– 585 nm (5,6), potassium titanyl phosphate (KTP) at 532 nm (7,8), pulsed dye at 585 nm (9 – 11) and 595 nm (12), krypton at 530 nm (13), copper vapor at 578 nm (14 – 16), copper bromide at 578 nm (17), alexandrite at 755 nm (18), diode at 810 nm (19), neodymium 245
246
Adrian, Tanghetti, and Kauvar
YAG at 1064 nm (20 – 22), and carbon dioxide at 10,600 nm (23 – 26) lasers and intense pulsed light have all shown a variable efficacy in the treatment of vascular lesions. Anatomic location, vessel size, color, depth, and skin type (epidermal melanin) are all important factors which must be considered in the choice of a light source for the treatment of these conditions. In this chapter, we will discuss current concepts in the use of KTP and diode lasers emitting radiation at 532 nm and their role in the treatment of vascular lesions. 2.
LASER – TISSUE INTERACTION
Examination of the absorption curve of hemoglobin and melanin shows well-defined peaks of hemoglobin absorption at 532 nm (Fig. 9.1). The insertion of a frequencydoubling crystal in the path of 1064 nm radiation produced from a neodymium-YAG rod can produce 532 nm light and this provides the opportunity to develop a wide variety of pulsed 532 nm lasers for the treatment of blood vessel disorders. A variety of factors play a role in the response of a chromophore (target) to energy at any given wavelength. Early experience with using argon 488 and 514 nm showed that epidermal melanin competed with hemoglobin at these wavelengths (2 –4) (Fig. 9.1). Absorption by melanin and lack of specific vascular effects at 488 and 514 nm was associated with postoperative complications including pigment disturbances as well as atrophic and hypertropic scarring. Elegant modeling studies of port-wine stains by Van Gemert et al. (27) suggested that wavelength, pulse duration, irradiance, and spot size were deemed relevant in the treatment of these lesions. They argued that 532 nm radiation has an absorption coefficient for blood, which is .585 and 590 nm (Table 9.1). This may explain why green light radiation at 532 nm has proven quite useful in the treatment of facial blood vessels,
Figure 9.1 Absorption spectra of major skin pigments at concentrations for which they typically occur. Values shown are absorption coefficients (ma) for pure water, human hemoglobins at 11 g/dL, and dihydroxyphenylalanine (DOPA)-melanin, which has an absorption spectrum similar to pigmented epidermis at 15-mg/dL concentration to water. DOPA-melanin concentration shown is approximately equivalent to heavily pigmented human epidermis. Absorption coefficient of single melanosomes is unknown. Hb, Hemoglobin: HbO2, oxyhemoglobin. (From Anderson RR. Optics of the skin. In: Lim HW, Soter MA, eds. Clinical photomedicine. New York: Marcel Dekker, 1993.)
Pulsed KTP (532 nm) Lasers
247
Table 9.1 Depth of Penetration Dependence on Wavelength Wavelength (nm)
Absorption coefficient (mm21)
Scattering coefficients (mm21)
Anisotrophy factor
48.0 47.5 47.3 47.2 47.0 46.8 46.7 46.6 46.4
0.995 0.995 0.995 0.995 0.995 0.995 0.995 0.995 0.995
Blood 415 500 532 545 560 577 585 590 633
300.0 11.5 26.6 33.0 20.0 35.4 19.1 6.9 5.0
Source: Van Gemert MJC, Pickering JW, Welch AJ. Modeling laser treatment or port-wine stains. In: Tan OT, ed. Management and Treatment of Benign Cutaneous Vascular Lesions. Philadelphia: Lea & Febiger, 1992.
port-wine stains and certain lower extremity telangiectasis. Certain investigators have suggested that one of the major limitations of 532 nm light is its limited dermal penetration. A closer look at Van Gemert’s modeling data, however, predicts a depth of maximum vascular damage at 1.4 nm for 532 nm radiation (Table 9.1), which may explain deep vascular effects seen during the application of this wave band of light for leg veins. Histologic studies using a high energy pulsed frequency doubled Nd-YAG laser at 532 nm (Versapulsew, Lumenis) demonstrate the effects of 532 nm radiation on dermal vasculature. Twenty-eight patients with lower extremity telangiectasia were treated with 16 – 20 J/cm2 using contact cooling, 3 – 5 mm spot sizes, and pulse durations of 10– 50 ms. Biopsies obtained immediately after treatment showed swelling of the vessel walls with loss of endothelium and intravascular coagulation without the erythrocyte extravasation typical of pulsed dye lasers (Fig. 9.2). In certain biopsies, a cuff of perivascular collagen coagulation was noted surrounded by normal collagen indicating that specific vascular effects could be produced. Response to laser treatment at 5 –7 days showed vessel wall inflammatory cell infiltration and necrosis only to be replaced at 3 weeks by a fibrotic perivascular scar in the dermis. This damage occurred in the mid reticular dermis presumably in areas unreachable by 532 nm radiation. Although the exact mechanism whereby these specific vascular effects are achieved at 532 nm is debated, there is no doubt that they occur and are responsible for clinical improvement of facial blood vessels, port wine stains and legs veins in response to this wavelength (28 –31). Pulse duration plays a significant role in treatment of vascular lesions. Studies by Van Gemert et al. (27) and Dierickx et al. (32) have demonstrated the need for lasers with a 1– 10 ms pulse duration in the treatment of port-wine stains. Small visible vessels generally require pulse durations at least 10 ms for optimum treatment. Larger vessels may require still longer pulse duration for vascular destruction. Longer pulse can be used to effectively treat larger blood vessels. Our findings and current techniques support the earlier work of Dierickx et al. (32) and Tanghetti. Rather than destroying the targeted vessels in one pass with a single high-energy pulse with unwanted heating of epidermis and dermis, repeated lower-energy passes can accomplish this task with less damage to the surrounding tissues as well as a deeper depth of injury to target vessels. Spot size is an issue, which cuts a number of ways. For the most superficial blood vessels, matching the spot size to the vessels targeted, especially without cooling, has
248
Adrian, Tanghetti, and Kauvar
Figure 9.2 Leg vein biopsy immediately post treatment with Versapulsew laser at 20 J/cm2, 50 ms pulse duration, and 5 mm spot. Source: Van Gemert MJC, Pickering JW, Welch AJ. Modeling laser treatment for port-wine stains. In: Tan OT, ed. Management and Treatment of Benign Cutaneous Vascular Lesions. Philadelphia: Lea & Febiger, 1992.
some merits. This will limit the damage to the epidermis, which cannot be protected by cooling while still treating the targeted vessels. The damage and subsequent crusting will generally be limited and minor. However, if deeper vessels are targeted, a spot size of at least 3 mm and preferably larger is ideal. The modeling studies of Van Gemert et al. (27) have suggested that the larger spot sizes are required for deeper penetration of laser light due to the scattering effects of the dermis. In clinical practice, we use the largest spot available matched with appropriate fluences combined with epidermal cooling. The Versapulse laser (Coherent/Lumenis) is no longer manufactured. The Diolite (Iridex) is a low power device with small spot sizes, and consequently can be only used to trace facial telangiectasia, but has no role in the treatment of broader vascular lesions such as facial erythema, poikiloderma, or port wine stains. The Aura (Laserscope) is a high powered pulsed KTP laser with a contact cooling sapphire tip, and can be used with spot sizes 1 – 5 mm, adjustable at 0.1 mm increments. The Gemini (Laserscope) is the newest pulsed KTP system, with almost twice the power of previously available
Pulsed KTP (532 nm) Lasers
249
Figure 9.3 Laserscope Aura/Gemini Versastat handpiece with an adjustable 1 – 5 mm spot size.
systems, and is equipped with both an adjustable 1– 5 mm spot size (Fig. 9.3), as well as a 10 mm (Fig. 9.4), photon recycling handpiece that has a water cooled sapphire tip. Photon recycling is a concept developed by Dr. Rox Anderson of Wellman Laboratories that uses a reflector in the handpiece to redirect the back-scattered photons back into the tissue, and substantially increases the effective fluence. The large spot size enables deeper penetration of the photons (Fig. 9.5) and delivery of higher effective fluences. With the new 10 mm spot, broader lesions such as facial erythema, poikiloderma and port wine stains can be treated with a lower risk of reticulation and increased efficacy. Cutaneous cooling has been a major advance in laser surgery and plays an important role in the treatment of vascular lesions (33,34). In addition to affording increased patient comfort during the procedure, higher energy is able to be used with reduced epidermal damage. When multiple pulses are delivered to a given vessel, epidermal cooling is
Figure 9.4 Laserscope Gemini VersaStat 10 mm handpiece with photon recycling.
250
Adrian, Tanghetti, and Kauvar
Figure 9.5 The optical penetration of the photons at 532 nm is greatly increased with a 10 mm compared to a 1 – 5 mm spot.
essential. Studies have shown that contact cooling using a sapphire chill tip can lower the temperature of the epidermis (100–120 nm) to 158C within 250 ms. Although cooling is beneficial in the treatment of vascular lesions, tanned and darker skinned individuals need to be approached with caution since melanin competes with hemoglobin at 532 nm. Treatment of tanned individuals may be associated with significant postoperative complications such as blistering, crusting, and prolonged hypopigmentation in treated sites.
3.
LASER PHYSICS
A number of 532 nm pulsed and quasi-continuous lasers are available through various laser manufacturers (Table 9.2). There are significant differences among these systems, which are important to clinical safety and efficacy. In general, laser systems with, large spot sizes and Table 9.2 Lasers of Wavelength 532 nm Manufacturer Laser Type Maximum power (W) Spot size (mm) Pulse rate (Hz) Pulse duration (ms) Contact cooling Other
Coherent Lumenis Versapulsew FD Nd:YAG Solid State 7.2 2 – 10 1 – 10 2 – 50 Yes No longer manufactured
Iridex Diolitew Diode Pumped FD Nd:YAG 3 0.2– 1.4 1 – 15 1 – 50 No
Laserscope Auraw FD Nd:YAG
Laserscope Geminiw FD Nd:YAG
60 1–5 1 – 10 1 – 50 Yes
275 1 – 5, 10 1–4 1 – 50 Yes
Pulsed KTP (532 nm) Lasers
251
cooling capable of delivering high energy fluences provides greater safety and efficacy in the treatment of vascular lesions. Unfortunately, these systems are generally more expensive than those without these features. Cutaneous cooling allows the delivery of higher energy fluences with increased patient comfort, safety and efficacy. Depending on the laser system one uses, treatment technique will vary. A detailed discussion regarding the clinical use of the Versapulsew laser will serve as a guideline for current technique using 532 nm lasers in the treatment of vascular lesions.
4. 4.1.
LASER TECHNIQUES Facial Telangiectasias
Dilated facial blood vessels or telangiectasias are a common occurrence affecting millions of individuals (35,36). While genetic factors may play a role in the development of these lesions, they are most commonly seen in patients of skin types I– III and may be associated with acne rosacea, chronic actinic damage, collagen vascular diseases, estrogens, overuse of topical cortico steroids, and photodamage. Lasers of 532 nm wavelength have proven effective in the treatment of facial telangiectasias (7,29). The availability of large spot sizes with high fluence and contact cooling of the epidermis laser provides excellent efficacy and safety in the treatment of this condition (Fig. 9.6). Small pink and red vessels ,0.3 mm in diameter are treated with between 9 and 13 J/cm2 using a 4– 6 mm spot size and pulse duration ranging between 10 and 30 ms. Vessels are treated with single, slightly overlapping pulses in an attempt to achieve a clinical endpoint of vessel disappearance. If vessels refill or persist during the treatment session, another series of pulses may be delivered in order to produce disappearance of the vessel. Blood vessels .0.4 mm are treated in a similar fashion but often respond to longer pulse durations in the 30–50 ms range. Single, slightly overlapping pulses with the same clinical endpoint as seen with smaller blood vessels are used. Blood vessels .1 mm in diameter may not disappear at the time of laser therapy, but will often develop which appears as a darkening of the vessel. This can be used as an effective end point. The clotted vessel will generally disappear over 1–2 weeks. Ultrasound gel has been quite useful in the use of the KTP laser for the treatment of port-wine stain and telangiectasias (37). This agent allows rapid and smooth movement of the chill tip over the skin. It also provides close contact of the chill tip with the epidermis facilitating heat transfer away from the epidermis during pulse delivery as well as after the treatment. Ultrasound gel may also help by means of refractive index matching. Gel is also quite helpful in treating irregular surfaces such as the nasolabial folds with a contact chilling
Figure 9.6 Facial telangiectasia before (a) and 1 month after (b). Treatment with Versapulsew laser: 12 J/cm2, 5 mm spot, 30 ms pulse.
252
Adrian, Tanghetti, and Kauvar
device where direct contact to the skin surface can only be made by a thick layer of gel between the skin and chilling device. Patients who have tanned skin or Fitzpatrick types IV–VI may blister and develop hypopigmentation of a temporary nature using 532 nm radiation. Tanned skin represents a relative contraindication to 532 nm laser treatment and we routinely ask patients to return after their tan has faded. At the completion of treatment, patients apply cool compresses to the treated area for 10–20 min. Patients can be seen 4–6 weeks later and retreated if necessary. Complications from Versapulse laser treatment of facial telangiectasias are uncommon but most often result from lack of contact of the chill tip with the epidermis or use of excessive energy fluence. These problems may be seen during treatment as immediate greying or blistering of the skin. If this occurs one should re-examine their technique to be sure that there is proper contact of the chill tip to the skin and that appropriate energy fluences are being used. Occasionally, when treating a patient with significant facial telangiectasias of the face edema and swelling of the face and lower eyelids will be seen after a night’s rest. This can last 1–3 days and can be treated by head elevation when sleeping. Our experience in the treatment of over 1000 patients with facial telangiectasia indicate that 85–90% of patients achieve .75% improvement of their telangiectasias from one treatment sessions. Approximately 15–20% of patients require touch up treatment sessions to achieve optimal results. A great benefit in the use of longer pulse 532 nm lasers is that postoperatively patients do not experience the excessive purpura as seen during the use of 0.45–1.5 ms pulsed dye lasers. Patients may return to their work or social activities within a relatively short period of time. The development of the 10 mm spot size with the Gemini laser has greatly improved the treatment of rosacea associated telangiectasia and erythema. The individual telangiectasia are traced with contiguous laser pulses using a 3 –4 mm spot, pulse durations of 20– 40 ms and fluences of 10– 15 J/cm2. The background erythema can then be treated using the 10 mm spot with pulse durations of 20 – 30 ms and fluences of 6 – 8 J/cm2. Patients can expect transient erythema for several hours without purpura, and the possibility of urticarial papules for up to one day. Excellent clearing of the erythema and telangiectasia is achieved in 2– 3 treatments (Fig. 9.7).
4.2.
Leg Telangiectasias
The use of lasers to treat lower extremity telangiectasias is a topic that has evoked a large amount of controversy (1). While sclerotherapy has been the treatment of choice, this treatment is not without problems. The versapulse, Aura and Gemini lasers effectively treat superficial leg telangiectasia up to 110 mm in diameter (28 –31) (Fig. 9.8). Patients
Figure 9.7 A patient with rosacea associated telangiectasia and erythema (a) before and (b) after one treatment with the Gemini laser. (Courtesy of Vic Ross, M.D. and Laserscope.)
Pulsed KTP (532 nm) Lasers
253
Figure 9.8 Leg veins before (a) and after (b). Versapulsew laser treatment 2 Rx.
with Fitzpatrick skin types I –III are excellent candidates for this treatment. It is best to avoid treating patients with tanned skin and use caution in treating darker skin types because of competition with epidermal melanin. Lower extremity blood vessels are treated using similar techniques as for facial blood vessels but, longer pulse durations at 40 – 50 ms are generally used with a 4 mm spot and energies between 20 and 24 J. Single slightly overlapping pulses are delivered along the course of the vein with observed clinical endpoints of vessel disappearance of small vessels or persistent intervascular coagulation of larger vessels. Graying or immediate blistering of skin are important signs indicating that it is necessary to reevaluate the adequacy of cutaneous cooling or energy fluence. Unlike the face, however, delayed blisters with these fluences are not uncommon when treating leg veins. Larger diameter and deeper vessels are now better treated with near infrared Nd:YAG, alexandrite and diode lasers. 4.3.
Port-Wine Stains
Port-wine stains remain a therapeutic challenge for clinicians. The flashlamp pumped pulse dye laser (450 ms) has long been recognized as the gold standard for the treatment of this condition (9,10). Studies by Van Gemert et al. (27) and Dierickx et al. (32) suggested that longer pulse durations in the range of 1–10 ms may be more ideal for the treatment of this condition. In a bilateral study comparing the Versapulse laser at 532 nm with a pulse dye laser at 585 nm, equivalent responses were noted in lightening of port-wine stains (38). Port-wine stains treated with the Versapulse laser require similar techniques to those used in the treatment of facial telangiectasias and leg veins (Fig. 9.9). Single, slightly overlapping pulses and after multiple passes and often multiple passes are delivered to the
Figure 9.9 Port-wine stain before (a) and after (b). Versapulsew laser treatment 2 Rx.
254
Adrian, Tanghetti, and Kauvar
affected areas. Treatment energy fluences range between 12 and 20 J/cm2 using 10–50 ms pulse durations. Once again, proper contact of the chill tip with the skin is essential to reduce postoperative blistering and crusting at treatment sites and to enhance patient comfort. The Versapulse and Aura/Gemini laser have been found useful in treating children and adults with port-wine stains, which no longer respond to pulse dye laser treatment. KTP laser retreatment may cause additional lightening in approximately 50% of lesions. A number of 532 nm lasers are capable of accepting scanners. Unfortunately, small spot sizes used with scanners decreases tissue transmission and makes treating deeper blood vessels difficult and lack of an effective fluence in the deeper dermis due to the scattering of light.
4.4.
Poikiloderma of Civatte
This clinical entity is a challenging problem for clinicians and treatment of this condition should be approached with cauation. The pulsed KTP laser has been found useful in the treatment of this condition, however, physicians must be careful to use lower fluences since neck skin may exhibit delayed wound healing, persistent hypopigmentation and scarring from overzealous laser treatment. Patients with this condition can be treated with the Versapulse laser using a 5 or 6 mm spot at 8.5 –12 J/cm2 with 10 –30 ms pulse durations. Typically one to two treatments will result in significant improvement. Careful choice of fluence and use of contact cooling should reduce the incidence of complications seen in the treatment of this condition. Urticarial swelling of the lower neck can occur with this condition for 1 –2 days after treatment. Poikiloderma of Civatte can now be treated with a better risk-benefit ratio using the 10 mm spot size available with the Gemini laser, contact cooling and lower fluences. These parameters provide a decreased incidence of reticulation and hypopigmentation. Small test areas should be performed to determine the optimal laser parameters for each patient.
4.5.
Hemangioma, Venous Lakes, Cherry Angioma, and Spider Telangiectasia
All of these conditions may be treated by means of 532 nm lasers. Depending on the laser, treatment parameters will vary. Versapulsew laser treatment of hemangiomas can successfully improve these lesions. Spot sizes of 5 –6 mm and fluences between 14 and 20 J may be used to flatten these lesions. Venous lakes, cherry angiomas, and spider telangiectasia respond to one or two pulses matching spot size to the size of these lesions. In some cases, most often involving hemangiomas, multiple treatment sessions are necessary and complete response may not be seen. Venous lakes, cherry angiomas and spider telangiectasia respond favorably in one or two treatment sessions.
4.6
Lentigines, Freckles, Macular Seborrheic Keratoses
The pulsed KTP laser can also be used effectively to treat pigmented lesions including lentigines, freckles and macular seborrheic keratoses. A 2 – 4 mm spot size is used with pulse durations of 10 –15 ms and fluences of 15– 20 J/cm2. An immediate endpoint of tissue graying, but not whitening, should be observed. Sometimes a second pulse is required to achieve this effect. A fine crusts develops and may be present for 5 – 10 days, depending on the lesion location. Patients are instructed to apply an antibiotic ointment such as bacitracin or poilysporin daily until the treated areas have healed.
Pulsed KTP (532 nm) Lasers
255
Treatment of pigmented lesions must not be performed in individuals with Fitzparick skintypes IV or higher, or in fair skinned patients who have a suntan present.
5.
SUMMARY
There is no doubt that 532 nm green light radiation is effective in the treatment of wide variety of vascular lesions including facial telangiectasia, port-wine stains, hemangiomas, leg veins, poikiloderma of civatte, cherry angioma, and venous ectasia. Systems with large spot sizes, high fluences, and cutaneous cooling appear safer and more effective in the treatment of these conditions. Physicians who use any of these lasers should learn the performance characteristics of each individual system and adhere to published guidelines in order to provide safe and effective laser treatment.
REFERENCES 1. 2. 3. 4. 5.
6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18.
Dover JS, Sadick NS, Goldman MP. The role of lasers and light sources in the treatement of leg veins. Dermatol Surg 1999; 25:328 – 336. Apfelbert DB, Masr MR, Lash H. Extended clinical use of the argon laser for cutaneous lesions. Arch Dermatol 1979; 115:719. Noe JM et al. Port wine stains and the response to argon laser therapy. Successful treatment and the predictive role of color, age and biopsy. Plast Reconstr Surg 1980; 65:130. Dolsky RL. Argon laser skin surgery. Surg Clin North Am 1984; 64:861. Broska P, Mattinho F, Goodman MM. Comparison of the argon tunable dye laser with the flashlamp pulsed dye laser in treatment of facial telangiectasia. J Dermatol Surg Oncol 1994; 20:749 – 753. Apfelberg DB. Argon-pumped tunable dye laser. Ann Plast Surg 1994; 32:394 – 400. Goldberg DJ, Meine JG. A comparison of four frequency doubled Nd:YAG (532 nm), Laser systems for treatment of facial telangiectasia. J Dermatol Surg 1999; 25:463 – 467. Smith T et al. 532 Nanometer green laser beam treatment of superficial varicosities of the lower extremities. Laser Surg Med 1988; 8:130. Tan OT, Shelwood DK et al. Treatment of children with port wine stains using the flashlamp pulsed tunable dye laser. N Engl J Med 1989; 320:416. Sherwood KA, Tan OT. Tretment of a capillary hemangioma with the flashlamp pumped dye laser. J Am Acad Dermatol 1990; 22:136. Goldman MP, Fitzpatrick RE. Pulsed-dye laser treatment of leg telangiectasias with and without simultaneous sclerotherapy. J Dermatol Surg Oncol 1990; 16:338. Hsia J et al. Treatment of leg telangiectasia using a long pulse dye laser at 595 nm. Lasers Surg Med 1997; 20:1– 5. Thibauh PK. A patient’s questionnaire evaluation of krypton laser treatment of facial telangiectases. Dermatol Surg 1997; 23:37– 41. Dinehart SM, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. J Dermatol Surg Oncol 1993; 19:370– 375. Key JM, Waner M. Selective destruction of facial telangiectasia using a copper vapor laser. Arch Otolaryngol Head Neck Surg 1992; 118– 509. Dinehart SM, Waner M. Comparison of the copper vapor and flashlamp-pulsed dye laser in the treatment of facial telangiectasia. J Am Acad Dermatol 1991; 24:116. McCoy D, Hanna M, Anderson P, McLennan G, Repacholi M. An evaluation of the copper bromide laser for treating telangiectasia. Dermatol Surg 1996; 22:551 – 557. McDaniel DH, Ash K, Lord J, Newman J, Adrian RM, Zukowski M. Laser therapy of spider leg veins: Clinical evaluation of a new long pulsed Alexandrite laser. J Dermatol Surg 1999; 25:52 – 58.
256 19.
20. 21. 22.
23. 24. 25. 26.
27.
28. 29. 30.
31. 32.
33.
34. 35. 36. 37. 38.
Adrian, Tanghetti, and Kauvar Adrian RM, Griffin L. Long pulse alexandrite (755 nm) and diode (800 nm) lasers in the treatment of lower extrement telangiectasia. A comparative clinical study. Laser Surg Med 1999; 11:20. Weiss RA, Weiss MA. Early clinical results with a mutiple synchronized pulse 1064 nm laser for leg telangiectasias and reticular veins. J Dermatol Surg 1999; 25:399 – 402. Landthaler M, Haina D, Brunner R, Waidelich W, Braun-Falco O. Neodymium:YAG laser therapy for vascular lesions. J Am Acad Dermatol 1986; 14:107– 117. Landhaler M, Hohenleutner U, El Raheem TA. Therapy of vascular lesions in the head and neck area by means of argon, ND:YAG, CO2 and flashlamp-pumped pulsed dye lasers. Adv Otorhinolaryngol 1995; 49:81 – 86. Lanigan SW, Cotterill JA. The treatment of port-wine stains with the carbon dioxide laser. Br J Dermatol 1990; 229. Backer JW, Ratz JL, Richfield DF. Histology of port-wine stains treated with carbon dioxide laser. J Am Acad Dermatol 1984; 10:1014. Kaplan I, Peled I. The carbon dioxide laser in the treatment of superficial telangiectases. Br J Plast Surg 1975; 28:214. Bailin PL. Treatment of port-wine stains with the CO2 laser: early results. In: Arndt KA, Noe JM, Rosen S, eds. Cutaneous Laser Therapy; Principles and Methods. Chichester: John Wiley & Sons, 1983. Van Gemert MJC, Pickering JW, Welch AJ. Modeling laser treatment of port-wine stains. In: Tan OT, ed. Management and Treatment of Benign Cutaneous Vascular Lesions. Philidelphia: Lea & Febiger, 1992. Adrian RM, Tanghetti ET. Long pulse 532 nm laser treatment of lower extremity telangiectasias: a clinical and histologic study. Dermatol Surg 1997; 24– 28. Adrian RM, Tanghetti ET. Long pulse 532 nm laser treatment of facial telangiectasia. Dermatol Surg 1997; 24:71– 74. Bernstein EF, Kornbluth S, Brown DB, Black J. Treatment of spider veins using a 10 millesecond pulse duration frequency doubled neodymium YAG laser. Dermatol Surg 1999; 25:316 – 320. Massey RA, Katz BE. Successful treatment of spider leg veins with a high energy long pulse frequency double neodymium: YAG laser (Help G). Dermatol Surg 1999; 25:677 – 680. Dierickix CC, Casparian JM, Venugopalan V et al. Thermal relaxation of port-wine stain vessels probed in vivo: the need for 1 –10 millisecond laser pulse treatment. J Invest Dermatol 1995; 105:709. Welsh AJ, Moramedi M et al. Evaluation of cooling techniques for the protection of the epidermis during Nd:YAG laser radiation of the skin. In: Joeffe SN, ed. Neodymium-YAG Lasers in Medicine and Surgery. New York: Elsevier Science, 1983. Zenzie HH, Altshuler GB, Smirnov MZ, Anderson RR. Evaluation of cooling methods for laser dermatology. Lasers Surg Med 2000; 26:130 – 144. Goldman MP, Bennett RG. Treatment of telangiectasia: a review. J Am Acad Dermatol 1987; 17:167 – 182. Goldman MP, Weiss RA, Brody HJ. Treatment of facial telangiectasia with sclerotherapy, laser surgery and electrodessication: a review. J Dermatol Surg Oncol 1993; 19:899 – 906. Kauvar AN, Frew KE, Friedman PM, Ohmeimus RG. Cooling gel improves pulsed KTP laser treatment of faceal telangiectasia. Lasers Surg Med 2002; 30:149 – 153. Tanghetti ET, Adrian RM. Long-pulsed 532 nm laser treatment of port wine stains. Laser Surg Med 1998; 10:36.
Pulsed KTP (532 nm) Lasers
257
VASCULAR LASER TREATMENT CONSENT The procedure planned is treatment with the VersaPulse Laser, Pulsed Dye Laser, LPIRAlexandrite, Diode or Long Pulse Nd:YAG laser. The purpose of this procedure is to lighten, fade, or remove abnormal blood vessels or birthmarks. Alternative treatment methods include electrosurgery, sclerotherapy or no treatment. I understand the risks of this procedure include possible pain, bleeding, infection, blistering, hypopigmentation, hyperpigmentation, scarring, and unforeseen complications. The risks of scarring appear to be very small compared with the risks of the older Argon and CO2 laser treatments but are still possible with the newer vascular laser treatments. I understand that there is a possibility that this procedure will fail, need to be repeated, or require additional treatment of complications. I understand my responsibility for properly fulfilling the appropriate aftercare instructions as explained by the doctor and/or his staff. I further agree that any pictures taken of me may be used for either teaching or publication as the doctor considers appropriate unless I notify him in writing that he is not to use these photographs. Although part of all of the costs for this procedure may be reimbursed by insurance companies, some policies or companies mat not cover the procedure because they consider it cosmetic or for other reasons. I understand that I am responsible for all costs of the procedure. I have been asked at this time whether I have any further questions about this procedure, and I do not. I understand the procedure, accept the risks, and request that Dr. Robert Adrian or his nurse perform this procedure on me. Patient Name (Please Print)
Date of Surgery
Patient Signature
Date of Signature
Witness Signature
10 Q-Switched Ruby Laser Vic A. Narurkar San Francisco and University of California at Davis, Davis, California, USA
1. Introduction 2. Background 3. Laser Physics 4. Laser – Tissue Interaction 5. Laser Treatment Principles 6. Lesions Amenable to Treatment with the QSRL 7. Complications 8. Conclusions References
1.
259 259 260 260 260 261 262 262 263
INTRODUCTION
The development of Q-switched solid state lasers has revolutionized the treatment of a variety of cutaneous lesions. The challenge in selective destruction of targets has been to spare competing structures in the epidermis and the dermis. Selective photothermolysis, the use of narrow bands of light and pulse widths, and photoacoustic effects allow Q-switched laser delivery systems to preferentially target pigment-containing structures such as lentigines, ephelides and tattoos. Q-switched ruby lasers (QSRLs) utilize a wavelength of 694 nm and pulse durations of 20 –30 ns to effectively treat a variety of benign pigmented lesions.
2.
BACKGROUND
The ruby laser was first introduced for dermatologic applications in the 1960s for the treatment of benign pigmented lesions and tattoos (1,2). Technical limitations of the early ruby laser systems prevented them from gaining wide acceptance. Reid et al. reported the modification of the free running ruby laser to a Q-switched system, thereby permitting 259
260
Narurkar
ultraselective destruction of amateur tattoos (3,4). Since that time, the QSRL has been used effectively for the treatment of benign epidermal pigmented lesions, dermal pigmented lesions, professional and amateur tattoos, and compassionate treatment of congenital nevi (5 –8).
3.
LASER PHYSICS
The Q-switched ruby laser typically employs pulse widths of 20 –40 ns, with this ultrashort pulse duration being shorter than thermal relaxation time of melanosomes, the target for destruction in epidermal and dermal pigmented lesions. The wavelength of 694 nm shows a high affinity for melanin, the target chromophore for pigmented lesions. Spot sizes of 2 – 4 mm are employed with fluences up to 10 J/cm2 to allow for optimal fluence to match spot size and ensure adequate destruction of the targets. Photoacoustic effects produced by the Q-switched mechanism produces a photomechanical effect which facilitates the destruction of melanosomes to be shattered into smaller particles which are later eliminated by the lymphatic system.
4.
LASER – TISSUE INTERACTION
Selective destruction of pigmented lesions and tattoos requires a careful interplay of wavelength, pulse duration, and fluence. Melanin, the endogenous chromophore has a broad absorption spectrum which has excellent absorption at 694 nm, the wavelength of the QSRL. Pulse durations are designed to reflect the thermal relaxation time of the target to be treated, which in the case of tattoos and pigmented lesions is the melanosome. Melanosomes have thermal relaxation times in the 50 – 100 ns range (9), sufficient energy fluence is also necessary to disrupt the desired targets. The QSRL employs an ultrashort pulse duration of 20 –40 ns and energy fluences to 10 J/cm2 (10), allowing for selective destruction of benign pigmented lesions and tattoos. Besides selective photothermolysis, photoacoustic effects produced by Q-switching (the use of an optomechanical shutter) are responsible for pigment destruction (11). The QSRL uses high energy, nanosecond pulse durations which produce expansion of ink particles followed by shattering. These laser irradiated fragments are then eliminated transepidermally and transdermally through the lymphatic system. Ultrastructural analysis has demonstrated reduction in dermal particles and fading of ink following QSRL treatment (12).
5.
LASER TREATMENT PRINCIPLES
QSRL treatment is a simple and well-tolerated office-based procedure. Patients are advised to avoid direct sun exposure and the use of tanning beds to avoid greater risks of unwanted melanocytic injury and pigmentation anomalies in treated areas. Anesthesia in the form of topical agents such as eutetic mixture of lidocaine (EMLA, Elamax) with or without the administration of field block anesthesia may be needed for treating tattoos. Pigmented lesions are usually treated with topical anesthesia or without any anesthesia. The treatment technique consists of delivering energy fluences which will produce a uniform whitening of the skin surface. For pigmented lesions, fluences of 2 –4 J are usually adequate, while for dermal tattoos and deeper dermal lesions fluences of 6 J and
Q-Switched Ruby Laser
261
higher are necessary. The goal is to select the initial energy fluence at the lowest possible setting which will produce a uniform whitening of the skin surface. On subsequent treatments fluences may be increased and as the lesions start to fade, pinpoint bleeding may be noticed as the initial clinical response. Small test sites are advisable immediately prior to proceeding with definitive treatment to establish the optimal energy fluence (13). The “snowflake” color appearance immediately following treatment is replaced by a transient urticarial and mildly purpuric response in about 20 min. Immediately postoperatively, a topical antibiotic or lubricant such as aquaphor is applied to the treated sites. Vesiculation and scabbing may occur and the patient is advised to continue treating these areas with emollients. Healing is usually complete by 10 –14 days. Fading of the tattoo pigment is evident at 4– 6 weeks and treatment intervals of at least 6 – 8 weeks are recommended. Transient hyperpigmentation or hypopigmentation that may develop can persist up to 6 months or longer. Benign pigmented lesions usually clear in one or two treatments. Deeper dermal lesions require multiple treatments. Amateur tattoos usually clear in three to four treatments while professional tattoos may require a significantly greater number of treatments and complete fading is not always possible (14,15).
6.
LESIONS AMENABLE TO TREATMENT WITH THE QSRL
Table 10.1 summarizes the variety of benign pigmented lesions and dermal lesions which can be effectively treated with the QSRL. Successful treatment of benign epidermal lesions includes the selective treatment of lentigines, ephelides, labial lentigines, and Peutz – Jehngers pigmented lesions (16,17). Typically, one to two treatments effectively clear epidermal pigmented lesions since the pigment is more superficial and the size of melanosomes is smaller. Examples of dermal pigmented lesions amenable to QSRL treatment include amateur tattoos, traumatic tattoos, professional tattoos, nevus of Ota/Ito and Beckers nevus. Since these lesions tend to be deeper, have higher pigment density and exhibit larger melanosome size, greater number of treatments are necessary (18). The QSRL can effectively fade black, blue, and green color tattoos. Shades of red and yellow are unresponsive. Other colors respond variably. Other lesions which show a variable response to QSRL treatment include cafe-au-lait macules, congenital nevi and infraorbital hyperpigmentation (19). Attempts to treat melasma and postinflammatory Table 10.1 Lesions Amenable to Treatment with the QSRL Tattoos Amateur Traumatic Professional (black, blue, green) Cosmetic Nevus of Ota/Ito Becker’s nevus Ephelides Lentigos Peutz – Jehngers hyperpigmentation Infraorbital hyperpigmentation Melanocytic nevi (mostly junctional)
262
Narurkar
hyperpigmentation have been generally disappointing with all pigmented lesion laser delivery systems. The treatment of melanocytic nevi with lasers remains controversial. Temporary fading is possible but recurrences are frequent as only the superficial portion of the nevus is destroyed. The deeper nevus cells may repopulate the superficial dermis and epidermis with resulting repigmentation. The danger is that a “nevus” treated with the laser is actually a “melanoma.” Laser treatment of a melanoma will make the diagnosis more difficult to make by altering the histologic features and delaying a definitive diagnosis. There are reports of treating congenital nevi with the QSRL, but recurrence is almost uniformly seen. If nevi are treated with the QSRL, close follow-up is important. Long-term studies are underway to establish the safety and efficacy of the QSRL, other Q-switched and long pulsed solid state lasers for the treatment of melanocytic nevi. Potential advantages of long pulsed solid state systems include longer thermal relaxation times which may facilitate better clearance. The longer pulse durations may also pose a disadvantage by producing higher risks of unwanted epidermal damage and scarring.
7.
COMPLICATIONS
The QSRL, if utilized properly and in the right patient group, carries a high safety margin. Complications are infrequent and can include hypopigmentation, hyperpigmentation, and textural change. Pigmentary changes are greatest in darker skin types because of increased interference of melanin absorption in darker skin types and excellent absorption of melanin at the 694 nm wavelength. Hyperpigmentation usually fades and can be prevented and/or corrected with the use of topical bleaching agents. Hypopigmentation is more persistent and not amenable to correction. Textural changes can occur if excessive energy fluence is utilized and is more prevalent in areas of the body susceptible to hypertrophic scarring. The risk of complications increase as the number of treatments of a given area increases. Spacing treatments further apart may reduce complication rates by allowing the tissue to recover more fully. An important complication for the QSRL and all Q-switched lasers is the concept of paradoxical darkening of tattoo ink. This can occur in cosmetic tattoos (e.g., lip-liner, eyeliner, areolar micropigmentation), skin-colored tattoos, and tattoos containing white ink. If these inks are exposed to the QSRL, these tattoo pigments promote reduction of titanium and ferric oxide components of the ink, thereby producing immediate black discoloration upon delivery of the laser energy. Single pulse test sites are recommended prior to proceeding with QSRL treatment. This black colored ink is variably responsive to additional QSRL treatment.
8.
CONCLUSIONS
The QSRL can successfully treat a variety of benign epidermal and dermal pigmented lesions and tattoos. The mechanism of selective photothermolysis and photoacoustic effects allow for selective destruction of these targets. A careful interplay of the 694 nm wavelength with a high affinity for melanin, an ultrashort pulse duration of 20 –40 ns and energy fluences of 10 J/cm2 permit the QSRL to allow for selective and effective destruction of these lesions. Complications are infrequent with a report of ,2% incidence of transient pigmentary changes, textural changes, and paradoxical darkening.
Q-Switched Ruby Laser
263
REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
14. 15.
16.
17.
18. 19.
Goldman L, Rockwell RJ, Meyer R et al. Laser treatment of tattoos: a preliminary survey of three years clinical experience. J Am Med Assoc 1967; 201:163 – 166. Yules RB, Laub DR, Honey R et al. The effect of Q-switched ruby laser radiation on dermal tattoo pigment in man. Arch Surg 1967; 95:179– 180. Reid WH, McLeod PJ, Ritchie A et al. Q-switched ruby laser treatment of black tattoos. Br J Plast Surg 1983; 36:455 – 459. Vance CA, McLeod PJ, Reid WH et al. Q-switched ruby laser treatment of tattoos: a further study. Lasers Surg Med 1985; 5:179. Goldberg DJ. Benign pigmented lesions of the skin: treatment with the Q-switched ruby laser. J Dermatol Surg Oncol 1993; 19:376– 379. Ashinoff R, Geronemus RG. Q-switched ruby laser treatment of benign pigmented lesions. Lasers Surg Med 1992; 4S:73. Taylor CR, Gange RW, Dover JS et al. Treatment of tattoos by the Q-switched ruby laser: a dose response study. Arch Dermatol 1990; 126:893 –899. Lowe NJ, Luftman D, Sawcer D. Q-switched ruby laser—further observations on treatment of professional tattoos. J Dermatol Surg Oncol 1994; 20:307– 311. Polla LL, Margolis RJ, Dover JS et al. Melanosomes are the primary target of Q-switched ruby laser irradiation in guinea pig skin. J Invest Dermatol 1986; 89:281 – 286. Scheibner A, Kenny G, White W et al. A superior model of tattoo removal using the Q-switched ruby laser. J Dermatol Surg Oncol 1990; 16:1091 – 1098. Anderson R, Parrish J. The optics of human skin. J Invest Dermatol 1981; 77:13 – 19. Taylor C, Anderson R, Gange R et al. Light and electron microscopic analysis of tattoos treated by Q-switched ruby laser. J Invest Dermatol 1991; 97:131 – 136. Kilmer SL, Anderson RR. Clinical use of the Q-switched ruby and the Q-switched Nd:YAG (1064 and 532 nm) lasers for the treatment of tattoos. J Dermatol Surg Oncol 1993; 19:330 – 338. DeCoste SD, Anderson RR. Comparison of Q-switched ruby and Q-switched Nd:YAG laser treatment of tattoos. Lasers Surg Med 1991; (suppl 3):64. Kilmer SL, Lee MS, Anderson RR. Treatment of multicolored tattoos with the frequency doubled Q-switched Nd:YAG laser: a dose response study with comparison to the Q-switched ruby laser. Lasers Surg Med 1993; (suppl 5):54. Oshihiro T, Maruyama Y, Makajima H et al. Treatment of pigmentation of the lips and oral mucosa in Peutz-Jehgers syndrome using ruby and argon lasers. Br J Plast Surg 1980; 33:346 – 349. McMeekin TO, Goodwin D. Comparison of Q-switched ruby, pigmented lesion dye and copper vapor laser treatment of benign pigmented lesions of the skin. Lasers Surg Med 1992; 4S(suppl):74. Goldberg DJ, Nychay SG. Q-switched ruby laser treatment of the nevus of Ota. J Dermatol Surg Oncol 1992; 18:817 – 821. Oshiro T, Maruyama Y. The ruby and argon lasers in the treatment of naevi. Ann Acad Med Singapore 1983; 12:388 – 395.
11 The Q-Switched Nd:YAG (1064 1 532 nm) Laser Suzanne L. Kilmer Laser & Skin Surgery Center of Northern California, Sacramento, California, USA
Macrene R. Alexiades-Armenakas Private Practice, New York, New York, USA
Vicki J. Levine New York University School of Medicine, New York, New York, USA
Robin Ashinoff Mohs and Laser Surgery, Hackensack University, Hackensack, New Jersey, USA
1. Background 1.1. Laser Instrumentation and Properties 1.2. Laser – Tissue Interactions 1.2.1. Theory of Selective Photothermolysis 1.2.2. Target Chromophore Specificity 1.2.3. Mechanisms of Target Destruction 1.3. Histology 1.3.1. Depth of Penetration 1.3.2. Tattoo Removal 1.3.3. Removal of Melanocytic Lesions 1.3.4. Hair Removal 2. Treatment Indications 2.1. Tattoo Removal 2.1.1. Background 2.1.2. Mechanisms of Laser-Induced Tattoo Lightening 2.1.3. Comparative Studies 2.1.4. Q-Switched Ruby Laser-Resistant Tattoos 2.1.5. Treatment of Tattoos in Darkly Pigmented Patients 2.1.6. Medicinal and Traumatic Tattoos 2.1.7. Cosmetic Tattoos 2.1.8. Disadvantages in Tattoo Removal 2.2. Removal of Pigmented Lesions 2.2.1. Pigmented Lesions in General 2.2.2. Acquired Melanocytic Nevi 2.2.3. Congenital Nevi
266 266 266 266 267 268 269 269 269 270 270 271 271 271 271 272 272 272 273 273 274 275 276 277 277 265
266
Kilmer et al.
2.3. Hair Removal 2.4. Rhytids 3. Laser Technique and Parameters 3.1. Tattoo Removal 3.1.1. General Parameters and Protective Equipment 3.1.2. Professional and Amateur Tattoo Removal 3.1.3. Cosmetic Tattoo Removal 3.1.4. Medicinal and Traumatic Tattoo Removal 3.1.5. Tattoo Treatment of Darker Skin Types 3.2. Removal of Melanocytic Lesions 3.2.1. Epidermal Lesions 3.2.2. Dermal Melanocytic Nevi 3.2.3. Common Acquired Nevi 3.3. Hair Removal 3.4. Rhytids 4. Pre- and Postprocedure Management 4.1. Preprocedure Considerations 4.2. Postprocedure Considerations 4.2.1. Wound Care 4.2.2. Complications 5. Summary References
1. 1.1.
277 277 278 278 278 278 278 279 279 279 279 279 279 280 280 280 280 280 280 281 281 282
BACKGROUND Laser Instrumentation and Properties
The neodymium:yttrium – aluminum –garnet (Nd:YAG) laser was developed by Geusic and colleagues in 1964 (1). Neodymium ions were introduced to the host crystal YAG and powered by a xenon arc lamp, a flashlamp pump consisting of a quartz tube containing xenon gas and fitted with two electrodes. A continuous high-density electrical discharge passes through the xenon gas and the emitted light is coupled via optical resonators into the gain medium (atoms predominantly in an excited rather than a resting state). This results in stimulated emission and the net release of energy as additional photons (2). The Nd:YAG laser has two major emission wavelengths in the near-infrared range, one at 1064 nm, and another at 1300 nm with selectivity determined by different optical resonators. Passing the 1064 nm beam through potassium titanyl phosphate (KTP) crystal in the laser cavity halves the wavelength (i.e., doubles the frequency) to 532 nm, which is in the green visible light range. The quality (Q)-switched (can abbreviate to QS) mechanism was first proposed in 1961 by Hellwarth (3). It employs rotating mirrors and other methods to store excessive energy within the laser cavity, then release it in very short bursts of high peak power (1000 W or 50 times the laser’s average power), with very short pulse durations of 4–10 ns. 1.2.
Laser – Tissue Interactions
1.2.1. Theory of Selective Photothermolysis The introduction of the theory of selective photothermolysis in 1982 by Anderson and Parrish (4) has enabled physician-scientists to design lasers that are highly specific for target structures in tissue and therefore less apt to cause scarring or pigmentary alteration.
The Q-Switched Nd:YAG Laser
267
Based upon this theory, laser parameters may be adjusted to maximize absorption by and destruction of a specific target structure and to minimize energy transfer to the surrounding tissue. First, the light pulse should be of a wavelength that is highly absorbed by the target structure and preferably less well absorbed by surrounding nontargeted chromophores. Second, the pulse should be of sufficiently high energy density that it heats the target tissue to a temperature that exceeds the vaporization (or destruction) threshold of the target (Beer’s law), such that the target is successfully destroyed while thermal energy is carried away as steam and plume. In laser–skin interactions, this destruction of the target is mediated by thermal denaturation, mechanical damage by rapid thermal expansion or phase changes, and changes in primary chemical structure (5,6). Third, it should do so in a sufficiently short pulse duration such that heat is dissipated by destruction of the target, as described above, before diffusion of heat to surrounding tissues has time to occur. In other words, the pulse duration must be shorter than the target structure’s thermal relaxation time (TRT), the time necessary for half of its thermal energy to be lost by diffusion to surrounding tissues, in order for maximal thermal confinement to occur. Thus, the wavelength, peak energy, and pulse duration specifically target a given structure (selective photo-); the light energy is subsequently converted into thermal energy in the target structure (-thermo-), and destroys the target by the aforementioned mechanisms (-lysis) before it can dissipate heat to surrounding tissues. The pulsed and Q-switched laser systems adhere most closely to this theory by delivering high-energy bursts of light, of an appropriate wavelength, in very short pulse durations resulting in very specific thermal, mechanical and/or chemical destruction with the lowest risk of adjacent tissue damage. 1.2.2. Target Chromophore Specificity As mentioned earlier, the specificity of a laser for a target structure in tissue is dependent upon several variables, including wavelength, depth of penetration, peak energy, and pulse duration. Wavelength. First, a wavelength selectively absorbed by the specific target is chosen. The relative concentration of the targeted chromophore in skin structures, interference by absorption by other surrounding chromophores, and depth of penetration of the chosen wavelength are all important. Both endogenous (melanin, hemoglobin) and exogenous (tattoo ink, traumatically implanted material) chromophores in skin absorb the 532 and 1064 nm wavelengths emitted by the Nd:YAG laser. The 1064 nm wavelength is well absorbed by melanin, black tattoo ink particles and, to a lesser extent, hemoglobin (Fig. 11.1) (7). The 532 nm wavelength is absorbed well by hemoglobin, melanin, and red tattoo ink. Depth of penetration. Second, the laser beam’s depth of penetration determines the accessibility to a given target and is dependent upon the wavelength, the radiant exposure (fluence), and the spot size. In general, a gradual increase in the depth of penetration into skin occurs at longer wavelengths over the 650– 1200 nm part of the spectrum due to decreased scattering (4), although the far-UV and mid-far-IR regions penetrate least well due to protein absorption and water absorption, respectively. Experiments performed in vitro and in vivo suggest a mean depth of penetration of approximately 3.2 mm or a 50% penetration depth of 1.6 mm for the 1064 nm Q-switched Nd:YAG laser in normal fair Caucasian skin (5,8,9). Spot size also affects depth of penetration, as a result of optical scattering that occurs as the beam penetrates the dermis (10). Spot sizes for the currently available QS Nd:YAG lasers range from 0.8 to 8.0 mm and should be used at a spot size of at least 3 mm for optimal penetration.
268
Kilmer et al.
Figure 11.1
Hemoglobin and melanin absorption curve.
Pulse duration. Finally, the pulse duration should be maximized to enhance energy delivery yet not exceed the TRT of a given structure. The TRT is dependent upon the diameter, volume and surface area of the target. For most targets, an estimation of the TRT in seconds is proportional to the diameter of the structure in millimeter squared (5). The estimated TRTs for a melanosome measuring 0.5 mm (5 1024 cm) in diameter is 25 1028 s (250 ns) and for a 0.1 mm diameter capillary is 1022 s or 10 ms. Black tattoo particles estimated as 0.1 to 5 microns in diameter (see section on pathology), possess TRTs of roughly 10 – 5000 ns. The Q-switched Nd:YAG laser operates in the nanosecond domain, therefore providing high specificity for melanosomes and black tattoo inks that possess very short TRTs. 1.2.3.
Mechanisms of Target Destruction
As noted earlier, target chromophore and tissue destruction may occur through several mechanisms. The primary mechanism is photothermal, where heating and subsequent vaporization or thermal denaturation of the target occurs. Another is photochemical, such that light energy causes chemical alterations in the molecular structure of the target. Finally, a photoacoustic effect is possible when ultrashort pulse durations generate
The Q-Switched Nd:YAG Laser
269
local pressure or shock waves. This may produce much of the damage associated with these QS lasers (11), as well as explain the remarkable purpura from shattered vessels seen when using the 532 nm wavelength. 1.3.
Histology
1.3.1. Depth of Penetration Anderson and coworkers (8) reported the first microscopic analysis of the effects of QS Nd:YAG laser irradiation. Exposures of animal skin to the 1064 nm wavelength at 1.0 J/cm2 altered melanosomes to a depth of 0.2 mm and at 3.0 J/cm2 to a depth of .1 mm (8). Investigators have since observed the QS Nd:YAG (1064 nm) laser penetrating up to 3– 6 mm in human subjects (12). The mean depth of penetration for the QS Nd:YAG (1064 nm) laser is 3.2 mm with a 50% penetration depth of 1.6 mm in normal fair Caucasian skin (5,8). The shorter 532 nm wavelength suffers more loss due to scattering and is better absorbed by melanin or hemoglobin, both limiting its depth of penetration. 1.3.2. Tattoo Removal Light and electron microscopic analysis was performed after QS Nd:YAG (1064 nm, 10 ns pulse duration, 6 –12 J/cm2 fluences, 2.5 mm spot size) laser irradiation of 25 tattoos (13). Following four treatments at 3 – 4-week intervals, skin biopsies demonstrated fragmentation of black ink particles that were present within cells in the dermis. Laserirradiated tattoo particles were smaller in size than preirradiation particles, and those located .1.5 mm depth in the dermis were larger and darker than those in the upper dermis (Fig. 11.2). The 532 nm green light effectively targeted red ink whereas green tattoo inks were unaltered. No fibrosis of the surrounding dermis was observed (13). Tattooed hairless guinea pigs irradiated with the QS ruby (694 nm, 20 –40 ns, 4.5 J/cm2, 6.5 mm), QS Nd:YAG (1064 and 532 nm, 7 and 4 J/cm2, respectively, 10 – 12 ns, 2 mm), and QS alexandrite (755 nm, 100 ns, 4 J/cm2, 3 mm) lasers were analyzed (14). At 6 weeks, the Nd:YAG laser at 1064 nm more effectively lightened the reddish-brown, dark brown, orange, and black tattoo inks, whereas red inks responded best to 532 nm. The alexandrite laser was more effective in lightening blue and green inks and the ruby laser was most effective for purple and violet inks. Scarring was not evident clinically, but epidermal and dermal damage were noted histologically to be most pronounced in the QS Nd:YAG laser-treated specimens, although this was prior to use of a larger spot size which diminishes side effects (10). Electron microscopic evaluation prior to irradiation showed polygonal pigment particles within intracellular organelles of fibroblasts, macrophages, and occasionally mast cells, in the superficial dermis. Immediately postirradiation, ablation and vacuolization of the pigment-laden cells was observed and 6 weeks later, the particles appeared more granular (14). Similar findings were noted in 35 tattoos biopsied before and following QS Nd:YAG (1064 þ 532 nm) laser treatment (15). Immediately postirradiation, ruptured blood vessels and corresponding areas of epidermal perforation were observed. Black pigment-containing cells formed vacuoles and ruptured after 1064 nm irradiation, red particles were altered and less numerous after 532 nm irradiation, and green, yellow, orange, and blue tattoo particles were unaltered by either wavelength. After three treatments, light amateur tattoos were histologically clear of residual pigment; professional or dense tattoos were clear in the papillary dermis, though the mid-dermis contained residual altered pigment, and the deep dermis contained unaltered pigment. After 6 months,
270
Kilmer et al.
Figure 11.2 Professional tattoo treated with the QS Nd:YAG laser (1064 nm). Histologic exam shows lighter laser irradiated tattoo particles more superficially and denser, poorly eradiated particles in lower dermis.
tattoos that were unresponsive to numerous treatments showed unaltered tattoo particles in the deep dermis at depths .1.5 mm. 1.3.3.
Removal of Melanocytic Lesions
In 1989, Anderson et al. compared the effects of the QS Nd:YAG laser pulses at 1064, 532, and 355 nm in guinea pigs. Although expected with the 532 nm wavelength, exposure to 1064 nm also showed melanosomal rupture in keratinocytes and melanocytes (8). The histologic effects of QS alexandrite (100 ns) and QS Nd:YAG (10 ns) lasers were compared at the same fluence (6.0 J/cm2) and spot size (3 mm) for treatment of benign acquired melanocytic nevi (16). Following three treatments at 6-week intervals, an equivalent reduction in epidermal melanin and melanocytes, and numbers of junctional and dermal melanocytic nests was noted for both lasers. Increased dermal melanophages and mild dermal fibrosis were also seen (16). Thus, the QS Nd:YAG (1064 nm) laser can rupture epidermal and dermal melanosomes. 1.3.4. Hair Removal Kilmer documented follicular pigment disruption with ring cell formation using a highpowered 1064 nm QS Nd:YAG (17) (Fig. 11.3) without use of an adjuvant topical carbon solution. Minimal thermal damage to the surrounding follicular apparatus or adjacent tissue was noted with these Q-switched pulses. In a separate study, 15 patients treated with the QS Nd:YAG resulted in a rapid switch from anagen to telogen and greater hair loss in sites with high anagen:telogen ratios (18). Thus, the mechanisms of laser-induced hair removal are beginning to be elucidated, but likely involve both destructive mechanisms
The Q-Switched Nd:YAG Laser
271
Figure 11.3 Hair follicle treated with the QS Nd:YAG laser (1064 nm). Note ring cell formation (arrow) with melanin particles at periphery of ring cells.
and disruption of the hair follicle cycle. More importantly, the shorter pulse width does not supply sufficient thermal damage to permanently destroy hair follicles.
2.
TREATMENT INDICATIONS
2.1. 2.1.1.
Tattoo Removal Background
Tattoos are caused by the intradermal placement and subsequent phagocytosis of ink particles by histiocytes, fibroblasts, and mast cells. The ink particles measure nanometers in size and are contained in phagolysosomes (5). Those used in amateur tattoos are carbonbased, such as India ink, graphite, or ash. Professional tattoos typically consist of insoluble metal salts, oxides, or organic complexes. Past methods of tattoo removal have included surgical excision, dermabrasion, salabrasion, and CO2 laser vaporization. Goldman and colleagues (19) were the first to note the effectiveness of normal-mode pulsed ruby laser treatment in tattoo removal. The QS ruby laser has since been reported to successfully treat tattoos in the 1960s and 1980s (19 –21). Since then, multiple studies have demonstrated the effectiveness of the Q-switched ruby laser in treating black, blue-black, and green tattoos. The QS Nd:YAG (1064 nm) laser offered the theoretical benefit of increased depth of penetration and decreased epidermal melanin absorption, and thus was the next laser evaluated for tattoo removal. When used with the frequency-doubling crystal in place, the 532 nm wavelength (green light) can target red inks but is also well absorbed by melanin. 2.1.2. Mechanisms of Laser-Induced Tattoo Lightening The mechanisms by laser-induced tattoo lightening are beginning to be elucidated. Electron microscopic studies of QS ruby laser irradiation have shown that ink particles are
272
Kilmer et al.
fractured into 10 –100 smaller fragments and that the phagocytic cells that contain them are ruptured (22). As discussed earlier, light and electron microscopic analyses after QS Nd:YAG (1064 nm) laser irradiation have demonstrated black ink fragmentation, vacuolization and rupture of pigment-containing cells, followed by rephagocytosis of fragmented particles by macrophage and fibroblasts, and probable lymphatic clearance (see section on Histology). In addition, laser-induced photochemical alterations of tattoo inks may play a role in both their treatment and in the untoward effect of tattoo irreversible immediate darkening (see following text) (23). 2.1.3. Comparative Studies The earliest use of the QS Nd:YAG (1064 nm) laser was to treat tattoos (12). A side-byside comparison of the QS ruby (694 nm, 40 ns) and QS Nd:YAG (1064 nm, 30 ns) lasers at equal fluences (2 –6 J/cm2) and equal exposure spot diameters (5 mm) found them to be equally effective in black ink removal. The QS Nd:YAG laser was less effective at green ink removal; however, it was less apt to produce postinflammatory hypopigmentation, blistering, or textural changes. Use of the 532 nm wavelength treats red ink effectively. Since then, several studies have directly compared the efficacy of the QS ruby and the QS Nd:YAG laser in the treatment of tattoos. One study (24) compared the QS ruby and QS Nd:YAG lasers and found the former to be more effective at black and green ink removal, whereas red ink was minimally lightened by 1064 and 694 nm, a color very responsive to 532 nm. On the other hand, the QS ruby laser caused hypopigmentation more commonly than the QS Nd:YAG (1064 nm) laser, which produced greater textural change in this study. These findings are consistent with other comparison studies (12,25). Of note, new QS Nd:YAG lasers have larger spot sizes and better beam profiles with better efficacy noted. 2.1.4. Q-Switched Ruby Laser-Resistant Tattoos Tattoos refractory to the QS ruby laser were treated with the QS Nd:YAG laser (1064 nm, 5 – 10 ns, up to 12 J/cm2, 2.5 mm) (26) and .50% lightening was observed after the first treatment, most notably with higher fluences. In a subsequent study (13) ruby laserresistant and untreated tattoos were treated with fluences of 6, 8, 10, and 12 J/cm2 over four sessions at 3– 4-week intervals. Lightening of tattoos to .75% and 95% was observed in 77% and 28% of black tattoos, respectively. The highest fluence of 12 J/cm2 was more effective at removing black ink as compared to 6– 8 J/cm2 and amateur tattoos cleared more easily than professional tattoos. Green, yellow, white, purple, red, and orange inks responded minimally with 1064 nm, whereas 694 nm cleared green ink more readily (27). Mild hyperpigmentation and slight textural changes cleared with time except in two cases of the latter. Thus, the QS Nd:YAG (1064 nm) laser appears to be highly effective in lightening QS ruby laser-resistant blue-black tattoos, likely due to its greater depth of penetration and shorter pulse width. 2.1.5. Treatment of Tattoos in Darkly Pigmented Patients The greatest advantage of the QS Nd:YAG (1064 nm) laser is its use in treating tattoos in darkly pigmented patients. In contrast, the 532 nm wavelength should be avoided in these patients. Grevelink et al. (28) compared the 1064 nm QS Nd:YAG and ruby lasers in treating five tattoos in skin types V and VI with effective tattoo removal of 50 –60% for the 60 – 95% respectively, supporting earlier findings. Importantly, however, the QS Nd:YAG caused transient hypopigmentation in one patient; whereas, the QS ruby laser led to hypopigmentation that ranged from transient to permanent, in all patients treated
The Q-Switched Nd:YAG Laser
273
(28). Skin type VI patients with amateur black tattoos were treated using the QS Nd:YAG (1064 nm, 6 ns, 3.2 – 8.3 J/cm2, and 3 mm spot size) and noted even better efficacy with no residual pigmentary or textural changes (29). Thus, because of its superior safety profile, the QS Nd:YAG at 1064 nm is preferable to the QS ruby laser for darkly pigmented patients. 2.1.6. Medicinal and Traumatic Tattoos Medicinal tattoos are often placed to identify the tumor or to mark radiation ports. Since these tattoos are usually small and consist of blue or black India ink, they can be easily removed with any of the QS lasers. Traumatic tattoos may occur secondary to trauma from motor vehicle accidents or other encounters with asphalt, explosives, or pencil puncture wounds. They are often carbon based in nature and located in the superficial dermis, which facilitates their removal. Several studies have shown that traumatic tattoos may be effectively treated with the QS Nd:YAG (1064 nm) laser, including one in which 50/51 traumatic tattoos completely cleared without textural or pigmentary changes (30). Other studies with QS Nd:YAG (1064 nm) laser treated traumatic tattoos reported similar results (31,32). Although comparative studies are lacking, the QS Nd:YAG (1064 nm) laser appears to be highly effective for traumatic tattoo removal, resulting in complete clearance in the majority of cases. In fact, in most cases, the associated scars improve as the traumatically implanted material is removed, decreasing the inflammatory and granulomatous changes triggered by the foreign material (Fig. 11.4). 2.1.7. Cosmetic Tattoos Cosmetic tattooing has become increasingly popular especially for eyebrow, lip, and eyeliner tattoos as well as, covering periorbital pigmentation, providing rosy cheeks,
Figure 11.4 Before and after QS Nd:YAG laser (1064 nm) treatment of remaining black panther tattoo. Note darkening of completely faded red claws on panther tattoo that occurred during treatment of the residual black ink.
274
Kilmer et al.
and disguising scars. The most frequently used inks include white, reddish-brown, red, flesh-tone, or dull orange. The tattoo industry is not regulated by a government agency, such as the Federal Drug Administration, so it is impossible to predict which pigments are present in each tattoo. Also, different tattoo artists may mix or even overlay the inks making it more difficult to identify which pigments were used. Development of immediate pigment darkening after pulsed laser treatment of tattoos is possible. This unfortunate occurrence is most often seen in the red, white, and fleshtoned ink colors frequently used in cosmetic tattoos. Blackened tattoo pigment cannot always be removed with successive laser treatments, therefore, a test site is recommended for any ink suspicious for potential darkening (see following text) (23,33).
2.1.8.
Disadvantages in Tattoo Removal
Tattoo ink restriction. The main disadvantage of the QS Nd:YAG laser (1064 nm) for tattoos is its restricted target color range to black and blue-black inks (34). The frequency-doubling feature of the laser to 532 nm may be employed to effectively treat red ink, and, to a lesser degree, orange and purple inks. Yellow, green and blue inks respond poorly to both frequencies (35). The risk of increased bleeding and tissue splatter during treatment has been noted but can be decreased by utilizing larger spot sizes with lower fluences (which gives equivalent efficacy). Tattoo ink darkening. As noted previously, darkening of flesh-colored tattoo pigments has been reported following treatment with several QS lasers, including the QS Nd:YAG (1064 nm) laser. Anderson et al. (23) first reported five cases of tattoo ink darkening, all with QS lasers. During QS Nd:YAG (1064 nm) treatment of a residual professional black ink tattoo immediate darkening occurred in adjacent normal skin in the site of an old completely faded red tattoo (Fig. 11.5). Two subsequent treatments of the darkened area with the same 1064 nm laser resulted in substantial, but incomplete clearing (23). The proposed mechanism for laser-induced tattoo ink darkening involves the reduction of ferric oxide, which has a reddish-brown color, to ferrous oxide, which is black (14). A retrospective study assessed 323 QS Nd:YAG laser-treated tattoos of which 180 were red, brown, yellow, orange, or white/flesh (36). Immediate darkening occurred in 33/180 tattoos during or after laser irradiation. White/flesh, crimson, brown, red, and yellow, in decreasing order of frequency, darkened either transiently or permanently. Red and brown tattoos darkened more frequently after 532 nm irradiation, as compared to 1064 nm; yellow tattoos darkened with equal frequency at the two wavelengths; and white/flesh-colored tattoos darkened after 1064 nm irradiation. An average of three additional laser treatments improved 20/33 of the darkened tattoos. Thus, roughly 20% of flesh-colored tattoos in this retrospective study darkened after QS Nd:YAG laser irradiation, with additional treatments improving most darkened tattoos; test sites help to predict how an individual tattoo will respond. Pigmentary alteration. The increased melanin absorption by shorter wavelengths leads to greater risk for epidermal disruption, especially with darker skin types or tanned individuals. Because of this, blistering and hypopigmentation is more common with the QS ruby, alexandrite, and frequency-doubled Nd:YAG (532 nm) lasers. Comparative studies, confirm that the QS Nd:YAG (1064 nm) laser results in a lower incidence of pigmentary changes and scarring, as compared to the QS ruby laser (37). Hypopigmentation is usually transient, especially with the 532 nm wavelength as its shallower depth of penetration minimizes lethal injury to the follicular melanocytic reservoir.
The Q-Switched Nd:YAG Laser
275
Figure 11.5 Before and after a single treatment of traumatic tattoo treated with QS Nd:YAG at 1064 nm. Note improvement of scarring as well.
Hyperpigmentation tends to be more skin type dependent, with melanocytes in darker skin types more likely to react to injury with increased production of melanin. This can be minimized with use of a broad-spectrum sunscreen, preferably zinc oxide, and usually clears with a topical preparation containing hydroquinone or time alone. Microexplosions of gunpowder traumatic tattoos. This interesting adverse effect first noted by Taylor (personal communication), was recently reported following QS Nd:YAG (1064 nm) laser irradiation of gunpowder traumatic tattoos (38). Three patients with traumatic tattoos caused by gunshot wounds at close range were treated with the QS Nd:YAG at fluences ranging from 4 to 6 J/cm2, a 10 ns pulse duration, and 3 mm spot size. Sparks, bleeding, and transepidermal pitting occurred immediately following each pulse, which resulted in scarring in each case. 2.2.
Removal of Pigmented Lesions
Pigmented lesions can be epidermal [lentigos, seborrheic keratoses, cafe´-au-lait macules (CALM), nevus spilus], dermal [nevus of Ota, postinflammatory hyperpigmentation (PIH), melasma] or both (melasma, Becker’s nevus, junctional, compound, and congenital melanocytic nevi).
276
Kilmer et al.
2.2.1. Pigmented Lesions in General The 532 nm wavelength for benign epidermal pigmented lesions was examined with a dose– response study (39). Increasing the fluence from 2 to 5 J/cm2 (in 1 J/cm2 increments) produced better clearing but also more purpura and post treatment erythema. Lentigos are purely epidermal lesions and clear easily with a single treatment (40) (Fig. 11.6) whereas CALM usually take a few treatments and may recur (39,41). Hyperpigmented scars may respond to QS 532 nm (42) with softening and decreased pigmentation. The efficacy and side effect profile of QS ruby and QS Nd:YAG (1064, 532 nm) lasers were compared in the treatment of cutaneous pigmented lesions, including lentigines, CALM, nevus of Ota, nevus spilus, Becker’s nevus, PIH, and melasma (43). Twenty patients with pigmented lesions were treated with the QS ruby and QS Nd:YAG laser at 532 nm (solar lentigos, melasma, PIH, Becker’s nevus, nevus spilus, and CALM) or 1064 nm (nevus of Ota). With the exception of melasma for which poor results (,25% clearing) were noted in all cases, the QS ruby laser produced good-to-excellent results (50–95% clearing), as opposed to fair-to-good (25–75% clearing) results for the QS Nd:YAG for all remaining conditions. Neither laser caused scarring or textural changes. Nevus of Ota. In a prospective trial, acquired bilateral nevus of Ota-like maculae were treated with the QS Nd:YAG laser (1064 nm, 8 – 10 J/cm2, 2– 4 mm spot sizes) (44) and found to have 100% clearance in 68/70 women after two to five treatments. Transient hyperpigmentation occurred in 50%, without scarring or textural changes, and no recurrence was noted at 3 –4 years follow-up. In a similar study (45), 50% (33/66) of patients who received more than two treatments showed good-to-excellent results. Additional studies evaluated the treatment and side effect profile of the QS Nd:YAG (1064 nm) laser for nevus of Ota, with excellent clearing observed (45 –47). In a retrospective analysis (46), 129 patients were interviewed that had been treated with the QS alexandrite, the QS 1064 nm Nd:YAG, or both lasers. Complete clearing versus .50% lightening occurred in 0%/25.9% of the QS alexandrite-treated, 1.9%/38.1% of the QS Nd:YAG-treated cases, and 8.3%/72.9% of cases treated with both, respectively. Hypoand hyperpigmentation, textural changes and scarring were more common in those treated with the QS alexandrite or both lasers. Of note, 13 (5.2%) patients with .90% clearance developed a recurrence 3 –4 years posttreatment. Thus, the aforementioned studies suggest that the QS ruby laser may be most efficacious for nevus of Ota but a larger comparative study needs to be done. The QS Nd:YAG (1064 nm) laser is more effective than the QS alexandrite laser however and offers the advantage of the lowest incidence of untoward effects, such as pigmentary or textural changes or scarring; as it causes less epidermal disruption and, for darker skinned patients, is the preferred wavelength.
Figure 11.6 Solar lentigos on the hands of a middle-aged man before and after a single treatment of frequency-doubled QS Nd:YAG laser (532 nm).
The Q-Switched Nd:YAG Laser
277
2.2.2. Acquired Melanocytic Nevi A side-by-side comparison of QS alexandrite (755 nm, 100 ns, 3 mm, and 6.0 J/cm2) and the Nd:YAG (1064 nm, 10 ns, 3 mm, 6.0 J/cm2) lasers for treatment of benign acquired melanocytic nevi (16) was done in 18 patients with a fluence of 6.0 J/cm2 and a 3 mm spot size. Three treatments at 6-week intervals, were done to opposite halves of a large (.1.5 cm) or to two small (.7 mm) adjacent nevi. After one treatment, 10% lightening was noted for both lasers whereas after three treatments, more lightening was observed after alexandrite (60%) than after Nd:YAG (30%) laser treatment possibly explained by the more superficial location of the target melanosomes (i.e., at the dermal – epidermal junction) in common acquired melanocytic nevi, as compared to nevi of Ota, which respond better to the longer and deeper penetrating wavelength of the QS Nd:YAG (1064 nm) laser.
2.2.3.
Congenital Nevi
Treatment of congenital nevi is much more controversial as the potential risk for malignant transformation is unknown. Reduction of the melanocytic load may decrease the risk or, conversely, irritation of the melanocytes by laser irradiation may increase the risk. Although most feel that the risk for triggering melanoma formation is low, it is currently not recommended to treat patients with a family or personal history of melanoma, as these patients are already at higher risk.
2.3.
Hair Removal
QS 1064 nm pulses effectively treated the deep dermal melanocytes in nevus of Ota suggesting follicular melanin was a viable target. A prospective trial assessing the effectiveness of QS Nd:YAG laser-induced hair removal was performed by Nanni and Alster (48). Attempts were made with the use of wax epilation, carbon suspension, and laser alone. None of the protocols utilizing the QS Nd:YAG laser was effective in permanently removing hair. Goldberg and coworkers (49) also evaluated topical suspensionassisted QS Nd:YAG (1064 nm) laser-induced hair removal in 35 subjects. At 12 weeks posttreatment, hair reduction of 65% was seen with mild hyperpigmentation in one patient. A comparison study by Kilmer et al. showed that a higher-powered QS Nd:YAG without topical carbon gave 30% permanent hair reduction 6 months after three treatments but this was much less than the LP alexandrite and ruby lasers (70%).
2.4.
Rhytids
A pilot study by Goldberg and Whitworth (50) compared the QS Nd:YAG (1064 nm) and two char-free CO2 lasers (10,600 nm) in 11 patients with facial rhytids. Rhytids were improved with QS Nd:YAG laser treatment in 9/11 patients: in three of these, improvement was equivalent between the QS Nd:YAG and the CO2 lasers, and in six patients, the CO2 lasers were more effective than the QS Nd:YAG laser. Re-epithelialization occurred after 3 – 5 days on the QS Nd:YAG sides and after 6 – 11 days on the CO2 laser sides of the face. No pigmentary alterations were observed. At 1-month postprocedure, erythema was observed in 11/11 CO2-treated sides and in the 3/11 Nd:YAG-treated sides that were most improved. More recently this technique as well as with the QS Nd:YAG alone have been shown to improve fine lines (51,52).
278
3.
Kilmer et al.
LASER TECHNIQUE AND PARAMETERS
3.1. 3.1.1.
Tattoo Removal General Parameters and Protective Equipment
The QS Nd:YAG emits both a 1064 nm and a 532 nm wavelength with a pulse duration of 10 ns, which is delivered by a mirrored, articulated arm. Current models have spot sizes of 0.8 – 8.0 mm and operate from 10 to 100 Hz. The 1064 nm wavelength is most effective for treating blue-black tattoos but ineffective for green or red inks. To maximize penetration, a spot size of 3 mm or greater should be employed. When using the 1064 nm wavelength and a spot size of 3– 4 mm, a starting fluence of 3.5– 4.0 J/cm2 should be employed. The desired clinical endpoint is whitening, which is thought to be secondary to water vapor generated beneath the epidermis. Whitening generally clears within 20 –30 min following treatment. Only occasional pinpoint bleeding should be observed; higher fluences that produce frank bleeding should be avoided since there may be higher risk of scarring and pigment alteration. If bleeding or skin breakage is observed, decrease the fluence by 0.5 – 1.0 J/cm2. If whitening is not achieved, the fluence should be increased by this amount. The test site should be evaluated after 4 –6 weeks, the time interval recommended between treatments. Pulses should be delivered with a 10% overlap. Due to the very short pulse duration, the QS Nd:YAG laser generates a significant amount of “tissue splatter,” the vaporization or aerosolization of cellular debris which is composed of viable cells (34). This poses a theoretic risk of infectious disease transmission, necessitating the use of a cone device or splatter shield supplied by the manufacturer to protect the operator. In addition, protective eyewear is mandatory in order to guard against ocular damage and airborne plume. Gloves and laser masks should be worn to protect from possible blood contamination aerosolized cellular debris (34). 3.1.2.
Professional and Amateur Tattoo Removal
Generally, professional tattoos require 8– 12 treatments while amateur tattoos usually clear in 4– 6 sessions. It is difficult to predict the number of treatment sessions needed. Response rates vary for poorly understood reasons, likely relating to types of tattoo inks, location in the dermis, and rates of cellular and lymphatic clearance (53). Optimal treatment intervals are currently recommended at 6 –8-week intervals. Treatment parameters should be titrated as discussed above after an initial test at 1064 nm, spot size of 3– 4 mm, and starting fluence of 3.5 – 4.0 J/cm2. 3.1.3.
Cosmetic Tattoo Removal
The patient must be warned of the potential darkening of the treatment site, which may be irreversible. A test site should always be performed with a single pulse using the appropriate wavelength, then wait long enough for any laser-induced whitening to dissipate to assess whether darkening has occurred. If the ink does not darken you can proceed with treatment. If it darkens, photograph and immediately treat again with the 1064 nm. Re-evaluate in 1 month and compare with the photograph to see if lightening has occurred. If there is doubt, take another photograph and retreat the test spot and wait an additional month. Once it appears that the darkened ink will respond to further treatment, the whole tattoo can be lased, assuming the entire tattoo was placed at one time and with the same ink as the test site. A case of QS Nd:YAG (1064 nm) laser removal of eyeliner tattoo was reported (54) using a 1.5 mm spot size at 6 J/cm2 delivered in two treatment sessions 6 weeks apart with
The Q-Switched Nd:YAG Laser
279
almost complete clearing of the tattoo. A metal ocular shield was placed over the globe and hair was protected with petrolatum during the procedure. An eye patch was applied for 3 h posttreatment and healing was complete in 5 days. 3.1.4. Medicinal and Traumatic Tattoo Removal Medicinal and traumatic tattoos are usually blue or black, the type of pigment is often carbon-based, and their location in the dermis is superficial, thereby making them good candidates for QS Nd:YAG (1064 nm) laser treatment (Fig. 11.4). Given the recent report of microexplosions and scarring secondary to irradiation of gunpowder traumatic tattoos (see earlier), proceed carefully and utilize test spots when treating such tattoos with the QS Nd:YAG laser. Otherwise these tattoos can be treated similarly to decorative tattoos with the likelihood that they will clear with fewer treatments given the pigment type and superficial location. Of note, some gang and prison tattoos, may be placed more deeply in the dermis, limiting the laser’s accessibility of the target. 3.1.5. Tattoo Treatment of Darker Skin Types The QS Nd:YAG (1064 nm) laser has been particularly effective with minimal risk of pigmentary change in tattoo removal among darker skin types (see section titled “Treatment of Tattoos in Darkly Pigmented Patients”). Begin with a test using fluences of 3.5 – 4.0 J/cm2, and titrating to the desired clinical endpoints, as described. Use of the 532 nm wavelength will be poorly tolerated due to its strong melanin absorption. 3.2. 3.2.1.
Removal of Melanocytic Lesions Epidermal Lesions
Epidermal lesion should be treated with the 532 nm wavelength laser. Brisk bright whitening should occur. Choose the appropriate spot size for the target lesion size and use the lowest fluence that still gives the desired whitening. Higher fluences produce more purpura, post op erythema with little or no added efficacy noted (39). Epidermolysis and pinpoint bleeding are not desired. 3.2.2.
Dermal Melanocytic Nevi
For dermal nevi, such as nevus of Ota, use 1064 nm for a blue-black to dark brown lesions but if it is light to medium brown, the pigment is usually more superficial and responds better to 532 nm. Sometimes a test site with both wavelengths is warranted. Metal eyeshields are needed to protect the eye when dealing with nevi that approach the lash line, otherwise wet gauze can be used to cover the area. Commence with the largest spot size and close to maximum fluence, increasing as tolerated. Of note, with a deeper nevus of Ota, brisk whitening is often not seen and pinpoint bleeding may occur several minutes after treatment. The test site should be evaluated after 6–8 weeks. Longer treatment intervals should be used to allow complete removal of targeted melanocytes and melanophages before treating the same area again. The risk of recurrence needs to be addressed at the time of consent. 3.2.3.
Common Acquired Nevi
The QS Nd:YAG (532 þ 1064 nm) is effective in lightening the junctional component of nevus spilus and some common acquired nevi (16). Lightening of nevi may theoretically preclude monitoring such nevi for the changes typically evaluated when examining a
280
Kilmer et al.
patient for melanoma, therefore, laser removal of common acquired nevi is discouraged in patients with dysplastic nevi or a personal or family history of melanoma. 3.3.
Hair Removal
Although the reports described herein suggest that the QS Nd:YAG (1064 nm) laser promotes a growth delay of up to 3 months—in most cases, hair completely regrows. Theoretically, the ideal lasers should target the stem cells of the hair follicle, which have recently been shown to reside in the bulge that is located at a depth of 1.5 mm (55). Such lasers would operate at a wavelength that penetrates to this depth optimally, namely 700 – 1000 nm. The pulse duration needs to be long enough to more effectively deposit heat in the follicle and permanently destroy it. Nd:YAG lasers in the millisecond range are now utilized. The QS Nd:YAG lasers do offer the ability to treat pseudofolliculitis barbae (56) by inducing a prolonged growth delay (temporary hair reduction), which may be preferable for those who do not wish to permanently eliminate beard hairs. 3.4.
Rhytids
Treatment of rhytids has been simplified to utilizing the 4 mm spot size and passing the beam over the area to be treated. In some cases, a topical carbon suspension is used to increase the effect although the added benefit is not clear. Pinpoint bleeding may occur necessitating use of ointment or a bandage immediately postop, although in most cases there is minimal epidermal disruption.
4. 4.1.
PRE- AND POSTPROCEDURE MANAGEMENT Preprocedure Considerations
A careful patient history should make note of any history of keloidal scarring, herpes simplex viral infections, or treatment with isotretinoin within the past year. A history regarding skin phototype should be taken in order to assess risk of pigmentary alteration. Written information regarding the nature of the procedure should be given to the patient preoperatively. Representative before and after photographs are helpful to prepare and inform the patient of what to expect. Patients should be advised that a test site may be necessary with a 6 – 8-week of treatment interval period, that multiple treatment sessions will be required, in the range four or more depending upon the indication, that total removal of the lesion may not be achieved, and that there is a possibility of recurrence in the case of nevi. Patients should be advised against treatment if they would be dissatisfied with a partially removed lesion. Aspirin and nonsteroidal pain relievers should be discontinued 1 week prior to laser treatment, if the risk of bleeding after treatment is a concern. A subset of patients may require either a topical anesthetic, such as EMLA cream (Astra, Westborough, MA), Ela-Max (Ferndale, Ferndale, MI) or injection of a local anesthetic, such as 1% lidocaine prior to treatment. 4.2.
Postprocedure Considerations
4.2.1. Wound Care Immediately following the procedure, a broad-spectrum antibiotic ointment, such as polysporin or mucipirocin, may be applied to the wound and covered with a nonstick dressing
The Q-Switched Nd:YAG Laser
281
for 24 h. Postoperative wound care consists of cleansing the wound, followed by the application of antibiotic ointment, twice daily until the wound has reepithelialized. Strict sun avoidance and regular application of a broad-spectrum sunblock is emphasized to minimize hyperpigmentation. 4.2.2.
Complications
Tattoo ink darkening. The tattoo ink darkening immediately after laser irradiation may occur in flesh-colored tattoos, such as white/flesh, crimson, brown, red, orange, flesh, and yellow (see earlier). All of the QS lasers may cause this untoward effect, which may be improved with further treatments or may be irreversible. The patient should be warned prior to applying a single test pulse, followed by observation. Tattoo ink darkening may subsequently be managed by further treatments with the QS Nd:YAG (1064 nm), as discussed earlier (23,36). Allergic reaction. The development of localized and generalized allergic reaction is another complication following tattoo removal with the QS Nd:YAG (1064 nm) and QS ruby lasers. Two women treated with these lasers developed pruritic eruptions days-toweeks following repeat laser treatments. A skin biopsy of one case demonstrated a superficial perivascular mononuclear infiltrate and a spongiotic dermatitis, consistent with an id reaction. The allergic reactions resolved with administration of antihistamines and topical or systemic corticosteroids (57). Various components of tattoo inks have been shown to cause sensitization. Laserinduced rupture of pigment-containing cells and extracellular release of pigment particles likely triggers the allergic response. QS lasers mobilize ink, in contrast to the older methods where ink was removed transepidermally. Cessation of QS laser therapy is recommended when urticarial reactions occur in order to avoid a systemic allergic reaction and/or anaphylaxis. Also of concern, compartment syndrome has been reported following QS Nd:YAG laser treatment of a forearm tattoo. The significant swelling that can occur, especially with circumfluential tattoos can lead to this potentially disastrous complication (58). Pigmentary alterations and scarring. A distinct advantage to the 1064 nm QS Nd:YAG laser is the low incidence of pigmentary alteration, as compared to the QS ruby and alexandrite lasers (24,37,39). The 532 nm wavelength does lead to temporary hypopigmentation but this tends to resolve quickly. Postinflammatory hyperpigmentation appears to be transient in most cases (44). It should be assessed at 4 –6 weeks postprocedure and is best managed by initiating treatment with a broad spectrum sunscreen (preferably zinc oxide), 4% hydroquinone, and possibly a topical steroid for more severe or recalcitrant cases. Textural changes have been noted but found to resolve with time as well. In some cases, permanent scarring has resulted. Photographs are helpful for documenting preexisting scars that can arise from placement of the tattoo itself, however, the ink may camouflage any scar formation. In addition, some tattoos are purposefully placed to cover up preexisting scars.
5.
SUMMARY
In summary, the QS Nd:YAG laser at 1064 nm is highly effective for removal of blue-black tattoos, especially for darkly pigmented patients and those with traumatic tattoos whereas the 532 nm wavelength is best for reddish tattoos. The incidence of
282
Kilmer et al.
postprocedural pigmentary changes, textural changes or scarring is lower for the QS Nd:YAG (1064 nm) as compared to other laser systems. The QS Nd:YAG (1064 nm) is also very effective in removal of dermal melanocytic lesions, and for enduring a prolonged telogen phase to help slow hair growth; this is especially helpful for psuedofolliculits barbae. Further research is needed to compare the QS Nd:YAG (1064 nm) to other lasers in the emerging field of nonablative facial rejuvenation.
REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9.
10.
11. 12. 13. 14.
15.
16.
17. 18. 19.
Geusic JE, Marcos HM, Van Uitert LG. Laser oscillations in Nd-doped yttrium aluminum, yttrium gallium, and gadolinium garnets. Appl Phys Lett 1967; 4:182. Itzkan I, Bourgelais DBC. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery. Philadelphia: Lippincott-Raven, 1997:11– 24. Hellwarth RW. In: Singer JR, ed. Advances in Quantum Electronics. Columbia University Press, 1961:334. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Anderson RR. In: Goldman MP, Fitzpatrick RE, eds. Cutaneous Laser Surgery. 2nd ed. St. Louis: Mosby, 1999:1– 18. Fitzpatrick RE, Golman MP. In: Golman MP, Fitzpatrick RE, eds. Cutaneous Laser Surgery. 2nd ed. St. Louis: Mosby, 1999:1 – 18. Anderson RR. In: Lim HW, Soter NA, eds. Clinical Photomedicine. New York: Marcel Dekker, 1993. Anderson RR. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery. Philadelphia: Lippincott-Raven, 1997:25– 51. Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd:YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 1989; 93(1):28–32. Kilmer SL, Farinelli WA, Tearney G, Anderson RR. Use of a larger spot size for the treatment of tattoos increases clinical efficacy and decreases potential side effect. Lasers Surg Med Suppl 1994; 6:51. Anderson RR, Parrish JA. Lasers in dermatology provide a model for exploring new applications in surgical oncology. Int Adv Surg Oncol 1982; 5:341– 358. Decoste SD, Anderson RR. Comparison of Q-switched ruby and Q-switched Nd:YAG laser treatment of tattoos. Lasers Surg Med 1991; 3(suppl):64. Kilmer SL, Lee MS, Grevelink JM, Flotte TJ, Anderson RR. The Q-switched Nd:YAG laser effectively treats tattoos. Arch Dermatol 1993; 129:971 – 978. Zelickson BD, Mehregan DA, Zarrin AA, Coles C, Hartwig P, Olson S, Leaf-Davis J. Clinical, histologic, and ultrastructural evaluation of tattoos treated with three laser systems. Laser Surg Med 1994; 15:364– 372. Ferguson JE, Andrew SM, Jones CJ, August PJ. The Q-switched neodymium:YAG laser and tattoos: a microscopic analysis of laser – tattoo interactions. Br J Dermatol 1997; 137(3):405– 410. Rosenbach A, Williams CM, Alster TS. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg 1997; 23:239 –245. Kilmer SL, Chotzen VA. Q-switched Nd:YAG laser (1064 nm) hair removal without adjuvant topical preparation. Lasers Surg Med Suppl 1997; 9:31. Kolinko V, Littler CM, Cole A. Influence of the anagen: telogen ratio on Q-switched Nd:YAG laser hair removal efficacy. Lasers Surg Med 2000; 26(1):33 – 40. Goldman L, Hornby P, Meyer R. Radiation from a Q-switched ruby laser with a total output of 10 megawatts on a tattoo of a man. J Invest Dermatol 1965; 44:69.
The Q-Switched Nd:YAG Laser 20.
21. 22. 23. 24. 25.
26. 27. 28.
29. 30. 31. 32. 33. 34. 35. 36. 37.
38. 39.
40.
41. 42.
283
Laub DR, Yules RB, Arras M, Murray DE, Crowley L, Chase RA. Preliminary histopathological observation of Q-switched ruby laser radiation on dermal tattoo pigment in man. J Surg Res 1968; 5:220 – 224. Reid WH, McLeod PJ, Ritchie A, Ferguson-Pell M. Q-switched ruby laser treatment of black tattoos. Br J Plast Surg 1983; 36:455– 459. Taylor CR, Anderson RR, Gange RW, Michaud NA, Flotte TJ. Light and electron microscopic analysis of tattoos treated by Q-switched ruby laser. J Invest Dermatol 1991; 97:131– 136. Anderson RR, Geronemus R, Kilmer SL et al. Cosmetic tattoo ink darkening: a complication of Q-switched and pulsed laser treatment. Arch Dermatol 1993; 129:1010 –1014. Levine VJ, Geronemus RG. Tattoo removal with the Q-switched ruby laser and the Q-switched Nd:YAG laser:a comparative study. Cutis 1995; 55:291 –296. Goyal S, Arndt KA, Stern RS, O’Hare D, Dover J. Laser treatment of tattoos:a prospective, paired, comparison study of the Q-switched Nd:YAG (1064 nm), frequency-doubled Q-switched Nd:YAG (532 nm), and Q-switched ruby lasers. J Am Acad Dermatal 1997; 36(10):122–125. Kilmer SL, Lee M, Farinelli W et al. Q-switched Nd:YAG laser (1064 nm) effectively treats Q-switched ruby laser resistant tattoos. Lasers Surg Med 1992; 4(suppl):72. Kilmer SL, Anderson RR. Clinical use of the Q-switched ruby and the Q-switched Nd:YAG (1064 nm and 532 nm) lasers for treatment of tattoos. J Dermatol Surg Oncol 1993; 19:330–338. Grevelink JM, Duke D, van Leeuwen RL, Gonzalez E, DeCoste SD, Anderson RR. Laser treatment of tattoos in darkly pigmented patients:efficacy and side effects. J Am Acad Dermatol 1996; 34(4):653– 656. Jones A, Roddey P, Orengo I, Rosen T. The Q-switched ND:YAG laser effectively treats tattoos in darkly pigmented skin. Dermatol Surg 1996; 22(12):999– 1001. Suzuki H. Treatment of traumatic tattoos with the Q-switched neodymium:YAG laser. Arch Dermatol 1996; 132:1226 – 1229. Troilius AM. Effective treatment of traumatic tattoos with a Q-switched Nd:YAG laser. Lasers Surg Med 1998; 22:103 – 108. Haywood RM, Monk BE, Mahaffey PJ. Treatment of traumatic tattoos with the Nd:YAG laser: a series of nine cases. Br J Plast Surg 1999; 52:97 – 98. Ross VE, Yashar S, Michaud N et al. Tattoo darkening and nonresponse after laser treatment: a possible role for titanium dioxide. Arch Dermatol 2001; 137:33. Kilmer SL, Casparian JC, Wimberly JM et al. Hazards of Q-switched lasers. Lasers Surg Med 1993; 5(suppl):56. Kilmer SL, Fitzpatrick RE, Goldman MP. In: Golman MP, Fitzpatrick RE, eds. Cutaneous Laser Surgery. 2nd ed. St. Louis: Mosby, 1999:213 –257. Peach AHS, Thomas K, Kenealy J. Colour shift following tattoo removal with Q-switched Nd:YAG laser (1064/532). Br J Plast Surg 1999; 52:482 – 487. Werner S, Drosner M, Raulin C. Tattoo removal Q-switched ruby laser (694 nm) and the Q-switched Nd:YAG laser (532 and 1064 nm). A retrospective study. Hautarzt 1999; 50(3):174– 180. Fusade T, Toubel G, Grognard C, Mazer JM. Treatment of gunpowder traumatic tattoo by Q-switched Nd:YAG laser: an unusual adverse effect. Dermatol Surg 2000; 26:1058 – 1059. Kilmer SL, Wheeland RG, Goldberg DJ, Anderson RR. Treatment of epidermal pigmented lesions with the frequency-doubled Q-switched Nd:YAG laser. A controlled, single-impact, dose – response, multicenter trial. Arch Dermatol 1994; 130(12):1515– 1519. Rashid T, Hussain I, Haider M, Haroon TS. Laser therapy of freckles and lentigines with quasi-continuous, frequency-doubled, Nd:YAG (532 nm) laser in Fitzpatrick skin type IV: a 24-month follow-up. J Cosmet Laser Ther 2002; 4(3 – 4):81– 85. McClaren ML, Chotzen VA, Kilmer SL. Treatment of a variety of pigmented lesions with the lightsheer diode laser system. Lasers Surg Med 2001; 13(suppl):52. Bowes LE, Nouri K, Berman B, Jimenez G, Pardo R, Rodriguez L, Spencer JM. Treatment of pigmented hypertrophic scars with the 585 nm pulsed dye laser and the 532 nm frequencydoubled Nd:YAG laser in the Q-switched and variable pulse modes: a comparative study. Dermatol Surg 2002; 28(8):714– 719.
284 43.
44. 45. 46. 47.
48.
49. 50. 51. 52. 53. 54. 55. 56. 57. 58.
Kilmer et al. Tse Y, Levine VJ, McClain SA, Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium:yttrium – aluminum-garnet laser. A comparative study. J Dermatol Surg Oncol 1994; 20:795 – 800. Kunachak S, Leelaudomlipi P. Q-switched Nd:YAG laser treatment for acquired bilateral nevus of Ota-like maculae: a long-term follow-up. Lasers Surg Med 2000; 26(4):476 – 479. Polnikorn N, Tanrattanakorn S, Goldberg DJ. Treatment of Hori’s nevus with the Q-switched Nd:YAG laser. Dermatol Surg 2000; 26(5):477– 480. Apfelberg DB. Argon and Q-switched yttrium-aluminum-garnet laser treatment of nevus of Ota. Ann Plast Surg 1995; 35(2):150–153. Chan HH, Leung RSC, Ying S-Y, Lai C-F, Kono T, Chua JK, Ho W-S. A retrospective analysis of complications in the treatment of nevus of Ota with the Q-switched alexandrite and Q-switched Nd:YAG lasers. Dermatol Surg 2000; 26(11):1000 –1006. Nanni CA, Alster TS. Optimizing treatment parameters for hair removal using a topical carbon-based solution and 1064-nm Q-switched neodymium:YAG laser energy. Arch Dermatol 1997; 133(12):1546 –1549. Goldberg DJ, Littler CM, Wheeland RG. Topical suspension-assisted Q-switched Nd:YAG laser hair removal. Dermatol Surg 1997; 23:741 – 745. Goldberg DJ, Whitworth J. Laser skin resurfacing with the Q-switched Nd:YAG laser. Dermatol Surg 1997; 23:903 – 907. Goldberg D, Metzler C. Skin resurfacing utilizing a low-fluence Nd:YAG laser. J Cutan Laser Ther 1999; 1(1):23 –27. Goldberg DJ, Silapunt S. Histologic evaluation of a Q-switched Nd:YAG laser in the nonablative treatment of wrinkles. Dermatol Surg 2001; 27(8):744 –746. Kilmer SL. Laser treatment of tattoos. Derm Therapy 2000; 13:69 – 79. Geronemus RG. Surgical pearl: Q-switched Nd:YAG laser removal of eyeliner tattoo. J Am Acad Dermatol 1996; 35:101 – 102. Taylor G, Lehrer MS, Jensen PJ, Sun TT, Lavker RM. Involvement of folliclular stem cells in forming not only the follicle but also the epidermis. Cell 2000; 102(4):451– 461. Kauvar A. Treatment of pseudofolliculitis barbe with a pulsed infrared laser. Arch Dermatol 2000; 136:1343 – 1346. Ashinoff RA, Levine VJ, Soter NA. Allergic reactions to tattoo pigment after laser treatment. Dermatol Surg 1995; 21:291. Rheingold LM, Fater MC, Courtiss EH. Compartment syndrome of the upper extremity following cutaneous laser surgery. Plast Reconstr Surg 1997; 99(5):1418– 1420.
12 Q-Switched Alexandrite Lasers Christopher A. Nanni Private Practice, Glendore, California, USA
1. Q-Switched Alexandrite Lasers 2. Endogenous Cutaneous Pigments 3. Exogenous Cutaneous Pigments 4. Treatment Considerations 5. Treatment Pearls 6. Treatment Side-Effects and Complications 7. Summary References
1.
285 287 287 288 289 291 292 293
Q-SWITCHED ALEXANDRITE LASERS
The Q-switched alexandrite laser has been used extensively in cutaneous surgery for the treatment of a variety of cutaneous pigmented lesions (1 –9). A stimulated or “excited” alexandrite crystal produces photons of 755 nm wavelength light which is classified as red or near-infrared electromagnetic radiation and utilizes pulse durations from 50 to 100 ns (5). Dermatologic and aesthetic surgeons often refer to this laser as a “pigmentspecific laser” due to its ability to treat both endogenous and exogenous skin pigments. Lentigos, common and congenital nevi, melasma, ephilides, Becker’s nevi, Nevus of Ota, nevus spilus, and infraorbital-hyperpigmentation all have been successfully treated with the alexandrite laser (1 – 8). Exogenous pigments such as blue, black, and green tattoos, as well as graphite, traumatic, and foreign-body tattoos also have been reported to respond well to the alexandrite’s 755 nm pigment-specific wavelength (1 – 9). The alexandrite crystal itself is produced via a thermal process whereby a primary rod is formed under extremely high temperatures. This primary rod is then used to harvest anywhere from 2 to 10 secondary, smaller-diameter rods which are cored out from its center (Fig. 12.1). Once the secondary rods are examined for any structural abnormalities, they may then be used as a lasing medium. Generally, alexandrite rods are photodynamically “stimulated” by flashlamps which excite the stable, “resting” electrons within the alexandrite crystal to higher energy states. Once these electrons are no longer 285
286
Nanni
Figure 12.1 A primary alexandrite rod from which smaller rods have been harvested (note cored-out portions).
stimulated by the flashlamp, they fall back to their previous resting state and simultaneously emit a discrete photon of light with a wavelength of 755 nm. The laser chamber with its essential elements can cause the excitation of multiple electrons and produce numerous photons of light in a process known as light amplification. The complete details of this process will not be covered here, but it is these complex events which allow us to produce intense, monochromatic, collimated, and coherent light from what is known as a laser. Alexandrite lasers produce pulses of light that range from nanoseconds to milliseconds in duration. The light energy from most alexandrite systems is delivered via a fiberoptic cable which is believed to produce a more homogenous beam profile with a more consistent distribution of energy (3,5). Those lasers which produce high-energy 755 nm wavelength light in the nanosecond range do so by a process called quality-switching or Q-switching (10). The laser chamber is able to store photons until they are released through a switching mechanism known as a quality switch (Q-switch). This process allows a great number of photons to be released in an intense, brief laser pulse. Lasers that do not utilize a Q-switch produce longer pulse durations of light and are known as “normal mode” or “long-pulsed” systems. According to the theory of selective photothermolysis, a laser will be most effective and least destructive if its wavelength is selectively absorbed by a target and if the laser energy is applied to the target for a duration less than its thermal relaxation time (TRT)—the time it takes a target to cool to 50% of its heated temperature (11). Larger targets have less surface area and therefore cool down more slowly than smaller structures; therefore, larger targets have longer thermal relaxation times. In other words, the brief nanosecond pulses from the Q-switched alexandrite laser is best suited for smaller cutaneous targets, as compared to larger targets which are more appropriate for the long-pulsed alexandrite systems. From a clinical perspective, the Q-switched lasers are designed to be absorbed by small particles of tattoo pigments free in the dermis and trapped within macrophages. They also effectively damage small particles of melanin contained within keratinocytes, melanocytes, and melanasomes. In this way, tattoos as well as unwanted endogenous pigmented lesions may be treated and eliminated with minimal risk to surrounding tissue. In contrast, long-pulsed lasers are best suited for larger structures such as unwanted body and facial hair where the cutaneous target is the pigmented hair shaft and follicle (12,13). Due to the short pulse durations generated by the Q-switched alexandrite laser, pigmented targets are exposed to laser light for only brief time intervals and therefore
Q-Switched Alexandrite Lasers
287
rapidly absorb laser energy. This absorbed light energy is then transformed into thermal energy within the target. The thermal energy is produced rapidly within a given target, often causing it to rupture explosively generating pressure or acoustic waves (4 –6,14). A target then, may not only sustain thermal damage but may also become injured from these acoustic waves. Therefore, Q-switched systems such as the alexandrite laser are said to have both thermal as well as photoacoustic effects on their targets.
2.
ENDOGENOUS CUTANEOUS PIGMENTS
Endogenous pigmented lesions may be characterized by their location in the skin (epidermal vs. dermal) as well as their biological origins (acquired vs. inherited). These classifications may assist the laser surgeon in choosing which laser is best equipped to treat which type of lesion. For example, lentigines are acquired and are superficially located in the epidermis. Therefore, a laser does not need to penetrate deeply into the skin in order to treat these pigmented lesions (15). However, a Nevus of Ota is characterized by deep dermal pigment and responds best to laser light that penetrates effectively into the dermis such as the red light of the ruby and alexandrite lasers (3,5,16). The fact that red laser light penetrates easily into the dermis allows the alexandrite laser to treat lesions such as congenital nevi and Nevus of Ota more effectively than laser systems with shorter wavelengths (5). It is of interest to note that the biological origins of a pigmented target does not always help a surgeon to predict which lesions will respond to laser treatment most effectively. For example, melasma which is thought to result from sun exposure and hormonal factors is acquired and can be very recalcitrant to any laser or medical treatments. By contrast, Nevus of Ota are inherited lesions which are quite effectively removed by red laser light. Therefore, whether a person is genetically programmed to develop a particular lesion or whether a pigmented lesion develops from environmental factors may not help to predict the level of difficulty in treating a specific lesion. Lentigines are clinically characterized as brown macules which develop on areas of sun-exposed skin such as the face, chest, upper back, and the extensor surfaces of the upper and lower extremities. These acquired lesions respond well to the alexandrite laser and are effectively removed after only one to two laser treatments. Lentigines generally do reoccur, but a treated area that is re-exposed to sunlight may develop new lesions quite easily. Other small, monochromatic macules that appear similar to lentigines are known as ephilides or “freckles” and characteristically darken dramatically upon sun exposure (16). These pigmented lesions are also sensitive to alexandrite laser treatment and may be effectively removed in a matter of only one to two laser sessions. Nevus of Ota appear as brown, black, or blue macules and patches that develop at the periorbital region at birth or during adolescence (3,16). An ethnic predisposition has been documented in the Japanese population where incidence rates reach 0.2 –0.6% (3,16). Alexandrite laser treatment may require 5– 10 laser sessions, at treatment intervals of 6 – 8 weeks to allow for any postinflammatory hyperpigmentation to fade. Success in treating this pigmented lesion is high and recurrences are rarely noted.
3.
EXOGENOUS CUTANEOUS PIGMENTS
Tattoos may be composed of a wide array of colors and may be quite detailed in terms of their artistic form and the manner in which the pigment itself is produced and placed within the dermis. Tattoos may be categorized as amateur or professional, and may be further subdivided into decorative, cosmetic, or traumatic categories (1 –9).
288
Nanni
The most important characteristic of a tattoo in terms of selecting an appropriate laser wavelength for treatment is pigment color (4,6,9). Almost all of the “tattoo lasers” including the Q-switched ruby, alexandrite, and neodymium:yttrium – aluminum-garnet (Nd:YAG) wavelengths are effective at treating blue and black colored tattoos and traumatic tattoos. However, green, red, orange, yellow, and more complex color mixtures may need a specific wavelength for effective treatment or may be resistant to all of the tattoo-laser wavelengths. The alexandrite laser effectively treats blue, black, and green colored tattoos (1 – 9). Green tattoos may also be treated with a ruby laser but the alexandrite wavelength is usually considered the laser of choice for the treatment of green pigment. Multiple treatments are the rule when treating a tattoo and the popular misconceptions regarding the ease of laser tattoo removal can make patient education an arduous task during the initial consultation. Amateur tattoos are usually composed of India ink and are placed superficially in the dermis compared to professional tattoos (4,6). They are also less densely pigmented and therefore require a fewer number of laser treatments in order to produce adequate clearance. Treatment of cosmetic tattoos (lip and eyeliner pigments, tattoos designed to camouflage scars, etc.) especially those containing white, flesh-tone, and pink pigments may result in an adverse response known as pigment darkening (17). Although not reported specifically with the alexandrite laser, immediate and irreversible pigment darkening of cosmetic tattoos may theoretically occur with any Q-switched laser system. This phenomenon is thought to be due to a chemical reaction whereby heat generated from the laser reduces an iron-containing tattoo pigment from ferric oxide to the ferrous oxide form. While continued laser treatment may eventually clear the darkened pigment, results are not predictable and additional procedures such as surgical excision or CO2 laser resurfacing may be needed in order to effectively eliminate it. Other factors that affect tattoo removal are the age of the tattoo, the amount of pigment contained within the tattoo, and the depth of pigment placed within the dermis (2,6). However, tattoo treatment outcomes may be quite variable despite a thorough understanding of the history and composition of a given tattoo. In general, older less densely pigmented, monochromatic tattoos respond best to laser treatment. However, accuracy in predicting the number of treatments necessary to eliminate a given tattoo is low, indicating that unknown factors or a complex interaction of events probably dictate how well a tattoo responds to laser treatment. Certainly, the immune system plays a role in tattoo removal as macrophages in the dermis attempt to engulf tattoo pigments which are too large to be digested and remain stationary in the dermis with the pigment internalized. Tattoo pigment may also be found in lymph nodes draining untreated tattoos, suggesting that the lymph system is attempting to clear away tattoo pigment as debris (6). The exact mechanisms of tattoo removal are unclear and are most likely a complex interplay of both mechanical and immunologic events.
4.
TREATMENT CONSIDERATIONS
The treatment of pigmented lesions is not a simple task and laser treatment is not necessarily the perfect solution to all things that are colored and contained within the skin. Several patient, lesion, and environmental factors must be considered prior to embarking on laser treatment of any cutaneous pigment. In general, the ideal laser patient is one who has a clearly defined pigmented lesion, a patient who has a full understanding of the potential complications of laser surgery, and of the number of treatments necessary to achieve
Q-Switched Alexandrite Lasers
289
adequate lesion clearance. The laser surgeon, therefore, must consider several factors when evaluating a potential laser candidate. First, the exact biological nature of the lesion to be treated must be clear from either clinical or histopathological findings. It is not appropriate to treat any pigmented lesion that is suspicious, irregular, unfamiliar, or in any way atypical. If the diagnosis of a cutaneous lesion is unclear, it is essential to first perform a biopsy of the lesion prior to commencing with laser treatment. Second, consider how effective a given laser treatment will be and explain to the patient how many treatments may be necessary before improvement is noted. Never guarantee complete removal of any lesion, as laser treatment is often unpredictable. It is better to set patient expectations low rather than disappoint someone who is counting on clearance in a specific time period. Tattoos often clear rapidly up to a certain point, then clearance may peak and flatten, requiring many more treatments to achieve removal beyond 80– 90% (1 – 9). Some lesions, such as a cafe´ au lait macule may respond well to laser treatment initially but then reoccur rapidly upon sun exposure. It is important to make it clear to the patient that some lesions have a tendency to be either resistant to laser treatment, or may recur after laser treatment, or may even worsen as a result of laser irradiation. Melasma for instance tends to be recalcitrant to many types of treatment and may even worsens after laser therapy (18). This adverse reaction should be communicated to the patient prior to treatment to assure that there are no misunderstandings. Finally, side effects and complications of laser treatment must be fully articulated. The alexandrite laser targets pigment and while the goal of laser treatment is to destroy excess or unwanted cutaneous pigment, normal epidermal melanin is often adversely affected as well. Patients with Fitzpatrick skin types IV – VI and those with tanned skin are at high risk for laser complications and should be treated with caution (19 –21). Hypopigmentation, hyperpigmentation, vesiculation, crusting, edema, and erythema may all occur. However, some of these reactions may even be considered a normal or expected response to laser therapy. When treating lentigines on the hands, for instance, erythema, edema, and pigment darkening occur, causing lentigines to become even more prominent than they were prior to laser therapy. This darkening then leads to a gradual fading of these pigmented macules; however, significant lesion clearance occurs only after several postoperative weeks. Therefore, the patient needs to be prepared for this darkening effect (Fig. 12.2) and should plan to have the appearance of their hands worsen before it improves after laser treatment.
5.
TREATMENT PEARLS
In general, the more densely pigmented a particular lesion the lower the fluence required for effective treatment. Test sites are often helpful, especially if there is a concern regarding pigment darkening in a cosmetic tattoo or skin dyspigmentation occurring in a person with a dark skin type (19,20). However, while they may be helpful, test areas are not infallible as only a small portion of a lesion in question is usually being tested. In a tattoo for instance, some areas may be deeply pigmented and some areas may be faded and contain minimal ink. Therefore, high fluences may be appropriate to treat those faded areas but not areas rich in pigment. Excessive fluences may result in tissue splatter, punctate bleeding, epidermolysis, and subsequent textural changes. It is best to treat initially with a low fluence (5 – 6 J/cm2) while subsequent treatments may be adjusted based upon the immediate tissue reaction and postlaser healing response. As a general rule, pigmented lesions should be thoroughly reevaluated prior
290
Nanni
Figure 12.2 Hyperpigmented and slightly crusted solar lentigines on the dorsal aspect of the hand, 1 week after Q-switched alexandrite laser treatment.
to each treatment. If significant color lightening has occurred and the patient has no major complaints regarding healing, an increase in laser fluence of 0.5 –1 J/cm2 may be considered (Table 12.1). As there becomes less target (pigment) the energy must be increased in order to destroy the small amount of color remaining. A desirable intraoperative reaction is one characterized by immediate tissue whitening, mild to moderate edema formation, the development of an erythematous flare, and minimal to no tissue bleeding (Fig. 12.3). Vesiculation, obvious bleeding, tissue splatter, a loud “snap” upon laser impact, and significant treatment pain are indications for decreasing energy fluences. Interestingly, the shorter the pulse duration of a Q-switched alexandrite laser, the more splatter and punctate bleeding; however, shorter pulse durations are also more effective in clearing tattoos. Treatment intervals should take into account the fact that adequate healing must occur prior to subsequent treatments to prevent side effects such as scarring. Tattoo pigment must be immunologically removed from the treatment site and this process can take from several weeks to months. Epidermal pigment usually darkens and then peels away during 2– 4 weeks postlaser treatment. In patients who experience postinflammatory hyperpigmentation, it is best to wait until the skin darkening has faded significantly prior to commencing with further treatments. Therefore, on average, pigmented lesions are treated at 4 –6-week intervals. Immediate postoperative care of pigmented lesions and tattoos includes a petroleum-based topical antibiotic ointment with a nonstick bandage to be used for the Table 12.1
Q-Switched Alexandrite Laser Treatment Guidelines
Lesion Amateur tattoo Professional tattoo Lentigo Common melanocytic nevus Nevus of Ota
Fluence (J/cm2)
Treatment schedule (weeks)
Average number of treatments required
6–9 5–9 6–8 6–9 5–9
6–8 6–8 6–8 6–8 8 – 12
4 –10 7 –20 1 –4 3 –10 7 –20
Q-Switched Alexandrite Lasers
291
Figure 12.3 A professional tattoo, before and immediately after treatment with a Q-switched ruby for the green pigment and Q-switched frequently-doubled Nd:YAG for the red pigment. Note the ash-white appearance. Courtesy of Arielle N. B. Kauvar, M.D.
first 1– 3 days. Sun protection and sun avoidance are key as the greater the amount of epidermal melanin present, the less effective treatment will be and the greater the potential for complications (18 –20). While it may be tempting for patients, they must be instructed not to pick, peel, or scrub the treatment area. Pigment should be allowed to fade or peel away on its own during the postoperative period to avoid subtle textural changes or scarring.
6.
TREATMENT SIDE-EFFECTS AND COMPLICATIONS
The alexandrite laser’s wavelength of 755 nm effectively penetrates the dermis and is only minimally absorbed by epidermal melanin (2– 9,18 –20). Through the principles of selective photothermolysis, the Q-switched alexandrite attempts to confine thermal damage to a specific pigmented target and therefore minimizes damage to surrounding tissue (11). However, the skin’s natural pigment composed of epidermal melanin also absorbs 755 nm light energy (9,20,21). Therefore, both hypopigmentation and hyperpigmentation have been reported following treatment with the alexandrite laser (2,4). As many as 50% of patients may experience hypopigmentation after QS alexandrite tattoo treatment. However, nearly all patients repigment normally within 3– 6 months (2,4,9,20 – 22). Skin lightening tends to occur more commonly in deeply pigmented skin and in recently sun exposed and tanned skin. Hypopigmentation is often related to the number of treatments a specific lesion receives with an average of seven treatments necessary to induce significant skin lightening (4). Hyperpigmentation, is a rare event, occurring in fewer than 1% of cases (20,21). Immediate treatment effects include mild pain and an ash white appearance of lasertreated skin (6,10). Textural changes and scarring occur only rarely with the alexandrite laser and are often a result of inappropriate wound care postoperatively (4). However, reversible textural changes have been reported with the alexandrite laser as they have been reported with the ruby and Nd:YAG laser systems (4). Punctate bleeding and tissue splatter may occur with the alexandrite laser especially at high fluences and with those alexandrite systems utilizing very brief pulse durations. However, these epidermal side effects do not occur as frequently as they do with the use of the ruby and Nd:YAG lasers (4,22). Although not specifically reported with Q-switched alexandrite laser
292
Nanni
treatment, immediate irreversible pigment darkening of cosmetic, white, flesh-tone, and pink tattoos may theoretically occur with the alexandrite laser as it has been reported with other Q-switched laser systems (17). Cutaneous allergic reactions to tattoos may occur shortly after their placement into the dermis or may be quiescent until the tattoo has been treated with laser radiation (23,24). Allergic reactions to red tattoo pigments are most commonly seen (23) (Fig. 12.4). Reports of allergic reactions to yellow and blue pigment dyes may also occur but are less likely (6). Tattoos that manifest an allergic dermatitis after undergoing laser treatment may be caused from the dispersion of intracellular pigment into the extracellular space where it becomes antigenic. In a case report from Ashinoff et al. (25) patients with no history of allergy to their tattoo pigment prior to laser treatment experienced both generalized and localized urticaria, pruritus, and eczematous reactions after receiving several laser treatments. 7.
SUMMARY
The Q-switched alexandrite laser produces 755 nm wavelength light using pulse durations within the nanosecond range (Table 12.2). This flashlamp-powered laser primarily targets both endogenous and exogenous pigments contained within the skin. Based upon the principles of selective photothermolysis, the alexandrite laser targets a specific cutaneous pigmented lesion by producing a wavelength that is absorbed by the target, and by delivering a discrete amount of laser energy at a time interval at or below the target’s thermal relaxation time. This pulsed laser technology decreases collateral thermal injury to healthy tissue by limiting heat diffusion from the target to surrounding healthy tissue. Endogenous pigments composed of melanin may appear clinically different in coloration dependent upon their depth within the skin and their density. Exogenous pigments such as tattoos are dyes which are placed within the dermis either intentionally or via a traumatic implantation. The alexandrite laser functions by producing 755 nm wavelength
Figure 12.4
Edema and crust due to an allergic dermatitis to red tattoo pigment.
Q-Switched Alexandrite Lasers Table 12.2
293
Q-Switched Alexandrite Systems and Specifications
Manufacturer/trade name Candela (ALEXLAZR)
Coherent (VersaPulse) Cynosure (Accolade)
Maximum fluence (J/cm2)
Spot size (mm)
Pulse duration (ns)
12 (2.4 mm spot) 10 (3.0 mm spot) 5.5 (4.0 mm spot) 1.6 – 14 15 (2.4 mm spot) 10 (3.0 mm spot)
20 3.0 4.0 2.0 – 6.0 2.4 3.0
50
45 69
light that is directed onto a cutaneous target. The target absorbs this intense light energy which is then converted into heat resulting in thermal injury. As this heat is generated quite rapidly during a laser pulse, the target expands and disintegrates causing an acoustic shock wave which is in turn destructive. Therefore, the Q-switched alexandrite laser destroys pigmented lesions through both thermal damage and photoacoustic effects. Inherent in all cutaneous laser procedures is an element of uncertainty in regards to efficacy and permanence. The Q-switched alexandrite laser also presents a challenge to both surgeon and patient in terms of predicting exactly how many treatments are necessary to eliminate a given lesion. Multiple treatments are the rule when using any pigment specific laser system. Alexandrite laser treatment of superficial, sun-induced lentigos may require only one to two treatments, whereas a professional multicolored tattoo may need 15 –20 treatments for greater than 90% clearance. This unpredictability in laser outcome is important to communicate to every patient prior to embarking on a treatment plan and underscores the importance of never guaranteeing complete removal of a lesion based upon a set number of laser sessions. In terms of complications and side effects, the Q-switched alexandrite has an excellent safety profile with few reported cases of long-term complications. Hypopigmentation, hyperpigmentation, vesicle formation, and crusting are the most common side effects which generally resolve in 1 –8 weeks. Scarring and permanent dyspigmentation are possible, as they are with any laser system, but these are extremely rare adverse events, especially in the hands of an experienced laser surgeon.
REFERENCES 1. 2. 3. 4. 5. 6. 7.
Alster TS. Successful elimination of traumatic tattoos with the Q-switched alexandrite (755-nm) laser. Ann Plast Surg 1995; 34:542– 545. Alster TS. Q-switched alexandrite laser treatment (755 nm) of professional and amateur tattoos. J Am Acad Dermatol 1995; 33:69 – 73. Alster TS, Williams CM. Treatment of nevus of Ota by the Q-switched alexandrite laser. Dermatol Surg 1995; 21:592 –596. Fitzpatrick RE, Goldman MP. Tattoo removal using the alexandrite laser. Arch Dermatol 1994; 130:1508 – 1514. Goldberg D. Laser treatment of pigmented lesions. In: Alster TS, Apfelberg DB, eds. Cosmetic Laser Surgery. New York: John Wiley & Sons Inc., 1998. Kilmer SL. Laser treatment of tattoos In: Alster TS, Apfelberg DB, eds. Cosmetic Laser Surgery. New York: John Wiley & Sons Inc., 1998. Kovac S, Alster TS. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of infraorbital dark circles. Dermatol Surg 1998.
294 8.
9. 10. 11. 12. 13.
14.
15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.
Nanni Rosenbach A, Williams CM, Alster TS. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg 1997; 23:239 –243. Spicer MS, Goldberg DJ. Lasers in dermatology. J Am Acad Dermatol 1996; 34:1– 25. Goldman MP, Fitzpatrick RE. Cutaneous Laser Surgery: The Art and Science of Selective Photothermolysis. St. Louis: Mosby, 1994. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Kurban AK, Morrison PR, Trainor SW, Tan OT. Pulse duration effects on cutaneous pigment. Lasers Surg Med 1992; 12:282. Nanni CA, Alster TS. A practical review of laser-assisted hair removal using the Q-switched Nd:YAG, long-pulsed ruby, and long-pulsed alexandrite lasers. Dermatol Surg 1998; 24:1399 – 1405. Ara G, Anderson RR, Mandel KG et al. Irradiation of pigmented melanoma cells with high intensity pulsed radiation generates acoustic waves and kills cells. Lasers Surg Med 1990; 10:52. Kilmer S, Wheeland R, Goldberg D et al. Treatment of epidermal pigmented lesions with the frequency-doubled Q-switched Nd:YAG laser. Arch Dermatol 1994; 130:1515 – 1519. Lever WF. Histopathology of the Skin. Philadelphia: J.B. Lippincott Co., 1990. Anderson RR, Geronemus R, Kilmer SL et al. Cosmetic tattoo ink darkening: a complication of Q-switched and pulsed-laser treatment. Arch Dermatol 1993; 129:1010 – 1014. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by QQ-switched ruby laser. J Dermatol Surg Oncol 1994; 20:592– 597. Ho C, Nguyen Q, Lowe NJ et al. Laser resurfacing in pigmented skin. Dermatol Surg 1995; 21:1035 – 1037. Nanni CA. Complications of laser surgery. Dermatol Clin North Am 1997; 15: 521 – 534. Nanni CA, Alster TS. Complications of cutaneous laser surgery: a review. Dermatol Surg 1998; 24:209 – 219. Stafford TJ, Lizek R, Tan OT. Role of the alexandrite laser for removal of tattoos. Lasers Surg Med 1995; 17:32– 38. Lowenthal LA. Reactions in green tattoos. Arch Dermatol 1973; 107:101 – 103. Novy FG. A generalized mercurial (cinnabar) reaction following tattooing. Arch Dermatol 1944; 49:172. Ashinoff R, Levine VJ, Soter NA. Allergic reactions to tattoo pigment after laser treatment. Dermatol Surg 1995; 21:291 –294.
Q-Switched Alexandrite Lasers
295
CONSENT FORM LASER TREATMENT OF PIGMENTED LESIONS I, , understand that I have a pigmented lesion known as a Dr. has explained to me that although laser surgery is effective in most cases, no guarantees can be made that I will benefit from treatment. I understand that several treatment sessions are usually needed in order to obtain a significant level of improvement. However, there are times when a tattoo or pigmented lesion will not completely clear. When this occurs, the treated lesion generally will become lighter and less densely colored; only rarely does a tattoo or pigmented lesion darken as a result of laser treatment. 1.
2.
3.
4.
5.
6.
7.
8.
9.
PAIN. Each laser pulse may feel similar to the snap of a rubber band. This discomfort is mild to moderate in severity and if needed, a numbing cream or injection can be given prior to treatment. WHITENING. Immediately after laser treatment, the surface of the treated area may appear white in color for 1 – 2 hours. There may also be redness around the treated site which fades within 1 –2 days. SWELLING. The treated area may become red and swollen. This swelling is an expected outcome to treatment and decreases in 1– 2 days. Ice packs and cold compresses may speed recovery. BLISTERS OR SCABS. If a blister or scab develops, notify your doctor. The area should be cleansed with peroxide and an ointment should be applied to the area twice daily. Do not pick at these areas. SKIN DARKENING (HYPERPIGMENTATION). This is usually a transient side-effect which normally resolves within 2– 3 months. This reaction is more common in patients who are sun-tanned, and those with naturally dark skin tone. Only rarely is this skin darkening permanent. SKIN LIGHTENING (HYPOPIGMENTATION). This may occur at the treatment site and is more common in areas which have received multiple treatments. These areas of light-colored skin usually repigment and only rarely are permanent. SCARRING. This is rare, but may occur if the treated area blisters, is traumatized, or scratched. It is important to follow the care your doctor prescribes after laser treatment to help avoid this complication. NO IMPROVEMENT OR WORSENING. Some pigmented lesions and tattoos may not respond to laser treatment or may reoccur. Some treatment sites may even darken after laser treatment, although this rarely occurs. ALLERGIC REACTION. An allergic reaction to the release of tattoo fragments in the skin can occur after laser treatment. Antibiotic ointments used after treatment may also cause a skin allergy.
13
Long-Pulsed Alexandrite Laser Cathy A. Slater Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Boice-Willis Clinic, Rock Mount, North Carolina, USA
John B. Newman Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Naval Medical Center Portsmouth, Portsmouth, Virginia, USA
David H. McDaniel Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Eastern Virginia Medical School, Norfolk, Viriginia, USA
1. 2. 3. 4.
Historical Background Scientific Background Clinical Studies Using a LPA Laser for Hair Removal Practical Applications of the LPA Laser for Hair Removal 4.1. Patient Expectation 4.2. Medical History 4.3. Physical Examination 4.4. Protocol for Using the LPA for Hair Removal 4.5. Eye Safety 4.6. Suggested Treatment Parameters 5. Leg Telangiectasia Treatment 6. Pseudofolliculitis Barbae 7. New Horizons References
1.
297 298 300 303 303 303 304 304 305 305 305 308 310 310
HISTORICAL BACKGROUND
Alexandrite lasers are solid-state lasers that emit a 755 nm wavelength. Long-pulsed alexandrite lasers have become popular for hair removal and leg vein treatment.
The opinions or assertions expressed herein are those of the authors and are not to be construed as official or as reflecting the views of the Department of the Navy, the Department of Defense, or Naval Medical Center Portsmouth. 297
298
Slater, Newman, and McDaniel
Alexandrite lasers first became well known in the late 1980s and early 1990s for use in laser lithostripsy to treat ureteral stones. Both Q-switched alexandrite and pulsed alexandrite lasers have been used (1 –3). Researchers have used alexandrite lasers as a light source in photodynamic therapy for cancer treatment and for inducing fluorescence imaging of tumors for detection and mapping (4 – 6). In dentistry, pulsed alexandrite lasers have been studied for dye-enhanced ablation of enamel (7). Early research into cutaneous medical uses of alexandrite lasers also involved “tissue welding” for skin closure, though this did not become a practical application (8). Significant breakthrough in using alexandrite lasers for cutaneous laser surgery came from the field of tattoo removal, when the Q-switched alexandrite laser showed promise as a treatment modality for tattoo removal without scarring (9). Soon the Q-switched alexandrite laser became established as one of several lasers effective in treating black, blue and gray tattoos (10 – 14). Along with other lasers targeting pigmented lesions, reports emerged using the Q-switched alexandrite laser for treatment of nevus of Ota (15), benign melanocytic nevi (16), and solar lentigos (17). In 1997, Alexandrite lasers emerged as a valuable tool for laser-assisted hair removal. Previous studies had already shown that ruby lasers were capable of hair removal. Spurred by public interest and cosmetic demand, the quest was on to develop the safest and most effective hair removal laser. Finkel et al. (18) published their favorable results using a pulsed alexandrite laser for hair removal. Further studies have confirmed efficacy of the alexandrite laser for hair removal. Leg vein treatment became the next focus of interest for alexandrite lasers. In 1999, McDaniel et al. (19) described results using the 755 nm long-pulsed alexandrite (LPA) laser for leg vein treatment. At present there are a number of LPA lasers available (Table 13.1). In addition to hair removal and leg vein treatment, LPA lasers show promise for treating pseudofolliculitis barbae.
2.
SCIENTIFIC BACKGROUND
The LPA laser operates on the principle of selective photothermolysis (20). This concept has been well described elsewhere in this book and in laser review articles (21 – 23). Table 13.1
Available Long-Pulsed Alexandrite Lasers (755 nm Wavelength) Gentle Lase
Apogee 6200
Apogee 9300
EpiTouch Plus
Manufacturer Price (US$) Pulse durations (ms) Spot sizes (mm)
Candela 69,000 3
Cynosure 64,500 5, 10, 20, 40
Cynosure 79,500 5, 10, 20, 40
ESC/Sharplan 79,000 2 – 40
8, 10, 12, 15 1 Up to 100 None
Cooling system
Yes, dynamic cooling
12.5, 15 (10 mm option) Up to 4 Up to 50 Option (70 70 mm) $11,000 Option $10,000
1 – 10 mm
Speed (Hz) Fluence (J/cm2) Scanner
12.5, 15 mm (10 mm option) Up to 3 Up to 50 Option (50 50 mm) $11,000 Option $10,000
Up to 5 Up to 50 Yes (50 50 mm) None, may be in future
Long-Pulsed Alexandrite Laser
299
Selective photothermolysis allows selective injury to a desired target while sparing the surrounding structures or tissues. Laser wavelength, pulse duration, and fluence are combined to achieve selective injury. Selective photothermolysis entails choosing a laser wavelength that will match a portion of the absorption spectrum of the intended target. Preferably the surrounding tissues will not absorb this wavelength or the absorption by the target will be greater than the interfering, nontarget chromophores. The alexandrite wavelength frequency of 755 nm has light absorption by both melanin and hemoglobin. Melanin selectively absorbs wavelengths between about 650 and 1000 nm. Oxyhemoglobin and water, which are competing chromophores, absorb less energy at these wavelengths. Compared to the alexandrite wavelength of 755 nm, ruby lasers emit at a wavelength of 694 nm, diode lasers around 800 nm, and Nd:YAG lasers at 1064 nm. In addition, a pulse duration should be chosen that is less than or equal to the thermal relaxation time of the target. Thermal relaxation time is the time required for the target object to cool to half of its peak temperature. The thermal relaxation time for a hair follicle with a 250 mm diameter is 70 ms. The thermal relaxation time for overlying epidermis is 3 – 10 ms. According to some theories, the pulse width for hair removal lasers should fall between these thermal relaxation times (24). Finally, the fluence of the laser light should be above the threshold fluence that would lead to irreversible damage of the intended target. Since hair shaft diameters vary, the optimal pulse duration may also vary. Melanin within the hair follicle is the target chromophore for laser hair removal. When the laser beam detects its color-specific target, light is absorbed in the hair shaft melanin. Heat is generated which damages the hair follicle and possibly some adjacent supporting structures such as vessels. The exact melanocytic target within the hair follicle that is responsible for hair reproduction remains uncertain. The targets probably include the groups of cells near the base of the shaft in the papilla and the germinative cells of follicle in the area one-third of the way down the shaft known as the bulge (24). Melanin allows selective targeting of hair in the skin, since melanin in the hair shaft or follicle provides a chromophore that is not present in the surrounding dermis. Melanin pigment is naturally present in abundance in darker hairs; however, in blonde and graying hair, melanin pigment is less abundant and of somewhat different composition. Melanin pigment is also present in the epidermis surrounding the follicles and must be protected from damage absorption by melanin. The darker the skin type, the more at risk the epidermis is during laser treatment. Some protection of the epidermis is usually accomplished by cooling the skin surface. Nonetheless, epidermal damage, especially in dark skin types presents a safety issue for all melanin-targeting laser systems. Individuals with dark hair and light skin tone currently experience the best treatment results. The ruby laser’s 694 nm wavelength is ideal for melanin absorption, and hence hair removal, but places darker skinned patients at risk for epidermal damage. On the other end of the spectrum, the Q-switched Nd:YAG laser’s 1064 nm wavelength is safer for hair removal treatment of darker skin but is less effective for long-term hair removal. However, the Nd:YAG appears more effective for hair removal when using the longpulse mode at high fluence rather than the Q-switch mode. The alexandrite’s 755 nm wavelength and the diode’s 800 nm wavelength balance the desire for effective hair removal but with more protection for the epidermis. The longer wavelengths of the alexandrite and diode lasers compared to the ruby allow a slightly greater depth of penetration, along with a potential lower risk of epidermal damage since there is slightly less melanin absorption at these wavelengths (25). A corollary of selective photothermolysis is the concept of thermokinetic selectivity (TKS). This theory proposes that for the same chromophore, longer pulse durations allow
300
Slater, Newman, and McDaniel
intrapulse cooling of smaller targets more rapidly than larger targets (24). In other words, the larger chomophore targets of the melanin in the hair follicle can be selectively injured more than the smaller chromophore targets of the melanin in the epidermis. Theoretically, if the pulse width is long enough, heat should build up within the hair follicle (the larger structure), and destroy both the hair follicle and structures immediately adjacent to it such as the bulge. The smaller melanin content in the epidermis (the smaller structure) is relatively spared because it is able to dissipate the heat more rapidly. Treatment safety may be improved if the pulse width selected is longer than the thermal relaxation time of the melanin in the epidermis but is shorter than the relaxation time of the melanin in the hair follicle. Theoretically, the epidermis can cool more efficiently and have reduced damage during the laser pulse. Some researchers (authors included) believe that much longer pulses (200 –800 ms) may also be effective and potentially safer for darker skin types. Anderson has recently introduced the concept of thermal destruction time (TDT) to illustrate this concept. Cooling devices such as dynamic cooling spray, contact cooling, or a chilled topical refractive index matching agent for the epidermis, can enhance cooling and protection. The concept of thermokinetic selectivity under girds the basis for using a long pulse duration in the LPA laser. Some LPA systems use trains of short pulses rather than a single continuous long pulse.
3.
CLINICAL STUDIES USING A LPA LASER FOR HAIR REMOVAL
Cosmetic concern over unwanted hair fuels the constant search for better removal techniques. Long pulsed alexandrite lasers join the ruby, diode, and the Nd:YAG lasers in the research and development of laser-assisted hair removal. Though the ruby has the highest wavelength selectivity for deep melanin absorption, the alexandrite has the advantages of a longer pulse width and a longer wavelength. The 755 nm wavelength, while slightly less selective for melanin, provides greater depth of penetration than the 694 nm one. Theoretically, the 755 nm wavelength of the alexandrite may be safer than the ruby for darker skin when no epidermal cooling is utilized, since the 755 nm wavelength is less well absorbed by melanin than the 694 nm wavelength. Finkel’s early study used a 2 ms free-running short-pulsed alexandrite laser at energy fluences of 25 –40 J/cm2 and showed significant hair growth delay. In this study, 126 patients who received up to five treatments at 4 –12-week intervals demonstrated 90% hair loss 3 months following the final treatment. Hair reduction was around 35% after one treatment (18). Connolly and paolini (26) also reported success using the alexandrite laser. They treated 20 patients with skin types I– V. Treatment parameters consisted of the LPA using a 10 ms spot, a 20-ms pulse width, and a fluence ranging from 14 to 25.6 J/cm2, depending on skin type. They found an 86% hair reduction at the 3-month follow-up period. Patient satisfaction was high and side effects minimal (26). Boss et al. (27) reported a comparison between the long- and short-pulsed alexandrite laser systems. They found no difference using the same fluence on paired anatomic sites between a 2-ms alexandrite laser and a 20-ms alexandrite laser in terms of return of hair growth and complications. Patients reported a 60 –80% reduction in hair growth at 6 months (27). Nanni and Alster (28,29) showed comparable clinical efficacy and side effects between alexandrite and long pulsed ruby lasers when used for hair removal. In addition, Nanni et al. have studied different pulse durations using the LPA laser. Thirty-six subjects were treated with an average fluence of 18 J/cm2, with a 10 mm spot size, on different quadrants at 5, 10, or 20 ms pulse duration. Hair counts were reduced by 66% at
Long-Pulsed Alexandrite Laser
301
1 month, 27% at 3 months, and 4% at 6 months. No significant differences in clinical efficacy or side effect profiles were observed between treatment quadrants, yet a trend towards less posttreatment erythema and hyperpigmentation was noted with the 20 ms pulse duration (30). McDaniel et al. (21) have also studied the safety and long-term efficacy of the LPA laser (Figs. 13.1 and 13.2). Thirty-one sites on 22 patients, skin types I–III, were treated at 755 nm, single pulse, 10 mm spot size, 10% overlap, pulse durations of 5, 10, and 20 ms, and a fluence of 20 J/cm2. Hair reduction at 6 months varied both with the pulse duration and anatomic location. Maximum reductions observed were 40%, 56%, 50%, and 15% for the lip, leg, back, and bikini areas, respectively. The 10 ms pulse duration at 20 J/cm2 produced the greatest hair reduction. No permanent adverse effects occurred (21). In contrast, Goldberg and Ahkami (31) compared a 2-ms and a 10-ms alexandrite laser for hair removal. Paired anatomic sites were evaluated 6 months after three treatments. Hair reduction was 33.1% for the 2-ms pulse duration and 33.9% for the 10-ms alexandrite laser, indicating no significant difference in response. No long-term side effects were noted (31). A comparative study between the topical carbon suspension-assisted Q-switched Nd:YAG treatment (the Softlight TM process) and the LPA was done by Rogers et al. (32) Fifteen patients were treated with both lasers on bilateral axilla, though the right axilla only received one alexandrite treatment, while the left axilla received two Nd:YAG treatments. Two months posttreatment, hair reduction was 55% for the alexandrite laser and 73% for the Nd:YAG; after 3 months, the alexandrite laser-treated patients showed a reduction of 19% and the Nd:YAG laser-treated patients showed a 27% reduction. Pain was evaluated on a scale of 0– 10, with 0 being the absence of pain and 10 being the worst. Patients reported average pain values of 8 and 4 for the LPA and Nd:YAG laser sites, respectively (32). In a comparison study between alexandrite laser and electrolysis for hair removal, the average clearance rate of the hairs was 74% by laser and 35% by electrolysis 6 months after the initial treatment. Laser hair removal was noted to be more expensive but 60 times faster and less painful
Figure 13.1 Digital videomicroscopic photos of the identical site of the right upper lip at 30 magnification. (a) Pretreatment and (b) 6 months posttreatment after two long-pulsed alexandrite laser treatments (4 months after second treatment). Note the decreased hair shaft diameter and pigmentation changes of the same hairs [from Ref. (21)].
302
Slater, Newman, and McDaniel
Figure 13.2 (a) Pretreatment of the right and left upper lip of a 34-year-old woman with Fitzpatrick Type II skin. (b) Two months posttreatment, right and left upper lip, using longpulsed alexandrite laser with 10 mm spot diameter at 20 J/cm2, single pulse technique, 10% overlap, pulse duration 10 ms, with chilled K-Y jelly. (c) Three months post initial treatment and 1 month post second treatment of the right upper lip only using the same parameters as in B. (d) 6 months after second treatment to left upper lip, 6 months post initial treatment, and 4 months after second treatment to the right upper lip only using the same parameters as in (b) [from Ref. (21)].
than electrolysis, in addition to being more effective (33). Raulin and Greve (34) reported their experience with the alexandrite laser in a retrospective study on 30 female patients using an LPA (20 ms, 755 nm, up to 30 J/cm2, with a 10 or 12.5 mm beam diameter) over an 18-month treatment period. After an average of eight treatments, an average clearance rate of 75% was achieved (34). Several studies have examined the safety of the LPA. Nanni and Alster (35) compared the side effects of the LPA with the Q-switched Nd:YAG and the long-pulsed ruby. A retrospective chart review of the side effects resulting from 900 laser treatments over a 24-month period showed varying degrees of pain, erythema, edema, hypopigmentation and hyperpigmentation, blistering, crusting, erosions, purpura, and folliculitis. The majority of undesirable tissue effects occurred on tanned skin or in skin types III or higher. The effects of seasonal variations, anatomic treatment location, and sun exposure were considered striking within the ruby and alexandrite laser groups. No infections, scarring, or long-term complications occurred (35). Of interest, pili bigeminy has been noted in pubic hairs treated with low fluences with both the alexandrite and ruby laser (36). Though caution should be used in treating dark skin patients with the alexandrite laser, Garcia et al.’s study (37) is encouraging. They treated 150 patients with Fitzpatrick skin types IV– VI exclusively for a total of 550 treatment sites. Complications occurred in only 2% of cases. Of note, they did not find prelaser skin testing helpful in predicting
Long-Pulsed Alexandrite Laser
303
the incidence of complications (37). Note: the authors of this chapter suggest caution about treating darker skin types with LPA without prior test areas. In conclusion, multiple studies have demonstrated the efficacy and safety of the pulsed alexandrite laser for hair removal. The longer pulse may have advantages over the shorter pulse alexandrite laser in term of side effects and efficacy, though there are conflicting reports. The optimal combination of wavelength, pulse duration, fluence, epidermal protective measures, and laser sources for hair removal are still in evolution. Further research and development is needed to define the best laser parameters for cutaneous therapies. New approaches and mathematical models to study lasers for hair removal are promising (38).
4. 4.1.
PRACTICAL APPLICATIONS OF THE LPA LASER FOR HAIR REMOVAL Patient Expectation
Patient expectations need to be discussed carefully. No laser produces permanent results all the time. The LPA usually produces a complete hair loss that is temporary, followed by a partial but long-term hair reduction. Patients need to understand the distinction between permanent hair reduction and permanent hair removal. Patients should expect sequential treatments. Realistic expectations should be clearly established. Patients need to know that results vary depending on skin type, hair color, anatomic site and the nature of the human hair growth cycle. In general, skin types V and VI do not respond as well. Also sometimes after two to three treatments, dark hair may turn light and be less responsive, though for most patients this lightening is an improvement compared to the previous dark color hair. Alternative treatments should be discussed, including shaving, waxing, depilatories, and electrolysis. Advantages of the LPA laser for hair removal include being a quick, effective, and safe treatment, with minimal discomfort, no recovery period. There is usually excellent temporary removal, and probable cumulative permanent reduction similar to diode lasers at equivalent parameters, though this has not been published at this writing. 4.2.
Medical History
Patient’s history should include patient’s general medical condition, local skin infections, history of scarring, medications, and skin or endocrine diseases. Patients with a history of herpes simplex may be placed on oral antiviral medications beginning the day before treatment when treating the upper lip or bikini line, though this is usually not necessary. Some authorities believe patients ideally should be off Accutane at least 6 months before hair removal. Shorter intervals off Accutane may be permissible as the presence of increased risk for laser hair removal has not been established. Patients should discontinue tretinoin 2 weeks prior to laser hair removal. Medications such as prednisone and cyclosporine may interfere with the final outcome and should be noted on the medical record. Laser hair removal should be avoided in patients on photosensitizing medications. Patients should be asked if cosmetic tattoos or permanent make up (including lip and eyebrow liner) exist in the areas to be treated. Laser treatment may possibly remove or lighten tattoos or nevi. Tattoos containing iron or titanium oxide pigment may darken; often flesh-toned, white, or burnt amber tattoos darken or change to an unacceptable color. Such areas should be avoided (or patients should be warned of these risks prior to treatment and test areas performed).
304
Slater, Newman, and McDaniel
The sun-tanned patient should be counseled extensively on the risk of posttreatment pigment changes. Individuals who have had recent sun exposure but yet have no visible tan are at higher risk for post treatment pigmentary changes also. Sun avoidance is strongly encouraged as the patient progresses through the treatment protocols.
4.3.
Physical Examination
Ascertain skin type such as Fitzpatrick classification of skin types. Type I Type II Type III Type IV Type V Type VI
Always burns, never tans Always burns, sometimes tans Sometimes burns, always tans Rarely burns, always tans Moderately pigmented Black skin
(The Lancer Ethnicity scale is also a useful adjunct to the Fitzpatrick skin types.) Skin types I–IV can be treated, but types V and VI are less good candidates. Recent improvements in epidermal cooling options are changing these guidelines. If any significant tan is present, it is best to postpone treatment until the tan is faded (6 weeks). Patients may use bleaching agents to lighten hyperpigmented areas to be treated. Patients should also avoid tanning parlors. The patient’s hair color should be noted. Dark hair usually shows better long-term reduction whereas blonde or white hair may show little or no reduction. Patients with red and gray can be advised that they may or may not achieve permanent hair reduction. The presence of tattoos or nevi in the treatment area should be noted. There should be no electrolysis, plucking, or waxing for 3 weeks prior to laser treatment. Hair is shaved prior to treatment; depilatory creams can be used if the patient objects to shaving. Patients will experience heat or feel pain similar to a rubber band snapping against skin. Chilling devices reduce this pain. Topical anesthesia is generally only used if patients are pain sensitive or if sensitive areas are treated such as the upper lip and the bikini line. Topical lidocaine or EMLA may be applied 60 –90 min prior to treatment. Application over large areas is not recommended because of the risk of systemic lidocaine toxicity.
4.4.
Protocol for Using the LPA for Hair Removal
The laser operator should wear gloves. All persons in the treatment room should wear appropriate protective eyewear. Remove any topical anesthetic. The hair is usually clipped to ,1 mm in length or shaved by patient prior to treatment. If no chilling device is available, laser pulses may be delivered through a thin (0.5 mm) layer of K-Y Jelly chilled in an ice water bath. Laser pulses are set at the desired fluence and spot size. Pulses are delivered with the handpiece pressed firmly perpendicular against the skin. Ideally, skin is stretched prior to delivery to ensure maximum skin contact. Mild pressure is applied in order to maximize skin contact and hence follicle penetration. The handpiece is then lifted and placed firmly on an adjacent site until entire area is treated. Pulses should be delivered with minimal to no overlap, but placed in a way to avoid checkerboard or corn row-putting patterns. The goal is to use a fluence in which the hair is carbonized, followed by very selective follicular swelling and redness. The endpoint is defined by a red halo around each hair but without vesiculation. A polarized light source with magnifying loupe aides in
Long-Pulsed Alexandrite Laser
305
visualization of the hair follicles. Often after a few days after treatment, hair casts may be shed from the hair follicle. The highest fluence tolerated is used to reach this optimal endpoint. Fluence levels that may lead to blister formation should be avoided, as this signifies epidermal damage and potential pigmentary changes. To decrease the risk of hypo- or hyperpigmentation, lower fluences than those suggested below should be used. If epidermal damage is present (blistering, graying) the fluence should be lowered. Multiple pulsing increases the risk of pigment changes. Wipe away damaged surface hair. After a few minutes, diffuse erythema and edema may appear. This sunburned feeling usually last 1 –3 h. Applying ice or cold compress immediately posttreatment will provide relief and reduce the swelling duration. If moderate erythema occurs, a mild topical steroid preparation may be applied. Sometimes redness lasts for a few days, but can be covered by make up. If there are blisters, then the patient should use an antibiotic ointment and call the physician. Patients should avoid sun exposure for at least a few days after treatment. All body sites except the eye can be treated. Second treatments should be given when the hair begins to regrow. This may be at different times for different body areas. Generally speaking, for the face, axilla, and bikini, treatment may be scheduled after 1 – 2 months; for the back and legs, 2 –3 months. 4.5.
Eye Safety
Lasers are capable of causing severe retinal injury when applied near the surface of a patient’s eye. This laser should not be used on or near the surface of patient’s eye. Use of this laser anywhere inside the bony orbit may potentially cause direct eye injury. Patient and operating personnel must wear proper eye protection to prevent inadvertent exposure to the eyes. Infrared light such as 755 nm can be especially dangerous because of our inability to see the laser light. 4.6.
Suggested Treatment Parameters
In general, select the largest available spot size which will deliver the desired fluence. Adjustments for photoaging and darker skin types are advisable and test spots should be utilized whenever there is uncertainty. Due to the variations in pulse durations and cooling options from the various manufacturers, the authors elected not to specify “cookbook” parameters for the LPA laser, but rather refer the reader to the clinical endpoint descriptions as well as the most current guidelines from the manufacturer of the specific model of laser in use (Sample Form 1 and Sample Form 2).
5.
LEG TELANGIECTASIA TREATMENT
The principle of selective thermolysis also applies to laser treatment of vascular lesions, where the target chromophore is hemoglobin. The heat generated after absorption by hemoglobin is transferred from blood to the vessel wall. The goal is to achieve the optimal combination of laser wavelength, pulse duration, and fluence to inflict irreversible damage to a given vascular structure. Telangiectasias are dilated venules, capillaries, or arterioles visible to the human eye and measuring 0.1 –1.0 mm in diameter. Telangiectasia may further be classified into four categories based on clinical appearance: linear, arborizing, spider, and papular (39).
306
Slater, Newman, and McDaniel
Unwanted spider telangiectasias on legs occur in 29 – 41% of women and in 6 – 15% of men. Leg telangiectasias develop in the second to third decade due to a number of factors including heredity, obesity, pregnancy, and trauma. Sclerotherapy remains the best overall treatment option for leg telangiectasias. However, side effects with sclerotherapy include pigment changes, cutaneous necrosis, pain, scarring, telangiectatic matting, and recurrence of telangiectasias (19). The LPA laser is one among a variety of lasers that has been used for treating leg telangiectasias. Other lasers which have been used for leg telangiectasias include the 585 nm pulsed dye laser; the longer pulsed dye lasers of 585, 595, and 600 nm wavelengths; the long-pulse frequency-doubled 532 nm Nd:YAG laser; the 810 nm diode laser; and an intense pulse light device with a spectrum of 515– 1200 nm (40 – 46). The response of spider veins on the legs to these devices has been met with varying degrees of success. Sclerotherapy remains the gold standard. In addition, laser adverse effects are often comparable and sometimes greater than traditional sclerotherapy. Also treatment with these devices is usually more costly than sclerotherapy. Leg telangiectasias have been more difficult to treat than facial telangiectasias. Leg telangiectasias often have a deeper location and a larger diameter. Nonetheless, lasers are improving in the treatment of leg spider veins. Lasers can be especially useful in the treatment of telangiectatic matting, in cases recalcitrant to sclerotherapy, and for patients who cannot tolerate needles. The target chromophore for leg telangiectasias is oxyhemoglobin, though deoxyhemoglobin may also be a secondary target with this wavelength. Oxyhemoglobin has several distinct peaks. The LPA laser has been attractive as a potential leg vein treatment because of its wavelength of 755 nm. Compared to the other lasers with wavelengths from 532 to 600 nm, the LPA 755 nm was intended to take advantage of targeting the absorption peak of hemoglobin where there is decreased interference by melanin. Another factor to consider is pulse duration. Based on the concept of selective photothermolysis, the pulse duration of laser light should be equal to or less than the thermal relaxation time of the vessel treated. The optimal pulse duration varies according to the vessel size Goldman and Fitzpatrick found that small leg telangiectasias ,0.2 mm in diameter responded well to flash lamp pulsed dye treatments. Larger telangiectatic vessels need to be treated with longer wavelength lasers in order to achieve deeper penetration. The longer wavelength of the LPA is another motivation is its use. McDaniel and colleagues examined the effectiveness of the 755 nm LPA laser for the treatment of leg telangiectasias (19) (Figs. 13.3 and 13.4). Twenty-eight patients with variable sized telangiectasias were evaluated using five treatment parameters (15 J/cm2 1 pulse, 20 J/cm2 1 pulse, 20 J/cm2 2 pulses, 20 J/cm2 3 pulses, or 30 J/cm2 1 pulse). The optimal treatment parameters for LPA therapy as a solo treatment (without combination sclerotherapy) appeared to be 20 J/cm2, double pulsed at a repetition rate of 1 Hz. After three treatments at 4-week intervals, subjective grading indicated a 63% reduction in leg telangiectasias. Vessels were grouped into small (,0.4 mm), intermediate (0.4 – 1.0 mm), and large (1.0 –3.0 mm). Medium-diameter vessels responded best with small vessel diameters responding poorly. In the aforementioned LPA leg vein study, 23.4% hypertonic saline sclerotherapy was performed 3– 7 days after laser therapy (20 J/cm2, single pulsed, 5 ms) which resulted in an 87% reduction in leg telangiectasias. The study also examined biopsies after LPA treatment. The biopsies revealed that vessel wall endothelial cell necrosis occurs 3–7 days post-LPA treatment, with fibrosis occurring at 3 weeks (Figs. 13.5 and 13.6). The optimal clinical window for sclerotherapy
Long-Pulsed Alexandrite Laser
307
Figure 13.3 (a) Leg veins pretreatment. (b) Two weeks after single treatment with long-pulsed alexandrite laser, 20 J/cm2, 10 ms pulse duration, single pass with 10 mm spot size [from Ref. (19)].
was felt to coincide with the period of endothelial cell necrosis. Overall, the authors conclude that LPA therapy is most effective for leg telangiectasias 0.4–3.0 mm in diameter and is ineffective for veins ,0.4 mm. The combination of LPA with sclerotherapy showed the best results. Sclerotherapy is advised 3–21 days post-LPA treatment. Compression stockings of 10–20 mm may be useful (7 days during waking hours is recommended). Caution must be exercised in using LPA therapy in patients who are tanned, possess darker ethnic skin types, or have severely photoaged skin. Pigmentary changes (primarily hypopigmentation) may result; usually such changes are transient but may be long lasting. LPA laser treatment is better tolerated with the addition of a cooling device. Kauvar and Lou (47) demonstrated excellent clinical results using dynamic cooling to treat of leg veins with fluences up to 80 J/cm2. Twenty patients with 54 treatment sites consisting of vessels 0.3 –2.0 mm in diameter were treated once using a 755 nm, 3 ms alexandrite laser (Candela) with an 8 m spot. At the 12-week follow up, 65% of 51 treatment sites showed .75% clearance, and there was .50% clearance in an additional 22% of sites. Hyperpigmentation occurred in approximately one-third of patients, but resolved within 3 months. The dramatic response observed by Kauvar and Lou can be attributed to the safe use of higher laser energies afforded by the cryogen cooling (Sample Form 3 and Sample Form 4).
308
Slater, Newman, and McDaniel
Figure 13.4 (a) Leg veins pretreatment. (b) Three months after long-pulsed alexandrite laser and sclerotherapy showing postinflammatory hyperpigmentation which resolved by 5 months [from Ref. (19)].
6.
PSEUDOFOLLICULITIS BARBAE
Pseudofolliculitis barbae is a disorder in which short hairs curl over and reenter the skin leading to a foreign body inflammatory reaction. This condition can occur in all skin types, but is found most frequently among African Americans. Shaving is a predisposing factor. In early stages, the clinical presentation is follculitis-like with erythematous papules and pustules. In some chronic cases, keloid scarring, hyperpigmentation, and hypopigmentation may occur. Pseudofolliculitis barbae can be recalcitrant to traditional treatments of topical tretinoin, topical steroids, and topical and oral antibiotics. Permanent hair removal is the only definitive cure. Laser hair removal is currently being studied as an approach to this condition, and hopefully it will offer the advantages of better efficacy, safety, and efficiency over traditional forms of hair removal, such as surgical depilation and electrolysis. Nanni et al. (48) have published an abstract on successful treatment of pseudofollculitis barbae with a long pulsed alexandrite laser. Ten patients with pseudofolliculitis barbae and skin types IV or greater were treated with a 755 nm wavelength, 20 ms pulse duration, 12.5 mm nonoverlapping spot size, and fluences from 5 to 8 J/cm2.
Long-Pulsed Alexandrite Laser
309
Figure 13.5 Histology with H&E stain, 45 magnification, showing telangiectasia 5 days after long-pulsed alexandrite laser treatment: 20 J/cm2, 10 ms pulse duration, single pass with 10 mm spot size [from Ref. (19)].
Patients were treated at 4-week intervals for a total of six treatments. All subjects achieved at least a 50% reduction in lesion count and subjective symptoms. One-fourth had a 75% or greater reduction in the signs and symptoms of pseudofolliculitis. No long-term side effects occurred. Hair regrowth was delayed for 4 months but was permanently removed (48).
Figure 13.6 Histology with H&E stain, 10 magnification, showing telangiectasia 21 days after long-pulsed alexandrite laser treatment: 20 J/cm2, 10 ms pulse duration, single pass with 10 mm spot size [from Ref. (19)].
310
7.
Slater, Newman, and McDaniel
NEW HORIZONS
Further advances in leg vein therapy appears very promising in the near future. Other possible applications of the LPA include use for congenital nevi, as recently described by Kilmer. Use for smaller diameter veins, and perhaps use for scarring, are other potential applications. REFERENCES 1. 2. 3. 4.
5. 6.
7. 8. 9. 10.
11. 12. 13. 14. 15. 16.
17.
18. 19.
Pertusa C, Albisu A, Acha M, Blasco M, Llarena R, Arregui P. Lithotripsy with the alexandrite laser: our initial 100 clinical cases. Eur Urol 1991; 20:269– 271. Strunge C, Brinkmann R, Flemming G, Engelhardt R. Interspersion of fragmented fiber’s splinters into tissue during pulsed alexandrite laser lithotripsy. Lasers Surg Med 1991; 11:183 – 187. Neuhaus H, Hoffmann W, Zillinger C, Classen M. Laser lithotripsy of difficult bile duct stones under direct visual control. Gut 1993; 34:415 –421. Selman SH, Hampton JA, Morgan AR, Keck RW, Balkany AD, Skalkos D. Copper benzochlorin, a novel photosensitizer for photodynamic therapy: effects on a transplantable urothelial tumor. Photochem Photobiol 1993; 57:681 –685. Hampton JA, Goldblatt PJ, Selman SH. Photodynamic therapy: a new modality for the treatment of cancer. Ann Clin Lab Sci 1994; 24:203– 221. Svanberg K, Wang I, Colleen S, Idvall I, Ingvar C, Rydell R, Jocham D, Diddens H, Bown S, Gregory G, Montan S, Andersson Engels S, Svanberg S. Clinical multi-colour fluorescence imaging of malignant tumours—initial experience. Acta Radiol 1998; 39:2– 9. Jennett E, Motamedi M, Rastegar S, Frederickson C, Arcoria C, Powers JM. Dye-enhanced ablation of enamel by pulsed lasers. J Dent Res 1994; 73:1841 –1847. DeCoste SD, Farinelli W, Flotte T, Anderson RR. Dye-enhanced laser welding for skin closure. Lasers Surg Med 1992; 12:25 – 32. Fitzpatrick RE, Goldman MP, Ruiz Esparza J. Use of the alexandrite laser (755 nm, 100 nsec) for tattoo pigment removal in an animal model. J Am Acad Dermatol 1993; 28(5 Pt 1):745– 750. Zelickson BD, Mehregan DA, Zarrin AA, Coles C, Hartwig P, Olson S, Leaf-Davis J. Clinical, histologic, and ultrastructural evaluation of tattoos treated with three laser systems. Lasers Surg Med 1994; 15:364– 372. Fitzpatrick RE, Goldman MP, Dierickx C. Laser ablation of facial cosmetic tattoos. Aesthetic Plast Surg 1994; 18:91 – 98. Fitzpatrick RE, Goldman MP. Tattoo removal using the alexandrite laser. Arch Dermatol 1994; 130:1508 – 1514. Stafford TJ, Lizek R, Tan OT. Role of the alexandrite laser for removal of tattoos. Lasers Surg Med 1995; 17:32– 38. Alster TS. Q-switched alexandrite laser treatment (755 nm) of professional and amateur tattoos. J Am Acad Dermatol 1995; 33:69 – 73. Alster TS, Williams CM. Treatment of nevus of Ota by the Q-switched alexandrite laser. Dermatol Surg 1995; 21:592 –596. Rosenbach A, Williams CM, Alster TS. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg 1997; 23:239 –245. Lee PK, Rosenberg CN, Tsao H, Sober AJ. Failure of Q-switched ruby laser to eradicate atypical-appearing solar lentigos: report of two cases. J Am Acad Dermatol 1998; 38(2 Pt 2):314– 317. Finkel B, Eliezri YD, Waldman A, Slatkine M. Pulsed alexandrite laser technology for noninvasive hair removal. J Clin Laser Med Surg 1997; 15:225 – 229. McDaniel DH, Ash K, Lord J, Newman J, Adrian RM, Zukowski M. Laser therapy of spider leg veins: clinical evaluation of a new long pulsed alexandrite laser. Dermatol Surg 1999; 25:52 – 58.
Long-Pulsed Alexandrite Laser 20. 21.
22. 23.
24. 25. 26. 27. 28.
29.
30. 31. 32.
33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44.
311
Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. McDaniel DH, Lord J, Ash K, Newman J, Zukowski M. Laser hair removal: a review and report on the use of the long-pulsed alexandrite laser for hair reduction of the upper lip, leg, back, and bikini region. Dermatol Surg 1999; 25:425 – 430. Alora MBT, Anderson RR. Recent developments in cutaneous lasers. Lasers Surg Med 2000; 26:108 – 118. Nanni CA, Alster TS. A practical review of laser-assisted hair removal using the Q-switched Nd:YAG, long-pulsed ruby, and long-pulsed alexandrite lasers. Dermatol Surg 1998; 24:1399 – 1405. Ash K, Lord J, Newman J, McDaniel DH. Hair removal using a long-pulsed alexandrite laser. Dermatol Clin 1999; 17:387 – 399. Dierickx C, Alora MB, Dover JS. A clinical overview of hair removal using lasers and light sources. Dermatol Clin 1999; 17:357– 366. Connolly CS, Paolini L. Study reveals successful removal of unwanted hair with LPIR laser. Cosmet Derm 1997; 10:38 – 40. Boss WK Jr, Usal H, Thompson RC, Fiorillo MA. A comparison of the long-pulse and shortpulse Alexandrite laser hair removal systems. Ann Plast Surg 1999; 42:381– 384. Nanni CA, Alster TS. Efficacy of multiple hair removal sessions using the Q-switched Nd:YAG, long-pulsed ruby, and long-pulsed alexandrite laser systems (abstr). Lasers Surg Med 1998; (suppl 10):40. Nanni CA, Alster TS. Complications of laser-assisted hair removal sessions using the Q-switched Nd:YAG, long-pulsed ruby, and long-pulsed alexandrite laser systems (abstr). Lasers Surg Med 1998; (suppl 10):67. Nanni CA, Alster TS. Long-pulsed alexandrite laser-assisted hair removal at 5, 10, and 20 millisecond pulse durations. Lasers Surg Med 1999; 24:332 – 337. Goldberg DJ, Ahkami R. Evaluation comparing multiple treatments with a 2-msec and 10-msec alexandrite laser for hair removal. Lasers Surg Med 1999; 25:223– 228. Rogers CJ, Glaser DA, Siegfried EC, Walsh PM. Hair removal using topical suspensionassisted Q-switched Nd:YAG and long-pulsed alexandrite lasers: a comparative study. Dermatol Surg 1999; 25:844 – 850. Gorgu M, Aslan G, Akoz T, Erdogbrevean B. Comparison of alexandrite laser and electrolysis for hair removal. Dermatol Surg 2000; 26:37– 41. Raulin C, Greve B. Temporary hair loss using the long-pulsed alexandrite laser at 20 milliseconds. Eur J Dermatol 2000; 10:103– 106. Nanni CA, Alster TS. Laser-assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. J Am Acad Dermatol 1999; 41:165– 171. Ye JN, Prasad A, Trivedi P, Knapp DP, Chu P, Edelstein LM. Pili bigeminy induced by low fluence therapy with hair removal alexandrite and ruby lasers. Dermatol Surg 1999; 25:969. Garcia C, Alamoudi H, Nakib M, Zimmo S. Alexandrite laser hair removal is safe for Fitzpatrick skin types IV– VI. Dermatol Surg 2000; 26:130 – 134. Kolinko V, Littler CM. Mathematical modeling for the prediction and optimization of laser hair removal. Lasers Surg Med 2000; 26:164 – 176. Goldman MP. Sclerotherapy: Treatment of Varicose and Telangiectatic Leg Veins. 2nd ed. St. Louis: Mosby, 1995:118. Maurer K. Photoderm sclerolaser: light devices clear leg veins. Skin Allergy News 1997; 8. Apfelberg DB, Smith T, Maser MR, Lash H, White DN. Study of three laser systems for the treatment of superficial varicosities of the lower extremity. Lasers Surg Med 1987; 7:219– 223. Klenle A, Hibst R. Optimal parameters for laser treatment of leg telangiectasia. Lasers Surg Med 1997; 20:346– 353. McDaniel DH, Apfelberg DB. Options for laser selection in the treatment of cutaneous vascular and pigmented disorders and tattoos. J Dermatol Surg Oncol 1993; 19:312 – 319. Green D. Photothermal removal of telangiectasias of the lower extremity with the Photoderm VL. J Am Acad Dermatol 1998; 38:61 –68.
312 45. 46.
47. 48.
Slater, Newman, and McDaniel Weiss RA, Weiss MA, Goldman MP. Photothermal sclerosis of resistant telangiectatic leg and facial veins using the Photoderma VL. Lasers Surg Med 1996; 8:40– 41. Goldman MP, Martin DE, Fitzpatrick RE, Ruiz-Esparza J. Pulsed dye laser treatment of telangiectasias with and without subtherapeutic sclerotherapy. J Am Acad Dermatol 1990; 23:23 – 30. Kauvar AN, Lou WW. Pulsed alexandrite laser for the treatment of leg telangiectasia and reticular veins. Arch Dermatol 2000; 136:1371 – 1375. Nanni C, Brancacciio R, Cooperman M. Successful treatment of pseudo-folliculitis barbae with long-pulsed alexandrite laser irradiation (abstr). Lasers Surg Med 1999; (suppl 11):61.
Sample Form 1 LPA Laser for Hair Removal Consent Form The procedure planned is laser-assisted hair removal using a long-pulsed alexandrite laser. The purpose of this procedure is to diminish or remove hairs. This procedure may require one or more treatments and may not produce permanent hair removal. Alternative methods are electrolysis, other laser-assisted hair removals and various topical therapies, shaving, etc. I understand that the risks of this procedure include possible pain, infection, scarring, drug reactions or interactions or unforeseen complications. There is also a risk of mismatch in the color or the texture of the skin, temporary redness, hive-like reaction or bruising, brownish skin discoloration, activation of fever blisters (herpes), temporary increased susceptibility to sunburn or persistent pinkness for months. I understand that there is a possibility that this procedure will fail, be unsuccessful, need to be repeated, or may require additional treatment of complications. If tattooed “permanent” makeup or a “decorative” tattoo is in the area to be treated with laser hair removal, lightening of decorative tattoos, or blackening of makeup tattooing can occur. I understand my responsibility for properly fulfilling the appropriate aftercare instructions as explained by Dr. ______________________ , his nurse and/or any written or videotape instructions provided. Although part or all of the cost for this procedure may, in rare situations, be reimbursed by insurance companies, many policies/companies consider this procedure cosmetic or not covered for various other reasons. I understand that I am responsible for all costs whether or not covered by my insurance. I have been asked at this time whether I have any questions about this procedure, and I do not. I understand the procedure and accept the risks, and request that this procedure be performed on me by Dr. ______________________ , Physician’s Assistant, or one of his laser nurses, laser technicians, or other laser doctors.
Patient Name
Date of Surgery
Time of Surgery
Signature of Patient
Witness
Today’s Date
Long-Pulsed Alexandrite Laser
313
Sample Form 2 LPA Laser for Hair Removal Aftercare Instructions After Treatment: Hair should gradually fall out within seven to ten days; occasionally it takes up to two weeks. If desired, remaining hairs may be removed after 4 –5 days by GENTLY using a Loofa pad or a gentle exfoliating wash IF the skin is not irritated. Shaving or tweezing is permitted after one week. Things to Avoid: 1.
Do not apply harsh skin products for one week (astringents, alcohol, witch hazel, Retin-A, Renova, glycolic Acid (AHA) or similar products).
2.
Do not allow skin to become sunburned or go to tanning beds for two weeks before and after treatment.
3.
Do not bleach hair. Do not wax or tweeze 4 weeks before next treatment.
4.
Do not go in hot tubs, Jacuzzi, pool or ocean for one week to reduce chance of irritation or infection.
5.
If possible, do not apply makeup for 24 hours.
Things to Do: 1.
Use intermittent cold compresses or ice packs.
2.
Take Tylenol or Advil if uncomfortable.
3.
Aloe gel may also be applied to soothe skin.
If Blistering, Crusting, or Oozing Occurs: Apply hydrogen peroxide, then Polysporin or Bacitracin ointment and promptly call our office and speak to the doctor or nurse.
314
Slater, Newman, and McDaniel
Sample Form 3 LPA Laser (and Sclerotherapy) for Leg Vein Treatment Consent Form I acknowledge that I have had an in-depth discussion on vein sclerotherapy and/or laser treatment in layperson’s terms with my physician. I understand the techniques, the indication for and limitations of the procedure. I understand that complications which could occur include, but are not limited to, pain with injection or laser treatment, brown or white discoloration of skin, temporary muscle cramps, local or generalized allergic reaction, temporary ankle swelling, development of new fine veins around treated site, hair loss, lumpy feeling along the vein and even an open sore, infection or scar. Most of these problems are minor and will clear with proper treatment. If laser treatment is selected, there is also risk of accidental eye injury from the laser beam if I remove my protective eyewear. The infrequent occurrence of permanent skin discoloration, failure to improve, or unforeseen complications have been discussed. I understand that treatment may be performed with different solutions or various lasers. Dr. has discussed the advantages and disadvantages of each and the reason for selection of the method he believes is best suited for my individual circumstances. I understand that for 24 –48 hours the post-procedural course should not include: strenuous exercise (e.g., stairmaster, leg work) exercise classes (e.g., aerobics), heavy work, i.e. lifting or hauling, jogging, running and/or other types of leg movement over and above routine walking or working unless specifically approved or suggested by Dr. . If my profession is one that requires heavy work/exercise/activity, I understand it is strongly recommended that therapy be performed before a 1– 2 day period of off time, such as a weekend. I understand to obtain maximum benefits from treatment, the above regimen should be adhered to, and that very heavy exercise/work normally performed by me will be gradually re-introduced over a period of 2– 5 days. I also realize dressing or pressure stockings (which may be applied after the procedure in selected patients) may be infrequently recommended in very specific cases and should be considered part of the post-procedural course, because they aid in achieving the best results. Although part of all of the costs for this procedure is still occasionally reimbursed by insurance companies, most policies/companies may consider the procedure cosmetic or not covered for various reasons. I understand that I am responsible for all costs not covered by my insurance. Since multiple treatments are usually required, this consent continues for subsequent treatments by Dr. regardless of the time between treatments. I have been asked at this time whether I have questions about this procedure, and I do not. I understand the procedure and accept the risks, and request that this procedure be performed on me by Dr. .
Patient Name
Date of Surgery
Time of Surgery
Signature of Patient
Witness
Today’s Date
Long-Pulsed Alexandrite Laser
315
Sample Form 4 LPA Laser/Sclerotherapy for Leg Veins Aftercare Instructions 1.
Most patients may return to work immediately or the next day; however, it is recommended to avoid strenuous activities for 24 hours if possible (e.g., Aerobics, running, biking, etc.)
2.
Some redness, burning or very mild ankle swelling is normal in first 24 hours. Report any increasing redness, warmth or tenderness after 24 hours to our office immediately.
3.
Avoid aspirin products one week before and 3 –4 days after treatment (Tylenol two hours prior to treatment will help alleviate discomfort).
4.
Avoid sun exposure for 24 hours; avoid tanning beds for at least one week before and after treatment.
5.
Continue usual skin care except avoid sunburn. Do not use tanning beds for at least one week before and after treatment.
6.
Do not wax, use depilatories or have electrolysis performed without our prior approval.
7.
Call us for special instructions if any blisters form.
8.
Use of compression stockings for up to 7 days after treatment may be useful in some cases (your doctor will advise you if these are suggested).
Even very limited use of tanning beds now appears hazardous to your health. We advise to NEVER use tanning beds. The discussion of tanning beds is only because we acknowledge their frequent usage.
14 Diode Lasers Murad Alam and David A. Wrone Northwestern University, Chicago, Illinois, USA
Beatrice Berkes Loma Linda University, Loma Linda, California, USA
1. Introduction 2. Background and Scientific Basis 3. Indications: Efficacy, Technique, and Potential Complications 3.1. Pulsed Diode Lasers (800 nm) 3.1.1. Hair Removal 3.1.2. Pseudofollicultis Barbae 3.1.3. Leg Veins 3.1.4. Other Vascular Lesions 3.1.5. Pigmented Lesions 3.2. Bare Fiber Diode Lasers (800 nm) 3.2.1. Saphenous Vein Closure 3.3. Diode Laser (1450 nm) 3.3.1. Nonablative Rejuvenation 3.3.2. Acne 3.4. Research Applications of Diode Lasers 3.4.1. Photodynamic Therapy 3.4.2. Laser Tissue Soldering 3.4.3. Wound Healing 3.4.4. Squamous Cell Carcinoma (SCC) 3.4.5. Imaging 4. Conclusions References
1.
317 318 319 319 319 325 325 326 326 326 326 327 327 328 329 329 329 330 330 330 330 331
INTRODUCTION
Diode lasers are small semiconductors (1,2). They have no moving parts, and since they are extremely energy efficient, minimal cooling needs. Such devices are durable, and can function for very long periods. 317
318
Alam, Wrone, and Berkes
There is some variability in the wavelength, frequency, and pulse parameters of diode lasers. Commonly used emission wavelengths include 800, 940, and 1450 nm. Most devices in dermatologic use emit at approximately 800 nm, which is a physiologically useful output. This wavelength is less well absorbed by melanin than are shorter wavelengths, and coincides with a small peak of hemoglobin absorption that permits the treatment of vascular lesions. Available since 1962, diode lasers have only recently been adapted for medical use. At present, 800 nm diode lasers are used most commonly for hair removal. Diode-pumped, frequency-doubled Nd:YAG lasers (532 nm) are used for the treatment of fine facial telangiectasia. Leg veins may be treated with variable efficacy with diode lasers in the 800 – 950 nm range. Longer wavelength diode lasers, specifically the 1450 nm lasers, are used for nonablative reduction of fine periorificial wrinkles, as well as for treatment of active acne. Investigational research applications of diode lasers include photodynamic therapy of cutaneous malignancies, laser welding, and facilitation of wound healing. These and other indications are detailed below.
2.
BACKGROUND AND SCIENTIFIC BASIS
Along with gas lasers and solid-state lasers, diode lasers are one of major classes of lasers available today (Table 14.1) (3). Like most other lasers, diode lasers include an optical gain medium in a resonant optical cavity. Diode lasers are different from these other types primarily in their capacity to be directly pumped by an electric current. This process tends to culminate in more efficient operation. Power conversion efficiencies approaching or exceeding 50% are not unusual for a diode laser, while efficiencies approximating 1–10% are closer to the norm for gas and solid-state lasers, which are typically pumped by plasma excitation or incoherent optical flashlamp source, respectively. Given their longer cavities and more narrow gain bandwidth, gas and solid-state lasers do, however, usually have more coherent outputs than simple semiconductor lasers. More advanced single-frequency diode lasers can have linewidths in the low megahertz range, as do the other classes of lasers. The crucial components of diode lasers are much smaller than those of other types of laser devices. Gas and solid-state lasers are typically many tens of centimeters in length, but diode laser chips are about the size of a grain of salt. Packaging and containment results in an overall size increase to approximately 1 cm3. Another characteristic of diode lasers that has led to their ubiquitous use is their high level of reliability. The useful lifetime of gas or solid-state lasers may be thousands of hours, but finely constructed and mounted diode lasers have useful lifetimes measured in centuries. Table 14.1
Listing of Available Lasers
Laser Lightsheer Palomar SLP1000 Opus Medical F1 MedArt R 435 MedDioStar HC/C Dornier Medilas D Candela Smoothbeam
Wavelength (nm)
Fluence (J/cm2)
Spot sizes (mm)
Pulsewidth (ms)
Pulse rate (Hz)
Cooling
800 810 810 810 810 940 1450
10–60 Max 574 Max 21 –40 90 W (power) Max 64 Max 100 Max 8– 25
9, 12 (square) 4, 8, 12 (round) 5, 7 1–8, scanner 10, 12, 14 0.5–6 4, 6
5–100 50–1000 15–40; XLP 50–1000 Variable 200–2000 250
up to 2 up to 3 up to 4 Variable up to 4 up to 5 1
Contact Contact Contact Contact Contact Contact DCD
Diode Lasers
319
Crystal structure within diode lasers consists of gallium arsenide, which may be doped with an additional element, such as aluminum or silicon. Passage of electric current through a single diode results in emission of light from its edge or surface. Multiple-diode lasers arrayed in lines or two-dimensional formats can replace flashlamps in the pumping of solid-state lasers. Indeed, the use of diode laser to pump solidstate lasers, as in the case of the diode-pumped Nd:YAG (see chapter on pulsed KTP lasers), is one of the most successful recent applications of diode lasers. Such pumped lasers provide the best advantages of both technologies.
3.
INDICATIONS: EFFICACY, TECHNIQUE, AND POTENTIAL COMPLICATIONS
3.1. 3.1.1.
Pulsed Diode Lasers (800 nm) Hair Removal
The most common dermatologic application of the long-pulse diode laser is hair removal. In general, the treatment technique resembles that for other lasers, including the ruby laser (694 nm), the alexandrite laser (755 nm), the intense pulsed light source (590 –1200 nm), and the neodymium:yttrium –aluminum-garnet (Nd:YAG) laser (1064 nm), used for the same purpose. The 800– 810 nm diode laser also operates on the principle of selective photothermolysis of the melanin in the hair follicles. Multiple treatments at approximately 1 month intervals are required [Figs. 14.1(a)– (c)] and dark hair on light skin is treated most safely and effectively (Figs. 14.2 – 14.5).
Figure 14.1 (a) Picture of hairs (close up) before removal (dark hairs, light skin). (b) Picture of hairs (close up) after three treatments (30– 40% reduction). (c) Picture of hairs (close up) after six treatments (60 – 70% reduction, and residual hairs slightly lighter and thinner).
320
Figure 14.2
Alam, Wrone, and Berkes
Picture of optimal candidate: very fair skin, dark black hair.
Mechanism. The mechanism for diode laser hair removal has been described in some detail. The target chromophore is melanin, which is found mostly in the epidermis, hair bulb, hair shaft, and bulge region and absorbs radiation at 300– 1200 nm (4 –10). For effective hair removal, the optimal laser beam for hair removal should penetrate 2 – 7 mm into the skin to encompass the entire follicle, specifically destroying the dermal papilla and the bulge region (11,12). Anagen hairs are believed to be most susceptible to laser injury, given that in the anagen phase stem cells migrate from the bulge to the dermal papilla,
Figure 14.3
Picture of suboptimal candidate: type II– III skin, brown hair.
Diode Lasers
Figure 14.4
321
Picture of suboptimal candidate: type IV – V skin, black hair.
where new hair is synthesized (13). The average depth of the anagen dermal papilla varies based on anatomic region, and may be 1 –4.7 mm deep, or commonly 2.5 –4 mm deep on the legs (13). For hair removal to be selective, thermal damage must be restricted to the follicle to prevent nonspecific tissue injury (15,16). Provided the pulse width is longer than the thermal relaxation time (TRT) (17) of adjacent structures but shorter than the TRT of hair follicles (40 –100 ms, for terminal hair follicles 200– 300 mm in diameter), the
Figure 14.5
Picture of suboptimal candidate: type I– II skin, blonde hair.
322
Alam, Wrone, and Berkes
follicles can be heated beyond their thermal damage threshold while the surrounding epidermis and other tissues are relatively spared (18). A pulse duration in excess of the TRT of epidermis (3 – 10 ms) permits heat extraction from the skin surface during the laser firing (19). Q-switched lasers with exceedingly brief nanosecond pulse durations typically have been unable to produce permanent hair loss due their inability to induce terminal disruption of the follicle. Very long pulse durations permit greater heat diffusion into the hair shaft and bulb, thus inducing more even heat distribution, but if pulses are much longer than the TRT, the effective volume that is heated will exceed the bounds of the hair unit targeted (11). Epidermal cooling during laser use not only decreases discomfort but also protects the epidermis from thermal damage, allowing higher fluences to be used (11). The most common cooling modalities with the long-pulse diode laser are the actively cooled sapphire window or the pulsed cryogen spray. Dermal compression achieved with the cooled window may decrease the distance to the hair bulb and partially exclude blood during treatment. For hair removal, larger spot sizes have been recommended to make it easier to avoid undesirable overlapping and because larger surface areas, such as backs, may be covered faster (16). The ideal exposure spot for hair removal has been postulated to be 10 mm or greater in diameter (11). Radiation from the 800 nm diode laser is 30% less absorbed by melanin than the 694 nm ruby laser, but optical penetration into the dermis is superior with the former device as light penetration increases with wavelength to a maximum of approximately 1000 nm (20,21). In addition to being associated with less epidermal absorption than the ruby, the diode is associated with less water absorption than the Nd:YAG laser (13). Overall, the 800 nm wavelength is poorly absorbed by water. For darker skinned patients, longer wavelength lasers, such as the Nd:YAG may be preferable to the diode since longer wavelengths are less absorbed by melanin and less likely to cause epidermal damage (22). Efficacy. There have been several small- to medium-sized studies to investigate the efficacy of the diode laser for hair removal. Most of these have been performed with 800 –810 nm devices (4,13,16,17,20,22 –28). One to four treatments have been typically delivered usually to patients with Fitzpatrick skin types I–IV, and fluences and follow-up periods have varied. Table 14.2 lists the parameter selection based on skin Table 14.2 Treatment Parameters (Hair Removal/Lightsheer): Parameter Selection as a Function of Skin Type (9 9 Spot) Initial fluence (J/cm2)
Fluence range (J/cm2)
I
40
15 – 60
II
35
15 – 60
III
30
10 – 45
IV
20–25
10 – 40
15–20 10–15 One level darker than patient type
10 – 35 10 – 30 —
Fitzpatrick type
V VI Tanned skin (all types)
Pulse duration Auto 30 ms if high density Auto 30 ms if high density Auto—finer hair 30 ms—coarser, denser 30 ms—finer hair 100 ms—coarse, dense 100 ms 100 ms 100 ms
Diode Lasers
323
type. Outcome parameters have ranged from physical to photographic comparison, often by blinded observers, as well as serial hair counts. While methodologies and results have varied, some general conclusions can be offered (11,29,30). Growth delay or degree of permanent reduction of hair appears associated with the peak fluence of individual treatments as well as the number of treatments. As the time from the last treatment increases, so does regrowth, with a corresponding reduction in the degree of hair reduction. Histologically, even when severe hair unit damage is observed, hairs are seen in some cases to regenerate, presumably because part of the bulge apparatus was inadvertently preserved. Another factor limiting the hair removal benefit of individual treatments is that only hairs in anagen phase are generally considered vulnerable to permanent laser hair removal. This has led to the recommendation that tweezing or waxing be eschewed for several weeks prior to laser treatments, but some new data suggests that this may not be necessary to ensure efficacy (Fig. 14.6) (31). Thinner, lighter hairs are less effectively treated since the small diameter and low endogenous melanin results in quick cooling and insufficient injury. Conversely, coarser dark hairs that are not completely destroyed may become finer and lighter after treatment. See Table 14.3 for parameter selection as a function of hair type. Hair removal using the diode laser has been compared to similar laser procedures with other devices. In two studies of the long-pulse diode vs. the long-pulse alexandrite laser, three to four treatments with each device resulted in approximately equivalent immediate and long-term hair reduction, as well as similar histologic findings, in patients with skin types I– IV (16,25). An additional study found that the alexandrite laser for this laser was less painful than the diode, but the pain from each treatment was reduced by preapplication of topical 5% lidocaine cream to the relevant skin area (28). Different results may be the norm in darker-skinned patients. Diode lasers (810 nm) with super long pulse (SLP) durations (200 –1000 ms) may be particularly effective in treating African-American patients (23) and types II – IV patients with suntans (32). There is some evidence to indicate that even the less long pulse durations (e.g., 100 ms
Figure 14.6 Starting several weeks before treatment and continuing until the end of the laser hair removal treatments, patients typically refrain from plucking and waxing hairs, although new evidence suggests this may not be necessary. Clipping and shaving hairs during the laser treatment course has always been deemed acceptable.
324
Alam, Wrone, and Berkes
Table 14.3 Treatment Parameters (Hair Removal/Lightsheer): Parameter Selection as a Function of Hair Type (9 9 Spot) Hair Light to medium brown Fine to medium diameter Light to medium brown Fine to medium diameter Dark brown to black Fine to medium diameter Dark brown to black Fine to medium diameter Dark brown to black Dark brown to black Light to dark brown Medium to large diameter Light to dark brown Medium to large diameter
Skin I –III
Hair density
Pulse duration
I –III
Lower density: axilla trunk, pubic, leg Higher density: cheeks upper lip, beard, chin Low and high density
Auto or 30 ms
I –III
Low and high density
Auto or 30 ms
IV IV V, VI
Low and high density Low and high density Low and high density
30 ms 30 or 100 ms 100 ms
Tanned
Low and high density
100 ms
I –III
Auto Auto or 30 ms
in a laser with 30– 100 ms range) may be safely used to treat patients with skin types V and VI, but postoperative complications may result (33). Far Eastern and Indian patients may likewise benefit from long-pulse lasers, although at least one study showed equivalent efficacy in hair reduction with normal pulse diode 800 nm diode laser and Nd:YAG laser for Chinese patients (22). Potential Complications. Unavoidable effects during treatment include mild pain or discomfort, followed by transient erythema and perifollicular edema that may last up to 24 h (Fig. 14.7). Other side effects (4,17,20,23,25,26,28,34) are more common at high fluences or in patients with relatively dark skin types. Vesiculation, blistering, erosions,
Figure 14.7 Perifollicular edema (goosebumps) and erythema right after laser (no hairs visible because they were shaved before laser treatment).
Diode Lasers
325
ulcerations, and crusting can occur in the short term, and these may culminate in longerlasting textural changes. Scarring is uncommon. More frequently, significant epidermal injury may lead to hyperpigmentation or hypopigmentation, which will almost always resolve within 6 months. Urticaria has been reported, and there is at least one report of urticarial vasculitis, possibly associated with the laser wavelength or the type of cooling used (34). Of course, a potential undesirable result is inadequate hair removal, or hair regrowth months to years after the last treatment. This problem may be remedied by more treatments, use of higher fluences or change of other parameters, and by substitution of the diode with another laser. For hair removal, the diode laser appears to be less painful than the Nd:YAG one (22,35). 3.1.2.
Pseudofollicultis Barbae
Pseudofolliculitis barbae, so-called “razor bumps,” have been treated with the 800 – 810 nm diode laser (17,36,37). The mechanism here appears to be hair removal, after which ingrown hairs and the resulting inflammatory, hyperpigmented, painful nodules are less likely. Multiple treatments at 4– 6-week intervals may reduce the incidence of pseudofolliculitis-associated papulopustules by 75%. There is variation among the recommended treatment settings, which range from 30– 38 J/cm2 and 20 ms pulse duration, to 10 J/cm2 at 30 ms (36,37). Black patients with pseudofolliculitis barbae may require up to 7 –10 treatments each, and pre- and posttreatment with 4% hydroquinone may be necessary to mitigate hyperpigmentation caused by the laser. During the treatment process, clear aloe vera gel (green-tinted gel is recognized as pigment and may burn the skin) can facilitate gliding of the handpiece over the skin, reduce friction trauma, and clear carbonated hair fragments from the lens. 3.1.3. Leg Veins While the diode laser is not commonly considered the most effective laser for the treatment of leg veins, it has been used for this purpose. At present, intense-pulsed light devices, pulsed-dye lasers, and most promisingly, Nd:YAG lasers, are more frequently employed in the treatment of small telangiectasia and medium-sized reticular veins of the legs. Efficacy. There are some data to confirm the efficacy of the long-pulsed diode for the treatment of leg veins. The 810 nm diode with super long pulse and sapphire-window cooling has been used to address smaller veins on the upper thighs and lower legs as well as larger reticular veins in the lower thigh and upper calves (38). Two treatments 4 – 6 weeks apart resulted in inconsistent but occasionally impressive outcomes, with 29% of the diode laser sites showing greater than 75% improvement, compared with 33% and 88% of the alexandrite laser and Nd:YAG laser sites, respectively, manifesting a commensurate degree of benefit. The 940 nm diode laser has also been reported to be successful for the treatment of leg veins (39). One report noted a greater than 50% clearance of vessels in 75% of subjects with a fluence of 300 – 350 J/cm2 using a single pass of a 1 mm spot at pulse width of 40 – 70 ms; at 815 J/cm2 and 50 ms using a 0.5 mm spot, greater than 75% improvement was noted in all subjects. Potential Complications. Short-term side effects after diode laser vein treatment include mild to moderate pain, urtication, and blurring of the treated vessels, all of which usually resolve within 24 h (38 –41). Hemosiderin deposition, especially in larger vessels, can culminate in hyperpigmentation along vessels (38). This can develop slowly and persist for weeks or months before gradually resolving. Hypopigmentation along the treated vessels, slight superficial textural changes, telangiectatic matting, and
326
Alam, Wrone, and Berkes
significant inflammation have also been reported. Telangiectatic matting may be less of a problem with the diode than with the alexandrite or Nd:YAG lasers (38). However, compared to radiofrequency (RF) endovenous treatment, diode fiber treatment appears more likely to induce vessel wall perforations that permit fluid extravasation after treatment; additionally, the peak temperatures attained during laser fiber treatment can approach 10008C while RF peaks remain below 1008C (41). 3.1.4.
Other Vascular Lesions
Mechanism. The vascular effect of the diode laser derives from the relatively deep penetration of long wavelength visible and near infrared light into the skin. Moreover, there is a small peak of hemoglobin absorption at 800– 900 nm (42,43). Efficacy. Spider veins to moderately deep larger reticular veins may be susceptible to 800, 810, 930, and 940 nm diode laser energy. Indeed, relatively larger vessels may respond better (42,43). The diode-pumped frequency-doubled 532 nm Nd:YAG laser is commonly used for the treatment of fine facial telangiectasia (44). This is a safe and effective device that can trace away fine vessels without the induction of purpura. Larger vessels on the nose or cheeks will often not resolve, and other vascular lasers, such as the pulsed-dye, or the intense-pulsed light device may be indicated if the further improvement is desired. 3.1.5.
Pigmented Lesions
The long-pulse diode laser is not the gold-standard for the treatment of pigmented lesions. In general, the most conservative authorities recommend that nevi and other structures potentially capable of malignant transformation not be deliberately treated with laser light, as this may theoretically induce atypia. Lentigines and tattoos, on the other hand, are most frequently treated with nanosecond domain Q-switched lasers. Efficacy. In one study assessing alternative treatments for solar lentigines, the diode-pumped 532 nm laser was compared to liquid nitrogen, the frequency-doubled Q-switched Nd:YAG 532 nm laser, and the krypton laser (521 and 530 nm) (45). While all the lasers were found to be superior to liquid nitrogen, the Q-switched device was associated with the least pain, erythema, and time to complete healing. The diodepumped laser was judged the second most effective modality. Potential Complications. Inadvertent treatment of nevi is possible during hair removal with the diode laser. Investigators noted new-onset clinical atypia without inflammation in preexisting nevi 1 month after patients underwent two laser hair treatments with the 810 nm device (46). Upon biopsy, the atypical nevi were found to be histologically similar, displaying subepidermal blisters and elongation and disruption of nevus cells. Only small foci of nevus cells could be identified in some specimens, all of which had homogenization of papillary dermal collagen. 3.2. 3.2.1.
Bare Fiber Diode Lasers (800 nm) Saphenous Vein Closure
Bare diode fibers have also been threaded into leg veins in interventional procedures designed to collapse these veins. In one study, an 810 nm sterile bare-tipped laser fiber was placed into vessels via percutaneous or stab wound incisions (40). Energy was delivered endovenously 1– 2 cm below the saphenofemoral junction and along the course of the greater saphenous vein while the fully advanced catheter was withdrawn in 3– 5 mm tugs.
Diode Lasers
327
Ten to 14 W were delivered in 1– 2 s bursts, treatment was followed by the wearing of class II (30 – 40 mmHg) support stockings, and sclerotherapy was used to treat the remaining branch varicosities after closure of the greater saphenous vein. The authors reported 100% short-term efficacy of the laser technique. In comparison with endovenous occlusion using RF energy aimed at sapheno-femoral reflux, laser occlusion of varicose veins appears relatively less efficacious. When an 810 nm bare-tipped diode fiber and a RF device were used on three goat jugular veins, the diameter of the lasered vessels was reduced by 26%, vs. 77% shrinkage with RF application (41). The technique of endoveneous laser therapy (EVLT) is obviously more complex than use of a standard out-of-the-box 800 – 810 nm diode laser (41). The bare-tipped optical fiber used is typically 600 mm in diameter, the target vein is compressed with tumescent anesthesia prior to entry to exclude intravenous blood as a chromophore, placement may be facilitated with duplex ultrasound guidance, and brief pulses are delivered as the fiber is pulled out at a steady rate.
3.3.
Diode Laser (1450 nm)
The 1450 nm diode laser is a 14 W device (Smoothbeam, Candela Corp, Wayland, MA) that also emits in the mid-infrared range. In investigational protocols, pulse widths of 160 – 260 ms have been used with a repetition rate of 0.5 –1.0 Hz. Cooling is via a dynamic cooling device (DCD), and laser energy is delivered through a 4 or 6 mm spot size (47).
3.3.1. Nonablative Rejuvenation Nonablative laser resurfacing is a process in which the epidermis is left grossly intact and the dermis is selectively heated by laser light so as to yield increase in collagen deposition and subjective improvement in the appearance of photodamaged skin. Efficacy. Very little published research is available regarding the nonablative efficacy of the 1450 nm diode laser, which is marketed as a nonablative device. An early report (48) indicated that the 980 nm diode laser emitting at 25 W, at a pulse duration of 400 ms, and 1 Hz, successfully treated in vitro breast and facial skin in a nonablative manner. Tissue shrinkage was immediately apparent after treatment, and new collagen formation was demonstrated by histology after 21 days. The epidermis was not visibly ablated. More recently, nonablative resurfacing of facial rhytides has been achieved with the 1450 nm diode laser, which is now the diode laser of choice for this indication (47). Goldberg et al. (47) in a recent study involving 19 women and 1 man, who collectively spanned Fitzpatrick skin types I– IV, and ranged in age from 42 to 70 years, treated Glogau class I and class II rhytides. In 12 subjects, the treated rhytides were perioribital, and in the remainder, they were perioral. Two to four treatment sessions, at 1-month intervals, were performed for each patient. Unfortunately, Goldberg et al., do not provide any treatment parameters such as fluence, pulse width, repetition rate, or number of passes. Outcome measures were pre- and postoperative photography, pre- and postoperative optical profilometry, and clinical assessment. Seven of 20 patients showed no obvious improvement after treatment, 10 experienced mild improvement, and 3 had moderate improvement at the sites of their laser-treated rhytides. Clinical improvement was correlated with optical profilometry findings but not with the number of treatments. Perioral sites were least improved.
328
Alam, Wrone, and Berkes
Additional studies are apparently in preparation. Tanzi and Alster (49 –51) describe studies in which they have found randomized patients to receiving treatment to either the left or the right sides of their faces, with the contralateral side serving as a control. A study of 20 patients has examined treatment of transverse neck lines, and outcome measures have included blinded rater assessment as well as in vivo microtopography (PRIMOS Imaging System; GFM, Germany). In this investigation, mean fluences of 11.6 J/cm2 were used with a 6 mm spot and cooling settings of 10 ms of precool, 20 ms of intracool, and 20 ms of postcool. According to Tanzi and Alster, the treated sides experienced clinical and histologic improvement of rhytides, with periorbital rhytides improving more than perioral rhytides. Three-dimensional in vivo microtopography confirmed this clinical finding. For the treatment of atrophic facial scars, 1450 nm diode laser has been compared to 1320 nm Nd:YAG laser, according to a pending study of 20 patients in which the diode treated side received fluences of 9– 14 J/cm2 via nonoverlapping 6 mm spots during a single pass. Possibly, the 1450 nm laser may be superior to the 1320 nm Nd:YAG device for nonablative treatment of atrophic facial scars. Potential Complications. Immediate erythema almost always occurs after nonablative use of the 1450 nm laser for treatment of facial rhytides. This can vary from mild to severe and may be concomitant with the emergence of small edematous papules, lasting 1– 7 days, which were first noted by Goldberg et al. (47). Postinflammatory hyperpigmentation is rare, and hypopigmentation, persistent erythema, and scarring are not reported. Overall, nonablative resurfacing is considered a “lunchtime” procedure, with rapidly resolving erythema and edema that is camouflaged by cosmetic cover-up. 3.3.2. Acne The 1450 nm laser has also been used for treatment of active acne. Acne treatment can be considered an extension of the nonablative applications of this laser since the mechanism, directed dermal injury, appears to be the same. Specifically, acne appeared improved following the laser-induced necrosis of sebaceous glands. Efficacy. Acne treatment with the 1450 nm device has been reported in studies that have targeted back acne. After recruiting 27 male subjects with back acne, Paithankar and colleagues (53) randomized a 36 cm2 area on one side of each back to be the treatment site, with an equivalent-sized area on the other side serving as a control treated with cryogen alone. Four treatments spaced 3 weeks apart were administered to the entire treatment sites, rather than to just where acneiform papules had been marked. The average treatment fluence was 18 J/cm2. Apart from clinical assessments, outcome measures included lesion counts and skin biopsies immediately after treatment, and at 6, 12, and 24-week follow-up visits. Paithankar et al. (53) found a statistically and clinically significant reduction in acne lesion counts after treatment, and the mean reduction was five or more lesions. Fourteen of the 15 patients completing their 24-week follow-up had no residual acne lesions on their treated areas. Histologic findings were epidermal preservation but rupture of the pilosebaceous unit and thermal coagulation of the sebaceous lobule and follicle. Given the low density of sebaceous glands on the back, these changes were not observed in many biopsy samples. The authors report that long-term follow-up biopsies of similarly treated back and face skin showed no difference from baseline in adnexal structures, including sebaceous glands and follicles. Significantly, research with shorter pulse (810 nm) diode lasers used in combination with indocyanine green (ICG) dye has indicated similar transient necrosis of sebaceous glands followed by long-term improvement
Diode Lasers
329
of acne (54). The underlying mechanism of epidermal sparing and dermal injury is consistent with the nonablative paradigm and different from aminolevulinic acid (ALA)-photodynamic therapy (PDT) and other laser/light based acne treatments that achieve their effect by depopulating P. acnes. Further studies of the treatment of facial acne are under way. Potential Complications. After the use of this laser for nonablative treatment of acne, side effects are similar as for the nonablative rejuvenation indication (15). The hallmarks are erythema and edema, with mild to severe hyperpigmentation in about 10% of subjects. Purpura and scarring are not seen.
3.4. 3.4.1.
Research Applications of Diode Lasers Photodynamic Therapy
One use of the diode laser is as the light source in the PDT of nonmelanoma skin cancers and other cutaneous malignancies (55) (see chapter on PDT). Diode lasers with wavelengths ranging from 600 to over 800 nm have been employed for this purpose, and some unusual treatment protocols have been attempted. For instance, pretreatment with the 1064 nm Q-switched Nd:YAG laser may enhance the susceptibility of melanoma to conventional photodynamic therapy with the 774 nm diode laser and injected Si(IV)-naphthalocyanine (56). At a fluence of 100 J/cm2, the 805 nm diode has also been demonstrated to be effective in the photodynamic therapy of AIDS-associated Kaposi’s sarcoma using ICG dye as the photosensitizer (57). Cutaneous Kaposi’s patients can expect blistering and crusting to heal within 2 weeks, after which they may have residual hyperpigmentation and an atrophic scar. Remissions have been noted to last at least 2 years (58). Other diodes used in photodynamic therapy include the 652 nm laser (59,60). 3.4.2.
Laser Tissue Soldering
Mechanism. Laser-assisted tissue soldering entails concurrent use of diode laser light and a solder mixture, including human albumin, hyaluronic acid, and ICG dye, that was developed at Columbia University (61,62). ICG is a tricarbocyanine dye with peak absorption between 780 and 805 nm (63,64). Efficacy. Some investigators have found that laser tissue soldering is effective for the closure of skin wounds. In one experiment, suturing was found to be faster than soldering, but tensile strength of the soldered wounds was immediately equivalent to that of sutured wounds at 7– 10 days (61). At 14 days, the laser soldered wounds continued to be stronger than the sutured sites, and no thermal injury or foreign body reactions marred the soldered areas. Another study observed little benefit to increasing ICG concentration during the soldering process, with wound tensile strength being more a function of laser power density (65). While higher fluences were associated with more secure closure, very high fluences also increased thermal damage, possibly compromising day 10 tensile strength. Indeed, high fluences may permit the laser solder process to function as an ablative modality comparable to CO2 laser for the removal of superficial cutaneous lesions (63). Laser-assisted closure may be useful even if solder is not used. When, after wounds were closed with deep sutures, superficial closure was attempted by either laser-assisted skin closure using an 815 nm diode laser or by the insertion of superficial sutures, the lasered wounds were treated more quickly, healed faster, developed better scars, and
330
Alam, Wrone, and Berkes
demonstrated greater tensile strength (66). The dearth of studies in this area suggests the need for more research to verify these results. 3.4.3.
Wound Healing
There have been reports that recurrent application of low-power diode laser energy can facilitate local wound healing. Six treatments from postoperative day 8 to day 26 with a 830 nm diode laser having a 0.03 cm2 spot size and fluence range of 0.5– 2.0 J/cm2 were reported to improve survival of skin grafts threatened by hematomas (67). Similarly, laser irradiation for 6 min per day for five consecutive days apparently increased survival of skin flaps in experimental subjects compared to controls (68). The mechanism is not understood but possibly laser stimulation of vessel proliferation may occur. Another low power (1.5 W) 815 nm diode laser system was found to induce expression of heat shock protein in rat skin, with this potentially contributing to tissue regrowth and rapid wound healing (69). A schedule of 12 daily and alternate day treatments with a 904 nm diode laser have been noted to result in diminished musculoskeletal discomfort associated with injuries and degenerative processes (70). Similar beneficial results have been seen with the joint application of diode laser and hyperbaric oxygen therapy in ischemic and diabetic wounds in rats, as well as in acute and chronic wounds in humans, including children, crew members on a submarine, and Navy SEAL team personnel (71). When surgical incisions are made with the diode laser, at 7, 14, and 21 days postinjury, the tensile strength of these healing wounds is less than that of similar incisions made with a scalpel (72). Laser incisions have more inflammation, a lag in fibroblast invasion, and delayed collagen production. 3.4.4.
Squamous Cell Carcinoma (SCC)
PDT for skin cancers has been performed with diode lasers, and is discussed extensively elsewhere in this book. Additionally, there is a single report (73) of diode laser used in direct treatment of cutaneous SCC. Specifically, multiple passes of carbon dioxide laser were used to debulk a 5 mm margin around visible SCC, and then a final pass with the 810 nm diode laser at 60 J/cm2, 30 ms pulse duration, and with a 9 9 mm spot size was used to remove hair follicles at the periphery. Follicular necrosis at the wound edges was confirmed by skin biopsy. The authors suggested that concurrent use of the diode laser may optimize the cure rate of SCC in nonglabrous skin. 3.4.5.
Imaging
Diode lasers can be used for skin imaging. A sensor mounted on a movable table can analyze healing wounds in a three-dimensional format which permits calculation of the lesion volume (74). Estimation of burn depth in burn wounds can also be performed with a diode laser (75). After the injection of ICG dye into the affected site, illumination with a 785 nm diode laser has been found to demonstrate a burn depth that correlates well with histology. 4.
CONCLUSIONS
While the diode laser is most commonly used for hair removal, it has been successfully applied to the treatment of vascular lesions, including leg veins. Data on the efficacy and safety profiles of less common indications is limited. Given current trends, nonablative resurfacing is likely to become a major application in the future.
Diode Lasers
331
REFERENCES 1. 2.
3. 4. 5. 6. 7. 8. 9.
10. 11. 12.
13. 14. 15. 16. 17. 18. 19. 20. 21.
22.
23.
24. 25.
Dover JS, Arndt KA, Geronemus RG, Alora MB, eds Introduction to lasers. In: Illustrated Cutaneous & Aesthetic Laser Surgery. New York: McGraw-Hill, 1999. Grevelink JM, Ross EV, Anderson RR. Lasers in dermatology. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds. Fitzpatrick’s Dermatology in General Medicine. New York: McGraw-Hill, 1999:2901 – 2921. Coldren LA, Corzine SW. Diode Lasers and Photonic Integrated Circuits. New York: John Wiley & Sons, 1995:1– 25. Baugh WP, Trafeli JP, Barnette DJ Jr, Ross EV. Hair reduction using a scanning 800 nm diode laser. Dermatol Surg 2001; 27:358– 364. Margolis RJ, Dover JS, Polla LL. Visible action spectrum for melanin-specific selective photothermolysis. Lasers Surg Med 1989; 9:389 – 397. Ross EV, Ladin Z, Kreindel M, Dierickx C. Theoretical considerations in laser hair removal. Dermatol Clin 1999; 17:333 – 355. Sun TT, Cotsarelis G, Lavker RM. Hair follicular stem cells: the bulge activation hypothesis. J Invest Dermatol 1991; 96:577 – 578. Lavker RM, Miller S, Wilson C. Hair follicle stem cells: their location, role in the hair cycle, and involvement in skin tumor formation. J Invest Dermatol 1993; 101:S16 – S26. Akiyama M, Dale BA, Sun TT, Holbrook KA. Characterization of hair follicle bulge in human fetal skin: the human fetal bulge is a pool of undifferentiated keratinocytes. J Invest Dermatol 1995; 105:844 – 850. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981; 77:13– 19. Ort RJ, Anderson RR. Optical hair removal. Semin Cutan Med Surg 1999; 18:149– 158. Anderson RR. Laser-tissue interaction is dermatology. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery. Philadelphia, PA: Lippincott-Raven, 1997:25 – 51. Baumler W, Schere K, Abels C, Neff S, Landthaler M, Szeimies RM. The effect of different spot sizes on the efficacy of hair removal using a long-pulsed diode laser. Raulin C, Greve B. Current status of photoepilation. Hautarzt 2000; 51:809 – 817. Hruza GJ. Laser surgery. In: Ratz JL, Padilla RS, Goldman MP, Geronemus RO, Maloney ME, eds. The Textbook of Dermatology Surgery. New York: Lippincott, 1998:335 – 338. Eremia S, Li C, Newman N. Laser hair removal with alexandrite versus diode laser using four treatment sessions: 1 year results. Dermatol Surg 27:925 – 930. Greppi I. Diode laser hair removal of the black patient. Lasers Surg Med 2001; 28:150 – 155. Littler CM. Topical suspension assisted Q-switched Nd:YAG laser hair removal: evaluation of a modified technique. Lasers Surg Med 1998; 10(suppl):43. Grossman MC, Dierickx CC, Farinelli WA. Damage to hair follicles by normal-mode ruby laser pulses. J Am Acad Dermatol 1996; 35:889– 894. Campos VB, Dierickx CC, Farinelli WA, Lin TYD, Manuskiatti W, Anderson RR. Hair removal with an 800-nm pulsed diode laser. J Am Acad Dermatol 2000; 43:442 – 447. Patterson MS, Wilson BC, Wyman DR. The propagation of optical radiation in tissue II: optical properties of tissues and resulting fluence distributions. Lasers Med Sci 1991; 6:379 – 390. Chan HH, Ying SY, Ho WS, Wong DSY, Lam LK. An in vivo study comparing the efficacy and complications of diode laser and long-pulsed Nd:YAG laser in hair removal in Chinese patients. Dermatol Surg 2001; 27:950 – 954. Rogachefsky AS, Silapunt S, Goldberg DJ. Evaluation of a new super-long-pulsed 810 nm diode laser for the removal of unwanted hair: the concept of thermal damage time. Dermatol Surg 2002; 28:410 –414. Williams RM, Gladstone HB, Moy RL. Hair removal using an 810 nm gallium arsenide semiconductor diode laser: a preliminary study. Dermatol Surg 1999; 25:935– 937. Handrick C, Alster TS. Comparison of long-pulsed diode and long-pulsed alexandrite lasers for hair removal: a long-term clinical and histologic study. Dermatol Surg 2001; 27:622 – 626.
332 26. 27.
28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38.
39. 40.
41. 42. 43. 44. 45. 46.
47.
48. 49. 50.
Alam, Wrone, and Berkes Lou WW, Quintana AT, Geronemus RG, Grossman MC. Prospective study of hair reduction by diode laser (800 nm) with long-term follow-up. Dermatol Surg 2000; 26:428 –432. Lin TYD, Dierickx CC, Campos VB, Farinelli WA, Rosenthal J, Anderson RR. Reduction of regrowing hair shaft size and pigmentation after ruby and diode laser treatment. Arch Dermatol Res 2000; 292:60 –67. Eremia S, Newman N. Topical anesthesia for laser hair removal: comparison of spot sizes and 755 nm versus 800 nm wavelengths. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Tope WD, Hordinsky MK. A hair’s breadth closer? Arch Dermatol 1998; 134:867 – 869. Lehrer MS, Crawford GH, Gelfand JM, Leyden JJ, Vittorio CC. The effect of wax epilation prior to hair removal with a long-pulsed alexandrite laser—a pilot study. Dermatol Surg 2003; 29:118–122. Rogachefsky AS, Silapunt S, Goldberg DJ. Evaluation of a super long pulsed 810-nm diode hair removal laser in suntanned individuals. J Cutan Laser Ther 2001; 3:57– 62. Adrian RM, Shay KP. 800 nanometer diode laser hair removal in African-American patients: a clinical and histologic study. J Cutan Laser Ther 2000; 2:183 – 190. Moreno-Arias GA, Tiffon T, Marti T, Camps-Fresneda A. Urticaria vasculitis induced by diode laser photo-epilation. Dermatol Surg 2000; 26:1082 – 1083. Nanni CA, Alster TS. Laser assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. J Am Acad Dermatol 1999; 41:165 – 171. Yamauchi PS, Kelly AP, Lask GP. Treatment of pseudofolliculitis barbae with the diode laser. J Cutan Laser Ther 1999; 1:109 – 111. Kauvar AN. Treatment of pseudofolliculitis with a pulsed infrared laser. Arch Dermatol 2000; 136:1343 – 1346. Eremia S, Li C, Umar SH. A side-by-side comparative study of 1064 nm Nd:YAG, 810 nm diode and 755 nm alexandrite lasers for treatment of 0.3– 3 mm leg veins. Dermatol Surg 2002; 28:224 – 230. Kaudewitz P, Klovekorn W, Rother W. Effective treatment of leg vein telangiectasia with a new 940 nm diode laser. Dermatol Surg 2001;27:101 –106. Navarro L, Min RJ, Bone C. Endovenous laser: a new minimally invasive method of treatment for varicose veins—preliminary observations using an 810 nm diode laser. Dermatol Surg 2001; 27:117–122. Weiss RA. Comparison of endovenous radiofrequency versus 810 nm diode laser occlusion of large veins in an animal model. Dermatol Surg 2002; 28:56 –61. Dover JS, Arndt KA. New approaches to the treatment of vascular lesions. Lasers Surg Med 2000; 26:158 – 163. Dover JS. New approaches to the laser treatment of vascular lesions. Australas J Dermatol 2000; 41:14 – 18. Goldberg DJ, Meine JG. Treatment of facial telangiectasia with the diode-pumped frequencydoubled Q-switched Nd:YAG laser. Dermatol Surg 1998; 24:828 – 832. Todd MM, Rallis TM, Gerwels JW, Hata TR. A comparison of 3 lasers and liquid nitrogen in the treatment of solar lentigines. Arch Dermatol 2000; 136:841 –846. Soden CE, Smith K, Skelton H. Histologic features seen in changing nevi after therapy with an 810 nm pulsed diode laser for hair removal in patients with dysplastic nevi. Int J Dermatol 2001; 40:500 – 504. Goldberg DJ, Rogachefsky AS, Silapunt S. Non-ablative laser treatment of facial rhytides: a comparison of 1450-nm diode laser treatment with dynamic cooling as opposed to treatment with dynamic cooling alone. Lasers Surg Med 2002; 30:79 – 81. Muccini JA, O’Donnell FE, Fuller T, Reinisch L. Laser treatment of solar elastosis with epithelial preservation. Lasers Surg Med 1998; 23:121– 127. Alster TS, Lupton JR. Are all infrared lasers equally effective in skin rejuvenation. Semin Cutan Med Surg 2002; 21:274– 279. Tanzi EL, Williams CM, Alster TS. Treatment of facial rhytides with a nonablative 1450 nm diode laser: a controlled clinical and histologic study. Dermatol Surg 2003; 29:124– 128.
Diode Lasers 51. 52. 53. 54. 55.
56.
57. 58.
59.
60. 61.
62. 63. 64. 65. 66.
67. 68. 69.
70. 71.
72.
73.
333
Alster TS, Tanzi EL. Treatment of transverse neck lines with a 1450 nm diode laser. Lasers Surg Med 2002; 14(suppl):33. Tanzi EL, Alster TS. Comparison of a 1450 nm diode laser and a 1320 nm Nd:YAG laser in the treatment of atrophic facial scars. Lasers Surg Med 2000; 27:1– 9. Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002; 31:106– 114. Lloyd JR, Mirkov M. Selective photothermolysis of the sebaceous glands for acne treatment. Lasers Surg Med 2002; 31:115 – 120. Katsumi T, Kato H, Okunaka T, Kuroiwa Y, Yoshiteru I, Saito K, Konaka C, Aizawa K. Photodynamic effect using a diode laser with mono-l-aspartyl chlorine e6 (NPe6) for implanted mouse tumor. J Clin Laser Med Surg 1994; 12:211 – 213. Busetti A, Soncin M, Jori G, Kenney ME, Rodgers MAJ. Treatment of malignant melanoma by high-peak-power 1064 nm irradiation followed by photodynamic therapy. Photochem Photobiol 1998; 68:377– 381. Abels C, Karrer S, Goetz AE, Landthaler M, Szeimies RM. Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi’s sarcoma. Br J Cancer 1998; 77:1015–1020. Szeimies RM, Lorenzen T, Karrer S, Abels C, Plettenberg A. Photochemotherapy of cutaneous AIDS-associated Kaposi sarcoma with indocyanine green and laser light. Hautarzt 2001; 52:322 – 326. Baas P, Murrer L, Zoetmulder FAN, Stewart FA, Ris HB, Zandwijk NV, Peterse JL, Rutgers EJT. Photodymanic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997; 76:819 – 826. Wyss P, Schwarz V, Dobler-Girdziunaite D, Hornung R, Walt H, Degen A, Fehr MK. Int J Cancer 2001; 93:720 – 724. Kirsch AJ, Duckett JW, Snyder HM, Canning DA, Harshaw DW, Howard P et al. Skin flap closure by dermal laser soldering: a wound healing model for sutureless hypospadias repair. Urology 1997; 20:263 –272. Bass LS, Libutti SK, Eaton AM. New solders for laser welding and sealing (abstract). Lasers Surg Med 1993; 5:A63. Diven DG, Pohl J. Dye-enhanced diode laser photothermal ablation of skin. J Am Acad Dermatol 1996; 35:211 – 215. DeCoste SD, Farinelli W, Flotte T. Dye-enhanced laser welding for skin closure. Lasers Surg Med 1992; 121:25– 32. Cooper CS, Schwartz IP, Suh D, Kirsch AJ. Optimal solder and power density for diode laser tissue soldering (LTS). Lasers Surg Med 2001; 29:53– 61. Capon A, Souil E, Gauthier B, Sumian C, Bachelet M, Buys B et al. Laser assisted skin closure (LASC) by using a 815-nm diode laser system accelerates and improves wound healing. Lasers Surg Med 2001; 28:168 – 175. Fujino T, Kiyoizumi T, Kubota J, Ohshiro T. Clinical effect of diode laser to improve fair take of grafted skin. Keio J Med 1986; 35:28 – 35. Kami T, Yoshimura Y, Nakajima T, Ohshiro T, Fujino T. Effects of low-power diode lasers on flap survival. Ann Plast Surg 1985; 14:278– 283. Souil E, Capon A, Mordon S, Dinh-Xuan AT, Polla BS, Bachelet M. Treatment with 815-nm diode laser induces long-lasting expression of 72-kDa heat shock protein in normal rat skin. Br J Dermatol 2001; 144:260– 266. Tam G. Low power laser therapy and analgesic action. J Clin Laser Med Surg 1999; 17:29–33. Whelan HT, Smits RL Jr, Buchman EV, Whelan NT, Turner SG, Margolis DA et al. Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg 2001; 19:305 – 314. Taylor DL, Schafer SA, Nordquist R, Payton ME, Dickey DT, Bartels KE. Comparison of a high power diode laser with the Nd:YAG laser using in situ wound strength analysis of healing cutaneous incisions. Lasers Surg Med 1997; 21:248 – 254. Fader DJ, Lowe L. Concomitant use of a high-energy pulsed CO2 laser and a long-pulsed (810 nm) diode laser for squamous cell carcinoma in situ. Dermatol Surg 2002; 28:97– 100.
334 74. 75.
Alam, Wrone, and Berkes Patete PV, Bulgrin JP, Shabani MM, Smith DJ. A non-invasive, three-dimensional, diagnostic laser imaging system for accurate wound analysis. Physiol Meas 1996; 17:71 – 79. Still JM, Law EJ, Klavuhn KG, Island TC, Holtz JZ. Diagnosis of burn depth using laser-induced indocyanine green fluorescence: a preliminary clinical trial. Burns 2001; 27:364 – 371.
Laser Hair Removal/Diode Laser Consent Form Lasers and other powerful light sources have been shown to reduce hair growth in many individuals. These technologies have been in use for several years. They operate by destroying the region that makes new hairs while sparing the rest of the skin from damage. However, there are risks, described below, that you should be aware of:
The treatment itself is associated with mild stinging discomfort that lasts while the laser is being used. Creams can be applied an hour before treatment to numb the skin to reduce this discomfort.
Blisters, scabs, crusts, and eroded areas can occasionally develop after treatment. These can last 1– 2 weeks, and usually are not associated with permanent effects. Redness can sometimes last for several weeks after treatment.
Darkening (hyperpigmentation) or lightening (hypopigmentation) of the treated skin area can occur. This is more common in dark-skinned or tanned individuals, and usually goes away completely with time. Skin darkening may be treated with bleaching agents and other medicines.
Bruising can occur after treatment and last up to two weeks. This bruising may change from a light purple to a dark purple/black, and then gradually fade as a brown discoloration of the skin. The brown color may not completely go away for several months.
Swelling after treatment can last up to a week. Some people experience more swelling, which is most common on the cheeks and upper lip. Redness associated with this swelling can be concealed by make-up, and ice-packs may help reduce the swelling.
Infection can occur. This is uncommon, but may require treatment with antibiotic ointments or oral antibiotics.
Changes in the texture of the skin and scarring can occur. These are uncommon side effects.
In most people, many treatments will be needed to provide enough hair removal for them to be satisfied. Hair removal may not be permanent, and some or all of the removed hair may regrow. Often the regrown hair will be lighter and thinner than before the treatment.
In some people, laser light can increase the growth of hair. This is uncommon, and when it is seen, tends to occur among darker skinned patients ethnically from southern Europe and the Mediterranean region. There are several steps you can take to help you get the good results from this treatment and have a low risk of side effects:
You will be given protective eyewear during the procedure to protect you from the laser light. We recommend that you wear this as directed, and additionally, we also recommend that you keep your eyes closed while the laser is on.
Diode Lasers
335
After the treatment, you can apply ice-packs or a cool dressing to soothe the area. We also recommend that you use a moisturizing ointment once or twice a day at home for the first week after treatment. During this time, clean the treated area gently.
Sunlight can cause skin aging and increase the risk of skin cancer. The risks of sunlight are even greater after a laser procedure, so we recommend that you reduce sun exposure as much as possible for 4– 6 weeks after the treatment. You should also wear sunscreen and a hat when you go out.
Please take this opportunity to make sure that you have shared your complete medical, surgical, and drug history with your physician. Knowing this information will help us treat you safely and appropriately.
If you have any problems with this procedure, please let us know as soon as possible so that we may take appropriate steps to protect your health. Before we can begin, please review the following statements: I certify that my physician has discussed this procedure with me and I have had an opportunity to ask questions about my condition, treatment procedure, risks and hazards involved. I believe I understand this procedure well enough to give permission to receive it. I further understand that rare or uncommon side effects that have not been discussed may occur, and there is no guarantee that this treatment will result in satisfactory hair removal. I request performance of the procedure described above. I also will follow the instructions. I have been given and notify the physician of any problems after the treatment. I agree to have before and after photographs taken. These photographs will be maintained in a confidential database, and may be used for educational purposes, including publication.
Patient/Guardian Name Patient/Guardian Signature Date I have explained the purpose, technique, benefits, and side effects of the laser hair removal procedure and alternative procedures. I have answered all questions and believe that the patient/guardian understands the procedure and its limitations.
Clinical Staff Signature
Date
Physician Signature
Date
15 Long-Pulsed Nd:YAG (1064 nm) Lasers Neil Sadick Weil Medical College of Cornell University, New York, USA
Arielle N. B. Kauvar New York Laser and Skin Care, New York; New York University School of Medicine, New York; and Suny Downstate Medical Center, New York, New York, USA
1. Introduction 2. Laser Physics 2.1. Wavelength 2.2. Pulse Duration 2.3. Spot Size 2.4. Skin Cooling and Epidermal Protection 3. Laser Tissue Interaction 3.1. Vascular Lesions 3.2. Hair Removal 3.3. Skin Rejuvenation 4. Clinical Studies 4.1. Vascular Lesions 4.2. Hair Removal and Pseudofolliculitis Barbae 4.3. Skin Rejuvenation 5. Presently Available Long-Pulsed Nd:YAG Lasers 6. Treatment Guidelines 6.1. Vascular Lesions 6.2. Hair Removal and Pseudofolliculitis Barbae 6.3. Skin Rejuvenation 7. Complications and Their Management 8. Conclusions References
1.
337 338 338 339 340 340 340 340 341 342 342 342 344 345 347 348 348 349 351 352 352 353
INTRODUCTION
The long-pulsed Nd:YAG laser has gained increasing popularity over recent years for treatment of both vascular and pigmented lesions as well as skin rejuvenation. 337
338
Sadick and Kauvar
The advantages of the 1064 nm wavelength are its deeply penetrating wavelength coupled with its hemoglobin absorption and to a lesser extent, water, and melanin absorption. Vascular lesions presently treated with the long-pulsed Nd:YAG laser include facial and leg telangiectasia, venulectasia and veins, spider and acquired angiomas, venous lakes, and larger vessel vascular malformations. Hair removal is another application of long pulsed Nd:YAG lasers which exhibit high safety profiles in the treatment of Fitzpatrick phototypes IV – VI as well as suntanned skin. The 1064 nm lasers are also being employed for rejuvenation of photodamaged skin based on their ability to heat dermal water and stimulate collagen production.
2.
LASER PHYSICS
2.1.
Wavelength
At 1064 nm, there is weak melanin, hemoglobin, and water absorption. The absorption by these discrete chromophores is low compared to vascular-specific and pigment-specific lasers, and the water absortion is much lower at 1064 nm compared to the mid-infrared wavelengths of 1.3– 1.5 mm (Fig. 15.1). Nd:YAG laser irradiation produces deeply penetrating photons into the dermis due to decreased scattering of light at this wavelength (1). The lack of very strong absorbing chromophores coupled with good dermal penetration results in deep tissue heating. Skin irradiation at 1064 nm produces volumetric heating of a cylinder of tissue below the laser pulse, extending millimeters into the dermis (Fig. 15.2). A 5 and 10 mm spot produce depth of penetrations of 5 and 10 mm, respectively, in skin.
20,000 10,000 Hb Absorbance (cm–1)
1000 Water 100 Melanin 10 HbO2 1
0.1 200
1000
5000
Wavelength (nm)
Figure 15.1 Absorption spectra of major skin pigments at concentrations for which they typically occur. Values shown are absorption coefficients (ma) for pure water, human hemoglobins at 11 g/dL, and dihydroxyphenylalanine (DOPA)-melanin, which has an absorption spectrum similar to pigmented epidermis at 15-mg/dL concentration to water. DOPA-melanin concentration shown is approximately equivalent to heavily pigmented human epidermis. Absorption coefficient of single melanosomes is unknown. Hb, Hemoglobin; HbO2, oxyhemoglobin. [Taken from Anderson RR (22).]
Long-Pulsed Nd:YAG (1064 nm) Lasers
Figure 15.2
2.2.
339
The depth of penetration increases with larger spot sizes. (Courtesy of Laserscope).
Pulse Duration
The theory of selective photothermolysis developed by Anderson and Parrish (2) describes the necessary requirements for selective destruction of site-specific targets in tissue using electromagnetic radiation. Selective targeting of tissue targets requires (a) the use of a wavelength preferentially absorbed by the chromophore, (b) a pulse duration less than or equal than the thermal relaxation time (TRT), or cooling time, of the targeted structure, and (c) sufficient fluence to produce irreversible damage. In 2001, Drs. Altshules, Anderson, and colleagues proposed the extended theory of selective photothermolysis (3), which describes the pulse duration requirements for nonuniformly pigmented structures in tissue, such as blood vessels and hair follicles. When treating a tattoo or pigmented lesion, heating of the structure will destroy the lesion, and the heat does not flow out of the target until it is fully damaged. When targeting a nonuniform structure, such as a blood vessel or a hair follicle, there are portions of the structure that exhibit much greater absorption than others. The weakly absorbing portions of the structure are then damaged by heat diffusion from the highly absorbing areas of the structure. In the case of a leg vein, the blood is the “absorber,” but closure of the vein requires coagulation of the vein wall which must be heated by diffusion from the blood. Similarly, the hair shaft and matrix cells are the “absorbers” for hair follicles, but the other follicular tissues including the stem cells do not contain chromophores absorbing in the near-infrared. Consequently, the treatment pulse duration for nonuniformly pigmented targets is significantly longer than the thermal relaxation time, and has been termed the thermal damage time (TDT).
340
2.3.
Sadick and Kauvar
Spot Size
Large spot sizes (Fig 15.2) will enhance photon penetration and will heat a deeper zone of tissue due to a reduction in the scattering of the photons. Light scattering occurs at the periphery of the beam and becomes less of a factor with larger spot sizes where the ratio of the surface area to the circumference of the beam is increased. A spot size of 1, 5, and 10 mm can be expected to produce approximate depths of penetration of 1, 5, and 10 mm in tissue. 2.4.
Skin Cooling and Epidermal Protection
Skin cooling for epidermal protection is essential with millisecond-domain Nd:YAG lasers. Heat must be extracted from the skin’s surface to prevent epidermal damage resulting from heat diffusion following volumetric heating of the dermis. Proper skin cooling techniques are essential to avoid epidermal damage and full thickness skin burns, particularly when very high fluencies are used for the treatment of vascular lesions. Inadvertent pulse overlapping and pulse stacking can lead to blisters, epidermal necrosis, and full thickness burns. Skin cooling techniques used with Nd:YAG lasers include cryogen spray cooling, contact cooling, and air cooling (Figs. 15.3 and 15.4).
3. 3.1.
LASER TISSUE INTERACTION Vascular Lesions
The 1064 nm wavelength exhibits oxyhemoglobin absorption as well as deep penetration into the dermis. There is a broad oxyhemoglobin absorption peak beyond 900 nm (Fig. 15.1) which enables selective photocoagulation of blood vessels when sufficiently high fluences are used. Compared to pulsed potassium – titanyl – phosphate (KTP) lasers (532 nm) and pulsed dye lasers (585 –600 nm) which penetrate skin to a depth of 1– 1.5 mm, the 1064 nm wavelength can penetrate skin to a depth of 5 – 10 mm (3) because of its lower scattering coefficient. The development of the pulsed Nd:YAG
Figure 15.3 Contact cooling with a water-cooled sapphire tip on the Laserscope Lyra handpiece.
Long-Pulsed Nd:YAG (1064 nm) Lasers
Figure 15.4
341
Cryogen spray cooling on the Candela GentleYAG.
laser greatly improved our ability to photocoagulate leg telangiectasia and reticular veins. Leg veins, compared to facial telangiectasia, have larger diameters, thicker vessel walls, a deeper location in skin and elevated hydrostatic pressures (4). The use of shorter, visible light wavelengths for vessels of larger diameter and deeper location produces partial vessel damage by photocoagulating a superficial layer of blood in the vessel (5). Full thickness coagulation and endothelial wall heating is required for vessel closure and irreversible damage. When sufficiently high fluences are used, and pulse durations are chosen to match the thermal damage times of the vessels, Nd:YAG lasers will safely and effectively photocoagulate telangiectasia and veins up to 4 mm in diameter. Heat diffusing from the blood will irreversibly damage the vessel wall. Pulsed Nd:YAG lasers may be used for the treatment of a wide range of vascular lesions including facial and leg telangiectasia, venulectasia and veins, venous lakes, spider and acquired angiomas, and venular vascular malformations. Pulse durations used for the treatment of telangictasia, venulectasia, and veins range from 20 to 100 ms, and full thickness coagulation of the vessels appears to be relativley independent of the chosen pulse duration within this range, assuming sufficient fluence is utilized. 3.2.
Hair Removal
The deep penetration depth of the Nd:YAG laser is also an advantage in laser hair removal because the hair follicles reside several millimeters below the skin surface. Melanin in the
342
Sadick and Kauvar
hair shaft and follicle provides the major chromophore for laser targeting of hair. The hair shaft and the bulb are the most melanin-rich portions of the anagen hair follicle, but the two potentially important targets for permanent inactivation of hair growth are the bulb, comprising the neurovascular papilla at the base of anagen hair follicles that supplies the matrix to produce the hair shaft, and the stem cells residing in the bulge, an area located near the insertion of the arrector pili muscle and residing 1.5 mm below the skin surface. Permanent hair removal is accomplished by thermally damaging the entire hair follicle tissues via heating of the pigmented portions of the follicle. Thermal damage times for hair follicles are in the 30 –100 ms range (6). Laser hair removal requires lasers that will target melanin in the hair follicles while avoiding damage in the pigmented epidermis. The shorter wavelengths used for hair removal including 694, 755, and 810 nm have higher melanin absorption coefficients, and the epidermis is protected by means of various cooling techniques used to prevent laser heating of the epidermal pigment. Melanin absorption at 1064 nm is lower, decreasing the risk of side effects related to damage of the melanin-containing epidermis, but sufficient to provide selective photothermolysis of the pigmented hair follicle. Of the hair removal systems that are available today, the 1064 nm laser provides the highest margin of safety for laser hair removal in phototypes V and VI skin. In individuals with phototypes V and VI, the pigmented hair follicle is usually darker than the pigmented epidermis. Although melanin absorption at 1064 nm is relatively weak, we can take advantage of the differences between the melanin concentration in the epidermis and the hair bulb and shaft. The relative absorption of 1064 nm laser light for black coarse hair is 1.5 times that of a deeply pigmented epidermis (7). With the application of deep cooling, the relative light absorption by the follicles allows selective heating of hairs without epidermal damage. 3.3.
Skin Rejuvenation
Water absorption at 1064 nm is weak compared to the mid-infrared wavelengths used for rejuvenation. The deep scattering at this wavelength and relatively weak absorption by the skin’s major chromphores results in volumetric heating of the dermis. When epidermal cooling methods are properly employed, the dermis is heated without the creation of an epidermal wound. This results in fibroblast activation and new collagen production. Electron microscopic analysis of skin following irradiation with a 1064 nm laser, pulse duration of 300 ms, spot size of 5 mm, and fluence of 13 J/cm2, showed a decrease in the collagen fiber diameter in the papillary dermis 1 and 3 months after treatment (8). This finding is consistent with the deposition of new collagen. Histological studies by Lee (9) demonstrated a zone of new collagen measuring 150 –200 mm following six treatments with a combination of a KTP and Nd:YAG laser. Six treatments with the Nd:YAG laser alone produced, in skin biopsies taken from treated skin of the inner arm, a new band of collagen measuring 50– 80 mm. Several clinical studies have demonstrated that skin textural improvement and tightening can be achieved using 1064 nm lasers (9 –11).
4. 4.1.
CLINICAL STUDIES Vascular Lesions
The first report of successful leg vein treatment with an Nd:YAG laser was using the Vasculight (Lumenis) (12) A 6 mm spot was used with pulse durations of 10 to 30 ms and fluences of 80– 120 J/cm2 with 75% clearance achieved at 3 months follow up. Similar results were reported by Kauvar et al. (13,14) using the Cool Glide (Atlus/Cutera) with
Long-Pulsed Nd:YAG (1064 nm) Lasers
343
a 10 mm spot, 50 mm pulse duration and a fluence of 100 J/m2 (9), and the Lyra (Laserscope), using a 3 mm spot, a 50 mm pulse duration, and a fluence of 150 J/cm2 (13). A comparative pilot study (15) evaluating leg vein treatment with a long-pulsed Nd:YAG laser and sclerotherapy demonstrated equivalent efficacy and side effect profiles. Sadick (16) found 64% of 24 patients showed .75% improvement at 1 year follow-up following a maximum of three treatments for vessels 0.204 mm in diameter. Matched bilateral patches of leg veins were treated in 20 patients, where one side was randomized to Nd:YAG laser treatment and the other to sotradechol sclerotherapy. One to Two treatments were performed at 8-week intervals. Clearing of laser treated areas was 2.5/4 compared to 2.3/4 for the sclerotherapy treated sites. There was no statistical difference between these side effects profiles observed on the sclerotherapy treated side and the laser treated side. This study demonstrated that equivalent results could be achieved with a long-pulsed Nd:YAG laser to sclerotherapy treatment. Facial telangictasia and veins have also been successfully treated with the long pulsed Nd:YAG laser (17). Thirty two sites were treated in 17 patients with skin types I– IV using an Nd:YAG laser equipped with cryogen cooling. Vessels up to 1 mm were treated with a 6 mm spot, 25 ms pulse width and a fluence of 125– 150 J/cm2. Reticular veins were treated with a 6 mm spot, 50– 100 ms pulse width and fluence of 150 J/cm2. Excellent resolution of the reticular veins was observed in the reticular veins, and good clearance in the telangictasia. In the authors’, experience excellent clearance of facial vessels .0.2 mm in diameter can be achieved with the appropriate pulse width and fluence combinations (Figs. 15.5– 15.7).
Figure 15.5 Before (a), immediately after 9 (b), and 3 weeks following treatment (c) with the GentleYAG 1064 nm laser using a 3 mm spot, 280 J/cm2, 40 ms pulse duration and a cryogen spray of 40 ms. (Courtesy of Candela.)
344
Sadick and Kauvar
Figure 15.6
4.2.
Before and 6 weeks after treatment with a 1064 nm laser. (Courtesy of Laserscope.)
Hair Removal and Pseudofolliculitis Barbae
A histological study of the long-pulsed Nd:YAG laser was preformed 24 – 72 h following laser irradiation of black hair using a 50 ms laser. Fluence dependent selective thermal injury to hair follicles was demonstrated with an average depth of injury being 1.06, 0.85, and 1.1 mm for fluences of 30, 50, and 100 J/m2, respectively (18). A prospective clinical study (19) of lower extremity hair removal was preformed in 29 subjects. Five test areas were treated 1– 5 times at monthly intervals. Up to five treatments produced hair loss of 71.5%, and a 40% reduction in hair was maintained at 1 year follow-up. Tanzi and Alster (20) studied 36 subjects with phototype I –VI skin and dark terminal hair with a 1064 nm using a 10 mm spot size at 30– 60 J/m2. Pulse durations were 10, 20, and 30 ms, respectively, for skin types I/II, III/VI, and V/IV. At 6 months following three consecutive laser treatments, there was a mean hair reduction of 41 – 40% on the face
Long-Pulsed Nd:YAG (1064 nm) Lasers
345
Figure 15.7 Treatment of nasal vessels with the GentleYAG using a 3 mm spot, 130 J/cm2, 20 ms pulse and cryogen spray of 40 ms. (Courtesy of Dr. Eubanks and Candela.)
and 48– 53% on the body. Ross et al. (21) demonstrated that a long-pulsed Nd:YAG laser equipped with contact cooling provided excellent cleaning of pseudofolliculitis barbae in skin types IV – VI. All test sites received treatment with a pulse duration of 50 ms. Five millimeter pulses were generated with a laser scanner without spot overlap. Hair and pulse counts were performed 90 days after treatment. There was 33%, 43%, and 40% hair reduction for fluences of 50, 80, and 100 J/cm2, respectively. Mean papules counts were 1.0 for the treated sites and 6 –95 for the control sites. This study demonstrated that the Nd:YAG laser is an excellent modality for the treatment of pseudofolliculitis barber in darker phototypes (Fig. 15.8).
4.3.
Skin Rejuvenation
The long-pulsed Nd:YAG laser, when used with epidermal cooling methods, can produce deep dermal tissue heating. These lasers have therefore been investigated for their ability
346
Figure 15.8 Laserscope.)
Sadick and Kauvar
Treatment of pseudofolliculitis barbae in type VI skin. (Courtesy of Dr. Vic Ross and
to stimulate neocollagenesis and collagen remodeling in an effort to achieve improvement in skin texture and laxity. Goldberg and Samady performed a split-face study comparing 3 to 5 treatments with an intensed pulsed light (IPL) (Lumenis/ESC), using 590 and 755 nm cutoff filters, with Nd:YAG laser treatment. The Nd:YAG laser (Lumenis/ESC) was with a 3–8 ms pulse, a 6 mm spot, and fluences of 100–130 J/cm2. There were similar improvements in wrinkles and skin texturein all treated sites, but the 1064 nm Nd:YAG laser was better tolerated in terms of treatment discomfort and had fewer side effects. Lee (10) treated 50 subjects with an Nd:YAG laser (lyra and Laserscope) with a 10 mm spot equipped with a sapphire chilled window at 58C, 30– 65 ms pulses and fluences of 24 – 30 J/cm2. Each subject received 3 –6 treatments and there was up to 18 months follow-up. There was a 10 – 20% reduction in redness, a 10– 30% improvement in skin tightness, but no observed improvement in skin pigmentation. Dayan et al. (9) used the same device with a 10 mm spot, 50 ms pulse duration, a fluence of 22 J/cm2 with contact cooling set at 1.58C, in 51 subjects who receive up to seven treatments
Long-Pulsed Nd:YAG (1064 nm) Lasers
347
with follow-up as long as 6 months. Objective grading of standardized photographs showed a 12% decrease in coarse wrinkles, a 17% decrease in skin laxity, and a global improvement of 20%. In a recent study, the long-pulsed Nd:YAG laser produced facial skin tightening comparable to radiofrequency treatment in a spilt-face comparison trail. Taylor performed a split-face and neck study in nine patients, comparing a radiofrequency device (Thermacool and Thermage) and a ling pulsed Nd:YAG laser (GentleYAG and Candela). The radiofrequency treatment consisted of three passes using standard treatment parameters, and the Nd:YAG laser was used to perform three passes with a 10 mm spot, 50 ms pulse, a 40 ms cryogen spurt with a 20 ms delay, and a fluence of 50 J/cm2. At 6 months follow-up, a blinded comparison of standardized photographs revealed the same or greater skin tightening on the Nd:YAG laser treated side. There was less pain and fewer side effects with laser treatment when compared with radiofrequency treatment (Fig. 15.9).
5.
PRESENTLY AVAILABLE LONG-PULSED Nd:YAG LASERS
There are multiple Nd:YAG lasers currently being manufactured (Table 15.1). Most of the systems come equipped with a range of spot sizes, millisecond-range pulse durations and skin cooling. The Candela and Cool Touch systems use cryogen cooling; the Cutera, Laserscope, Lumenis, Sciton, and Wavelight devices use contact cooling; and the Cynosure system uses air cooling. The 10 mm headpiece on the Gemini Laser employs photon recycling to improve utilization of the energy generated by the laser. At 1064 nm, 60% of the indent photons are back-scattered out of the tissue. Photons recycling uses a reflector to redirect the back-scattered photons to the target tissue, thereby increasing the effective fluence by 50% (Figs. 15.10 and 15.11).
Figure 15.9 Before and 6 months after treatment with a long-pulsed Nd:YAG laser equipped with cryogen cooling. (Courtesy of Dr. Mark Taylor and Candela.)
348
Sadick and Kauvar
Table 15.1
1 Long-Pulsed Nd:YAG Lasers.
Manufacturer Laser Name Candela Gentle YAG Cool Touch Varia Cutera/Atlus Cool Glide Cynosure Cynergy Fontana Dualis Laserscope Lyra Gemini Lumenis Quantum VasuLight Sciton Profile Wavelight Mydon
6. 6.1.
Max. Energy (J)
Pulse Duration (ms)
Spot Size (mm)
600
0.25 – 300
1.5– 10
Cryogen
500
0.3 –500
3 – 10
Cryogen
300
0.1 –300
3 – 10
Contact
300
0.4 –300
3 – 10
Air
400
5 – 200
2 – 10
900 900
20– 100 10– 100
1 – 5, 10 1 – 5, 10
90– 150 90– 150
5 – 38 2 – 48
6 6
Contact
400
0.1 –200